SMILES,Label,DrugBank ID,Name,Patent_id,Status,NCT_Number,Conditions,Gender,Age_y,Funder_Type,Study Designs,Locations,CPC,Gender_code_0,Gender_code_1,Gender_code_2,Gender_code_3,Age_code_0,Age_code_1,Age_code_2,Age_code_3,Age_code_4,Age_code_5,Allocation_Type_0,Allocation_Type_1,Allocation_Type_2,Allocation_Type_3,Intervention_Model_0,Intervention_Model_1,Intervention_Model_2,Intervention_Model_3,Intervention_Model_4,Intervention_Model_5,Country_0,Country_1,Country_2,Country_3,Country_4,Country_5,Funder_Type_0,Funder_Type_1,Funder_Type_2,Funder_Type_3,Funder_Type_4,Funder_Type_5,claims_#,Duration,Patent_#,PCT_code_0,PCT_code_1,PCT_code_2,CPC_code_0,CPC_code_1,CPC_code_2,CPC_code_3,CPC_code_4,CPC_code_5,logP,MW,PSA,HBA,HBD,Rings,Polarizability,Refractivity,Bond_#,Bioavailability_0,Bioavailability_1,Bioavailability_2,ECFP4.1,ECFP4.2,ECFP4.3,ECFP4.4,ECFP4.5,ECFP4.6,ECFP4.7,ECFP4.8,ECFP4.9,ECFP4.10,ECFP4.11,ECFP4.12,ECFP4.13,ECFP4.14,ECFP4.15,ECFP4.16,ECFP4.17,ECFP4.18,ECFP4.19,ECFP4.20,ECFP4.21,ECFP4.22,ECFP4.23,ECFP4.24,ECFP4.25,ECFP4.26,ECFP4.27,ECFP4.28,ECFP4.29,ECFP4.30,ECFP4.31,ECFP4.32,ECFP4.33,ECFP4.34,ECFP4.35,ECFP4.36,ECFP4.37,ECFP4.38,ECFP4.39,ECFP4.40,ECFP4.41,ECFP4.42,ECFP4.43,ECFP4.44,ECFP4.45,ECFP4.46,ECFP4.47,ECFP4.48,ECFP4.49,ECFP4.50,ECFP4.51,ECFP4.52,ECFP4.53,ECFP4.54,ECFP4.55,ECFP4.56,ECFP4.57,ECFP4.58,ECFP4.59,ECFP4.60,ECFP4.61,ECFP4.62,ECFP4.63,ECFP4.64,ECFP4.65,ECFP4.66,ECFP4.67,ECFP4.68,ECFP4.69,ECFP4.70,ECFP4.71,ECFP4.72,ECFP4.73,ECFP4.74,ECFP4.75,ECFP4.76,ECFP4.77,ECFP4.78,ECFP4.79,ECFP4.80,ECFP4.81,ECFP4.82,ECFP4.83,ECFP4.84,ECFP4.85,ECFP4.86,ECFP4.87,ECFP4.88,ECFP4.89,ECFP4.90,ECFP4.91,ECFP4.92,ECFP4.93,ECFP4.94,ECFP4.95,ECFP4.96,ECFP4.97,ECFP4.98,ECFP4.99,ECFP4.100,ECFP4.101,ECFP4.102,ECFP4.103,ECFP4.104,ECFP4.105,ECFP4.106,ECFP4.107,ECFP4.108,ECFP4.109,ECFP4.110,ECFP4.111,ECFP4.112,ECFP4.113,ECFP4.114,ECFP4.115,ECFP4.116,ECFP4.117,ECFP4.118,ECFP4.119,ECFP4.120,ECFP4.121,ECFP4.122,ECFP4.123,ECFP4.124,ECFP4.125,ECFP4.126,ECFP4.127,ECFP4.128
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,1,DB00007,__LEUPROLIDE,5728396,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,13.5033573584673,886.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,1209.3983,429.04,16.0,16.0,6.0,126.8,327.24,32.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Not Yet Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,1,DB00014,__GOSERELIN,7118552,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/326,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,67.8453356331752,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.3,1269.4105,495.89,18.0,17.0,6.0,131.22,325.84,33.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00050,__CETRORELIX,5198533,Completed,,SUBFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,58.21885459660361,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.33,1431.0379999999998,495.67,18.0,17.0,6.0,148.93,384.16,38.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,1,0,1,1,1
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT01211327,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kabgayi Hospital, Gitarama/Muhanga, Rwanda",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Unknown status,NCT00797030,DRY EYE SYNDROMES|HIV SEROPOSITIVITY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil",A61K38/13,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Withdrawn,NCT03710044,ATOPIC DERMATITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Investigational site, Rotterdam, Netherlands",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Terminated,NCT00553735,DRY EYE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT02660684,GRAFT VS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Daegu, Gyeongsangnam-do, Korea, Republic of|Hwasun-gun, Jeonranam-do, Korea, Republic of|Seoul, Korea, Republic of",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00195468,KIDNEY FAILURE|GRAFT VS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Curitiba, PR, Brazil|Rio de Janeiro, RJ, Brazil|Rio de Janeiro, RJ, Brazil|Porto Alegre, RS, Brazil|Porto Alegre, RS, Brazil|Ribeirao Preto, RS, Brazil|Sao Jose do Rio Preto, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Sao Paulo, SP, Brazil|Torreon, Coahuila, Mexico|Chihuahua, Mexico|Mexico City DF, Mexico",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT00209859,RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hvidovre University Hospital, Hvidovre, Denmark",A61K38/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C,1,DB00091,__CYCLOSPORINE,4839342,Completed,NCT02864706,HEART TRANSPLANTATION,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Århus N, Denmark|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden",A61K38/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,21.3228197704265,3200.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,1202.635,278.8,12.0,5.0,1.0,133.6,327.14,15.0,1.0,0.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccccc2)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB00104,__OCTREOTIDE,5538739,Completed,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/31,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,66.1368816608144,16.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.42,1019.25,332.22,12.0,13.0,5.0,107.65,269.77,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N(C)[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB00106,__ABARELIX,5843901,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.8242674387564,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,1416.09,424.98,16.0,13.0,6.0,149.31,373.91,38.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Active Not Recruiting,,CARDIOPULMONARY BYPASS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
C/C1=C2/N=C(/C=C3\N=C(/C(C)=C4/[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@](C)([C@@H]5N=C1[C@](C)(CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]1[C@@H](CO)O[C@H](n6cnc7cc(C)c(C)cc76)[C@@H]1O)[C@H]5CC(N)=O)N4[Co+]C#N)[C@@](C)(CC(N)=O)[C@@H]3CCC(N)=O)C(C)(C)[C@@H]2CCC(N)=O,1,DB00115,__CYANOCOBALAMIN,7229636,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/186,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,39.49157066880221,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1355.3652,477.85,18.0,9.0,8.0,138.79,337.48,27.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0
O=C(O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@H]12,1,DB00121,__BIOTIN,3946115,Unknown Status,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/158,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.17,244.31099999999998,78.43,3.0,3.0,2.0,24.92,60.05,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[N+](C)(C)CCO,1,DB00122,__CHOLINE,,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.6,104.1708,20.23,1.0,1.0,0.0,12.57,42.19,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,NCT03089216,TOOTH BLEACHING|TOOTH SENSITIVITY,All,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07K14/672,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07K14/672,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,,HEART TRANSPLANTATION,,,,,"FISABIO, Elche, Alicante, Spain",C07K14/672,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
N=C(N)NCCC[C@H](N)C(=O)O,1,DB00125,__ARGININE,4271152,Completed,,TOOTH BLEACHING,,,,,"FISABIO, Elche, Alicante, Spain",C07K14/672,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,15.376085751247402,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,174.201,125.22,6.0,5.0,0.0,17.8,53.92,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Unknown status,NCT00862693,GLOMERULONEPHRITIS|AUTOIMMUNE DISEASES,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renal Division, Peking University First Hospital, Beijing, Beijing, China",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Completed,NCT00319761,IGA NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Withdrawn,NCT00508898,SYSTEMIC LUPUS ERYTHEMATOSUS|NEPHRITIS|PROTEINURIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)(C)O)C[C@@H](O)C[C@@H]1O,1,DB00136,__CALCITRIOL,6051567,Unknown status,NCT00712205,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Medicine, Bruderholz, Baselland, Switzerland",A61K9/0019,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,8.54226986180414,825.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.51,416.6365,60.69,3.0,3.0,3.0,51.02,126.53,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C,1,DB00140,__RIBOFLAVIN,3936272,Completed,NCT00202228,HIV INFECTIONS|AIDS|LACTIC ACIDOSIS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Queen's University, Kingston, Ontario, Canada",G01N15/042,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,11.8606131542742,4111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,376.3639,155.05,9.0,5.0,3.0,37.5,96.27,5.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O,1,DB00146,__CALCIFEDIOL,6582727,Completed,NCT02805907,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Servicio Murciano de Salud, Murcia, Spain",A61K9/4816,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,19.4829462617302,571.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.71,400.6371,40.46,2.0,2.0,3.0,50.32,125.06,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,"Active, not recruiting",NCT03621553,SARCOIDOSIS|VITAMIN D INSUFFICIENCY,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)/C=C/[C@H](C)C(C)C,1,DB00153,__ERGOCALCIFEROL,4572915,Completed,NCT04472481,ACTIVE RHEUMATOID ARTHRITIS,All,33 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Souzan Ezzat Gado, Tanta, EL-gharbia, Egypt",A61K9/1075,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,21.8484979157682,655.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.59,396.6484,20.23,1.0,1.0,3.0,50.73,128.89,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0
Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1,1,DB00158,__FOLIC_ACID,3960757,Completed,NCT01308255,RHEUMATOID ARTHRITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Chapel Allerton Hospital, Leeds, West Yorkshire, United Kingdom",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,6253.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.04,441.3975,208.99,12.0,6.0,3.0,42.06,111.01,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,1,DB00162,__VITAMIN_A,3932634,Unknown status,NCT01705457,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,20 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tehran University of Medical Sciences,, Tehran, Iran, Islamic Republic of",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,3344.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.38,286.4516,20.23,1.0,1.0,1.0,36.54,97.92,5.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1c(C)c2c(c(C)c1O)CC[C@@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)O2,1,DB00163,__VITAMIN_E,3932634,Completed,NCT02019186,TYPE 1 DIABETES,All,8 Years to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.1090987494609,9855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.84,430.7061,29.46,2.0,1.0,2.0,55.29,135.37,12.0,1.0,0.0,0.0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0
Cc1ncc(CO)c(CO)c1O,1,DB00165,__PYRIDOXINE,6340695,"Active, not recruiting",NCT03302299,TUBERCULOSIS|HIV/AIDS|ALCOHOL ABUSE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mbarara University of Science and Technology/Mbarara Regional Referral Hospital, Mbarara, Uganda",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,7.063800078030338,2814.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,169.1778,73.58,4.0,3.0,1.0,17.11,44.11,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1
O=C(O)CCCC[C@@H]1CCSS1,1,DB00166,__LIPOIC_ACID,4100150,Completed,NCT01056497,TYPE 2 DIABETES|PREDIABETES,All,"20 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Toronto General Hospital, Toronto, Ontario, Canada",C07K14/565,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,19.022977884556106,2457.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,206.326,37.3,2.0,1.0,1.0,21.74,54.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT00785473,"MULTIPLE SCLEROSIS, OSTEOPOROSIS",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University Hospital of North Norway, Tromsø, Norway",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01390480,TYPE 1 DIABETES,All,"6 Years to 60 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Medical University Graz, Graz, Austria",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01052181,OBESITY|INSULIN RESISTANCE,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Sitaram Bhartia Institute of Science and Research, New Delhi, Delhi, India",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)C,1,DB00169,__CHOLECALCIFEROL,5994329,Completed,NCT01601847,WHEEZING|ALLERGY,All,up to 1 Year   (Child),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Montefiore Medical Center, New York, New York, United States|Case Western Reserve University, Cleveland, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Medical University of South Carolina, Charleston, South Carolina, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,44.0,15.540360171666698,1534.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.98,384.6377,20.23,1.0,1.0,3.0,49.6,123.22,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Unknown status,NCT00843661,HIV|HYPERLIPIDEMIA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale di Circolo and Fondazione Macchi, Varese, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT01301066,DYSLIPIDEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix, Arizona, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Coral Gables, Florida, United States|Fort Lauderdale, Florida, United States|Fort Pierce, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|St. Louis, Missouri, United States|Hillsborough, New Jersey, United States|Randolph, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Huntersville, North Carolina, United States|Addison, Texas, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Annandale, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT00630734,HIV INFECTIONS|HYPERLIPIDEMIA,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT00117494,HYPERLIPIDEMIA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"service de Médecine Interne Hopital Hotel Dieu, Paris, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)O)[C@H]21,1,DB00175,__PRAVASTATIN,5622985,Completed,NCT00227500,HIV INFECTIONS|LIPID METABOLISM|GLUCOSE METABOLISM|METABOLIC ABNORMALITY|LIPODYSTROPHY|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"St. Vincents Hospital, Sydney, New South Wales, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,24.1154849175547,325.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.23,424.5277,124.29,6.0,4.0,2.0,46.56,113.6,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00162955,NON-HODGKIN'S LYMPHOMA,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Graduate School of Medicine, Osaka City University, Osaka, Japan",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00154271,HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00170937,METABOLIC SYNDROME|HYPERTENSION|PRE-HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Novartis Pharmaceuticals, E. Hanover, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00241072,HYPERTENSION|IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00426348,GLOMERULONEPHRITIS|IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Unknown status,NCT02765594,PRIMARY IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peing Union Medical College Hospital, Beijing, China",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Completed,NCT00367562,IGA NEPHROPATHY,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Britanico de Buenos Aires, Buenos Aires, Argentina",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1)[C@H](C(=O)O)C(C)C,1,DB00177,__VALSARTAN,5972990,Withdrawn,NCT00745953,METABOLIC SYNDROME|LIPOTOXICITY,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,82.99143719583559,398.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.68,435.5188,112.07,6.0,2.0,3.0,47.27,134.77,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,NCT01115426,IGA GLOMERULONEPHRITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Mater Domini"" Hospital, Catanzaro, Calabria, Italy",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Unknown status,NCT01743014,DIABETES TYPE 2|DIABETIC NEPHROPATHY|VASCULAR DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AHEPA University Hospital, Thessaloniki, Greece|Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece",A61K38/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCC[C@@H]21,1,DB00178,__RAMIPRIL,5403856,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/556,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,416.5106,95.94,5.0,2.0,3.0,44.79,111.19,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NCC(CC(=O)O)c1ccc(Cl)cc1,1,DB00181,__BACLOFEN,6024981,Completed,,SPASTICITY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,351.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.13,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CC(N)Cc1ccccc1,1,DB00182,__AMPHETAMINE,6322819,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,37.22458366701571,874.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.85,135.2062,26.02,1.0,1.0,1.0,16.17,43.71,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Recruiting,NCT04490057,TOBACCO USE CESSATION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University School of Medicine, New Haven, Connecticut, United States|SUNY Downstate STAR Clinic, Brooklyn, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Suspended,NCT00701207,PULMONARY SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Ohio State University, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN1CCC[C@H]1c1cccnc1,1,DB00184,__NICOTINE,5656255,Active Not Recruiting,,NICOTINE DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,34.4319185198874,1931.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.87,162.2316,16.13,2.0,0.0,2.0,18.59,49.66,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2Cl)=NC1O,1,DB00186,__LORAZEPAM,4028466,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,187.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.98,321.158,61.69,3.0,2.0,3.0,30.33,82.7,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
COC(=O)CCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00187,__ESMOLOL,6310094,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,9.56077126840386,564.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.02,295.374,67.79,4.0,2.0,1.0,33.68,81.05,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Unknown status,NCT02559154,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai General Hospital, Shanghai, China",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Recruiting,NCT04348006,NEWLY DIAGNOSED MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baghdad Hematology center - Baghdad Medical City, Baghdad, Bab-Almuadham, Iraq",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Unknown status,NCT02844322,WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Completed,NCT01103778,CHRONIC KIDNEY DISEASE|IGA NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Rogosin Institute, New York, New York, United States",C07K5/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,1,DB00188,__BORTEZOMIB,6083903,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,61.63576254132521,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,384.23699999999997,124.44,6.0,4.0,2.0,40.48,99.37,9.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
C[C@@](Cc1ccc(O)c(O)c1)(NN)C(=O)O,1,DB00190,__CARBIDOPA,6500867,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,30.0622189367338,800.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.16,226.2292,115.81,6.0,5.0,1.0,21.81,68.77,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/2081,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,NCT02246712,NEUROPATHIC PAIN|TYPE 1 DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Estadual Paulista Julio de Mesquita Filho, Araraquara, SP, Brazil",A61K9/2081,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,1,DB00193,__TRAMADOL,5464632,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2081,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,11.269225240764598,385.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.71,263.3752,32.7,3.0,1.0,2.0,30.45,78.27,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT02181946,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT01535469,CRYPTOCOCCAL MENINGITIS|CRYPTOCOCCUS NEOFORMANS|CRYPTOCOCCOSIS,All,"14 Years and older   (Child, Adult, Older Adult)",Other|U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Infectious Disease Institute, Makerere University, Kampala, Uganda|Kampala Capital Council Authority Clinics, Kampala, Uganda",C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT00001542,ACQUIRED IMMUNODEFICIENCY SYNDROME|CANDIDIASIS|ORAL CANDIDIASIS,All,"Child, Adult, Older Adult",NIH,Primary Purpose: Treatment,"National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States",C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT00553137,OROPHARYNGEAL CANDIDIASIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ART clinic Muhimbili National Hospital/Muhimbili University College of Health Sciences, Dar es Salaam, Tanzania",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,,CRYPTOCOCCOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
OC(Cn1cncn1)(Cn1cncn1)c1ccc(F)cc1F,1,DB00196,__FLUCONAZOLE,4404216,Completed,NCT00000951,"CANDIDIASIS, ORAL|HIV INFECTIONS",All,"13 Years and older   (Child, Adult, Older Adult)",NIH|Other,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of California / San Diego Treatment Ctr, San Diego, California, United States|San Francisco Gen Hosp, San Francisco, California, United States|Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Howard Univ, Washington, District of Columbia, United States|Institute for Clinical Research, Washington, District of Columbia, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Emory Univ, Atlanta, Georgia, United States|Emory Hemo Comp Evaluation Clinic / East TN Comp Hemo Ctr, Atlanta, Georgia, United States|Queens Med Ctr, Honolulu, Hawaii, United States|Univ of Hawaii, Honolulu, Hawaii, United States|Northwestern Univ Med School, Chicago, Illinois, United States|Cook County Hosp, Chicago, Illinois, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|Louis A Weiss Memorial Hosp, Chicago, Illinois, United States|Indiana Univ Hosp, Indianapolis, Indiana, United States|Division of Inf Diseases/ Indiana Univ Hosp, Indianapolis, Indiana, United States|Methodist Hosp of Indiana / Life Care Clinic, Indianapolis, Indiana, United States|Univ of Iowa Hosp and Clinic, Iowa City, Iowa, United States|State of MD Div of Corrections / Johns Hopkins Univ Hosp, Baltimore, Maryland, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Harvard (Massachusetts Gen Hosp), Boston, Massachusetts, United States|Boston Med Ctr, Boston, Massachusetts, United States|Hennepin County Med Clinic, Minneapolis, Minnesota, United States|Univ of Minnesota, Minneapolis, Minnesota, United States|St Paul Ramsey Med Ctr, St Paul, Minnesota, United States|St Louis Regional Hosp / St Louis Regional Med Ctr, St Louis, Missouri, United States|Univ of Nebraska Med Ctr, Omaha, Nebraska, United States|Albert Einstein College of Medicine, Bronx, New York, United States|SUNY / Erie County Med Ctr at Buffalo, Buffalo, New York, United States|Beth Israel Med Ctr, New York, New York, United States|Bellevue Hosp / New York Univ Med Ctr, New York, New York, United States|Saint Clare's Hosp and Health Ctr, New York, New York, United States|Cornell Univ Med Ctr, New York, New York, United States|Mem Sloan - Kettering Cancer Ctr, New York, New York, United States|St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr, New York, New York, United States|Mount Sinai Med Ctr, New York, New York, United States|St Mary's Hosp (Univ of Rochester/Infectious Diseases), Rochester, New York, United States|Univ of Rochester Medical Center, Rochester, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Duke Univ Med Ctr, Durham, North Carolina, United States|Univ of Cincinnati, Cincinnati, Ohio, United States|Univ of Kentucky Lexington, Cincinnati, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Ohio State Univ Hosp Clinic, Columbus, Ohio, United States|Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States|Univ of Pennsylvania at Philadelphia, Philadelphia, Pennsylvania, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Tennessee / E Tennessee Comprehensive Hemophilia Ctr, Knoxville, Tennessee, United States|Univ of Texas Galveston, Galveston, Texas, United States|Univ of Washington, Seattle, Washington, United States|Univ of Puerto Rico, San Juan, Puerto Rico",C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,15.408940635331302,275.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.58,306.2708,81.65,5.0,1.0,3.0,26.52,97.2,5.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Completed,NCT00368342,ASTHMA,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1694,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00199,__ERYTHROMYCIN,3960757,Recruiting,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1694,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,4982.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.37,733.9268,193.91,13.0,5.0,3.0,78.21,186.04,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,1,1,0,0,0
CC1=C2[N+]3=C(C=C4[N+]5=C(C(C)=C6N7[C@@H]8[C@H](CC(N)=O)[C@@]6(C)CCC(=O)NC[C@@H](C)OP(=O)([O-])O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)n6c[n+](c9cc(C)c(C)cc96)[Co-3]753(O)[N+]3=C1[C@@H](CCC(N)=O)[C@](C)(CC(N)=O)[C@]83C)[C@@H](CCC(N)=O)C4(C)C)[C@@H](CCC(N)=O)[C@]2(C)CC(N)=O,1,DB00200,__HYDROXOCOBALAMIN,5834448,Completed,,VITAMIN B12 DEFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/19,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,23.8526458448838,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-14.0,1346.3551,437.23,14.0,10.0,12.0,135.56,340.03,16.0,1.0,0.0,0.0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00201,__CAFFEINE,5972916,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,20.468592784246,2772.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.24,194.1906,58.44,3.0,0.0,2.0,18.95,49.83,0.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,NEUROMUSCULAR BLOCKADE,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C,1,DB00202,__SUCCINYLCHOLINE,4474752,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,234.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,290.399,52.6,2.0,0.0,0.0,33.15,100.94,11.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Unknown status,NCT02524184,OBESITY,Male,20 Years to 30 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Wuhan General Hospital, Wuhan, Hubei, China",C07D487/04,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Active Not Recruiting,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12,1,DB00203,__SILDENAFIL,5250534,Completed,,LEFT VENTRICULAR DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,16.7231359986858,278.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.8,474.57599999999996,109.13,8.0,1.0,4.0,51.18,139.44,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,NCT00367081,TOXOPLASMIC ENCEPHALITIS|AIDS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Chiang Mai University hospital (2003-2004), Chiang Mai, Thailand",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,MALARIA IN PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCc1nc(N)nc(N)c1-c1ccc(Cl)cc1,1,DB00205,__PYRIMETHAMINE,4062940,Completed,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,8.18086613688166,247.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.62,248.71099999999998,77.82,4.0,2.0,2.0,25.79,71.54,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Recruiting,NCT04160026,"MALARIA IN PREGNANCY|ADHERENCE, TREATMENT",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Kenya Medical Research Institute, Kisumu, Kenya",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Recruiting,NCT04319705,"ASTHMA|COPD|EXACERBATION COPD|ASTHMA; EOSINOPHILIC|BRONCHIAL DISEASES|LUNG DISEASES, OBSTRUCTIVE|LUNG DISEASES|IMMUNE SYSTEM DISEASES",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00207,__AZITHROMYCIN,5192535,Terminated,NCT02003911,ASTHMA,All,4 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The Children's Hospital at Montefiore, Bronx, New York, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.394915706687996,310.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.03,748.9845,180.08,13.0,5.0,3.0,83.11,194.11,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0
COc1ccc(-c2ccc3cc(C(=O)O)ccc3c2)cc1C12CC3CC(CC(C3)C1)C2,1,DB00210,__ADAPALENE,4717720,Completed,NCT00907101,P ACNES COLONIZATION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Skin Study Center, Broomall, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,20.8628513932524,431.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.06,412.5201,46.53,3.0,1.0,6.0,47.65,122.07,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cccc(Nc2ccncc2S(=O)(=O)NC(=O)NC(C)C)c1,1,DB00214,__TORASEMIDE,4743693,Recruiting,NCT03354897,CARDIOVASCULAR DISEASES|HYPERTENSION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Glasgow Clinical Research Facility, Glasgow, United Kingdom",C07D213/74,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,241.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,348.42,100.19,5.0,3.0,2.0,36.15,91.89,4.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB00215,__CITALOPRAM,,Terminated,NCT01436643,DEPRESSION|RELAPSING-REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Achim, Germany|Novartis Investigative Site, Altenholz-Stift, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Honnef, Germany|Novartis Investigative Site, Baesweiler, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Butzbach, Germany|Novartis Investigative Site, Grevenbroich, Germany|Novartis Investigative Site, Heidenheim, Germany|Novartis Investigative Site, Klingenmünster, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Merzig, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Oberhausen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weil am Rhein, Germany|Novartis Investigative Site, Zwickau, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.4,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB00215,__CITALOPRAM,,Recruiting,NCT03499171,GERD,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","UZ Leuven, Leuven, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.4,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12,1,DB00218,__MOXIFLOXACIN,4990517,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D401/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,19.220107189059306,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.01,401.4314,82.11,7.0,2.0,5.0,41.24,106.22,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,DB00220,__NELFINAVIR,5484926,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,DB00220,__NELFINAVIR,5484926,Completed,NCT00141284,HEPATITIS C INFECTION,All,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Bakersfield, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Toronto, Ontario, Canada",C07C323/60,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,DB00220,__NELFINAVIR,5484926,Completed,NCT00006190,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Diagnostic,"UT Southwestern Medical Center, Dallas, Texas, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,DB00220,__NELFINAVIR,5484926,Completed,NCT00023400,HIV INFECTIONS|TUBERCULOSIS,All,"Child, Adult, Older Adult",U.S. Fed,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",C07C323/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,DB00220,__NELFINAVIR,5484926,Unknown status,NCT00005000,HIV INFECTION,All,"Child, Adult, Older Adult",Industry,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,"Agouron Pharmaceuticals Inc, San Diego, California, United States",C07C323/60,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,23.425532351793603,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,567.7819999999998,101.9,5.0,4.0,4.0,63.8,162.67,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,1,DB00224,__INDINAVIR,5413999,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,24.049775149387003,1144.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.26,613.7895,118.03,7.0,4.0,5.0,68.63,175.89,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,1,DB00224,__INDINAVIR,5413999,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,24.049775149387003,1144.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.26,613.7895,118.03,7.0,4.0,5.0,68.63,175.89,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,1,DB00224,__INDINAVIR,5413999,Completed,NCT00050180,HEALTHY|HIV INFECTIONS,All,18 Years to 60 Years   (Adult),NIH,Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,24.049775149387003,1144.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.26,613.7895,118.03,7.0,4.0,5.0,68.63,175.89,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O,1,DB00224,__INDINAVIR,5413999,Completed,NCT00002376,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Kaiser Foundation Hospital, San Francisco, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,24.049775149387003,1144.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.26,613.7895,118.03,7.0,4.0,5.0,68.63,175.89,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Completed,NCT00407511,DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPN)|POSTHERPETIC NEURALGIA (PHN)|HIV-RELATED NEUROPATHIC PAIN (HIV)|CHEMOTHERAPY INDUCED NEUROPATHIC PAIN,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tijuana, B. C., Mexico|Pfizer Investigational Site, Mexicali, B.c., Mexico|Pfizer Investigational Site, Mexico, Distrito Federal, Mexico|Pfizer Investigational Site, Acapulco, Guerrero, Mexico|Pfizer Investigational Site, México, Monterrey, NL, Mexico|Pfizer Investigational Site, Merida, Yucatan, Mexico|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Caracas, Distrito Capital, Venezuela",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](CN)CC(=O)O,1,DB00230,__PREGABALIN,6197819,Unknown status,NCT03584074,SPINAL STENOSIS LUMBAR,All,"40 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,70.8351300848066,363.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,159.2261,63.32,3.0,2.0,0.0,18.08,43.68,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,1,DB00231,__TEMAZEPAM,5211954,Completed,NCT00465972,HIV INFECTIONS|INSOMNIA,All,"18 Years to 69 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Medical Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,12.5834206041191,579.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,300.74,52.9,3.0,1.0,3.0,30.32,81.01,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CN1C(=O)C(O)N=C(c2ccccc2)c2cc(Cl)ccc21,1,DB00231,__TEMAZEPAM,5211954,Completed,NCT02153788,INSOMNIA,All,"18 Years to 69 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,12.5834206041191,579.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.16,300.74,52.9,3.0,1.0,3.0,30.32,81.01,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CCOc1ccccc1O[C@H](c1ccccc1)[C@H]1CNCCO1,1,DB00234,__REBOXETINE,6028070,Unknown status,NCT00209807,MAJOR DEPRESSION|PAIN|ABDOMINAL PAIN,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitari vall d'Hebron, Barcelona, Catalonia, Spain",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,17.183104375859802,547.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.06,313.397,39.72,4.0,1.0,3.0,34.51,89.48,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00552240,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1100.1512.28 Boehringer Ingelheim Investigational Site, Beverly Hills, California, United States|1100.1512.20 Boehringer Ingelheim Investigational Site, Los Angeles, California, United States|1100.1512.15 Boehringer Ingelheim Investigational Site, Denver, Colorado, United States|1100.1512.26 Boehringer Ingelheim Investigational Site, Washington, District of Columbia, United States|1100.1512.17 Boehringer Ingelheim Investigational Site, Fort Lauderdale, Florida, United States|1100.1512.14 Boehringer Ingelheim Investigational Site, Orlando, Florida, United States|1100.1512.23 Boehringer Ingelheim Investigational Site, Vero Beach, Florida, United States|1100.1512.29 Boehringer Ingelheim Investigational Site, Maywood, Illinois, United States|1100.1512.11 Boehringer Ingelheim Investigational Site, Neptune, New Jersey, United States|1100.1512.25 Boehringer Ingelheim Investigational Site, Newark, New Jersey, United States|1100.1512.18 Boehringer Ingelheim Investigational Site, Somers Point, New Jersey, United States|1100.1512.22 Boehringer Ingelheim Investigational Site, Winston-Salem, North Carolina, United States|1100.1512.21 Boehringer Ingelheim Investigational Site, Philadelphia, Pennsylvania, United States|1100.1512.13 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States|1100.1512.30 Boehringer Ingelheim Investigational Site, Dallas, Texas, United States|1100.1512.19 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States|1100.1512.16 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1100.1512.24 Boehringer Ingelheim Investigational Site, Houston, Texas, United States|1100.1512.27 Boehringer Ingelheim Investigational Site, Annandale, Virginia, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT01772940,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cliniques Universitaires de Lubumbashi, Lubumbashi, Katanga, Congo",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Recruiting,NCT02712801,HIV/AIDS AND INFECTIONS,All,up to 1 Day   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China|Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Maternal and Child Health Hospital of Sichuan Province, Chengdu, Sichuan, China|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China|Maternal and Child Health Hospital of Yunan Province, Kunming, Yunnan, China",C07D471/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Unknown status,NCT00122226,HIV INFECTIONS|LIPODYSTROPHY,Male,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland|Academic Medical Center, Amsterdam, Netherlands|Medisch Centrum Jan van Goyen, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Oosterpark, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Prinsengracht, Amsterdam, Netherlands|Slotervaart ziekenhuis, Amsterdam, Netherlands|VUMC Free University Medical Center, Amsterdam, Netherlands|Ziekenhuis Leyenburg, den Haag, Netherlands|Kennemer Gasthuis, location Elisabeth, Haarlem, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|Hospital Clinic, Barcelona, Spain|Royal Free Hospital, London, United Kingdom",C07D471/14,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00144157,ACQUIRED IMMUNODEFICIENCY SYNDROME,Female,19 Years to 45 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Capetown, South Africa|Boehringer Ingelheim Investigational Site, Parow, South Africa|Boehringer Ingelheim Investigational Site, Soweto, South Africa",C07D471/14,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,"Active, not recruiting",NCT03088410,HIV|INSULIN SENSITIVITY|DIABETES MELLITUS,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana",C07D471/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00143689,HIV|MITOCHONDRIAL TOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McMaster University, Hamilton, Ontario, Canada|University of Ottawa Health Services, Ottawa, Ontario, Canada|Maple Leaf Clinic, Toronto, Ontario, Canada|Clinique Medicale L'Actuel, Montreal, Quebec, Canada",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Terminated,NCT00523458,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Universitario Prof. Edgard Santos/Universidade Federal da Bahia, Salvador, Bahia, Brazil",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT01637558,TUBERCULOSIS|HIV,All,1 Month to 12 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Queen Elizabeth Central Hospital, Blantyre, Malawi|Red Cross Childrens Hospital, Cape Town, Western Cape, South Africa|KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town, Western Cape, South Africa|Desmond Tutu Centre, Cape Town, Western Cape, South Africa",C07D471/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00144261,"HIV INFECTIONS|METABOLISM, LIPIDS",All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Prevention,"1100.1426.01 Academic Medical Centre, Amsterdam, Netherlands|1100.1426.02 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|1100.1426.44001 Boehringer Ingelheim Investigational Site, London, United Kingdom",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00274001,HIV INFECTIONS|QUALITY OF LIFE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Ospedale Regionale, Ancona, Italy|Ospedale Santa Maria Annunziata, Antella (fi), Italy|Clinica di Malattie Infettive, Bari, Italy|Ospedali Riuniti di Bergamo, Bergamo, Italy|Ospedale degli Infermi di Biella, Biella, Italy|Istituto di Malattie Infettive, Bologna, Italy|Ospedale Civile, Brescia, Italy|Spedali Civili di Brescia, Brescia, Italy|Ospedale di Circolo di Busto, Busto Arsizio (va), Italy|Ospedale SS. Trinità, Cagliari, Italy|Azienda Ospedaliera Arcispedale S. Anna, Ferrara, Italy|Ospedale San Martino, Genova, Italy|Presidio Ospedaliero ""A. Manzoni"", Lecco, Italy|Azienda Ospedaliera Carlo Poma, Mantova, Italy|Ospedale Luigi Sacco, Milano, Italy|Fondazione Centro S. Raffaele del Monte Tabor, Milano, Italy|Azienda Ospedaliera ""Luigi Sacco"", Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|Policlinico Universitario, Modena, Italy|Ospedale A. Cotugno, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|IRCCS Policlinico San Matteo, Pavia, Italy|Ospedale Civile, Piacenza, Italy|Ospedale Cisanello, Pisa, Italy",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00144248,HIV INFECTIONS|HEPATIC INSUFFICIENCY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boehringer Ingelheim Investigational Site, Bakersfield, California, United States|Boehringer Ingelheim Investigational Site, San Francisco, California, United States|California Pacific Medical Center, San Francisco, California, United States|Albany Medical College, MC 142, Albany, New York, United States|Boehringer Ingelheim Investigational Site, Providence, Rhode Island, United States|Hopital de l'Hotel Dieu, Lyon cedex 02, France|Hopital Pitie Salpetriere, Paris, France|Hospital Clinico y Provincial de Barcelona - HIV, Barcelona, Spain",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Cc1ccnc2c1NC(=O)c1cccnc1N2C1CC1,1,DB00238,__NEVIRAPINE,5366972,Completed,NCT00405171,HIV INFECTIONS|HYPERCHOLESTEROLEMIA|ANTIRETROVIRAL THERAPY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Côte de Nacre University hospital, Caen, France",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,16.328877389679402,408.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.75,266.2979,58.12,4.0,1.0,4.0,27.8,77.48,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Recruiting,NCT04550455,MULTIPLE SCLEROSIS,All,"21 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Multiple Sclerosis Center of Northeastern New York, P.C., Latham, New York, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1,1,DB00242,__CLADRIBINE,7888328,Recruiting,NCT03963375,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Washington University School of Medicine, Saint Louis, Missouri, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,82.6957432390808,2619.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.12,285.687,119.31,7.0,3.0,3.0,25.93,67.18,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Nc1ccc(O)c(C(=O)O)c1,1,DB00244,__MESALAZINE,5541170,Completed,NCT01090102,HIV INFECTIONS|SEXUALLY TRANSMITTED DISEASES|IMMUNE SYSTEM DISEASES|LENTIVIRUS INFECTIONS|ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California, San Francisco-San Francisco General Hospital, San Francisco, California, United States",A61K9/2846,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.690281114601902,1899.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.75,153.1354,83.55,4.0,3.0,1.0,14.26,40.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
Nc1ccc(O)c(C(=O)O)c1,1,DB00244,__MESALAZINE,5541170,Unknown status,NCT01789294,INTESTINAL LNH,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Departments of Pediatrics, Sapienza - University of Rome, Rome, Italy",A61K9/2846,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.690281114601902,1899.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.75,153.1354,83.55,4.0,3.0,1.0,14.26,40.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21,1,DB00248,__CABERGOLINE,5705510,Active Not Recruiting,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,26.415326803425106,154.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.97,451.6043,71.68,4.0,2.0,4.0,52.5,133.5,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Unknown status,NCT02550080,ALLERGIC CUTANEOUS VASCULITIS|URTICARIA|PSORIASIS|ACNE|BULLOUS SKIN DISEASES|STERILE PUSTULOSIS|LEPROSY|PNEUMOCYSTIS PNEUMONIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Shandong Provincial Institute of Dermatology and Venereology, Jinan, Shandong, China",A61K9/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Terminated,NCT01115244,DERMATITIS HERPETIFORMIS,All,"12 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University - One Hundred Oaks, Nashville, Tennessee, United States",A61K9/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,1,DB00250,__DAPSONE,5863560,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,28.4851845007084,2014.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.19,248.301,86.18,4.0,2.0,2.0,25.05,68.99,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,NCT00366067,BRONCHIAL ASTHMA,All,4 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"""Rea"" Rehabilitation Centre, Tbilisi, Georgia",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
O=C1NC(=O)C(c2ccccc2)(c2ccccc2)N1,1,DB00252,__PHENYTOIN,3962430,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61L2/0023,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,252.268,58.2,2.0,2.0,3.0,25.48,70.18,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,"Active, not recruiting",NCT02844634,HIV|SYPHILIS,Male,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"BC Centre for Disease Control, Vancouver, British Columbia, Canada",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Recruiting,NCT03980223,GONORRHEA|CHLAMYDIA|SYPHILIS,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"San Francisco City Clinic / San Francisco Department of Public Health, San Francisco, California, United States|University of California, San Francisco / Zuckerberg San Francisco General Hospital/UCSF, San Francisco, California, United States|University of Washington, Seattle, Washington, United States",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Recruiting,NCT04050540,HIV INFECTIONS|HIV/AIDS|NEISSERIA GONORRHEAE INFECTION|CHLAMYDIA TRACHOMATIS INFECTION|SYPHILIS INFECTION,Female,18 Years to 30 Years   (Adult),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Kenya Medical Research Institute, Kisumu, Kenya",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Not yet recruiting,NCT02864550,SYPHILIS|SEXUALLY TRANSMITTED INFECTIONS,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00989742,LYMPHANGIOLEIOMYOMATOSIS|TUBEROUS SCLEROSIS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Nottingham University Hospitals, Nottingham, United Kingdom",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,NCT00246324,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Active Not Recruiting,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21,1,DB00254,__DOXYCYCLINE,5789395,Completed,,RABIES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,23.1298383950389,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.72,444.4346,181.62,9.0,6.0,4.0,43.65,113.89,2.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1,DB00257,__CLOTRIMAZOLE,4073901,Terminated,NCT00671528,"DERMATITIS, ATOPIC|ECZEMA, ATOPIC|SKIN DISEASES, ECZEMATOUS",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D249/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,25.0354216719029,1845.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.48,344.837,17.82,1.0,0.0,4.0,36.25,103.76,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0
Clc1ccccc1C(c1ccccc1)(c1ccccc1)n1ccnc1,1,DB00257,__CLOTRIMAZOLE,4073901,Terminated,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,25.0354216719029,1845.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.48,344.837,17.82,1.0,0.0,4.0,36.25,103.76,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,0
CC(=O)[O-].CC(=O)[O-].[Ca+2],1,DB00258,__CALCIUM_ACETATE,6576665,Not Yet Recruiting,,SMALLPOX,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,26.2181974989219,5.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.24,158.166,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
N[C@@H]1CONC1=O,1,DB00260,__CYCLOSERINE,,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,102.0919,64.35,3.0,2.0,1.0,8.87,21.85,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00992056,HYPERTENSION,Female,"46 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Clinical Pharmacology Clinical Pharmacology Research Unit (CPRU) 1500 NW 12th Ave 15-West., Miami, Florida, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT00775671,METABOLIC SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COCCc1ccc(OCC(O)CNC(C)C)cc1,1,DB00264,__METOPROLOL,9504655,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,9.92217499332635,777.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.8,267.3639,50.72,4.0,2.0,1.0,31.9,76.7,9.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CCCN(CCC)CCc1cccc2c1CC(=O)N2,1,DB00268,__ROPINIROLE,5422123,Enrolling by Invitation,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,396.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.16,260.3746,32.34,2.0,1.0,2.0,31.19,81.43,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,ALCOHOL ABUSE,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC1(C)O[C@@H]2CO[C@@]3(COS(N)(=O)=O)OC(C)(C)O[C@H]3[C@@H]2O1,1,DB00273,__TOPIRAMATE,5998380,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,49.8080042711349,138.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.29,339.36199999999997,115.54,8.0,1.0,3.0,32.42,72.3,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CCCc1nc(C(C)(C)O)c(C(=O)O)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB00275,__OLMESARTAN,5616599,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.98,446.5016,129.81,7.0,3.0,4.0,47.46,137.32,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O,1,DB00277,__THEOPHYLLINE,3935196,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.26,180.16400000000002,69.3,3.0,1.0,2.0,16.86,44.93,0.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Terminated,NCT00414453,NEUROPATHIC PAIN|CHRONIC PAIN|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Rochester Medical Center, Rochester, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT03630198,KELOID|ALOPECIA AREATA|ACNE|HYPERTROPHIC SCAR|EPIDERMAL INCLUSION CYST|FRONTAL FIBROSING ALOPECIA|LICHEN PLANO-PILARIS|KERATOACANTHOMA|PLAQUE PSORIASIS|LICHEN SIMPLEX CHRONICUS|PRURIGO NODULARIS|NUMMULAR ECZEMA|GRANULOMA ANNULARE|MORPHEA|LICHEN PLANUS,All,"12 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCN(CC)CC(=O)Nc1c(C)cccc1C,1,DB00281,__LIDOCAINE,5234957,Recruiting,NCT04003012,LEUKEMIA-LYMPHOMA,All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Supportive Care,"CAMC - Women and Children's Hospital, Charleston, West Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,19.5815109139818,1859.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.81,234.3373,32.34,2.0,1.0,1.0,27.77,73.93,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1,1,DB00285,__VENLAFAXINE,5916923,Terminated,NCT01436643,DEPRESSION|RELAPSING-REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Achim, Germany|Novartis Investigative Site, Altenholz-Stift, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Honnef, Germany|Novartis Investigative Site, Baesweiler, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Butzbach, Germany|Novartis Investigative Site, Grevenbroich, Germany|Novartis Investigative Site, Heidenheim, Germany|Novartis Investigative Site, Klingenmünster, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Merzig, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Oberhausen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weil am Rhein, Germany|Novartis Investigative Site, Zwickau, Germany",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,26.678165876096,374.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.69,277.4018,32.7,3.0,1.0,2.0,32.33,83.02,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CNCC[C@@H](Oc1ccccc1C)c1ccccc1,1,DB00289,__ATOMOXETINE,5658590,Terminated,NCT00299234,ATTENTION DEFICIT HYPERACTIVITY DISORDER,All,"6 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Monarch Medical Research - Child and Adolescent Neurology, Norfolk, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,31.2449947637528,104.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.95,255.3547,21.26,2.0,1.0,2.0,29.79,79.44,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0
O=C(O)CCCc1ccc(N(CCCl)CCCl)cc1,1,DB00291,__CHLORAMBUCIL,4147767,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",A61K9/1658,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,18.070186246124106,5183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.81,304.212,40.54,3.0,1.0,1.0,31.98,79.68,9.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,1,DB00294,__ETONOGESTREL,5150718,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,7.490913571120548,417.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,324.4565,37.3,2.0,1.0,4.0,37.77,96.35,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3C(=C)C[C@@]21CC,1,DB00294,__ETONOGESTREL,5150718,Completed,NCT02357368,HIV|CONTRACEPTION,Female,18 Years to 45 Years   (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Grady Health System, Atlanta, Georgia, United States|The Ponce de Leon Center of the Grady Health System, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinical Research Network, Atlanta, Georgia, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,7.490913571120548,417.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,324.4565,37.3,2.0,1.0,4.0,37.77,96.35,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5,1,DB00295,__MORPHINE,5378474,Unknown status,NCT02135055,INFLAMMATORY DISORDER OF IMMUNE SYSTEM|SEPSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/5078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,22.3413211770262,2179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.99,285.3377,52.93,4.0,2.0,5.0,29.94,80.12,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C,1,DB00297,__BUPIVACAINE,8182835,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,85.6855376907123,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.2,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Terminated,NCT00998582,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hennepin County Medical Center, Minneapolis, Minnesota, United States|Abbott Northwestern Hospital and Clinics, Minneapolis, Minnesota, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Completed,NCT01458977,HIV|DYSLIPIDEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Valle Hebrón, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Completed,NCT04050371,HIV PREVENTION|TRANSGENDER HEALTH,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"San Francisco AIDS foundation, San Francisco, California, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Recruiting,NCT03058835,PREP ADHERENCE MONITORING,Female,18 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|New Jersey Medical School Clinical Research Center, Newark, New Jersey, United States|West Virginia University, Morgantown, West Virginia, United States",C07D411/04,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,"Active, not recruiting",NCT03771638,"ADHERENCE, MEDICATION|RISK BEHAVIOR|PRE-EXPOSURE PROPHYLAXIS|HIV PREVENTION",All,18 Years to 35 Years   (Adult),Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Emory University, School of Public Health, Atlanta, Georgia, United States",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C,1,DB00300,__TENOFOVIR_DISOPROXIL,5814639,"Active, not recruiting",NCT03120936,TRANSGENDER PERSONS|PRE-EXPOSURE PROPHYLAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Tri-City Health Center, Fremont, California, United States|Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Tom Waddell Urban Health Clinic, San Francisco, California, United States|San Francisco Community Health Clinic, San Francisco, California, United States|Castro-Mission Health Center, San Francisco, California, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,108.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,519.448,185.44,10.0,1.0,2.0,49.18,118.59,17.0,1.0,0.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
NC[C@H]1CC[C@H](C(=O)O)CC1,1,DB00302,__TRANEXAMIC_ACID,8273795,Recruiting,NCT03789422,CHRONIC SPONTANEOUS URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU Grenoble-Alpes, Grenoble, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,49.4137456621285,532.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.4,157.2102,63.32,3.0,2.0,1.0,17.28,41.9,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)Nc4cccc(C(=O)O)c4)C3)[C@H](C)[C@H]12,1,DB00303,__ERTAPENEM,5478820,Unknown status,NCT01159379,IGE-MEDIATED HYPERSENSITIVITY|ALLERGY,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Allergy Department, Catholic University of the Sacred Heart, Rome, Italy",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,26.7110207601798,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.2,475.515,156.27,8.0,5.0,4.0,48.77,121.8,7.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0
C=C(c1ccc(C(=O)O)cc1)c1cc2c(cc1C)C(C)(C)CCC2(C)C,1,DB00307,__BEXAROTENE,5780676,Completed,NCT01007448,REFRACTORY CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Florida Academic Dermatology Centers, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Rush University, Chicago, Illinois, United States|Tulane, New Orleans, Louisiana, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota Medical School, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Rochester, New York, United States|Duke University, Durham, North Carolina, United States|Wake Forest University Health, Winston-Salem, North Carolina, United States|University Hospitals-Case Medical Center, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt, Nashville, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute At the University of Utah, Salt Lake City, Utah, United States",C07C65/19,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,37.22458366701571,808.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.86,348.4779,37.3,2.0,1.0,3.0,40.89,117.12,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00309,__VINDESINE,,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00309,__VINDESINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.53,753.941,164.82,9.0,5.0,9.0,81.39,210.32,7.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CCCC(CCC)C(=O)O,1,DB00313,__VALPROIC_ACID,6419953,Terminated,NCT00854581,LYMPHOMA|PRECANCEROUS/NONMALIGNANT CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,42.9084786135238,1051.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.54,144.2114,37.3,2.0,1.0,0.0,17.0,40.25,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H]([C@H]2CCN=C(N)N2)NC(=O)/C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC1=O.NCCC[C@H](N)CC(=O)NC[C@@H]1NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@H]([C@H]2CCN=C(N)N2)NC(=O)/C(=C\NC(N)=O)NC1=O,1,DB00314,__CAPREOMYCIN,4026766,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07G11/00,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,12.846259676789998,513.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.2,1321.4123,378.42,14.0,14.0,4.0,65.97,162.2,19.0,1.0,0.0,0.0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,0,1,1,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CC(=O)Nc1ccc(O)cc1,1,DB00316,__ACETAMINOPHEN,5972916,Completed,NCT00377364,ASTHMA|RHEUMATIC DISEASE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,20.468592784246,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.51,151.1626,49.33,2.0,2.0,1.0,15.52,42.9,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@H]3[C@H]1C5,1,DB00327,__HYDROMORPHONE,5968551,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,50.7607959095669,1264.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.69,285.3377,49.77,4.0,1.0,5.0,30.02,78.26,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0
COc1ccc2c(c1)c(CC(=O)O)c(C)n2C(=O)c1ccc(Cl)cc1,1,DB00328,__INDOMETHACIN,8734847,Completed,,FAMILY PLANNING,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.981827142241096,3062.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,357.788,68.53,4.0,1.0,3.0,36.64,94.81,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",A61K9/0014,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown status,NCT02057796,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia|CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Yopougon, Côte D'Ivoire|ISS ImmunoSuppression Service, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Unknown status,NCT01782950,AIDS WITH TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Kampala, Uganda",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO,1,DB00330,__ETHAMBUTOL,5322689,Completed,NCT00002343,MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,27.3681184418571,286.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.12,204.3098,64.52,4.0,4.0,0.0,24.47,57.89,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02526615,INSULIN SENSITIVITY|TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turku PET Centre, Turku, Finland|Turku university hospital, PET center, Turku, Finland|Turku PET Centre (Turku University Hospital), Turku, Finland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01718093,TYPE 1 DIABETES,All,"13 Years to 18 Years   (Child, Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baylor College of Medicine, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01099618,KETOSIS PRONE DIABETES|DIABETES KETOACIDOSIS|HYPERGLYCEMIA,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Grady Memorial Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT03029390,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,31 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01612858,LIPODYSTROPHY|HIV INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,"Active, not recruiting",NCT03774108,PREDIABETES|HIV-1-INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Terminated,NCT00682890,POLYCYSTIC OVARY SYNDROME|PCOS|INSULIN SENSITIVITY,Female,18 Years to 45 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","General Clinical Research Center, Richmond, Virginia, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT00437333,PCOS,Female,20 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02733679,ATAXIA-TELANGIECTASIA,All,18 Years to 30 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ninewells Hospital, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03570632,"DIABETES MELLITUS, TYPE 1|PREGNANCY IN DIABETES",Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Magee Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States",4,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03513874,TYPE 1 DIABETES MELLITUS|AUTOIMMUNE DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03590262,TYPE 1 DIABETES MELLITUS|METFORMIN,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shenzhen People's Hospital, Shenzhen, Guangdong, China",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Withdrawn,NCT02881528,PREDIABETIC STATE,All,5 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NHS Ayrshire & Arran, Kilmarnock, Ayrshire, United Kingdom|NHS Grampian, Aberdeen, Grampian, United Kingdom|NHS Lanarkshire, Wishaw, Lanarkshire, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Recruiting,NCT03765359,DIABETIC PREGNANCY|INSULIN RESISTANCE|TYPE1DIABETES,Female,"Child, Adult, Older Adult",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Helsinki University Hospital, Helsinki, Finland|Central Finland Health Care District, Jyväskylä, Finland|Oulu University hospital, Oulu, Finland|Tampere University Hospital, Tampere, Finland|Turku University Hospital, Turku, Finland",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Unknown status,NCT03639545,"VASCULAR STIFFNESS|HYPOGLYCEMIC AGENTS|DIABETES COMPLICATIONS|DIABETES MELLITUS, TYPE 1",All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Centre Ljubljana, Ljubljana, Slovenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT02741960,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ethics Committee of Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Not yet recruiting,NCT04145687,LUPUS NEPHRITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Fangfang Sun, MD, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Completed,NCT01410604,OBESITY,All,"9 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Infantil de México Federico Gómez, México, Distrito Federal, Mexico|Hospital Regional de Alta Especialidad del Bajío, León, Guanajuato, Mexico",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CN(C)C(=N)NC(=N)N,1,DB00331,__METFORMIN,6288095,Active Not Recruiting,,HIV-1 INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,80.757305078133,88.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,129.1636,88.99,5.0,4.0,0.0,13.43,56.64,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",F04B53/125,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,COLD,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Completed,,EXERCISE-INDUCED BRONCHOSPASM,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2,1,DB00332,__IPRATROPIUM,5964416,Not Yet Recruiting,,ASTHMA IN CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",F04B53/125,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.89,332.463,46.53,2.0,1.0,3.0,37.57,105.9,6.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Recruiting,NCT03089983,OPIOID DEPENDENCE|ADDICTION|HIV/AIDS|TUBERCULOSIS|HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Kajang Prison, Kajang, Selangor, Malaysia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,NCT01733693,OPIOID-RELATED DISORDERS|HIV|HIV INFECTIONS,All,"18 Years to 68 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fordham University, The Bronx, New York, United States|Albert Einstein College of Medicine of Yeshiva University, The Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,NCT01936857,HIV|SUBSTANCE RELATED DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bac Giang PAC OPC, Bac Giang, Vietnam|Dong Da OPC, Hanoi, Vietnam|Hoang Mai HIV Clinic, Hanoi, Vietnam|Long Bien, Hanoi, Vietnam|Tu Liem, Hanoi, Vietnam|Thanh Hoa PAC OPC, Thanh Hoa, Vietnam",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,NCT02396979,HUMAN IMMUNODEFICIENCY VIRUS|ACQUIRED IMMUNODEFICIENCY SYNDROME|OPIATE ADDICTION|DRUG DEPENDENCE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Active Not Recruiting,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1,1,DB00333,__METHADONE,3947592,Completed,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,46.2596767900778,1074.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,309.4452,20.31,2.0,0.0,2.0,36.28,97.27,7.0,0.0,1.0,0.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT00895921,DIABETES,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"VA San Diego Healthcare System, San Diego, California, United States",C07D495/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1cc2c(s1)Nc1ccccc1N=C2N1CCN(C)CC1,1,DB00334,__OLANZAPINE,5229382,Completed,NCT00190749,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,13.9304708515575,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,312.432,30.87,4.0,1.0,4.0,35.37,93.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)NCC(O)COc1ccc(CC(N)=O)cc1,1,DB00335,__ATENOLOL,4256108,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61F9/0017,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,66.0,21.8813527998521,533.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,266.3361,84.58,4.0,3.0,1.0,29.98,73.51,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00337,__PIMECROLIMUS,5912238,Completed,NCT00666302,"DERMATITIS, ATOPIC",All,"16 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Francisco, California, United States|Kansas City, Kansas, United States|Ann Arbor, Michigan, United States|St Louis, Missouri, United States|New York, New York, United States|Winston-Salem, North Carolina, United States|Cincinnati, Ohio, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|Norfolk, Virginia, United States|Halifax, Nova Scotia, Canada|Halifax, Nova Scotia, Canada",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,58.9088071623647,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,810.46,158.13,10.0,2.0,4.0,87.79,214.03,6.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00337,__PIMECROLIMUS,5912238,Completed,NCT00120302,ATOPIC DERMATITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","This study is not being conducted in the United States, Novartis Pharmaceuticals UK, Frimley, United Kingdom",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,58.9088071623647,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,810.46,158.13,10.0,2.0,4.0,87.79,214.03,6.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00337,__PIMECROLIMUS,5912238,Completed,NCT00484003,ATOPIC ECZEMA,All,2 Years to 12 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigative Sites, Various Cities, South Africa",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,58.9088071623647,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,810.46,158.13,10.0,2.0,4.0,87.79,214.03,6.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@H](Cl)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00337,__PIMECROLIMUS,5912238,Completed,,MILD TO MODERATE ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D498/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,58.9088071623647,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,810.46,158.13,10.0,2.0,4.0,87.79,214.03,6.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,NCT02552537,FOOD ALLERGY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Hospital Clinico San Carlos, Madrid, Spain|University Hospital Zurich, Zurich, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Active Not Recruiting,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TOLERANCE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
COc1ccc2nc(S(=O)Cc3ncc(C)c(OC)c3C)[nH]c2c1,1,DB00338,__OMEPRAZOLE,5690960,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,37.94739111686071,294.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,37.45,93.66,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown status,NCT02057796,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia|CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Yopougon, Côte D'Ivoire|ISS ImmunoSuppression Service, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Completed,NCT00402610,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Universitario Reina Sofía, Córdoba, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown status,NCT01782950,AIDS WITH TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Kampala, Uganda",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NC(=O)c1cnccn1,1,DB00339,__PYRAZINAMIDE,,Unknown Status,,HEPATITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,123.1127,68.87,3.0,1.0,1.0,11.13,30.45,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00561717,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT02543346,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","Biogenics Research Chamber, San Antonio, Texas, United States|Kingston General Hospital, Kingston, Ontario, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01916226,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Aventura, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lenexa, Kansas, United States|GSK Investigational Site, Overland Park, Kansas, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, Saint Louis, Missouri, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01940393,URTICARIA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medellin, Medellin, Antioquia, Colombia",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,NCT00240032,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,ALLERGIES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,PERENNIAL ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00341,__CETIRIZINE,6469009,Completed,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,78.45746319226271,145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.98,388.88800000000003,53.01,5.0,1.0,3.0,41.88,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
COc1ccc([C@@H]2Sc3ccccc3N(CCN(C)C)C(=O)[C@@H]2OC(C)=O)cc1,1,DB00343,__DILTIAZEM,5286497,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,9.363641963900688,2015.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.09,414.51800000000003,59.08,4.0,0.0,3.0,43.65,114.37,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1
Nc1ccc(C(=O)NCC(=O)O)cc1,1,DB00345,__AMINOHIPPURIC_ACID,4292154,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N27/44747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,194.1873,92.42,4.0,3.0,1.0,19.13,50.82,3.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00351,__MEGESTROL_ACETATE,5145684,Completed,NCT00002345,ANOREXIA|CACHEXIA|HIV INFECTIONS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Primary Purpose: Treatment,"Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States|Yale Univ Med School, New Haven, Connecticut, United States|Georgetown Univ Med Ctr, Washington, District of Columbia, United States|Miriam Hosp, Providence, Rhode Island, United States",B82Y5/00,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,19.450091377646306,2187.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.71,384.51599999999996,60.44,3.0,0.0,4.0,43.51,108.66,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,1,DB00359,__SULFADIAZINE,3960661,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",C12P19/40,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,14.193309924228402,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.25,250.27700000000002,97.97,5.0,2.0,2.0,24.39,64.2,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1,1,DB00359,__SULFADIAZINE,3960661,Completed,NCT00367081,TOXOPLASMIC ENCEPHALITIS|AIDS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"Chiang Mai University hospital (2003-2004), Chiang Mai, Thailand",C12P19/40,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,14.193309924228402,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.25,250.27700000000002,97.97,5.0,2.0,2.0,24.39,64.2,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,1,DB00367,__LEVONORGESTREL,5785053,Terminated,NCT02531321,CONTRACEPTION|HIV,Female,18 Years to 45 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States",A61F6/18,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.831906199305902,883.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,312.4458,37.3,2.0,1.0,4.0,36.73,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,1,DB00367,__LEVONORGESTREL,5785053,Completed,NCT02357368,HIV|CONTRACEPTION,Female,18 Years to 45 Years   (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Grady Health System, Atlanta, Georgia, United States|The Ponce de Leon Center of the Grady Health System, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinical Research Network, Atlanta, Georgia, United States",A61F6/18,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,13.831906199305902,883.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,312.4458,37.3,2.0,1.0,4.0,36.73,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,1,DB00367,__LEVONORGESTREL,5785053,Completed,NCT00570440,PREGNANCY PREVENTION,Female,18 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"PROFAMILIA - Santo Domingo, Dominican Republic, Ens. Luperon, Santo Domingo, Dominican Republic|PROFAMILIA - Managua, Nicaragua, Managua, Nicaragua",A61F6/18,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.831906199305902,883.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,312.4458,37.3,2.0,1.0,4.0,36.73,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
Nc1ccn(C[C@@H](CO)OCP(=O)(O)O)c(=O)n1,1,DB00369,__CIDOFOVIR,5142051,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",C07F9/6512,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.0,61.3072137004866,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,279.187,145.68,8.0,4.0,1.0,24.44,60.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
CN1CCN2c3ncccc3Cc3ccccc3C2C1,1,DB00370,__MIRTAZAPINE,5178878,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,8.903673586726619,166.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.9,265.3529,19.37,3.0,0.0,4.0,30.35,82.66,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1
CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,1,DB00373,__TIMOLOL,5231095,Withdrawn,NCT01927406,THYROID EYE DISEASE|OCULAR HYPERTENSION|GLAUCOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Stanford Hospital and Clinics, Stanford, California, United States",C07D285/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,27.2695537896055,870.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.44,316.42,79.74,7.0,2.0,2.0,33.86,83.92,7.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1
O=C1c2cccc3c2[C@H](CCC3)CN1[C@@H]1CN2CCC1CC2,1,DB00377,__PALONOSETRON,5202333,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",C07D471/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,50.0,22.7355797860325,147.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,296.414,23.55,2.0,0.0,5.0,33.9,88.52,1.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1c1ccccc1Cl,1,DB00381,__AMLODIPINE,6162802,Completed,NCT00741078,HYPERTENSION,All,"25 Years to 75 Years   (Adult, Older Adult)",Other,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,"Gil Medical Center, Incheon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,172.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.22,408.876,99.88,5.0,2.0,2.0,42.31,108.64,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,1,DB00394,__BECLOMETHASONE_DIPROPIONATE,5776432,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,37.22458366701571,676.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.69,521.0419999999998,106.97,5.0,1.0,4.0,54.41,134.79,8.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@@]21C,1,DB00394,__BECLOMETHASONE_DIPROPIONATE,5776432,Completed,NCT00395408,ASTHMA,All,6 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,37.22458366701571,676.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.69,521.0419999999998,106.97,5.0,1.0,4.0,54.41,134.79,8.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CC(=O)[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB00396,__PROGESTERONE,5543150,Completed,NCT02970552,PRETERM BIRTH,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Kamwala District Health Centre, Lusaka, Zambia",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,23.0,34.694757592558304,3548.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.58,314.4617,34.14,2.0,0.0,4.0,37.26,92.71,1.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1,1,DB00398,__SORAFENIB,7351834,Completed,NCT02961998,HEPATOCELLULAR CARCINOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D209/46,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,98.630362019754,1553.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,464.825,92.35,3.0,3.0,3.0,41.11,114.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00795483,HIV INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00029224,BREAST CANCER|MULTIPLE MYELOMA|PROSTATE CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stockton Hematology Oncology Medical Group, Stockton, California, United States|Osceola Cancer Center, Kissimmee, Florida, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Hematology-Oncology Associates PC, Albuquerque, New Mexico, United States|New Mexico Oncology Hematology Consultants, Albuquerque, New Mexico, United States|Hematology Oncology Associates, PC, Medforo, Oregon, United States|Virginia Physicians, Inc, Richmond, Virginia, United States",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Recruiting,NCT02286830,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Odense University Hospital, Odense C, Denmark",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00434447,BONE NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Novartis Investigative Site, Canberra, Australian Capital Territory, Australia|Novartis Investigative Site, Concord, New South Wales, Australia|Novartis Investigative Site, Liverpool, New South Wales, Australia|Novartis Investigative Site, Wagga Wagga, New South Wales, Australia|Novartis Investigative Site, Redcliffe, Queensland, Australia|Novartis Investigative Site, Townsville, Queensland, Australia|Novartis Investigative Site, Woolloongabba, Queensland, Australia|Novartis Investigative Site, Ballarat, Victoria, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Frankston, Victoria, Australia",C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Completed,NCT00219219,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bologna, Bologna, Italy",C07F9/65031,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
O=P(O)(O)C(O)(Cn1ccnc1)P(=O)(O)O,1,DB00399,__ZOLEDRONIC_ACID,4939130,Not yet recruiting,NCT04115397,SEROPOSITIVE MUSKULOSKELETAL COMPLAINTS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07F9/65031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,16.1317480851762,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.93,272.0896,153.11,8.0,5.0,1.0,20.1,52.16,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1c1ccccc1[N+](=O)[O-],1,DB00401,__NISOLDIPINE,5422123,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2086,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.468592784246,168.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.63,388.4144,110.45,5.0,1.0,2.0,39.72,105.91,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CN1CCN(C(=O)O[C@H]2c3nccnc3C(=O)N2c2ccc(Cl)cn2)CC1,1,DB00402,__ESZOPICLONE,6319926,Completed,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,39.754409741473104,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.97,388.80800000000005,91.76,6.0,0.0,4.0,37.67,95.89,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
Cc1nnc2n1-c1ccc(Cl)cc1C(c1ccccc1)=NC2,1,DB00404,__ALPRAZOLAM,6024981,Completed,,PANIC DISORDER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,762.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.23,308.765,43.07,3.0,0.0,4.0,32.22,98.88,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,NCT00801879,STAPHYLOCOCCUS AUREUS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Project Samaritan Inc., Bronx, New York, United States|Columbia University, New York, New York, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,NCT00179959,ATOPIC DERMATITIS,All,6 Months to 17 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Childrens Memorial Hospital, Chicago, Illinois, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Active Not Recruiting,,STAPHYLOCOCCUS AUREUS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
C/C(=C\C(=O)OCCCCCCCCC(=O)O)C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O,1,DB00410,__MUPIROCIN,6013657,Completed,,CHRONIC RHINOSINUSITIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.135896014291802,384.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.25,500.6222,146.05,8.0,4.0,2.0,55.5,129.39,17.0,1.0,0.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT02526615,INSULIN SENSITIVITY|TYPE 2 DIABETES,All,"40 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Turku PET Centre, Turku, Finland|Turku university hospital, PET center, Turku, Finland|Turku PET Centre (Turku University Hospital), Turku, Finland",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00372086,TYPE 1 DIABETES|PUBERTY: >TANNER 2 BREAST DEVELOPMENT OR TESTIS >4ML,All,"10 Years to 18 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Sydney Children's Hospital, Sydney, New South Wales, Australia",C07D277/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,NCT00746174,INSULIN SENSITIVITY,All,"30 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States",C07D277/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,IMPAIRED GLUCOSE TOLERANCE,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CN(CCOc1ccc(CC2SC(=O)NC2=O)cc1)c1ccccn1,1,DB00412,__ROSIGLITAZONE,5002953,Completed,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,55.0,14.9161173740733,175.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,357.42699999999996,71.53,5.0,1.0,3.0,37.8,97.79,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCCN[C@H]1CCc2nc(N)sc2C1,1,DB00413,__PRAMIPEXOLE,4886812,Not Yet Recruiting,,CIRCADIAN RHYTHM DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/82,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,13.996180619725196,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.18,211.327,50.94,3.0,2.0,2.0,24.47,59.77,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00415,__AMPICILLIN,3931150,Completed,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2488141440275,1774.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.88,349.405,112.73,5.0,3.0,3.0,34.54,87.52,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)COc3ccccc3)C(=O)N2[C@H]1C(=O)O,1,DB00417,__PHENOXYMETHYLPENICILLIN,4046759,Recruiting,,INFECTIOUS DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D499/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,24.411178874309503,110.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,350.39,95.94,5.0,2.0,3.0,34.37,85.77,5.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO,1,DB00419,__MIGLUSTAT,5472969,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,13.766196431138198,165.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-1.1,219.278,84.16,5.0,4.0,1.0,23.99,55.74,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,NCT00335413,HYPERTENSION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]2CC[C@@]3(C)[C@@H](CC[C@@]34CCC(=O)O4)[C@@H]21,1,DB00421,__SPIRONOLACTONE,9757394,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,10.480708022752,601.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.1,416.57300000000004,60.44,3.0,0.0,5.0,46.03,113.5,2.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/585,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)C(c1ccccc1)C1CCCCN1,1,DB00422,__METHYLPHENIDATE,5958446,Completed,NCT00576472,ACUTE LYMPHOBLASTIC LEUKEMIA|BRAIN TUMORS,All,"6 Years to 18 Years   (Child, Adult)",Other|NIH,"Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Supportive Care","Duke University Medical Center, Durham, North Carolina, United States|Medical University of South Carolina, Charleston, South Carolina, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States",A61L15/585,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,75.0,52.83065360685021,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.21,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,1,DB00425,__ZOLPIDEM,6761910,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.158873898848,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,307.3895,37.61,2.0,0.0,3.0,35.06,93.58,3.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0
CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,1,DB00426,__FAMCICLOVIR,5246937,Completed,,GENITAL HERPES,,,,,"FISABIO, Elche, Alicante, Spain",C07C69/007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,19.975769522988106,547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,321.3318,122.22,6.0,1.0,2.0,32.83,81.54,9.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1
Oc1ncnc2[nH]ncc12,1,DB00437,__ALLOPURINOL,8084483,Completed,NCT02829177,TYPE 1 DIABETES|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Steno Diabetes Center, Gentofte, Denmark",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,36.994599478428704,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.41,136.1115,74.69,4.0,2.0,2.0,11.7,34.98,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC,1,DB00440,__TRIMETHOPRIM,5763449,Recruiting,NCT03042260,"LUPUS ERYTHEMATOSUS, SYSTEMIC",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico Distrito Federal, DF, Mexico",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,22.045627220271395,888.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.26,290.3177,105.51,7.0,2.0,2.0,29.71,81.51,5.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Unknown status,NCT01501136,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,1,DB00441,__GEMCITABINE,4808614,Recruiting,NCT04040491,PERIPHERAL T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D317/30,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,20.8628513932524,1700.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.14,263.1981,108.38,6.0,3.0,2.0,21.45,53.25,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,Completed,NCT00662545,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General HIV Clinical Trials Group, San Francisco, California, United States",C07D239/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,Unknown status,NCT03062813,HEPATITIS B VIRUS ASSOCIATED NEPHROTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China",C07D239/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,"Active, not recruiting",NCT01907230,RHEUMATOID ARTHRITIS|HEPATITIS B REACTIVATION|EXPOSURE TO HEPATITIS B VIRUS,All,"20 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Division of Gastroenterology & Division of Allergy Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan",C07D239/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)nc(N)[nH]c32)C[C@H](O)[C@H]1CO,1,DB00442,__ENTECAVIR,5206244,Completed,NCT00926757,NON HODGKIN'S LYMPHOMA|HEPATITIS B,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei, Taiwan",C07D239/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,19.220107189059306,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,277.2792,125.76,7.0,4.0,3.0,27.31,71.0,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Recruiting,NCT04114097,ATOPIC DERMATITIS|ATOPIC ECZEMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Department of Dermatology and Allergy, Hellerup, Region Hovedstaden, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00963573,RHINITIS,All,6 Years to 12 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Completed,NCT00209859,RHEUMATOID ARTHRITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hvidovre University Hospital, Hvidovre, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB00443,__BETAMETHASONE,6126920,Unknown status,NCT03215407,RHEUMATOID ARTHRITIS OF KNEE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.6906096634427,1325.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.81,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](c6cccs6)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00444,__TENIPOSIDE,4766149,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,2806.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,656.654,160.83,12.0,3.0,8.0,64.83,155.61,6.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1,1,DB00445,__EPIRUBICIN,4950738,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",A61K41/0042,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.5387790303702,4375.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.88,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,1,DB00448,__LANSOPRAZOLE,4628098,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",C07D213/68,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,16.3617322737633,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.361,67.87,4.0,1.0,3.0,34.59,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,1,DB00451,__LEVOTHYROXINE,6399101,Withdrawn,NCT01276782,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,18 Years to 45 Years   (Adult),Other,"Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Johns Hopkins University, Baltimore, Maryland, United States",A61K9/2009,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,26.1524877307542,1921.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.15,776.87,92.78,4.0,3.0,2.0,49.4,126.79,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02932774,"ALLERGIC RHINITIS|HAY FEVER|SAR|RHINITIS, ALLERGIC, SEASONAL",All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,1,DB00455,__LORATADINE,6132758,Completed,NCT00730912,PERENNIAL ALLERGIC RHINITIS,All,"3 Years to 64 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,28.5508942688761,219.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.8,382.88300000000004,42.43,2.0,0.0,4.0,41.67,116.98,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC,1,DB00457,__PRAZOSIN,4130647,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,17.380233680363,616.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.93,383.4011,106.95,7.0,1.0,4.0,40.49,104.5,4.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,1,DB00465,__KETOROLAC,5110493,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",A61K9/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,16.920265303188902,1024.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.66,255.2686,59.3,3.0,1.0,3.0,26.67,70.19,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0
C=C[C@H]1CN2CC[C@H]1C[C@H]2[C@H](O)c1ccnc2ccc(OC)cc12,1,DB00468,__QUININE,3960559,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",H01L23/291,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,31.507833836423696,2213.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,324.4168,45.59,4.0,1.0,4.0,35.96,94.69,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0
CN1C(C(=O)Nc2ccccn2)=C(O)c2sccc2S1(=O)=O,1,DB00469,__TENOXICAM,4636498,Unknown Status,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,16.953120187272805,1159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.42,337.37,99.6,5.0,2.0,3.0,31.96,83.93,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Withdrawn,NCT02569073,ESOPHAGEAL DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Temple University Hospital, Philadelphia, Pennsylvania, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Completed,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,1,DB00470,__DRONABINOL,6703418,Completed,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,141.17743690835502,1151.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.29,314.4617,29.46,2.0,1.0,3.0,38.96,96.73,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT00488176,SEASONAL ALLERGIC RHINITIS,All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Department of Pediatrics and Allergy, Medical University of Lodz Lodz, Poland, Lodz, Poland",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00092092,BRONCHIAL ASTHMA,All,6 Years to 11 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02410278,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Research Site, Jonesboro, Arkansas, United States|Research Site, Carmichael, California, United States|Research Site, La Jolla, California, United States|Research Site, La Mesa, California, United States|Research Site, Pomona, California, United States|Research Site, Simi Valley, California, United States|Research Site, Aurora, Colorado, United States|Research Site, Colorado Springs, Colorado, United States|Research Site, Fairfield, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Jacksonville, Florida, United States|Research Site, Naples, Florida, United States|Research Site, Ormond Beach, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Rome, Georgia, United States|Research Site, Smyrna, Georgia, United States|Research Site, Chicago, Illinois, United States|Research Site, Flossmoor, Illinois, United States|Research Site, Indianapolis, Indiana, United States|Research Site, Louisville, Kentucky, United States|Research Site, Scarborough, Maine, United States|Research Site, Farmington Hills, Michigan, United States|Research Site, Chesterfield, Missouri, United States|Research Site, Kansas City, Missouri, United States|Research Site, Saint Louis, Missouri, United States|Research Site, Freehold, New Jersey, United States|Research Site, Amherst, New York, United States|Research Site, New York, New York, United States|Research Site, Patchogue, New York, United States|Research Site, Hendersonville, North Carolina, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Sanford, North Carolina, United States|Research Site, Winston-Salem, North Carolina, United States|Research Site, Dayton, Ohio, United States|Research Site, Dayton, Ohio, United States|Research Site, Uniontown, Ohio, United States|Research Site, Oklahoma City, Oklahoma, United States|Research Site, Portland, Oregon, United States|Research Site, Tualatin, Oregon, United States|Research Site, Dickson City, Pennsylvania, United States|Research Site, Greensburg, Pennsylvania, United States|Research Site, Hershey, Pennsylvania, United States|Research Site, Wilkes-Barre, Pennsylvania, United States|Research Site, Nashville, Tennessee, United States|Research Site, Dallas, Texas, United States|Research Site, Round Rock, Texas, United States|Research Site, Alexandria, Virginia, United States|Research Site, Newport News, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Madison, Wisconsin, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00295022,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston, Ontario, Canada",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00590772,PERENNIAL ALLERGIC RHINITIS,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT03380975,ASTHMA AND ALLERGIC RHINITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dr. Faisal Faiyaz Zuberi, Karachi, Sindh, Pakistan",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT03369119,ACUTE ASTHMA|ACUTE WHEEZY BRONCHITIS,All,6 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Keçiören, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00559546,SEASONAL ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS|ATOPIC ECZEMA|ASTHMA,All,18 Years to 40 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT02534467,"DERMATITIS, ATOPIC",All,6 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The Royal Children's Hospital, Parkville, Victoria, Australia",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00557284,ATOPIC DERMATITIS,All,1 Year to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","1st Allergy & Clinical Research Centers, Centennial, Colorado, United States|1st Allergy & Clinical Research Centers, Thornton, Colorado, United States",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01618929,BRONCHIAL ASTHMA|FOOD ALLERGY|CHILDREN,All,"6 Years to 18 Years   (Child, Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cansin Sackesen, Ankara, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01304901,ASTHMA|ACUTE ASTHMA,All,6 Months to 5 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Keçiören, Turkey",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01147510,PERSISTENT ASTHMA|ELDERLY,All,"60 Years to 75 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ajou University Medical Center, Suwon, Korea, Republic of",A61K9/1623,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT01011452,ACUTE ASTHMA EXACERBATION,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Norfolk and Norwich University Hospital, Norwich, United Kingdom",A61K9/1623,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,NCT00935415,EXERCISE-INDUCED ASTHMA|ASTHMA,All,6 Years to 14 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pediatric Dept Hospital of Bolzano, Bolzano, Italy",A61K9/1623,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)O)CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1,1,DB00471,__MONTELUKAST,8007830,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1623,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,42.711349309020704,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.25,586.183,70.42,4.0,2.0,5.0,66.36,169.5,12.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,1,DB00472,__FLUOXETINE,5945416,Terminated,NCT01436643,DEPRESSION|RELAPSING-REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Achim, Germany|Novartis Investigative Site, Altenholz-Stift, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Honnef, Germany|Novartis Investigative Site, Baesweiler, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Butzbach, Germany|Novartis Investigative Site, Grevenbroich, Germany|Novartis Investigative Site, Heidenheim, Germany|Novartis Investigative Site, Klingenmünster, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Merzig, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Oberhausen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weil am Rhein, Germany|Novartis Investigative Site, Zwickau, Germany",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,29.2408468346372,587.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.09,309.3261,21.26,2.0,1.0,2.0,30.33,80.37,7.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1
CNCCC(Oc1ccc(C(F)(F)F)cc1)c1ccccc1,1,DB00472,__FLUOXETINE,5945416,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,29.2408468346372,587.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.09,309.3261,21.26,2.0,1.0,2.0,30.33,80.37,7.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1
C=CCC1(C(C)C#CCC)C(=O)NC(=O)N(C)C1=O,1,DB00474,__METHOHEXITAL,4126684,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.425532351793603,204.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.43,262.3043,66.48,3.0,1.0,1.0,27.4,71.51,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,NEUROPATHIC PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNCC[C@H](Oc1cccc2ccccc12)c1cccs1,1,DB00476,__DULOXETINE,5023269,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D333/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,51.0,14.4890038809831,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.72,297.415,21.26,2.0,1.0,3.0,33.15,87.73,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,1,DB00477,__CHLORPROMAZINE,3976763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/539,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,15.8360541284215,1011.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,318.8640000000001,6.48,2.0,0.0,3.0,35.1,93.76,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O,1,DB00479,__AMIKACIN,7718189,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,79.0,57.95601552393271,878.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-3.2,585.6025,331.94,17.0,13.0,3.0,58.06,129.84,10.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT04038411,NK/T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,,NEWLY DIAGNOSED MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
Nc1cccc2c1CN(C1CCC(=O)NC1=O)C2=O,1,DB00480,__LENALIDOMIDE,5635517,Recruiting,NCT04040491,PERIPHERAL T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D401/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,10.3164336023326,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.43,259.2606,92.5,4.0,2.0,3.0,25.55,68.3,1.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
O=C(c1ccc(OCCN2CCCCC2)cc1)c1c(-c2ccc(O)cc2)sc2cc(O)ccc12,1,DB00481,__RALOXIFENE,5393763,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,13.5362122425511,440.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.45,473.583,70.0,5.0,2.0,5.0,52.55,135.48,7.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00346216,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carol M. Johnson MD, LLC, Alabaster, Alabama, United States|Orthopaedics West, Bessemer, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Simon Williamson Clinic/Clinical Research Advantage, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Cahaba Research Inc., Birmingham, Alabama, United States|Winston Technology Inc., Haleyville, Alabama, United States|Clinical Research Consultants, Inc, Hoover, Alabama, United States|Medical Affiliated Research Center, Incorporated, Huntsville, Alabama, United States|Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States|Montgomery Rheumatology Associates, Montgomery, Alabama, United States|James P. Beretta, PC, Pelham, Alabama, United States|Alabama Clinical Research Associates, Pell City, Alabama, United States|Pell City Internal and Family Medicine, Pell City, Alabama, United States|Scottsboro Quick Care Clinic, Scottsboro, Alabama, United States|Clinic for Rheumatic Diseases, Tuscaloosa, Alabama, United States|Terence T. Hart , MD, Tuscumbia, Alabama, United States|Clinical Research Advantage Inc./ Warner Family Practice, PC, Chandler, Arizona, United States|ArthroCare, Arthritis Care & Research P.C., Gilbert, Arizona, United States|Clinical Research Advantage Inc., /Thunderbird Internal Medicine, Glendale, Arizona, United States|Arizona Center for Clinical Research, Glendale, Arizona, United States|Clinical Research Advantage, Inc./ Lenzmeier Family Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Novara Clinical Research, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Mesa, Arizona, United States|Sun Valley Arthritis Center, Limited, Peoria, Arizona, United States|Lovelace Scientific Resources, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./ Family Practice Specialists, LTD, Phoenix, Arizona, United States|NPHC Research, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Precision Trials AZ. LLC; AZ, Phoenix, Arizona, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Southwest Health Ltd., Scottsdale, Arizona, United States|Advanced Arthritis Care and Research, Scottsdale, Arizona, United States|Arizona Pain Specialist, PLLC, Scottsdale, Arizona, United States|Sonora Quest Laboratories, Scottsdale, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc./Skyline Medical Center PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Warner Family Practice, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc/Manning Family Care, Tempe, Arizona, United States|Clinical Research Advantage, Incl Colorado Springs Health Partners, East, Tempe, Arizona, United States|Family Medicine Associates/Clinical Research Advantage, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC, Tempe, Arizona, United States|ARA-Arizona Research Associates, Tucson, Arizona, United States|Canyon Clinical Research LLC, Tucson, Arizona, United States|Tucson Clinical Researh, Tucson, Arizona, United States|ACRC/Arizona Clinical Research Center, Incorporated, Tucson, Arizona, United States|Clinical Research Advantage, Inc./ Orange Grove Family Practice, Tucson, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Fayetteville Diagnostic Clinic Limited, Fayetteville, Arkansas, United States|Hearne Family Practice Clinic, Little Rock, Arkansas, United States|Larry S. Watkins, M.D., Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Rx Medical Research of AR, Little Rock, Arkansas, United States|Anaheim Family Medical Center, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Advanced Arthritis & Rheumatology Center, Artesia, California, United States|Bina Akamdar MD, Azusa, California, United States|Rx for Life, Inc, Bell, California, United States|Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad, Carlsbad, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Northern California Research, Carmichael, California, United States|CORE Orthopaedic Medical Center, Encinitas, California, United States|Arthritis Medical Clinic of North County, Inc., Escondido, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Valley Research, Fresno, California, United States|Creekside Clinical Research, Greenbrae, California, United States|C. V. Mehta, MD Medical Corporation, Hemet, California, United States|Talbert Medical Group, Huntington Beach, California, United States|Alia Clinical Research, Inc, Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Lindora Research Center, Irvine, California, United States|Office of Dr. Robert L. Freed, MD, Irvine, California, United States|Office of Dr. Alan Schenk, Laguna Hills, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Jeremy Anuntiyo, Lakewood, California, United States|Premiere Clinical Research, LLC, Lakewood, California, United States|Stuart J. Finkelstein, Lakewood, California, United States|Clinical Trials Research, Lincoln, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Narbonne Multi-Specialty Medical Group Inc., Lomita, California, United States|Office of Dr. Arvind J. Mehta, Long Beach, California, United States|Pacific Internal Medicine Group, Inc, Long Beach, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|National Institute of Clinical Research, Long Beach, California, United States|Alliance Research, LLC, Long Beach, California, United States|Valerius Medical Group and Research Center, Los Alamitos, California, United States|IMD Medical Group, Los Angeles, California, United States|Pacific Arthritis Care Center, Los Angeles, California, United States|Wagdy W. Kades, MD, Inc., Los Angeles, California, United States|Samaritan Center for Medical Research Medical Group, Los Gatos, California, United States|Office of Lewis Gamarra, MD M.P.H., Los Osos, California, United States|Adegbenga A. Adetola, M.D., Lynwood, California, United States|Facey Medical Group, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Desert Medical Group, Palm Springs, California, United States|The Office of Dr. Marcos Yang, Palos Verdes Estates, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Sierra Rheumatology, Roseville, California, United States|Center for Clinical Trials of Sacramento, Inc., Sacramento, California, United States|Sacramento Heart and Vascular Research Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|San Diego Arthritis Medical Clinic, San Diego, California, United States|Wetlin Research Associates, Inc, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|San Jose Valley Research, Inc., San Jose, California, United States|Comprehensive Adult Risk Evaluation, San Leandro, California, United States|East Bay Rheumatology Medical Group Inc, San Leandro, California, United States|Central Coast Pathology Consultants, San Luis Obispo, California, United States|Coastal Medical Research Group, Inc., San Luis Obispo, California, United States|Family Medical Center, San Luis Obispo, California, United States|Office of Ajay G. Meka, MD, Santa Ana, California, United States|Pacific Arthritis Center Medical Group, Santa Maria, California, United States|Orrin M. Troum & Medical Associates, Santa Monica, California, United States|Northern California Medical Associates, Santa Rosa, California, United States|Robert Simon, MD, Sherman Oaks, California, United States|St. Joseph Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Paradigm Clinical Research Institute, Inc., Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Inland Rheumatology and Osteoporosis Medical Group, Upland, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|Bayview Research Group, Valley Village, California, United States|Medvin Clinical Research, Van Nuys, California, United States|Center for Clinical Trials of San Gabriel, West Covina, California, United States|Agilence Arthritis and Osteoporosis Medical Center, Inc., Whittier, California, United States|Avalon Family Medical Group, Wilmington, California, United States|Darrell E. Gorman, MD, Arvada, Colorado, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Azmi Emil Farag, MD, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Colorado Springs Health Partners- East/Clinical Research Advantage, Colorado Springs, Colorado, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|Saint Luke's Medical Clinic, Fort Collins, Colorado, United States|New West Physicians, Golden, Colorado, United States|Ranch View Family Medicine, Highlands Ranch, Colorado, United States|Colorado Center for Bone Research PC, Lakewood, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Arthritis and Osteoporosis Center, PC, Hamden, Connecticut, United States|Robert Lang, MD, P.C., Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Office of Edward J. McDermott, Jr., MD, New London, Connecticut, United States|Orthopaedics Foundation for Active Lifestyles, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Arthritis Center of Connecticut, Waterbury, Connecticut, United States|Rheumatology Consultants of Delaware, Lewes, Delaware, United States|Office of Cynthia Morgan, MD, Washington, D.C., District of Columbia, United States|The Center for Rheumatology and Bone Research, Washington, D.C., District of Columbia, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|RASF - Clinical Research Center, Boca Raton, Florida, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Family Healthcare of Chipley, Chipley, Florida, United States|Health First Clinical Research Group, Inc., Chipley, Florida, United States|Southern Family Healthcare and Health First Research Group Inc., Chipley, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Alba Clinical Research, Clearwater, Florida, United States|Appletree Medical, Clearwater, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Rameshwar N. Mathur, MD, PA, Cocoa, Florida, United States|Nature Coast Clinical Research, LLC, Crystal River, Florida, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Omega Research Consultants, LLC, DeBary, Florida, United States|Physicians Research Alliance, LLC, DeBary, Florida, United States|Deerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States|Doctors Medical Center of Walton County, DeFuniak Springs, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Associates, LLC/Florida Orthopaedic Associates, P.A., DeLand, Florida, United States|Cohen Medical Associates, PA, Delray Beach, Florida, United States|Clark Family Medicine & Emerald Coast Research Group, Destin, Florida, United States|SJS Clinical Research, Inc, Destin, Florida, United States|Robert W. Levin MD, Dunedin, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|M&O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Maxine Hamilton, MD PA, Fort Lauderdale, Florida, United States|Holy Cross Medical Group Northridge Internal Medicine, Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Emerald Coast Mood & Memory, Fort Walton Beach, Florida, United States|White-Wilson Medical Center, PA, Fort Walton Beach, Florida, United States|Cardiology West, Gainesville, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|Southeastern Integrated Medical, PL, Gainesville, Florida, United States|Shands at the University of Florida, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Genetic Medical Research Corporation, Hialeah, Florida, United States|Direct Helpers Medical Center, Inc., Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Orthopaedic Associates of South Broward, P.A., Hollywood, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clincal Research, Jacksonville, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|Dr. Ricardo A. Bedoya, M.D., Jupiter, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Christopher Chappel, Kissimmee, Florida, United States|Florida Arthritis Center, LLC, Lake Mary, Florida, United States|Pedro Ylisastigui, MD, Lehigh Acres, Florida, United States|Adult Medicine Specialists, Longwood, Florida, United States|Genesis Research International, Longwood, Florida, United States|Doctors Inn, Madeira Beach, Florida, United States|Everest Medical Care and Palm Court Research Group, Marianna, Florida, United States|Panhandle Family Care Associates & Emerald Coast Research Group, Marianna, Florida, United States|The Doctor's Office, Marianna, Florida, United States|Health First Medical Group, Melbourne, Florida, United States|Holmes Regional Medical Center, Melbourne, Florida, United States|Pharmaceutical Research Associates, Merritt Island, Florida, United States|Orthopaedic Specialist of Miami Beach, Miami Beach, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Crystal Biomedical Research, LLC, Miami Lakes, Florida, United States|Pembroke Clinical Trials, Miami Lakes, Florida, United States|Homestead Associates in Research, Inc, Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|Miami International Cardiology Consultants, Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|The Center for Arthritis and Rheumatic Diseases, Miami, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|DC Health Clinical Trials, Miami, Florida, United States|School of Clinical Research USA, LLC, Miami, Florida, United States|Advance Medical Research Services, Corp, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Cardiology Group, Miami, Florida, United States|M & M Medical Center, Miami, Florida, United States|Office of Dr. Juvenal E. Martinez, MD, PA, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Jeffrey Alper M.D. Research, Naples, Florida, United States|Anchor Health Centers, Naples, Florida, United States|Medical Surgical Specialists, Physicians Regional Medical Center, Naples, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Magnolia Research Group, Inc., Ocala, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Southeastern Rehabilitation Medicine, Ocala, Florida, United States|Tequesta Research Group, Ocala, Florida, United States|CEC Research, INC., Ocoee, Florida, United States|Florida Heart Group, PA, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|DCT FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|DCT-FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|Arthur L. Hall MD PA, Orlando, Florida, United States|Block and Nation, PA, Oviedo, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Florida Med Center of Countryside, Palm Harbor, Florida, United States|Rene CaSanova Medical Office Inc, Pembroke Pines, Florida, United States|Boulevard Professional Centre, Pembroke Pines, Florida, United States|Research Physician Network Alliance, Pembroke Pines, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|South Florida Research Solutions, LLC, Pembroke Pines, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Sunbelt Research, LLC, Plantation, Florida, United States|Boca Raton Clinical Research, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Administrative Address: Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Edgar R. Blecker, MD, Sebastian, Florida, United States|Phoenix Clinical Research, LLC., Tamarac, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Soutwest Florida Clinical Research Center, Tampa, Florida, United States|Clinyx/Floria Cardiovascular, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|West Wind'r Research, Tampa, Florida, United States|Health Point Medical Group, Inc, Tampa, Florida, United States|Causeway Medical Clinic, Tampa, Florida, United States|Office of Alastair C. Kennedy, MD, Vero Beach, Florida, United States|Metabolic Research Institute, Incorporated, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Central Florida Primary Care, Winter Park, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|The Kaufmann Clinic, Atlanta, Georgia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Corp., Atlanta, Georgia, United States|Atlanta Vascular Research Foundation, Atlanta, Georgia, United States|Executive Health and Research Associates, Atlanta, Georgia, United States|Southern Clinical Research and Management, Inc. (SCRAM), Augusta, Georgia, United States|Masters of Clinical Research, Inc., Augusta, Georgia, United States|Amelia Medical Plaza, Bainbridge, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|Abdul Bari MD Inc, Cairo, Georgia, United States|Southern Clinical Research Management and Consulting, Cairo, Georgia, United States|North Georgia Rheumatology Group, PC, Duluth, Georgia, United States|United Osteoporosis Centers, Gainesville, Georgia, United States|North Georgia Rheumatology Group, PC, Lawrenceville, Georgia, United States|GCH Research Dr. G Craig Heigerick DO, Lilburn, Georgia, United States|Mercer University Mercer Medicine, Macon, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Marietta, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Atlanta Center for Clinical Research, Roswell, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Archibold Primary Care, Thomasville, Georgia, United States|Clinical Trial Providers, Inc., Tucker, Georgia, United States|VSC, Valdosta, Georgia, United States|Kaufmann Clinic, INC, Woodstock, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Orthopedic Health Care Clinic, Boise, Idaho, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Eagle's View Family Medicine, Boise, Idaho, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|CTL Research, Eagle, Idaho, United States|Women's Healthcare Associates P.A. dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|AMR Sakeena Research, Aurora, Illinois, United States|Arthur I Davida, MD PC, Bloomingdale, Illinois, United States|Cardiac Wellness Consultants, Chicago, Illinois, United States|Chicago Peripheral Nerve Center, Chicago, Illinois, United States|ICCT Research International Incorporated, Chicago, Illinois, United States|Claude Mandel Medical Center, Chicago, Illinois, United States|Windy City Orthopedics and Sports Medicine, Evanston, Illinois, United States|South Suburban Health Professional Group, Hazel Crest, Illinois, United States|Prairie Rheumatology Associates, SC, Joliet, Illinois, United States|Lake Zurich Family Treatment Center, Lake Zurich, Illinois, United States|Southern Illiniois Clinical Research Centre, O'Fallon, Illinois, United States|Speciality phhysicians of Illinois, LLC, Olympia Fields, Illinois, United States|Redhead Research Inc., DBA Research Associates of Central Illinois, Peoria, Illinois, United States|Trinity Medical Center, Rock Island, Illinois, United States|Rockford Health Physicians, Rockford, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Prairie Education & Research, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Robert D. Barnes, MD, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|Clinical Research Advantage/Family Medicine Associates, Evansville, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Internal Medicine Center of Northwest Indiana, P.C., Gary, Indiana, United States|Beacon Medical Group Rheumatology, Granger, Indiana, United States|American Health Network of IN, LLC, Greenfield, Indiana, United States|Diagnostic Rheumatology And Research, PC, Indianapolis, Indiana, United States|Investigators research Group, Indianapolis, Indiana, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States|Arthritis Associates of Southern Indiana, Jeffersonville, Indiana, United States|Research Institute of Middle America/River Cities Cardiology, Jeffersonville, Indiana, United States|Beacon Medical Group LaPorte, LaPorte, Indiana, United States|Cardiovascular Clinics, PC, Merrillville, Indiana, United States|Community Clinical Research Center, Muncie, Indiana, United States|Medical Specialists Clinical Research Center, Munster, Indiana, United States|Medical Specialists, Munster, Indiana, United States|Arthritis Associates of Southern Indiana, New Albany, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Physician's Clinic of Iowa, PC, Cedar Rapids, Iowa, United States|Ridge Family Practice, PC/Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Office of Jerrold V Flatt, Des Moines, Iowa, United States|Medical Associates Clinic, PC, Dubuque, Iowa, United States|Family Health Center of Waterloo, PC, Waterloo, Iowa, United States|Northeast IA Medical Education Foundation/Family Practice Center, Waterloo, Iowa, United States|Heartland Research Associates LLC, Arkansas City, Kansas, United States|Community House of Wellness, Kansas City, Kansas, United States|Associates Reseach Inc., Lansing, Kansas, United States|Radiant Research, Inc., Overland Park, Kansas, United States|International Clinical Research Institute, Inc, Overland Park, Kansas, United States|Arthritis Specialists of Greater KC, Overland Park, Kansas, United States|Pinnacle Medical Research, Overland Park, Kansas, United States|Quivira Internal Medicine, Overland Park, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Via Christi Clinic, Wichita, Kansas, United States|Howard L. Feinberg, D.O., Ashland, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Internal Medicine Research Association, Campbellsville, Kentucky, United States|Center for Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States|Arthritis Center of Lexington, Lexington, Kentucky, United States|Kentuckiana Center for Better Bone and Joint Health, Louisville, Kentucky, United States|KY Research PLLC., Louisville, Kentucky, United States|University Medical Associates, Louisville, Kentucky, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Office of Gaurang B. Shah,MD, PSC, Richmond, Kentucky, United States|Richmond Regional Research, Richmond, Kentucky, United States|Chandler Family Practice, Bossier City, Louisiana, United States|McFarland Family Clinic, Shreveport, Louisiana, United States|TFD Research, LLC, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|Central Maine Heart & Vascular Institute, Lewiston, Maine, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Health Trends Research, LLC, Baltimore, Maryland, United States|One Heart, LLC, Baltimore, Maryland, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Pa, Baltimore, Maryland, United States|Saint Agnes HealthCare Incorporated, Baltimore, Maryland, United States|Stephen R Smith, MD FACP, Baltimore, Maryland, United States|MidAtlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Peter A. Holt, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates PA, Bel Air, Maryland, United States|Shah Associates MD, LLC, Charlotte Hall, Maryland, United States|Cardiovascular Specialists, LLC, Columbia, Maryland, United States|Johns Hopkins University, Columbia, Maryland, United States|The Osteoporosis & Clinical Trials Center, Cumberland, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|The Spine & Joint Center, Greenbelt, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|Community Health Research, North East, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Shah Associates, Prince Frederick, Maryland, United States|Cardiac Associates, Shady Grove Adventist Hospital, Rockville, Maryland, United States|The Center for Rheumatology and Bone Research, Rockville, Maryland, United States|Rockville Internal Medicine Group, Rockville, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Midatlantic Cardiovascular Associates, P.A., Westminster, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Genesis Clinical Research & Consulting, Fall River, Massachusetts, United States|NECCR Internal Medicine and Cardiology Associates, LLC, Fall River, Massachusetts, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Pentucket Medical Associates, Incorporated, Haverhill, Massachusetts, United States|Clinical Research Center of Cape Cod, Inc., Hyannis, Massachusetts, United States|Charles River Medical Associates, Pchi, Natick, Massachusetts, United States|Novex Clinical Research, LLC, New Bedford, Massachusetts, United States|Northampton Internal Medicine Associates, PC, Northampton, Massachusetts, United States|FutureCare Studies, Springfield, Massachusetts, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Great Lakes Research Group, Incorporated, Bay City, Michigan, United States|Professional Clinical Research-Benzonia, Benzonia, Michigan, United States|Cadillac Clinical Research, Cadillac, Michigan, United States|Livernois Family Medical Services, Detroit, Michigan, United States|Office of Dr. Susan Courtnage, Eaton Rapids, Michigan, United States|McLaren Regional Medical Center-Research Dept., Flint, Michigan, United States|Grand Valley Medical Specialist, PLC, Grand Rapids, Michigan, United States|Spectrum Health Medical Group-Rheumatology, Grand Rapids, Michigan, United States|Michigan Medical Cardiovascular PC, Grand Rapids, Michigan, United States|Professional Clinical Research, Interlochen, Michigan, United States|Justus J Fiechtner, MD, Lansing, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Synergy Medical Education Alliance, Saginaw, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Troy Internal Medicine Research, Troy, Michigan, United States|St. Luke's Hospital Association of Duluth, DBA St Luke's Rheumatology Assoc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Inc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Central Minnesota Heart Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|St. Paul Heart Clinic, Saint Paul, Minnesota, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Planters Clinic, Port Gibson, Mississippi, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|Cape Girardeau Physicians Associates, Cape Girardeau, Missouri, United States|Patterson Medical Clinic / d.b.a. Prime Care Research Associates, Florissant, Missouri, United States|Allergy Asthma Immunology Services, LLC, Jefferson City, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States|Truman Medical Center, Inc., Kansas City, Missouri, United States|Clinical Research Advantage, Inc./Manning Family Care, LLC, Kansas City, Missouri, United States|St. Louis Center for Clinical Research, Saint Louis, Missouri, United States|Physician Groups, LC, DBA Rheumatology and Internal Medicine Associates, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|Barbara A. Caciolo, MD, Saint Louis, Missouri, United States|A & A Pain Institute, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Patients First Health Care, LLC, Washington, Missouri, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Alliance Medical Center, Alliance, Nebraska, United States|Cody Medical Associates, Alliance, Nebraska, United States|Bellevue Family Practice/Clinical Research Advantage, Inc., Bellevue, Nebraska, United States|Clinical Research Advantage, Inc./ Skyline Medical Center, PC, Elkhorn, Nebraska, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Internal Medicine Associates, PC, Grand Island, Nebraska, United States|Physician, Research Collaboration, Southwest Family Health, Lincoln, Nebraska, United States|Lincoln Internal Medicine Associates, Lincoln, Nebraska, United States|Platte River Nephrology, North Platte, Nebraska, United States|Quality Clinical Research LLC, Omaha, Nebraska, United States|Westroads Medical Group, Omaha, Nebraska, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Primary Care Physicians, LLP, Omaha, Nebraska, United States|Clinical Research Advantage, Inc., Henderson, Nevada, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Henderson, Nevada, United States|Sierra Internal Medicine Associates, Incline Village, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage/Peter Philander, MD, Las Vegas, Nevada, United States|Rancho Internal Medicine, Las Vegas, Nevada, United States|Steven D. Folkerth, MD, Las Vegas, Nevada, United States|Ladner Family Practice, Las Vegas, Nevada, United States|VA Southern Nevada Healthcare System, North Las Vegas, Nevada, United States|Arthritis Center of Reno, Reno, Nevada, United States|New Jersey Physicians, LLC, Clifton, New Jersey, United States|Clifton-Wallington Medical Group, Clifton, New Jersey, United States|Anderson and Collins, Clinical Research Inc., Edison, New Jersey, United States|Drs. Collins and Uthappa, Edison, New Jersey, United States|Central Jersey Health Care, Elizabeth, New Jersey, United States|Andron Medical Associates, Englewood, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Hazlet Health Care, Hazlet, New Jersey, United States|Family Care Physicians, Lawrenceville, New Jersey, United States|Penn Cardiac Care at Mercer Bucks, Lawrenceville, New Jersey, United States|Family Medicine of Lindenwold, Lindenwold, New Jersey, United States|Rheumatology and Arthritis Associates PC, Medford, New Jersey, United States|Adult & Pediatric Rheumatology, Midland Park, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Maynard Holgado LLC, Sicklerville, New Jersey, United States|Shore Health Group, Toms River, New Jersey, United States|Hopewell Valley Medical Group, P.A., Trenton, New Jersey, United States|Arthritis, Rheumatic and Back Disease Associates, PA, Voorhees, New Jersey, United States|Lourdes Medical Associates, Willingboro, New Jersey, United States|Kenneth F. Solinsky, MD, Babylon, New York, United States|LifeLine Research Institute, Brooklyn, New York, United States|Lee Medical Associates, Dunkirk, New York, United States|AMS Research, Elmira, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Drug Trials America, Inc., Hartsdale, New York, United States|United Health Service Hospitals, Office of Clinical Trials, Johnson City, New York, United States|IMA Medical Research PC, Kew Gardens, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Infusion Center, Lake Success, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Investigational Pharmacy, Lake Success, New York, United States|NYU Langone Rheumatology Associates Long Island, Lake Success, New York, United States|Office of Dr. Allen Chodock, Mamaroneck, New York, United States|Winthrop University Hospital / Clinical Trials Center, Mineola, New York, United States|New York University Pain Management Center, New York, New York, United States|NYU Pain Research, New York, New York, United States|Office of Dr. Richard Stern, New York, New York, United States|DiGiovanna Family Care Center, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|AAIR Research Center, Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Office of Dr. Chadia Morcos, Syosset, New York, United States|Arthritis Health Associates, Syracuse, New York, United States|Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York, Syracuse, New York, United States|East Meadow Family Practice Associates, PC, Wantagh, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Asheville Arthritis & Osteoporosis, PA, Asheville, North Carolina, United States|Kernodle Clinic Inc., Burlington, North Carolina, United States|Calabash Medical Center, Calabash, North Carolina, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|Chapel Hill Family Medicine, Chapel Hill, North Carolina, United States|Thurston Arthritis Reaserch Ctr, Chapel Hill, North Carolina, United States|Mid Carolina Cardiology Research, Charlotte, North Carolina, United States|Presbyterian Novant Heart and Wellness, Charlotte, North Carolina, United States|Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|Duke Health Center at Pickett Road, Durham, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Physicians East P. A., Greenville, North Carolina, United States|Physicians East, PA, Greenville, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|PMG Research Of Hickory, LLC, Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Research Institute of the Carolinas, PLLC, Mooresville, North Carolina, United States|Crystal Coast Family Practice, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Pinehurst Medical Clinic. Inc., Pinehurst, North Carolina, United States|Blue Ridge Family Physicians, PPLC, Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Boice-Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Tabor City Family Medicine, Tabor City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research Wilmington Research Associates, Wilmington, North Carolina, United States|Natalie A. Doyle, MD PA, Wilson, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Clinical Trials of America, inc, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, Fargo, North Dakota, United States|Daystar Clinical Research, Akron, Ohio, United States|CFP Research, Inc., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Feldman Family Practice, Columbus, Ohio, United States|MidWest Cardiology Research Foundation, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Remington-Davis Incorporated, Columbus, Ohio, United States|Midtowne Family Practice Centre, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Cleveland Clinic Fairview Cardiovascular Medicine, Fairview Park, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|TriPhase Research, Ltd., Franklin, Ohio, United States|Holzer Clinic, Inc, Gallipolis, Ohio, United States|Office of Dr. Saleem Khan, MD, Inc, London, Ohio, United States|North Central Research, Mansfield, Ohio, United States|OhioHealth Research Institute, Mansfield, Ohio, United States|R&R Research-Smith Clinic, Marion, Ohio, United States|David R. Mandel, MD, Inc, Mayfield, Ohio, United States|Paramount Medical Research and Consulting, LLC, Middleburg Heights, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Family Medicine and Occupational Health Center, Inc., Shaker Heights, Ohio, United States|Abner Cordero, M.D., Tiffin, Ohio, United States|Arthritis Associates of Northwest Ohio, Inc., Toledo, Ohio, United States|Mercy St Vincent Medical Center, Toledo, Ohio, United States|Toledo Cardiology Consultants c/o Cardiac Research, Toledo, Ohio, United States|South Toledo Internists, Toledo, Ohio, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|UT Medical Center Medicine Clinic, Toledo, Ohio, United States|Trenton Family Medicine, Trenton, Ohio, United States|Lake Medical Research, LLC, Willoughby Hills, Ohio, United States|Pharmacotherapy Research Associates Incorporated, Zanesville, Ohio, United States|LION Research, Norman, Oklahoma, United States|Integris Physicians Services, Oklahoma City, Oklahoma, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Integris Physician Services, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Healthcare Research Consultants, Tulsa, Oklahoma, United States|Integrated Medical Research, PC, Ashland, Oregon, United States|Lane Medical Research Group, Eugene, Oregon, United States|Oregon Medical Group Adult Medicine Clinic, Eugene, Oregon, United States|Oregon Medical Group Clinical Research, Eugene, Oregon, United States|Institute of Diabetes and Endocrinology, Medford, Oregon, United States|Rogue Valley Physicians-Clinical Research Group, Medford, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Affinity Research, Portland, Oregon, United States|Portland Rheumatology Clinic, LLC, Portland, Oregon, United States|Internal Medicine Research, Portland, Oregon, United States|University Orthopedics Center, Altoona, Pennsylvania, United States|Tri-State Medical Group, Beaver, Pennsylvania, United States|East Penn Rheumatology Associates, PC, Bethlehem, Pennsylvania, United States|Buckingham Family Medicine, Buckingham, Pennsylvania, United States|Camp Hill Clinical Research Center, Camp Hill, Pennsylvania, United States|Butler Medical Associates, Chicora, Pennsylvania, United States|Perkiomen Valley Family Practice, PC, Collegeville, Pennsylvania, United States|Rheumatology Associates, Ltd, Colmar, Pennsylvania, United States|Office of J. Miller Oppy, MD, Youghiogheny Primary Care Practice, Connellsville, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Saint Vincent Consultant in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Arthritis Associates, Erie, Pennsylvania, United States|Center for Assessment and Research of Erie, Erie, Pennsylvania, United States|Stan F. Slabic, M.D., Erie, Pennsylvania, United States|AMH Feasterville Family HealthCare Center, Feasterville, Pennsylvania, United States|Westmoreland Neurology Associates, Incorporated, Greensburg, Pennsylvania, United States|Harleysville Medical Assoc, Harleysville, Pennsylvania, United States|Lederach Family Medicine, Harleysville, Pennsylvania, United States|Dr. Bruce Morrison, Family Practice, Huntingdon Valley, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Lansdale Medical Group Family Practice, Lansdale, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Lehigh Wellness Center Outpatient Services, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Dairyland Medical Center, Red Lion, Pennsylvania, United States|Sfm Clinical Trials, PC, Scotland, Pennsylvania, United States|Elite Medical Research, Inc., Sellersville, Pennsylvania, United States|Prime Health Network, Springfield, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|The Office of Dr. Joseph T. Morelli, DO, Stoneboro, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|PEAK Research, LLC, Upper Saint Clair, Pennsylvania, United States|Allegheny Rheumatology - WPAHS - ASRI, Wexford, Pennsylvania, United States|Clinical Research Center of Reading, LLC, Wyomissing, Pennsylvania, United States|Cardiology Consultants of Philadelphia, Yardley, Pennsylvania, United States|Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Hugo M. Yamada, MD, Lincoln, Rhode Island, United States|Rheumatology Associates, Pawtucket, Rhode Island, United States|Medical Office Center, Providence, Rhode Island, United States|Anderson Heart, Anderson, South Carolina, United States|AnMed Health, Anderson, South Carolina, United States|Low Country Rheumatology, PA/Low Country Research Center, Charleston, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|St. Andrews Medical, Charleston, South Carolina, United States|Neem Research Group Inc., Columbia, South Carolina, United States|Columbia Arthritis Center Pa, Columbia, South Carolina, United States|MedTrial, Columbia, South Carolina, United States|Clinical Research Associates, LLC, Florence, South Carolina, United States|Palmetto Clinical Trial Services, LLC, Greenville, South Carolina, United States|Paris View Family Practice, Greenville, South Carolina, United States|John Milas, Greer, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Palmetto Clinical Trial Services, LLC at the Family Healthcare Center, Laurens, South Carolina, United States|Berkeley Medical Center, Moncks Corner, South Carolina, United States|PMG Research of Charleston, Mount Pleasant, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Coulter Clinic, Orangeburg, South Carolina, United States|Orangeburg Medical Associates, PA, Orangeburg, South Carolina, United States|The Carolina Center for Rheumatology & Arthritis Care, PA, Rock Hill, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|Palmetto Research, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Odyssey Research/Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Regional Health Clinic Research, Rapid City, South Dakota, United States|Regional Medical Clinic-Rheumatology, Rapid City, South Dakota, United States|Health Concepts, Rapid City, South Dakota, United States|Brown Clinic PLLP, Watertown, South Dakota, United States|Odyssey Research, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Internal Medicine & Pediatric Associates of Bristol, Bristol, Tennessee, United States|PMG Research of Bristol, Bristol, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, inc., Germantown, Tennessee, United States|Arthritis Clinic, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|State of Franklin Healthcare Associates Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Holston Valley Surgery Center, Kingsport, Tennessee, United States|Gupta, Ramesh C MD, Memphis, Tennessee, United States|Access Clinical Trials, Inc., Nashville, Tennessee, United States|Premier Orthopaedics, Nashville, Tennessee, United States|The Cholesterol Center of Nashville, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Amarillo Medical Specialists, LLP, Amarillo, Texas, United States|Pharma Tex Research, LLC, Amarillo, Texas, United States|Family Health Care Association, Arlington, Texas, United States|South Arlington Primary Care Associates PA, Arlington, Texas, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States|Southeast Texas Cardiology Associates, Beaumont, Texas, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Kaner Medical Group PA, Bedford, Texas, United States|Nexxus Research Group, LLC, Bedford, Texas, United States|Texas Orthopedic Specialists, PLLC, Bedford, Texas, United States|MedicalEdge Healthcare Group, PA, dba Leading Edge Research, PA, Carrollton, Texas, United States|Prentiss Family Medicine, Colleyville, Texas, United States|Carlos B. Everett, MD, Corpus Christi, Texas, United States|Discovery Clinical Research, Corpus Christi, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Soltero Cardiovascular Research Center/Baylor University Medical Center, Dallas, Texas, United States|Arthritis Care and Diagnostic Center, P.A., Dallas, Texas, United States|Medical Specialists Associated, Dallas, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|SouthWest Rheumatology, P.A., Dallas, Texas, United States|DCT - Genesis Neighborhood Research, LLC dba Discovery Clinical Trials, Dallas, Texas, United States|Rajendra K. Marwah, MD, El Paso, Texas, United States|Kaner Medical Group, PA, Euless, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T & R Clinic, P. A., Fort Worth, Texas, United States|Rheumatology-UTMB, Galveston, Texas, United States|Towngate Plaza Medical Center, Garland, Texas, United States|ProCare Clinical Trials, Grand Prairie, Texas, United States|The Office of Amer Zaheer MD, PA, Houston, Texas, United States|Salim Gopalani, MD, PA, Houston, Texas, United States|Office of Cyril Wolf, MD, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Kelsey Seybold Clinic, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|MCA Research, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|One World Medical Associates, P.A., Lewisville, Texas, United States|Pri-Med Care, Lewisville, Texas, United States|South Texas Institute of Health, McAllen, Texas, United States|DCT - Genesis Seidmeyer Research, LLC dba Discovery Clinical Trials, McKinney, Texas, United States|Southwest Rheumatology, PA, Mesquite, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Basin Orthopedics Surgical Specialists, Odessa, Texas, United States|Center for Hypertension and Internal Medicine, Odessa, Texas, United States|Odessa Heart Institute, Odessa, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Office of David K. McDonald, M.D.. P.A., Pasadena, Texas, United States|Centex Studies, Inc., Pharr, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|DCT-Genesis naini, LLC dba Discovery Clinical Trials, Plano, Texas, United States|North Texas Medical Research, Plano, Texas, United States|MedicalEdge Healthcare Group, PA, Richardson, Texas, United States|Texas Health Physicians Group, Richardson, Texas, United States|Ivan N. Mefford, MD, PhD, PA, Richmond, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Quality Assurance Research Center, San Antonio, Texas, United States|Quality Research Inc., San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|GSA Research, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Radiant Research San Antonio Northeast, San Antonio, Texas, United States|Briggs Clinical Research, LLC, San Antonio, Texas, United States|DCT - Barlite, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|WellMed Clinical Research, San Antonio, Texas, United States|DCT-Westover Hills, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|The Office of Shahbaz Yazdani, MD, PA, San Antonio, Texas, United States|Southlake Clinical Trials, Southlake, Texas, United States|Sugar Land Med-Ped Clinic, PA, Sugar Land, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Crossroads Clinical Research, Victoria, Texas, United States|Office of Pamela Dugano-Daphnis, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Burke Internal Medicine, Burke, Virginia, United States|Center for Arthritis and Rheumatic Diseases, Chesapeake, Virginia, United States|Bayview Physicians oa Cardiovascular Associates, Ltd, Chesapeake, Virginia, United States|David Ramstad, MD, MPH and Associates, Chesapeake, Virginia, United States|Danville Internal Medicine, Inc., Danville, Virginia, United States|Danville Orthopedic Clinic, Danville, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice, Hampton, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Bruton Avenue Family Practice, Newport News, Virginia, United States|Internal Medicine Kidney and Hypertension Center, Norfolk, Virginia, United States|National Clinical Research - Norfolk Inc., Norfolk, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Ettrick Health Center, Petersburg, Virginia, United States|Arthritis and Rheumatic Research, Portsmouth, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Harbourview Professional Center, Suffolk, Virginia, United States|Chase Research Group, LLC, Virginia Beach, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Highline Medical Center Laboratory, Burien, Washington, United States|Puget Sound Osteoporosis Center, Seattle, Washington, United States|Arthritis Northwest, Seattle, Washington, United States|Arthritis Northwest Rheumatology, Spokane, Washington, United States|Lawrence S. Eastburn, MD, PS, Spokane, Washington, United States|Pulmonary and Research Associates, Spokane, Washington, United States|The Office of William Gray, Md, Family Practice, Spokane, Washington, United States|John F. Long, D.O., Spokane, Washington, United States|George H. Krick, MD, Tacoma, Washington, United States|Northwest Family and Spinal Clinic, Tacoma, Washington, United States|Rheumatology Infusion Services, Tacoma, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Research Department, Wenatchee, Washington, United States|Clinical Trials Northwest, Yakima, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|University Cardiovascular Services. Robert C. Byrd Clinical Center, Huntington, West Virginia, United States|WVVA Healthcare Alliance, Lewisburg, West Virginia, United States|Parkersburg Cardiology Associates, Parkersburg, West Virginia, United States|Meriter Medical Group, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|UW Health Physicians, Madison, Wisconsin, United States|St. Lukes Pain Management Center, Milwaukee, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Aspirus Cardiovascular Associates - Rhinelander, Rhinelander, Wisconsin, United States|Aspirus Cardiovascular Associates, Wausau, Wisconsin, United States|Aspirus Heart & Vascular lnstitute--Research & Education), Wausau, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Hunter Clinical Research, Broadmeadow, New South Wales, Australia|Wesley Medical Centre, Auchenflower, Queensland, Australia|Australian Clinical Research Organisation, Caboolture, Queensland, Australia|Rheumatology Department, Cairns, Queensland, Australia|AusTrials Pty Ltd, Kippa Ring, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Monash Medical Centre, Department of Rheumatology, Clayton, Victoria, Australia|Rheumatology Department, Heidelberg West, Victoria, Australia|Emeritus Research, Malvern East, Victoria, Australia|The Goatcher Clinical Research Unit, Shenton Park, Western Australia, Australia|The Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia|CLINCOR - Clinica de Exames Cardiologicos e Ecografia S/C Ltda, Maceio, AL, Brazil|Hospital do Coracao de Alagoas, Maceio, AL, Brazil|CIP - Centro Internacional de Pesquisas, Goiania, GO, Brazil|Via Medica - Centro Clinico, Goiania, GO, Brazil|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, MG, Brazil|Hopsital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital e Maternidade Angelina Caron, Sala Pesquisa Clinica, Campina Grande do Sul, PR, Brazil|CEPEME-CERHFAC Centro de Estudos e Pesquisas Medicas, Curitiba, PR, Brazil|Centro de Estudos do Hospital de Clínicas da UFPR, Curitiba, PR, Brazil|Hospital Universitário Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, Brazil|CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, RJ, Brazil|Hospital Ipanema Plus, Rio de Janeiro, RJ, Brazil|Clinica de Reumatologia do Centro Médico BarraShopping, Rio de Janeiro, RJ, Brazil|Centro de Pesquisa Clinica, Porto Alegre, RS, Brazil|Associação Hospitalar Moinhos de Vento (AHMV) / CMIC, Porto Alegre, RS, Brazil|Hospital São Lucas - Pontificia, Porto Alegre, RS, Brazil|Hospital e Maternidade Celso Pierro - Puc Campinas, Campinas, Sao Paulo, Brazil|Centro de Ensino e Pesquisa Hospital Sao Lucas, Aracaju, SE, Brazil|PUC Campinas, Campinas, SP, Brazil|Hospital das Clinicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina de Marilia, Marilia, SP, Brazil|Hospital de Base - Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Setor de Lip., Arterosc. e BioVasc. - Disc. de Cardiologia, Sao Paulo, SP, Brazil|CEPIC - Centro Paulista de Investigacao Clínica, Sao Paulo, SP, Brazil|IMA Brasil - Instituto de Medicina Avancada, Sao Paulo, SP, Brazil|CPCLIN - Centro de Pesquisas Clínicas, São Paulo, SP, Brazil|Hospital Sao Salvador - Medicos Reunidos Ltda., Goiania-GO, Brazil|Ambulatorio de Especialidades Mario Covas, Marilia/SP, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital das Clinicas da UFPE, Recife - Pernambuco, Brazil|Hospital Dos Servidores Do Estado do Rio de Janeiro, Rio de Janeiro, Brazil|Faculdade de Medicina DO ABC, Santo Andre, Brazil|South Calgary Medical Clinic - Sunpark Professional Center, Calgary, Alberta, Canada|Allin Clinic, Edmonton, Alberta, Canada|Dr. MPJ Senaratne Professional Corporation, Edmonton, Alberta, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Ocean West Research Clinic Inc., Surrey, British Columbia, Canada|Prohealth Clinical Research Inc., Vancouver, British Columbia, Canada|Office of Dr. Milton F. Baker, Victoria, British Columbia, Canada|The Medical Arts Health Research Group, West Vancouver, British Columbia, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd/Ltee, Moncton, New Brunswick, Canada|Eric N. Grant Professional Corporation, Quispamis, New Brunswick, Canada|Office of Dr. Brian N. Craig, Saint John, New Brunswick, Canada|Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada|Paradise Medical Clinic, Paradise, Newfoundland and Labrador, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Nexus Clinic Research, St. John's, Newfoundland and Labrador, Canada|The Clinical Trials Centre, St. John's, Newfoundland and Labrador, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|MSHJ Research Associates, Inc., Halifax, Nova Scotia, Canada|Colchester Research Group, Truro, Nova Scotia, Canada|Office of Dr. Rohit Nagpal, Brampton, Ontario, Canada|Aggarwal and Associates Ltd., Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|Corunna Medical Research Center, Corunna, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Office of Dr. Jonathan D. Adachi, Hamilton, Ontario, Canada|Office of Dr. John Mutrie, Kitchener, Ontario, Canada|KW Musculoskeletal Research Inc., Kitchener, Ontario, Canada|East London Medical Centre, London, Ontario, Canada|London East Medical Centre, London, Ontario, Canada|Office of Dr. Gordon Schacter, London, Ontario, Canada|Office of Dr. William Blake Bowler, London, Ontario, Canada|Office of Dr. Robert G. Luton, London, Ontario, Canada|Malton Medical Centre, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Office of Dr. Azim M. Velji, Niagara Falls, Ontario, Canada|AIM Health Group Trainyards Health and Wellness Centre, Ottawa, Ontario, Canada|London Road Diagnostic Clinic & Medical Center, Sarnia, Ontario, Canada|London Road Diagnostic Clinic & Medical Centre, Sarnia, Ontario, Canada|Office of Dr. Swaran K. Syan, Sudbury, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|Prime Health Clinical Research, Toronto, Ontario, Canada|Office of Dr. Ira Bernstein, Toronto, Ontario, Canada|Office of Dr. Subodh Kanani, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|North Walkerville Orthopaedic Associates, Windsor, Ontario, Canada|Research Office, Windsor, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|Clinique de Medicine Familiale de Cowansville, Cowansville, Quebec, Canada|Centre de recherche clinique Adapra Inc., L'Ancienne-Lorette, Quebec, Canada|Centre de Recherche Hochelaga/ Clinique Medicale Hochelaga, Montreal, Quebec, Canada|Recherche Medicale Appliquee Informatics (AMIR) Inc., Montreal, Quebec, Canada|Kells Medical Research Group, Inc., Pointe-Claire, Quebec, Canada|Le Manoir de l'Atrium, Quebec City, Quebec, Canada|Clinique Services Sante Rosemere, Rosemere, Quebec, Canada|Centre Medical des Carrieres, Saint-Marc-des-Carrieres, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivieres, Quebec, Canada|Cardiology and Research, Westmount, Quebec, Canada|Downtown Medical Specialists, Saskatoon, Saskatchewan, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada|Hospital Pablo Tobon Uribe - Unidad de Investigaciones, Medellin, Antioquia, Colombia|Reumalab S.A.S., Medellin, Antioquia, Colombia|IPS Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Fundacion Cardioinfantil, Bogota, Cundinamarca, Colombia|Clinica Colsanitas Sa, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|Fundacion Valle del Lili, Cali, Colombia|Clínica Vía San Juan, La union de Tres Rios, Cartago, Costa Rica|Clinica San Agustin, Desamparados Centro, San Jose, Costa Rica|Hospital CIMA San Jose, Escazu, San Jose, Costa Rica|Hospital Hotel La Catolica, Goicoechea, San Jose, Costa Rica|Consultorio Privado Dr. Alberto Lainez Ventosilla, Moravia, San José, Costa Rica|Centro Medico San Rafael, Alajuela, Costa Rica|Centro de Reumatologia y Osteoporosis, Cartago, Costa Rica|Clínica Garzona, Cartago, Costa Rica|Clinica de Especialidades Medicas Drs. Saenz Castro, Heredia, Costa Rica|Clínica Monte Sión, Heredia, Costa Rica|Clínica San Antonio, Heredia, Costa Rica|Centro Medico San Jose, San Jose, Costa Rica|Edificio Panda, San Jose, Costa Rica|Hospital Clinica Biblica, San Jose, Costa Rica|Hospital Clínica Biblica, San Jose, Costa Rica|Oficina Privada, San Jose, Costa Rica|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Centre for Assessment and Treatment of Rheumatic Diseases, Department of Medicine and Geriatrics, New Territories, NT, Hong Kong|Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Medicine, North District Hospital, Sheung Shui, NT, Hong Kong|Centro de Investigacion del Noroeste SC, Tijuana, Baja California, Mexico|Comite Mexicano para la Prevencion de la Osteoporosis, A.C., Mexico, D.f., Mexico|Instituto Mexicano de Investigación Clínica, S.A. de C.V, Mexico, D.f., Mexico|CIF-BIOTEC, Medica Sur, Mexico, DF, Mexico|Centro Medico Toluca, Metepec, Estado de Mexico, Mexico|Hospital Regional ISSSTE, Leon, Guanajuato, Mexico|Instituto Jalisciense de Investigación Clínica SA de CV, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Basica y Clinica SC., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Dr. Mario Alvizouri Muñoz Ac Del Hospital General Dr. Miguel Silva, Morelia, Michoacan, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Unidad Regional de Reumatologia y Osteoporosis, San Luis Potosi, SLP, Mexico|Clinicos Asociados BOCM, S.C., Mexico City, Mexico|Centro de Investigación Marbella, Panama City, Panama|IPC - Centro de Salud Integral S.A., San Isidro, Lima, Peru|Centro Empresarial - Altavista Polo 4, Santiago de Surco, Lima, Peru|Instituto de Ginecologia y Reproducción & Cirugia Minimamente Invasiva, Santiago de Surco, Lima, Peru|Clinica San Felipe, Lima, Peru|Centro de Investigaciones Medical, Lima, Peru|Clinica San Juan Bautista, Lima, Peru|Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines|De La Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines|Chong Hua Hospital, Cebu City, Philippines|Southern Philippines Medical Center, Davao City, Philippines|Jose R. Reyes Memorial Medical Center, Manila, Philippines|Chinese General Hospital and Medical Center, Manila, Philippines|Hospital Research Unit, University of Santo Tomas Hospital, Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Chang Gung Memorial Hospital-Kaohsiung branch, Section of Allergy, Immunology, Nio Sung Township, Kaohsiung County, Taiwan|Tri-Service General Hospital, Neihu District, Taipei City, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Gueishan Township, Taoyuan County, Taiwan|Chi-Mei Medical Center, Tainan, Yung Kang, Taiwan|Buddhist Tzu Chi Dailin General Hospital, Chia-Yi County, Taiwan|Chung-Ho Memorial Hospital, Kaoshiung Medical University Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-service General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|CRI ""Clinical Territorial Medical Association ""University Clinic"",, Simferopol, Crimea, Ukraine|Municipal Medical Institution ""City Clinical Hospital #3"", Department of Rheumatology, Chernivtsi, Ukraine|MI Dnipropetrovsk Regional Clinical Hospital named after I.I Mechnikov, Dnipropetrovsk, Ukraine|State Institution ""Dnipropetrovsk Medical Academy of MOH, Ukraine, Dnipropetrovsk, Ukraine|Rheumatology Department, MMI ""City Clinical Hospital #5"", DNMU n.a. M.Gorkyy,, Donetsk, Ukraine|Donetsk National Med University, Chair of Propaedeutics and Internal Medicine, Donetsk, Ukraine|Municipal Establishment of Health Care, Kharkiv, Ukraine|City Clinical Hospital # 8, Dept of Cardiology and Functional Diagnostics, Kharkiv, Ukraine|City Clinical Hospital #1, Kyiv, Ukraine|National Scientific Center ""The Strazhesko Institute of Cardiology"", Kyiv, Ukraine|State Institution ""Republican clinical hospital of MOH of Ukraine"", Kyiv, Ukraine|Family Medicine Department of NMAPE named after PL Shupyk,, Kyiv, Ukraine|Lutsk City Clinical Hospital, Lutsk, Ukraine|Municipal City Clinical Hospital #5, Lviv, Ukraine|Center of Reconstructive and Regenerative Medicine (University clinic) of, Odesa, Ukraine|Treatment-and-Diagnostic Center LLC ""Desna"" Ltd, Ternopil, Ukraine|Municipal enterprise "" City Hospital # 7"",, Zaporizhzhia, Ukraine|Municipal Institution ""Zaporizhzhya City Multiple Discipline Clinical Hospital #9"", Zaporizhzhya, Ukraine|Zhytomyr Regional Clinical Hospital n.a. O.F. Gerbachevs'kyy/ Rheumatology Center, Zhytomyr, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT02961998,HEPATOCELLULAR CARCINOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00447759,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern Denmark, Odense, Denmark|Julius Clinical Research, Zeist, Netherlands|University of Aberdeen, Aberdeen, United Kingdom|University of Birmingham, Birmingham, United Kingdom|University of Dundee, Dundee, United Kingdom|University of Edinburgh, Edinburgh, United Kingdom|University of Glasgow, Glasgow, United Kingdom|NHS Highlands, Inverness, United Kingdom|University of Nottingham, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00807846,"ARTHRITIS, JUVENILE RHEUMATOID",All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Catalina Pointe Clinical Research, Inc., Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital-San Diego, San Diego, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center / Division of Rheumatology, Washington, District of Columbia, United States|Arthritis Associates of South Florida, Delray Beach, Florida, United States|Delray Research Associates, Delray Beach, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Administrative Site-Hawaii Pacific Health Research Institute, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Kosair Charities Pediatric Clinical Research Unit - University of Louisville, Louisville, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University Pediatric Rheumatology of Kentucky, Louisville, Kentucky, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States|Akron Children's Hospital, Akron, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Roberto del Rio, Santiago, RM, Chile|Hospital Regional de Concepcion Guillermo Grant Benavente, Concepcion, VIII Region, Chile|Instituto de Atencion Pediatrica, San Jose, Costa Rica|Clinica San Borja/Centro de Investigacion de Reumatologia, San Borja, Lima, Peru|Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia, San Isidro, Lima, Peru|Philippine General Hospital, Manila, Philippines|University of Santo Tomas Hospital, Manila, Philippines|State Healthcare Institution of Moscow ""Izmailovskaya City Children's Hospital"", Moscow, Russian Federation|First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia, Moscow, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|SEIHPE ""Smolensk State Medical Academy""of the Minzdravsocrazvitiya of Russia, Smolensk, Russian Federation|Institute of Rheumatology, Belgrade, Serbia|Children's Clinic of Internal Medicine, Nis, Serbia|Clinical Research Unit, Pretoria, Gauteng Province, South Africa|CHUV - Unit of Immuno-Allergology and Rhumatology, CH-1011 Lausanne, Switzerland|Universitaets-Kinderspital, CH-8032 Zuerich, Switzerland|Department of Cardioreumatology, Kharkiv, Ukraine|Institute of Pediatrics, Obstetrics and Gynecology, Kiev, Ukraine|Kyiv City Children Clinical Hospital #1, Kyiv, Ukraine|Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases, Simferopol, Ukraine|Zaporizhzhya Regional Clinical Pediatric Hospital, Zaporizhzhya, Ukraine",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,NCT00624559,HYPERTENSION,All,22 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","University of Delaware, Newark, Delaware, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,PEPTIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Cc1ccc(-c2cc(C(F)(F)F)nn2-c2ccc(S(N)(=O)=O)cc2)cc1,1,DB00482,__CELECOXIB,5972986,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,24.37832399022561,616.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.99,381.37199999999996,77.98,3.0,1.0,3.0,35.2,92.23,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Withdrawn,NCT02568111,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Brc1c(NC2=NCCN2)ccc2nccnc12,1,DB00484,__BRIMONIDINE,5424078,Active Not Recruiting,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,49.3808907780447,272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,292.135,62.2,5.0,2.0,3.0,25.74,68.49,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,1,DB00486,__NABILONE,3944673,Completed,NCT00480181,NEUROPATHIC PAIN|MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg, Manitoba, Canada",C07C49/747,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,1,DB00486,__NABILONE,3944673,Completed,NCT00381264,MULTIPLE SCLEROSIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"South Florida Medical Research, Aventura, Florida, United States|Sunrise Clinical Research, Inc., Hollywood, Florida, United States|Naples Anesthesia and Pain Associates, Naples, Florida, United States|Lazlo Mate, MD, West Palm Beach, Florida, United States",C07C49/747,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,1,DB00486,__NABILONE,3944673,Completed,,DIABETIC NEUROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(=O)C[C@@H]21,1,DB00486,__NABILONE,3944673,Completed,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/747,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,9.7907554569909,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.5,372.5408,46.53,3.0,1.0,3.0,44.91,110.2,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,1,DB00490,__BUSPIRONE,3976776,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1
O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(c2ncccn2)CC1,1,DB00490,__BUSPIRONE,3976776,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,38.0,13.3719378221318,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,385.5031,69.64,6.0,0.0,4.0,44.12,108.89,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00127959,HEPATITIS B INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, NH, Netherlands",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00192595,HIV INFECTION|HEPATITIS B COINFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Thai Red Cross AIDS Research Centre, Bangkok, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT01772940,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cliniques Universitaires de Lubumbashi, Lubumbashi, Katanga, Congo",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00335322,HIV INFECTION,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT01340950,HIV INFECTIONS|CENTRAL NERVOUS SYSTEM DISEASES|DEMENTIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Beijing Ditan Hospital, Beijing, Beijing, China|Beijing YouAn Hospital, Beijing, Beijing, China",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",C07D411/04,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Terminated,NCT00854581,LYMPHOMA|PRECANCEROUS/NONMALIGNANT CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Recruiting,NCT02712801,HIV/AIDS AND INFECTIONS,All,up to 1 Day   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China|Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Maternal and Child Health Hospital of Sichuan Province, Chengdu, Sichuan, China|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China|Maternal and Child Health Hospital of Yunan Province, Kunming, Yunnan, China",C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Unknown status,NCT00122226,HIV INFECTIONS|LIPODYSTROPHY,Male,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland|Academic Medical Center, Amsterdam, Netherlands|Medisch Centrum Jan van Goyen, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Oosterpark, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Prinsengracht, Amsterdam, Netherlands|Slotervaart ziekenhuis, Amsterdam, Netherlands|VUMC Free University Medical Center, Amsterdam, Netherlands|Ziekenhuis Leyenburg, den Haag, Netherlands|Kennemer Gasthuis, location Elisabeth, Haarlem, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|Hospital Clinic, Barcelona, Spain|Royal Free Hospital, London, United Kingdom",C07D411/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00141284,HEPATITIS C INFECTION,All,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Bakersfield, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Toronto, Ontario, Canada",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Unknown status,NCT00162643,ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Especialidades Centro Medico Nacional siglo XXI, Mexico City, D.f., Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, DF, Mexico|Hospital General Regional #53, Los Reyes La Paz, Estado de Mexico, Mexico|Hospital General Regional #72, Tlalnepantla, Estado de Mexico, Mexico|Hospital General Regional de Leon, Leon, Guanajuato, Mexico",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00851630,HIV|TUBERCULOSIS,All,"13 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kilimanjaro Christian Medical Centre, Moshi, Tanzania",C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,"Active, not recruiting",NCT03088410,HIV|INSULIN SENSITIVITY|DIABETES MELLITUS,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Botswana-Harvard AIDS Institute Partnership, Gaborone, Botswana",C07D411/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00495,__ZIDOVUDINE,5905082,Completed,NCT00143689,HIV|MITOCHONDRIAL TOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McMaster University, Hamilton, Ontario, Canada|University of Ottawa Health Services, Ottawa, Ontario, Canada|Maple Leaf Clinic, Toronto, Ontario, Canada|Clinique Medicale L'Actuel, Montreal, Quebec, Canada",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1543.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.1,267.2413,108.3,6.0,2.0,2.0,24.93,61.7,3.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314,1,DB00497,__OXYCODONE,5508042,Terminated,NCT00414453,NEUROPATHIC PAIN|CHRONIC PAIN|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Rochester Medical Center, Rochester, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,10.3492884864165,1114.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.04,315.3636,59.0,5.0,1.0,5.0,32.79,84.04,1.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01772940,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cliniques Universitaires de Lubumbashi, Lubumbashi, Katanga, Congo",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01332227,"HIV, COMBINATION THERAPY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health For Life Clinic Pllc, Little Rock, Arkansas, United States|Eisenhower Medical Center, Palm Springs, California, United States|Metropolis Medical Pc, San Francisco, California, United States|Consultive Medicine, Daytona Beach, Florida, United States|Orange County Health Dept., Orlando, Florida, United States|Triple O Medical Services, P.A., West Palm Beach, Florida, United States|The Research Institute, Springfield, Massachusetts, United States|Aids Care, Rochester, New York, United States|Local Institution, Paris, Cedex 12, France|Local Institution, Lyons Cedex 04, France|Local Institution, Orleans Cedex 2, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Bochum, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Munich, Germany|Local Institution, Genova, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Roma, Italy|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Brighton, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Sheffield, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01258439,HIV|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holdsworth House Medical Practice, Sydney, New South Wales, Australia|St Vincent Hospital, Clinical Research Program, Sydney, New South Wales, Australia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Terminated,NCT00855413,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Not yet recruiting,NCT04183738,HIV-INFECTION/AIDS|HUMAN HERPESVIRUS 4 INFECTIONS|CYTOMEGALOVIRUS INFECTIONS|HUMAN HERPESVIRUS 8 INFECTION|HUMAN PAPILLOMA VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT00605098,HIV INFECTIONS|PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Geral de Nova Iguaçu (HGNI), Nova Iguaçu, Rio de Janeiro, Brazil|Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, RJ, Brazil|Hospital dos Servidores do Estado, Rio de Janeiro, Brazil",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Unknown status,NCT01829802,CHRONIC INFECTION WITH HIV,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundacion Huesped, Buenos Aires, Argentina|Dra Luna Norma, Cordoba, Argentina",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT00630734,HIV INFECTIONS|HYPERLIPIDEMIA,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Unknown status,NCT00426296,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Whitman-Walker Clinic, Washington, District of Columbia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01691794,"HIV, PEDIATRIC",All,6 Years to 17 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children'S Hospital, Phoenix, Arizona, United States|Grady Health System Ponce Family And Youth Clinic, Atlanta, Georgia, United States|Children'S Medical Center Of Dallas, Dallas, Texas, United States|Local Institution, Buenos Aires, Bs As, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Sao Paulo, SP, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Puebla, Mexico|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Bloemfontein, FREE State, South Africa|Local Institution, Soweto, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT00135356,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Honolulu, Hawaii, United States|Local Institution, Huntersville, North Carolina, United States|Local Institution, Houston, Texas, United States|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Bondy Cedex, France|Local Institution, Lagny-sur-Marne, France|Local Institution, Lyon Cedex 02, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nice Cedex, France|Local Institution, Paris Cedex 12, France|Local Institution, Frankfurt/ Main, Germany|Local Institution, Muenchen, Germany|Local Institution, Brescia, Italy|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Roma, Italy|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Puebla, Mexico|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Barcelona, Spain|Local Institution, Elche (Alicante), Spain|Local Institution, Guipuzcoa, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Brighton, East Sussex, United Kingdom|Local Institution, London, Greater London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT02348177,ACQUIRED IMMUNODEFICIENCY SYNDROME|TUBERCULOSIS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Children's Infectious Disease Clinical Research Unit; University of Stellenbosch, Cape Town, Western Cape, South Africa|Enhancing Care Foundation; Wendworth Hospital, Durban, South Africa|Perinatal HIV Research Unit, Johannesburg, South Africa|Shandukani Research WRHI, Johannesburg, South Africa|Empilweni Services and Research Unit, Johannesburg, South Africa",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Terminated,NCT01700790,AIDS|TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Nacional de Infectologia Evandro Chagas - Fiocruz(INI), Laboratorio de Pesquisa Clinica em Micobacterioses(LAPCLINTB), Rio de Janeiro, RJ, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Terminated,NCT02503462,AIDS-RELATED DEMENTIA COMPLEX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01935674,HIV|HYPERCHOLESTEROLAEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic of Barcelona, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@H](C(=O)N[C@@H](Cc2ccccc2)C[C@H](O)[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)C(C)C)cs1,1,DB00503,__RITONAVIR,5541206,Completed,NCT01189695,HIV|AIDS|LOPINAVIR|TREATMENT FAILURE,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,15.178956446744197,1408.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,720.944,145.78,6.0,4.0,4.0,76.23,194.59,18.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,1,0,1
COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3,1,DB00514,__DEXTROMETHORPHAN,5980882,Completed,NCT02062710,COUGH REFLEX SENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Einstein Division/Montefiore Medical Center, Bronx, New York, United States",A61K47/6903,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,30.785026386578693,672.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,271.404,12.47,2.0,0.0,4.0,31.86,82.56,1.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0
CC1=C(/C=C/C(C)=C\C=C\C(C)=C\C(=O)O)C(C)(C)CCC1,1,DB00523,__ALITRETINOIN,5932622,Terminated,NCT01231854,ATOPIC DERMATITIS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Sachsen, Germany",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,49.8737140393026,1115.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.66,300.4351,37.3,2.0,1.0,1.0,35.95,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(c2ccccc2)c2ccccc2)C1c1cccc([N+](=O)[O-])c1,1,DB00528,__LERCANIDIPINE,4705797,Unknown status,NCT00564057,HIV INFECTIONS|HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Insubria, Department of Clinical Medicine, Varese, Italy",C07C205/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,32.8220291997782,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.42,611.7272,113.69,6.0,1.0,4.0,65.78,177.85,14.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,1
O=C(O)P(=O)(O)O,1,DB00529,__FOSCARNET,,Completed,NCT00002146,CYTOMEGALOVIRUS INFECTIONS|HIV INFECTIONS|HYPOCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"Oklahoma City Veterans Administration Med Ctr, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,126.0053,94.83,5.0,3.0,0.0,7.89,19.07,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)P(=O)(O)O,1,DB00529,__FOSCARNET,,Completed,NCT00002125,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Dr Ralph Hansen, Beverly Hills, California, United States|Dr Milan Fiala, Los Angeles, California, United States|Dr G Michael Wool, Los Angeles, California, United States|AIDS Community Research Consortium, Redwood City, California, United States|Ingenix Kern McNeill Decatur, Atlanta, Georgia, United States|Dr John Karedes, Indianapolis, Indiana, United States|Dr Paul Benson, Berkley, Michigan, United States|Dr Ronald Nahass, Somerville, New Jersey, United States|Dr Ronald J Grossman, New York, New York, United States|Community Health Network, Rochester, New York, United States|Austin Infectious Disease Consultants, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,126.0053,94.83,5.0,3.0,0.0,7.89,19.07,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00526305,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Ntra. Sra. Sonsoles, Avila, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital vall d'Hebrón, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Hospital de Cruces, Bilbao, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Morales Meseguer, Murcia, Spain|Hospital General Universitario Morales Meseguer., Murcia, Spain|Hospital Santa María del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|H. Carlos Haya, Málaga, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital de Sagunto, Sagunto, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H.U. Virgen del Rocio, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital dr. Peset, Valencia, Spain|Hospital General Universitario, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT02645565,LUPUS NEPHRITIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Unknown status,NCT00400075,POLYARTERITIS NODOSA|MICROSCOPIC POLYANGIITIS,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Terminated,NCT01861561,RENAL INSUFFICIENCY|INFECTION,All,up to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nephrology division, Department of Pediatrics, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=P1(N(CCCl)CCCl)NCCCO1,1,DB00531,__CYCLOPHOSPHAMIDE,3987166,"Active, not recruiting",NCT03218852,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,52.9292182591018,692.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,261.086,41.57,2.0,1.0,1.0,23.72,58.48,5.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CS(=O)(=O)c1ccc(C2=C(c3ccccc3)C(=O)OC2)cc1,1,DB00533,__ROFECOXIB,5474995,Completed,NCT00157872,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D275/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,23.0312737427873,348.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.32,314.356,60.44,3.0,0.0,3.0,31.74,84.08,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,NCT03716804,UNCOMPLICATED URINARY TRACT INFECTION|ANTIBIOTIC RESISTANT INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Combined Military Hosptal, Dhaka, Dhaka, Bangladesh",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O,1,DB00537,__CIPROFLOXACIN,5286754,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,64.8883960656276,849.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.57,331.3415,72.88,6.0,2.0,4.0,33.12,87.94,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0
CN(C)CCOc1ccc(/C(=C(/CCCl)c2ccccc2)c2ccccc2)cc1,1,DB00539,__TOREMIFENE,4696949,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C43/225,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,19.975769522988106,1776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.65,405.96,12.47,2.0,0.0,3.0,46.49,133.41,9.0,0.0,1.0,0.0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNCCC=C1c2ccccc2CCc2ccccc21,1,DB00540,__NORTRIPTYLINE,4175119,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,198.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.65,263.3767,12.03,1.0,1.0,3.0,31.87,96.21,3.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00541,__VINCRISTINE,6723338,Completed,,PERIPHERAL T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,48.6580833281997,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.36,824.972,171.17,9.0,3.0,9.0,88.32,221.48,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@H]1CCc2ccccc2N(CC(=O)O)C1=O,1,DB00542,__BENAZEPRIL,6162802,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,105.33275837286101,681.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.14,424.4895,95.94,5.0,2.0,3.0,44.98,115.23,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0
O=c1[nH]cc(F)c(=O)[nH]1,1,DB00544,__FLUOROURACIL,6670335,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,33.8405306063779,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.58,130.0772,58.2,2.0,2.0,1.0,9.46,26.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1,1,DB00545,__PYRIDOSTIGMINE,3931205,Recruiting,NCT03510546,MYASTHENIA GRAVIS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Department of Neurology Aarhus University Hospital, Aarhus, Midtjylland, Denmark",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,29.635105443643603,905.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.1,181.2117,33.42,1.0,0.0,1.0,19.38,49.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,NCT03050294,ATOPIC DERMATITIS|PSORIASIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Health Sciences Department of Dermatology, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00547,__DESOXIMETASONE,5990100,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,14.8504076059056,768.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.13,376.4617,74.6,4.0,2.0,4.0,40.09,101.17,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
O=C(O)CCCCCCCC(=O)O,1,DB00548,__AZELAIC_ACID,6534070,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,30.8507361547465,3639.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.37,188.2209,74.6,4.0,2.0,0.0,20.5,46.54,8.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCc1cc(=O)[nH]c(=S)[nH]1,1,DB00550,__PROPYLTHIOURACIL,4369172,Unknown status,NCT01056419,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ankara University, Medical School, Ibni Sina Hospital, Endocrinology and Metabolic Diseases Department, Ankara, Turkey",A61K9/2054,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,13.010534097209305,202.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.53,170.232,41.13,1.0,2.0,1.0,17.79,48.9,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
OC[C@H]1O[C@@H](n2cnc3c2N=CNC[C@H]3O)C[C@@H]1O,1,DB00552,__PENTOSTATIN,4151347,Unknown Status,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/052,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.831906199305902,1542.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,268.2691,112.13,7.0,4.0,3.0,26.34,64.98,2.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
COc1c2occc2cc2ccc(=O)oc12,1,DB00553,__METHOXSALEN,4129575,Completed,NCT00221039,CUTANEOUS T CELL LYMPHOMA|MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush-Presbyterian Hospital, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|University Hospital of Cleveland/Case Western Reserve University, Cleveland, Ohio, United States|University of Pittsburgh, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.000657097681604,590.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,216.192,48.67,2.0,0.0,3.0,20.98,56.85,1.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1c2occc2cc2ccc(=O)oc12,1,DB00553,__METHOXSALEN,4129575,Terminated,,CUTANEOUS T-CELL LYMPHOMA (MYCOSIS FUNGOIDES),,,,,"FISABIO, Elche, Alicante, Spain",C07D493/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.000657097681604,590.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1,216.192,48.67,2.0,0.0,3.0,20.98,56.85,1.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,1,DB00555,__LAMOTRIGINE,5698226,Completed,NCT00153244,BRONCHIAL ASTHMA,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,18.333025318795,193.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,256.091,90.71,5.0,2.0,2.0,23.1,66.62,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0
Nc1nnc(-c2cccc(Cl)c2Cl)c(N)n1,1,DB00555,__LAMOTRIGINE,5698226,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,18.333025318795,193.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,256.091,90.71,5.0,2.0,2.0,23.1,66.62,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Active Not Recruiting,,SIGNS AND SYMPTOMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
FC(F)(F)C(F)(F)C(F)(F)F,1,DB00556,__PERFLUTREN,6723303,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/223,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,106.482679315797,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.96,188.0193,0.0,0.0,0.0,0.0,7.1,17.54,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,NCT01250652,CHRONIC URTICARIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical University Sofia, Department of Allergology, Sofia, Bulgaria",A61K9/209,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
OCCOCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB00557,__HYDROXYZINE,4175119,Terminated,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,573.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.43,374.904,35.94,4.0,1.0,3.0,41.99,107.07,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COc1ccccc1Oc1c(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)nc(-c2ncccn2)nc1OCCO,1,DB00559,__BOSENTAN,5292740,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,20.928561161420106,93.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,551.614,145.65,9.0,2.0,4.0,57.89,166.66,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02275299,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03254589,"RHEUMATOID ARTHRITIS|STIFFNESS, AORTIC|ENDOTHELIAL DYSFUNCTION|CARDIOVASCULAR RISK FACTOR",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Withdrawn,NCT00037115,DEMYELINATING DISORDERS|MULTIPLE SCLEROSIS|OPTIC NEURITIS|MYELITIS|NEURITIS,All,18 Years to 50 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MidAmerica Neuroscience Institute, Kansas City, Missouri, United States",A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00112034,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double,"MS Academic Coordinating Center, Cleveland, Ohio, United States",A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00443430,JUVENILE CHRONIC POLYARTHRITIS|JUVENILE IDIOPATHIC ARTHRITIS|JUVENILE RHEUMATOID ARTHRITIS,All,2 Years to 17 Years   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Texas Scottish Rite Hospital, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, United States",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00029523,MENINGEAL NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barrow Neurological Institute, Phoenix, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of Southern California, Norris Cancer Center, Los Angeles, California, United States|University of Colorado Hospital, Anschutz Cancer Pavilion, Denver, Colorado, United States|Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory Clinic, Department of Neurosurgery, Atlanta, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Rush Cancer Institute, Chicago, Illinois, United States|Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center Dept. of Neurology, Boston, Massachusetts, United States|Park Nicollet Institute, Oncology Research Program, Minneapolis, Minnesota, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University Hospital of Cleveland, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Utah, Hunsman Cancer Institute, Salt lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT02660684,GRAFT VS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Daegu, Gyeongsangnam-do, Korea, Republic of|Hwasun-gun, Jeonranam-do, Korea, Republic of|Seoul, Korea, Republic of",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03689465,HEMATOPOIETIC STEM CELL TRANSPLANTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Chenzhou First People's Hospital, Chenzhou, Hunan, China|Peking University People's Hospital, Beijing, China",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02323659,"LYMPHOMA, T-CELL, CUTANEOUS|MYCOSIS FUNGOIDES",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz, Poland",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00153530,CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Charite Campus Benjamin Franklin, Berlin, Germany",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Terminated,NCT00918554,SARCOID-ASSOCIATED UVEITIS|OCULAR SARCOIDOSIS|MACULAR EDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hôpital Avicenne - Service de Médecine Interne, Bobigny, France|CHU Michallon de Grenoble, Grenoble, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Recruiting,NCT03492658,RHEUMATOID ARTHRITIS|RHEUMATIC DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Leiden University Medical Center, Leiden, Netherlands",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT02714634,RHEUMATOID ARTHRITIS|INSUFFICIENT RESPONSE TO METHOTREXATE.,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Terminated,NCT01927757,MODERATE TO SEVERE RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Tuscaloosa, Alabama, United States|Research Site, Scottsdale, Arizona, United States|Research Site, Covina, California, United States|Research Site, Hemet, California, United States|Research Site, Murrieta, California, United States|Research Site, San Diego, California, United States|Research Site, Victorville, California, United States|Research Site, Denver, Colorado, United States|Research Site, Brandon, Florida, United States|Research Site, Dunedin, Florida, United States|Research Site, Largo, Florida, United States|Research Site, Palm Harbor, Florida, United States|Research Site, Tampa, Florida, United States|Research Site, Lawrenceville, Georgia, United States|Research Site, Bowling Green, Kentucky, United States|Research Site, Paducah, Kentucky, United States|Research Site, Fall River, Massachusetts, United States|Research Site, Battle Creek, Michigan, United States|Research Site, Lincoln, Nebraska, United States|Research Site, Smithtown, New York, United States|Research Site, Charlotte, North Carolina, United States|Research Site, Middleburg Heights, Ohio, United States|Research Site, Duncansville, Pennsylvania, United States|Research Site, Hixson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, Corpus Christi, Texas, United States|Research Site, Houston, Texas, United States|Research Site, Victoria, Texas, United States|Research Site, Chesapeake, Virginia, United States|Research Site, Roanoke, Virginia, United States|Research Site, Seattle, Washington, United States|Research Site, Clarksburg, West Virginia, United States|Research Site, Victoria, British Columbia, Canada|Research Site, Quispamsis, New Brunswick, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, St. John's, Newfoundland and Labrador, Canada|Research Site, Burlington, Ontario, Canada|Research Site, Hamilton, Ontario, Canada|Research Site, Mississauga, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Quebec City, Quebec, Canada|Research Site, Quebec, Canada|Research Site, Caguas, Puerto Rico",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Skåne University Hospital, Department of Rheumatology, Lund, Skåne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, Göteborg, Västra Götaland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Completed,NCT00037102,MULTIPLE SCLEROSIS,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M5/2425,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
CN(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB00563,__METHOTREXATE,6746429,Unknown status,NCT00291915,RHEUMATOID ARTHRITIS|ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Cochin, Paris, France",A61M5/2425,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.9186841618924,2117.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.91,454.4393,210.54,12.0,5.0,3.0,44.54,119.21,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1
NC(=O)N1c2ccccc2C=Cc2ccccc21,1,DB00564,__CARBAMAZEPINE,5284662,Completed,NCT00207428,BRONCHIAL ASTHMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.7910840058317,220.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1,236.2686,46.33,1.0,1.0,3.0,25.0,71.89,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1,1,DB00567,__CEPHALEXIN,3931404,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,25.0682765559867,1218.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.55,347.389,112.73,5.0,3.0,3.0,32.52,88.97,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,DB00570,__VINBLASTINE,3932417,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,15409.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,810.9741,154.1,9.0,3.0,9.0,87.46,222.42,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT01070225,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Unviersity of Dundee, Dundee, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
CC(C)NCC(O)COc1cccc2ccccc12,1,DB00571,__PROPRANOLOL,6500454,Not yet recruiting,NCT04508244,TRAUMA|BRAIN INJURIES|STRESS REACTION|BETA BLOCKERS|TROPONIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,14.8832624899895,1234.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.03,259.3434,41.49,3.0,2.0,2.0,29.98,76.83,6.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0
Clc1cccc(Cl)c1NC1=NCCN1,1,DB00575,__CLONIDINE,5869100,Unknown status,NCT01052623,ATAXIA TELANGIECTASIA|GROWTH FAILURE,All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Children's Hospital, Goethe-University, Frankfurt am Main, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,19.5486560298979,3720.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.55,230.09400000000002,36.42,3.0,2.0,2.0,21.7,59.09,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Completed,NCT01026454,HSV INFECTION|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thika Partners in Prevention, Thika, Kenya",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Terminated,NCT00079911,HERPES GENITALIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Altamonte Springs, Florida, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Voorhees, New Jersey, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Kowloon Bay, Hong Kong",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Completed,NCT00161434,HERPES SIMPLEX|HIV INFECTIONS,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Virology Research Clinic, Seattle, Washington, United States",C07D473/00,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21,1,DB00577,__VALACICLOVIR,4957924,Completed,NCT00527618,GENITAL HERPES|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Virology Research Clinic, Seattle, Washington, United States",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,25.4625351649931,393.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,324.3357,146.85,8.0,3.0,2.0,31.96,80.63,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1,1,DB00580,__VALDECOXIB,5633272,Completed,NCT00650455,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Birmingham, Alabama, United States|Pfizer Investigational Site, Huntsville, Alabama, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Glendale, Arizona, United States|Pfizer Investigational Site, Mesa, Arizona, United States|Pfizer Investigational Site, Paradise Valley, Arizona, United States|Pfizer Investigational Site, Phoenix, Arizona, United States|Pfizer Investigational Site, Scottsdale, Arizona, United States|Pfizer Investigational Site, Tucson, Arizona, United States|Pfizer Investigational Site, Fullerton, California, United States|Pfizer Investigational Site, Rancho Mirage, California, United States|Pfizer Investigational Site, San Diego, California, United States|Pfizer Investigational Site, Fort Lauderdale, Florida, United States|Pfizer Investigational Site, Jacksonville, Florida, United States|Pfizer Investigational Site, Jupiter, Florida, United States|Pfizer Investigational Site, Ocala, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Palm Harbor, Florida, United States|Pfizer Investigational Site, Tampa, Florida, United States|Pfizer Investigational Site, West Palm Beach, Florida, United States|Pfizer Investigational Site, Zephyrhills, Florida, United States|Pfizer Investigational Site, Idaho Falls, Idaho, United States|Pfizer Investigational Site, Chicago, Illinois, United States|Pfizer Investigational Site, Springfield, Illinois, United States|Pfizer Investigational Site, Indianapolis, Indiana, United States|Pfizer Investigational Site, Frederick, Maryland, United States|Pfizer Investigational Site, Greenbelt, Maryland, United States|Pfizer Investigational Site, Lansing, Michigan, United States|Pfizer Investigational Site, Jackson, Mississippi, United States|Pfizer Investigational Site, Marlton, New Jersey, United States|Pfizer Investigational Site, Passaic, New Jersey, United States|Pfizer Investigational Site, Teaneck, New Jersey, United States|Pfizer Investigational Site, Brooklyn, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, New York, New York, United States|Pfizer Investigational Site, Columbus, Ohio, United States|Pfizer Investigational Site, Allentown, Pennsylvania, United States|Pfizer Investigational Site, Duncansville, Pennsylvania, United States|Pfizer Investigational Site, Erie, Pennsylvania, United States|Pfizer Investigational Site, Johnstown, Pennsylvania, United States|Pfizer Investigational Site, Mechanicsburg, Pennsylvania, United States|Pfizer Investigational Site, Philadelphia, Pennsylvania, United States|Pfizer Investigational Site, Philadephia, Pennsylvania, United States|Pfizer Investigational Site, Providence, Rhode Island, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, El Paso, Texas, United States|Pfizer Investigational Site, Fort Worth, Texas, United States|Pfizer Investigational Site, Plano, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, San Antonio, Texas, United States|Pfizer Investigational Site, Arlington, Virginia, United States|Pfizer Investigational Site, Seattle, Washington, United States|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Saskatoon, Saskatchewan, Canada",C07D261/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,23.6555165403807,182.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.32,314.3590000000001,86.19,3.0,1.0,3.0,31.76,84.71,3.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O,1,DB00584,__ENALAPRIL,8568747,Completed,NCT00367562,IGA NEPHROPATHY,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Britanico de Buenos Aires, Buenos Aires, Argentina",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,11.7291936179387,1303.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.19,376.4467,95.94,5.0,2.0,2.0,40.41,99.57,10.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01454791,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MS Center at Evergreen Healthcare, Kirkland, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Unknown status,NCT01067430,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northumbria Healthcare NHS Foundation Trust, North Shields, Tyne and Wear, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00447759,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"60 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern Denmark, Odense, Denmark|Julius Clinical Research, Zeist, Netherlands|University of Aberdeen, Aberdeen, United Kingdom|University of Birmingham, Birmingham, United Kingdom|University of Dundee, Dundee, United Kingdom|University of Edinburgh, Edinburgh, United Kingdom|University of Glasgow, Glasgow, United Kingdom|NHS Highlands, Inverness, United Kingdom|University of Nottingham, Nottingham, United Kingdom|University of Oxford, Oxford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB00586,__DICLOFENAC,6407079,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1298.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.98,296.149,49.33,3.0,2.0,2.0,27.93,75.46,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT00119015,"RHINITIS, ALLERGIC, PERENNIAL",All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT01554488,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00616538,ATOPIC DERMATITIS,All,"6 Months to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT01915914,SKIN DISEASES,All,"1 Year to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Shenzhen, Guangdong, China|GSK Investigational Site, Changsha, Hunan, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Terminated,NCT01845025,PERSISTENT ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Avondale, Arizona, United States|Novartis Investigative Site, North Hollywood, California, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Conyers, Georgia, United States|Novartis Investigative Site, Stone Mountain, Georgia, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Gaithersburg, Maryland, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, North Massapequa, New York, United States|Novartis Investigative Site, Elizabeth City, North Carolina, United States|Novartis Investigative Site, Winston Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oaks, Pennsylvania, United States|Novartis Investigative Site, East Greenwich, Rhode Island, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Saint George, Utah, United States|Novartis Investigative Site, Mequon, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB00588,__FLUTICASONE_PROPIONATE,6743413,Completed,NCT00692978,HEALTHY|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Asthma Lab, Royal Brompton Hospital, London, United Kingdom|Department of Nuclear Medicine, Royal Brompton Hospital, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,566.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.69,500.57099999999997,80.67,4.0,1.0,4.0,49.26,121.65,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
COc1cc2nc(N3CCN(C(=O)C4COc5ccccc5O4)CC3)nc(N)c2cc1OC,1,DB00590,__DOXAZOSIN,4188390,Completed,NCT01946035,ALLERGIC RHINITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Brian Lipworth, Dundee, United Kingdom",C07D319/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.8360541284215,320.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,451.4751,112.27,9.0,1.0,5.0,47.17,121.64,4.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1
N=C(N)NC(=O)c1nc(Cl)c(N)nc1N,1,DB00594,__AMILORIDE,4178374,Completed,NCT02875886,CHRONIC KIDNEY DISEASE,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ErasmusMC, Rotterdam, Netherlands",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,20.041479291155802,2363.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.48,229.627,156.79,7.0,5.0,1.0,20.0,67.18,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(=O)NC[C@H]1CN(c2ccc(N3CCOCC3)c(F)c2)C(=O)O1,1,DB00601,__LINEZOLID,5688792,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D413/10,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,20.468592784246,159.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,337.3461,71.11,5.0,1.0,3.0,34.06,84.47,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0
CC[C@@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,1,DB00602,__IVERMECTIN,6103248,Completed,,LYMPHATIC FILARIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A01N53/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,26.809585412431396,1324.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.83,1736.1589,170.06,13.0,3.0,14.0,96.87,230.33,15.0,1.0,0.0,0.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,NCT02357368,HIV|CONTRACEPTION,Female,18 Years to 45 Years   (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Grady Health System, Atlanta, Georgia, United States|The Ponce de Leon Center of the Grady Health System, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinical Research Network, Atlanta, Georgia, United States",A61K9/0019,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,1,DB00603,__MEDROXYPROGESTERONE_ACETATE,6495534,Completed,,BONE DENSITY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0019,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,31.080720343333503,1467.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.42,386.5244,60.44,3.0,0.0,4.0,44.05,107.81,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,GASTROESOPHAGEAL REFLUX,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,1,DB00604,__CISAPRIDE,5648093,Terminated,,GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/60,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,25.7910840058317,205.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,465.945,86.05,6.0,2.0,3.0,49.11,122.93,9.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT03449758,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT02463331,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,NCT01980745,"HEPATITIS, AUTOIMMUNE",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of São Paulo School of Medicine, Sao Paulo, Brazil",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,,RABIES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB00608,__CHLOROQUINE,4181725,Completed,,MALARIA IN PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,674.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.28,319.872,28.16,3.0,1.0,2.0,37.29,96.42,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1cc(C(N)=S)ccn1,1,DB00609,__ETHIONAMIDE,3950522,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,12.5505657200353,1984.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.88,166.243,38.91,1.0,1.0,1.0,17.99,50.19,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Oc1ccc2c(c1)[C@@]13CCCC[C@@]1(O)[C@@H](C2)N(CC1CCC1)CC3,1,DB00611,__BUTORPHANOL,4315936,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,26.021068194418696,660.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.65,327.4605,43.7,3.0,2.0,5.0,37.94,95.92,2.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0
CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1,1,DB00612,__BISOPROLOL,4258062,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D303/24,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.8156430316844,141.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,325.443,59.95,5.0,2.0,1.0,38.5,92.15,12.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O,1,DB00613,__AMODIAQUINE,4806537,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.0720959362615,121.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.83,355.861,48.39,4.0,2.0,3.0,38.89,103.29,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,1,DB00614,__FURAZOLIDONE,3980434,Completed,,GASTRIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,13.5362122425511,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.15,225.1583,98.18,5.0,0.0,2.0,19.78,50.08,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,1,DB00614,__FURAZOLIDONE,3980434,Completed,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,13.5362122425511,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.15,225.1583,98.18,5.0,0.0,2.0,19.78,50.08,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
O=C1OCCN1N=Cc1ccc([N+](=O)[O-])o1,1,DB00614,__FURAZOLIDONE,3980434,Not Yet Recruiting,,DYSPEPSIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,13.5362122425511,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.15,225.1583,98.18,5.0,0.0,2.0,19.78,50.08,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Completed,NCT02184078,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Completed,NCT00023400,HIV INFECTIONS|TUBERCULOSIS,All,"Child, Adult, Older Adult",U.S. Fed,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Arkansas Veterans Health System, Little Rock, Arkansas, United States|LA County/USC Medical Center, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Denver Department of Public Health and Hospitals, Denver, Colorado, United States|Washington, D.C. VAMC, Washington, District of Columbia, United States|Chicago VA Medical Center (Lakeside), Chicago, Illinois, United States|Hines VA Medical Center, Hines, Illinois, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States|Boston Medical Center, Boston, Massachusetts, United States|New Jersey Medical School, Newark, New Jersey, United States|New York University School of Medicine, New York, New York, United States|Columbia University/Presbyterian Medical Center, New York, New York, United States|Harlem Hospital Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Nashville VA Medical Center, Nashville, Tennessee, United States|University of North Texas Health Science Center, Fort Worth, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Audi L. Murphy VA Hospital, San Antonio, Texas, United States|Seattle King County Health Department, Seattle, Washington, United States|University of British Columbia, Vancouver, British Columbia, Canada|University of Manitoba, Winnipeg, Manitoba, Canada|Montreal Chest Institute McGill University, Montreal, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Recruiting,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(c3C2=O)C2=NC3(CCN(CC(C)C)CC3)NC2=C(NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C4=O,1,DB00615,__RIFABUTIN,9050263,Completed,NCT00002343,MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,15.8360541284215,155.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.25,847.0047,205.55,13.0,5.0,6.0,90.72,232.64,5.0,1.0,0.0,0.0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)ccc(Cl)c4[C@@H](O)[C@H]3C[C@@H]12,1,DB00618,__DEMECLOCYCLINE,3966922,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,59.237356003203296,643.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,464.853,181.62,9.0,6.0,4.0,43.8,114.35,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,NCT01297777,SYSTEMIC MASTOCYTOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Spain",C07D409/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Recruiting,NCT01491763,ACUTE LYMPHOBLASTIC LEUKEMIA PH POSITIVE,All,"up to 55 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|H. Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain|Hospital de Mataró, Mataró, Barcelona, Spain|Hospital Universitario de Canarias, Tenerife, Canarias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, La Coruña, Spain|Clínica Universitaria de Navarra, Pamplona, Navarra, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital General de Albacete, Albacete, Spain|Hospital de Alcorcón, Alcorcón, Spain|Hospital General de Alicante., Alicante, Spain|Hospital de Cabueñes, Asturias, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clinic y Provincial de Barcelona, Barcelona, Spain|Hospital Clínico y Provincial de Barcelona, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau., Barcelona, Spain|Hospital de la Santa Creu i Sant Pau., Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital de la santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Duran i Reynals - ICO L'Hospitalet, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Complejo Hospitalario de Cáceres, Cáceres, Spain|Complejo Hospitalario Reina Sofía, Córdoba, Spain|Area Hospitalaria Juan Ramón Jimenez, Huelva, Spain|Hospital Juan Ramón Jiménez, Huelva, Spain|Hospital del SAS de Jerez de la Frontera, Jerez de la Frontera, Spain|Hospital general de Jerez de la Frontera, Jerez de la Frontera, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica La Concepción, Madrid, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre. Madrid, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital de Madrid, S.A.- Norte Hospital General, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Hospital Universitario Princcipe de Asturias, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Univeristario Morales Messeguer, Murcia, Spain|Hospital Sta. Maria del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital de Mérida, Mérida, Spain|Hospital del Río Carrión, Palencia, Spain|Hospital de Gran Canaria Doctor Negrín, Palma De Gran Canaria, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital de Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital Clínico de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital de Donostia, San Sebastián, Spain|Hoaspital Marqués de Valdecilla, Santander, Spain|Hospital General de Segovia, Segovia, Spain|Complejo Hospitalario Regional Virgen del Rocío, Sevilla, Spain|Hospital Joan XIII de, Tarragona, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Clínico de Valencia., Valencia, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Universitario Dr. Peset, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Xeral-Cies, Vigo, Spain|Hospital do Meixoeiro, Vigo, Spain|Hospital Txagorritxu, Vitoria, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",C07D409/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,DB00619,__IMATINIB,5521184,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,25.002566787819,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,493.6027,86.28,7.0,2.0,5.0,55.54,148.93,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Recruiting,NCT03832010,ATOPIC DERMATITIS|ECZEMA,All,2 Years to 17 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins Hospital, Baltimore, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT02680301,"DERMATITIS, ATOPIC",All,3 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Specially for Children Dermatology, Austin, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT01599273,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Severance hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO,1,DB00620,__TRIAMCINOLONE,5976573,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,39.9843939300601,1433.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,394.4339,115.06,6.0,4.0,4.0,39.79,99.38,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1
C[C@]12COC(=O)C[C@@H]1CC[C@@H]1[C@@H]2CC[C@@]2(C)[C@H]1CC[C@]2(C)O,1,DB00621,__OXANDROLONE,6090799,Completed,NCT00006167,HIV WASTING SYNDROME,All,"18 Years and older   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Treatment,"Tufts University School of Medicine, Boston, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,60.8801002073964,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.36,306.4397,46.53,2.0,1.0,4.0,35.29,84.75,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1,1,DB00623,__FLUPHENAZINE,3993072,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M31/002,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,13.240518285796401,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.4,437.522,29.95,4.0,1.0,4.0,44.92,117.27,7.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT00009555,HIV INFECTION,Male,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Treatment,"USC CRS, Los Angeles, California, United States|Charles R. Drew Univ. of Medicine and Science, Div. of Infectious Diseases, Los Angeles, California, United States|Stanford CRS, Palo Alto, California, United States|Ucsd, Avrc Crs, San Diego, California, United States|Ucsf Aids Crs, San Francisco, California, United States|Santa Clara Valley Med. Ctr., San Jose, California, United States|San Mateo County AIDS Program, San Mateo, California, United States|Marin County Dept. of Health & Human Services, HIV/AIDS Program & Specialty Clinic, San Rafael, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Queens Med. Ctr., Honolulu, Hawaii, United States|Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Indiana Univ. School of Medicine, Wishard Memorial, Indianapolis, Indiana, United States|Methodist Hosp. of Indiana, Indianapolis, Indiana, United States|IHV Baltimore Treatment CRS, Baltimore, Maryland, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|St. Louis ConnectCare, Infectious Diseases Clinic, Saint Louis, Missouri, United States|Washington U CRS, St Louis, Missouri, United States|Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr., Omaha, Nebraska, United States|NY Univ. HIV/AIDS CRS, New York, New York, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States|Univ. of Pennsylvania Health System, Presbyterian Med. Ctr., Philadelphia, Pennsylvania, United States|Pitt CRS, Pittsburgh, Pennsylvania, United States|Puerto Rico-AIDS CRS, San Juan, Puerto Rico",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,NCT01127659,HYPOGONADISM,Male,"30 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","115 Flint Road, Williamsville, New York, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Withdrawn,NCT01689896,LOW TESTOSTERONE|HYPOGONADISM|PAIN,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Johns Hopkins Medical Institutions, Baltimore, Maryland, United States",A61K9/7084,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,1,DB00624,__TESTOSTERONE,5152997,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/7084,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,19.9429146389042,2816.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.99,288.4244,37.3,2.0,1.0,4.0,33.88,84.43,0.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00924898,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00127959,HEPATITIS B INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, NH, Netherlands",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00365612,HIV INFECTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hobson City, Alabama, United States|Phoenix, Arizona, United States|Beverly HIlls, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Oakland, California, United States|San Diego, California, United States|San Francisco, California, United States|Tarzana, California, United States|Denver, Colorado, United States|Norwalk, Connecticut, United States|Washington, District of Columbia, United States|Ft. Lauderdale, Florida, United States|Hollywood, Florida, United States|Miami, Florida, United States|Orlando, Florida, United States|Pensacola, Florida, United States|Port St Lucie, Florida, United States|Safety Harbor, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Aurora, Illinois, United States|Chicago, Illinois, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|Grosse Pointe Woods, Michigan, United States|Minneapolis, Minnesota, United States|St. Louis, Missouri, United States|Hillsborough, New Jersey, United States|Newark, New Jersey, United States|Newark, New Jersey, United States|Somers Point, New Jersey, United States|Albany, New York, United States|Brooklyn, New York, United States|Mount Vernon, New York, United States|New York, New York, United States|Rochester, New York, United States|Charlotte, North Carolina, United States|Greenville, North Carolina, United States|Winston-Salem, North Carolina, United States|Akron, Ohio, United States|Philadelphia, Pennsylvania, United States|Providence, Rhode Island, United States|Dallas, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Annandale, Virginia, United States|Hampton, Virginia, United States|Spokane, Washington, United States|Ponce, Puerto Rico|San Juan, Puerto Rico",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00192595,HIV INFECTION|HEPATITIS B COINFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Thai Red Cross AIDS Research Centre, Bangkok, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00549198,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Aarhus N, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Garches, France|GSK Investigational Site, Levallois-Perret, France|GSK Investigational Site, Saint Denis Cedex 01, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Ferrara, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Legnano (MI, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Lausanne, Switzerland|GSK Investigational Site, St Gallen, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Woolwich, London, London, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Brighton, Sussex East, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Farnworth, Bolton, United Kingdom|GSK Investigational Site, Gloucester, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Middlesborough, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Terminated,NCT01014481,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT01585038,CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Unknown status,NCT00162643,ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Especialidades Centro Medico Nacional siglo XXI, Mexico City, D.f., Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, DF, Mexico|Hospital General Regional #53, Los Reyes La Paz, Estado de Mexico, Mexico|Hospital General Regional #72, Tlalnepantla, Estado de Mexico, Mexico|Hospital General Regional de Leon, Leon, Guanajuato, Mexico",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00116116,HIV INFECTIONS|AIDS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Bakersfield, California, United States|Local Institution, San Francisco, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, New York, New York, United States|Local Institution, Greenville, North Carolina, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Dallas, Texas, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00006190,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Diagnostic,"UT Southwestern Medical Center, Dallas, Texas, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00556634,HIV-1 INFECTION|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital de Jerez, Jerez de la Frontera, Cadiz, Spain|Hospital Torrecardenas, Almeria, Spain|Hospital Universitario Puerta del Mar, Cadiz, Spain|Hospital Universitario Reina Sofía, Cordoba, Spain|Hospital Juan Ramon Jimenez, Huelva, Spain|Hospital Universitario Carlos Haya, Malaga, Spain|Hospital Universitario Virgen de la Victoria, Malaga, Spain|Hospitales Universitarios Virgen del Rocio, Seville, Spain|Hospital Universitario de Valme, Seville, Spain|Hospital Universitario Virgen Macarena, Seville, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Terminated,NCT01194856,HIV INFECTION|MITOCHONDRIAL DYSFUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Unknown status,NCT01147107,"HEPATITIS C, CHRONIC|HIV INFECTION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Viet Tiep General Hospital, Hai Phong, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Terminated,NCT00533390,TUBERCULOSIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Federal do Espirito Santo, Vitoria, Espirito Santo, Brazil|FIOCRUZ Instituto de Pesquisa Clinica Evandro Chagas, Rio de Janeiro, Brazil",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT01075152,CRYPTOCOCCAL MENINGITIS|HIV INFECTIONS|AIDS,All,"14 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"GF Jooste Hospital, Cape Town, South Africa|Infectious Disease Institute, Mulago Hospital, Makerere University, Kampala, Uganda|Mbarara University of Science and Technology, Mbarara, Uganda",C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT01900015,HCV COINFECTION|HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital La Línea, La Línea de la Concepción, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Infanta Elena, Huelva, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario Carlos Haya, Málaga, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|H.U. Valme, Seville, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Completed,NCT00444379,KAPOSI'S SARCOMA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Terminated,NCT00775606,ACQUIRED IMMUNE DEFICIENCY SYNDROME,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Medical Center, Chicago, Illinois, United States|Howard Brown Health Center, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C1Nc2ccc(Cl)cc2[C@@](C#CC2CC2)(C(F)(F)F)O1,1,DB00625,__EFAVIRENZ,5814639,Terminated,NCT01980342,DRUG INTERACTION,Female,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Johns Hopkins University Bayview Medical Center, Baltimore, Maryland, United States",C07D411/04,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,97.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.89,315.675,38.33,2.0,1.0,3.0,26.81,71.34,3.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,DB00626,__BACITRACIN,,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.9,1422.693,530.87,20.0,17.0,4.0,149.32,363.14,31.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,0
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Terminated,NCT01683656,HIV|ATHEROSCLEROSIS,All,"40 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital Berne Inselspital, Berne, BE, Switzerland|University Hospital Basel, Basel, BS, Switzerland|University Hospitals Genève, Geneva, GE, Switzerland|Kantonsspital St Gallen, St Gallen, SG, Switzerland|EOC Ente Ospedaliero Cantonale, civico, Lugano, TI, Switzerland|CHUV Cantonal University Hospital Vaud, Lausanne, VD, Switzerland|University Hospital Zurich, Zurich, ZH, Switzerland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)c1cccnc1,1,DB00627,__NIACIN,6080428,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,3424.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.29,123.1094,50.19,3.0,1.0,1.0,11.3,31.16,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
O=C(O)C1N=C(c2ccccc2)c2cc(Cl)ccc2NC1=O,1,DB00628,__CLORAZEPIC_ACID,WO-1998022114-A1,Unknown Status,,"LYMPHOMA, T-CELL, CUTANEOUS",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.68,314.723,78.76,4.0,2.0,3.0,30.63,82.68,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0
NCCCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00630,__ALENDRONIC_ACID,5358941,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,22.7355797860325,8.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,249.09599999999998,161.31,8.0,6.0,0.0,19.4,47.37,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0
Cc1cccc([C@H](C)c2c[nH]cn2)c1C,1,DB00633,__DEXMEDETOMIDINE,5344840,Recruiting,NCT03069638,JUVENILE IDIOPATHIC ARTHRITIS|JOINT INFLAMMATION,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oulu university hospital, Oulu, Finland",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,19.745785334401106,276.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.28,200.2795,28.68,1.0,1.0,2.0,23.32,62.98,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00195429,KIDNEY FAILURE|GRAFT VS HOST DISEASE,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sao Paulo, Brazil",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT03829371,MULTIPLE MYELOMA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, TO, Italy",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02115997,WEGENER'S GRANULOMATOSIS OR MICROSCOPIC POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Sir Gangaram Hospital, New Delhi, Delhi, India|Medanta-The Medicity, Gurgaon, Haryana, India|Fortis Memorial Research Instititute, Gurgaon, Haryana, India|Apollo BGS Hospitals, Mysuru, Karnataka, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India|Manipal Hospital, Bangalore, India|St. John's Medical College Hospital; Rheumatology, Bangalore, India|Chanre Rheumatology and Immunology Center and Research, Bangalore, India|MULJIBHAI PATEL UROLOGICAL HOSPITAL; Nephrology, Gujarat, India|Medica Superspeciality Hospital, Kolkata, India|Jasleen Hospital, Nagpur, India|Max Super Speciality Hospital, New Delhi, India|All India Institute of Medical Sciences (AIIMS); Rheumatology, New Delhi, India|Indraprastha Apollo Hospitals; Department of Rheumatology, New Delhi, India|Fortis Hospital, Noida, India|Christian Med Clg & Hspt, Vellore, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04276233,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01356511,"PURPURA, THROMBOCYTOPENIC, IDIOPATHIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Shandong University, Jinan, Shandong, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Terminated,NCT02780479,ASTHMA|STATUS ASTHMATICUS|WHEEZES,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wolfson Children Hospital, Jacksonville, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01241006,ASTHMA|REACTIVE AIRWAY DISEASE,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alameda County Medical Center, Oakland, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02463331,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00987116,MYASTHENIA GRAVIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hopital Raymond Poincaré, Garches, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,"Active, not recruiting",NCT03218852,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02703194,IMMUNOGLOBULIN G4 RELATED SCLEROSING DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese PLA General Hospital, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT02809079,NEUROMYELITIS OPTICA SPECTRUM DISORDERS|MYCOPHENOLATE MOFETIL|EFFICACY AND SAFETY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04424862,EFFICACY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Frienship Hospital, Capital Medical University, Beijing, Beijing, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT02184299,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Withdrawn,NCT01210677,CARDIAC SARCOIDOSIS|SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Ottawa Heart Institute, Ottawa, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Terminated,NCT01411514,MULTIPLE SCLEROSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Osepdale Civico, Lugano, Ticino, Switzerland",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Recruiting,NCT04169100,LONG QT SYNDROME|CONNECTIVE TISSUE DISEASES|RHEUMATOID ARTHRITIS,All,"18 Years to 89 Years   (Adult, Older Adult)",Other|U.S. Fed,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"VA New York Harbor Healthcare System, NY and Brooklyn Campuses, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Not yet recruiting,NCT04542278,THYROID DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00975078,ADRENAL GLAND HYPOFUNCTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Division of Endocrinology University Hospital Basel, Basel, Switzerland",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Unknown status,NCT01400464,GIANT CELL ARTERITIS,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHU de CAEN, Caen, Etat, France|Hôpital Cochin-APHP, Paris, Etat, France|Centre Hospitalier Universitaire de Toulouse, Toulouse, Etat, France|CH de Valenciennes, Valenciennes, Etat, France|CHU Avicennes, Bobigny, France|CHU Jean Verdier (AP-HP), Bondy, France|Hôpital Gabriel Montpied, Clermont-Ferrand, France|CHU de Lille, Lille, France|Centre Hospitalier Universitaire de Limoges, Limoges, France|CHU de Nantes, Nantes, France|Hôpital Pitié-Salpêtrière-APHP, Paris, France|CHU de Rouen, Rouen, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT01169597,POLYMYALGIA RHEUMATICA,All,"50 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinica Reumatologica, Dipartimento di medicina Interna, Università di Genova, Genova, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT03098823,"LUPUS ERYTHEMATOSUS, SYSTEMIC|LUPUS ERYTHEMATOSUS|FATIGUE",All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cedars-Sinai Medical Center, Los Angeles, California, United States|The Regents of the University of California, Los Angeles, Los Angeles, California, United States|University of California-Irvine, Orange, California, United States|Stanford University, Palo Alto, California, United States|The Regents of the University of California, San Diego, San Diego, California, United States|University of California-San Francisco, San Francisco, California, United States|Yale School of Medicine, New Haven, Connecticut, United States|University of Florida College of Medicine, Gainesville, Florida, United States|Miller School of Medicine at the University of Miami, Miami, Florida, United States|Northwestern University, Chicago, Illinois, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Maryland School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMASS Memorial Medical Center-Memorial Campus, Worcester, Massachusetts, United States|The Hospital for Special Surgery, New York, New York, United States|Columbia University Medical Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The MetroHealth System, Cleveland, Ohio, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Hershey Medical Center, Hershey, Pennsylvania, United States|Temple University, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Completed,NCT00472030,BULLOUS PEMPHIGOID,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa, Department of Dermatology, Iowa City, Iowa, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00635,__PREDNISONE,6488960,Terminated,NCT00203047,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.6532783014024,1832.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,358.4281,91.67,5.0,2.0,4.0,38.17,97.57,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,1,DB00640,__ADENOSINE,5731296,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,60.2887122938869,1415.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,267.2413,139.54,8.0,4.0,3.0,25.28,63.2,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT01205347,MYOCARDIAL INFARCTION,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital de Base do Distrito Federal, Brasilia, DF, Brazil",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Unknown status,NCT00866229,SYSTEMIC LUPUS ERYTHEMATOSUS|HIGH LDL CHOLESTEROL LEVEL,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",C07D205/08 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Terminated,NCT00739050,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D205/08 ,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT04177173,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Hospital, Lahore, Punjab, Pakistan",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,1,DB00641,__SIMVASTATIN,RE42461,Completed,NCT00492765,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Coordinating Research Site, Copenhagen, Denmark",C07D205/08 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,200.973325940984,1639.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,418.5662,72.83,3.0,1.0,3.0,47.88,117.68,7.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Terminated,NCT01601899,MITOCHONDRIAL TOXICITY|METABOLIC COMPLICATIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Themba Lethu Clinic, Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng, South Africa",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00618176,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00116116,HIV INFECTIONS|AIDS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Bakersfield, California, United States|Local Institution, San Francisco, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, New York, New York, United States|Local Institution, Greenville, North Carolina, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00006190,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Diagnostic,"UT Southwestern Medical Center, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Cc1cn([C@H]2C=C[C@@H](CO)O2)c(=O)[nH]c1=O,1,DB00649,__STAVUDINE,7135465,Completed,NCT00055120,HIV INFECTIONS|AIDS-RELATED OPPORTUNISTIC INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, Davis Medical Center, Sacramento, California, United States|University of California, San Diego Antiviral Rese, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|San Mateo County AIDS Program, Stanford, California, United States|Santa Clara Valley Medical Center, Stanford, California, United States|Stanford Univ, Stanford, California, United States|Willow Clinic, Stanford, California, United States|Harbor General/UCLA, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Denver, Colorado, United States|Univ of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Cook County Hospital Core Center, Chicago, Illinois, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Indiana University Hosp, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Harvard (Massachusetts General Hospital), Boston, Massachusetts, United States|Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Hennepin County Medical Clinic, Minneapolis, Minnesota, United States|St. Louis Connect Care, St. Louis, Missouri, United States|Washington University (St. Louis), St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|NYU/Bellevue, New York, New York, United States|Columbia University, New York, New York, United States|Community Health Network, Inc., Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Presbyterian Medical Center - University of PA, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Comprehensive Care Clinic, Nashville, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Univ of Texas, Galveston, Galveston, Texas, United States|University of Washington (Seattle), Seattle, Washington, United States|University of Puerto Rico, San Juan, Puerto Rico|University of Witwatersrand, Parktown, Johannesburg, South Africa",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,34.0,67.5496416764204,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.73,224.2133,78.87,4.0,2.0,2.0,21.33,55.32,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0
Nc1nc2c(c(=O)[nH]1)N(C=O)C(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)CN2,1,DB00650,__LEUCOVORIN,4148999,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,473.44599999999997,215.55,11.0,7.0,3.0,46.33,126.66,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Completed,NCT00002146,CYTOMEGALOVIRUS INFECTIONS|HIV INFECTIONS|HYPOCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"Oklahoma City Veterans Administration Med Ctr, Oklahoma City, Oklahoma, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Recruiting,NCT04497766,ASTHMA IN CHILDREN,All,2 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"King edward medical university/mayo hospital lahore, Lahore, Punjab, Pakistan",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Mg+2],1,DB00653,__MAGNESIUM_SULFATE,6946149,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.7072013799051,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.84,120.368,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",A61M5/31511,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT01217138,ANAPHYLAXIS,All,21 Years to 26 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),,A61M5/31511,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
CNC[C@H](O)c1ccc(O)c(O)c1,1,DB00668,__EPINEPHRINE,5665071,Completed,NCT01705964,ASTHMA,All,6 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Kosair Children's Hospital, Louisville, Kentucky, United States",A61M5/31511,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,14.4561489968993,1353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,183.2044,72.72,4.0,4.0,1.0,19.04,49.23,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C=CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C(=N\OCC(=O)O)c3csc(N)n3)[C@H]2SC1,1,DB00671,__CEFIXIME,9233112,Completed,NCT03716804,UNCOMPLICATED URINARY TRACT INFECTION|ANTIBIOTIC RESISTANT INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Combined Military Hosptal, Dhaka, Dhaka, Bangladesh",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,55.1633503768044,1027.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.25,453.45,184.51,10.0,4.0,3.0,41.62,104.91,8.0,0.0,1.0,0.0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,1,DB00673,__APREPITANT,5145684,Terminated,NCT01625455,SEZARY SYNDROME|PRURITUS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vanderbilt University Medical Center, Nashville, Tennessee, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,534.4267,75.19,5.0,2.0,4.0,45.56,116.93,8.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,NCT01612871,BREAST CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Val d'Aurelle - Paul Lamarque, Montpellier, France|Institut Claudius REGAUD Toulouse, Toulouse, France",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC/C(=C(\c1ccccc1)c1ccc(OCCN(C)C)cc1)c1ccccc1,1,DB00675,__TAMOXIFEN,6127425,Completed,,PCOS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,27.2695537896055,7013.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.93,371.5146,12.47,2.0,0.0,3.0,44.19,128.43,8.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT01529749,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Unknown status,NCT02231125,IGA NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The First Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Chao-yang Hospital, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Dong Zhi Men Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China|Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China|PLA Navy General Hospital, Beijing, Beijing, China|The Second Artillery General Hospital Of Chinese People's Liberation Army, Beijing, Beijing, China|Da Ping Hospital Of Third Military Medical University, Chongqing, Chongqing, China|Yongchuan Hospital Of Chongqing Medical University, Chongqing, Chongqing, China|Chinese People's Liberation Army No.180 Hospital, Quanzhou, Fujian, China|Chinese People's Liberation Army No.174 Hospital, Xiamen, Fujian, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|The Second Hospital of Lanzhou University, Lanzhou, Gansu, China|421 Hospital of PLA, Guangzhou, Guangdong, China|Guangdong Province Hospital of Traditional Chinese Medicine(TCM), Guangzhou, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China|Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|The Affiliated Baiyun Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Affiliated Hospital Of Zun Yi Medical College, Zunyi, Guizhou, China|Hainan Medical College Affiliated Hospital, Haikou, Hainan, China|Hainan Provincial Nong Ken Hospital, Haikou, Hainan, China|Affiliated Hospital of Cheng De Medical College, Chengde, Hebei, China|First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China|Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China|TCM Hospital of Shi Jia Zhuang City, Shijiazhuang, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Heilongjiang Provincial Academy of Traditional Chinese Medicine, Haerbin, Heilongjiang, China|The Second Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science And Technology, Luoyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Huang Gang Central Hospital, Huanggang, Hubei, China|Hubei Provincial Hospital Of TCM, Wuhan, Hubei, China|Wuhan Integrated TCM & Western Medicine Hospital, Wuhan, Hubei, China|Zhong Nan Hospital of Wuhan University, Wuhan, Hubei, China|The Second Xiang Ya Hospital of Central South University, Changsha, Hunan, China|The Third Xiang Ya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, China|Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, China|Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu, China|Taizhou Traditional Chinese Medicine Hospital, Taizhou, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|Chinese People's Liberation Army No.94 Hospital, Nanchang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital Of Jilin University, Changchun, Jilin, China|Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian, Liaoning, China|The First Affiliated Hospital Of Dalian Medical University, Dalian, Liaoning, China|First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning, China|People's Liberation Army No.202 Hospital, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The First Hospital Of China Medical University, Shenyang, Liaoning, China|The General Hospital Of Shenyang Military Region, Shenyang, Liaoning, China|Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China|The General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Jinan General Hospital of PLA, Jinan, Shandong, China|Qi Lu Hospital of Shandong University, Jinan, Shandong, China|Affiliated Hospital of Jining Medical University, Jining, Shandong, China|Jining No.1 People's Hospital, Jining, Shandong, China|Chinese People's Liberation Army No.88 Hospital, Taian, Shandong, China|Yantai Yu Huang Ding Hospital, Yantai, Shandong, China|Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China|Chang Hai Hospital of the Second Military Medical University, Shanghai, Shanghai, China|Ren Ji Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|Shanxi Provincial People's Hospital, Xian, Shanxi, China|The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi, China|Hua Xi Hospital of Sichuan University, Chengdu, Sichuan, China|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Hospital of ITCWM, Nankai Hospital, Tianjin, Tianjin, China|The First Hospital of Shi He Zi Medical University, Shihezi, Xinjiang, China|The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Yan'an Hospital of Kunming City, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,NCT01115426,IGA GLOMERULONEPHRITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Mater Domini"" Hospital, Catanzaro, Calabria, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB00678,__LOSARTAN,5210079,Completed,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,15.0803917944927,357.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.5,422.911,92.51,5.0,2.0,4.0,44.86,131.85,8.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Terminated,NCT00386997,FUNGAL INFECTION,All,"55 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Gilead Sciences GmbH, Martinsried/Munich, Germany",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Unknown status,NCT02686853,CRYPTOCOCCAL MENINGITIS,All,"14 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,1,DB00681,__AMPHOTERICIN_B,6406713,Completed,,VISCERAL LEISHMANIASIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,85.6855376907123,1454.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.66,924.079,319.61,17.0,12.0,3.0,99.45,244.67,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,"Active, not recruiting",NCT02295475,ANTIPHOSPHOLIPID SYNDROME|THROMBOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The James Comprehensive Cancer Center, Columbus, Ohio, United States|Intermountain Medical Center, Murray, Utah, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Recruiting,NCT02303171,RECURRENT MISCARRIAGE|ANTIPHOSPHOLIPID SYNDROME,Female,20 Years to 38 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Obstetrics and Gynecology Department in Mansoura University Hospital, Mansourah, Dakahlia, Egypt|Private practice settings, Mansourah, Dakahlia, Egypt",7,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Active Not Recruiting,,ANTIPHOSPHOLIPID SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O,1,DB00682,__WARFARIN,3932656,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,24.77258259923201,179.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.41,308.3279,63.6,3.0,1.0,3.0,31.93,86.86,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,NCT00050180,HEALTHY|HIV INFECTIONS,All,18 Years to 60 Years   (Adult),NIH,Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Unknown status,NCT02135055,INFLAMMATORY DISORDER OF IMMUNE SYSTEM|SEPSIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2,1,DB00683,__MIDAZOLAM,8217033,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,37.68455204418978,189.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.89,325.767,30.18,2.0,0.0,4.0,32.7,99.43,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O,1,DB00684,__TOBRAMYCIN,5149694,Completed,,CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,34.0048050267972,662.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-3.0,467.5145,268.17,14.0,10.0,3.0,47.18,106.69,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00687,__FLUDROCORTISONE,4041055,Unknown status,NCT01453959,HYPERTENSION,All,"40 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"General Hospital of School of Medicine - Universiy of Sao Paulo, Sao Paulo, SP, Brazil",C07J1/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00687,__FLUDROCORTISONE,4041055,Withdrawn,,ADRENAL INSUFFICIENCY,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,626.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.35,380.4504,94.83,5.0,3.0,4.0,39.53,96.93,2.0,0.0,1.0,0.0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,1,0,0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT00843856,"GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hammersmith Hospital, London, United Kingdom",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Recruiting,NCT02630628,LUPUS NEPHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT00863252,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT02342145,BETA-THALASSEMIA MAJOR,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Union hospital of fujian medical university, Fuzhou, Fujian, China|the zhongshan hospital of Xiamen University, Xia'men, Fujian, China|The affiliated hospital of guangxi medical university, Nanning, Guangxi, China|Affiliated Drum Tower Hospital, Nanjing medical university, Nanjing, Jiangsu, China|Kunming general hospital of chengdu military region, Kunming, Yunnan, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT02864706,HEART TRANSPLANTATION,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Århus N, Denmark|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden",C07D307/88,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT02900443,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Sint Antonius Hospital, Nieuwegein, Netherlands|Radboud University Medical Centre, Nijmegen, Netherlands",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Recruiting,NCT03689465,HEMATOPOIETIC STEM CELL TRANSPLANTATION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China|The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China|Xiangya Hospital, Central South University, Changsha, Hunan, China|Chenzhou First People's Hospital, Chenzhou, Hunan, China|Peking University People's Hospital, Beijing, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT03582878,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Clinical and Experimental Medicine, Prague, Czechia",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Not yet recruiting,NCT04376528,"HEPATITIS, AUTOIMMUNE|PRIMARY BILIARY CHOLANGITIS|IMMUNOSUPPRESSION",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Unknown status,NCT02809079,NEUROMYELITIS OPTICA SPECTRUM DISORDERS|MYCOPHENOLATE MOFETIL|EFFICACY AND SAFETY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Completed,NCT01101802,SYSTEMIC LUPUS ERYTHEMATOSUS|ATHEROSCLEROSIS,Female,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Lupus Research Unit, St Thomas' Hospital, London, United Kingdom",C07D307/88,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Recruiting,NCT03170323,IDIOPATHIC MEMBRANOUS NEPHROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangzhou, Guangdong, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Not yet recruiting,NCT04424862,EFFICACY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing Frienship Hospital, Capital Medical University, Beijing, Beijing, China",C07D307/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)OCCN1CCOCC1)C(=O)OC2,1,DB00688,__MYCOPHENOLATE_MOFETIL,5543408,Active Not Recruiting,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.041479291155802,259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.17,433.4947,94.53,6.0,1.0,3.0,45.54,117.1,10.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",A61K9/1278,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00694,__DAUNORUBICIN,8518437,Active Not Recruiting,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/1278,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,129.448243290416,5938.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.68,527.5199,185.84,11.0,5.0,5.0,52.94,132.89,4.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1,1,DB00698,__NITROFURANTOIN,4053593,Completed,NCT03716804,UNCOMPLICATED URINARY TRACT INFECTION|ANTIBIOTIC RESISTANT INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Combined Military Hosptal, Dhaka, Dhaka, Bangladesh",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,22.505595597445502,397.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.03,238.15900000000002,118.05,5.0,1.0,2.0,20.49,52.11,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,1,DB00701,__AMPRENAVIR,5585397,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D231/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,36.7646152898416,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.85,505.62699999999995,131.19,6.0,3.0,3.0,53.6,134.08,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,1,DB00701,__AMPRENAVIR,5585397,Unknown status,NCT00005017,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Jaime Hernandez, Research Triangle Park, North Carolina, United States",C07D231/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,36.7646152898416,776.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.85,505.62699999999995,131.19,6.0,3.0,3.0,53.6,134.08,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1,DB00704,__NALTREXONE,5792477,Recruiting,NCT03089983,OPIOID DEPENDENCE|ADDICTION|HIV/AIDS|TUBERCULOSIS|HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Kajang Prison, Kajang, Selangor, Malaysia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,52.0,15.310375983079698,233.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,341.4009,70.0,5.0,2.0,6.0,35.97,91.5,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1,DB00704,__NALTREXONE,5792477,Withdrawn,NCT00854230,HIV INFECTION|HEAVY ALCOHOLIC CONSUMPTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,52.0,15.310375983079698,233.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,341.4009,70.0,5.0,2.0,6.0,35.97,91.5,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
O=C1CC[C@@]2(O)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CC2)[C@H]1O5,1,DB00704,__NALTREXONE,5792477,Completed,NCT01377168,HIV|ALCOHOL USE DISORDER,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asociación Civil Impacta Salud y Educación, Lima, Peru",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,15.310375983079698,233.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,341.4009,70.0,5.0,2.0,6.0,35.97,91.5,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00662545,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General HIV Clinical Trials Group, San Francisco, California, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00192595,HIV INFECTION|HEPATITIS B COINFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Thai Red Cross AIDS Research Centre, Bangkok, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Terminated,NCT01014481,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bamrasnaradura Infectious Diseases Institute, Ministry of Public Health, Nonthaburi, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",C07D411/04,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00005764,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"THE Clinic, Los Angeles, California, United States|Tower Infectious Disease Med Ctr, Los Angeles, California, United States|St Lukes Medical Group, San Diego, California, United States|UCSD Treatment Ctr, San Diego, California, United States|Dupont Circle Physicians Group, Washington, District of Columbia, United States|North Broward Hosp District / HIV Clinical Research, Fort Lauderdale, Florida, United States|Duval County Health Department, Jacksonville, Florida, United States|Infectious Disease Research Institute Inc, Tampa, Florida, United States|Northstar Med Clinic, Chicago, Illinois, United States|Jersey Shore Med Ctr, Neptune, New Jersey, United States|South Jersey Infectious Diseases Inc, Somers Point, New Jersey, United States|Infectious Disease Specialists of NJ, Union, New Jersey, United States|Bronx Veterans Affairs Med Ctr, Bronx, New York, United States|Infectious Diseases Assoc of Brooklyn, Brooklyn, New York, United States|Long Island College Hospital, Brooklyn, New York, United States|Mt Vernon Hospital, Mt. Vernon, New York, United States|Dr Lawrence Fontana, New York, New York, United States|Liberty Medical / Cabrini Hospital / Dept of Infec Diseases, New York, New York, United States|Howard Grossman, New York, New York, United States|Boriken Neighborhood Health Center, New York, New York, United States|Univ of North Carolina / SOCA, Chapel Hill, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States|Anderson Clinical Research, Pittsburgh, Pennsylvania, United States|Central Texas Clinical Research, Austin, Texas, United States|Gathe, Joseph, M.D., Houston, Texas, United States|Diversified Med Practices, PA, Houston, Texas, United States|Univ of Texas / Med School at Houston, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States|Swedish Med Ctr, Seattle, Washington, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Recruiting,NCT02712801,HIV/AIDS AND INFECTIONS,All,up to 1 Day   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China|Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Maternal and Child Health Hospital of Sichuan Province, Chengdu, Sichuan, China|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China|Maternal and Child Health Hospital of Yunan Province, Kunming, Yunnan, China",C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00141284,HEPATITIS C INFECTION,All,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Bakersfield, California, United States|Pfizer Investigational Site, Miami, Florida, United States|Pfizer Investigational Site, Shreveport, Louisiana, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Toronto, Ontario, Canada",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Unknown status,NCT00162643,ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Especialidades Centro Medico Nacional siglo XXI, Mexico City, D.f., Mexico|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, DF, Mexico|Hospital General Regional #53, Los Reyes La Paz, Estado de Mexico, Mexico|Hospital General Regional #72, Tlalnepantla, Estado de Mexico, Mexico|Hospital General Regional de Leon, Leon, Guanajuato, Mexico",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00143689,HIV|MITOCHONDRIAL TOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McMaster University, Hamilton, Ontario, Canada|University of Ottawa Health Services, Ottawa, Ontario, Canada|Maple Leaf Clinic, Toronto, Ontario, Canada|Clinique Medicale L'Actuel, Montreal, Quebec, Canada",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00116116,HIV INFECTIONS|AIDS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Bakersfield, California, United States|Local Institution, San Francisco, California, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Jacksonville, Florida, United States|Local Institution, Miami, Florida, United States|Local Institution, New York, New York, United States|Local Institution, Greenville, North Carolina, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Dallas, Texas, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT02770508,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Consultorio Infectológico Dr. Pryluka, Caba, Buenos Aires, Argentina|Hospital Cosme Argerich, Caba, Buenos Aires, Argentina|Hospital Italiano, Caba, Buenos Aires, Argentina|Fundacion huesped, Caba, Buenos Aires, Argentina|Centro de Estudios Infectologicos SA (CTD Stamboulian), Caba, Buenos Aires, Argentina",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1ccn([C@@H]2CS[C@H](CO)O2)c(=O)n1,1,DB00709,__LAMIVUDINE,5905082,Completed,NCT00192621,HIV INFECTIONS|DYSLIPIDEMIAS|GLUCOSE METABOLISM DISORDERS|METABOLIC DISEASES|LIPODYSTROPHY|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"St Vincents Hospital, Sydney, New South Wales, Australia",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,82.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,229.25599999999997,88.15,5.0,2.0,2.0,21.7,55.16,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Withdrawn,NCT00662077,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital - Lluita Sida Foundation, Badalona, Barcelona, Spain",C07F9/405,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT01287533,RHEUMATOID ARTHRITIS|OSTEOPOROSIS|OSTEOPENIA,Female,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Seoul National University Hospital, Seoul, Korea, Republic of",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O,1,DB00710,__IBANDRONATE,4927814,Completed,NCT00668330,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","School of Pharmacy CUHK, Hong Kong, China",C07F9/405,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,34.4319185198874,637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,319.2289,138.53,8.0,5.0,0.0,29.51,71.16,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB00717,__NORETHISTERONE,6036976,Completed,NCT02905890,BACTERIAL VAGINOSIS|HIV,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"MRC/UVRI Mengo Clinic and Research Station, Kampala, Uganda",A61K9/1647,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.905911825704802,1272.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.72,298.4192,37.3,2.0,1.0,4.0,34.59,87.42,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O,1,DB00722,__LISINOPRIL,9463183,Completed,NCT01535235,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","San Francisco General Hospital, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,11.1706605885131,274.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,405.4879,132.96,7.0,4.0,2.0,43.5,107.37,12.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,1,DB00724,__IMIQUIMOD,4689338,Completed,NCT00761371,WARTS,All,"18 Years to 69 Years   (Adult, Older Adult)",Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Départment de Gynécologie-Obstétrique CHU Saint-Pierre, Brussels, Belgium|Service de Dermatologie CHU Saint-Pierre, Brussels, Belgium|Service Dermatologie C.H. François Rabelais (César de Paepe), Brussels, Belgium|Service de Dermatologie Hôpital Erasme, Brussels, Belgium|Service de Dermatologie et Vénéréologie Hôpital Saint Jacques, Besancon Cedex, France|Cabinet Médical, Bordeaux, France|Service de Dermatologie, Hôpital Ambroise Paré, Boulogne Billancourt, France|Service de Maladies Infectieuses Hôpital de la Conception, Marseille, France|Service de Dermatologie Hôtel Dieu, Nantes, France|Service de Dermatologie Hôpital de l'Archet II, Nice, France|Service Dermatologie Hopital COCHIN - Pavillon Tarnier, Paris, France|Cabinet Médical, Paris, France|Institut Alfred Fournier, Paris, France|Cabinet Médical, Paris, France|Service de Dermatologie Groupe Hospitalier Bichat Claude Bernard, Paris, France|Service de Dermatologie Hopital Tenon, Paris, France|Service de Dermatologie Groupe Hospitalier La Grave, Toulouse, France|Service de Dermatologie Centre Hospitalier de Valence, Valence, France",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)Cn1cnc2c(N)nc3ccccc3c21,1,DB00724,__IMIQUIMOD,4689338,Withdrawn,NCT01663558,ANAL DYSPLASIA|HUMAN PAPILLOMA VIRUS|HIV,Male,"18 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NMCSD, San Diego, California, United States",C07D471/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,21.289964886342602,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.83,240.3036,56.73,3.0,1.0,3.0,26.67,72.54,2.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1nc2n(c(=O)c1CCN1CCC(c3noc4cc(F)ccc34)CC1)CCCC2,1,DB00734,__RISPERIDONE,5792477,Completed,NCT00190749,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,15.310375983079698,156.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.27,410.4845,61.94,4.0,0.0,5.0,45.27,114.55,4.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@](=O)Cc3ncc(C)c(OC)c3C)nc2c1,1,DB00736,__ESOMEPRAZOLE,5900424,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,55.1962052608883,222.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.66,345.416,77.1,5.0,1.0,3.0,35.81,93.66,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Recruiting,NCT03539601,ATOPIC DERMATITIS,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dermatology Trial Associates, Bryant, Arkansas, United States|California Dermatology & Clinical Research Institute, Encinitas, California, United States|Park Avenue Dermatology, Orange Park, Florida, United States|Lenus Research & Medical Group, LLC, Sweetwater, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|DS Research, Louisville, Kentucky, United States|Virgo-Carter Pediatrics, Silver Spring, Maryland, United States|M3-Wake Research, Inc., Raleigh, North Carolina, United States|Arlington Research Center Inc, Arlington, Texas, United States|Tanner Clinic, Layton, Utah, United States|Virginia Clinical Research, Inc, Norfolk, Virginia, United States|Hopital Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Klinikum der Universitat Munchen, Munchen, Bayern, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz, Bad Bentheim, Niedersachsen, Germany|Universitatsklinikum Bonn, Bonn, NRW, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany|ISA - Interdisciplinary Study Association GmbH, Berlin, Germany|UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore, L'Aquila, AQ, Italy|DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria, Genova, GE, Italy|Ospedale San Pietro Fatebenefratelli, Roma, RM, Italy|Azienda Ospedaliero - Universitaria Policlinico Tor Vergata, Roma, Rome, Italy|Silmedic sp. z o.o, Katowice, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, Poland|Klinika Ambroziak Sp. z O. O., Warszawa, Poland|ROYALDERM Agnieszka Nawrocka, Warszawa, Poland|Barn och Ungdomskliniken, Orebro, Sweden|Avdelningen for Kliniska Provningar, Orebro, Sweden|Universitatsklinik fuer Dermatologie, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitats-Kinderspital Zurich, Zurich, Switzerland|Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, United Kingdom|NHS Tayside, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom|NHS Tayside, Dundee, Scotland, United Kingdom|Sheffield Children's NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Recruiting,NCT03832010,ATOPIC DERMATITIS|ECZEMA,All,2 Years to 17 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins Hospital, Baltimore, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00741,__HYDROCORTISONE,5635497,Completed,NCT01070225,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Unviersity of Dundee, Dundee, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,26.1524877307542,4442.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.79,362.4599,94.83,5.0,3.0,4.0,39.45,97.4,2.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB00742,__MANNITOL,3932678,Completed,NCT01642745,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Saskatchewan, Saskatoon, Saskatchewan, Canada",A23L27/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,18.628719275549802,9603.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.04,38.4,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CC(c1cc2ccccc2s1)N(O)C(N)=O,1,DB00744,__ZILEUTON,4873259,Completed,NCT01805687,ASTHMA,All,18 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States",C07D307/81,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,20.961416045504,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,236.29,66.56,2.0,2.0,2.0,24.14,61.96,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Completed,NCT00118378,HIV INFECTIONS|FATIGUE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
NC(=O)CS(=O)C(c1ccccc1)c1ccccc1,1,DB00745,__MODAFINIL,RE37516,Recruiting,NCT03621761,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Michigan, Ann Arbor, Michigan, United States|The University of Washington, Seattle, Washington, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,33.5119817655393,214.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.71,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CCc1cccc2c3c([nH]c12)C(CC)(CC(=O)O)OCC3,1,DB00749,__ETODOLAC,3939178,Completed,NCT02881619,MEDICAMENTS SUBSTANCES IN THERAPEUTIC USE,All,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D495/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,57.0,41.0686051048276,2463.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,287.3535,62.32,3.0,2.0,3.0,31.94,81.16,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PERIODONTAL DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCNC(C)C(=O)Nc1ccccc1C,1,DB00750,__PRILOCAINE,6031007,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,30.785026386578693,1115.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.87,220.3107,41.13,2.0,2.0,1.0,25.98,67.86,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,NCT02251613,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,,HYPERSENSITIVITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1=NCC2c3ccccc3Cc3ccccc3N12,1,DB00751,__EPINASTINE,7429602,Completed,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,12.1234522269451,349.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.53,249.3104,41.62,3.0,1.0,4.0,27.33,76.9,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1
NC1CC1c1ccccc1,1,DB00752,__TRANYLCYPROMINE,3961073,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,11.039241052177598,31.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.5,133.194,26.02,1.0,1.0,2.0,15.51,41.7,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
FC(F)OC(Cl)C(F)(F)F,1,DB00753,__ISOFLURANE,,Completed,,"NEOPLASMS, BREAST",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,184.49200000000002,9.23,1.0,0.0,0.0,9.73,23.04,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)C(C)(C)CCC1,1,DB00755,__TRETINOIN,5955109,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",A61Q19/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,75.1391198997925,9501.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.66,300.442,37.3,2.0,1.0,1.0,36.85,97.79,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Unknown status,NCT01743014,DIABETES TYPE 2|DIABETIC NEPHROPATHY|VASCULAR DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AHEPA University Hospital, Thessaloniki, Greece|Aristotle University of Thessaloniki/ AHEPA University Hospital, Thessaloniki, Greece",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
COC(=O)[C@H](c1ccccc1Cl)N1CCc2sccc2C1,1,DB00758,__CLOPIDOGREL,4847265,Enrolling by invitation,NCT03188705,"HEART DISEASES|CORONARY DISEASE|CORONARY ARTERY DISEASE|CARDIOVASCULAR DISEASES|MYOCARDIAL ISCHEMIA|ARTERY OCCLUSION|ASPIRIN SENSITIVITY|CLOPIDOGREL, POOR METABOLISM OF|PLATELET DYSFUNCTION|PLATELET THROMBUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Amish Research Clinic, Lancaster, Pennsylvania, United States",C07D495/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,16.920265303188902,353.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,321.822,29.54,2.0,0.0,3.0,33.19,84.93,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",A61K9/4808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,GASTRIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
CN(C)[C@@H]1C(O)=C(C(N)=O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12,1,DB00759,__TETRACYCLINE,6350468,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,4978.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.56,444.4346,181.62,9.0,6.0,4.0,43.03,114.19,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](C(=O)N(C)C)C3)[C@H](C)[C@H]12,1,DB00760,__MEROPENEM,4943569,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C07F7/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,33.5119817655393,161.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,383.463,110.18,6.0,3.0,3.0,39.29,97.89,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT01458600,GRAVES´ DISEASE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Departmenty of Endocrinology, Skane University Hospital, Malmö, Sweden|Department of Endocrinology, Karolinska Hospital, Stockholm, Sweden|Department of Internal Medicine, section of Endocrinology, Sodersjukhuset, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150137,TOXIC NODULAR GOITRE|GRAVES DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
Cn1cc[nH]c1=S,1,DB00763,__METHIMAZOLE,,Completed,NCT00150124,TOXIC NODULAR GOITRE|GRAVES' DISEASE,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Endocrinology, Odense University Hospital, Odense, Funen, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,114.169,15.27,0.0,1.0,1.0,11.64,33.23,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00236106,ATOPIC DERMATITIS,All,5 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00394355,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",A61M15/0065,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0065,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,NCT03011632,SINUSITIS|ASTHMA,All,4 Years to 8 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Lodz, Poland",A61M15/0065,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB00764,__MOMETASONE,5394868,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0065,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,14.6532783014024,183.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.81,427.361,74.6,4.0,2.0,4.0,43.82,110.29,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Active Not Recruiting,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,ACUTE OTITIS MEDIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
O=C(O)[C@H]1/C(=C/CO)O[C@@H]2CC(=O)N21,1,DB00766,__CLAVULANIC_ACID,6878386,Completed,,CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,716.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.2,199.1608,87.07,5.0,2.0,2.0,18.13,44.25,2.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,C07D313/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",C07D313/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",C07D313/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21,1,DB00768,__OLOPATADINE,5116863,Completed,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D313/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,62.8185383683443,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.99,337.4122,49.77,4.0,1.0,3.0,37.44,109.55,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)O,1,DB00770,__ALPROSTADIL,5886039,Unknown Status,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,36.0,45.5040144561489,391.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.04,354.48699999999997,94.83,5.0,3.0,1.0,42.13,98.32,13.0,0.0,1.0,0.0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT04038411,NK/T CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT03707847,ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Recruiting,NCT04490590,NK/T-CELL LYMPHOMA,All,"10 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Completed,,ACUTE LYMPHOBKASTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1O,1,DB00773,__ETOPOSIDE,4701327,Unknown Status,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,29.569395675475803,8681.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.73,588.5566,160.83,12.0,3.0,7.0,58.77,139.02,5.0,1.0,0.0,0.0,1,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
CCCCS(=O)(=O)N[C@@H](Cc1ccc(OCCCCC2CCNCC2)cc1)C(=O)O,1,DB00775,__TIROFIBAN,5658929,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07C311/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,24.969711903735103,371.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.78,440.597,104.73,6.0,3.0,2.0,49.27,117.48,13.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0
NC(=O)N1c2ccccc2CC(=O)c2ccccc21,1,DB00776,__OXCARBAZEPINE,8119148,Completed,NCT00142025,BRONCHIAL ASTHMA,All,"17 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,134.080781946241,36.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.76,252.268,63.4,2.0,1.0,3.0,25.72,71.56,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,NCT00439062,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Nazilli State Hospital, Nazilli, Aydin, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=NOCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB00778,__ROXITHROMYCIN,,Unknown Status,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,837.0465,216.89,16.0,5.0,3.0,91.84,211.24,13.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Unknown status,NCT01052623,ATAXIA TELANGIECTASIA|GROWTH FAILURE,All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Children's Hospital, Goethe-University, Frankfurt am Main, Germany",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT02352090,CONTRACEPTION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Helsinki University Central Hospital, Kätilöopisto Maternity Hospital, Helsinki, Finland|Oulu University Hospital, Department of Gynecology and Obstetrics, Oulu, Finland",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00829114,HIV/AIDS|HIV INFECTIONS,Female,18 Years to 35 Years   (Adult),Other|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,", RHRU National Office, University of Witwatersand, Esselent St. Hillbrow, Johannesburg, South Africa|Makerere University Medical School, Mulago Hospital, Department of Obstetrics and Gynecology, Kampala, Uganda",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Terminated,NCT02531321,CONTRACEPTION|HIV,Female,18 Years to 45 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Recruiting,NCT04079218,HIV INFECTION|VAGINAL ATROPHY|MENOPAUSE|MENOPAUSE RELATED CONDITIONS|AGING|PREMATURE AGING|ATROPHIC VAGINITIS|DYSBIOSIS|VAGINITIS,Female,"45 Years to 70 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Albert Einstein College of Medicine, Bronx, New York, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
C[C@]12CC[C@@H]3c4ccc(O)cc4CC[C@H]3[C@@H]1CC[C@@H]2O,1,DB00783,__ESTRADIOL,5223261,Completed,NCT00570440,PREGNANCY PREVENTION,Female,18 Years to 30 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"PROFAMILIA - Santo Domingo, Dominican Republic, Ens. Luperon, Santo Domingo, Dominican Republic|PROFAMILIA - Managua, Nicaragua, Managua, Nicaragua",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,17.9387667097887,3087.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.57,272.382,40.46,2.0,2.0,4.0,32.13,79.9,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,0,0
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,1,DB00787,__ACYCLOVIR,RE39264,Completed,NCT01026454,HSV INFECTION|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thika Partners in Prevention, Thika, Kenya",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,127.082691636378,2362.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.95,225.2046,114.76,7.0,3.0,2.0,21.51,54.63,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,1,DB00787,__ACYCLOVIR,RE39264,Completed,NCT00527618,GENITAL HERPES|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Virology Research Clinic, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,127.082691636378,2362.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.95,225.2046,114.76,7.0,3.0,2.0,21.51,54.63,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Nc1nc(=O)c2ncn(COCCO)c2[nH]1,1,DB00787,__ACYCLOVIR,RE39264,Completed,NCT00362596,HIV|HERPES,Female,18 Years to 49 Years   (Adult),U.S. Fed|Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,"TUC, Chiang Rai, Thailand",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,127.082691636378,2362.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.95,225.2046,114.76,7.0,3.0,2.0,21.51,54.63,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT02451748,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Outpatient Care Center, Chicago, Illinois, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Not yet recruiting,NCT04015596,PANDAS|ANXIETY DISORDER|AUTOIMMUNE DISEASES|OBSESSIVE-COMPULSIVE DISORDER,All,6 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Completed,NCT00807846,"ARTHRITIS, JUVENILE RHEUMATOID",All,2 Years to 17 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Catalina Pointe Clinical Research, Inc., Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Children's Hospital-San Diego, San Diego, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|Children's National Medical Center / Division of Rheumatology, Washington, District of Columbia, United States|Arthritis Associates of South Florida, Delray Beach, Florida, United States|Delray Research Associates, Delray Beach, Florida, United States|Miami Children's Hospital, Miami, Florida, United States|Administrative Site-Hawaii Pacific Health Research Institute, Honolulu, Hawaii, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Kosair Charities Pediatric Clinical Research Unit - University of Louisville, Louisville, Kentucky, United States|Kosair Children's Hospital, Louisville, Kentucky, United States|University of Louisville, Louisville, Kentucky, United States|University Pediatric Rheumatology of Kentucky, Louisville, Kentucky, United States|Children's Hospital and Medical Center, Omaha, Nebraska, United States|University of Nebraska Medical Center Pediatric Research Office, Omaha, Nebraska, United States|Akron Children's Hospital, Akron, Ohio, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Hospital Roberto del Rio, Santiago, RM, Chile|Hospital Regional de Concepcion Guillermo Grant Benavente, Concepcion, VIII Region, Chile|Instituto de Atencion Pediatrica, San Jose, Costa Rica|Clinica San Borja/Centro de Investigacion de Reumatologia, San Borja, Lima, Peru|Clinica Ricardo Palma/Sitio de Investigacion de Reumatologia, San Isidro, Lima, Peru|Philippine General Hospital, Manila, Philippines|University of Santo Tomas Hospital, Manila, Philippines|State Healthcare Institution of Moscow ""Izmailovskaya City Children's Hospital"", Moscow, Russian Federation|First Moscow State Medical University I.M. Sechenov of the Minzdravsocrazvitiya of Russia, Moscow, Russian Federation|Smolensk Regional Clinical Hospital, Smolensk, Russian Federation|SEIHPE ""Smolensk State Medical Academy""of the Minzdravsocrazvitiya of Russia, Smolensk, Russian Federation|Institute of Rheumatology, Belgrade, Serbia|Children's Clinic of Internal Medicine, Nis, Serbia|Clinical Research Unit, Pretoria, Gauteng Province, South Africa|CHUV - Unit of Immuno-Allergology and Rhumatology, CH-1011 Lausanne, Switzerland|Universitaets-Kinderspital, CH-8032 Zuerich, Switzerland|Department of Cardioreumatology, Kharkiv, Ukraine|Institute of Pediatrics, Obstetrics and Gynecology, Kiev, Ukraine|Kyiv City Children Clinical Hospital #1, Kyiv, Ukraine|Crimean State Medical University, Chair of Pediatrics with a course of Children Infectious Diseases, Simferopol, Ukraine|Zaporizhzhya Regional Clinical Pediatric Hospital, Zaporizhzhya, Ukraine",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)O)ccc2c1,1,DB00788,__NAPROXEN,5637320,Recruiting,NCT03697720,DYSMENORRHEA|PAIN,Female,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NorthShore University Health System, Evanston, Illinois, United States",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,37.8816813486929,2972.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.29,230.2592,46.53,3.0,1.0,2.0,24.81,64.85,3.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Completed,NCT00259610,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Recruiting,NCT03254589,"RHEUMATOID ARTHRITIS|STIFFNESS, AORTIC|ENDOTHELIAL DYSFUNCTION|CARDIOVASCULAR RISK FACTOR",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Southern Adelaide Local Health Network, Bedford Park, South Australia, Australia",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
O=C(O)c1cc(/N=N/c2ccc(S(=O)(=O)Nc3ccccn3)cc2)ccc1O,1,DB00795,__SULFASALAZINE,4849416,Terminated,NCT00637780,"ARTHRITIS, JUVENILE RHEUMATOID",All,6 Years to 17 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospitals Case Medical Center, Cleveland, Ohio, United States|Private Office, Guadalajara, Jalisco, Mexico",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,11.7620485020226,1339.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,398.39300000000003,141.31,8.0,3.0,3.0,39.69,104.6,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0
CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,1,DB00798,__GENTAMICIN,,Terminated,NCT00671528,"DERMATITIS, ATOPIC|ECZEMA, ATOPIC|SKIN DISEASES, ECZEMATOUS",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.6,477.5954,199.73,12.0,8.0,3.0,51.92,118.02,7.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Unknown status,NCT02008214,HEPACIVIRUS|HIV INFECTIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
CC(=O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,1,DB00806,__PENTOXIFYLLINE,4189469,Not yet recruiting,NCT03859570,LUPUS NEPHRITIS,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Metrohealth Medical Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,45.471159572065105,704.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.08,278.307,75.51,4.0,0.0,2.0,29.27,73.52,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT03250910,"HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF|HUMAN IMMUNODEFICIENCY VIRUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00845676,HEPATITIS C|HUMAN IMMUNODEFICIENCY VIRUS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General Hospital/UCSF, San Francisco, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00356486,HIV INFECTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Badalona, Badalona, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital General de Vic, Vic, Barcelona, Spain|Hospital de Donostia, San Sebastián, Donostia, Spain|Hospital General Universitario de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Gregorio Marañón., Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital La Paz, Madrid, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT02247440,HEPATITIS C INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanpatong Hospital, San Pa Tong, Chiang Mai, Thailand|Nakornping Hospital, Chiang Mai, Thailand|Chiangrai Prachanukroh Hospital, Chiang Rai, Thailand|Chonburi Hospital, Chon Buri, Thailand|Samutsakhon Hospital, Samut Sakhon, Thailand",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Terminated,NCT00687544,"HEPATITIS C, CHRONIC|HEPACIVIRUS|HIV INFECTIONS",All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00353418,"HEPATITIS C, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Unknown status,NCT00611819,CHRONIC HEPATITIS C|CO-INFECTION HIV-HCV,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Elche, Elche, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital de Jerez, Jerez de la Frontera, Cádiz, Spain|Hospital Xeral-Cíes, Vigo, Pontevedra, Spain|Hospital de Gandia, Gandia, Valencia, Spain|Hospital General de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital General de Castellón, Castellón, Spain|Hospital Clínico San Cecilio, Granada, Spain|Hospital Infanta Elena, Huelva, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital la Paz, Madrid, Spain|Hospital General de Murcia, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen Macarena, Sevilla, Spain|Hospital la Fe, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain|Hospital Arnau de Vilanova, Valencia, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00553930,"HEPATITIS C, CHRONIC|HIV INFECTIONS",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Service.Hospitales Universitarios Virgen del Rocio, Sevilla, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT00530972,CHRONIC HEPATITIS C|HIV INFECTIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Carlos III, Madrid., Madrid, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT01925183,"HEPATITIS C, CHRONIC|HIV",All,18 Years to 64 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Completed,NCT01684787,CHRONIC HEPATITIS C,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital de Txagorritxu, Vitoria, Alava, Spain|Consorci Sanitari Integral, Hospitalet, Barcelona, Spain|Hospital Universitari of Bellvitge, Hospitalet, Barcelona, Spain|Hospital General de Mataró, Mataró, Barcelona, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, Spain|Hospital de Donostia, San Sebastián, Guipúzcoa, Spain|Hospital Xeral-Cíes, Vigo, Pontevedra, Spain|Hospital de Cruces, Baracaldo, Vizcaya, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu i Sant Pau, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital San Jorge, Huesca, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Terminated,NCT01443923,HEPATITIS|HIV/AIDS,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Unity Health Care, Inc./DC General, Washington, DC, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)n1,1,DB00811,__RIBAVIRIN,6172046,Terminated,NCT02717949,LIVER DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,39.622990205137604,1618.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.9,244.2047,143.72,7.0,4.0,2.0,22.18,64.57,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",A61N1/303,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,1,DB00813,__FENTANYL,6169920,Completed,NCT00524160,ARTHRITIS|OSTEOARTHRITIS|RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61N1/303,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,58.0,74.7448612907862,622.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,336.4705,23.55,2.0,0.0,3.0,40.03,103.48,6.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+],1,DB00815,__SODIUM_LAURYL_SULFATE,3930956,Completed,NCT02168478,ALLERGY,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Michael Caswell PhD., CCRC,CCRA, Fairfield, New Jersey, United States",C12Q1/6888,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,26.2510523830058,14051.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.86,288.379,66.43,3.0,0.0,0.0,31.17,67.81,12.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC(C)c1cccc(C(C)C)c1O,1,DB00818,__PROPOFOL,5714520,Completed,NCT02246023,LUNG CANCER|SARCOIDOSIS|INTERSTITIAL PNEUMONIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University Hospital Zurich, Zurich, Switzerland",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,39.0,34.4647734039713,568.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.81,178.2707,20.23,1.0,1.0,1.0,21.61,56.42,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)Nc1nnc(S(N)(=O)=O)s1,1,DB00819,__ACETAZOLAMIDE,,Not yet recruiting,NCT04118387,SLEEP DISORDERED BREATHING|ABLE BODIED,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","John D. Dingell VA Medical Center, Detroit, MI, Detroit, Michigan, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,222.245,115.04,5.0,2.0,1.0,19.16,47.36,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0
CN1CC(=O)N2[C@H](Cc3c([nH]c4ccccc34)[C@H]2c2ccc3c(c2)OCO3)C1=O,1,DB00820,__TADALAFIL,5859006,Completed,NCT02595684,OBESITY,Male,30 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapéutica Experimental y Clínica, Guadalajara, Jalisco, Mexico",C07D471/14,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,29.897944516314503,38.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,389.404,74.87,4.0,1.0,6.0,40.92,104.08,1.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,1,DB00836,__LOPERAMIDE,6103260,Terminated,NCT02217982,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rocky Mountain MS Research Group, Salt Lake City, Utah, United States",8,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,36.9617445943448,375.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,477.038,43.78,3.0,1.0,4.0,52.67,139.32,7.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,1
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,1,DB00836,__LOPERAMIDE,6103260,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",8,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,36.9617445943448,375.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,477.038,43.78,3.0,1.0,4.0,52.67,139.32,7.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,1
CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1,1,DB00836,__LOPERAMIDE,6103260,Withdrawn,,FECAL INCONTINENCE,,,,,"FISABIO, Elche, Alicante, Spain",8,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,36.9617445943448,375.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.44,477.038,43.78,3.0,1.0,4.0,52.67,139.32,7.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,1,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@H]1C(=O)CO,1,DB00838,__CLOCORTOLONE,4376767,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",C07J71/0031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,129.0,26.3496170352573,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.73,410.907,74.6,4.0,2.0,4.0,41.8,105.74,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
CC(CCc1ccc(O)cc1)NCCc1ccc(O)c(O)c1,1,DB00841,__DOBUTAMINE,4425336,Suspended,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,19.5815109139818,420.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.97,301.3801,72.72,4.0,4.0,2.0,34.44,88.39,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1Nc2ccc(Cl)cc2C(c2ccccc2)=NC1O,1,DB00842,__OXAZEPAM,4028466,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,14.9161173740733,579.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.01,286.71299999999997,61.69,3.0,2.0,3.0,28.38,77.89,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT03109314,AMBLYOPIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of California, Berkeley, Berkeley, California, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,NCT00315367,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Medical College of Wisconsin, Milwaukee, Wisconsin, United States",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
COc1cc2c(cc1OC)C(=O)C(CC1CCN(Cc3ccccc3)CC1)C2,1,DB00843,__DONEPEZIL,4895841,Completed,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.1215425368077,230.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,379.49199999999996,38.77,4.0,0.0,4.0,44.34,112.11,6.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
Oc1ccc2c3c1O[C@H]1[C@@H](O)CC[C@@]4(O)[C@@H](C2)N(CC2CCC2)CC[C@]314,1,DB00844,__NALBUPHINE,4237140,Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,18.5301546232982,597.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,357.4434,73.16,5.0,3.0,6.0,38.59,97.0,2.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)N=c1cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,1,DB00845,__CLOFAZIMINE,4100271,Completed,NCT01290744,BORDERLINE LEPROMATOUS LEPROSY|LEPROMATOUS LEPROSY,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Cebu Skin Clinic, Cebu, Vesayas, Philippines",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,28.4523296166245,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.39,473.39599999999996,39.99,4.0,1.0,5.0,51.52,142.55,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0
OCCN1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1,1,DB00850,__PERPHENAZINE,4175119,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/209,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,22.2756114088585,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.15,403.969,29.95,4.0,1.0,4.0,44.77,116.1,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,BRONCHITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CN[C@@H](C)[C@@H](O)c1ccccc1,1,DB00852,__PSEUDOEPHEDRINE,6037353,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,60.4201318302223,899.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,165.2322,32.26,2.0,2.0,1.0,18.83,49.69,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Terminated,NCT01211665,"IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME|LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hastings, Nebraska, United States|Research Site, Bochum, Germany|Research Site, Wurzburg, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00443430,JUVENILE CHRONIC POLYARTHRITIS|JUVENILE IDIOPATHIC ARTHRITIS|JUVENILE RHEUMATOID ARTHRITIS,All,2 Years to 17 Years   (Child),Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Stanford University Medical Center, Palo Alto, California, United States|Rady Children's Hospital, San Diego, California, United States|University of California San Francisco Medical Center, San Francisco, California, United States|Children's Hospital of Boston, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Children's Hospital at Montefiore, Bronx, New York, United States|Schneider Children's Hospital, New Hyde Park, New York, United States|Duke University, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Children's Hospital of Columbus, Columbus, Ohio, United States|Oklahoma University Health Science Center, Oklahoma City, Oklahoma, United States|Texas Scottish Rite Hospital, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States|Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00526409,ACUTE LYMPHOBLASTIC LEUKEMIA,All,up to 16 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital materno Infantil vall d'Hebrón, Barcelona, Spain|Hospital Niño Jesús, Madrid, Spain|Hospital Virgen de la Arrixaca, Murcia, Spain|Hospital Infantil Carlos Haya, Málaga, Spain",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT03265405,SARCOIDOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Postgraduate Institute of Medical Education and Research, Chandigarh, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Recruiting,NCT04314193,"SARCOIDOSIS, PULMONARY",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jeroen Bosch Ziekenhuis, 's-Hertogenbosch, Netherlands|Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands|Academisch Medisch Centrum, Amsterdam, Netherlands|Rijnstate Ziekenhuis, Arnhem, Netherlands|Catharina Ziekenhuis, Eindhoven, Netherlands|Medisch Spectrum Twente, Enschede, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Zuyderland Medisch Centrum, Heerlen, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Haaglanden Medisch Centrum, Leidschendam, Netherlands|Sint Antonius Ziekenhuis, Nieuwegein, Netherlands|Canisius Wilhelmina Ziekenhuis, Nijmegen, Netherlands|Erasmus MC, Rotterdam, Netherlands|Isala Klinieken, Zwolle, Netherlands",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00445081,ATOPIC DERMATITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Hospital of Dermatology and Venerology Graz, Graz, Austria|Dept. of Dermatology, Medical Faculty, TU Dresden, Dresden, Germany|Dpt. of Dermatology, Medical Faculty Eppendorf, Hamburg, Germany|University Hospital Kiel, Kiel, Germany|Dpt. of Dermatology, University Hospital Münster, Münster, Germany",A61K9/0056,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT00312325,REGIONAL BLOOD FLOW|OPTIC DISK,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Pharmacology, Vienna, Austria",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT02644499,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry, Pondicherry UT, India",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Completed,NCT04146220,LUPUS NEPHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,ADVANCED FOLLICULAR LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,1,DB00860,__PREDNISOLONE,5178878,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,1053.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.66,360.444,94.83,5.0,3.0,4.0,38.69,98.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
O=C(O)c1cc(-c2ccc(F)cc2F)ccc1O,1,DB00861,__DIFLUNISAL,4131618,Terminated,NCT01676363,HIV INFECTION,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Immunodeficiency Clinic, St. Paul's Hospital, Vancouver, British Columbia, Canada",C07C65/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,11.893468038358,2259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,250.1976,57.53,3.0,2.0,2.0,22.29,60.86,2.0,0.0,1.0,0.0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,1,DB00863,__RANITIDINE,5098715,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",A61K9/2806,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,15.1132466785765,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,314.4,83.58,5.0,2.0,1.0,33.78,94.15,10.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Unknown status,NCT03062813,HEPATITIS B VIRUS ASSOCIATED NEPHROTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT03918265,AUTOIMMUNE HEMOLYTIC ANEMIA|PURE RED CELL APLASIA|EVANS SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01828879,"DERMATITIS, ATOPIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hanoi, Vietnam|Hochiminh, Vietnam",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00654355,ATOPIC DERMATITIS,All,2 Years to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept of Dermatology, WFUHS, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01745159,MODERATE/SEVERE ATOPIC DERMATITIS,All,2 Years to 15 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing, China|Chongqing, China|Guangzhou, China|Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT04114097,ATOPIC DERMATITIS|ATOPIC ECZEMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Department of Dermatology and Allergy, Hellerup, Region Hovedstaden, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03464435,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01092806,POST TRANSPLANT DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Oslo univeristy hospital, Rikshospitalet, Oslo, Norway",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00195429,KIDNEY FAILURE|GRAFT VS HOST DISEASE,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00843856,"GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hammersmith Hospital, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00667056,DERMATITIS,All,"17 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington, District of Columbia, United States|Kansas City, Kansas, United States|Shawnee, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Lynchburg, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT03737708,RHEUMATOID ARTHRITIS,All,"19 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site KR82003, Daegu, Korea, Republic of|Site KR82007, Daegu, Korea, Republic of|Site KR82006, Daejeon, Korea, Republic of|Site KR82002, Incheon, Korea, Republic of|Site KR82009, Seongnam, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82005, Seoul, Korea, Republic of|Site KR82010, Seoul, Korea, Republic of|Site KR82012, Seoul, Korea, Republic of|Site KR82013, Suwon, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT00125307,"LUPUS NEPHRITIS|LUPUS ERYTHEMATOSUS, SYSTEMIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Recruiting,NCT02630628,LUPUS NEPHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC,1,DB00864,__TACROLIMUS,5260301,Completed,NCT01649427,PHARMACOKINETICS STUDY IN DE NOVO KIDNEY TRANSPLANTATION,All,18 Years to 64 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Kaiserslautern, Germany|Novartis Investigative Site, Koeln-Merheim, Germany",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,11.269225240764598,91.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.19,804.0182,178.36,11.0,3.0,4.0,87.41,215.62,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,DB00871,__TERBUTALINE,3937838,Unknown status,NCT00914797,ASTHMA,Male,18 Years to 45 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Bispebjerg Hospital, Respiratory Research Unit, Kobenhavn NV, Denmark",1,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1cc(O)cc(O)c1,1,DB00871,__TERBUTALINE,3937838,Completed,NCT00124995,STATUS ASTHMATICUS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"CT Children's Medical Center, Hartford, Connecticut, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,31.672108256843,886.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.55,225.2842,72.72,4.0,4.0,1.0,24.78,63.04,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",C07J43/003,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CCOC(=O)O[C@]1(C(=O)OCCl)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14596,__LOTEPREDNOL_ETABONATE,4996335,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",C07J43/003,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,113.0,62.5885541797572,124.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.08,466.96,99.13,5.0,1.0,4.0,48.43,118.17,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Completed,NCT00195429,KIDNEY FAILURE|GRAFT VS HOST DISEASE,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Unknown status,NCT03582878,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute for Clinical and Experimental Medicine, Prague, Czechia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](O)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB00877,__SIROLIMUS,5212155,Withdrawn,NCT02990312,HIV|KIDNEY TRANSPLANT|HIV RESERVOIR|CCR5,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of human virology, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,21.5856588430973,1254.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.85,914.187,195.43,12.0,3.0,4.0,101.74,250.66,6.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Enrolling by invitation,NCT04240509,HIV INFECTIONS|SEXUALLY TRANSMITTED DISEASES,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The Miriam Hospital, Providence, Rhode Island, United States",C07D411/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT00924898,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT00127959,HEPATITIS B INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, NH, Netherlands",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Unknown status,NCT03120494,HIV/AIDS,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Puerto Rico Community Network for Clinical Research on AIDS (PR-CoNCRA), San Juan, Puerto Rico",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Unknown status,NCT03220152,HIV PREVENTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Instituto Nacional de Infectologia Evandro Chagas (INI) - Fiocruz, Rio de Janeiro, Brazil",C07D411/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT01715636,HIV NONOCCUPATIONAL POST-EXPOSURE PROPHYLAXIS IN MEN WHO HAVE SEX WITH MEN,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydney Sexual Heatlh Centre, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Melbourne Sexual Health Centre, Melbourne, Victoria, Australia",C07D411/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT01458977,HIV|DYSLIPIDEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Valle Hebrón, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT01274780,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT04050371,HIV PREVENTION|TRANSGENDER HEALTH,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"San Francisco AIDS foundation, San Francisco, California, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Recruiting,NCT03058835,PREP ADHERENCE MONITORING,Female,18 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|New Jersey Medical School Clinical Research Center, Newark, New Jersey, United States|West Virginia University, Morgantown, West Virginia, United States",C07D411/04,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,"Active, not recruiting",NCT03771638,"ADHERENCE, MEDICATION|RISK BEHAVIOR|PRE-EXPOSURE PROPHYLAXIS|HIV PREVENTION",All,18 Years to 35 Years   (Adult),Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Emory University, School of Public Health, Atlanta, Georgia, United States",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,"Active, not recruiting",NCT03120936,TRANSGENDER PERSONS|PRE-EXPOSURE PROPHYLAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Tri-City Health Center, Fremont, California, United States|Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Tom Waddell Urban Health Clinic, San Francisco, California, United States|San Francisco Community Health Clinic, San Francisco, California, United States|Castro-Mission Health Center, San Francisco, California, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT00444379,KAPOSI'S SARCOMA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Completed,NCT00055120,HIV INFECTIONS|AIDS-RELATED OPPORTUNISTIC INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, Davis Medical Center, Sacramento, California, United States|University of California, San Diego Antiviral Rese, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|San Mateo County AIDS Program, Stanford, California, United States|Santa Clara Valley Medical Center, Stanford, California, United States|Stanford Univ, Stanford, California, United States|Willow Clinic, Stanford, California, United States|Harbor General/UCLA, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Denver, Colorado, United States|Univ of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Cook County Hospital Core Center, Chicago, Illinois, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Indiana University Hosp, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Harvard (Massachusetts General Hospital), Boston, Massachusetts, United States|Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Hennepin County Medical Clinic, Minneapolis, Minnesota, United States|St. Louis Connect Care, St. Louis, Missouri, United States|Washington University (St. Louis), St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|NYU/Bellevue, New York, New York, United States|Columbia University, New York, New York, United States|Community Health Network, Inc., Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Presbyterian Medical Center - University of PA, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Comprehensive Care Clinic, Nashville, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Univ of Texas, Galveston, Galveston, Texas, United States|University of Washington (Seattle), Seattle, Washington, United States|University of Puerto Rico, San Juan, Puerto Rico|University of Witwatersrand, Parktown, Johannesburg, South Africa",C07D411/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Nc1nc(=O)n([C@@H]2CS[C@H](CO)O2)cc1F,1,DB00879,__EMTRICITABINE,5814639,Recruiting,NCT03163277,HIV|NEUROCOGNITIVE DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Torino, Torino, Italy",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,247.247,88.15,5.0,2.0,2.0,21.79,55.37,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1,1,DB00882,__CLOMIFENE,,Completed,NCT01004068,POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.08,405.96,12.47,2.0,0.0,3.0,46.72,133.76,9.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CN1[C@H]2CCC[C@@H]1C[C@H](NC(=O)c1nn(C)c3ccccc13)C2,1,DB00889,__GRANISETRON,5952340,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,39.7215548573892,477.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.64,312.4170000000001,50.16,3.0,1.0,4.0,35.57,101.83,2.0,0.0,1.0,0.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1,1,DB00900,__DIDANOSINE,5880106,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,17.183104375859802,2081.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.99,236.2273,88.74,6.0,2.0,3.0,22.9,58.59,2.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1
O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1,1,DB00900,__DIDANOSINE,5880106,Completed,NCT00256828,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de Área de Elda, Elda, Alicante, Spain|Hospital de Orihuela-Vega Baja, San Bartolomé-Orihuela, Orihuela, Alicante, Spain|Hospital General-Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Dureta, Palma de Mallorca, Baleares, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital de Terrassa, Terrassa, Barcelona, Spain|Hospital Sant Llorenc de Viladecans, Viladecans,, Barcelona, Spain|Hospital General de Jerez de la Frontera11407, Jerez, Cadiz, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Sierrallana de Torrelavega, Torrelavega, Cantabria, Spain|Hospital Provincial Nuestra Señora de la Montaña-Complejo Hospitalario de Cáceres, Caceres, Cáceres, Spain|Hospital Comarcal de la Selva, Blanes, Gerona, Spain|Hospital de Figueres, Figueras, Gerona, Spain|Hospital de Palamós, Palamos, Gerona, Spain|Hospital Donostia, San Sebastian, Guipuzcoa, Spain|Hospital Arquitecto Marcide, Ferrol, La Coruña, Spain|Hospital Príncipe de Asturias, Alcala de Henares, Madrid, Spain|Hospital Severo Ochoa, Leganes, Madrid, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital Meixoeiro, Vigo, Pontevedra, Spain|Hospital Xeral-Cíes de Vigo, Vigo, Pontevedra, Spain|Hospital General Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario de San Juan de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu y Sant Pau, Barcelona, Spain|Hospital General Vall D'Hebrón, Barcelona, Spain|Hospital de Mollet, Barcelona, Spain|Consorcio Sanitario de Mataró, Barcelona, Spain|Hospital De Vic, Barcelona, Spain|Hospital General Yagüe, Burgos, Spain|Hospital General de Castellón, Castellon, Spain|Hospital Provincial Reina Sofía de Córdoba, Cordoba, Spain|Hospital Clínico Universitario San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General San Jorge, Huesca, Spain|Hospital Ciudad de Jaén, Jaen, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Comarcal Axarquía de Vélez, Malaga, Spain|Hospital General Universitario de Murcia, Murcia, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital de Covadonga-Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital General de Segovia, Segovia, Spain|Hospital La Fe de Valencia, Valencia, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital del Río Hortega, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Miguel Servet, Zaragoza, Spain",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.183104375859802,2081.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.99,236.2273,88.74,6.0,2.0,3.0,22.9,58.59,2.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1
O=c1nc[nH]c2c1ncn2[C@H]1CC[C@@H](CO)O1,1,DB00900,__DIDANOSINE,5880106,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",7,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,17.183104375859802,2081.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.99,236.2273,88.74,6.0,2.0,3.0,22.9,58.59,2.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1
CCNC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCc1ccccc1,1,DB00905,__BIMATOPROST,6403649,Completed,NCT02059655,GRAVES' OPHTHALMOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University Hospital of Wales, Cardiff, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,27.170989137353892,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.41,415.5656,89.79,4.0,4.0,2.0,48.24,122.83,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,NCT01331317,CARDIOVASCULAR DISEASE|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Steno Diabetes Center A/S, Gentofte, Denmark",C07C401/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
C[C@@H](/C=C/[C@@H](C)[C@H]1CC[C@H]2/C(=C/C=C3C[C@@H](O)C[C@H](O)C3)CCC[C@@]21C)C(C)(C)O,1,DB00910,__PARICALCITOL,5246925,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C401/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,11.269225240764598,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.27,416.6365,60.69,3.0,3.0,3.0,51.06,127.95,5.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0
CCS(=O)(=O)CCn1c([N+](=O)[O-])cnc1C,1,DB00911,__TINIDAZOLE,4119723,Completed,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,15.0803917944927,340.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.41,247.27200000000002,97.78,5.0,0.0,1.0,23.27,57.66,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
CCOc1cc(CC(=O)N[C@@H](CC(C)C)c2ccccc2N2CCCCC2)ccc1C(=O)O,1,DB00912,__REPAGLINIDE,6677358,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,49.01948705312221,158.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.05,452.5857,78.87,5.0,2.0,3.0,51.49,131.83,10.0,0.0,1.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
NC12CC3CC(CC(C3)C1)C2,1,DB00915,__AMANTADINE,RE39069,Completed,NCT00950196,ATAXIA|CHOREA|DYSTONIA|PARKINSONISM|FATIGUE,All,4 Years to 50 Months   (Child),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sheba Medical Center, Ramat Gan, Israel",A61K9/0004,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,52.4692498819277,1321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.53,151.2487,26.02,1.0,1.0,3.0,17.92,45.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
NC12CC3CC(CC(C3)C1)C2,1,DB00915,__AMANTADINE,RE39069,Completed,,ATAXIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0004,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,52.4692498819277,1321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.53,151.2487,26.02,1.0,1.0,3.0,17.92,45.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
NC12CC3CC(CC(C3)C1)C2,1,DB00915,__AMANTADINE,RE39069,Completed,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0004,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,54.0,52.4692498819277,1321.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.53,151.2487,26.02,1.0,1.0,3.0,17.92,45.54,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
Cc1ncc([N+](=O)[O-])n1CCO,1,DB00916,__METRONIDAZOLE,5536743,Completed,NCT01018095,TRICHOMONAS INFECTIONS|HIV INFECTIONS,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"HIV Outpatient Clinic, New Orleans, Louisiana, United States|NOAIDS, New Orleans, Louisiana, United States|Crossroads Clinic, Jackson, Mississippi, United States|Thomas St Clinic, Houston, Texas, United States|Northwest Clinic, Houston, Texas, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,60.0,22.7355797860325,1267.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.15,171.15400000000002,83.87,4.0,1.0,1.0,15.82,41.22,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CN(C)CCc1c[nH]c2ccc(CS(=O)(=O)N3CCCC3)cc12,1,DB00918,__ALMOTRIPTAN,5565447,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,17.2488141440275,92.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,335.464,56.41,3.0,1.0,3.0,37.01,94.52,5.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,NCT00446056,ASTHMA,All,6 Years to 14 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3CC(=O)c3sccc32)CC1,1,DB00920,__KETOTIFEN,4232002,Completed,NCT00133627,SEASONAL ALLERGIC CONJUNCTIVITIS,All,"3 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital of Shanghai Medical University, Shanghai, China",A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,23.1626932791227,287.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.49,309.425,20.31,2.0,0.0,4.0,34.61,101.73,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT01733693,OPIOID-RELATED DISORDERS|HIV|HIV INFECTIONS,All,"18 Years to 68 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fordham University, The Bronx, New York, United States|Albert Einstein College of Medicine of Yeshiva University, The Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Unknown status,NCT00124358,OPIOID-RELATED DISORDERS|HIV INFECTIONS|AIDS,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"El Rio Santa Cruz Neighborhood Health Center, Tucson, Arizona, United States|Organization to Achieve Solutions in Substance Abuse, Oakland, California, United States|University of California San Francisco, San Francisco, California, United States|Yale University School of Medicine AIDS Program, New Haven, Connecticut, United States|University of Miami School of Medicine, Miami, Florida, United States|The CORE Center, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Montefiore Medical Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|The Miriam Hospital, Providence, Rhode Island, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT01936857,HIV|SUBSTANCE RELATED DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bac Giang PAC OPC, Bac Giang, Vietnam|Dong Da OPC, Hanoi, Vietnam|Hoang Mai HIV Clinic, Hanoi, Vietnam|Long Bien, Hanoi, Vietnam|Tu Liem, Hanoi, Vietnam|Thanh Hoa PAC OPC, Thanh Hoa, Vietnam",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT00763958,OPIOID DEPENDENCE|HIV,Female,"19 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT00263458,HIV|BUPRENORPHINE|OPIOID DEPENDENCE,All,"19 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Positive Health Program, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,NCT02519387,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|LOWER BACK PAIN|JOINT PAIN|MUSCLE PAIN,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital University Sains Malaysia, Kota Bahru, Kelantan, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia|University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,DB00921,__BUPRENORPHINE,5240711,Completed,,HIP ARTHROPLASTY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,11.2035154725969,326.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.53,467.6401,62.16,5.0,2.0,7.0,53.11,131.76,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
C[C@@H]1CC(=O)NN=C1c1ccc(NN=C(C#N)C#N)cc1,1,DB00922,__LEVOSIMENDAN,6340764,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",G01N30/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,11.039241052177598,104.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,280.2847,113.43,6.0,2.0,2.0,28.67,77.63,3.0,0.0,1.0,0.0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
CN(C)CCC=C1c2ccccc2C=Cc2ccccc21,1,DB00924,__CYCLOBENZAPRINE,7387793,Unknown Status,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,55.0976406086367,112.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.73,275.3874,3.24,1.0,0.0,3.0,32.95,102.62,3.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,NCT00384904,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Garden State Infectious Disease Associates, Pa, Voorhees, New Jersey, United States|Unc Center For Aids Research, Chapel-Hill, North Carolina, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, London, Greater London, United Kingdom",A61K9/5047,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",A61K9/5047,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
NC(N)=Nc1nc(CSCCC(N)=NS(N)(=O)=O)cs1,1,DB00927,__FAMOTIDINE,5075114,Completed,,PEPTIC ULCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/5047,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,19.05583276864,1184.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.2,337.445,175.83,8.0,4.0,1.0,31.66,80.46,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,1,DB00932,__TIPRANAVIR,5852195,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,25.561099817244703,252.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.29,602.664,105.59,5.0,2.0,4.0,60.87,154.57,11.0,1.0,0.0,0.0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1
CCC[C@@]1(CCc2ccccc2)CC(O)=C([C@H](CC)c2cccc(NS(=O)(=O)c3ccc(C(F)(F)F)cn3)c2)C(=O)O1,1,DB00932,__TIPRANAVIR,5852195,Completed,NCT00607958,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07D405/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,25.561099817244703,252.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.29,602.664,105.59,5.0,2.0,4.0,60.87,154.57,11.0,1.0,0.0,0.0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT00584987,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
Cc1cc(C(C)(C)C)c(O)c(C)c1CC1=NCCN1,1,DB00935,__OXYMETAZOLINE,6413499,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,25.7582291217478,470.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.7,260.3746,44.62,3.0,2.0,2.0,30.64,79.8,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01388595,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,DB00938,__SALMETEROL,6743413,Completed,NCT00950794,ASTHMA|BRONCHIAL ASTHMA,All,"15 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,108.05971375182199,934.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.82,415.5656,81.95,5.0,4.0,2.0,50.6,122.39,16.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0
Nc1ccn([C@H]2CC[C@@H](CO)O2)c(=O)n1,1,DB00943,__ZALCITABINE,4704357,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",G01N33/5008,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,25.1011314400706,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,211.2178,88.15,5.0,2.0,2.0,20.86,52.24,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Enrolling by invitation,NCT03188705,"HEART DISEASES|CORONARY DISEASE|CORONARY ARTERY DISEASE|CARDIOVASCULAR DISEASES|MYOCARDIAL ISCHEMIA|ARTERY OCCLUSION|ASPIRIN SENSITIVITY|CLOPIDOGREL, POOR METABOLISM OF|PLATELET DYSFUNCTION|PLATELET THROMBUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Amish Research Clinic, Lancaster, Pennsylvania, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT02090413,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Research Site, Cork, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Dublin, Ireland|Research Site, Basingstoke, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Edinburgh, United Kingdom|Research Site, Exeter, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leicester, United Kingdom|Research Site, Liverpool, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, London, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Norwich, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Plymouth, United Kingdom|Research Site, Salford, United Kingdom|Research Site, Swansea, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT00371501,ATHEROSCLEROSIS|THROMBOEMBOLISM|SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Tuen Mun Hospital, Hong Kong, Hong Kong",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,"Active, not recruiting",NCT00135226,DIABETES,All,"40 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Clinical Trial Service Unit, University of Oxford, Oxford, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01397513,"DIABETES MELLITUS, TYPE 1",All,"30 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)Oc1ccccc1C(=O)O,1,DB00945,__ACETYLSALICYLIC_ACID,6015577,Completed,NCT01867281,"ASTHMA, ASPIRIN-INDUCED",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Allergy and Immunology, Rasool-e-Akram Hospital, Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,57.233208074087706,7103.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.43,180.1574,63.6,3.0,1.0,1.0,17.1,44.45,3.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01469234,RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01940393,URTICARIA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medellin, Medellin, Antioquia, Colombia",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",A61K9/0056,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00794768,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02551536,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT02175485,RHINITIS ALLERGIC,All,"20 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 392-001, Shinjuku-ku, Japan",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00741897,"RHINITIS, ALLERGIC, PERENNIAL",All,6 Years to 11 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sanofi-aventis administrative office, Makati City, Philippines",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00637884,CAT INDUCED ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
CC(C)(C(=O)O)c1ccc(C(O)CCCN2CCC(C(O)(c3ccccc3)c3ccccc3)CC2)cc1,1,DB00950,__FEXOFENADINE,5178878,Completed,NCT00547768,ALLERGY,All,"12 Years to 55 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Sanofi-Aventis, Bridgewater, New Jersey, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,133.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.02,501.6564,81.0,5.0,3.0,4.0,57.42,147.98,10.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C08G73/08,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT02057796,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia|CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Yopougon, Côte D'Ivoire|ISS ImmunoSuppression Service, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT01875952,HUMAN IMMUNODEFICIENCY VIRUS (HIV)|TUBERCULOSIS (TB)|LATENT TUBERCULOSIS INFECTION (LTI),All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Instituto Nacional de Salud Publica, Mexico, Cuernavaca Morelos, Mexico|Clínica Especializada CONDESA, Mexico City, D.F, Mexico",C08G73/08,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Completed,NCT00164281,TUBERCULOSIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Gaborone and Francistown Health Clinics, Gaborone and Francistown, Botswana",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Completed,NCT01494038,HIV INFECTIONS|TUBERCULOSIS,Female,"13 Years and older   (Child, Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Prevention","Gaborone CRS, Gaborone, Botswana|Molepolole CRS, Gaborone, Botswana|Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS, Port-au-Prince, Haiti|Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India|Soweto IMPAACT CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Fam-Cru Crs, Cape Town, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda|Seke North CRS, Chitungwiza, Zimbabwe|St Mary's CRS, Chitungwiza, Zimbabwe|Harare Family Care CRS, Harare, Zimbabwe",C08G73/08,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Unknown status,NCT01782950,AIDS WITH TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Kampala, Uganda",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,"Active, not recruiting",NCT03302299,TUBERCULOSIS|HIV/AIDS|ALCOHOL ABUSE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Mbarara University of Science and Technology/Mbarara Regional Referral Hospital, Mbarara, Uganda",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
NNC(=O)c1ccncc1,1,DB00951,__ISONIAZID,3944522,Recruiting,NCT03089983,OPIOID DEPENDENCE|ADDICTION|HIV/AIDS|TUBERCULOSIS|HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Kajang Prison, Kajang, Selangor, Malaysia",C08G73/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,44.9783363108072,3284.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.71,137.1393,68.01,3.0,2.0,1.0,13.21,37.46,1.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Terminated,NCT01211665,"IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME|LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hastings, Nebraska, United States|Research Site, Bochum, Germany|Research Site, Wurzburg, Germany",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Withdrawn,NCT00037115,DEMYELINATING DISORDERS|MULTIPLE SCLEROSIS|OPTIC NEURITIS|MYELITIS|NEURITIS,All,18 Years to 50 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MidAmerica Neuroscience Institute, Kansas City, Missouri, United States",A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00425724,"PURPURA, SCHOENLEIN-HENOCH",All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept. of Pediatrics, Oulu University Hospital, Oulu, Finland",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00185510,"DERMATITIS, ATOPIC",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Not yet recruiting,NCT03098225,THYROID ASSOCIATED OPHTHALMOPATHY,All,"35 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,,A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT02378298,"OPHTHALMOPATHY, THYROID-ASSOCIATED",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Center for Endocrinology and Metabolism, Sahlgrenska University Hospital, Gothenburg, Sweden|MedTech West, Institute of Neuro Science and Physiology, Department for Clinical Neuro Science and Rehabilitation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden|Department of Ophthalmology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Rheumatology, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden|Department of Radiology, Karolinska University Hospital, Stockholm, Sweden",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT03948191,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years to 76 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Unknown status,NCT01969019,GRAVES' OPHTHALMOPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Institute of Endocrine and Metabolic Diseases Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai, Shanghai, China",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT01838174,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States|University of Pennsylvania Scheie Eye Institute, Philadelphia, Pennsylvania, United States",A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Recruiting,NCT02115997,WEGENER'S GRANULOMATOSIS OR MICROSCOPIC POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yashoda Hospital, Hyderabad, Andhra Pradesh, India|Sir Gangaram Hospital, New Delhi, Delhi, India|Medanta-The Medicity, Gurgaon, Haryana, India|Fortis Memorial Research Instititute, Gurgaon, Haryana, India|Apollo BGS Hospitals, Mysuru, Karnataka, India|Kokilaben Dhirubhai Ambani Hospital & Medical Research Institute; Department of Rheumatologz, Mumbai, Maharashtra, India|Manipal Hospital, Bangalore, India|St. John's Medical College Hospital; Rheumatology, Bangalore, India|Chanre Rheumatology and Immunology Center and Research, Bangalore, India|MULJIBHAI PATEL UROLOGICAL HOSPITAL; Nephrology, Gujarat, India|Medica Superspeciality Hospital, Kolkata, India|Jasleen Hospital, Nagpur, India|Max Super Speciality Hospital, New Delhi, India|All India Institute of Medical Sciences (AIIMS); Rheumatology, New Delhi, India|Indraprastha Apollo Hospitals; Department of Rheumatology, New Delhi, India|Fortis Hospital, Noida, India|Christian Med Clg & Hspt, Vellore, India",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT01382940,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Uni Of Alabama,Birmingham; Medicine - Rheumatology, Birmingham, Alabama, United States|Clnical & Translational Reseach Center for Alabama, PC, Tuscaloosa, Alabama, United States|ArthroCare, Arthritis Care; and Research P.C., Gilbert, Arizona, United States|Valley Arthritis Care, Phoenix, Arizona, United States|Catalina Pointe Rheumatology, Tucson, Arizona, United States|Medvin Clinical Research, Covina, California, United States|Triwest Research Associates, La Mesa, California, United States|Medvin Clinical Research, Los Angeles, California, United States|Brigid Freyne-Private Practice; Internal Medicine, Rheum, Murrieta, California, United States|Desert Medical Advances; Rheumatology, Palm Desert, California, United States|San Diego Arthritis Med Clnc, San Diego, California, United States|Pacific Arthritis Ctr Med Grp, Santa Maria, California, United States|Inland Rheumatology; Clinical Trials, Inc., Upland, California, United States|Medvin Clinical Research, Whittier, California, United States|Arthritis Assoc & Osteoporosis; Ctr of Colorado Springs, Colorado Springs, Colorado, United States|Denver Arthritis Clinic, Denver, Colorado, United States|Rheum & Internal Med Assoc-Bri, Bridgeport, Connecticut, United States|Arthritis & Osteoporosis Center Pc, Hamden, Connecticut, United States|Rheumatolgy Consultants of Deleware, Lewes, Delaware, United States|Javed Rheumatology Associates, Inc., Newark, Delaware, United States|Arthritis & Rheumatism; Disease Specialities, Aventura, Florida, United States|Florida Arthritis Center, PI, Lake Mary, Florida, United States|Omega ResearchConsultants LLC, Orlando, Florida, United States|Millenium Research, Ormond Beach, Florida, United States|Arthritis Center Palm Harbor, Palm Harbor, Florida, United States|Arthritis Rsrch of Florida, Inc., Palm Harbor, Florida, United States|Center For Arthritis; Research Dept, South Miami, Florida, United States|University of South Florida, Tampa, Florida, United States|Florida Medical Clinic; Clinical Research, Zephyrhills, Florida, United States|Parris & Associates, Lawrenceville, Georgia, United States|St. Luke's Intermountain Research Center, Boise, Idaho, United States|Institute of Arthritis Research, Idaho Falls, Idaho, United States|Quad City Rheumatology, Sc, Moline, Illinois, United States|Physician'S Clinic of Iowa, Cedar Rapids, Iowa, United States|Bluegrass Comm Research, Inc., Lexington, Kentucky, United States|Klein & Associates, M.D. P.A., Cumberland, Maryland, United States|Klein & Associates, M.D., P.A., Hagerstown, Maryland, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Arthritis and Osteoporosis; Treatment and Research Center, Flowood, Mississippi, United States|Jackson Arthritis Clinic, Flowood, Mississippi, United States|North Mississippi Med Clinics, Inc., Tupelo, Mississippi, United States|David S Rosenberg, Florissant, Missouri, United States|Arthritis Center of Reno, Reno, Nevada, United States|Rheumatology Research Group, Lebanon, New Hampshire, United States|Rheumatology Associates Of New Jersey, Teaneck, New Jersey, United States|The Center for Rheumatology, Albany, New York, United States|Arthritis & Osteoporosis Center, Brooklyn, New York, United States|NYU Center for Musculoskeletal Care, New York, New York, United States|Buffalo Rheumatology Associates, Orchard Park, New York, United States|Office of Premier Chatpar Md, Plainview, New York, United States|Aair Research Center, Rochester, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Arthritis Health Associates; Clinical Research, Syracuse, New York, United States|Arth&OsteoConsof theCarolinas-Charlotte, Charlotte, North Carolina, United States|Box Arthritis & Rheumatology, Charlotte, North Carolina, United States|Carolina Bone & Joint P.A., Charlotte, North Carolina, United States|Physicians East Pa, Greenville, North Carolina, United States|Shanahan Rheumatology & Immunology, PLLC, Raleigh, North Carolina, United States|Crystal Arthritis Center, Inc., Akron, Ohio, United States|CarePoint East, Columbus, Ohio, United States|Stat Research, Inc, Dayton, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|LION Research, Norman, Oklahoma, United States|Arthritis and Rheumatology; Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|East Penn Rheumatology Associates, Pc, Bethlehem, Pennsylvania, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|Pivotal Clinical Research, Llc, Perkasie, Pennsylvania, United States|Arthritis Group, Philadelphia, Pennsylvania, United States|Rheumatic Disease Associates; Clinical Research Unit, Willow Grove, Pennsylvania, United States|Clinical Research Center of Reading, Wyomissing, Pennsylvania, United States|Pennsylvania Regional Center for Arthritis and Osteoporosis Research, Wyomissing, Pennsylvania, United States|Low Country Rheumatology, PA, Charleston, South Carolina, United States|Rheumatology Associates, Charleston, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Ramesh Gupta - PP, Memphis, Tennessee, United States|Amarillo Center For Clinical Research, Amarillo, Texas, United States|Lovelace Scientific Resources Inc., Austin, Texas, United States|Adriana Pop-Moody MD Clinic PA, Corpus Christi, Texas, United States|Arthritis Centers of Texas, Dallas, Texas, United States|Southwest Rheumatology, Mesquite, Texas, United States|Arthritis Clinic of Northern Virginia, Arlington, Virginia, United States|Apex Clinical Research, Kennewick, Washington, United States|Seattle Arthritis Clinic, Seattle, Washington, United States|Arthritis Northwest, Spokane, Spokane, Washington, United States|Cedar Medical Center, Tacoma, Washington, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT02645565,LUPUS NEPHRITIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB00959,__METHYLPREDNISOLONE,3962414,Completed,NCT00112034,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double,"MS Academic Coordinating Center, Cleveland, Ohio, United States",A61F9/0017,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,19.450091377646306,446.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,374.4706,94.83,5.0,3.0,4.0,40.77,103.04,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00794846,SEASONAL ALLERGIC RHINITIS|PERENNIAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT01940393,URTICARIA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medellin, Medellin, Antioquia, Colombia",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT02507635,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00359138,HYPERSENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00264303,CHRONIC IDIOPATHIC URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Brugge, Belgium|Brussels, Belgium|Liege, Belgium|Merksem, Belgium|Sint-Niklaas, Belgium|Woluwe-St-Lamb, Belgium|Bernay, France|Besancon, France|Hyeres, France|Les Milles, France|Marseille, France|Montpellier, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Poitiers, France|Quimper, France|Saint-Mande, France|Troyes, France|Valence, France|Villejuif, France|Augsburg, Germany|Berlin, Germany|Dresden, Germany|Dusseldorf, Germany|Erlangen, Germany|Gottingen, Germany|Hamburg, Germany|Hannover, Germany|Koln, Germany|Leipzig, Germany|Mahlow, Germany|Mainz, Germany|Munchen, Germany|Viersen, Germany|Caserta, Italy|Catania, Italy|Cesena, Italy|Genova, Italy|Modena, Italy|Palermo, Italy|Pavia, Italy|Roma, Italy|Siena, Italy|Udine, Italy|Verona, Italy|Johor Bharu, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Negeri Sembilan, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Sarawak, Malaysia|Brasov, Romania|Bucharest, Romania|Dolj, Romania|Sibiu, Romania|Cape Town, South Africa|Durban, South Africa|Lenasia, South Africa|Albacete, Spain|Barcelona, Spain|Coruna, Spain|Granada, Spain|Madrid, Spain|Malaga, Spain|Murcia (El Palmar), Spain|Oviedo, Spain|Santiago de Compostela, Spain|Sevila, Spain|Valencia, Spain|Amersham, United Kingdom|Cardiff, United Kingdom|Irvine, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Nuneaton, United Kingdom|Salford, United Kingdom",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00867191,SEASONAL ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00805584,"RHINITIS, ALLERGIC, SEASONAL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00783354,URTICARIA|CHRONIC IDIOPATHIC URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00311844,"CONJUNCTIVITIS, ALLERGIC",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00600847,ACQUIRED COLD URTICARIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Allergie-Centrum-Charité Berlin, Berlin, Germany",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc2c(c1)CCc1cccnc1C2=C1CCNCC1,1,DB00967,__DESLORATADINE,5178878,Completed,NCT00780403,ALLERGIES,All,6 Years to 11 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,8.903673586726619,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.48,310.82099999999997,24.92,2.0,1.0,4.0,34.35,101.04,0.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,1,DB00972,__AZELASTINE,5164194,Terminated,NCT02953106,"ASTHMA, ALLERGIC|RHINITIS,ALLERGIC|ALLERGY",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.2223454280375,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.81,381.898,35.91,3.0,0.0,4.0,41.54,110.52,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
O=C1[C@H](CC[C@H](O)c2ccc(F)cc2)[C@@H](c2ccc(O)cc2)N1c1ccc(F)cc1,1,DB00973,__EZETIMIBE,RE42461,Unknown status,NCT00843661,HIV|HYPERLIPIDEMIA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale di Circolo and Fondazione Macchi, Varese, Italy",C07D205/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,200.973325940984,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.14,409.4252,60.77,3.0,2.0,4.0,41.65,108.86,6.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Completed,NCT02352090,CONTRACEPTION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Helsinki University Central Hospital, Kätilöopisto Maternity Hospital, Helsinki, Finland|Oulu University Hospital, Department of Gynecology and Obstetrics, Oulu, Finland",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Completed,NCT00829114,HIV/AIDS|HIV INFECTIONS,Female,18 Years to 35 Years   (Adult),Other|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,", RHRU National Office, University of Witwatersand, Esselent St. Hillbrow, Johannesburg, South Africa|Makerere University Medical School, Mulago Hospital, Department of Obstetrics and Gynecology, Kampala, Uganda",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,DB00977,__ETHINYLESTRADIOL,5876746,Terminated,NCT02531321,CONTRACEPTION|HIV,Female,18 Years to 45 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Southern California, Los Angeles, California, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,41.0,32.8220291997782,1235.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.63,296.4034,40.46,2.0,2.0,4.0,34.53,87.37,0.0,0.0,1.0,0.0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT00819637,ACUTE ASTHMA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Henry Ford Hospital Emergency Department, Detroit, Michigan, United States",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT00460577,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",All,5 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator site - five sites in Caracas, Caracas, Venezuela|Novartis Investigator Site, Maracaibo, Venezuela",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT01845025,PERSISTENT ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Avondale, Arizona, United States|Novartis Investigative Site, North Hollywood, California, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Conyers, Georgia, United States|Novartis Investigative Site, Stone Mountain, Georgia, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Covington, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Gaithersburg, Maryland, United States|Novartis Investigative Site, Picayune, Mississippi, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, North Massapequa, New York, United States|Novartis Investigative Site, Elizabeth City, North Carolina, United States|Novartis Investigative Site, Winston Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Oaks, Pennsylvania, United States|Novartis Investigative Site, East Greenwich, Rhode Island, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Memphis, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Saint George, Utah, United States|Novartis Investigative Site, Mequon, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT03563001,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME|SMALL AIRWAY DISEASE|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Terminated,NCT01912872,SEVERE IGE-MEDIATED ASTHMA,All,"6 Years to 55 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Tuxtla Gutierrez, Chiapas, Mexico|Novartis Investigative Site, Mexico City, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Edo. De México, Mexico|Novartis Investigative Site, Nezahualcoyotl, Estado De Mexico, Mexico|Novartis Investigative Site, Pachuca de Soto, Hidalgo, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadaljara, Jalisco, Mexico|Novartis Investigative Site, Tepic, Nayarit, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mérida, Yucatán, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1,1,DB00983,__FORMOTEROL,6123924,Unknown status,NCT02345993,ASTHMA|ASTHMATIC CRISIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","National Institute of Respiratory Diseases, Mexico, Distrito Federal, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
C[N+]1(C)CCC(OC(=O)C(O)(c2ccccc2)C2CCCC2)C1,1,DB00986,__GLYCOPYRRONIUM,6433003,Completed,NCT02622243,ASTHMA,All,"19 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma Research Lab, Saskatoon, Saskatchewan, Canada",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,27.7952319349473,191.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.2,318.4305,46.53,2.0,1.0,3.0,35.88,101.08,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00029523,MENINGEAL NEOPLASMS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barrow Neurological Institute, Phoenix, Arizona, United States|Alta Bates Comprehensive Cancer Center, Berkeley, California, United States|University of Southern California, Norris Cancer Center, Los Angeles, California, United States|University of Colorado Hospital, Anschutz Cancer Pavilion, Denver, Colorado, United States|Georgetown University Medical Center Hematology/Oncology, Washington, District of Columbia, United States|Mayo Clinic, Jacksonville, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory Clinic, Department of Neurosurgery, Atlanta, Georgia, United States|Straub Clinic and Hospital, Honolulu, Hawaii, United States|Rush Cancer Institute, Chicago, Illinois, United States|Loyola University Medical Center, Dept. of Hematology/Oncology, Maywood, Illinois, United States|Beth Israel Deaconess Medical Center Dept. of Neurology, Boston, Massachusetts, United States|Park Nicollet Institute, Oncology Research Program, Minneapolis, Minnesota, United States|JFK Neuroscience Institute, Edison, New Jersey, United States|Bowman Gray School of Medicine/Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States|Case Western Reserve University Hospital of Cleveland, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University of Texas Health Science Center, San Antonio, Texas, United States|University of Utah, Hunsman Cancer Institute, Salt lake City, Utah, United States|Virginia Mason Medical Center, Seattle, Washington, United States|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Toronto Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada",A61K9/127,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",A61K9/127,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",A61K9/127,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Active Not Recruiting,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/127,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O)c(=O)n1,1,DB00987,__CYTARABINE,5455044,Completed,,ACUTE LYMPHOBKASTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/127,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,28.6494589211277,1620.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.2,243.2166,128.61,7.0,4.0,2.0,22.21,54.54,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NCCc1ccc(O)c(O)c1,1,DB00988,__DOPAMINE,3947590,Completed,,ESRD,,,,,"FISABIO, Elche, Alicante, Spain",C07D207/46,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,14.0618903878929,5659.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.4,153.1784,66.48,3.0,3.0,1.0,16.21,43.25,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,1,DB00989,__RIVASTIGMINE,4948807,Completed,NCT01348282,NEUROCOGNITIVE DISTURBANCE|HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundació LLuita contra la SIDA, Badalona, Barcelona, Spain",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,17.2159592599437,115.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,250.3367,32.78,2.0,0.0,1.0,28.53,73.37,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,1,DB00989,__RIVASTIGMINE,4948807,Terminated,NCT00881205,MULTIPLE SCLEROSIS|COGNITIVE IMPAIRMENT,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Aalen, Germany|Novartis Investigative Site, Abensberg, Germany|Novartis Investigative Site, Achim, Germany|Novartis Investigative Site, Alzenau, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Mergentheim, Germany|Novartis Investigative Site, Bayreuth, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative SIte, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Böblingen, Germany|Novartis Investigative Site, Düsseldorf, Germany|Novartis Investigative Site, Eisenach, Germany|Novartis Investigative Site, Ellwangen, Germany|Novartis Investigative Site, Erbach, Germany|Novartis Investigative Site, Erlangen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Essen, Germany|Novartis Investigative Site, Giessen, Germany|Novartis Investigative Site, Göttingen, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigational Site, Hamburg, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Itzehoe, Germany|Novartis Investigative Site, Kaltenkirchen, Germany|Novartis Investigative Site, Koeln, Germany|Novartis Investigative Site, Krefeld, Germany|Novartis Investigative Site, Lappersdorf, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Ludwigshafen, Germany|Novartis Investigative Site, Lüneburg, Germany|Novartis Investigative Site, Neu-Ulm, Germany|Novartis Investigative Site, Neuburg, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Osnabruck, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Stade, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Stuttgart, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Unterhaching, Germany|Novartis Investigative Site, Viernheim, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Wolfratshausen, Germany",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,17.2159592599437,115.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,250.3367,32.78,2.0,0.0,1.0,28.53,73.37,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,1,DB00989,__RIVASTIGMINE,4948807,Completed,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2159592599437,115.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,250.3367,32.78,2.0,0.0,1.0,28.53,73.37,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0
CCN(C)C(=O)Oc1cccc([C@H](C)N(C)C)c1,1,DB00989,__RIVASTIGMINE,4948807,Completed,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,17.2159592599437,115.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.45,250.3367,32.78,2.0,0.0,1.0,28.53,73.37,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,NCT01612871,BREAST CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Val d'Aurelle - Paul Lamarque, Montpellier, France|Institut Claudius REGAUD Toulouse, Toulouse, France",C07J1/0011,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,NCT00649090,BREAST NEOPLASM,Female,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Aalst, Belgium|Pfizer Investigational Site, Antwerpen, Belgium|Pfizer Investigational Site, Arlon, Belgium|Pfizer Investigational Site, Baudour, Belgium|Pfizer Investigational Site, Bonheiden, Belgium|Pfizer Investigational Site, Bouge, Belgium|Pfizer Investigational Site, Boussu, Belgium|Pfizer Investigational Site, Braine-l'Alleud, Belgium|Pfizer Investigational Site, Brasschaat, Belgium|Pfizer Investigational Site, Brugge, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussels, Belgium|Pfizer Investigational Site, Brussel, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Bruxelles, Belgium|Pfizer Investigational Site, Charleroi, Belgium|Pfizer Investigational Site, Chenee, Belgium|Pfizer Investigational Site, Chimay, Belgium|Pfizer Investigational Site, Dendermonde, Belgium|Pfizer Investigational Site, Duffel, Belgium|Pfizer Investigational Site, Edegem, Belgium|Pfizer Investigational Site, Eupen, Belgium|Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Gilly (Charleroi), Belgium|Pfizer Investigational Site, Gosselies, Belgium|Pfizer Investigational Site, Halle, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Herstal, Belgium|Pfizer Investigational Site, Hornu, Belgium|Pfizer Investigational Site, Huy, Belgium|Pfizer Investigational Site, Kortrijk, Belgium|Pfizer Investigational Site, La Louviere, Belgium|Pfizer Investigational Site, Leuven, Belgium|Pfizer Investigational Site, Libramont, Belgium|Pfizer Investigational Site, Liege, Belgium|Pfizer Investigational Site, Lier, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Mechelen, Belgium|Pfizer Investigational Site, Merksem, Belgium|Pfizer Investigational Site, Mons, Belgium|Pfizer Investigational Site, Montigny-le-Tilleul, Belgium|Pfizer Investigational Site, Mouscron, Belgium|Pfizer Investigational Site, Namur, Belgium|Pfizer Investigational Site, Ottignies, Belgium|Pfizer Investigational Site, Rocourt, Belgium|Pfizer Investigational Site, Roeselare, Belgium|Pfizer Investigational Site, Seraing, Belgium|Pfizer Investigational Site, Sint-Niklaas, Belgium|Pfizer Investigational Site, Soignies, Belgium|Pfizer Investigational Site, Tongeren, Belgium|Pfizer Investigational Site, Torhout, Belgium|Pfizer Investigational Site, Tournai, Belgium|Pfizer Investigational Site, Turnhout, Belgium|Pfizer Investigational Site, Verviers, Belgium|Pfizer Investigational Site, Waregem, Belgium|Pfizer Investigational Site, Wilrijk, Belgium|Pfizer Investigational Site, Yvoir, Belgium",C07J1/0011,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Completed,,"NEOPLASMS, BREAST",,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2[C@H](CC[C@]3(C)C(=O)CC[C@@H]23)[C@@]2(C)C=CC(=O)C=C12,1,DB00990,__EXEMESTANE,4808616,Recruiting,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0011,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,31.7706729090946,512.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,296.4034,34.14,2.0,0.0,4.0,33.71,89.03,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT01112215,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vall d'Hebron Hospital, Barcelona, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT03449758,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 250007, Argenteuil, France|Investigational Site Number 250006, Besancon, France|Investigational Site Number 250027, Bobigny, France|Investigational Site Number 250016, Bordeaux, France|Investigational Site Number 250014, Caen, France|Investigational Site Number 250032, CAHORS Cedex 9, France|Investigational Site Number 250019, Cannes, France|Investigational Site Number 250013, Cholet, France|Investigational Site Number 250002, Clermont Ferrand, France|Investigational Site Number 250009, Echirolles, France|Investigational Site Number 250005, La Roche Sur Yon, France|Investigational Site Number 250024, Le Mans Cedex 9, France|Investigational Site Number 250004, Lille Cedex, France|Investigational Site Number 250012, Limoges Cedex, France|Investigational Site Number 250021, Lyon, France|Investigational Site Number 250018, Montivilliers, France|Investigational Site Number 250029, MONTPELLIER Cedex 5, France|Investigational Site Number 250025, NANTES Cedex 1, France|Investigational Site Number 250026, Nice cedex 1, France|Investigational Site Number 250020, Paris Cedex 10, France|Investigational Site Number 250011, PARIS Cedex 13, France|Investigational Site Number 250010, Paris, France|Investigational Site Number 250015, Paris, France|Investigational Site Number 250028, Paris, France|Investigational Site Number 250033, Paris, France|Investigational Site Number 250031, Poitiers, France|Investigational Site Number 250023, Pontoise, France|Investigational Site Number 250017, RENNES Cedex, France|Investigational Site Number 250008, Rouen, France|Investigational Site Number 250001, St Etienne, France|Investigational Site Number 250034, Strasbourg Cedex 2, France|Investigational Site Number 250022, Toulouse, France|Investigational Site Number 250003, Tours, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT02645565,LUPUS NEPHRITIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Unknown status,NCT02900443,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands|Leiden University Medical Centre, Leiden, Netherlands|Sint Antonius Hospital, Nieuwegein, Netherlands|Radboud University Medical Centre, Nijmegen, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Recruiting,NCT03164473,EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hôpital Cochin, Paris, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Withdrawn,NCT02281799,PANCREATITIS|INFLAMMATORY BOWEL DISEASES,All,"5 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shaare Zedek, Jerusalem, Israel",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Terminated,NCT00128895,VASCULITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VU University Medical Centre, Amsterdam, Netherlands|University Medical Centre Groningen, Groningen, Netherlands|Martini Hospital Groningen, Groningen, Netherlands|Medical Centre Leeuwarden, Leeuwarden, Netherlands|University Hospital Maastricht, Maastricht, Netherlands|UMC St Radboud, Nijmegen, Netherlands|Erasmus Medical Centre, Rotterdam, Netherlands|University Medical Centre Utrecht, Utrecht, Netherlands",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Unknown status,NCT00400075,POLYARTERITIS NODOSA|MICROSCOPIC POLYANGIITIS,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00755859,IGA NEPHROPATHY,All,"16 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital ""Bolognini"", Seriate, BG, Italy|Hospital of Montichiari, Montichiari, Brescia, Italy|Hospital ""S.Anna"", Como, CO, Italy|Hospital ""Istituti Ospitalieri"", Cremona, CR, Italy|Hospital ""S.Marta e S.Venera"",, Acireale, CT, Italy|Hospital ""S.Vincenzo"", Taormina, CT, Italy|Department of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, LC, Italy|Hospital ""Maggiore"", Lodi, LO, Italy|Hospital ""Uboldo"", Cernusco sul Naviglio, MI, Italy|Hospital of Desio, Desio, MI, Italy|Hospital ""Maggiore"" IRCCS, Milano, MI, Italy|Hospital ""A.Segni"", Ozieri, Nuoro, Italy|Hospital ""Spedali Civili"", Brescia, Italy|""G. Brotzu"" Hospital, Cagliari, Italy|Hospital ""Cannizzaro"", Catania, Italy|Hospital ""Careggi"", Firenze, Italy|Hospital of University, Foggia, Italy|Hospital ""C. Poma"", Mantova, Italy|Hospital ""S. Francesco"", Nuoro, Italy|Hospital ""V. Cervello"", Palermo, Italy|University Hospital, Parma, Italy|Fondazione Maugeri"" IRCCS, Pavia, Italy|CNR-IBIM, Reggio Calabria, Italy|Hospital ""S. Maria Nuova"", Reggio Emilia, Italy|Hospital of Sondrio, Sondrio, Italy|CMID, Torino, Italy|Hospital ""Belcolle"", Viterbo, Italy|Inselspital, Bern, Switzerland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,NCT00987116,MYASTHENIA GRAVIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hopital Raymond Poincaré, Garches, France",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Active Not Recruiting,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
Cn1cnc([N+](=O)[O-])c1Sc1ncnc2nc[nH]c12,1,DB00993,__AZATHIOPRINE,4452794,Completed,,"HEPATITIS, AUTOIMMUNE",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,17.8730569416209,1549.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.84,277.263,118.1,6.0,1.0,3.0,24.26,70.95,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT02466191,PENDULAR NYSTAGMUS|OCULOPALATAL TREMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon, Lyon, France",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00904202,POSTHERPETIC NEURALGIA|DIABETIC NEUROPATHY|COMPLEX REGIONAL PAIN SYNDROME|CARPAL TUNNEL SYNDROME|HIV NEUROPATHY|IDIOPATHIC SENSORY NEUROPATHY|PERIPHERAL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Birmingham, Alabama, United States|Hueytown, Alabama, United States|Phoenix, Arizona, United States|Pembroke Pines, Florida, United States|New York, New York, United States|Rochester, New York, United States|Altoona, Pennsylvania, United States",C07C229/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,NCT00153283,BRONCHIAL ASTHMA,All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C229/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,NEUROPATHIC PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCC1(CC(=O)O)CCCCC1,1,DB00996,__GABAPENTIN,6054482,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/28,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,62.9828127887636,456.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,171.2368,63.32,3.0,2.0,1.0,18.92,46.33,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07F9/5537,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,"Active, not recruiting",NCT02577783,MULTIPLE MYELOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,NCT00969462,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Departmetn of Medicine. Meir Medical Center, Kfar-Saba, Israel",C07F9/5537,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",C07F9/5537,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,1,DB00997,__DOXORUBICIN,5013556,Completed,,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/5537,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,18.5301546232982,5989.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.41,543.5193,206.07,12.0,6.0,5.0,53.87,134.59,5.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CN[C@@H]1CCc2[nH]c3ccc(C(N)=O)cc3c2C1,1,DB00998,__FROVATRIPTAN,5464864,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,22.47274071336161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,243.3043,70.91,2.0,3.0,3.0,27.55,71.84,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00170937,METABOLIC SYNDROME|HYPERTENSION|PRE-HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Novartis Pharmaceuticals, E. Hanover, New Jersey, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Withdrawn,NCT00745953,METABOLIC SYNDROME|LIPOTOXICITY,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",C07D405/14,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT02875886,CHRONIC KIDNEY DISEASE,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ErasmusMC, Rotterdam, Netherlands",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Completed,NCT00896389,HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Amish Research Clinics, Lancaster, Pennsylvania, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,1,DB00999,__HYDROCHLOROTHIAZIDE,5616599,Active Not Recruiting,,GLUCOSE METABOLISM DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,26.1524877307542,551.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.16,297.7390000000001,118.36,5.0,3.0,2.0,25.35,63.11,1.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Withdrawn,NCT02319564,WHEEZE,All,12 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00667797,ASTHMA|COPD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Birmingham, Alabama, United States|Chula Vista, California, United States|Oakland, California, United States|Wheat Ridge, Colorado, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Brandon, Florida, United States|Des Moines, Iowa, United States|Johnson City, New Jersey, United States|Great Neck, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Winston Salem, North Carolina, United States|Portland, Oregon, United States|Pittsburg, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Morgantown, West Virginia, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT03493503,CHILDHOOD ASTHMA WITH STATUS ASTHMATICUS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00070707,"RHINITIS, ALLERGIC, SEASONAL|ASTHMA",All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Not yet recruiting,NCT04184609,"ASTHMA IN CHILDREN|DYSPNEA; ASTHMATIC|OBESITY, CHILDHOOD",All,9 Years to 12 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Nevada Las Vegas, Las Vegas, Nevada, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Recruiting,NCT03586544,"ASTHMA IN CHILDREN|OBESITY, CHILDHOOD|EXERCISE INDUCED BRONCHOSPASM",All,8 Years to 12 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Childrens Lung Specialists, Las Vegas, Nevada, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Suspended,NCT02966184,STATUS ASTHMATICUS,All,5 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norton Children's Hospital, Louisville, Kentucky, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT00273689,EXERCISE INDUCED BRONCHOSPASM,All,7 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of New Mexico, Albuquerque, New Mexico, United States",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT00900874,BRONCHIAL ASTHMA,All,5 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","AIIMS, New Delhi, India",B65D83/54,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Completed,NCT03044938,ASTHMA|HEART RATE FAST,All,20 Years to 59 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Jaqueline Ribas de Melo, Sao Paulo, São Paulo, Brazil",B65D83/54,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,"Active, not recruiting",NCT03924635,AIRWAY INFLAMMATION|ASTHMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Bradford, United Kingdom|Research Site, Dundee, United Kingdom|Research Site, Nottingham, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Watford, United Kingdom",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Unknown status,NCT01721291,CHRONIC OBSTRUCTIVE PULMONARY DISEASE|ASTHMA|HEALTHY SUBJECTS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Brompton Hospital & Imperial College London, London, United Kingdom",B65D83/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1,1,DB01001,__SALBUTAMOL,5775321,Active Not Recruiting,,AIRWAY INFLAMMATION,,,,,"FISABIO, Elche, Alicante, Spain",B65D83/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,42.4813651204336,760.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.86,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCN1CCCC[C@H]1C(=O)Nc1c(C)cccc1C,1,DB01002,__LEVOBUPIVACAINE,5708011,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,21.059980697755602,210.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,288.4277,32.34,2.0,1.0,2.0,34.45,90.19,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,1,DB01003,__CROMOGLICIC_ACID,4145438,Completed,NCT02371941,EOSINOPHILIC ESOPHAGITIS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LeBonheur Children's Hospital, Memphis, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,1,DB01003,__CROMOGLICIC_ACID,4145438,Completed,,"OESOPHAGITIS, EOSINOPHILIC",,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0
O=C(O)c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)O)cc(=O)c34)cccc2o1,1,DB01003,__CROMOGLICIC_ACID,4145438,Unknown Status,,DYSPEPSIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,16.953120187272805,844.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.84,468.3665,165.89,11.0,3.0,4.0,44.38,114.11,8.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0
Nc1nc2c(ncn2COC(CO)CO)c(=O)[nH]1,1,DB01004,__GANCICLOVIR,5378475,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,35.0,46.39109632641321,1907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,255.2306,134.99,7.0,4.0,2.0,24.15,61.03,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Completed,NCT00005018,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"East Bay AIDS Ctr, Berkeley, California, United States|Pacific Oaks Research, Beverly Hills, California, United States|Altamed Medical Health Services, Los Angeles, California, United States|St Lukes Medical Group, San Diego, California, United States|Pacific Horizons Med Group, San Francisco, California, United States|Gary Richmond MD, Fort Lauderdale, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Saint Josephs Comprehensive Research Institute, Tampa, Florida, United States|Northstar Med Clinic, Chicago, Illinois, United States|Univ of Kentucky Med Ctr, Lexington, Kentucky, United States|Boston Med Ctr / Evans - 556, Boston, Massachusetts, United States|CRI of New England, Brookline, Massachusetts, United States|Univ of Nebraska Medical Ctr, Omaha, Nebraska, United States|Beth Israel Med Ctr, New York, New York, United States|Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States|Univ of North Carolina / Infectious Disease Division, Chapel Hill, North Carolina, United States|Univ of NC Infectious Diseases, Wilmington, North Carolina, United States|Anderson Clinical Research Inc, Reading, Pennsylvania, United States|Miriam Hosp, Providence, Rhode Island, United States|Burnside Clinic, Columbia, South Carolina, United States|Univ of Texas Med Branch, Galveston, Texas, United States|Univ of Texas / Thomas Street Clinic, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
NC(=O)NO,1,DB01005,__HYDROXYUREA,,Active Not Recruiting,,SICKLE CELL ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,76.0547,75.35,2.0,3.0,0.0,5.94,14.91,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,NCT01612871,BREAST CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Val d'Aurelle - Paul Lamarque, Montpellier, France|Institut Claudius REGAUD Toulouse, Toulouse, France",C07D213/57,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,1,DB01006,__LETROZOLE,4978672,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/57,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,27.3681184418571,752.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.86,285.3027,78.29,4.0,0.0,3.0,29.59,94.47,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Completed,NCT00361140,"MYELODYSPLASTIC SYNDROMES|MYELOPROLIFERATIVE DISORDERS|LEUKEMIA, LYMPHOCYTIC|MYELOMA|LYMPHOMA",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Recruiting,NCT02670564,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Hôpital Cantonal de Genève, Département de Pédiatrie, Geneva, Cansearch Laboratory, Switzerland|Universitäts-Kinderspital beider Basel (UKBB), Onkologie/Hämatologie, Basel, Switzerland|HUG Hôpitaux Universitaire de Genève, Unité d'onco-hématologie pédiatrique, Geneva, Switzerland|Universitäts-Kinderspital, Zurich, Switzerland",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CS(=O)(=O)OCCCCOS(C)(=O)=O,1,DB01008,__BUSULFAN,5430057,Completed,,"LEUKEMIA, LYMPHOCYTIC",,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.0928355818394,3071.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.9,246.30200000000002,86.74,4.0,0.0,0.0,23.64,49.57,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,CHILDREN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,LYMPHEDEMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB01009,__KETOPROFEN,4097522,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,4089.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.56,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@@H](NCCCc1cccc(C(F)(F)F)c1)c1cccc2ccccc12,1,DB01012,__CINACALCET,6011068,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,103.0,60.8801002073964,33.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.57,357.412,12.03,1.0,1.0,3.0,37.9,100.12,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Unknown status,NCT02360202,BULLOUS PEMPHIGOID,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Rouen University Hospital, Rouen, France",A61K8/062,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Not yet recruiting,NCT03926377,OSTEOPOROSIS|BULLOUS PEMPHIGOID,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K8/062,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,DB01013,__CLOBETASOL_PROPIONATE,6106848,Completed,,PSORIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/062,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.9904515493131,799.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.49,466.97,80.67,4.0,1.0,4.0,48.28,119.32,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,NCT00000816,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Primary Purpose: Treatment,"USC CRS, Los Angeles, California, United States|Stanford CRS, Palo Alto, California, United States|Ucsf Aids Crs, San Francisco, California, United States|Santa Clara Valley Med. Ctr., San Jose, California, United States|San Mateo County AIDS Program, San Mateo, California, United States|Harbor-UCLA Med. Ctr. CRS, Torrance, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Univ. of Miami AIDS CRS, Miami, Florida, United States|Queens Med. Ctr., Honolulu, Hawaii, United States|Univ. of Hawaii at Manoa, Leahi Hosp., Honolulu, Hawaii, United States|Northwestern University CRS, Chicago, Illinois, United States|Cook County Hosp. CORE Ctr., Chicago, Illinois, United States|Rush Univ. Med. Ctr. ACTG CRS, Chicago, Illinois, United States|Indiana Univ. School of Medicine, Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Methodist Hosp. of Indiana, Indianapolis, Indiana, United States|Tulane/LSU Maternal/Child CRS, New Orleans, Louisiana, United States|Johns Hopkins Adult AIDS CRS, Baltimore, Maryland, United States|Massachusetts General Hospital ACTG CRS, Boston, Massachusetts, United States|Bmc Actg Crs, Boston, Massachusetts, United States|Beth Israel Deaconess - East Campus A0102 CRS, Boston, Massachusetts, United States|Beth Israel Deaconess Med. Ctr., ACTG CRS, Boston, Massachusetts, United States|Hennepin County Med. Ctr., Div. of Infectious Diseases, Minneapolis, Minnesota, United States|University of Minnesota, ACTU, Minneapolis, Minnesota, United States|St. Louis ConnectCare, Infectious Diseases Clinic, St Louis, Missouri, United States|Washington U CRS, St. Louis, Missouri, United States|Univ. of Nebraska Med. Ctr., Durham Outpatient Ctr., Omaha, Nebraska, United States|SUNY - Buffalo, Erie County Medical Ctr., Buffalo, New York, United States|NY Univ. HIV/AIDS CRS, New York, New York, United States|Beth Israel Med. Ctr. (Mt. Sinai), New York, New York, United States|Univ. of Rochester ACTG CRS, Rochester, New York, United States|Unc Aids Crs, Chapel Hill, North Carolina, United States|Carolinas HealthCare System, Carolinas Med. Ctr., Charlotte, North Carolina, United States|Regional Center for Infectious Disease, Wendover Medical Center CRS, Greensboro, North Carolina, United States|Univ. of Cincinnati CRS, Cincinnati, Ohio, United States|MetroHealth CRS, Cleveland, Ohio, United States|Case CRS, Cleveland, Ohio, United States|The Ohio State Univ. AIDS CRS, Columbus, Ohio, United States|Hosp. of the Univ. of Pennsylvania CRS, Philadelphia, Pennsylvania, United States|University of Washington AIDS CRS, Seattle, Washington, United States|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Mbeya Med. Research Program, Mbeya Referral Hosp. CRS, Mbeya, Tanzania",A61L15/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,NCT00137657,HIV|MALARIA|DIARRHEA|PNEUMONIA|OPPORTUNISTIC INFECTIONS,All,"15 Years and older   (Child, Adult, Older Adult)",U.S. Fed|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,"CDC KEMRI Research Institute, Kisumu, Kenya",A61L15/64,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
Cc1cc(NS(=O)(=O)c2ccc(N)cc2)no1,1,DB01015,__SULFAMETHOXAZOLE,3983209,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,118.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.79,253.278,98.22,4.0,2.0,2.0,24.99,64.5,2.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
COc1ccc(Cl)cc1C(=O)NCCc1ccc(S(=O)(=O)NC(=O)NC2CCCCC2)cc1,1,DB01016,__GLYBURIDE,6303146,Completed,,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,27.105279369186203,439.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.78,494.004,113.6,5.0,3.0,3.0,51.75,126.98,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,0,0
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2-c2nn[nH]n2)cc1,1,DB01029,__IRBESARTAN,5270317,Completed,NCT00347087,CHRONIC HEART FAILURE,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Applied Cachexia Research, Cardiology Dept. Charite Medical School, Virchow Klinikum, Berlin, Germany",C07D231/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,24.805437483315806,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,428.5294,87.13,5.0,1.0,5.0,47.59,136.72,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1
CCCN(CCC)S(=O)(=O)c1ccc(C(=O)O)cc1,1,DB01032,__PROBENECID,3959253,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",C07H13/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,34.760467360726,3576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.52,285.3590000000001,74.68,4.0,1.0,1.0,29.96,73.81,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
S=c1nc[nH]c2nc[nH]c12,1,DB01033,__MERCAPTOPURINE,,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.13,152.17700000000005,53.07,3.0,2.0,2.0,14.04,43.6,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Unknown status,NCT00843661,HIV|HYPERLIPIDEMIA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ospedale di Circolo and Fondazione Macchi, Varese, Italy",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Terminated,NCT01574131,SECOND OR THIRD DEGREE BURNS,All,"4 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Texas Medical Branch, Galveston, Texas, United States",B82Y5/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)OC(=O)C(C)(C)Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1,1,DB01039,__FENOFIBRATE,5145684,Completed,NCT00745407,HYPERTRIGLYCERIDEMIA,All,"25 Years to 80 Years   (Adult, Older Adult)",Other,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,"Gil Medical Center, Incheon, Korea, Republic of",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.450091377646306,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.86,360.83099999999996,52.6,3.0,0.0,2.0,38.15,97.13,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02559154,MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai General Hospital, Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Unknown status,NCT02844309,WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1CCC(N2C(=O)c3ccccc3C2=O)C(=O)N1,1,DB01041,__THALIDOMIDE,6235756,Recruiting,NCT03122431,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)|JUVENILE SLE|CUTANEOUS LUPUS,All,"5 Years to 64 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,44.9783363108072,969.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.42,258.2295,83.55,4.0,1.0,3.0,24.42,64.32,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,1,DB01042,__MELPHALAN,8410077,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,76.0,40.8714758003244,5796.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.22,305.2,66.56,4.0,2.0,1.0,31.38,78.23,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Recruiting,NCT03703856,ALZHEIMER DISEASE,All,"50 Years to 80 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Teaching Facility (CTF-B102) at UCSD Medical Center, San Diego, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Completed,NCT02466191,PENDULAR NYSTAGMUS|OCULOPALATAL TREMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospices Civils de Lyon, Lyon, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
CC12CC3CC(C)(C1)CC(N)(C3)C2,1,DB01043,__MEMANTINE,5061703,Completed,NCT00638027,MULTIPLE SCLEROSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Rochester, Rochester, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,18.5958643914659,484.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.31,179.3018,26.02,1.0,1.0,3.0,21.82,54.49,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D498/18,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT02057796,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia|CePReF Centre de Prise en charge de Recherche et de Formation, Abidjan, Yopougon, Côte D'Ivoire|ISS ImmunoSuppression Service, Mbarara, Uganda|Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT00620438,HIV INFECTIONS|TUBERCULOSIS,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Makerere University, Kampala, Uganda",C07D498/18,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01045,__RIFAMPICIN,3963705,Unknown status,NCT01782950,AIDS WITH TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Kampala, Uganda",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.77258259923201,841.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,822.9402,220.15,14.0,6.0,5.0,86.46,225.58,5.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0
CCCCC(F)(F)[C@@]1(O)CC[C@H]2[C@@H](CC(=O)[C@@H]2CCCCCCC(=O)O)O1,1,DB01046,__LUBIPROSTONE,5317032,Completed,NCT01236534,MULTIPLE SCLEROSIS|CONSTIPATION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Rochester, Rochester, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,16.9859750713566,12.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,390.468,83.83,5.0,2.0,2.0,42.35,95.6,11.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1
CC(=O)OCC(=O)[C@@]12OC(C)(C)O[C@@H]1C[C@H]1[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]12C,1,DB01047,__FLUOCINONIDE,6765001,Completed,NCT01049243,ATOPIC DERMATITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,30.949300806998,752.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,494.5249,99.13,6.0,1.0,5.0,48.97,120.56,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Completed,NCT00549198,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Aarhus N, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Garches, France|GSK Investigational Site, Levallois-Perret, France|GSK Investigational Site, Saint Denis Cedex 01, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Ferrara, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Legnano (MI, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Lausanne, Switzerland|GSK Investigational Site, St Gallen, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Woolwich, London, London, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Brighton, Sussex East, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Farnworth, Bolton, United Kingdom|GSK Investigational Site, Gloucester, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Middlesborough, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Recruiting,NCT02957864,"RENAL INSUFFICIENCY,CHRONIC|HIV|THERAPEUTIC AGENT TOXICITY",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ziekenhuis Rijnstate, Arnhem, Gelderland, Netherlands|MC Slotervaart, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Unknown status,NCT01059422,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Research Institute of Epidemiology, Moscow, Russian Federation",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Completed,NCT00005764,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"THE Clinic, Los Angeles, California, United States|Tower Infectious Disease Med Ctr, Los Angeles, California, United States|St Lukes Medical Group, San Diego, California, United States|UCSD Treatment Ctr, San Diego, California, United States|Dupont Circle Physicians Group, Washington, District of Columbia, United States|North Broward Hosp District / HIV Clinical Research, Fort Lauderdale, Florida, United States|Duval County Health Department, Jacksonville, Florida, United States|Infectious Disease Research Institute Inc, Tampa, Florida, United States|Northstar Med Clinic, Chicago, Illinois, United States|Jersey Shore Med Ctr, Neptune, New Jersey, United States|South Jersey Infectious Diseases Inc, Somers Point, New Jersey, United States|Infectious Disease Specialists of NJ, Union, New Jersey, United States|Bronx Veterans Affairs Med Ctr, Bronx, New York, United States|Infectious Diseases Assoc of Brooklyn, Brooklyn, New York, United States|Long Island College Hospital, Brooklyn, New York, United States|Mt Vernon Hospital, Mt. Vernon, New York, United States|Dr Lawrence Fontana, New York, New York, United States|Liberty Medical / Cabrini Hospital / Dept of Infec Diseases, New York, New York, United States|Howard Grossman, New York, New York, United States|Boriken Neighborhood Health Center, New York, New York, United States|Univ of North Carolina / SOCA, Chapel Hill, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States|Anderson Clinical Research, Pittsburgh, Pennsylvania, United States|Central Texas Clinical Research, Austin, Texas, United States|Gathe, Joseph, M.D., Houston, Texas, United States|Diversified Med Practices, PA, Houston, Texas, United States|Univ of Texas / Med School at Houston, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States|Swedish Med Ctr, Seattle, Washington, United States",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Completed,NCT01886638,HIV|CARDIOVASCULAR DISEASE,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alfred Health, Melbourne, Victoria, Australia",C07D473/00,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1,1,DB01048,__ABACAVIR,5089500,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,9.396496847984553,748.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.61,286.3323,101.88,6.0,3.0,4.0,30.43,82.62,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00145730,"OSTEOARTHRITIS, HIP|ARTHROPLASTY, REPLACEMENT, HIP|ARTHRITIS, RHEUMATOID",All,"Child, Adult, Older Adult",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,,A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",A61K9/0056,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)Cc1ccc(C(C)C(=O)O)cc1,1,DB01050,__IBUPROFEN,5215755,Completed,NCT00346216,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Carol M. Johnson MD, LLC, Alabaster, Alabama, United States|Orthopaedics West, Bessemer, Alabama, United States|Central Alabama Research, Birmingham, Alabama, United States|Simon Williamson Clinic/Clinical Research Advantage, Inc., Birmingham, Alabama, United States|Achieve Clinical Research, LLC, Birmingham, Alabama, United States|Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States|Cahaba Research Inc., Birmingham, Alabama, United States|Winston Technology Inc., Haleyville, Alabama, United States|Clinical Research Consultants, Inc, Hoover, Alabama, United States|Medical Affiliated Research Center, Incorporated, Huntsville, Alabama, United States|Rheumatology Associates of North Alabama, PC, Huntsville, Alabama, United States|Montgomery Rheumatology Associates, Montgomery, Alabama, United States|James P. Beretta, PC, Pelham, Alabama, United States|Alabama Clinical Research Associates, Pell City, Alabama, United States|Pell City Internal and Family Medicine, Pell City, Alabama, United States|Scottsboro Quick Care Clinic, Scottsboro, Alabama, United States|Clinic for Rheumatic Diseases, Tuscaloosa, Alabama, United States|Terence T. Hart , MD, Tuscumbia, Alabama, United States|Clinical Research Advantage Inc./ Warner Family Practice, PC, Chandler, Arizona, United States|ArthroCare, Arthritis Care & Research P.C., Gilbert, Arizona, United States|Clinical Research Advantage Inc., /Thunderbird Internal Medicine, Glendale, Arizona, United States|Arizona Center for Clinical Research, Glendale, Arizona, United States|Clinical Research Advantage, Inc./ Lenzmeier Family Medicine, Glendale, Arizona, United States|Clinical Research Advantage, Inc./Central Arizona Medical Associates, PC, Mesa, Arizona, United States|Novara Clinical Research, Mesa, Arizona, United States|Clinical Research Advantage, Inc., Mesa, Arizona, United States|Sun Valley Arthritis Center, Limited, Peoria, Arizona, United States|Lovelace Scientific Resources, Inc., Phoenix, Arizona, United States|Clinical Research Advantage, Inc./ Family Practice Specialists, LTD, Phoenix, Arizona, United States|NPHC Research, Phoenix, Arizona, United States|Phoenix Clinical, Phoenix, Arizona, United States|Arizona Research Center, Inc., Phoenix, Arizona, United States|Precision Trials AZ. LLC; AZ, Phoenix, Arizona, United States|43rd Medical Associates, P.C., Phoenix, Arizona, United States|Southwest Health Ltd., Scottsdale, Arizona, United States|Advanced Arthritis Care and Research, Scottsdale, Arizona, United States|Arizona Pain Specialist, PLLC, Scottsdale, Arizona, United States|Sonora Quest Laboratories, Scottsdale, Arizona, United States|Cochise Clinical Research, Sierra Vista, Arizona, United States|Clinical Research Advantage, Inc./Skyline Medical Center PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Warner Family Practice, PC, Tempe, Arizona, United States|Clinical Research Advantage, Inc/Manning Family Care, Tempe, Arizona, United States|Clinical Research Advantage, Incl Colorado Springs Health Partners, East, Tempe, Arizona, United States|Family Medicine Associates/Clinical Research Advantage, Tempe, Arizona, United States|Clinical Research Advantage, Inc./Fiel Family and Sports Medicine, PC, Tempe, Arizona, United States|ARA-Arizona Research Associates, Tucson, Arizona, United States|Canyon Clinical Research LLC, Tucson, Arizona, United States|Tucson Clinical Researh, Tucson, Arizona, United States|ACRC/Arizona Clinical Research Center, Incorporated, Tucson, Arizona, United States|Clinical Research Advantage, Inc./ Orange Grove Family Practice, Tucson, Arizona, United States|Genova Clinical Research, Tucson, Arizona, United States|Eclipse Clinical Research, Tucson, Arizona, United States|Fayetteville Diagnostic Clinic Limited, Fayetteville, Arkansas, United States|Hearne Family Practice Clinic, Little Rock, Arkansas, United States|Larry S. Watkins, M.D., Little Rock, Arkansas, United States|Lynn Institute of the Ozarks, Little Rock, Arkansas, United States|Rx Medical Research of AR, Little Rock, Arkansas, United States|Anaheim Family Medical Center, Anaheim, California, United States|Advanced Research Center, Anaheim, California, United States|Advanced Arthritis & Rheumatology Center, Artesia, California, United States|Bina Akamdar MD, Azusa, California, United States|Rx for Life, Inc, Bell, California, United States|Clinical Research Advantage Inc., /Cassidy Medical Group-Carlsbad, Carlsbad, California, United States|Capitol Interventional Cardiology, Carmichael, California, United States|Northern California Research, Carmichael, California, United States|CORE Orthopaedic Medical Center, Encinitas, California, United States|Arthritis Medical Clinic of North County, Inc., Escondido, California, United States|Med Investigations, Inc., Fair Oaks, California, United States|Valley Research, Fresno, California, United States|Creekside Clinical Research, Greenbrae, California, United States|C. V. Mehta, MD Medical Corporation, Hemet, California, United States|Talbert Medical Group, Huntington Beach, California, United States|Alia Clinical Research, Inc, Huntington Park, California, United States|Time Clinical Research Inc., Huntington Park, California, United States|Lindora Research Center, Irvine, California, United States|Office of Dr. Robert L. Freed, MD, Irvine, California, United States|Office of Dr. Alan Schenk, Laguna Hills, California, United States|Prime Care Clinical Research, Laguna Hills, California, United States|Jeremy Anuntiyo, Lakewood, California, United States|Premiere Clinical Research, LLC, Lakewood, California, United States|Stuart J. Finkelstein, Lakewood, California, United States|Clinical Trials Research, Lincoln, California, United States|VA Loma Linda Healthcare System, Loma Linda, California, United States|Narbonne Multi-Specialty Medical Group Inc., Lomita, California, United States|Office of Dr. Arvind J. Mehta, Long Beach, California, United States|Pacific Internal Medicine Group, Inc, Long Beach, California, United States|Long Beach Center for Clinical Research, Long Beach, California, United States|National Institute of Clinical Research, Long Beach, California, United States|Alliance Research, LLC, Long Beach, California, United States|Valerius Medical Group and Research Center, Los Alamitos, California, United States|IMD Medical Group, Los Angeles, California, United States|Pacific Arthritis Care Center, Los Angeles, California, United States|Wagdy W. Kades, MD, Inc., Los Angeles, California, United States|Samaritan Center for Medical Research Medical Group, Los Gatos, California, United States|Office of Lewis Gamarra, MD M.P.H., Los Osos, California, United States|Adegbenga A. Adetola, M.D., Lynwood, California, United States|Facey Medical Group, Mission Hills, California, United States|Providence Clinical Research, North Hollywood, California, United States|Desert Medical Group, Palm Springs, California, United States|The Office of Dr. Marcos Yang, Palos Verdes Estates, California, United States|Bayview Research Group, LLC, Paramount, California, United States|Sierra Rheumatology, Roseville, California, United States|Center for Clinical Trials of Sacramento, Inc., Sacramento, California, United States|Sacramento Heart and Vascular Research Center, Sacramento, California, United States|California Research Foundation, San Diego, California, United States|San Diego Arthritis Medical Clinic, San Diego, California, United States|Wetlin Research Associates, Inc, San Diego, California, United States|Medical Associates Research Group, San Diego, California, United States|San Jose Valley Research, Inc., San Jose, California, United States|Comprehensive Adult Risk Evaluation, San Leandro, California, United States|East Bay Rheumatology Medical Group Inc, San Leandro, California, United States|Central Coast Pathology Consultants, San Luis Obispo, California, United States|Coastal Medical Research Group, Inc., San Luis Obispo, California, United States|Family Medical Center, San Luis Obispo, California, United States|Office of Ajay G. Meka, MD, Santa Ana, California, United States|Pacific Arthritis Center Medical Group, Santa Maria, California, United States|Orrin M. Troum & Medical Associates, Santa Monica, California, United States|Northern California Medical Associates, Santa Rosa, California, United States|Robert Simon, MD, Sherman Oaks, California, United States|St. Joseph Medical Associates, Stockton, California, United States|Westlake Medical Research, Thousand Oaks, California, United States|Paradigm Clinical Research Institute, Inc., Torrance, California, United States|Orange County Research Center, Tustin, California, United States|Inland Rheumatology and Osteoporosis Medical Group, Upland, California, United States|Inland Rheumatology Clinical Trials, Inc., Upland, California, United States|Bayview Research Group, Valley Village, California, United States|Medvin Clinical Research, Van Nuys, California, United States|Center for Clinical Trials of San Gabriel, West Covina, California, United States|Agilence Arthritis and Osteoporosis Medical Center, Inc., Whittier, California, United States|Avalon Family Medical Group, Wilmington, California, United States|Darrell E. Gorman, MD, Arvada, Colorado, United States|Aurora Denver Cardiology Associates, Aurora, Colorado, United States|Azmi Emil Farag, MD, Colorado Springs, Colorado, United States|Lynn Institute of the Rockies, Colorado Springs, Colorado, United States|Colorado Springs Health Partners- East/Clinical Research Advantage, Colorado Springs, Colorado, United States|Mountain View Clinical Research, Inc., Denver, Colorado, United States|Saint Luke's Medical Clinic, Fort Collins, Colorado, United States|New West Physicians, Golden, Colorado, United States|Ranch View Family Medicine, Highlands Ranch, Colorado, United States|Colorado Center for Bone Research PC, Lakewood, Colorado, United States|South Denver Cardiology Associates, PC, Littleton, Colorado, United States|Lynn Institute of Pueblo, Pueblo, Colorado, United States|Connecticut Clinical Research, LLC, Bridgeport, Connecticut, United States|Connecticut Gastroenterology Institute, Bristol, Connecticut, United States|Arthritis and Osteoporosis Center, PC, Hamden, Connecticut, United States|Robert Lang, MD, P.C., Hamden, Connecticut, United States|Coastal Connecticut Research, LLC, New London, Connecticut, United States|Office of Edward J. McDermott, Jr., MD, New London, Connecticut, United States|Orthopaedics Foundation for Active Lifestyles, Stamford, Connecticut, United States|Stamford Therapeutics Consortium, Stamford, Connecticut, United States|New England Research Associates, LLC, Trumbull, Connecticut, United States|Arthritis Center of Connecticut, Waterbury, Connecticut, United States|Rheumatology Consultants of Delaware, Lewes, Delaware, United States|Office of Cynthia Morgan, MD, Washington, D.C., District of Columbia, United States|The Center for Rheumatology and Bone Research, Washington, D.C., District of Columbia, United States|Medical Specialist of the Palm Beaches, Atlantis, Florida, United States|South Florida Medical Research, Aventura, Florida, United States|RASF - Clinical Research Center, Boca Raton, Florida, United States|Orthopedic Research Institute, Boynton Beach, Florida, United States|Clinical Research of Brandon, LLC, Brandon, Florida, United States|Family Healthcare of Chipley, Chipley, Florida, United States|Health First Clinical Research Group, Inc., Chipley, Florida, United States|Southern Family Healthcare and Health First Research Group Inc., Chipley, Florida, United States|Florida Research & Testing, LLC, Clearwater, Florida, United States|Alba Clinical Research, Clearwater, Florida, United States|Appletree Medical, Clearwater, Florida, United States|Innovative Research of West Florida, Inc., Clearwater, Florida, United States|Clinical Research of West Florida, Clearwater, Florida, United States|Rameshwar N. Mathur, MD, PA, Cocoa, Florida, United States|Nature Coast Clinical Research, LLC, Crystal River, Florida, United States|Atlantic Institute of Clinical Research, Daytona Beach, Florida, United States|International Medical Research, Daytona Beach, Florida, United States|Omega Research Consultants, LLC, DeBary, Florida, United States|Physicians Research Alliance, LLC, DeBary, Florida, United States|Deerfield Beach Cardiology Associates, Deerfield Beach, Florida, United States|Doctors Medical Center of Walton County, DeFuniak Springs, Florida, United States|Avail Clinical Research, LLC, DeLand, Florida, United States|Florida Research Associates, LLC/Florida Orthopaedic Associates, P.A., DeLand, Florida, United States|Cohen Medical Associates, PA, Delray Beach, Florida, United States|Clark Family Medicine & Emerald Coast Research Group, Destin, Florida, United States|SJS Clinical Research, Inc, Destin, Florida, United States|Robert W. Levin MD, Dunedin, Florida, United States|Riverside Clinical Research, Edgewater, Florida, United States|Fleming Island Center for Clinical Research, Fleming Island, Florida, United States|Invesclinic, Fort Lauderdale, Florida, United States|M&O Clinical Research, LLC, Fort Lauderdale, Florida, United States|Maxine Hamilton, MD PA, Fort Lauderdale, Florida, United States|Holy Cross Medical Group Northridge Internal Medicine, Fort Lauderdale, Florida, United States|Clinical Physiology Associates, Fort Myers, Florida, United States|Emerald Coast Mood & Memory, Fort Walton Beach, Florida, United States|White-Wilson Medical Center, PA, Fort Walton Beach, Florida, United States|Cardiology West, Gainesville, Florida, United States|Florida Research Network, LLC, Gainesville, Florida, United States|Southeastern Integrated Medical, PL, Gainesville, Florida, United States|Shands at the University of Florida, Gainesville, Florida, United States|University of Florida, Gainesville, Florida, United States|Genetic Medical Research Corporation, Hialeah, Florida, United States|Direct Helpers Medical Center, Inc., Hialeah, Florida, United States|Indago Research & Health Center, Inc., Hialeah, Florida, United States|Reliable Clinical Research, LLC, Hialeah, Florida, United States|Orthopaedic Associates of South Broward, P.A., Hollywood, Florida, United States|Advanced Research Institute of Miami, Homestead, Florida, United States|Pasco Cardiology Center, Hudson, Florida, United States|Nature Coast Clinical Research, Inverness, Florida, United States|Westside Center for Clinical Research, Jacksonville, Florida, United States|East Coast Institute for Research, LLC, Jacksonville, Florida, United States|Jacksonville Center for Clincal Research, Jacksonville, Florida, United States|St. Vincent's Cardiology, Jacksonville, Florida, United States|Dr. Ricardo A. Bedoya, M.D., Jupiter, Florida, United States|Drug Study Institute, Jupiter, Florida, United States|Christopher Chappel, Kissimmee, Florida, United States|Florida Arthritis Center, LLC, Lake Mary, Florida, United States|Pedro Ylisastigui, MD, Lehigh Acres, Florida, United States|Adult Medicine Specialists, Longwood, Florida, United States|Genesis Research International, Longwood, Florida, United States|Doctors Inn, Madeira Beach, Florida, United States|Everest Medical Care and Palm Court Research Group, Marianna, Florida, United States|Panhandle Family Care Associates & Emerald Coast Research Group, Marianna, Florida, United States|The Doctor's Office, Marianna, Florida, United States|Health First Medical Group, Melbourne, Florida, United States|Holmes Regional Medical Center, Melbourne, Florida, United States|Pharmaceutical Research Associates, Merritt Island, Florida, United States|Orthopaedic Specialist of Miami Beach, Miami Beach, Florida, United States|AMPM Research Clinic, Miami Gardens, Florida, United States|Crystal Biomedical Research, LLC, Miami Lakes, Florida, United States|Pembroke Clinical Trials, Miami Lakes, Florida, United States|Homestead Associates in Research, Inc, Miami, Florida, United States|Pharmax Research Clinic, Miami, Florida, United States|Life Spring Research Foundation, Miami, Florida, United States|Miami International Cardiology Consultants, Miami, Florida, United States|Florida Medical Center & Research, Inc., Miami, Florida, United States|The Center for Arthritis and Rheumatic Diseases, Miami, Florida, United States|Well Pharma Medical Research Corporation, Miami, Florida, United States|DC Health Clinical Trials, Miami, Florida, United States|School of Clinical Research USA, LLC, Miami, Florida, United States|Advance Medical Research Services, Corp, Miami, Florida, United States|Future Care Solution, LLC, Miami, Florida, United States|New Horizon Research Center, Miami, Florida, United States|Miami Cardiology Group, Miami, Florida, United States|M & M Medical Center, Miami, Florida, United States|Office of Dr. Juvenal E. Martinez, MD, PA, Miami, Florida, United States|Anchor Research Center, Naples, Florida, United States|Jeffrey Alper M.D. Research, Naples, Florida, United States|Anchor Health Centers, Naples, Florida, United States|Medical Surgical Specialists, Physicians Regional Medical Center, Naples, Florida, United States|Suncoast Clinical Research, Inc., New Port Richey, Florida, United States|Magnolia Research Group, Inc., Ocala, Florida, United States|Ocala Rheumatology Research Center, Ocala, Florida, United States|Paddock Park Clinical Research, Ocala, Florida, United States|Southeastern Rehabilitation Medicine, Ocala, Florida, United States|Tequesta Research Group, Ocala, Florida, United States|CEC Research, INC., Ocoee, Florida, United States|Florida Heart Group, PA, Orlando, Florida, United States|Florida Hospital, Orlando, Florida, United States|Compass Research, LLC, Orlando, Florida, United States|DCT FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|DCT-FMC, LLC dba Discovery Clinical Trials, Orlando, Florida, United States|Arthur L. Hall MD PA, Orlando, Florida, United States|Block and Nation, PA, Oviedo, Florida, United States|Arthritis Research of Florida, Inc., Palm Harbor, Florida, United States|Florida Med Center of Countryside, Palm Harbor, Florida, United States|Rene CaSanova Medical Office Inc, Pembroke Pines, Florida, United States|Boulevard Professional Centre, Pembroke Pines, Florida, United States|Research Physician Network Alliance, Pembroke Pines, Florida, United States|South Broward Research LLC, Pembroke Pines, Florida, United States|South Florida Research Solutions, LLC, Pembroke Pines, Florida, United States|DMI Research, Inc., Pinellas Park, Florida, United States|Sunbelt Research, LLC, Plantation, Florida, United States|Boca Raton Clinical Research, Plantation, Florida, United States|St. Johns Center for Clinical Research, Ponte Vedra, Florida, United States|Accord Clinical Research, LLC, Port Orange, Florida, United States|Administrative Address: Florida Arthritis & Osteoporosis Center, Port Richey, Florida, United States|Heart & Vascular Center Research, Sarasota, Florida, United States|Edgar R. Blecker, MD, Sebastian, Florida, United States|Phoenix Clinical Research, LLC., Tamarac, Florida, United States|Clinical Research of West Florida, Tampa, Florida, United States|Soutwest Florida Clinical Research Center, Tampa, Florida, United States|Clinyx/Floria Cardiovascular, Tampa, Florida, United States|Stedman Clinical Trials, LLC, Tampa, Florida, United States|West Wind'r Research, Tampa, Florida, United States|Health Point Medical Group, Inc, Tampa, Florida, United States|Causeway Medical Clinic, Tampa, Florida, United States|Office of Alastair C. Kennedy, MD, Vero Beach, Florida, United States|Metabolic Research Institute, Incorporated, West Palm Beach, Florida, United States|Palm Beach Research Center, West Palm Beach, Florida, United States|Central Florida Primary Care, Winter Park, Florida, United States|Florida Medical Clinic, PA, Zephyrhills, Florida, United States|The Kaufmann Clinic, Atlanta, Georgia, United States|Piedmont Heart Institute, Atlanta, Georgia, United States|Arthritis and Rheumatology of Georgia, Atlanta, Georgia, United States|Atlanta Center for Clinical Research, Corp., Atlanta, Georgia, United States|Atlanta Vascular Research Foundation, Atlanta, Georgia, United States|Executive Health and Research Associates, Atlanta, Georgia, United States|Southern Clinical Research and Management, Inc. (SCRAM), Augusta, Georgia, United States|Masters of Clinical Research, Inc., Augusta, Georgia, United States|Amelia Medical Plaza, Bainbridge, Georgia, United States|Bainbridge Medical Associates, Bainbridge, Georgia, United States|Abdul Bari MD Inc, Cairo, Georgia, United States|Southern Clinical Research Management and Consulting, Cairo, Georgia, United States|North Georgia Rheumatology Group, PC, Duluth, Georgia, United States|United Osteoporosis Centers, Gainesville, Georgia, United States|North Georgia Rheumatology Group, PC, Lawrenceville, Georgia, United States|GCH Research Dr. G Craig Heigerick DO, Lilburn, Georgia, United States|Mercer University Mercer Medicine, Macon, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Drug Studies America, Marietta, Georgia, United States|Clinical Research Advantage, Inc./Urban Family Practice Associates, PC, Marietta, Georgia, United States|In-Quest Medical Research, LLC, Norcross, Georgia, United States|Harbin Clinic, Rome, Georgia, United States|Atlanta Center for Clinical Research, Roswell, Georgia, United States|Herman Clinical Research, LLC, Suwanee, Georgia, United States|Archibold Primary Care, Thomasville, Georgia, United States|Clinical Trial Providers, Inc., Tucker, Georgia, United States|VSC, Valdosta, Georgia, United States|Kaufmann Clinic, INC, Woodstock, Georgia, United States|North Georgia Clinical Research, Woodstock, Georgia, United States|North Georgia Internal Medicine, Woodstock, Georgia, United States|East-West Medical Research Institute, Honolulu, Hawaii, United States|Orthopedic Health Care Clinic, Boise, Idaho, United States|Sonora Clinical Research, LLC, Boise, Idaho, United States|Eagle's View Family Medicine, Boise, Idaho, United States|Coeur D'Alene Arthritis Clinic, Coeur d'Alene, Idaho, United States|CTL Research, Eagle, Idaho, United States|Women's Healthcare Associates P.A. dba Rosemark WomenCare Specialists, Idaho Falls, Idaho, United States|Idaho Arthritis and Osteoporosis Center, Meridian, Idaho, United States|Advanced Clinical Research, Meridian, Idaho, United States|AMR Sakeena Research, Aurora, Illinois, United States|Arthur I Davida, MD PC, Bloomingdale, Illinois, United States|Cardiac Wellness Consultants, Chicago, Illinois, United States|Chicago Peripheral Nerve Center, Chicago, Illinois, United States|ICCT Research International Incorporated, Chicago, Illinois, United States|Claude Mandel Medical Center, Chicago, Illinois, United States|Windy City Orthopedics and Sports Medicine, Evanston, Illinois, United States|South Suburban Health Professional Group, Hazel Crest, Illinois, United States|Prairie Rheumatology Associates, SC, Joliet, Illinois, United States|Lake Zurich Family Treatment Center, Lake Zurich, Illinois, United States|Southern Illiniois Clinical Research Centre, O'Fallon, Illinois, United States|Speciality phhysicians of Illinois, LLC, Olympia Fields, Illinois, United States|Redhead Research Inc., DBA Research Associates of Central Illinois, Peoria, Illinois, United States|Trinity Medical Center, Rock Island, Illinois, United States|Rockford Health Physicians, Rockford, Illinois, United States|Prairie Cardiovascular Consultants, Springfield, Illinois, United States|Prairie Education & Research, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Springfield Clinic, Springfield, Illinois, United States|Deerbrook Medical Associates, Vernon Hills, Illinois, United States|Community Clinical Research Center, Anderson, Indiana, United States|American Health Network of Indiana, LLC, Avon, Indiana, United States|Robert D. Barnes, MD, LLC, Evansville, Indiana, United States|Clinical Research Advantage, Inc., Evansville, Indiana, United States|Destiny Clinical Research, LLC, Evansville, Indiana, United States|Clinical Research Advantage/Family Medicine Associates, Evansville, Indiana, United States|American Health Network of Indiana, LLC, Franklin, Indiana, United States|Internal Medicine Center of Northwest Indiana, P.C., Gary, Indiana, United States|Beacon Medical Group Rheumatology, Granger, Indiana, United States|American Health Network of IN, LLC, Greenfield, Indiana, United States|Diagnostic Rheumatology And Research, PC, Indianapolis, Indiana, United States|Investigators research Group, Indianapolis, Indiana, United States|Dawes Fretzin Clinical Research Group, LLC, Indianapolis, Indiana, United States|Dawes Fretzin Dermatology Group, LLC, Indianapolis, Indiana, United States|Arthritis Associates of Southern Indiana, Jeffersonville, Indiana, United States|Research Institute of Middle America/River Cities Cardiology, Jeffersonville, Indiana, United States|Beacon Medical Group LaPorte, LaPorte, Indiana, United States|Cardiovascular Clinics, PC, Merrillville, Indiana, United States|Community Clinical Research Center, Muncie, Indiana, United States|Medical Specialists Clinical Research Center, Munster, Indiana, United States|Medical Specialists, Munster, Indiana, United States|Arthritis Associates of Southern Indiana, New Albany, Indiana, United States|Buynak Clinical Research, Valparaiso, Indiana, United States|Physician's Clinic of Iowa, PC, Cedar Rapids, Iowa, United States|Ridge Family Practice, PC/Clinical Research Advantage, Inc., Council Bluffs, Iowa, United States|Midwest Cardiovascular Research Foundation, Davenport, Iowa, United States|Office of Jerrold V Flatt, Des Moines, Iowa, United States|Medical Associates Clinic, PC, Dubuque, Iowa, United States|Family Health Center of Waterloo, PC, Waterloo, Iowa, United States|Northeast IA Medical Education Foundation/Family Practice Center, Waterloo, Iowa, United States|Heartland Research Associates LLC, Arkansas City, Kansas, United States|Community House of Wellness, Kansas City, Kansas, United States|Associates Reseach Inc., Lansing, Kansas, United States|Radiant Research, Inc., Overland Park, Kansas, United States|International Clinical Research Institute, Inc, Overland Park, Kansas, United States|Arthritis Specialists of Greater KC, Overland Park, Kansas, United States|Pinnacle Medical Research, Overland Park, Kansas, United States|Quivira Internal Medicine, Overland Park, Kansas, United States|Health Science Research Center, Pratt, Kansas, United States|Heartland Research Associates, LLC, Wichita, Kansas, United States|Via Christi Clinic, Wichita, Kansas, United States|Howard L. Feinberg, D.O., Ashland, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Graves Gilbert Clinic, Bowling Green, Kentucky, United States|Internal Medicine Research Association, Campbellsville, Kentucky, United States|Center for Arthritis and Osteoporosis, Elizabethtown, Kentucky, United States|Arthritis Center of Lexington, Lexington, Kentucky, United States|Kentuckiana Center for Better Bone and Joint Health, Louisville, Kentucky, United States|KY Research PLLC., Louisville, Kentucky, United States|University Medical Associates, Louisville, Kentucky, United States|Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States|Office of Gaurang B. Shah,MD, PSC, Richmond, Kentucky, United States|Richmond Regional Research, Richmond, Kentucky, United States|Chandler Family Practice, Bossier City, Louisiana, United States|McFarland Family Clinic, Shreveport, Louisiana, United States|TFD Research, LLC, Shreveport, Louisiana, United States|Maine Research Associates, Auburn, Maine, United States|Southern Maine Health Care, Biddeford, Maine, United States|Central Maine Heart & Vascular Institute, Lewiston, Maine, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Health Trends Research, LLC, Baltimore, Maryland, United States|One Heart, LLC, Baltimore, Maryland, United States|Chesapeake CardioVascular Associates, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates, Pa, Baltimore, Maryland, United States|Saint Agnes HealthCare Incorporated, Baltimore, Maryland, United States|Stephen R Smith, MD FACP, Baltimore, Maryland, United States|MidAtlantic Cardiovascular Associates, PA, Baltimore, Maryland, United States|Peter A. Holt, Baltimore, Maryland, United States|Midatlantic Cardiovascular Associates PA, Bel Air, Maryland, United States|Shah Associates MD, LLC, Charlotte Hall, Maryland, United States|Cardiovascular Specialists, LLC, Columbia, Maryland, United States|Johns Hopkins University, Columbia, Maryland, United States|The Osteoporosis & Clinical Trials Center, Cumberland, Maryland, United States|Arthritis Treatment Center, Frederick, Maryland, United States|The Spine & Joint Center, Greenbelt, Maryland, United States|Klein & Associates, MD, PA, Hagerstown, Maryland, United States|Community Health Research, North East, Maryland, United States|MD Medical Research, Oxon Hill, Maryland, United States|Shah Associates, Prince Frederick, Maryland, United States|Cardiac Associates, Shady Grove Adventist Hospital, Rockville, Maryland, United States|The Center for Rheumatology and Bone Research, Rockville, Maryland, United States|Rockville Internal Medicine Group, Rockville, Maryland, United States|IRC Clinics, Towson, Maryland, United States|Midatlantic Cardiovascular Associates, P.A., Westminster, Maryland, United States|The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States|Primary Care Cardiology Research, Ayer, Massachusetts, United States|Genesis Clinical Research & Consulting, Fall River, Massachusetts, United States|NECCR Internal Medicine and Cardiology Associates, LLC, Fall River, Massachusetts, United States|Phase III Clinical Research, Fall River, Massachusetts, United States|Pentucket Medical Associates, Incorporated, Haverhill, Massachusetts, United States|Clinical Research Center of Cape Cod, Inc., Hyannis, Massachusetts, United States|Charles River Medical Associates, Pchi, Natick, Massachusetts, United States|Novex Clinical Research, LLC, New Bedford, Massachusetts, United States|Northampton Internal Medicine Associates, PC, Northampton, Massachusetts, United States|FutureCare Studies, Springfield, Massachusetts, United States|Reliant Medical Group, Inc., Worcester, Massachusetts, United States|Great Lakes Research Group, Incorporated, Bay City, Michigan, United States|Professional Clinical Research-Benzonia, Benzonia, Michigan, United States|Cadillac Clinical Research, Cadillac, Michigan, United States|Livernois Family Medical Services, Detroit, Michigan, United States|Office of Dr. Susan Courtnage, Eaton Rapids, Michigan, United States|McLaren Regional Medical Center-Research Dept., Flint, Michigan, United States|Grand Valley Medical Specialist, PLC, Grand Rapids, Michigan, United States|Spectrum Health Medical Group-Rheumatology, Grand Rapids, Michigan, United States|Michigan Medical Cardiovascular PC, Grand Rapids, Michigan, United States|Professional Clinical Research, Interlochen, Michigan, United States|Justus J Fiechtner, MD, Lansing, Michigan, United States|Michigan Cardiovascular Institute, Saginaw, Michigan, United States|Synergy Medical Education Alliance, Saginaw, Michigan, United States|Shores Rheumatology, Saint Clair Shores, Michigan, United States|Oakland Medical Research Center, Troy, Michigan, United States|Troy Internal Medicine Research, Troy, Michigan, United States|St. Luke's Hospital Association of Duluth, DBA St Luke's Rheumatology Assoc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Inc., Duluth, Minnesota, United States|St. Luke's Hospital Association of Duluth, Duluth, Minnesota, United States|Central Minnesota Heart Center at St. Cloud Hospital, Saint Cloud, Minnesota, United States|St. Paul Heart Clinic, Saint Paul, Minnesota, United States|The Center for Clinical Trials, Biloxi, Mississippi, United States|Planters Clinic, Port Gibson, Mississippi, United States|North Mississippi Medical Clinics, Inc., Tupelo, Mississippi, United States|Cape Girardeau Physicians Associates, Cape Girardeau, Missouri, United States|Patterson Medical Clinic / d.b.a. Prime Care Research Associates, Florissant, Missouri, United States|Allergy Asthma Immunology Services, LLC, Jefferson City, Missouri, United States|Jefferson City Medical Group, Jefferson City, Missouri, United States|University of Missouri Kansas City School of Medicine, Kansas City, Missouri, United States|Truman Medical Center, Inc., Kansas City, Missouri, United States|Clinical Research Advantage, Inc./Manning Family Care, LLC, Kansas City, Missouri, United States|St. Louis Center for Clinical Research, Saint Louis, Missouri, United States|Physician Groups, LC, DBA Rheumatology and Internal Medicine Associates, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|Barbara A. Caciolo, MD, Saint Louis, Missouri, United States|A & A Pain Institute, Saint Louis, Missouri, United States|Sundance Clinical Research, LLC, Saint Louis, Missouri, United States|Mercy Medical Research Institute, Springfield, Missouri, United States|Patients First Health Care, LLC, Washington, Missouri, United States|Glacier View Research Institute, Cardiology, Kalispell, Montana, United States|Alliance Medical Center, Alliance, Nebraska, United States|Cody Medical Associates, Alliance, Nebraska, United States|Bellevue Family Practice/Clinical Research Advantage, Inc., Bellevue, Nebraska, United States|Clinical Research Advantage, Inc./ Skyline Medical Center, PC, Elkhorn, Nebraska, United States|Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC, Fremont, Nebraska, United States|Internal Medicine Associates, PC, Grand Island, Nebraska, United States|Physician, Research Collaboration, Southwest Family Health, Lincoln, Nebraska, United States|Lincoln Internal Medicine Associates, Lincoln, Nebraska, United States|Platte River Nephrology, North Platte, Nebraska, United States|Quality Clinical Research LLC, Omaha, Nebraska, United States|Westroads Medical Group, Omaha, Nebraska, United States|Heartland Clinical Research, Inc., Omaha, Nebraska, United States|Clinical Research Advantage, Inc./Primary Care Physicians, LLP, Omaha, Nebraska, United States|Clinical Research Advantage, Inc., Henderson, Nevada, United States|Clinical Research Advantage, Inc./Rita B. Chuang, MD, LLC, Henderson, Nevada, United States|Sierra Internal Medicine Associates, Incline Village, Nevada, United States|Clinical Research Center of Nevada, Las Vegas, Nevada, United States|Clinical Research Advantage/Peter Philander, MD, Las Vegas, Nevada, United States|Rancho Internal Medicine, Las Vegas, Nevada, United States|Steven D. Folkerth, MD, Las Vegas, Nevada, United States|Ladner Family Practice, Las Vegas, Nevada, United States|VA Southern Nevada Healthcare System, North Las Vegas, Nevada, United States|Arthritis Center of Reno, Reno, Nevada, United States|New Jersey Physicians, LLC, Clifton, New Jersey, United States|Clifton-Wallington Medical Group, Clifton, New Jersey, United States|Anderson and Collins, Clinical Research Inc., Edison, New Jersey, United States|Drs. Collins and Uthappa, Edison, New Jersey, United States|Central Jersey Health Care, Elizabeth, New Jersey, United States|Andron Medical Associates, Englewood, New Jersey, United States|Advocare Heights Primary Care, Haddon Heights, New Jersey, United States|Hazlet Health Care, Hazlet, New Jersey, United States|Family Care Physicians, Lawrenceville, New Jersey, United States|Penn Cardiac Care at Mercer Bucks, Lawrenceville, New Jersey, United States|Family Medicine of Lindenwold, Lindenwold, New Jersey, United States|Rheumatology and Arthritis Associates PC, Medford, New Jersey, United States|Adult & Pediatric Rheumatology, Midland Park, New Jersey, United States|The Valley Hospital, Ridgewood, New Jersey, United States|Maynard Holgado LLC, Sicklerville, New Jersey, United States|Shore Health Group, Toms River, New Jersey, United States|Hopewell Valley Medical Group, P.A., Trenton, New Jersey, United States|Arthritis, Rheumatic and Back Disease Associates, PA, Voorhees, New Jersey, United States|Lourdes Medical Associates, Willingboro, New Jersey, United States|Kenneth F. Solinsky, MD, Babylon, New York, United States|LifeLine Research Institute, Brooklyn, New York, United States|Lee Medical Associates, Dunkirk, New York, United States|AMS Research, Elmira, New York, United States|Regional Clinical Research, Inc., Endwell, New York, United States|Drug Trials America, Inc., Hartsdale, New York, United States|United Health Service Hospitals, Office of Clinical Trials, Johnson City, New York, United States|IMA Medical Research PC, Kew Gardens, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Infusion Center, Lake Success, New York, United States|NYU Langone Medical Center, Laura and Issac Perlmutter Cancer Center, Investigational Pharmacy, Lake Success, New York, United States|NYU Langone Rheumatology Associates Long Island, Lake Success, New York, United States|Office of Dr. Allen Chodock, Mamaroneck, New York, United States|Winthrop University Hospital / Clinical Trials Center, Mineola, New York, United States|New York University Pain Management Center, New York, New York, United States|NYU Pain Research, New York, New York, United States|Office of Dr. Richard Stern, New York, New York, United States|DiGiovanna Family Care Center, North Massapequa, New York, United States|Hudson Valley Heart Center, Poughkeepsie, New York, United States|AAIR Research Center, Rochester, New York, United States|Institute for Clinical Studies, Rosedale, New York, United States|Rheumatology Associates of Long Island, Smithtown, New York, United States|Office of Dr. Chadia Morcos, Syosset, New York, United States|Arthritis Health Associates, Syracuse, New York, United States|Crouse Medical Practice, PLLC d/b/a Internist Associates of Central New York, Syracuse, New York, United States|East Meadow Family Practice Associates, PC, Wantagh, New York, United States|Southgate Medical Group, West Seneca, New York, United States|Great Lakes Medical Research, Westfield, New York, United States|Buffalo Cardiology and Pulmonary Associates, PC, Williamsville, New York, United States|Upstate Clinical Research Associates, Williamsville, New York, United States|Asheville Arthritis & Osteoporosis, PA, Asheville, North Carolina, United States|Kernodle Clinic Inc., Burlington, North Carolina, United States|Calabash Medical Center, Calabash, North Carolina, United States|PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States|Chapel Hill Family Medicine, Chapel Hill, North Carolina, United States|Thurston Arthritis Reaserch Ctr, Chapel Hill, North Carolina, United States|Mid Carolina Cardiology Research, Charlotte, North Carolina, United States|Presbyterian Novant Heart and Wellness, Charlotte, North Carolina, United States|Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, North Carolina, United States|PMG Research of Charlotte, Charlotte, North Carolina, United States|Barat Research Group, Inc., Charlotte, North Carolina, United States|Sensenbrenner Primary Care, Charlotte, North Carolina, United States|Duke Health Center at Pickett Road, Durham, North Carolina, United States|Bland Clinic, PA, Greensboro, North Carolina, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Physicians East P. A., Greenville, North Carolina, United States|Physicians East, PA, Greenville, North Carolina, United States|Clinical Trials of America, Inc., Hickory, North Carolina, United States|PMG Research Of Hickory, LLC, Hickory, North Carolina, United States|Peters Medical Research, High Point, North Carolina, United States|Research Institute of the Carolinas, PLLC, Mooresville, North Carolina, United States|Crystal Coast Family Practice, Morehead City, North Carolina, United States|Burke Primary Care, Morganton, North Carolina, United States|Pinehurst Medical Clinic, Inc., Pinehurst, North Carolina, United States|Pinehurst Medical Clinic. Inc., Pinehurst, North Carolina, United States|Blue Ridge Family Physicians, PPLC, Raleigh, North Carolina, United States|PMG Research of Raleigh, LLC, Raleigh, North Carolina, United States|Wake Internal Medicine Consultants, Inc., Raleigh, North Carolina, United States|Wake Research Associates, LLC, Raleigh, North Carolina, United States|Boice-Willis Clinic, Rocky Mount, North Carolina, United States|PMG Research of Salisbury, Salisbury, North Carolina, United States|Tabor City Family Medicine, Tabor City, North Carolina, United States|PMG Research of Wilmington, Wilmington, North Carolina, United States|PMG Research Wilmington Research Associates, Wilmington, North Carolina, United States|Natalie A. Doyle, MD PA, Wilson, North Carolina, United States|Ardmore Family Practice, Winston-Salem, North Carolina, United States|Clinical Trials of America, Inc., Winston-Salem, North Carolina, United States|Clinical Trials of America, inc, Winston-Salem, North Carolina, United States|PMG Research of Winston-Salem, Winston-Salem, North Carolina, United States|Winston-Salem Health Care, Winston-Salem, North Carolina, United States|Plains Clinical Research Center, Fargo, North Dakota, United States|Daystar Clinical Research, Akron, Ohio, United States|CFP Research, Inc., Cincinnati, Ohio, United States|Rapid Medical Research, Inc., Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Feldman Family Practice, Columbus, Ohio, United States|MidWest Cardiology Research Foundation, Columbus, Ohio, United States|Riverside Methodist Hospital, Columbus, Ohio, United States|Remington-Davis Incorporated, Columbus, Ohio, United States|Midtowne Family Practice Centre, Columbus, Ohio, United States|PriMed Clinical Research, Dayton, Ohio, United States|HWC Women's Research Center, Englewood, Ohio, United States|Cleveland Clinic Fairview Cardiovascular Medicine, Fairview Park, Ohio, United States|Prestige Clinical Research, Franklin, Ohio, United States|TriPhase Research, Ltd., Franklin, Ohio, United States|Holzer Clinic, Inc, Gallipolis, Ohio, United States|Office of Dr. Saleem Khan, MD, Inc, London, Ohio, United States|North Central Research, Mansfield, Ohio, United States|OhioHealth Research Institute, Mansfield, Ohio, United States|R&R Research-Smith Clinic, Marion, Ohio, United States|David R. Mandel, MD, Inc, Mayfield, Ohio, United States|Paramount Medical Research and Consulting, LLC, Middleburg Heights, Ohio, United States|Newark Physician Associates, Newark, Ohio, United States|Family Medicine and Occupational Health Center, Inc., Shaker Heights, Ohio, United States|Abner Cordero, M.D., Tiffin, Ohio, United States|Arthritis Associates of Northwest Ohio, Inc., Toledo, Ohio, United States|Mercy St Vincent Medical Center, Toledo, Ohio, United States|Toledo Cardiology Consultants c/o Cardiac Research, Toledo, Ohio, United States|South Toledo Internists, Toledo, Ohio, United States|University of Toledo Health Science Campus, Toledo, Ohio, United States|UT Medical Center Medicine Clinic, Toledo, Ohio, United States|Trenton Family Medicine, Trenton, Ohio, United States|Lake Medical Research, LLC, Willoughby Hills, Ohio, United States|Pharmacotherapy Research Associates Incorporated, Zanesville, Ohio, United States|LION Research, Norman, Oklahoma, United States|Integris Physicians Services, Oklahoma City, Oklahoma, United States|Integris Cardiovascular Physicians LLC, Oklahoma City, Oklahoma, United States|Integris Family Care Central, Oklahoma City, Oklahoma, United States|Integris Physician Services, Oklahoma City, Oklahoma, United States|Lynn Health Science Institute, Oklahoma City, Oklahoma, United States|Healthcare Research Consultants, Tulsa, Oklahoma, United States|Integrated Medical Research, PC, Ashland, Oregon, United States|Lane Medical Research Group, Eugene, Oregon, United States|Oregon Medical Group Adult Medicine Clinic, Eugene, Oregon, United States|Oregon Medical Group Clinical Research, Eugene, Oregon, United States|Institute of Diabetes and Endocrinology, Medford, Oregon, United States|Rogue Valley Physicians-Clinical Research Group, Medford, Oregon, United States|Fanno Creek Clinic, Portland, Oregon, United States|Affinity Research, Portland, Oregon, United States|Portland Rheumatology Clinic, LLC, Portland, Oregon, United States|Internal Medicine Research, Portland, Oregon, United States|University Orthopedics Center, Altoona, Pennsylvania, United States|Tri-State Medical Group, Beaver, Pennsylvania, United States|East Penn Rheumatology Associates, PC, Bethlehem, Pennsylvania, United States|Buckingham Family Medicine, Buckingham, Pennsylvania, United States|Camp Hill Clinical Research Center, Camp Hill, Pennsylvania, United States|Butler Medical Associates, Chicora, Pennsylvania, United States|Perkiomen Valley Family Practice, PC, Collegeville, Pennsylvania, United States|Rheumatology Associates, Ltd, Colmar, Pennsylvania, United States|Office of J. Miller Oppy, MD, Youghiogheny Primary Care Practice, Connellsville, Pennsylvania, United States|Brandywine Clinical Research, Downingtown, Pennsylvania, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|Saint Vincent Consultant in Cardiovascular Diseases, LLC, Erie, Pennsylvania, United States|Arthritis Associates, Erie, Pennsylvania, United States|Center for Assessment and Research of Erie, Erie, Pennsylvania, United States|Stan F. Slabic, M.D., Erie, Pennsylvania, United States|AMH Feasterville Family HealthCare Center, Feasterville, Pennsylvania, United States|Westmoreland Neurology Associates, Incorporated, Greensburg, Pennsylvania, United States|Harleysville Medical Assoc, Harleysville, Pennsylvania, United States|Lederach Family Medicine, Harleysville, Pennsylvania, United States|Dr. Bruce Morrison, Family Practice, Huntingdon Valley, Pennsylvania, United States|Detweiler Family Medicine and Associates, PC, Lansdale, Pennsylvania, United States|Green and Seidner Family Practice Associates, Lansdale, Pennsylvania, United States|Lansdale Medical Group Family Practice, Lansdale, Pennsylvania, United States|Bucks County Clinical Research, Morrisville, Pennsylvania, United States|Pearl Clinical Research, Inc., Norristown, Pennsylvania, United States|Lehigh Wellness Center Outpatient Services, Philadelphia, Pennsylvania, United States|Founders Research Corporation, Philadelphia, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Dairyland Medical Center, Red Lion, Pennsylvania, United States|Sfm Clinical Trials, PC, Scotland, Pennsylvania, United States|Elite Medical Research, Inc., Sellersville, Pennsylvania, United States|Prime Health Network, Springfield, Pennsylvania, United States|University Orthopedics Center, State College, Pennsylvania, United States|The Office of Dr. Joseph T. Morelli, DO, Stoneboro, Pennsylvania, United States|Tipton Medical and Diagnostic Center, Tipton, Pennsylvania, United States|Pish Medical Associates, Uniontown, Pennsylvania, United States|PEAK Research, LLC, Upper Saint Clair, Pennsylvania, United States|Allegheny Rheumatology - WPAHS - ASRI, Wexford, Pennsylvania, United States|Clinical Research Center of Reading, LLC, Wyomissing, Pennsylvania, United States|Cardiology Consultants of Philadelphia, Yardley, Pennsylvania, United States|Jeffry A. Lindenbaum DO, PC, Yardley, Pennsylvania, United States|New England Center for Clinical Research, Cranston, Rhode Island, United States|Partners in Clinical Research, Cumberland, Rhode Island, United States|Hugo M. Yamada, MD, Lincoln, Rhode Island, United States|Rheumatology Associates, Pawtucket, Rhode Island, United States|Medical Office Center, Providence, Rhode Island, United States|Anderson Heart, Anderson, South Carolina, United States|AnMed Health, Anderson, South Carolina, United States|Low Country Rheumatology, PA/Low Country Research Center, Charleston, South Carolina, United States|Clinical Trials of South Carolina, Charleston, South Carolina, United States|St. Andrews Medical, Charleston, South Carolina, United States|Neem Research Group Inc., Columbia, South Carolina, United States|Columbia Arthritis Center Pa, Columbia, South Carolina, United States|MedTrial, Columbia, South Carolina, United States|Clinical Research Associates, LLC, Florence, South Carolina, United States|Palmetto Clinical Trial Services, LLC, Greenville, South Carolina, United States|Paris View Family Practice, Greenville, South Carolina, United States|John Milas, Greer, South Carolina, United States|Radiant Research, Inc, Greer, South Carolina, United States|DeGarmo Institute of Medical Research, Greer, South Carolina, United States|Mountain View Clinical Research, Inc., Greer, South Carolina, United States|Palmetto Clinical Trial Services, LLC at the Family Healthcare Center, Laurens, South Carolina, United States|Berkeley Medical Center, Moncks Corner, South Carolina, United States|PMG Research of Charleston, Mount Pleasant, South Carolina, United States|North Myrtle Beach Family Practice, North Myrtle Beach, South Carolina, United States|Coulter Clinic, Orangeburg, South Carolina, United States|Orangeburg Medical Associates, PA, Orangeburg, South Carolina, United States|The Carolina Center for Rheumatology & Arthritis Care, PA, Rock Hill, South Carolina, United States|Hillcrest Clinical Research, LLC, Simpsonville, South Carolina, United States|Hillcrest Family Practice, Simpsonville, South Carolina, United States|Palmetto Research, Spartanburg, South Carolina, United States|Palmetto Clinical Research, Summerville, South Carolina, United States|Southeastern Research Associates, Inc., Taylors, South Carolina, United States|Odyssey Research/Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Sanford Clinic - Aberdeen, Aberdeen, South Dakota, United States|Regional Health Clinic Research, Rapid City, South Dakota, United States|Regional Medical Clinic-Rheumatology, Rapid City, South Dakota, United States|Health Concepts, Rapid City, South Dakota, United States|Brown Clinic PLLP, Watertown, South Dakota, United States|Odyssey Research, Watertown, South Dakota, United States|Holston Medical Group, Bristol, Tennessee, United States|Internal Medicine & Pediatric Associates of Bristol, Bristol, Tennessee, United States|PMG Research of Bristol, Bristol, Tennessee, United States|Parkway Medical Group, Fayetteville, Tennessee, United States|Stern Cardiovascular Foundation, inc., Germantown, Tennessee, United States|Arthritis Clinic, Jackson, Tennessee, United States|The Jackson Clinic, PA, Jackson, Tennessee, United States|State of Franklin Healthcare Associates Clinical Research, Johnson City, Tennessee, United States|Holston Medical Group, Kingsport, Tennessee, United States|Holston Valley Surgery Center, Kingsport, Tennessee, United States|Gupta, Ramesh C MD, Memphis, Tennessee, United States|Access Clinical Trials, Inc., Nashville, Tennessee, United States|Premier Orthopaedics, Nashville, Tennessee, United States|The Cholesterol Center of Nashville, Nashville, Tennessee, United States|Nashville Medical Research Institute, Nashville, Tennessee, United States|Quality Medical Research, Nashville, Tennessee, United States|Amarillo Medical Specialists, LLP, Amarillo, Texas, United States|Pharma Tex Research, LLC, Amarillo, Texas, United States|Family Health Care Association, Arlington, Texas, United States|South Arlington Primary Care Associates PA, Arlington, Texas, United States|DCT - Anchor, LLC dba Discovery Clinical Trials, Arlington, Texas, United States|DCT-AACT, LLC dba Discovery Clinical Trials, Austin, Texas, United States|Southeast Texas Cardiology Associates, Beaumont, Texas, United States|Southeast Texas Clinical Research Center, Beaumont, Texas, United States|Kaner Medical Group PA, Bedford, Texas, United States|Nexxus Research Group, LLC, Bedford, Texas, United States|Texas Orthopedic Specialists, PLLC, Bedford, Texas, United States|MedicalEdge Healthcare Group, PA, dba Leading Edge Research, PA, Carrollton, Texas, United States|Prentiss Family Medicine, Colleyville, Texas, United States|Carlos B. Everett, MD, Corpus Christi, Texas, United States|Discovery Clinical Research, Corpus Christi, Texas, United States|Texas Health Physicians Group, Dallas, Texas, United States|Soltero Cardiovascular Research Center/Baylor University Medical Center, Dallas, Texas, United States|Arthritis Care and Diagnostic Center, P.A., Dallas, Texas, United States|Medical Specialists Associated, Dallas, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|SouthWest Rheumatology, P.A., Dallas, Texas, United States|DCT - Genesis Neighborhood Research, LLC dba Discovery Clinical Trials, Dallas, Texas, United States|Rajendra K. Marwah, MD, El Paso, Texas, United States|Kaner Medical Group, PA, Euless, Texas, United States|The Medical Group of Texas, Fort Worth, Texas, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|T & R Clinic, P. A., Fort Worth, Texas, United States|Rheumatology-UTMB, Galveston, Texas, United States|Towngate Plaza Medical Center, Garland, Texas, United States|ProCare Clinical Trials, Grand Prairie, Texas, United States|The Office of Amer Zaheer MD, PA, Houston, Texas, United States|Salim Gopalani, MD, PA, Houston, Texas, United States|Office of Cyril Wolf, MD, Houston, Texas, United States|Village Family Practice, Houston, Texas, United States|Kelsey Seybold Clinic, Houston, Texas, United States|Oxford Clinical Research, LLC, Houston, Texas, United States|MCA Research, Houston, Texas, United States|Texas Health Physicians Group, Irving, Texas, United States|One World Medical Associates, P.A., Lewisville, Texas, United States|Pri-Med Care, Lewisville, Texas, United States|South Texas Institute of Health, McAllen, Texas, United States|DCT - Genesis Seidmeyer Research, LLC dba Discovery Clinical Trials, McKinney, Texas, United States|Southwest Rheumatology, PA, Mesquite, Texas, United States|Midland Clinical Research Center, Midland, Texas, United States|Basin Orthopedics Surgical Specialists, Odessa, Texas, United States|Center for Hypertension and Internal Medicine, Odessa, Texas, United States|Odessa Heart Institute, Odessa, Texas, United States|Permian Research Foundation, Odessa, Texas, United States|Office of David K. McDonald, M.D.. P.A., Pasadena, Texas, United States|Centex Studies, Inc., Pharr, Texas, United States|Clinical Investigations of Texas, LLC, Plano, Texas, United States|DCT-Genesis naini, LLC dba Discovery Clinical Trials, Plano, Texas, United States|North Texas Medical Research, Plano, Texas, United States|MedicalEdge Healthcare Group, PA, Richardson, Texas, United States|Texas Health Physicians Group, Richardson, Texas, United States|Ivan N. Mefford, MD, PhD, PA, Richmond, Texas, United States|Paragon Research Center, LLC, San Antonio, Texas, United States|Quality Assurance Research Center, San Antonio, Texas, United States|Quality Research Inc., San Antonio, Texas, United States|Physician PrimeCare Research Institute, PLLC dba Health Texas Research Institute, San Antonio, Texas, United States|GSA Research, San Antonio, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Radiant Research San Antonio Northeast, San Antonio, Texas, United States|Briggs Clinical Research, LLC, San Antonio, Texas, United States|DCT - Barlite, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|S.A.M. Clinical Research Center, San Antonio, Texas, United States|WellMed Clinical Research, San Antonio, Texas, United States|DCT-Westover Hills, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|DCT - Stone Oak, LLC dba Discovery Clinical Trials, San Antonio, Texas, United States|The Office of Shahbaz Yazdani, MD, PA, San Antonio, Texas, United States|Southlake Clinical Trials, Southlake, Texas, United States|Sugar Land Med-Ped Clinic, PA, Sugar Land, Texas, United States|Crossroads Clinical Research, LLC, Victoria, Texas, United States|Crossroads Clinical Research, Victoria, Texas, United States|Office of Pamela Dugano-Daphnis, Webster, Texas, United States|Advanced Research Institute, Ogden, Utah, United States|Advanced Clinical Research, West Jordan, Utah, United States|Burke Internal Medicine & Research, Burke, Virginia, United States|Burke Internal Medicine, Burke, Virginia, United States|Center for Arthritis and Rheumatic Diseases, Chesapeake, Virginia, United States|Bayview Physicians oa Cardiovascular Associates, Ltd, Chesapeake, Virginia, United States|David Ramstad, MD, MPH and Associates, Chesapeake, Virginia, United States|Danville Internal Medicine, Inc., Danville, Virginia, United States|Danville Orthopedic Clinic, Danville, Virginia, United States|Seven Corners Medical Research Center, Falls Church, Virginia, United States|Hampton Family Practice, Hampton, Virginia, United States|Manassas Clinical Research Center, Manassas, Virginia, United States|Bruton Avenue Family Practice, Newport News, Virginia, United States|Internal Medicine Kidney and Hypertension Center, Norfolk, Virginia, United States|National Clinical Research - Norfolk Inc., Norfolk, Virginia, United States|Sentara Medical Group, Norfolk, Virginia, United States|Ettrick Health Center, Petersburg, Virginia, United States|Arthritis and Rheumatic Research, Portsmouth, Virginia, United States|Roanoke Heart Institute, Roanoke, Virginia, United States|Harbourview Professional Center, Suffolk, Virginia, United States|Chase Research Group, LLC, Virginia Beach, Virginia, United States|The Center for Excellence in Aging and Geriatric Health, Williamsburg, Virginia, United States|Highline Medical Center Laboratory, Burien, Washington, United States|Puget Sound Osteoporosis Center, Seattle, Washington, United States|Arthritis Northwest, Seattle, Washington, United States|Arthritis Northwest Rheumatology, Spokane, Washington, United States|Lawrence S. Eastburn, MD, PS, Spokane, Washington, United States|Pulmonary and Research Associates, Spokane, Washington, United States|The Office of William Gray, Md, Family Practice, Spokane, Washington, United States|John F. Long, D.O., Spokane, Washington, United States|George H. Krick, MD, Tacoma, Washington, United States|Northwest Family and Spinal Clinic, Tacoma, Washington, United States|Rheumatology Infusion Services, Tacoma, Washington, United States|Tacoma Center for Arthritis Research, PS, Tacoma, Washington, United States|Wenatchee Valley Medical Center, Research Department, Wenatchee, Washington, United States|Clinical Trials Northwest, Yakima, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Mountain State Clinical Research, Clarksburg, West Virginia, United States|University Cardiovascular Services. Robert C. Byrd Clinical Center, Huntington, West Virginia, United States|WVVA Healthcare Alliance, Lewisburg, West Virginia, United States|Parkersburg Cardiology Associates, Parkersburg, West Virginia, United States|Meriter Medical Group, Madison, Wisconsin, United States|University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, United States|UW Health Physicians, Madison, Wisconsin, United States|St. Lukes Pain Management Center, Milwaukee, Wisconsin, United States|Zablocki VA Medical Center, Milwaukee, Wisconsin, United States|Aspirus Cardiovascular Associates - Rhinelander, Rhinelander, Wisconsin, United States|Aspirus Cardiovascular Associates, Wausau, Wisconsin, United States|Aspirus Heart & Vascular lnstitute--Research & Education), Wausau, Wisconsin, United States|Aspirus Wausau Hospital, Wausau, Wisconsin, United States|Allegiance Research Specialists, LLC, Wauwatosa, Wisconsin, United States|Hunter Clinical Research, Broadmeadow, New South Wales, Australia|Wesley Medical Centre, Auchenflower, Queensland, Australia|Australian Clinical Research Organisation, Caboolture, Queensland, Australia|Rheumatology Department, Cairns, Queensland, Australia|AusTrials Pty Ltd, Kippa Ring, Queensland, Australia|Core Research Group, Milton, Queensland, Australia|AusTrials Pty Ltd, Sherwood, Queensland, Australia|Monash Medical Centre, Department of Rheumatology, Clayton, Victoria, Australia|Rheumatology Department, Heidelberg West, Victoria, Australia|Emeritus Research, Malvern East, Victoria, Australia|The Goatcher Clinical Research Unit, Shenton Park, Western Australia, Australia|The Colin Bayliss Research and Teaching Unit, Victoria Park, Western Australia, Australia|CLINCOR - Clinica de Exames Cardiologicos e Ecografia S/C Ltda, Maceio, AL, Brazil|Hospital do Coracao de Alagoas, Maceio, AL, Brazil|CIP - Centro Internacional de Pesquisas, Goiania, GO, Brazil|Via Medica - Centro Clinico, Goiania, GO, Brazil|CMIP - Centro Mineiro de Pesquisa, Juiz de Fora, MG, Brazil|Hopsital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, Brazil|Hospital e Maternidade Angelina Caron, Sala Pesquisa Clinica, Campina Grande do Sul, PR, Brazil|CEPEME-CERHFAC Centro de Estudos e Pesquisas Medicas, Curitiba, PR, Brazil|Centro de Estudos do Hospital de Clínicas da UFPR, Curitiba, PR, Brazil|Hospital Universitário Clementino Fraga Filho - UFRJ, Rio de Janeiro, RJ, Brazil|CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda, Rio de Janeiro, RJ, Brazil|Hospital Ipanema Plus, Rio de Janeiro, RJ, Brazil|Clinica de Reumatologia do Centro Médico BarraShopping, Rio de Janeiro, RJ, Brazil|Centro de Pesquisa Clinica, Porto Alegre, RS, Brazil|Associação Hospitalar Moinhos de Vento (AHMV) / CMIC, Porto Alegre, RS, Brazil|Hospital São Lucas - Pontificia, Porto Alegre, RS, Brazil|Hospital e Maternidade Celso Pierro - Puc Campinas, Campinas, Sao Paulo, Brazil|Centro de Ensino e Pesquisa Hospital Sao Lucas, Aracaju, SE, Brazil|PUC Campinas, Campinas, SP, Brazil|Hospital das Clinicas da UNICAMP, Campinas, SP, Brazil|Hospital das Clinicas da Faculdade de Medicina de Marilia, Marilia, SP, Brazil|Hospital de Base - Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, SP, Brazil|Hospital Alemao Oswaldo Cruz, Sao Paulo, SP, Brazil|Setor de Lip., Arterosc. e BioVasc. - Disc. de Cardiologia, Sao Paulo, SP, Brazil|CEPIC - Centro Paulista de Investigacao Clínica, Sao Paulo, SP, Brazil|IMA Brasil - Instituto de Medicina Avancada, Sao Paulo, SP, Brazil|CPCLIN - Centro de Pesquisas Clínicas, São Paulo, SP, Brazil|Hospital Sao Salvador - Medicos Reunidos Ltda., Goiania-GO, Brazil|Ambulatorio de Especialidades Mario Covas, Marilia/SP, Brazil|Hospital Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil|Hospital das Clinicas da UFPE, Recife - Pernambuco, Brazil|Hospital Dos Servidores Do Estado do Rio de Janeiro, Rio de Janeiro, Brazil|Faculdade de Medicina DO ABC, Santo Andre, Brazil|South Calgary Medical Clinic - Sunpark Professional Center, Calgary, Alberta, Canada|Allin Clinic, Edmonton, Alberta, Canada|Dr. MPJ Senaratne Professional Corporation, Edmonton, Alberta, Canada|Medical Arts Health Research Group, Kelowna, British Columbia, Canada|The Medical Arts Health Research Group, Penticton, British Columbia, Canada|Ocean West Research Clinic Inc., Surrey, British Columbia, Canada|Prohealth Clinical Research Inc., Vancouver, British Columbia, Canada|Office of Dr. Milton F. Baker, Victoria, British Columbia, Canada|The Medical Arts Health Research Group, West Vancouver, British Columbia, Canada|Rivergrove Medical Clinic, Winnipeg, Manitoba, Canada|Manitoba Clinic, Winnipeg, Manitoba, Canada|G.A. Research Associates Ltd/Ltee, Moncton, New Brunswick, Canada|Eric N. Grant Professional Corporation, Quispamis, New Brunswick, Canada|Office of Dr. Brian N. Craig, Saint John, New Brunswick, Canada|Commonwealth Medical Clinic, Mount Pearl, Newfoundland and Labrador, Canada|Paradise Medical Clinic, Paradise, Newfoundland and Labrador, Canada|White Hills Medical Clinic, St. John's, Newfoundland and Labrador, Canada|Nexus Clinic Research, St. John's, Newfoundland and Labrador, Canada|The Clinical Trials Centre, St. John's, Newfoundland and Labrador, Canada|Topsail Road Medical Clinic, St. John's, Newfoundland and Labrador, Canada|MSHJ Research Associates, Inc., Halifax, Nova Scotia, Canada|Colchester Research Group, Truro, Nova Scotia, Canada|Office of Dr. Rohit Nagpal, Brampton, Ontario, Canada|Aggarwal and Associates Ltd., Brampton, Ontario, Canada|Aviva Clinical Trial Group Inc., Burlington, Ontario, Canada|Corunna Medical Research Center, Corunna, Ontario, Canada|C & L Research, Fort Erie, Ontario, Canada|Office of Dr. Jonathan D. Adachi, Hamilton, Ontario, Canada|Office of Dr. John Mutrie, Kitchener, Ontario, Canada|KW Musculoskeletal Research Inc., Kitchener, Ontario, Canada|East London Medical Centre, London, Ontario, Canada|London East Medical Centre, London, Ontario, Canada|Office of Dr. Gordon Schacter, London, Ontario, Canada|Office of Dr. William Blake Bowler, London, Ontario, Canada|Office of Dr. Robert G. Luton, London, Ontario, Canada|Malton Medical Centre, Mississauga, Ontario, Canada|The Arthritis Program Research Group Inc., Newmarket, Ontario, Canada|SKDS Research Inc., Newmarket, Ontario, Canada|Office of Dr. Azim M. Velji, Niagara Falls, Ontario, Canada|AIM Health Group Trainyards Health and Wellness Centre, Ottawa, Ontario, Canada|London Road Diagnostic Clinic & Medical Center, Sarnia, Ontario, Canada|London Road Diagnostic Clinic & Medical Centre, Sarnia, Ontario, Canada|Office of Dr. Swaran K. Syan, Sudbury, Ontario, Canada|Keele Medical Place, Toronto, Ontario, Canada|Prime Health Clinical Research, Toronto, Ontario, Canada|Office of Dr. Ira Bernstein, Toronto, Ontario, Canada|Office of Dr. Subodh Kanani, Toronto, Ontario, Canada|Manna Research, Toronto, Ontario, Canada|North Walkerville Orthopaedic Associates, Windsor, Ontario, Canada|Research Office, Windsor, Ontario, Canada|Clinical Research and Arthritis Centre, Windsor, Ontario, Canada|Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|ECOGENE-21 / Centre de sante et de services sociaux de Chicoutimi, Chicoutimi, Quebec, Canada|Clinique de Medicine Familiale de Cowansville, Cowansville, Quebec, Canada|Centre de recherche clinique Adapra Inc., L'Ancienne-Lorette, Quebec, Canada|Centre de Recherche Hochelaga/ Clinique Medicale Hochelaga, Montreal, Quebec, Canada|Recherche Medicale Appliquee Informatics (AMIR) Inc., Montreal, Quebec, Canada|Kells Medical Research Group, Inc., Pointe-Claire, Quebec, Canada|Le Manoir de l'Atrium, Quebec City, Quebec, Canada|Clinique Services Sante Rosemere, Rosemere, Quebec, Canada|Centre Medical des Carrieres, Saint-Marc-des-Carrieres, Quebec, Canada|St-Jerome Medical Research Inc., St-Jerome, Quebec, Canada|Centre de Recherche Musculo-Squelettique, Trois-Rivieres, Quebec, Canada|Cardiology and Research, Westmount, Quebec, Canada|Downtown Medical Specialists, Saskatoon, Saskatchewan, Canada|Recherche Clinique Sigma, Inc., Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Québec, Quebec, Canada|Hospital Pablo Tobon Uribe - Unidad de Investigaciones, Medellin, Antioquia, Colombia|Reumalab S.A.S., Medellin, Antioquia, Colombia|IPS Rodrigo Botero S.A.S., Medellin, Antioquia, Colombia|Fundacion Cardioinfantil, Bogota, Cundinamarca, Colombia|Clinica Colsanitas Sa, Bogota, Cundinamarca, Colombia|Fundacion Cardiovascular de Colombia, Floridablanca, Santander, Colombia|Fundacion Valle del Lili, Cali, Colombia|Clínica Vía San Juan, La union de Tres Rios, Cartago, Costa Rica|Clinica San Agustin, Desamparados Centro, San Jose, Costa Rica|Hospital CIMA San Jose, Escazu, San Jose, Costa Rica|Hospital Hotel La Catolica, Goicoechea, San Jose, Costa Rica|Consultorio Privado Dr. Alberto Lainez Ventosilla, Moravia, San José, Costa Rica|Centro Medico San Rafael, Alajuela, Costa Rica|Centro de Reumatologia y Osteoporosis, Cartago, Costa Rica|Clínica Garzona, Cartago, Costa Rica|Clinica de Especialidades Medicas Drs. Saenz Castro, Heredia, Costa Rica|Clínica Monte Sión, Heredia, Costa Rica|Clínica San Antonio, Heredia, Costa Rica|Centro Medico San Jose, San Jose, Costa Rica|Edificio Panda, San Jose, Costa Rica|Hospital Clinica Biblica, San Jose, Costa Rica|Hospital Clínica Biblica, San Jose, Costa Rica|Oficina Privada, San Jose, Costa Rica|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Centre for Assessment and Treatment of Rheumatic Diseases, Department of Medicine and Geriatrics, New Territories, NT, Hong Kong|Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong|Department of Medicine, North District Hospital, Sheung Shui, NT, Hong Kong|Centro de Investigacion del Noroeste SC, Tijuana, Baja California, Mexico|Comite Mexicano para la Prevencion de la Osteoporosis, A.C., Mexico, D.f., Mexico|Instituto Mexicano de Investigación Clínica, S.A. de C.V, Mexico, D.f., Mexico|CIF-BIOTEC, Medica Sur, Mexico, DF, Mexico|Centro Medico Toluca, Metepec, Estado de Mexico, Mexico|Hospital Regional ISSSTE, Leon, Guanajuato, Mexico|Instituto Jalisciense de Investigación Clínica SA de CV, Guadalajara, Jalisco, Mexico|Centro de Estudios de Investigacion Basica y Clinica SC., Guadalajara, Jalisco, Mexico|Unidad de Investigacion Dr. Mario Alvizouri Muñoz Ac Del Hospital General Dr. Miguel Silva, Morelia, Michoacan, Mexico|Hospital Central ""Dr. Ignacio Morones Prieto"" Unidad Regional de Reumatologia y Osteoporosis, San Luis Potosi, SLP, Mexico|Clinicos Asociados BOCM, S.C., Mexico City, Mexico|Centro de Investigación Marbella, Panama City, Panama|IPC - Centro de Salud Integral S.A., San Isidro, Lima, Peru|Centro Empresarial - Altavista Polo 4, Santiago de Surco, Lima, Peru|Instituto de Ginecologia y Reproducción & Cirugia Minimamente Invasiva, Santiago de Surco, Lima, Peru|Clinica San Felipe, Lima, Peru|Centro de Investigaciones Medical, Lima, Peru|Clinica San Juan Bautista, Lima, Peru|Mary Mediatrix Medical Center, Lipa City, Batangas, Philippines|De La Salle Health Sciences Institute, Dasmarinas, Cavite, Philippines|Chong Hua Hospital, Cebu City, Philippines|Southern Philippines Medical Center, Davao City, Philippines|Jose R. Reyes Memorial Medical Center, Manila, Philippines|Chinese General Hospital and Medical Center, Manila, Philippines|Hospital Research Unit, University of Santo Tomas Hospital, Manila, Philippines|St. Luke's Medical Center, Quezon City, Philippines|Chang Gung Memorial Hospital-Kaohsiung branch, Section of Allergy, Immunology, Nio Sung Township, Kaohsiung County, Taiwan|Tri-Service General Hospital, Neihu District, Taipei City, Taiwan|Chang Gung Medical Foundation-Linkou Branch, Gueishan Township, Taoyuan County, Taiwan|Chi-Mei Medical Center, Tainan, Yung Kang, Taiwan|Buddhist Tzu Chi Dailin General Hospital, Chia-Yi County, Taiwan|Chung-Ho Memorial Hospital, Kaoshiung Medical University Hospital, Kaohsiung, Taiwan|Chung Shan Medical University Hospital, Taichung, Taiwan|Taichung Veterans General Hospital, Taichung, Taiwan|Tri-service General Hospital, Taipei City, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan|CRI ""Clinical Territorial Medical Association ""University Clinic"",, Simferopol, Crimea, Ukraine|Municipal Medical Institution ""City Clinical Hospital #3"", Department of Rheumatology, Chernivtsi, Ukraine|MI Dnipropetrovsk Regional Clinical Hospital named after I.I Mechnikov, Dnipropetrovsk, Ukraine|State Institution ""Dnipropetrovsk Medical Academy of MOH, Ukraine, Dnipropetrovsk, Ukraine|Rheumatology Department, MMI ""City Clinical Hospital #5"", DNMU n.a. M.Gorkyy,, Donetsk, Ukraine|Donetsk National Med University, Chair of Propaedeutics and Internal Medicine, Donetsk, Ukraine|Municipal Establishment of Health Care, Kharkiv, Ukraine|City Clinical Hospital # 8, Dept of Cardiology and Functional Diagnostics, Kharkiv, Ukraine|City Clinical Hospital #1, Kyiv, Ukraine|National Scientific Center ""The Strazhesko Institute of Cardiology"", Kyiv, Ukraine|State Institution ""Republican clinical hospital of MOH of Ukraine"", Kyiv, Ukraine|Family Medicine Department of NMAPE named after PL Shupyk,, Kyiv, Ukraine|Lutsk City Clinical Hospital, Lutsk, Ukraine|Municipal City Clinical Hospital #5, Lviv, Ukraine|Center of Reconstructive and Regenerative Medicine (University clinic) of, Odesa, Ukraine|Treatment-and-Diagnostic Center LLC ""Desna"" Ltd, Ternopil, Ukraine|Municipal enterprise "" City Hospital # 7"",, Zaporizhzhia, Ukraine|Municipal Institution ""Zaporizhzhya City Multiple Discipline Clinical Hospital #9"", Zaporizhzhya, Ukraine|Zhytomyr Regional Clinical Hospital n.a. O.F. Gerbachevs'kyy/ Rheumatology Center, Zhytomyr, Ukraine",A61K9/0056,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,25.4953900490769,3547.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.5,206.2808,37.3,2.0,1.0,1.0,23.76,60.73,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(C1CCCCC1)N1CC(=O)N2CCc3ccccc3C2C1,1,DB01058,__PRAZIQUANTEL,4283400,Completed,NCT02878564,SCHISTOSOMIASIS MANSONI|HIV,Female,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"UVRI-IAVI HIV Vaccine program, Entebbe, Wakiso, Uganda",A23K10/20,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,251.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.42,312.4061,40.62,2.0,0.0,4.0,34.84,88.79,1.0,0.0,1.0,0.0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Completed,NCT00001658,AUTOIMMUNE DISEASE|MENTAL DISORDER|OBSESSIVE COMPULSIVE DISORDER|STREPTOCOCCAL INFECTION|TIC DISORDER,All,"Child, Adult, Older Adult",NIH,Primary Purpose: Treatment,"National Institute of Mental Health (NIMH), Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03172676,IMMUNE THROMBOCYTOPENIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut Medical School, Assiut, Egypt",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](N)c3ccc(O)cc3)C(=O)N2[C@H]1C(=O)O,1,DB01060,__AMOXICILLIN,6878386,Recruiting,NCT03404804,PENICILLIN ALLERGY|PEDIATRIC EMERGENCY MEDICINE,All,2 Years to 16 Years   (Child),Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"David Vyles, Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,93.0,60.190147641635285,497.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.75,365.404,132.96,6.0,4.0,3.0,35.53,89.5,4.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1
CCN(CC)CC#CCOC(=O)C(O)(c1ccccc1)C1CCCCC1,1,DB01062,__OXYBUTYNIN,5164190,Completed,NCT00629642,MULTIPLE SCLEROSIS|NEUROGENIC BLADDER|SPINAL CORD DISEASES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brisbane, Australia|Melbourne, Australia|Perth, Australia|Randwick, Australia|Antwerpen, Belgium|Esneux, Belgium|Fraiture-en-Condroz, Belgium|Gent, Belgium|Leuven, Belgium|Melsbroek, Belgium|Brno, Czechia|Ceske Budejovice, Czechia|Prague, Czechia|Caen, France|Garches, France|Paris, France|Ploemeur, France|Berlin, Germany|Hagenow, Germany|Heidelberg, Germany|Kiel, Germany|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Firenze, Italy|Milan, Italy|Rome, Italy|Torino, Italy|Apeldoorn, Netherlands|Eindhoven, Netherlands|Nijmegen, Netherlands|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|San Juan de Alicante, Alicante, Spain|Badalona, Barcelona, Spain|Getafe, Madrid, Spain|La Coruna, Spain|Cardiff, United Kingdom|Newcastle Upon Tyne, United Kingdom",A61K9/7061,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,23.228403047290502,333.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.36,357.4864,49.77,3.0,1.0,2.0,41.25,105.26,10.0,0.0,1.0,0.0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C281/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07C281/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT01332227,"HIV, COMBINATION THERAPY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health For Life Clinic Pllc, Little Rock, Arkansas, United States|Eisenhower Medical Center, Palm Springs, California, United States|Metropolis Medical Pc, San Francisco, California, United States|Consultive Medicine, Daytona Beach, Florida, United States|Orange County Health Dept., Orlando, Florida, United States|Triple O Medical Services, P.A., West Palm Beach, Florida, United States|The Research Institute, Springfield, Massachusetts, United States|Aids Care, Rochester, New York, United States|Local Institution, Paris, Cedex 12, France|Local Institution, Lyons Cedex 04, France|Local Institution, Orleans Cedex 2, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Bochum, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Munich, Germany|Local Institution, Genova, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Roma, Italy|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Brighton, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Sheffield, United Kingdom",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT01274780,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic, Barcelona, Spain",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Terminated,NCT01194856,HIV INFECTION|MITOCHONDRIAL DYSFUNCTION,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic, Cleveland, Ohio, United States",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Unknown status,NCT01829802,CHRONIC INFECTION WITH HIV,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundacion Huesped, Buenos Aires, Argentina|Dra Luna Norma, Cordoba, Argentina",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Unknown status,NCT00426296,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Whitman-Walker Clinic, Washington, District of Columbia, United States",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT01691794,"HIV, PEDIATRIC",All,6 Years to 17 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children'S Hospital, Phoenix, Arizona, United States|Grady Health System Ponce Family And Youth Clinic, Atlanta, Georgia, United States|Children'S Medical Center Of Dallas, Dallas, Texas, United States|Local Institution, Buenos Aires, Bs As, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Salvador, Bahia, Brazil|Local Institution, Salvador, Bahia, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Sao Paulo, SP, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Puebla, Mexico|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Bloemfontein, FREE State, South Africa|Local Institution, Soweto, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa",C07C281/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT00135356,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Local Institution, Ft. Lauderdale, Florida, United States|Local Institution, Honolulu, Hawaii, United States|Local Institution, Huntersville, North Carolina, United States|Local Institution, Houston, Texas, United States|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Bondy Cedex, France|Local Institution, Lagny-sur-Marne, France|Local Institution, Lyon Cedex 02, France|Local Institution, Lyon Cedex 03, France|Local Institution, Nice Cedex, France|Local Institution, Paris Cedex 12, France|Local Institution, Frankfurt/ Main, Germany|Local Institution, Muenchen, Germany|Local Institution, Brescia, Italy|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Roma, Italy|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Puebla, Mexico|Local Institution, Szczecin, Poland|Local Institution, Wroclaw, Poland|Local Institution, Barcelona, Spain|Local Institution, Elche (Alicante), Spain|Local Institution, Guipuzcoa, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Brighton, East Sussex, United Kingdom|Local Institution, London, Greater London, United Kingdom",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Unknown status,NCT01105611,HEPATITIS C INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Genitourinary Medicine and Infectious Diseases, St. James's Hospital, Dublin, Ireland|Mater Misericordiae University Hospital, Dublin, Ireland",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Withdrawn,NCT01225705,HIV|HEPATITIS C,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Auguste Viktoria Hospital (AVK), Berlin, Germany|Praxiszentrum Kaiserdamm, Berlin, Germany|Private Practice Dupke, Carganico, Baumgarten, Berlin, Germany|Department of Internal Medicine I, Bonn University, Bonn, Germany|University of Essen, Essen, Germany|Infektiologikum Frankfurt, Frankfurt / Main, Germany|University of Frankfurt, Frankfurt / Main, Germany|Infektionsmedizinisches Centrum Hamburg (ICH), Hamburg, Germany",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT01928407,HIV-1 INFECTION|IMMUNOSUPPRESSION-RELATED INFECTIOUS DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Zobda Quitman, Fort De France, Martinique, France|Centre Hospitalier D'Argenteuil, Argenteuil, France|Hopital Saint-Jacques, Besancon, France|Hopital Avicenne, Bobigny, France|Hopital Jean Verdier, Bondy, France|Hopital Saint-Andre, Bordeaux, France|Chu Cote de Nacre, Caen, France|Hopital Louis Mourier, Colombes, France|Hopital Le Bocage, Dijon, France|Hopital Raymond Poincare, Garches, France|C.H.D de Vendee, La Roche Sur Yon, France|Hopital Dupuytren, Limoges, France|Hopital Sainte-Marguerite, Marseille, France|Centre Hospitalier de Melun, Melun, France|Hopital L'Archet, Nice, France|Hopital Lariboisiere, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hopital Necker, Paris, France|Hopital Bichat, Paris, France|Hopital Tenon, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hopital Cochin, Paris, France|Hopital Europeen Georges Pompidou, Paris, France|Hopital Saint-Jean Roussillon, Perpignan, France|Hopital Rene Dubos, Pontoise, France|C.H.R.A, Pringy, France|Hopital Civil, Strasbourg, France|Hopital Gustave Dron, Tourcoing, France|Hopital Bretonneau, Tours, France",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT04531072,DRUG INTERACTION,All,"18 Years to 70 Years   (Adult, Older Adult)",U.S. Fed|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Apin (Aids Prevention Initiatives in Nigeria) clinic, Lagos University Teaching Hospital, Suru Lere, Lagos State, Nigeria",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT00940771,PEDIATRIC HIV|HIV INFECTIONS,All,"6 Years to 18 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States",C07C281/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,1,DB01072,__ATAZANAVIR,5849911,Completed,NCT00447070,HIV INFECTIONS|DYSLIPIDEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Treatment,"University Hospital Zurich, Infectiology, Zurich, ZH, Switzerland",C07C281/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,20.2057537115751,105.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.08,704.8555,171.22,7.0,5.0,3.0,76.73,191.8,18.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00220311,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,1,DB01073,__FLUDARABINE,7547776,Completed,NCT00361140,"MYELODYSPLASTIC SYNDROMES|MYELOPROLIFERATIVE DISORDERS|LEUKEMIA, LYMPHOCYTIC|MYELOMA|LYMPHOMA",All,"16 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,113.776463582414,682.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.62,285.235,139.54,8.0,4.0,3.0,25.33,64.06,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT01985789,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","University of Saskatchewan, Saskatoon, Saskatchewan, Canada",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT02062710,COUGH REFLEX SENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Einstein Division/Montefiore Medical Center, Bronx, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,NCT00648973,NASAL CONGESTION,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Benchmark Research - Austin, Austin, Texas, United States|Allergy and Asthma Associates, Austin, Texas, United States|Lovelace Scientific Resources, Austin, Texas, United States|Allergy/Immunology Research Center of North Texas, Dallas, Texas, United States|Kerrville Research Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Benchmark Research - San Angelo, San Angelo, Texas, United States|Sun Research Institute, San Antonio, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Diagnostics Research Group, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1,1,DB01075,__DIPHENHYDRAMINE,8263647,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,53.0606377954372,1708.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,255.3547,12.47,2.0,0.0,2.0,29.86,79.93,6.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT02577042,AGING-RELATED INFLAMMATION IN HIV-INFECTED PATIENTS,All,"60 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Terminated,NCT00355251,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01263938,HIV DEMENTIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Recruiting,NCT03692754,"IMMUNE THROMBOCYTOPENIA|PURPURA, THROMBOCYTOPENIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu hospital, Shandong University, Jinan, Shandong, China",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT01497912,TYPE 1 DIABETES MELLITUS|DYSLIPIDEMIA,All,"30 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Stockholm, Sweden",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00120887,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Prevention,"Johns Hopkins Lupus Center 1830 E Monument Street, Ste 7500, Baltimore, Maryland, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Completed,NCT00356473,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(C)c1c(C(=O)Nc2ccccc2)c(-c2ccccc2)c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01076,__ATORVASTATIN,4681893,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,13.7004866629704,122.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.24,558.6398,111.79,5.0,4.0,4.0,59.39,158.2,12.0,1.0,0.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0
CC(O)(P(=O)(O)O)P(=O)(O)O,1,DB01077,__ETIDRONIC_ACID,,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,206.0282,135.29,7.0,5.0,0.0,13.97,34.51,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CCCCCNC(=N)N/N=C/c1c[nH]c2ccc(OC)cc12,1,DB01079,__TEGASEROD,5510353,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D409/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.4417955194151,53.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,301.394,85.29,5.0,4.0,2.0,34.96,110.25,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC[C@@H]1C(=O)OC[C@@H]1Cc1cncn1C,1,DB01085,__PILOCARPINE,3947573,Completed,NCT00438048,PRIMARY SJOGREN|SECONDARY SJOGREN|XEROSTOMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Unidad Docente Asociada Dermatologia. Escuela de MEdicina Pontificia Universidad Catolica de Chile, Santiago, Region Metropolitana, Chile",C08L71/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,17.380233680363,24.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.15,208.2569,44.12,2.0,0.0,2.0,22.34,56.53,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,,PLASMODIUM FALCIPARUM,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
COc1cc(NC(C)CCCN)c2ncccc2c1,1,DB01087,__PRIMAQUINE,4074972,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,15.376085751247402,413.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.76,259.3467,60.17,4.0,2.0,2.0,29.92,78.51,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,NCT00403650,SARCOIDOSIS|PULMONARY ARTERIAL HYPERTENSION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Cincinnati, Cincinnati, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC#CCC(C)[C@H](O)/C=C/[C@@H]1[C@H]2C/C(=C/CCCC(=O)O)C[C@H]2C[C@H]1O,1,DB01088,__ILOPROST,EP-1089970-B1,Unknown Status,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,57.5289020308425,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.22,360.494,77.76,4.0,3.0,2.0,42.68,105.18,9.0,0.0,1.0,0.0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0
CC(C)n1c(/C=C/[C@H](O)C[C@H](O)CC(=O)O)c(-c2ccc(F)cc2)c2ccccc21,1,DB01095,__FLUVASTATIN,5354772,Completed,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,10.5464177909197,1359.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.69,411.4659,82.69,4.0,3.0,3.0,44.31,114.86,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Unknown status,NCT02275299,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Peking Union Medical College Hospital, Beijing, Beijing, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Completed,NCT02703194,IMMUNOGLOBULIN G4 RELATED SCLEROSING DISEASE,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chinese PLA General Hospital, Beijing, China",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Recruiting,NCT04020328,"GLOMERULONEPHRITIS, IGA|RENAL INSUFFICIENCY, CHRONIC",All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Xu Yi, Shenzhen, Guangdong, China",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Unknown status,NCT02024334,JUVENILE IDIOPATHIC ARTHRITIS,All,"2 Years to 19 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Mashhad, Khorasan Razavi, Iran, Islamic Republic of",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
Cc1oncc1C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB01097,__LEFLUNOMIDE,5504084,Recruiting,,IGA GLOMERULONEPHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,24.345469106141802,1785.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.52,270.2073,55.13,2.0,1.0,2.0,23.11,64.16,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Unknown status,NCT00866229,SYSTEMIC LUPUS ERYTHEMATOSUS|HIGH LDL CHOLESTEROL LEVEL,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",C07D239/42 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00117494,HYPERLIPIDEMIA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"service de Médecine Interne Hopital Hotel Dieu, Paris, France",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Terminated,NCT00673582,ATHEROSCLEROSIS|HIV INFECTIONS,All,"35 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The St. Paul's Hospital HIV Metabolic Clinic & The BC Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT01813357,HIV|CARDIOVASCULAR DISEASE,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Alfred Hospital, Melbourne, Victoria, Australia|Hospitaux Universitaires de Geneve, Geneve, Switzerland",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT02234492,HUMAN IMMUNODEFICIENCY VIRUS (HIV)|CARDIOVASCULAR DISEASE (CVD),All,"40 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"The Ottawa Hospital-General Campus, Ottawa, Ontario, Canada|University of Ottawa Heart Institute, Ottawa, Ontario, Canada",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,NCT00371501,ATHEROSCLEROSIS|THROMBOEMBOLISM|SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Tuen Mun Hospital, Hong Kong, Hong Kong",C07D239/42 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Active Not Recruiting,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1/C=C/[C@@H](O)C[C@@H](O)CC(=O)O,1,DB01098,__ROSUVASTATIN,RE37314,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/42 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,35.351855274235604,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.47,481.538,140.92,8.0,3.0,2.0,48.55,121.44,9.0,0.0,1.0,0.0,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21,1,DB01104,__SERTRALINE,4962128,"Active, not recruiting",NCT04094870,PERINATAL DEPRESSION|HIV-1-INFECTION,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kamwala District Health Centre, Lusaka, Zambia|University Teaching Hospital, Lusaka, Zambia",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,11.2035154725969,358.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.06,306.23,12.03,1.0,1.0,3.0,32.44,85.74,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(COC(N)=O)CS[C@H]12)c1ccco1,1,DB01112,__CEFUROXIME,,Completed,NCT03716804,UNCOMPLICATED URINARY TRACT INFECTION|ANTIBIOTIC RESISTANT INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Combined Military Hosptal, Dhaka, Dhaka, Bangladesh",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.24,424.385,173.76,7.0,3.0,3.0,38.75,97.17,8.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1
O=C1C(O)=C([C@H]2CC[C@H](c3ccc(Cl)cc3)CC2)C(=O)c2ccccc21,1,DB01117,__ATOVAQUONE,5998449,Completed,NCT00421473,HIV INFECTIONS|MALARIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Elisabeth hospital, Tilburg, Brabant, Netherlands|Alysis Zorggroep loc. Rijnstate, Arnhem, Gelderland, Netherlands|Radboud University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid Holland, Netherlands|Erasmus MC, Rotterdam, Zuid Holland, Netherlands",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,25.199696092322196,296.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.74,366.837,54.37,3.0,1.0,4.0,39.64,103.11,2.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Suspended,NCT03608163,"DIABETES MELLITUS, TYPE 1|HYPOGLYCEMIA|HYPOGLYCEMIA UNAWARENESS",All,21 Years to 55 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Albert Einstein College of Medicine, Bronx, New York, United States",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Completed,NCT00131755,"DIABETES MELLITUS, TYPE 1",All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University Hospital of Trondheim, Trondheim, Norway",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC1=NS(=O)(=O)c2cc(Cl)ccc2N1,1,DB01119,__DIAZOXIDE,4396616,Completed,NCT01488136,TYPE 1 DIABETES,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","NHS Tayside, Dundee, United Kingdom",C07D225/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,22.899854206451806,909.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.09,230.671,58.53,4.0,1.0,2.0,20.98,54.84,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,1,DB01131,__PROGUANIL,5084449,Completed,NCT00421473,HIV INFECTIONS|MALARIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Elisabeth hospital, Tilburg, Brabant, Netherlands|Alysis Zorggroep loc. Rijnstate, Arnhem, Gelderland, Netherlands|Radboud University Medical Centre Nijmegen, Nijmegen, Gelderland, Netherlands|Leids Universitair Medisch Centrum, Leiden, Zuid Holland, Netherlands|Erasmus MC, Rotterdam, Zuid Holland, Netherlands",C07C317/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,13.7004866629704,658.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.29,253.731,83.79,5.0,5.0,1.0,26.75,91.65,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01612858,LIPODYSTROPHY|HIV INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Boston, Massachusetts, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT02733679,ATAXIA-TELANGIECTASIA,All,18 Years to 30 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ninewells Hospital, Dundee, Angus, United Kingdom",C07D213/30,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",C07D213/30,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Terminated,NCT00742326,HIV|HEPATITIS C|LIVER DISEASE|FATTY LIVER|STEATOSIS,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","VA Medical Center, Washington, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Recruiting,NCT03878459,TYPE 1 DIABETES,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University Health System Texas Diabetic Institute, San Antonio, Texas, United States",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Completed,NCT01322308,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,C07D213/30,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1,1,DB01132,__PIOGLITAZONE,4687777,Unknown status,NCT01253928,ESRD,All,"20 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nephrology Service Department of Medicine CHUV, Lausanne, Vaud, Switzerland",C07D213/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,18.9901230004722,541.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,356.439,68.29,4.0,1.0,3.0,37.91,97.39,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12,1,DB01136,__CARVEDILOL,6022562,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",A61K9/5026,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,51.7464424320827,334.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.05,406.4742,75.74,5.0,3.0,4.0,45.03,115.64,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D413/06,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C[C@H]1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01137,__LEVOFLOXACIN,5053407,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",C07D413/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,63.377071397769896,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCCCCOc1ccc(-c2cc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](O)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@H](O)CC(N)=O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)c(OS(=O)(=O)O)c5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)no2)cc1,1,DB01141,__MICAFUNGIN,5376634,Completed,NCT01200355,ACUTE MYELOGENOUS LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",C07K7/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,42.3499455840982,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.67,1270.274,510.14,22.0,16.0,7.0,128.22,303.07,18.0,1.0,0.0,0.0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0
CN(C)CCC=C1c2ccccc2COc2ccccc21,1,DB01142,__DOXEPIN,6211229,Completed,NCT00465972,HIV INFECTIONS|INSOMNIA,All,"18 Years to 69 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Medical Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,13.5033573584673,975.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.08,279.3761,12.47,2.0,0.0,3.0,32.47,98.24,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
NCCCNCCSP(=O)(O)O,1,DB01143,__AMIFOSTINE,5424471,Completed,NCT00158041,HEAD AND NECK CANCER|LUNG CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Mt. Sinai Medical Center, Miami Beach, Florida, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,22.47274071336161,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,214.22299999999998,95.58,5.0,4.0,0.0,21.01,51.28,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Completed,,SUBSTANCE-RELATED DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CNCCCN1c2ccccc2CCc2ccccc21,1,DB01151,__DESIPRAMINE,3961060,Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,24.5754532947288,76.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,266.3807,15.27,2.0,1.0,3.0,31.74,85.31,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Active Not Recruiting,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,NICOTINE DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1,1,DB01156,__BUPROPION,5358970,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,14.423294112815402,185.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.28,239.74099999999999,29.1,2.0,1.0,1.0,25.93,67.7,4.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCN(CC)CCOC(=O)c1ccc(N)cc1Cl,1,DB01161,__CHLOROPROCAINE,8969412,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,101.882995544056,725.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,270.755,55.56,3.0,1.0,1.0,28.74,75.1,7.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CC1COc2c(N3CCN(C)CC3)c(F)cc3c(=O)c(C(=O)O)cn1c23,1,DB01165,__OFLOXACIN,5401741,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,23.4912421199613,725.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.02,361.3675,73.32,7.0,1.0,4.0,36.69,94.94,2.0,0.0,1.0,0.0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Active Not Recruiting,,CEREBRAL SMALL VESSELS DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
O=C1CCc2cc(OCCCCc3nnnn3C3CCCCC3)ccc2N1,1,DB01166,__CILOSTAZOL,5728563,Completed,,ARTERIOSCLEROSIS OBLITERANS,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,32.854884083862,313.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.38,369.4607,81.93,5.0,1.0,4.0,41.15,117.13,7.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Terminated,NCT01282879,GRAFT VS HOST DISEASE,All,"19 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Chonnam National University Hwasun Hospital, Hwasun, Jeollanam-do, Korea, Republic of|Soonchunhyang University Bucheon Hospital, Bucheon, Kyounggi-do, Korea, Republic of|Gachon University Gil Hospital, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Inje University Pusan Paik Hospital, Pusan, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Chung-ang University Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Seoul Hospital, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Terminated,NCT00787917,CYSTIC FIBROSIS|ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator Site, Leuven, Belgium|Novartis Investigator Site, Berlin, Germany|Novartis Investigator Site, Bonn, Germany|Novartis Investigator Site, Munich, Germany|Novartis Investigator Site, Milan, Italy|Novartis Investigator Site, Rome, Italy|Novartis Investigator Site, Nijmegen, Netherlands|Novartis Investigator Site, Utrecht, Netherlands|Novartis Investigator Site, Cambridge, United Kingdom|Novartis Investigator Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,,NEUTROPENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
CCC(C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,1,DB01167,__ITRACONAZOLE,6407079,Completed,,MYCOSES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,163.551612969465,1346.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.48,705.633,100.79,9.0,0.0,7.0,74.71,200.4,11.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0
NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB01172,__KANAMYCIN,3932615,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",A61K9/16,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,22.2099016406907,3358.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-3.1,484.4986,282.61,15.0,11.0,3.0,47.57,106.13,6.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Terminated,NCT00151294,DEPRESSION|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"NewYork Presbyterian Hospital, White Plains, New York, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Terminated,NCT01797380,DEPRESSION|HIV,Female,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Duke University Medical Center, Durham, North Carolina, United States",C07D307/87,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Unknown status,NCT00209807,MAJOR DEPRESSION|PAIN|ABDOMINAL PAIN,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitari vall d'Hebron, Barcelona, Catalonia, Spain",C07D307/87,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT00621946,SEVERE ASTHMA|MODERATE OR SEVERE MAJOR DEPRESSIVE DISORDER,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","The UT Southwestern Medical Center at Dallas, Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21,1,DB01175,__ESCITALOPRAM,RE34712,Completed,NCT01324700,DEPRESSION|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Health Services Research","Parkland Health and Hospital System (Asthma, Allergy, & Arthritis Clinics), Dallas, Texas, United States",C07D307/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,11.4992094293517,68.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.58,324.3919,36.26,3.0,0.0,3.0,35.3,94.02,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",A61K47/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Recruiting,NCT01366898,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"55 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol and all Hospital Pethema, Badalona, Barcelona, Spain",A61K47/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O,1,DB01177,__IDARUBICIN,4534971,Unknown status,NCT01990807,"CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|PHILADELPHIA CHROMOSOME, PH^1^, ABSENT|B-CELL CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA",All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Scienses, Tianjin, Tianjin, China",A61K47/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,33.7748208382102,1372.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.69,497.4939,176.61,10.0,5.0,5.0,50.33,126.43,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
O=P1(NCCCl)OCCCN1CCCl,1,DB01181,__IFOSFAMIDE,5252341,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,13.831906199305902,2428.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.57,261.086,41.57,2.0,1.0,1.0,23.94,58.48,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0
C=CCN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,1,DB01183,__NALOXONE,6159498,Suspended,NCT03608163,"DIABETES MELLITUS, TYPE 1|HYPOGLYCEMIA|HYPOGLYCEMIA UNAWARENESS",All,21 Years to 55 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Albert Einstein College of Medicine, Bronx, New York, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,27.3681184418571,1213.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.47,327.3743,70.0,5.0,2.0,5.0,33.83,88.72,2.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01201,__RIFAPENTINE,5306715,Recruiting,NCT03089983,OPIOID DEPENDENCE|ADDICTION|HIV/AIDS|TUBERCULOSIS|HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Kajang Prison, Kajang, Selangor, Malaysia",C07D498/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,14.0,39.5572804369699,300.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.83,877.0307,220.15,14.0,6.0,6.0,93.14,242.0,6.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c(/C=N/N5CCN(C6CCCC6)CC5)c(O)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01201,__RIFAPENTINE,5306715,Not yet recruiting,NCT04551573,TUBERCULOSIS|HIV,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Yale New Haven Hospital, New Haven, Connecticut, United States",C07D498/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,39.5572804369699,300.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.83,877.0307,220.15,14.0,6.0,6.0,93.14,242.0,6.0,1.0,0.0,0.0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0
CC[C@@H](C(N)=O)N1CCCC1=O,1,DB01202,__LEVETIRACETAM,6471992,Completed,NCT00423527,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Neurology, Odense University Hospital, Odense C, Denmark",A61K9/2072,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,56.2475615515718,30.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.64,170.21200000000005,63.4,2.0,1.0,1.0,17.79,44.08,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",C12C3/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00199069,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C12C3/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Completed,NCT00304291,"NEUROMYELITIS OPTICA|MYELITIS, TRANSVERSE|DEMYELINATING AUTOIMMUNE DISEASES, CNS|AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM",All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baird Multiple Sclerosis Center, Buffalo, New York, United States",C12C3/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,1,DB01204,__MITOXANTRONE,3977953,Unknown status,NCT02021825,NEUROMYELITIS OPTICA|NEUROMYELITIS OPTICA SPECTRUM DISORDERS,All,18 Years to 55 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, Beijing, China",C12C3/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,11.9263229224419,950.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.91,444.4809,163.18,10.0,8.0,3.0,48.49,123.53,12.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Recruiting,NCT03172676,IMMUNE THROMBOCYTOPENIA,All,"1 Year to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut Medical School, Assiut, Egypt",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O,1,DB01211,__CLARITHROMYCIN,6010718,Completed,NCT00368342,ASTHMA,All,"Child, Adult, Older Adult",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7891743156943,721.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.18,747.9534,182.91,13.0,4.0,3.0,82.03,190.79,8.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0
CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,1,DB01217,__ANASTROZOLE,RE36617,Completed,NCT01612871,BREAST CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Val d'Aurelle - Paul Lamarque, Montpellier, France|Institut Claudius REGAUD Toulouse, Toulouse, France",C07D239/26,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,47.3438879648452,907.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,293.3663,78.29,4.0,0.0,2.0,31.97,97.47,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01220,__RIFAXIMIN,6861053,Withdrawn,NCT01654939,HIV|HEPATITIS C,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0
CO[C@H]1/C=C/O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(c5c(nc6cc(C)ccn65)c4c3C2=O)NC(=O)/C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C,1,DB01220,__RIFAXIMIN,6861053,Completed,NCT01946906,COMMON VARIABLE IMMUNODEFICIENCY (CVID),All,"18 Years to 74 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Oslo University Hospital, Oslo, Norway",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,31.0,66.6625598061561,159.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.94,785.8785,198.38,11.0,5.0,6.0,82.26,216.69,3.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Completed,NCT03649334,HEMATOLOGICAL MALIGNANCY (LEUKEMIA- LYMPHOMA),All,2 Years to 7 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Other","Mansoura University, Mansourah, DK, Egypt",C07D307/52,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC1(c2ccccc2Cl)CCCCC1=O,1,DB01221,__KETAMINE,3966793,Active Not Recruiting,,"PAIN, CHRONIC",,,,,"FISABIO, Elche, Alicante, Spain",C07D307/52,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,33.0848682724491,249.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,237.725,29.1,2.0,1.0,2.0,24.97,65.55,2.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT03369847,ASTHMA|PEDIATRIC ALL,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kings County Hospital Center, Brooklyn, New York, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02019758,EOSINOPHILIC ESOPHAGITIS,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02409563,ALLERGIC RHINITIS,All,6 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT02696850,RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS|ALLERGIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT01270256,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Chicago, Chicago, Illinois, United States",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT03563001,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA-CHRONIC OBSTRUCTIVE PULMONARY DISEASE OVERLAP SYNDROME|SMALL AIRWAY DISEASE|QUALITY OF LIFE",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT03615742,EXPOSURE TO POLLUTION|GLUCOCORTICOID RESISTANCE,All,19 Years to 49 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University of British Columbia, Vancouver, British Columbia, Canada",A61K9/008,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Not yet recruiting,NCT04342039,EPIGENETIC EFFECTS OF INTRANASAL STEROIDS|ENVIRONMENTAL EXPOSURE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science",,A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Recruiting,NCT04171180,COUGH VARIANT ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the Second Affiliated Hospital of Zhejiang University School of Medicin, Hangzhou, Zhejiang, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Unknown status,NCT02934945,BRONCHIAL ASTHMA,All,"15 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Terminated,NCT01912872,SEVERE IGE-MEDIATED ASTHMA,All,"6 Years to 55 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Tuxtla Gutierrez, Chiapas, Mexico|Novartis Investigative Site, Mexico City, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Distrito Federal, Mexico|Novartis Investigative Site, Mexico, Edo. De México, Mexico|Novartis Investigative Site, Nezahualcoyotl, Estado De Mexico, Mexico|Novartis Investigative Site, Pachuca de Soto, Hidalgo, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Guadaljara, Jalisco, Mexico|Novartis Investigative Site, Tepic, Nayarit, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Monterrey, Nuevo León, Mexico|Novartis Investigative Site, Mérida, Yucatán, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Terminated,NCT01070888,EXERCISE INDUCED ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brigham and Women's Hospital, Boston, Massachusetts, United States|Children's Hospital Boston, Boston, Massachusetts, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,NCT00733473,ASTHMA|ACUTE ASTHMA,All,6 Months to 6 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kecioren Education and Training Hospital, Ankara, Kecioren, Turkey",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Active Not Recruiting,,AIRWAY INFLAMMATION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01222,__BUDESONIDE,6123924,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.67276535452471,838.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.42,430.5339,93.06,6.0,2.0,5.0,47.11,116.11,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D281/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1,1,DB01224,__QUETIAPINE,4879288,Completed,,ALCOHOL ABUSE,,,,,"FISABIO, Elche, Alicante, Spain",C07D281/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,31.639253372759104,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.93,383.50699999999995,48.3,5.0,1.0,4.0,42.78,114.09,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1
COc1cc2c(cc1OC)[C@@H](Cc1cc(OC)c(OC)c(OC)c1)[N+](C)(CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]1(C)CCc3cc(OC)c(OC)cc3[C@H]1Cc1cc(OC)c(OC)c(OC)c1)CC2,1,DB01226,__MIVACURIUM,4761418,Completed,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C07D217/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,36.53463110125461,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,1029.2608,144.9,12.0,0.0,6.0,116.68,308.74,30.0,1.0,0.0,0.0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C,1,DB01229,__PACLITAXEL,5439686,Active Not Recruiting,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/6925,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,29.4708310232242,5311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,853.9061,221.29,10.0,4.0,7.0,87.17,218.29,14.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,1,DB01232,__SAQUINAVIR,5196438,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,28.090925891702,1170.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.04,670.8408,166.75,7.0,5.0,5.0,73.76,186.67,13.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,1,DB01232,__SAQUINAVIR,5196438,Completed,NCT00717067,HIV INFECTION,All,"18 Years to 85 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Muenchen, Germany",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,28.090925891702,1170.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.04,670.8408,166.75,7.0,5.0,5.0,73.76,186.67,13.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0
CC(C)(C)NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2CN1C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)c1ccc2ccccc2n1,1,DB01232,__SAQUINAVIR,5196438,Completed,NCT00050180,HEALTHY|HIV INFECTIONS,All,18 Years to 60 Years   (Adult),NIH,Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C07D401/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,28.090925891702,1170.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.04,670.8408,166.75,7.0,5.0,5.0,73.76,186.67,13.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,PREGNANCY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1cc(Cl)c(N)cc1OC,1,DB01233,__METOCLOPRAMIDE,6024981,Completed,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,515.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.18,299.796,67.59,4.0,2.0,1.0,32.7,83.52,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03071822,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT01501136,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT04083066,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT04094805,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu hospital, Shandong University, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01356511,"PURPURA, THROMBOCYTOPENIC, IDIOPATHIC",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Shandong University, Jinan, Shandong, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03705273,ASTHMA|CROUP,All,1 Year to 7 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University Medical Center, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01119287,ALLERGIC CONJUNCTIVITIS,All,18 Years to 64 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01211327,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Kabgayi Hospital, Gitarama/Muhanga, Rwanda",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Not yet recruiting,NCT03210545,ADDISON DISEASE,All,20 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Centrum for Endocrinology and Metabolism, Sahlgenska University Hospital, Gothenburg, Sweden",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Enrolling by invitation,NCT03900624,ASTHMA CHILDHOOD,All,5 Years to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Recruiting,NCT03889743,ASTHMA|INFLAMMATION,All,3 Months to 24 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Turku University Hospital, Turku, Finland|Haukeland University Hospital, Bergen, Norway|Akershus University Hospital, Oslo, Norway|Ullevål University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway|University Hospital of North Norway, Tromsø, Norway|St Olavs Hospital, Trondheim, Norway|Karolinska Universitetssjukhuset, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Terminated,NCT02780479,ASTHMA|STATUS ASTHMATICUS|WHEEZES,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wolfson Children Hospital, Jacksonville, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,NCT01241006,ASTHMA|REACTIVE AIRWAY DISEASE,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alameda County Medical Center, Oakland, California, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,DB01234,__DEXAMETHASONE,6284804,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,12.813404792706196,2045.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,392.4611,94.83,5.0,3.0,4.0,40.71,102.49,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
N[C@@H](Cc1ccc(O)c(O)c1)C(=O)O,1,DB01235,__LEVODOPA,6858199,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,49.0,56.4775457401589,1144.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.3,197.1879,103.78,5.0,4.0,1.0,18.91,49.08,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
FCOC(C(F)(F)F)C(F)(F)F,1,DB01236,__SEVOFLURANE,5990176,Completed,NCT02054143,SEVOFLURANE ANESTHESIA,All,18 Years to 60 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of Debrecen Medical and Health Science Center Department of Anesthesiology and Intensive Care, Debrecen, Hungary",0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.8405306063779,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,200.0548,9.23,1.0,0.0,0.0,9.83,23.3,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,"Active, not recruiting",NCT02809677,ASTHMA|MAJOR DEPRESSIVE DISORDER,All,"7 Years to 70 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Texas Southwestern Medical Center Psychoneuroendocrine Research Program, Dallas, Texas, United States",C07D215/227,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,NCT00895921,DIABETES,Male,"40 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"VA San Diego Healthcare System, San Diego, California, United States",C07D215/227,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Active Not Recruiting,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1,1,DB01238,__ARIPIPRAZOLE,5006528,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/227,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,17.61021786895,56.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,448.385,44.81,4.0,1.0,4.0,49.23,124.34,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1
CCCCC[C@H](O)/C=C/[C@H]1[C@H](O)C[C@@H]2O/C(=C\CCCC(=O)O)C[C@@H]21,1,DB01240,__EPOPROSTENOL,8318802,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,69.8166286782069,658.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.83,352.4651,86.99,5.0,3.0,2.0,41.09,99.01,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0
Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,1,DB01241,__GEMFIBROZIL,4126637,Withdrawn,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/235,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,1026.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.61,250.3334,46.53,3.0,1.0,1.0,28.9,71.82,6.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0
CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc21,1,DB01242,__CLOMIPRAMINE,5008262,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,35.8775334195774,561.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,314.8520000000001,6.48,2.0,0.0,3.0,35.73,95.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0
Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1,1,DB01254,__DASATINIB,6596746,Unknown status,NCT02690922,PH+ ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tongji hospital, Wuhan, Hubei, China",C07D491/113,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,39.2615864802152,1137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,488.006,106.51,8.0,3.0,4.0,51.58,133.08,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1
C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2C[C@@H]3CC[C@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,1,DB01256,__RETAPAMULIN,RE39128,Completed,NCT01126268,IMPETIGO|FOLLICULITIS|SECONDARILY INFECTED ECZEMA|MINOR SOFT TISSUE INFECTIONS,All,"9 Months to 98 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Houston Medical Center Building, Houston, Texas, United States",C07D451/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,91.53370705763969,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,517.763,66.84,4.0,1.0,5.0,59.82,145.45,6.0,0.0,1.0,0.0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
C=C[C@]1(C)C[C@@H](OC(=O)CS[C@H]2C[C@@H]3CC[C@H](C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,1,DB01256,__RETAPAMULIN,RE39128,Completed,NCT01064947,ATOPIC DERMATITIS|SECONDARY INFECTION,All,"2 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"DermResearch, PLLC, Louisville, Kentucky, United States",C07D451/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,91.53370705763969,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,517.763,66.84,4.0,1.0,5.0,59.82,145.45,6.0,0.0,1.0,0.0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01260,__DESONIDE,6387383,Completed,NCT02732314,"DERMATITIS, ATOPIC|ECZEMA",All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Research Associates, LLC, Raleigh, North Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,59.0,21.3228197704265,656.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.31,416.5073,93.06,6.0,2.0,5.0,44.59,112.06,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@H]4[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,DB01260,__DESONIDE,6387383,Completed,NCT00690833,ATOPIC DERMATITIS,All,"3 Months and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wake Forest University Health Sciences Dermatology, Winston-Salem, North Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,59.0,21.3228197704265,656.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.31,416.5073,93.06,6.0,2.0,5.0,44.59,112.06,2.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01235819,TYPE 1 DIABETES,All,"12 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Command Hospital, Lucknow, UP, India",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01530178,"DIABETES MELLITUS, TYPE 1",All,"13 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Albert Einstein College of Medicine CRC, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F,1,DB01261,__SITAGLIPTIN,6303661,Completed,NCT01099618,KETOSIS PRONE DIABETES|DIABETES KETOACIDOSIS|HYPERGLYCEMIA,All,"19 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Grady Memorial Hospital, Atlanta, Georgia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,79.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.95,407.3136,77.04,4.0,1.0,3.0,32.66,87.49,5.0,0.0,1.0,0.0,0,1,0,1,1,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT03558412,T-LYMPHOBLASTIC LYMPHOMA,All,"14 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1,1,DB01262,__DECITABINE,5654333,Unknown status,NCT03579082,DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,25.988213310334892,1199.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-2.0,228.2053,120.74,7.0,3.0,2.0,21.15,50.68,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT01200355,ACUTE MYELOGENOUS LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Memorial Sloan Kettering Cancer Center, New York, New York, United States",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC[C@@H]([C@H](C)O)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@@H]5CO[C@@](Cn6cncn6)(c6ccc(F)cc6F)C5)cc4)CC3)cc2)c1=O,1,DB01263,__POSACONAZOLE,5703079,Completed,NCT02805946,ALLOGENEIC STEM CELL TRANSPLANT|ACUTE GRAFT VERSUS HOST DISEASE|ACUTE MYELOID LEUCAEMIA|MYELO DYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Universitaire Ziekenhuizen Leuven, Leuven, Belgium|Radboudumc, Nijmegen, Netherlands",C07D249/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,30.949300806998,12.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,700.7774,111.79,9.0,1.0,7.0,73.83,200.71,12.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Completed,NCT00677300,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dallas VA Medical Center, Dallas, Texas, United States|Parkland Health & Hospital System, Dallas, Texas, United States",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/26,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Completed,NCT01274780,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic, Barcelona, Spain",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Completed,NCT01258439,HIV|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holdsworth House Medical Practice, Sydney, New South Wales, Australia|St Vincent Hospital, Clinical Research Program, Sydney, New South Wales, Australia",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Unknown status,NCT02404233,HIV POSITIVE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Therapeutic Concepts, P.A., Houston, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Terminated,NCT00855413,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Recruiting,NCT03163277,HIV|NEUROCOGNITIVE DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Torino, Torino, Italy",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Not yet recruiting,NCT04183738,HIV-INFECTION/AIDS|HUMAN HERPESVIRUS 4 INFECTIONS|CYTOMEGALOVIRUS INFECTIONS|HUMAN HERPESVIRUS 8 INFECTION|HUMAN PAPILLOMA VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Completed,NCT00630734,HIV INFECTIONS|HYPERLIPIDEMIA,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Denver, Aurora, Colorado, United States",C07D239/26,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Terminated,NCT02503462,AIDS-RELATED DEMENTIA COMPLEX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Unknown status,NCT01013987,HIV-1 ADULTS PATIENTS|AIDS|TRIPLE CLASS FAILURE,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundación Huésped, Ciudad de Buenos Aires, Argentina",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Completed,NCT01928407,HIV-1 INFECTION|IMMUNOSUPPRESSION-RELATED INFECTIOUS DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hopital Zobda Quitman, Fort De France, Martinique, France|Centre Hospitalier D'Argenteuil, Argenteuil, France|Hopital Saint-Jacques, Besancon, France|Hopital Avicenne, Bobigny, France|Hopital Jean Verdier, Bondy, France|Hopital Saint-Andre, Bordeaux, France|Chu Cote de Nacre, Caen, France|Hopital Louis Mourier, Colombes, France|Hopital Le Bocage, Dijon, France|Hopital Raymond Poincare, Garches, France|C.H.D de Vendee, La Roche Sur Yon, France|Hopital Dupuytren, Limoges, France|Hopital Sainte-Marguerite, Marseille, France|Centre Hospitalier de Melun, Melun, France|Hopital L'Archet, Nice, France|Hopital Lariboisiere, Paris, France|Hopital Saint Antoine, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hopital Necker, Paris, France|Hopital Bichat, Paris, France|Hopital Tenon, Paris, France|Hopital Pitie-Salpetriere, Paris, France|Hopital Cochin, Paris, France|Hopital Europeen Georges Pompidou, Paris, France|Hopital Saint-Jean Roussillon, Perpignan, France|Hopital Rene Dubos, Pontoise, France|C.H.R.A, Pringy, France|Hopital Civil, Strasbourg, France|Hopital Gustave Dron, Tourcoing, France|Hopital Bretonneau, Tours, France",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CO[C@H]2OCC[C@@H]12)S(=O)(=O)c1ccc(N)cc1,1,DB01264,__DARUNAVIR,5843946,Unknown status,NCT02337322,ACQUIRED IMMUNE DEFICIENCY SYNDROME VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic of Barcelona, Barcelona, BCN, Spain",C07D239/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,63.245651861434496,169.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.76,547.664,140.42,7.0,3.0,4.0,57.49,142.34,11.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Not yet recruiting,NCT04191278,HIV/AIDS|SMOKING|SMOKING CESSATION|HIV,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Completed,NCT02922387,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|COMMUNITY ACQUIRED PNEUMONIA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Recruiting,NCT04490057,TOBACCO USE CESSATION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University School of Medicine, New Haven, Connecticut, United States|SUNY Downstate STAR Clinic, Brooklyn, New York, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
c1cnc2cc3c(cc2n1)C1CNCC3C1,1,DB01273,__VARENICLINE,6410550,Completed,NCT02233231,ASTHMA,All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.8877389679459,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.39,211.268,37.81,3.0,1.0,4.0,23.12,61.3,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1ccc(C[C@@H](C)NC[C@H](O)c2ccc(O)c(NC=O)c2)cc1,1,DB01274,__ARFORMOTEROL,5795564,Terminated,NCT00819637,ACUTE ASTHMA,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Henry Ford Hospital Emergency Department, Detroit, Michigan, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,29.3722663709727,1132.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.91,344.4049,90.82,5.0,4.0,2.0,36.56,97.87,8.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00442767,TYPE 1 DIABETES,All,"12 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,DB01278,__PRAMLINTIDE,5814600,Completed,NCT00502138,IDDM,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States",A61K38/28,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,51.5493131275796,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-28.0,3949.44,1690.64,59.0,56.0,8.0,395.67,983.93,109.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1
CSCC[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)O)C(C)C)C(C)C)C(C)C,1,DB01284,__TETRACOSACTIDE,4127537,Completed,NCT01371526,ADRENAL FAILURE,All,"16 Years to 66 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom",C07K14/6755,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,17.4130885644469,168.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.95,2933.49,1158.72,46.0,42.0,9.0,309.35,790.98,93.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,1,1,1
CC(Cc1ccc(O)cc1)NCC(O)c1cc(O)cc(O)c1,1,DB01288,__FENOTEROL,4275219,Completed,NCT00460577,"ACUTE BRONCHIAL OBSTRUCTION, ASTHMA",All,5 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigator site - five sites in Caracas, Caracas, Venezuela|Novartis Investigator Site, Maracaibo, Venezuela",C07C309/63,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,20.961416045504,784.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.36,303.3529,92.95,5.0,5.0,2.0,31.75,85.0,6.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,Recruiting,NCT04160026,"MALARIA IN PREGNANCY|ADHERENCE, TREATMENT",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Kenya Medical Research Institute, Kisumu, Kenya",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,Completed,NCT00270530,PLACENTAL MALARIA INFECTION|HIV INFECTIONS|STILLBIRTH|PREMATURITY|NEONATAL DEATHS,Female,18 Years to 50 Years   (Adult),Other|U.S. Fed,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,"Tropical Diseases Research Centre, Ndola, Zambia",1,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,1,DB01299,__SULFADOXINE,4041160,Completed,NCT00144352,MALARIA|HIV|AIDS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CDC KEMRI Research Institute, Kisumu, Kenya",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,19.3186718413109,94.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.72,310.329,116.43,7.0,2.0,2.0,30.01,77.81,4.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,1,DB01319,__FOSAMPRENAVIR,6436989,Completed,NCT00242216,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thomas Street Health Center, Houston, Texas, United States",C07D307/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,55.8533029425655,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.84,585.607,177.72,8.0,4.0,3.0,57.77,144.95,13.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,1,DB01319,__FOSAMPRENAVIR,6436989,Completed,NCT01222611,CHRONIC HIV INFECTION|HCV COINFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Doce de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain",C07D307/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,55.8533029425655,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.84,585.607,177.72,8.0,4.0,3.0,57.77,144.95,13.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(C)CN(C[C@@H](OP(=O)(O)O)[C@H](Cc1ccccc1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)c1ccc(N)cc1,1,DB01319,__FOSAMPRENAVIR,6436989,Completed,NCT01010399,HYPERTRIGLYCERIDEMIA|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Franco Felizarta, MD, Bakersfield, California, United States",C07D307/20,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,55.8533029425655,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.84,585.607,177.72,8.0,4.0,3.0,57.77,144.95,13.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,0
CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@H](CC[C@@]4(C)[C@H]3C[C@H]([N+]3(C)CCCCC3)[C@@H]4OC(C)=O)[C@@]2(C)C[C@@H]1N1CCCCC1,1,DB01339,__VECURONIUM,,Completed,,NEUROMUSCULAR BLOCKADE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.07,557.8274,55.84,3.0,0.0,6.0,66.85,169.31,6.0,0.0,1.0,0.0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,1
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Completed,NCT02246998,HIV-1 INFECTION,All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brussels, Belgium|Ghent, Belgium|Lyon, France|Paris, France|Rennes, France|Tourcoing, France|Dublin, Ireland|Barcelona, Spain|Madrid, Spain|Seville, Spain|Birmingham, United Kingdom|Bournemouth, United Kingdom|Brighton, United Kingdom|Bristol, United Kingdom|Coventry, United Kingdom|Liverpool, United Kingdom|London, United Kingdom|Manchester, United Kingdom|Newcastle, United Kingdom|Sheffield, United Kingdom",A61K49/0452,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Completed,NCT02522338,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"CHU de SAINT-ETIENNE, Saint-etienne, France",A61K49/0452,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC(=O)N(CC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(C(=O)NCC(O)CO)c1I,1,DB01362,__IOHEXOL,4278654,Not Yet Recruiting,,HYPOTHYROIDISM,,,,,"FISABIO, Elche, Alicante, Spain",A61K49/0452,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,24.37832399022561,610.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.8,821.1379,199.89,9.0,8.0,1.0,60.37,148.84,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Completed,NCT01091337,ASTHMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Philippine General Hospital, Manila, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](NC(C)C)[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12,1,DB01366,__PROCATEROL,4616022,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D215/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,328.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.28,290.3575,81.59,4.0,4.0,2.0,31.69,84.58,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
C#CCN[C@@H]1CCc2ccccc21,1,DB01367,__RASAGILINE,5387612,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,20.698576972833106,136.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.26,171.2383,12.03,1.0,1.0,2.0,20.25,54.47,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0
O=C([O-])O.[Na+],1,DB01390,__SODIUM_BICARBONATE,5840737,Completed,NCT02502071,TYPE 1 DIABETES|DIABETIC NEPHROPATHY|DIABETIC KIDNEY DISEASE,All,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,28.32091008028911,11.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.06,84.0066,60.36,3.0,1.0,0.0,3.86,20.34,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(Oc1ccccc1C(=O)O)c1ccccc1O,1,DB01399,__SALSALATE,3954533,Completed,NCT00339833,TYPE 2 DIABETES|DIABETES,All,18 Years to 45 Years   (Adult),NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","NIDDK, Phoenix, Phoenix, Arizona, United States",C06B23/007,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,78.1617692355079,627.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,258.2262,83.83,4.0,2.0,2.0,24.92,67.1,4.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0
CN(C)C(=O)Oc1cc(OC(=O)N(C)C)cc(C(O)CNC(C)(C)C)c1,1,DB01408,__BAMBUTEROL,5709884,Unknown status,NCT02002754,EOSINOPHILIC BRONCHITIS|COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Guangzhou Institute of Respiratory Disease, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,35.680404115074204,498.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.69,367.44,91.34,4.0,2.0,1.0,40.74,98.28,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",A61K9/0075,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21,1,DB01409,__TIOTROPIUM,5478578,Completed,NCT00152984,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"CHU Sart Tilman, Angleur, Belgium|A.Z. VUB, Brussel, Belgium|Boehringer Ingelheim Investigational Site, Genk, Belgium|Boehringer Ingelheim Investigational Site, Hasselt, Belgium|St. Elisabethziekenhuis, Herentals, Belgium|Clinique Reine Astrid, Malmedy, Belgium|Sint-Elisabethziekenhuis, Turnhout, Belgium|VGH Research Pavillion, Vancouver, British Columbia, Canada|BG 034, Room C2027, Winnipeg, Manitoba, Canada|Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Respiratory Research Lab, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Department of Respiratory Medicine, Toronto, Ontario, Canada|Centre de Recherche Clinique -CUSE, Sherbrooke, Quebec, Canada|Hopital Laval, Ste-Foy, Quebec, Canada|Lungemedicinsk Forskning 2B, Aarhus, Denmark|Lungemedicinsk afdeling Y, Hellerup, Denmark|Medicinsk afdeling B0642, Hiller?d, Denmark|Lungemedicinsk Klinik, Hvidovre, Denmark|H:S Bispebjerg Hospital, K?benhavn NV, Denmark|Lungemedicinsk Forskning, Odense C, Denmark|Hopital d'Annecy, Annecy, France|Hopital Prive Antony, Antony cedex, France|Boehringer Ingelheim Investigational Site, Chamalieres, France|Hopital Gabriel Montpied, Clermont Ferrand cedex 1, France|Hopital Ambroise Pare, Marseille, France|Hopital Notre Dame de Bon Secours, Metz cedex 1, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Hopital Arnaud de Villeneuve, Montpellier, France|Boehringer Ingelheim Investigational Site, Nantes, France|Centre Medical Erdre St Augustin, Nantes, France|Boehringer Ingelheim Investigational Site, Nice, France|Hopital Maison blanche, Reims cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Berlin, Germany|MEDARS GmbH, Berlin, Germany|Boehringer Ingelheim Investigational Site, Bonn, Germany|Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|Boehringer Ingelheim Investigational Site, Furth, Germany|Inamed Research GmbH & Co. KG, Gauting, Germany|Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|ClinPharm Internat. GmbH & Co. KG, Gorlitz, Germany|Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg, Germany|Med. Einrichtung der Universitat zu Koln, Koln, Germany|Boehringer Ingelheim Investigational Site, Minden, Germany|Boehringer Ingelheim Investigational Site, Munchen, Germany|Boehringer Ingelheim Investigational Site, Rudersdorf, Germany|A. O. Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, Italy|A.O. S. Martino e Cliniche Universitarie di Genova, Genova, Italy|Universita di Genova, Genova, Italy|A.O. Pisana, Pisa, Italy|Ziekenhuisgroep Twent, Almelo, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Atrium medisch centrum, Heerlen, Netherlands|Ziekenhuigroep Twente, Hengelo, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Maxima Medisch Centrum, Velthoven, Netherlands|Boehringer Ingelheim Investigational Site, Bellville, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Durban, South Africa|Boehringer Ingelheim Investigational Site, George, South Africa|Boehringer Ingelheim Investigational Site, Paarl, South Africa|Boehringer Ingelheim Investigational Site, Pretoria, South Africa|Boehringer Ingelheim Investigational Site, Somerset West, South Africa",A61K9/0075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,16.3617322737633,37.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.8,392.51199999999994,59.06,3.0,1.0,5.0,39.52,109.18,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01333800,ASTHMA,All,6 Years to 15 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hospital San Rafael, Bogotá, Colombia",A61K9/124,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT00806754,"RHINITIS, ALLERGIC, PERENNIAL",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Altana/Nycomed, Encinitas, California, United States|Altana/Nycomed, Los Angeles, California, United States|Altana/Nycomed, Mission Viejo, California, United States|Altana/Nycomed, San Diego, California, United States|Altana/Nycomed, San Jose, California, United States|Altana/Nycomed, Colorado Springs, Colorado, United States|Altana/Nycomed, Denver, Colorado, United States|Altana/Nycomed, Lakewood, Colorado, United States|Altana/Nycomed, Gainesville, Georgia, United States|Altana/Nycomed, Savannah, Georgia, United States|Altana/Nycomed, Stockbridge, Georgia, United States|Altana/Nycomed, Overland Park, Kansas, United States|Altana/Nycomed, Metairie, Louisiana, United States|Altana/Nycomed, Shreveport, Louisiana, United States|Altana/Nycomed, Bethesda, Maryland, United States|Altana/Nycomed, North Dartmouth, Massachusetts, United States|Altana/Nycomed, Novi, Michigan, United States|Altana/Nycomed, Rolla, Missouri, United States|Altana/Nycomed, Papillion, Nebraska, United States|Altana/Nycomed, Skillman, New Jersey, United States|Altana/Nycomed, Raleigh, North Carolina, United States|Altana/Nycomed, Cincinnati, Ohio, United States|Altana/Nycomed, Sylvania, Ohio, United States|Altana/Nycomed, Ashland, Oregon, United States|Altana/Nycomed, Medford, Oregon, United States|Altana/Nycomed, Portland, Oregon, United States|Altana/Nycomed, Pittsburgh, Pennsylvania, United States|Altana/Nycomed, Upland, Pennsylvania, United States|Altana/Nycomed, Charleston, South Carolina, United States|Altana/Nycomed, Dallas, Texas, United States|Altana/Nycomed, San Antonio, Texas, United States|Altana/Nycomed, South Burlington, Vermont, United States|Altana/Nycomed, Newport News, Virginia, United States|Altana/Nycomed, Richmond, Virginia, United States|Altana/Nycomed, Milwaukee, Wisconsin, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01430260,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"handok pharmaceuticals co. LTD, Seoul, Korea, Republic of",A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT01654536,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Associates of Southern California, Mission Viejo, California, United States|CHOC PSF AMC - Division of Allergy, Asthma and Immunology, Orange, California, United States|Allergy Associates Medical Group Inc., San Diego, California, United States|Bensch Research Associates, Stockton, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|DataQuest Medical Research LLC, Lawerenceville, Georgia, United States|Asthma & Allergy Consultants, PC, Lilburn, Georgia, United States|Gordon D Raphael, MD, Bethesda, Maryland, United States|Medical Education and Research Management Services of New England, Gardner, Massachusetts, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Respiratory Medicine Research Institute of Michigan, PLC, Ypsilanti, Michigan, United States|Clinical Research Institute Inc., Minneappolis, Minnesota, United States|The Clinical Research Center, LLC, St. Louis, Missouri, United States|Clinical Research Group of Montanta, Bozeman, Montana, United States|Ocean Allergy & Respiratory Research Center, Brick, New Jersey, United States|Atlantic Research Center, LLC, Ocean, New Jersey, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy and Asthma Center of NC, PA, High Point, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Allergy Assocaites Research Center, Portland, Oregon, United States|Valley Clinical Research Center, Bethlehem, Pennsylvania, United States|Asthma and Allergy Research Associates, Upland, Pennsylvania, United States|National Allergy, Asthma & Uticaria Centers of Charleston, P.A., Charleston, South Carolina, United States|Isis Clinical Research, LLC, Austin, Texas, United States|Sirius Clinical Research LLC, Austin, Texas, United States|Pharmaceutical Research and Consulting Inc., Dallas, Texas, United States|Kerrville Research Associates, PA, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Biogenics Research Institute, San Antonio, Texas, United States|Sylvana Research Associates, San Antonio, Texas, United States|ASTHMA Inc. Clinical Research Center, Seattle, Washington, United States",A61K9/124,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
CC(C)C(=O)OCC(=O)[C@@]12O[C@H](C3CCCCC3)O[C@@H]1C[C@H]1[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]12C,1,DB01410,__CICLESONIDE,5695743,Completed,NCT03839433,BRONCHIAL ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K9/124,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,57.2003531900039,415.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.08,540.697,99.13,6.0,1.0,6.0,60.18,146.28,6.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,1,0,1
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,NCT02747381,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Completed,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)CCCC(C)C)C[C@@H](O)C[C@@H]1O,1,DB01436,__ALFACALCIDOL,4012509,Unknown Status,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23K20/174,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,20.4028830160783,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.68,400.6371,40.46,2.0,2.0,3.0,50.55,124.7,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,0
CN[C@@H](C)Cc1ccccc1,1,DB01577,__METAMFETAMINE,3968245,Recruiting,NCT03825536,HIV-1-INFECTION|METHAMPHETAMINE-DEPENDENCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","San Francisco General Hospital, San Francisco, California, United States",A61K47/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.193309924228402,1437.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,149.2328,12.03,1.0,1.0,1.0,18.04,48.48,3.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Completed,NCT02864706,HEART TRANSPLANTATION,All,"Child, Adult, Older Adult",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Århus N, Denmark|Novartis Investigative Site, Oslo, Norway|Novartis Investigative Site, Göteborg, Sweden|Novartis Investigative Site, Linkoping, Sweden|Novartis Investigative Site, Lund, Sweden",C07D498/18,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,"Active, not recruiting",NCT03525834,RENAL ANGIOMYOLIPOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Wuhan, Hubei, China|Novartis Investigative Site, Shanghai, Shanghai, China|Novartis Investigative Site, Chengdu, Sichuan, China|Novartis Investigative Site, Beijing, China|Novartis Investigative Site, Beijing, China",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB01590,__EVEROLIMUS,5665772,Completed,NCT02429869,HIV|KIDNEY TRANSPLANT|LIVER TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"University of California, San Francisco, San Francisco, California, United States",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,29.109427298301807,997.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.01,958.24,204.66,13.0,3.0,4.0,106.61,261.71,9.0,1.0,0.0,0.0,0,1,1,0,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,0
O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,1,DB01591,__SOLIFENACIN,6017927,Completed,NCT00629642,MULTIPLE SCLEROSIS|NEUROGENIC BLADDER|SPINAL CORD DISEASES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brisbane, Australia|Melbourne, Australia|Perth, Australia|Randwick, Australia|Antwerpen, Belgium|Esneux, Belgium|Fraiture-en-Condroz, Belgium|Gent, Belgium|Leuven, Belgium|Melsbroek, Belgium|Brno, Czechia|Ceske Budejovice, Czechia|Prague, Czechia|Caen, France|Garches, France|Paris, France|Ploemeur, France|Berlin, Germany|Hagenow, Germany|Heidelberg, Germany|Kiel, Germany|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Firenze, Italy|Milan, Italy|Rome, Italy|Torino, Italy|Apeldoorn, Netherlands|Eindhoven, Netherlands|Nijmegen, Netherlands|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|San Juan de Alicante, Alicante, Spain|Badalona, Barcelona, Spain|Getafe, Madrid, Spain|La Coruna, Spain|Cardiff, United Kingdom|Newcastle Upon Tyne, United Kingdom",C07D453/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,28.9122979937986,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.9,362.473,32.78,2.0,0.0,5.0,40.13,106.06,3.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,1
CC1(C)C[C@@H]1C(=O)N/C(=C\CCCCSC[C@H](N)C(=O)O)C(=O)O,1,DB01597,__CILASTATIN,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,358.45300000000015,129.72,6.0,4.0,1.0,38.28,92.85,11.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCC/N=C/N)C[C@H]12,1,DB01598,__IMIPENEM,8487093,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,53.980574549785395,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.19,299.346,116.22,6.0,3.0,2.0,31.1,75.84,6.0,0.0,1.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,1
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,NCT00426348,GLOMERULONEPHRITIS|IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,,ARTERIOSCLEROSIS OBLITERANS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
CC(C)(Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)Sc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1,1,DB01599,__PROBUCOL,4719237,Completed,,GLOMERULONEPHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,23.4583872358775,847.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.92,516.842,40.46,2.0,2.0,2.0,62.35,159.26,8.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT01576731,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Clínic of Barcelona, Barcelona, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT01772940,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cliniques Universitaires de Lubumbashi, Lubumbashi, Katanga, Congo",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Recruiting,NCT02712801,HIV/AIDS AND INFECTIONS,All,up to 1 Day   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Maternal and Child Health Hospital of Guangdong Province, Guangzhou, Guangdong, China|Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China|Maternal and Child Health Hospital of Sichuan Province, Chengdu, Sichuan, China|Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China|Maternal and Child Health Hospital of Yunan Province, Kunming, Yunnan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Unknown status,NCT00122226,HIV INFECTIONS|LIPODYSTROPHY,Male,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single|Primary Purpose: Prevention,"Helsinki University Central Hospital, Helsinki, Finland|Academic Medical Center, Amsterdam, Netherlands|Medisch Centrum Jan van Goyen, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Oosterpark, Amsterdam, Netherlands|Onze Lieve Vrouwe Gasthuis, location Prinsengracht, Amsterdam, Netherlands|Slotervaart ziekenhuis, Amsterdam, Netherlands|VUMC Free University Medical Center, Amsterdam, Netherlands|Ziekenhuis Leyenburg, den Haag, Netherlands|Kennemer Gasthuis, location Elisabeth, Haarlem, Netherlands|Leids Universitair Medisch Centrum, Leiden, Netherlands|Erasmus Universitair Medisch Centrum, Rotterdam, Netherlands|Hospital Clinic, Barcelona, Spain|Royal Free Hospital, London, United Kingdom",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00143689,HIV|MITOCHONDRIAL TOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"McMaster University, Hamilton, Ontario, Canada|University of Ottawa Health Services, Ottawa, Ontario, Canada|Maple Leaf Clinic, Toronto, Ontario, Canada|Clinique Medicale L'Actuel, Montreal, Quebec, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00444379,KAPOSI'S SARCOMA|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Infectious Diseases Institute, Mulago Hospital, Kampala, Uganda",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Terminated,NCT00775606,ACQUIRED IMMUNE DEFICIENCY SYNDROME,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rush University Medical Center, Chicago, Illinois, United States|University of Illinois Medical Center, Chicago, Illinois, United States|Howard Brown Health Center, Chicago, Illinois, United States|University of Chicago Hospital, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00055120,HIV INFECTIONS|AIDS-RELATED OPPORTUNISTIC INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of California, Davis Medical Center, Sacramento, California, United States|University of California, San Diego Antiviral Rese, San Diego, California, United States|San Francisco General Hospital, San Francisco, California, United States|San Mateo County AIDS Program, Stanford, California, United States|Santa Clara Valley Medical Center, Stanford, California, United States|Stanford Univ, Stanford, California, United States|Willow Clinic, Stanford, California, United States|Harbor General/UCLA, Torrance, California, United States|University of Colorado Health Sciences Center, Denver, Denver, Colorado, United States|Univ of Miami, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Cook County Hospital Core Center, Chicago, Illinois, United States|Methodist Hospital of Indiana, Indianapolis, Indiana, United States|Indiana University Hosp, Indianapolis, Indiana, United States|Wishard Hospital, Indianapolis, Indiana, United States|University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Harvard (Massachusetts General Hospital), Boston, Massachusetts, United States|Beth Israel Deaconess - West Campus, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Hennepin County Medical Clinic, Minneapolis, Minnesota, United States|St. Louis Connect Care, St. Louis, Missouri, United States|Washington University (St. Louis), St. Louis, Missouri, United States|Beth Israel Medical Center, New York, New York, United States|NYU/Bellevue, New York, New York, United States|Columbia University, New York, New York, United States|Community Health Network, Inc., Rochester, New York, United States|University of Rochester Medical Center, Rochester, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Case Western Reserve University, Cleveland, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Presbyterian Medical Center - University of PA, Philadelphia, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States|Comprehensive Care Clinic, Nashville, Tennessee, United States|University of Texas, Southwestern Medical Center, Dallas, Texas, United States|Univ of Texas, Galveston, Galveston, Texas, United States|University of Washington (Seattle), Seattle, Washington, United States|University of Puerto Rico, San Juan, Puerto Rico|University of Witwatersrand, Parktown, Johannesburg, South Africa",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00605098,HIV INFECTIONS|PREGNANCY,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Geral de Nova Iguaçu (HGNI), Nova Iguaçu, Rio de Janeiro, Brazil|Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, RJ, Brazil|Hospital dos Servidores do Estado, Rio de Janeiro, Brazil",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT02348177,ACQUIRED IMMUNODEFICIENCY SYNDROME|TUBERCULOSIS,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Children's Infectious Disease Clinical Research Unit; University of Stellenbosch, Cape Town, Western Cape, South Africa|Enhancing Care Foundation; Wendworth Hospital, Durban, South Africa|Perinatal HIV Research Unit, Johannesburg, South Africa|Shandukani Research WRHI, Johannesburg, South Africa|Empilweni Services and Research Unit, Johannesburg, South Africa",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Terminated,NCT01700790,AIDS|TUBERCULOSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto Nacional de Infectologia Evandro Chagas - Fiocruz(INI), Laboratorio de Pesquisa Clinica em Micobacterioses(LAPCLINTB), Rio de Janeiro, RJ, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT01189695,HIV|AIDS|LOPINAVIR|TREATMENT FAILURE,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00866021,HIV/HCV CO-INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain|Hospital Donostia, San Sebastian, Guipuzcoa, Spain|Hospital General Sta. Mª del Rosell, Cartagena, Murcia, Spain|Hospital General de Castellón, Castellón, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital la Paz, Madrid, Spain|Hospital La Princesa, Madrid, Spain|Hospital La Fe, Valencia, Spain|Hospital General Universitario de Valencia, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00810108,HIV/AIDS TREATMENT|HIV INFECTIONS,Female,6 Years to 17 Years   (Child),NIH|Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego - Skaggs School of Pharmacy and School of Medicine, San Diego, California, United States|Children's National Medical Center, Washington, District of Columbia, United States",4,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Terminated,NCT00981318,HIV INFECTIONS|ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barry M. Rodwick, M. D., Safety Harbor, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT00771498,HIV INFECTION|TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label),"University of Espirito Santo, Vitoria, ES, Brazil|Instituto de Pesquisa Clinica Evandro Chagas (IPEC), Rio de Janeiro, RJ, Brazil|Instituto Oswaldo Cruz (IOC), Rio de Janeiro, RJ, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
Cc1cccc(C)c1OCC(=O)N[C@@H](Cc1ccccc1)[C@@H](O)C[C@H](Cc1ccccc1)NC(=O)[C@H](C(C)C)N1CCCNC1=O,1,DB01601,__LOPINAVIR,6037157,Completed,NCT01637558,TUBERCULOSIS|HIV,All,1 Month to 12 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Queen Elizabeth Central Hospital, Blantyre, Malawi|Red Cross Childrens Hospital, Cape Town, Western Cape, South Africa|KIDCRU, Tygerberg Hospital, Department of Paediatrics and Child Health, Stellenbosch University, South Africa., Cape Town, Western Cape, South Africa|Desmond Tutu Centre, Cape Town, Western Cape, South Africa",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,44.584077701800794,282.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.91,628.8008,120.0,5.0,4.0,4.0,68.78,179.36,15.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
C[C@]1(Cn2ccnn2)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O,1,DB01606,__TAZOBACTAM,6207661,Recruiting,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,25.1011314400706,446.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.8,300.291,122.46,7.0,1.0,3.0,26.22,74.82,3.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0
O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1,1,DB01609,__DEFERASIROX,6465504,Completed,,MYELODYSPLASTIC SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,23.4912421199613,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,373.3615,108.47,6.0,3.0,4.0,38.52,125.32,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Completed,NCT00264290,HIV INFECTIONS|CYTOMEGALOVIRUS INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","San Francisco General Hospital - General Clinical Research Center, San Francisco, California, United States",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Withdrawn,NCT00361933,GIANT LYMPH NODE HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)nc(N)[nH]c21,1,DB01610,__VALGANCICLOVIR,6083953,Completed,NCT01255644,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Vienna, Austria",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,40.017248814144004,162.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,354.3617,167.08,9.0,4.0,2.0,34.88,86.6,9.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT00259610,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Unknown status,NCT02714634,RHEUMATOID ARTHRITIS|INSUFFICIENT RESPONSE TO METHOTREXATE.,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Unknown status,NCT02765594,PRIMARY IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peing Union Medical College Hospital, Beijing, China",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Recruiting,NCT03122431,SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)|JUVENILE SLE|CUTANEOUS LUPUS,All,"5 Years to 64 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Not yet recruiting,NCT04316494,ANCA ASSOCIATED VASCULITIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|WEGENER GRANULOMATOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12,1,DB01611,__HYDROXYCHLOROQUINE,4181725,Completed,NCT00413361,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Investigator)|Primary Purpose: Prevention","Chu Pitie Salpetriere, Paris, France|Hopital la Pitié Salpétrière Assistance Publique, Paris, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,32.000657097681604,450.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.87,335.87199999999996,48.39,4.0,2.0,2.0,38.3,97.97,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CCCc1ccccc1)CCCc1ccccc1,1,DB01616,__ALVERINE,5705675,Completed,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",C07C319/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,24.279759337974,67.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.73,281.4351,3.24,1.0,0.0,2.0,35.42,92.67,9.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,1,DB01618,__MOLINDONE,4065453,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,13.831906199305902,165.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,276.374,45.33,3.0,1.0,3.0,32.0,81.06,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
CN(C)CCC(c1ccccc1)c1ccccn1,1,DB01620,__PHENIRAMINE,4000302,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,20.4357379001622,367.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,240.3434,16.13,2.0,0.0,2.0,28.41,76.05,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CN(C)CCC(c1ccccc1)c1ccccn1,1,DB01620,__PHENIRAMINE,4000302,Unknown Status,,SEASONAL ALLERGIC CONJUNCTIVITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,20.4357379001622,367.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,240.3434,16.13,2.0,0.0,2.0,28.41,76.05,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT04144101,RHEUMATOID ARTHRITIS,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
Cc1ccc(-c2ncc(Cl)cc2-c2ccc(S(C)(=O)=O)cc2)cn1,1,DB01628,__ETORICOXIB,5861419,Completed,NCT00927004,OSTEOARTHRITIS|PAIN,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Perth Hospital, Perth, Western Australia, Australia",C07D213/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,18.300170434711106,383.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,358.842,59.92,4.0,0.0,3.0,36.42,95.04,3.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1
OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01638,__SORBITOL,,Completed,NCT02634073,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other,"GSK Investigational Site, Overland Park, Kansas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,182.1718,121.38,6.0,6.0,0.0,17.12,38.4,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1,1,DB01656,__ROFLUMILAST,5712298,Unknown status,NCT01830959,SARCOIDOSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07C235/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,25.298260744573803,549.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.47,403.207,60.45,4.0,1.0,3.0,35.9,93.92,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",C07C51/377,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1,1,DB01751,__TETRAIODOTHYROACETIC_ACID,4490221,Completed,NCT01371526,ADRENAL FAILURE,All,"16 Years to 66 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom",C07C51/377,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,19.9429146389042,24.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,747.8288,66.76,3.0,2.0,2.0,45.76,119.04,4.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(O)CO,1,DB01839,__PROPYLENE_GLYCOL,,Completed,,MYOPIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,76.0944,40.46,2.0,2.0,0.0,8.01,18.97,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)/C=C/c1ccc(O)c(O)c1,1,DB01880,"__3,4-DIHYDROXYCINNAMIC_ACID",3965033,Completed,NCT02556814,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Qilu Hospital, Shandong University, Jinan, Shandong, China",A61K9/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,28.68231380521161,3049.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.67,180.1574,77.76,4.0,3.0,1.0,17.34,47.02,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,DB01914,__D-GLUCOSE,,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.23,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,1,DB02379,__BETA-D-GLUCOSE,3964974,Recruiting,NCT02102243,HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"UT Southwestern Medical Center, Dallas, Texas, United States",C12Q1/54,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,33.380562229203804,1910.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,180.1559,110.38,6.0,5.0,1.0,16.43,35.92,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,1,DB02709,__RESVERATROL,5747536,Completed,NCT03349619,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Biomedicine and Molecular Immunology (IBIM) - National Research Council of Palermo, Palermo, Italy",0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Oc1ccc(/C=C/c2cc(O)cc(O)c2)cc1,1,DB02709,__RESVERATROL,5747536,Unknown status,NCT01997762,GESTATIONAL DIABETES,Female,18 Years to 40 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Manitoba Institute of Child Health, Winnipeg, Manitoba, Canada",0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,19.05583276864,5538.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,228.2433,60.69,3.0,3.0,2.0,24.55,67.46,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)COP(=O)(O)O)c2cc1C,1,DB03247,__FLAVIN_MONONUCLEOTIDE,3960840,Completed,,KERATOCONUS,,,,,"FISABIO, Elche, Alicante, Spain",C07H21/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,41.0686051048276,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.78,456.3438,201.58,11.0,6.0,3.0,42.19,107.14,7.0,1.0,0.0,0.0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0
NC(N)=O,1,DB03904,__UREA,,Unknown status,NCT00771121,ATOPIC ECZEMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,,"Sophiahemmet, Stockholm, Sweden|Sophiahemmet, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(N)=O,1,DB03904,__UREA,,Completed,,DENTIN SENSITIVITY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(N)=O,1,DB03904,__UREA,,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(N)=O,1,DB03904,__UREA,,Unknown Status,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,60.0553,69.11,1.0,2.0,0.0,5.1,13.14,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc3[n+](cc2c1OC)CCc1cc2c(cc1-3)OCO2,1,DB04115,__BERBERINE,3943251,"Active, not recruiting",NCT03029390,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,31 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,13.3719378221318,596.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.18,336.3612,40.8,4.0,0.0,5.0,36.92,93.52,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
O=C(O)CC(O)(CC(=O)O)C(=O)O,1,DB04272,__CITRIC_ACID,8481083,Completed,NCT03578900,XEROSTOMIA|HYPOSALIVATION|QUALITY OF LIFE|SJOGREN'S SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,11.0,56.937514117333,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-1.3,192.1235,132.13,7.0,4.0,0.0,15.54,35.62,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0
OC[C@H]1O[C@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,DB04282,__2-DEOXY-2-FLUORO-Α-D-GLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,182.1469,90.15,5.0,4.0,1.0,15.44,34.23,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC(O)C(=O)O,1,DB04398,__LACTIC_ACID,6248726,Completed,NCT01591993,SKIN IRRITANCY TESTS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Diagnostic","Dermatology Department. Hospital Central ""Dr. Ignacio Morones Prieto"", San Luis Potosí, Mexico",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.79,90.0779,57.53,3.0,2.0,0.0,8.05,18.84,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(O)C(=O)O,1,DB04398,__LACTIC_ACID,6248726,Completed,NCT00881348,HYGIENE,All,18 Years to 60 Years   (Adult),Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sanofi-Aventis Administrative Office, Sao Paulo, Brazil",7,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,104.609950923016,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.79,90.0779,57.53,3.0,2.0,0.0,8.05,18.84,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C13K5/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,NCT00497692,HYGIENE,Female,18 Years to 60 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Sanofi-aventis, São Paulo, Brazil",C13K5/00,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ALCOHOL ABUSE,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O,1,DB04465,__LACTOSE,4001198,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C13K5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,12.813404792706196,54.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,342.2965,189.53,11.0,8.0,2.0,31.32,68.34,4.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
S=P(N1CC1)(N1CC1)N1CC1,1,DB04572,__THIOTEPA,4766149,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,27.532392862276396,109.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.17,189.218,9.03,3.0,0.0,3.0,18.23,50.72,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT01533272,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Clinic de Barcelona, Barcelona, Spain",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Withdrawn,NCT00782301,"HEPATITIS B|HUMAN IMMUNODEFICIENCY VIRUS|HEPATITIS C, CHRONIC",All,"16 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Safety Harbor, Florida, United States|Pfizer Investigational Site, Wilton Manors, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Mt. Vernon, New York, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Bellaire, Texas, United States|Pfizer Investigational Site, Conroe, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Stafford, Texas, United States|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Bydgoszcz, Poland",C07D401/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Recruiting,NCT03163277,HIV|NEUROCOGNITIVE DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Torino, Torino, Italy",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Withdrawn,NCT02990312,HIV|KIDNEY TRANSPLANT|HIV RESERVOIR|CCR5,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of human virology, Baltimore, Maryland, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Unknown status,NCT01013987,HIV-1 ADULTS PATIENTS|AIDS|TRIPLE CLASS FAILURE,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundación Huésped, Ciudad de Buenos Aires, Argentina",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Terminated,NCT00981318,HIV INFECTIONS|ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barry M. Rodwick, M. D., Safety Harbor, Florida, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Unknown status,NCT01235013,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínic i Provincial, Barcelona, Spain",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT03218592,HIV/AIDS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Clinical and Translational Research Center, UNC Hospitals, Chapel Hill, North Carolina, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT03402815,HIV INFECTION WITH OTHER CONDITIONS|CARDIOVASCULAR RISK FACTOR|ATHEROSCLEROSIS|INFLAMMATION,All,"50 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Elisabetta Schiaroli, Perugia, Italy",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT01866267,HUMAN IMMUNODEFICIENCY VIRUS|AIDS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Hope Foundation, Inc., Bellaire, Texas, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT01449006,HUMAN IMMUNODEFICIENCY VIRUS (HIV)|HIV ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND),All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT02881762,HEPATITIS C|HUMAN IMMUNODEFICIENCY VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Human Virology at the University of Maryland School of Medicine, Baltimore, Maryland, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT01327547,HIV COINFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The Office of Dr. Franco Antonio Felizarta, M.D., Bakersfield, California, United States|AIDS Research Alliance, Los Angeles, California, United States|Alameda Health System - Highland Hospital, Oakland, California, United States|University of California Davis Research, Sacramento, California, United States|University of California, Sacramento, California, United States|University of California, San Francisco - Hepatitis/HIV Clinical Trials Group (HHCTG), San Francisco, California, United States|University of California, San Francisco - Mt. Zion Hospital, San Francisco, California, United States|Community AIDS Resource Inc dba Care Resource, Miami, Florida, United States|University of South Florida Health - HIV Clinical Research Unit, Tampa, Florida, United States|Rowan Tree Medical, P.A., Wilton Manors, Florida, United States|Georgia Regents Medical Center, Augusta, Georgia, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Henry Ford Hospital, Detroit, Michigan, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Icahn School of Medicine at Mount Sinai, New York, New York, United States|Mount Sinai Faculty Practice Associates, New York, New York, United States|The Mount Sinai Hospital, New York, New York, United States|New York Medical College, Valhalla, New York, United States|I.D. Consultants, P.A., Charlotte, North Carolina, United States|Kaiser Permanente Sunnybrook Medical Office, Clackamas, Oregon, United States|Kaiser Permanente Northwest, Portland, Oregon, United States|Southwest Infectious Disease Clinical Research Inc., Dallas, Texas, United States|University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, United States|University Health Care Center Downtown, San Antonio, Texas, United States|Fakultni nemocnice Brno, Brno, Czechia|Hopital de la Croix Rousse, Lyon cedex 4, France|Centre Hospitalier Cochin Saint Vincent de Paul, Paris CEDEX 14, France|Hopital Tenon, Service des Maladies Infectieuses, Paris, France|EPIMED - Gesellschaft fuer epidemiologische und klinische Forschung in der Medizin mbH, Berlin, Germany|Universitaetsklinikum Bonn, Immunologische Ambulanz HIV, Bonn, Germany|ifi - Studien und Projekte GmbH, Hamburg, Germany|Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum der Universitaet zu Koeln, Koeln, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Egyesített Szent István és Szent László Kórház Rendelőintézet, Budapest, Hungary|EMC Instytut Medyczny S.A. Przychodnia przy ul. Lowieckiej, Wroclaw, Dolnoslaskie, Poland|Wojewodzki Szpital Obserwacyjno - Zakazny im. Tadeusza Browicza w Bydgoszczy, Bydgoszcz, Poland|SPZOZ Wojewodzki Szpital Zakazny, Warszawa, Poland|Ararat Research Center, Ponce, Puerto Rico|Farmacia UPR-CTU, San Juan, Puerto Rico|University of Puerto Rico - School of Medicine, San Juan, Puerto Rico|Hospital Universitari Vall dHebron, Barcelona, Spain|Hospital Reina Sofia Hospital Provincial, Cordoba, Spain|Hospital Carlos Iii, Madrid, Spain|Hospital Nuestra Señora de Valme, Sevilla, Spain|Consorcio Hospital General Universitario de Valencia, Valencia, Spain|Harrison Wing Research Office, Guys and St. Thomas NHS Foundation Trust, London, United Kingdom|St Stephen's AIDS Trust, London, United Kingdom",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1,1,DB04835,__MARAVIROC,6586430,Completed,NCT01637259,PROTEINURIA|HIV,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label),"Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad de Buenos Aires, Argentina|Hospital General de Agudos J M Ramos Mejia, Buenos Aires, Ciudad de Buenos Aires, Argentina|Fundación IDEAA, Buenos Aires, Ciudad de Buenos Aires, Argentina|St. Vincent's Hospital, Sydney, New South Wales, Australia|Brisbane Sexual Health and HIV Service, Brisbane, Queensland, Australia|Southern Alberta Clinic, Calgary, Alberta, Canada|University Health Network - Toronto General Hospital, Toronto, Ontario, Canada|Clinic Opus/Lori, Montreal, Quebec, Canada|Klinikum der Universitat Zu Koln, Cologne, Germany|Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, MX-Ambulanz, Dusseldorf, Germany|Nagoya Medical Center, Nagoya, Japan|Instituto Nacional de Ciencias Medicas y Nutriciòn Salvador Zubiran, Mexico City, Tlalpan DF, Mexico|Chulalongkorn University Hospital, Bangkok, Thailand|Western General Hospital, Edinburgh, Lothian, United Kingdom|Brighton & Sussex University NHS Trust, Brighton, Sussex, United Kingdom",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,42.9741883816916,47.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,513.6655,63.05,4.0,1.0,5.0,56.02,142.88,8.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1,1,0,1,0,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,NCT02344602,TYPE 1 DIABETES,All,18 Years to 40 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renal Physiology Laboratory, University Health Network, Toronto, Ontario, Canada",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
Cc1nc(-c2ccc(OCC(C)C)c(C#N)c2)sc1C(=O)O,1,DB04854,__FEBUXOSTAT,5614520,Completed,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,25.7910840058317,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.8,316.375,83.21,5.0,1.0,2.0,33.88,93.93,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,NCT00992056,HYPERTENSION,Female,"46 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Clinical Pharmacology Clinical Pharmacology Research Unit (CPRU) 1500 NW 12th Ave 15-West., Miami, Florida, United States",3,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,NCT00775671,METABOLIC SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","Vanderbilt University Medical Center, Nashville, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1,1,DB04861,__NEBIVOLOL,6545040,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,134.442185671163,110.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.44,405.435,70.95,5.0,3.0,4.0,41.98,103.32,6.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01356381,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Novartis Investigative Site, Newcastle Upon Tyne, United Kingdom",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1CCCN1C(=O)CNC12CC3CC(CC(O)(C3)C1)C2,1,DB04876,__VILDAGLIPTIN,WO-2001052825-A2,Completed,NCT01147276,DIABETES|HYPOGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Department of Clinical Sciences Lund, Lund University, Lund, Sweden",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,32.7488,386.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.12,303.3993,76.36,4.0,2.0,4.0,33.17,82.0,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
OCC(CO)N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O,1,DB04878,__VOGLIBOSE,4701559,Unknown status,NCT02097342,TYPE 2 DIABETES MELLITUS|INSULIN SENSITIVITY/RESISTANCE,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Postgraduate Institute of Medical Education & Research, Chandigarh, India",C07D307/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,69.7180640259553,8054.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.3,267.2762,153.64,8.0,8.0,1.0,26.02,59.55,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0
O=C(O)CCCN1CCC(OC(c2ccc(Cl)cc2)c2ccccn2)CC1,1,DB04890,__BEPOTASTINE,6780877,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",C07D401/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,35.3847101583194,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.64,388.88800000000003,62.66,5.0,1.0,3.0,42.18,105.1,8.0,0.0,1.0,0.0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Withdrawn,NCT01359826,SYSTEMIC LUPUS ERYTHEMATOSUS|WIDESPREAD PAIN|FIBROMYALGIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Loma Linda University Medical Center, Loma Linda, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
CCN(CC)C(=O)C1(c2ccccc2)CC1CN,1,DB04896,__MILNACIPRAN,6602911,Completed,NCT01225991,RHEUMATOID ARTHRITIS,All,"50 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA Semel Institute, Los Angeles, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.515801145814,19.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.72,246.354,46.33,2.0,1.0,2.0,28.25,73.81,5.0,0.0,1.0,0.0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1
Cc1ccc(=O)n(-c2ccccc2)c1,1,DB04951,__PIRFENIDONE,7988994,Unknown status,NCT03260556,"SARCOIDOSIS, PULMONARY",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,58.3174192488552,419.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,185.2218,20.31,1.0,0.0,2.0,20.28,57.0,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,NCT02039011,ASTHMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Asthma and Allergy Research Group, University of Dundee, Dundee, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCc1cc2c(cc1CC)CC(NC[C@H](O)c1ccc(O)c3[nH]c(=O)ccc13)C2,1,DB05039,__INDACATEROL,6878721,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,58.3174192488552,28.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.31,392.4907,81.59,4.0,4.0,4.0,44.96,118.1,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0
O=[N+]([O-])c1cn2c(n1)OC[C@@H](OCc1ccc(OC(F)(F)F)cc1)C2,1,DB05154,__PRETOMANID,,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.8,359.2574,91.33,6.0,0.0,3.0,30.26,73.91,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,1,DB05219,__CRISABOROLE,8168614,Recruiting,NCT03539601,ATOPIC DERMATITIS,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dermatology Trial Associates, Bryant, Arkansas, United States|California Dermatology & Clinical Research Institute, Encinitas, California, United States|Park Avenue Dermatology, Orange Park, Florida, United States|Lenus Research & Medical Group, LLC, Sweetwater, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|DS Research, Louisville, Kentucky, United States|Virgo-Carter Pediatrics, Silver Spring, Maryland, United States|M3-Wake Research, Inc., Raleigh, North Carolina, United States|Arlington Research Center Inc, Arlington, Texas, United States|Tanner Clinic, Layton, Utah, United States|Virginia Clinical Research, Inc, Norfolk, Virginia, United States|Hopital Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Klinikum der Universitat Munchen, Munchen, Bayern, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz, Bad Bentheim, Niedersachsen, Germany|Universitatsklinikum Bonn, Bonn, NRW, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany|ISA - Interdisciplinary Study Association GmbH, Berlin, Germany|UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore, L'Aquila, AQ, Italy|DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria, Genova, GE, Italy|Ospedale San Pietro Fatebenefratelli, Roma, RM, Italy|Azienda Ospedaliero - Universitaria Policlinico Tor Vergata, Roma, Rome, Italy|Silmedic sp. z o.o, Katowice, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, Poland|Klinika Ambroziak Sp. z O. O., Warszawa, Poland|ROYALDERM Agnieszka Nawrocka, Warszawa, Poland|Barn och Ungdomskliniken, Orebro, Sweden|Avdelningen for Kliniska Provningar, Orebro, Sweden|Universitatsklinik fuer Dermatologie, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitats-Kinderspital Zurich, Zurich, Switzerland|Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, United Kingdom|NHS Tayside, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom|NHS Tayside, Dundee, Scotland, United Kingdom|Sheffield Children's NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,62.457134643421796,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.6,251.05,62.48,3.0,1.0,3.0,25.9,65.6,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,1,DB05219,__CRISABOROLE,8168614,Recruiting,NCT03832010,ATOPIC DERMATITIS|ECZEMA,All,2 Years to 17 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins Hospital, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,62.457134643421796,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.6,251.05,62.48,3.0,1.0,3.0,25.9,65.6,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1,1,DB05219,__CRISABOROLE,8168614,Recruiting,NCT03868098,"DERMATITIS, ATOPIC",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Innovaderm Research Inc., Montréal, Quebec, Canada",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,36.0,62.457134643421796,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.6,251.05,62.48,3.0,1.0,3.0,25.9,65.6,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nc1ccc(S(=O)(=O)[N-]c2ncccn2)cc1.[Ag+],1,DB05245,__SILVER_SULFADIAZINE,3983209,Completed,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,765.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.19,357.13699999999994,95.17,6.0,1.0,2.0,24.1,63.4,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1,1,DB05316,__PIMAVANSERIN,7115634,Completed,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,69.6523542577876,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.19,427.564,44.81,3.0,1.0,3.0,47.76,122.93,8.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,1
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Completed,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,1,DB05351,__DEXLANSOPRAZOLE,6238994,Withdrawn,,CHEST PAIN,,,,,"FISABIO, Elche, Alicante, Spain",H01L28/84,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,38.5387790303702,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.84,369.36,67.87,4.0,1.0,3.0,34.5,87.61,6.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,METASTATIC HORMONE REFRACTORY PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2c1cccnc1,1,DB05812,__ABIRATERONE,5604213,Recruiting,,CASTRATION-RESISTANT PROSTATIC CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07J41/0005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.1,349.509,33.12,2.0,1.0,5.0,42.04,107.3,1.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CCOC(=O)C(C)=O,1,DB05869,__ETHYL_PYRUVATE,,Unknown Status,,WARTS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.24,116.1152,43.37,2.0,0.0,0.0,11.39,27.51,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,1,DB06145,__SPIRAMYCIN,,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.99,843.065,195.38,15.0,4.0,4.0,91.15,219.25,11.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Completed,NCT01457430,HEREDITARY ANGIOEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Diego Veterans Affairs Medical Center, La Jolla, California, United States|UCLA - David Geffen School of Medicine, Los Angeles, California, United States|Institute for Allergy and Asthma, Wheaton, Maryland, United States|Penn State University, Hershey, Pennsylvania, United States|AARA Research Center, Dallas, Texas, United States",C07K7/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Terminated,NCT01574248,ACE INHIBITOR-ASSOCIATED ANGIOEDEMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Diego, San Diego, California, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",C07K7/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
N=C(N)NCCC[C@H](NC(=O)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H]1Cc2ccccc2CN1C(=O)[C@H](CO)NC(=O)[C@H](Cc1cccs1)NC(=O)CNC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](N)CCCNC(=N)N)C(=O)O,1,DB06196,__ICATIBANT,5648333,Recruiting,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,33.0,25.2654058604899,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.2,1304.54,516.22,23.0,18.0,7.0,135.1,363.79,30.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
Cn1c(=O)cc(N2CCC[C@@H](N)C2)n(Cc2ccccc2C#N)c1=O,1,DB06203,__ALOGLIPTIN,5965584,Completed,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,18.103041130208002,32.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.66,339.3916,93.67,5.0,1.0,3.0,35.44,104.26,3.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0
CC[C@@H](c1cccc(O)c1)[C@@H](C)CN(C)C,1,DB06204,__TAPENTADOL,6071970,Terminated,,PERIPHERAL NEUROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,185.0,59.9930183371321,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.47,221.3385,23.47,2.0,1.0,1.0,26.58,69.56,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
O=C(O)CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]4[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]5[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]6[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]7[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]8[C@@H](CSCCC(=O)O)O[C@H](O[C@@H]9[C@@H](CSCCC(=O)O)O[C@H](O[C@H]1[C@H](O)[C@H]2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O,1,DB06206,__SUGAMMADEX,7265099,Completed,,NEUROMUSCULAR BLOCKADE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,84.8970204726996,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-0.69,2002.12,769.76,48.0,24.0,9.0,189.62,432.64,40.0,1.0,0.0,0.0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0
CC(=O)Oc1cc2c(s1)CCN(C(C(=O)C1CC1)c1ccccc1F)C2,1,DB06209,__PRASUGREL,5288726,Completed,NCT01305369,CHRONIC ASTHMA,All,"18 Years to 74 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medicina 3 Ospedale San Paolo Dipartimento di Medicina Chirurgia e Odontoiatria, Università di Milano, Milan, Italy",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,56.0,17.478798332614602,25.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.67,373.441,46.61,3.0,0.0,4.0,37.7,96.81,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Completed,NCT01098487,"PURPURA, THROMBOCYTOPAENIC, IDIOPATHIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Caen cedex 9, France|GSK Investigational Site, Créteil, France|GSK Investigational Site, Pessac Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Shatin, New Territories, Hong Kong|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Vicenza, Veneto, Italy|GSK Investigational Site, Seongnam-si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, St Petersburg, Russian Federation",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,NCT04518475,PRIMARY IMMUNE THROMBOCYTOPENIA,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Not yet recruiting,NCT04102033,IMMUNE THROMBOCYTOPENIA,All,1 Year to 17 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Completed,NCT00888901,IDIOPATHIC THROMBOCYTOPENIC PURPURA,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Recruiting,,APLASTIC ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O,1,DB06210,__ELTROMBOPAG,6280959,Withdrawn,,THROMBOCYTOPAENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,53.0,16.0331834329246,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.02,442.4666,114.59,7.0,3.0,4.0,47.7,126.48,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)[C@H](C)[C@H]12,1,DB06211,__DORIPENEM,5317016,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C307/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,21.5199490749296,64.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,420.504,162.06,8.0,5.0,3.0,42.37,99.88,6.0,0.0,1.0,0.0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,ADVANCED CANCERS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCC[C@@H](O)c3cc(Cl)ccc32)c(C)c1,1,DB06212,__TOLVAPTAN,5753677,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,78.0,35.3847101583194,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.14,448.941,69.64,3.0,2.0,4.0,48.16,129.16,3.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,NCT01019486,CORONARY ARTERY DISEASE|TYPE 1 DIABETES MELLITUS,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,NCT00862641,"ASTHMA|CORONARY ARTERY DISEASE|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Montgomery, Alabama, United States|Anaheim, California, United States|Encinitas, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Long Beach, California, United States|Mission Viejo, California, United States|Roseville, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Deland, Florida, United States|Miami, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Stockbridge, Georgia, United States|Aurora, Illinois, United States|Topeka, Kansas, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|No. Dartmouth, Massachusetts, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Papillion, Nebraska, United States|Brick, New Jersey, United States|Raleigh, North Carolina, United States|Chardon, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma, Oklahoma, United States|Medford, Oregon, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1,1,DB06213,__REGADENOSON,6403567,Completed,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07H19/16,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,35.64754923099029,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.89,390.35400000000004,186.46,10.0,5.0,4.0,37.48,95.48,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,OSTEONECROSIS,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
[Fe+2].[Fe+3].[Fe+3].[O-2].[O-2].[O-2].[O-2],1,DB06215,__FERUMOXYTOL,6599498,Recruiting,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",B82Y5/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,40.674346495821204,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.77,231.53099999999998,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
CN1CC2c3ccccc3Oc3ccc(Cl)cc3C2C1.O=C(O)/C=C\C(=O)O,1,DB06216,__ASENAPINE,5763476,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,19.9100597548204,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.72,401.84,12.47,1.0,0.0,4.0,30.9,81.65,2.0,0.0,1.0,0.0,0,0,1,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0
O=C(NC[C@H]1CN(c2ccc(N3CCOCC3=O)cc2)C(=O)O1)c1ccc(Cl)s1,1,DB06228,__RIVAROXABAN,7157456,Completed,NCT02116036,ANTIPHOSPHOLIPID ANTIBODY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University of Alberta Hospital, Edmonton, Alberta, Canada|Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada|Hamilton General Hospital, Hamilton, Ontario, Canada|St. Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada|The Ottawa Hospital, Ottawa, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,30.0,72.7078584775868,200.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.74,435.881,88.18,5.0,1.0,4.0,43.41,104.74,5.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Recruiting,NCT03789422,CHRONIC SPONTANEOUS URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CHU Grenoble-Alpes, Grenoble, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00826943,ALLERGIC RHINITIS,All,"18 Years to 77 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Vanderbilt University Asthma, Sinus, and Allergy Clinic, Nashville, Tennessee, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT01586091,PRURITUS|CHRONIC URTICARIA|ALLERGIC RHINITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","University of Berlin Charité, Department of Dermatology and Allergy, Berlin, Germany",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00894231,PERENNIAL ALLERGIC RHINITIS,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AAADRS, Coral Gables, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00160680,"RHINITIS, ALLERGIC, PERENNIAL",,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Genova, Italy",4,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00884325,ATOPIC DERMATITIS|PRURITUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DermResearch, PLLC, Louisville, Kentucky, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00359138,HYPERSENSITIVITY,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT01250652,CHRONIC URTICARIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical University Sofia, Department of Allergology, Sofia, Bulgaria",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,DB06282,__LEVOCETIRIZINE,5698558,Completed,NCT00264303,CHRONIC IDIOPATHIC URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Brugge, Belgium|Brussels, Belgium|Liege, Belgium|Merksem, Belgium|Sint-Niklaas, Belgium|Woluwe-St-Lamb, Belgium|Bernay, France|Besancon, France|Hyeres, France|Les Milles, France|Marseille, France|Montpellier, France|Nancy, France|Nantes, France|Nice, France|Nimes, France|Paris, France|Poitiers, France|Quimper, France|Saint-Mande, France|Troyes, France|Valence, France|Villejuif, France|Augsburg, Germany|Berlin, Germany|Dresden, Germany|Dusseldorf, Germany|Erlangen, Germany|Gottingen, Germany|Hamburg, Germany|Hannover, Germany|Koln, Germany|Leipzig, Germany|Mahlow, Germany|Mainz, Germany|Munchen, Germany|Viersen, Germany|Caserta, Italy|Catania, Italy|Cesena, Italy|Genova, Italy|Modena, Italy|Palermo, Italy|Pavia, Italy|Roma, Italy|Siena, Italy|Udine, Italy|Verona, Italy|Johor Bharu, Malaysia|Kelantan, Malaysia|Kuala Lumpur, Malaysia|Negeri Sembilan, Malaysia|Perak, Malaysia|Pulau Pinang, Malaysia|Sarawak, Malaysia|Brasov, Romania|Bucharest, Romania|Dolj, Romania|Sibiu, Romania|Cape Town, South Africa|Durban, South Africa|Lenasia, South Africa|Albacete, Spain|Barcelona, Spain|Coruna, Spain|Granada, Spain|Madrid, Spain|Malaga, Spain|Murcia (El Palmar), Spain|Oviedo, Spain|Santiago de Compostela, Spain|Sevila, Spain|Valencia, Spain|Amersham, United Kingdom|Cardiff, United Kingdom|Irvine, United Kingdom|Leicester, United Kingdom|London, United Kingdom|Nuneaton, United Kingdom|Salford, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,10.6121275590874,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.98,388.89,53.01,5.0,1.0,3.0,41.93,106.87,8.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C2)CC(=O)[C@H](C)/C=C(\C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)/C=C/C=C/C=C/1C,1,DB06287,__TEMSIROLIMUS,5362718,Completed,NCT01180049,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mercy Research Institute, Miami, Florida, United States|Veterans Affairs New Jersey Healthcare System-Hematology/Oncology Section (111), East Orange, New Jersey, United States|Mercy Clinic Oklahoma Communities dba Mercy Clinic Oncology/Hematology-McAuley, Oklahoma City, Oklahoma, United States|Mercy Hospital Oklahoma City-Oncology Infusion, Oklahoma City, Oklahoma, United States|Amy Shen, RPh, Seattle, Washington, United States|VA Puget Sound Health Care System, Seattle, Washington, United States|St George Hospital, Kogarah, New South Wales, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Royal Hobart Hospital, Hobart, Tasmania, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czech Republic, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|CHU de Nancy, Vandoeuvre les Nancy, France|Klinik fuer Onkologie und Haematologie, Medizinische Klinik IV, Aachen, Germany|Klinikum Johannes-Gutenberg -Universitaet, III. Medizinische Klinik und Poliklinik, Mainz, Germany|Presidio Ferrarotto - A.O.U. - PoliclinicoVittorio Emanuele, Catania, Italy|Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Modena, Italy|Struttura Complessa di Ematologia, Dipartimento di Oncologia ed Ematologia-, Torino, Italy|Severance Hospital, Yonsei University, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Malopolskie Centrum Medyczne S.C., Krakow, Poland|Institutul Clinic Fundeni Bucuresti, Sectia II Hematologie, Bucuresti, Romania|Spitalul Clinic Coltea, Clinica de Hematologie, Bucuresti, Romania|Spitalul Universitar de Urgenta Bucuresti, Clinica de Hematologie, Bucuresti, Romania|Republican Clinical Oncology Dispensary of the Ministry of Healthcare of Tatarstan Republic, Kazan, Russian Federation|GBOU VPO ""First Saint-Petersburg State Medical University n.a. I.P.Pavlov"", Saint-Petersburg, Russian Federation|Institute of Pediatric Hematology and Transplantology R.M.Gorbacheva, Saint-Petersburg, Russian Federation|Clinical Centre of Serbia,Clinic for Hematology, Belgrade, Serbia|Oncology Institute of Vojvodina, Sremska Kamenica, Serbia",C07D498/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,6.7023963531078605,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,1030.2871,241.96,14.0,4.0,4.0,112.71,277.07,11.0,1.0,0.0,0.0,0,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,1,DB06290,__SIMEPREVIR,7671032,Withdrawn,NCT02206932,"HEPATITIS C, CHRONIC|HIV CDC CATEGORY A1",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,57.0,61.0772295118996,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.69,749.939,156.89,9.0,2.0,7.0,80.38,206.95,7.0,0.0,1.0,0.0,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT04014192,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Recruiting,NCT02981069,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Science Center, San Antonio, Texas, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02962492,EVALUATE KETOGENIC STRESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT03338855,"DIABETES MELLITUS, TYPE 2|SKELETAL MUSCLE INSULIN SENSITIVITY",All,"40 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","Research Site, Maastricht, Netherlands",A61K47/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Unknown status,NCT02211742,FASTING GLUCOSE|GLUCOSE EXCURSION|GLYCEMIC CONTROL,Male,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical University Innsbruck, Department of Internal Medicine I, Innsbruck, Tirol, Austria",A61K47/12,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1,1,DB06292,__DAPAGLIFLOZIN,6956026,Completed,NCT02700334,PREDIABETES|IMPAIRED FASTING GLUCOSE|IMPAIRED GLUCOSE TOLERANCE,All,30 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico",A61K47/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,68.0,93.3407256822522,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.52,408.87300000000016,99.38,6.0,4.0,3.0,42.36,104.93,6.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,NK/T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,NK/T-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1cc(F)ccc1NC(=O)c1ccc(CNC(=O)/C=C/c2cccnc2)cc1,1,DB06334,__TUCIDINOSTAT,,Recruiting,,PERIPHERAL T CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,390.418,97.11,4.0,3.0,3.0,41.27,112.68,6.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Unknown status,NCT02307695,TYPE 1 DIABETES,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,"DIABETES MELLITUS, NON-INSULIN-DEPENDENT",,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,1,DB06335,__SAXAGLIPTIN,6414126,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,20.8957062773362,401.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.88,315.41,90.35,4.0,2.0,5.0,34.22,83.99,2.0,0.0,1.0,0.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Completed,NCT02602704,RHEUMATOID ARTHRITIS,Female,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hanyang University, Seoul, Korea, Republic of",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
Cc1c(-c2ccc(O)cc2)n(Cc2ccc(OCCN3CCCCCC3)cc2)c2ccc(O)cc12,1,DB06401,__BAZEDOXIFENE,5998402,Suspended,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,107.0,32.0992217499332,283.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.03,470.61300000000006,57.86,4.0,2.0,5.0,54.06,141.9,7.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1
NC(=O)C[S@@](=O)C(c1ccccc1)c1ccccc1,1,DB06413,__ARMODAFINIL,4927855,Completed,NCT00737204,HIV INFECTIONS|FATIGUE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,39.754409741473104,527.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.75,273.35,60.16,2.0,1.0,2.0,28.2,77.39,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,1,DB06414,__ETRAVIRINE,6878717,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",5,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,65.34836444280171,123.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.67,435.277,120.64,6.0,2.0,3.0,41.09,111.87,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,1,DB06414,__ETRAVIRINE,6878717,Completed,NCT01121809,HIV-1 INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospitales Universitarios Virgen del Rocio, Sevilla, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,65.34836444280171,123.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.67,435.277,120.64,6.0,2.0,3.0,41.09,111.87,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,1,DB06414,__ETRAVIRINE,6878717,Terminated,NCT00855413,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,65.34836444280171,123.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.67,435.277,120.64,6.0,2.0,3.0,41.09,111.87,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0
Cc1cc(C#N)cc(C)c1Oc1nc(Nc2ccc(C#N)cc2)nc(N)c1Br,1,DB06414,__ETRAVIRINE,6878717,Withdrawn,NCT00782301,"HEPATITIS B|HUMAN IMMUNODEFICIENCY VIRUS|HEPATITIS C, CHRONIC",All,"16 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Clearwater, Florida, United States|Pfizer Investigational Site, Orlando, Florida, United States|Pfizer Investigational Site, Safety Harbor, Florida, United States|Pfizer Investigational Site, Wilton Manors, Florida, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, Atlanta, Georgia, United States|Pfizer Investigational Site, New Orleans, Louisiana, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Worcester, Massachusetts, United States|Pfizer Investigational Site, Mt. Vernon, New York, United States|Pfizer Investigational Site, Tulsa, Oklahoma, United States|Pfizer Investigational Site, Bellaire, Texas, United States|Pfizer Investigational Site, Conroe, Texas, United States|Pfizer Investigational Site, Dallas, Texas, United States|Pfizer Investigational Site, Stafford, Texas, United States|Pfizer Investigational Site, Vancouver, British Columbia, Canada|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Bydgoszcz, Poland",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,65.34836444280171,123.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.67,435.277,120.64,6.0,2.0,3.0,41.09,111.87,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0
COCCCN1CCC(NC(=O)c2cc(Cl)c(N)c3c2OCC3)CC1,1,DB06480,__PRUCALOPRIDE,6413988,Unknown Status,,GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,8.18086613688166,98.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.09,367.87,76.82,5.0,2.0,3.0,39.08,100.67,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,1
Cc1ccc(Nc2nccc(N(C)c3ccc4c(C)n(C)nc4c3)n2)cc1S(N)(=O)=O,1,DB06589,__PAZOPANIB,7105530,Recruiting,,SOFT TISSUE SARCOMA ADULT,,,,,"FISABIO, Elche, Alicante, Spain",C07D231/56,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,56.773239696913606,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.59,437.51800000000003,119.03,7.0,2.0,4.0,45.41,132.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0
CCO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1,1,DB06590,__CEFTAROLINE_FOSAMIL,6417175,Completed,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/65613,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,25.0682765559867,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.79,684.67,223.24,13.0,4.0,5.0,63.9,171.63,11.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1
Cc1[nH]c2ccccc2c1CCNCc1ccc(/C=C/C(=O)NO)cc1,1,DB06603,__PANOBINOSTAT,6552065,Recruiting,NCT02386800,PRIMARY MYELOFIBROSIS|CHRONIC IDIOPATHIC MYELOFIBROSIS|POST POLYCYTHEMIA VERA MYELOFIBROSIS|POST ESSENTIAL THROMBOCYTHAEMIA MYELOFIBROSIS|STEROID REFRACTORY GRAFT VERSUS HOST DISEASE,All,"1 Month and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Cape Town, Western Province, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Bangkok, Bangkoknoi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",C07D471/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,19.680075566233302,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.16,349.434,77.15,3.0,4.0,3.0,38.94,105.5,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,Completed,NCT02958969,VENOUS THROMBOEMBOLISM|MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
COc1ccc(-n2nc(C(N)=O)c3c2C(=O)N(c2ccc(N4CCCCC4=O)cc2)CC3)cc1,1,DB06605,__APIXABAN,6413980,"Active, not recruiting",NCT02295475,ANTIPHOSPHOLIPID SYNDROME|THROMBOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The James Comprehensive Cancer Center, Columbus, Ohio, United States|Intermountain Medical Center, Murray, Utah, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,30.325058009404696,179.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,459.4971,110.76,5.0,1.0,5.0,49.62,126.9,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
Nc1ccncc1,1,DB06637,__DALFAMPRIDINE,5540938,Unknown status,NCT02259361,MULTIPLE SCLEROSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Multiple Sclerosis Center, Tel-hashomer, Ramat-gan, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,21.191400234091,6.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.08,94.1145,35.88,2.0,2.0,1.0,9.66,40.09,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,DB06663,__PASIREOTIDE,6225284,Completed,NCT03080181,CUSHING DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,40.05010369822779,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,1047.2062,281.2,10.0,9.0,8.0,111.29,286.66,18.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
N#Cc1ccc2[nH]cc(CCCCN3CCN(c4ccc5oc(C(N)=O)cc5c4)CC3)c2c1,1,DB06684,__VILAZODONE,5532241,Withdrawn,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,21.0928355818394,62.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,441.5249,102.29,4.0,2.0,5.0,50.03,129.71,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1
[N-]=[N+]=O,1,DB06690,__NITROUS_OXIDE,,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.45,44.0128,51.21,2.0,0.0,0.0,2.55,27.67,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1cc(C(C)(C)C)cc(C)c1CC1=NCCN1,1,DB06694,__XYLOMETAZOLINE,3933999,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.1011314400706,156.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.68,244.3752,24.39,2.0,1.0,2.0,29.85,77.82,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0
CCCCCCOC(=O)/N=C(/N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1,1,DB06695,__DABIGATRAN_ETEXILATE,6087380,Completed,,VENOUS THROMBOEMBOLISM,,,,,"FISABIO, Elche, Alicante, Spain",C07D277/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,28.715168689295396,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.17,627.7332,154.03,8.0,2.0,4.0,70.65,176.43,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Terminated,NCT01728961,HIV INFECTION|MALARIA,All,3 Years to 12 Years   (Child),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"College of Med. JHU CRS (30301), Blantyre, Malawi|University of North Carolina Lilongwe (12001), Lilongwe, Malawi|Makerere University - JHU Research Collaboration (30293), Kampala, Uganda",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT00869700,HIV INFECTIONS|MALARIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groote Schuur Hospital, Ward J51, Old Main Building, Cape Town, Western Province, South Africa",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT00885287,"MALARIA, FALCIPARUM|HIV INFECTIONS",All,"15 Years to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Muheza Designated District Hospital, Muheza, Tanga Region, Tanzania",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,"Active, not recruiting",NCT03453840,UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA,All,6 Months to 10 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MGH campus, Busia, Uganda|IDRC- Tororo Research Clinic and Tororo District Hospital, Tororo, Uganda",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT04531072,DRUG INTERACTION,All,"18 Years to 70 Years   (Adult, Older Adult)",U.S. Fed|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Apin (Aids Prevention Initiatives in Nigeria) clinic, Lagos University Teaching Hospital, Suru Lere, Lagos State, Nigeria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,PLASMODIUM FALCIPARUM,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CO[C@H]1O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@H]1C)[C@]42OO3,1,DB06697,__ARTEMETHER,,Completed,NCT00790881,MALARIA|HIV,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groote Schuur Hospital, Research ward, Cape Town, South Africa",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.02,298.3746,46.15,5.0,0.0,4.0,32.12,74.66,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Suspended,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(NC(=O)[C@@H]2CC(=O)NC(=O)N2)cc1)C(=O)N[C@H](Cc1ccc(NC(N)=O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O,1,DB06699,__DEGARELIX,5925730,Terminated,,RECURRENT PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,27.2695537896055,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.66,1632.29,512.87,18.0,17.0,8.0,168.98,431.13,41.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,1,1,0,1,0,1
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
CN(C)CC(c1ccc(O)cc1)C1(O)CCCCC1,1,DB06700,__DESVENLAFAXINE,6673838,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,22.801289554200203,131.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.6,263.3752,43.7,3.0,2.0,2.0,30.29,78.54,4.0,0.0,1.0,0.0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,1,DB06701,__DEXMETHYLPHENIDATE,5908850,Completed,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,25.95535842625101,8.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.47,233.3062,38.33,2.0,1.0,2.0,26.24,66.73,4.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
O=C([O-])C[N+]12CC[N+]3(CC(=O)[O-])CC[N+]4([C@@H](CO)[C@@H](O)CO)CC[N+](CC(=O)[O-])(CC1)[Gd-]234,1,DB06703,__GADOBUTROL,5980864,Completed,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D257/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,103.722869052752,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,604.72,181.08,9.0,3.0,4.0,45.39,143.47,10.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0
NC(N)=NCc1cccc(I)c1,1,DB06704,__IOBENGUANE,4584187,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61K51/0406,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,60.6829709028932,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.53,275.0896,64.4,3.0,2.0,1.0,21.93,58.32,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,1,DB06708,__LUMEFANTRINE,5677331,Unknown status,NCT00620438,HIV INFECTIONS|TUBERCULOSIS,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Makerere University, Kampala, Uganda",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.7442041931045,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.34,528.94,23.47,2.0,1.0,4.0,60.69,160.81,10.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,1,DB06708,__LUMEFANTRINE,5677331,Completed,NCT00619944,HIV INFECTION,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Infectious Diseases Institute, Faculty of Medicine, Makerere University, Kampala, Uganda",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.7442041931045,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.34,528.94,23.47,2.0,1.0,4.0,60.69,160.81,10.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C/c1ccc(Cl)cc1,1,DB06708,__LUMEFANTRINE,5677331,Completed,NCT00790881,MALARIA|HIV,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groote Schuur Hospital, Research ward, Cape Town, South Africa",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,42.7442041931045,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.34,528.94,23.47,2.0,1.0,4.0,60.69,160.81,10.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CC(=O)OC(C)C[N+](C)(C)C,1,DB06709,__METHACHOLINE,4059686,Not yet recruiting,NCT03105843,ASTHMA|COUGH|COUGH VARIANT ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Kingston Health Sciences Centre, Kingston, Ontario, Canada",A61K9/2027,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,26.021068194418696,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.7,160.234,26.3,1.0,0.0,0.0,18.43,55.76,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)C[N+](C)(C)C,1,DB06709,__METHACHOLINE,4059686,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",A61K9/2027,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,26.021068194418696,220.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.7,160.234,26.3,1.0,0.0,0.0,18.43,55.76,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
c1ccc2c(CC3=NCCN3)cccc2c1,1,DB06711,__NAPHAZOLINE,3933999,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,25.1011314400706,530.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.44,210.2744,24.39,2.0,1.0,3.0,23.77,65.52,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0
[I-].[K+],1,DB06715,__POTASSIUM_IODIDE,,Completed,NCT00946296,GRAVES DISEASE|HYPERTHYROIDISM,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"UMASS Memorial Health Care, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.2,166.0028,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Recruiting,NCT02370550,SJOGREN'S SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Peking University People's Hospital, Beijing, Beijing, China",A61K33/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT03089216,TOOTH BLEACHING|TOOTH SENSITIVITY,All,18 Years to 35 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61K33/10,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].[Ca+2],1,DB06724,__CALCIUM_CARBONATE,5989588,Completed,NCT00785473,"MULTIPLE SCLEROSIS, OSTEOPOROSIS",All,18 Years to 50 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","University Hospital of North Norway, Tromsø, Norway",A61K33/10,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,25.7582291217478,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,100.087,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(O)COC(=O)Cc1ccccc1Nc1c(Cl)cccc1Cl,1,DB06736,__ACECLOFENAC,4548952,Completed,NCT04144101,RHEUMATOID ARTHRITIS,All,"20 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,19.252962073143106,222.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.88,354.18,75.63,4.0,2.0,2.0,32.76,86.32,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,1,DB06766,__ALCAFTADINE,5468743,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,23.7212263085484,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,307.3895,38.13,3.0,0.0,4.0,34.68,102.88,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1
CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1,1,DB06766,__ALCAFTADINE,5468743,Unknown status,NCT01808768,ALLERGIC CONJUNCTIVITIS|RHINOCONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"STARx Research Center, Edison, New Jersey, United States|STARx, Springfield, New Jersey, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,23.7212263085484,9.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.09,307.3895,38.13,3.0,0.0,4.0,34.68,102.88,1.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,1,DB06769,__BENDAMUSTINE,8436190,Completed,NCT01056510,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pori, Finland|Vantaa, Finland|Argenteuil, France|Avignon, France|Blois, France|Bordeaux, France|Brest, France|La Roche Sur Yon, France|La Tronche, France|Le Mans, France|Lens, France|Limoges, France|Lyon, France|Marseille, France|Mulhouse, France|Nice, France|Nimes, France|Paris, France|Paris, France|Perpignan, France|Pierre Benite, France|Salouel, France|Coimbra, Portugal|Lisboa, Portugal|Lisboa, Portugal|Porto, Portugal|Porto, Portugal|Vitoria, Alava, Spain|Elche, Alicante, Spain|Jerez de La Frontera, Cadiz, Spain|Torrelavega, Cantabria, Spain|La Coruna, La Coruña, Spain|Alcorcon, Madrid, Spain|Cartagena, Murcia, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|Huelva, Spain|Leon, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Malaga, Spain|Murcia, Spain|Murcia, Spain|Salamanca, Spain|Sevilla, Spain|Tarragona, Spain|Valencia, Spain|Zaragoza, Spain|Falun, Sweden|Kristianstad, Sweden|Luleå, Sweden|Sundsvall, Sweden|Uddevalla, Sweden|Umea, Sweden|Uppsala, Sweden|Tunis, Tunisia|Ankara, Turkey|Ankara, Turkey|Ankara, Turkey|Bursa, Turkey|Edirne, Turkey|Istanbul, Turkey|Istanbul, Turkey|Izmir, Turkey|Kayseri, Turkey|Kocaeli, Turkey|Samsun, Turkey|Blackpool, United Kingdom|Bournemouth, United Kingdom|Edinburgh, United Kingdom|Leeds, United Kingdom|London, United Kingdom|Maidstone, United Kingdom|Manchester, United Kingdom|Manchester, United Kingdom|Oxford, United Kingdom|Romford, United Kingdom|Somerset, United Kingdom|Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,1,DB06769,__BENDAMUSTINE,8436190,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,87.78825027207952,515.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.07,358.26300000000015,58.36,4.0,1.0,2.0,38.19,92.92,9.0,0.0,1.0,0.0,1,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Active Not Recruiting,,METASTATIC HORMONE REFRACTORY PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
CO[C@H]1C[C@H]2OC[C@@]2(OC(C)=O)[C@H]2[C@H](OC(=O)c3ccccc3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C(C)=C([C@@H](OC)C(=O)[C@]12C)C3(C)C,1,DB06772,__CABAZITAXEL,5438072,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,20.2714634797429,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.69,835.9324,202.45,10.0,3.0,6.0,86.25,213.4,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,1,1,0,1,0,0
COc1cc(CNC(=O)CCCC/C=C/C(C)C)ccc1O,1,DB06774,__CAPSAICIN,6239180,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,41.4300088297501,241.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.8,305.4119,58.56,3.0,2.0,1.0,36.32,90.32,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1
CCNC(=NCCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCCN=C(NCC)NCC)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@@H](Cc1cccnc1)NC(=O)[C@@H](Cc1ccc(Cl)cc1)NC(=O)[C@@H](Cc1ccc2ccccc2c1)NC(C)=O)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(N)=O)NCC,1,DB06785,__GANIRELIX,5767082,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",C07K7/23,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,60.4529867143062,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.42,1570.35,451.49,20.0,16.0,6.0,170.37,423.46,44.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Completed,,NEUROENDOCRINE TUMOURS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Recruiting,,NEUROENDOCRINE TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
CC(C)C1NC(=O)C(CCCCN)NC(=O)C(Cc2c[nH]c3ccccc23)NC(=O)C(Cc2ccc(O)cc2)NC(=O)C(NC(=O)C(N)Cc2ccc3ccccc3c2)CSSCC(C(=O)NC(C(N)=O)C(C)O)NC1=O,1,DB06791,__LANREOTIDE,5595760,Unknown Status,,CONGENITAL HYPERINSULINISM,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/284,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,22.505595597445502,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.87,1096.33,355.08,12.0,13.0,6.0,114.68,292.92,17.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Not Yet Recruiting,,SMALLPOX,,,,,"FISABIO, Elche, Alicante, Spain",C01F17/005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-].O=C([O-])[O-].O=C([O-])[O-].[La+3].[La+3],1,DB06792,__LANTHANUM_CARBONATE,5968976,Terminated,,KIDNEY DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",C01F17/005,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,21.5199490749296,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.65,457.835,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NCc1ccc(S(N)(=O)=O)cc1,1,DB06795,__MAFENIDE,3983209,Terminated,,BURN,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,20.008624407072002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.37,186.232,86.18,3.0,2.0,1.0,18.24,46.69,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
NC(=O)Cc1cccc(C(=O)c2ccccc2)c1N,1,DB06802,__NEPAFENAC,6403609,Completed,,EPIRETINAL MEMBRANE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,30.949300806998,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.53,254.2839,86.18,3.0,2.0,2.0,26.63,74.46,4.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(Nc1ccc([N+](=O)[O-])cc1Cl)c1cc(Cl)ccc1O,1,DB06803,__NICLOSAMIDE,4283400,Recruiting,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",A23K10/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,23.0312737427873,319.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.49,327.12,95.15,4.0,2.0,2.0,28.47,80.51,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0
c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1,1,DB06809,__PLERIXAFOR,RE42152,Completed,NCT01164475,NON-HODGKIN'S LYMPHOMA,All,"18 Years to 78 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Princess Margaret Hospital, Toronto, Ontario, Canada|Samsung Medical Center, Seoul, Korea, Republic of|St. Mary's Hospital, Seoul, Korea, Republic of|National Taiwan University Hospital, Taipei, Taiwan|Taipei Veterans General Hospital, Taipei, Taiwan",C07D401/14 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,217.99215589642398,89.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,502.782,78.66,8.0,6.0,3.0,60.51,155.01,4.0,1.0,0.0,0.0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1
C#CCC(Cc1cnc2nc(N)nc(N)c2n1)c1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB06813,__PRALATREXATE,6028071,Recruiting,NCT03150602,"PERIPHERAL T CELL LYMPHOMA|PROGRESSION, DISEASE",All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ntional Taiwan University Hospital, Taipei, Taiwan",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,11.5320643134355,86.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.1,477.4726,207.3,11.0,5.0,3.0,47.31,126.82,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01576731,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Hospital Clínic of Barcelona, Barcelona, Spain",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07D239/557,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01332227,"HIV, COMBINATION THERAPY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health For Life Clinic Pllc, Little Rock, Arkansas, United States|Eisenhower Medical Center, Palm Springs, California, United States|Metropolis Medical Pc, San Francisco, California, United States|Consultive Medicine, Daytona Beach, Florida, United States|Orange County Health Dept., Orlando, Florida, United States|Triple O Medical Services, P.A., West Palm Beach, Florida, United States|The Research Institute, Springfield, Massachusetts, United States|Aids Care, Rochester, New York, United States|Local Institution, Paris, Cedex 12, France|Local Institution, Lyons Cedex 04, France|Local Institution, Orleans Cedex 2, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Bochum, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Munich, Germany|Local Institution, Genova, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Roma, Italy|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Brighton, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Sheffield, United Kingdom",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01258439,HIV|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holdsworth House Medical Practice, Sydney, New South Wales, Australia|St Vincent Hospital, Clinical Research Program, Sydney, New South Wales, Australia",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Unknown status,NCT01059422,HIV INFECTIONS|TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Central Research Institute of Epidemiology, Moscow, Russian Federation",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01121809,HIV-1 INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospitales Universitarios Virgen del Rocio, Sevilla, Spain",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Unknown status,NCT01147107,"HEPATITIS C, CHRONIC|HIV INFECTION",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Viet Tiep General Hospital, Hai Phong, Vietnam|Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01900015,HCV COINFECTION|HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital La Línea, La Línea de la Concepción, Cádiz, Spain|Hospital Universitario Reina Sofía, Córdoba, Spain|Hospital Infanta Elena, Huelva, Spain|Complejo Hospitalario de Jaen, Jaen, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Regional Universitario Carlos Haya, Málaga, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Hospital Universitario Virgen del Rocío, Sevilla, Spain|H.U. Valme, Seville, Spain",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Unknown status,NCT01829802,CHRONIC INFECTION WITH HIV,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundacion Huesped, Buenos Aires, Argentina|Dra Luna Norma, Cordoba, Argentina",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Unknown status,NCT01453933,HIV INFECTION|ENDOTHELIAL DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Onze Lieve Vrouwe Gasthuis, Amsterdam, Noord Holland, Netherlands|University Medical Center Utrecht, Utrecht, Netherlands",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT00843713,HIV INFECTION|INFLAMMATION|CARDIOVASCULAR DISEASE|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01087840,HIV PREVENTION|HIV INFECTIONS,Male,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sydney Sexual Health, Sydney Hospital, Sydney, New South Wales, Australia|St. Vincent's Hospital, 390 Victoria Rd, Darlinghurst, Sydney, New South Wales, Australia",C07D239/557,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT01679964,HIV INFECTION|ADVERSE DRUG REACTION|QUALITY OF LIFE,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan|E-Da Hospital, Kaohsiung, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Taipei City Hospital, Taipei, Taiwan|Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Withdrawn,NCT01173510,HIV INFECTIONS|ACQUIRED IMMUNE DEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Withdrawn,NCT01225705,HIV|HEPATITIS C,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Auguste Viktoria Hospital (AVK), Berlin, Germany|Praxiszentrum Kaiserdamm, Berlin, Germany|Private Practice Dupke, Carganico, Baumgarten, Berlin, Germany|Department of Internal Medicine I, Bonn University, Bonn, Germany|University of Essen, Essen, Germany|Infektiologikum Frankfurt, Frankfurt / Main, Germany|University of Frankfurt, Frankfurt / Main, Germany|Infektionsmedizinisches Centrum Hamburg (ICH), Hamburg, Germany",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT00939874,HIV|OSTEOPENIA|OSTEOPOROSIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"East Sydney Doctors, Sydney, New South Wales, Australia|Holdsworth Medical Practice, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Terminated,NCT01448486,HUMAN IMMUNODEFICIENCY VIRUS (HIV)|HIV ASSOCIATED NEUROCOGNITIVE DISORDERS (HAND),All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT03374358,HIV SEROPOSITIVITY|METABOLIC SYNDROME|FATTY LIVER,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Aurora hospital, Department of Infectious Diseases, Helsinki, Finland",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Completed,NCT02577042,AGING-RELATED INFLAMMATION IN HIV-INFECTED PATIENTS,All,"60 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Unknown status,NCT01013987,HIV-1 ADULTS PATIENTS|AIDS|TRIPLE CLASS FAILURE,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundación Huésped, Ciudad de Buenos Aires, Argentina",C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1,1,DB06817,__RALTEGRAVIR,7169780,Not yet recruiting,NCT04258475,CALCIUM SUPPLEMENTATION IN HIV PATIENTS USING RALTEGRAVIR,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,C07D239/557,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,44.0,51.3193289389925,106.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,444.4163,150.02,7.0,3.0,3.0,42.47,112.59,6.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1
COc1ccc(/C=C/C(=O)Nc2ccccc2C(=O)O)cc1OC,1,DB07615,__TRANILAST,4070484,Completed,NCT00818805,ALLERGIC CONJUNCTIVITIS,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,13.1090987494609,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.89,327.3313,84.86,5.0,2.0,2.0,34.2,91.52,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
O=C(O)C(Cl)Cl,1,DB08809,__DICHLOROACETIC_ACID,,Unknown Status,,INSULIN RESISTANCE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.99,128.942,37.3,2.0,1.0,0.0,9.32,22.62,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C1[C@H]2[C@@H]3CC[C@@H](C3)[C@H]2C(=O)N1C[C@@H]1CCCC[C@H]1CN1CCN(c2nsc3ccccc23)CC1,1,DB08815,__LURASIDONE,5532372,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,34.0705147949649,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.25,492.676,56.75,5.0,0.0,7.0,56.26,139.33,5.0,0.0,1.0,0.0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,NCT02874092,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"New York University School of Medicine, New York, New York, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CCCSc1nc(N[C@@H]2C[C@H]2c2ccc(F)c(F)c2)c2nnn([C@@H]3C[C@H](OCCO)[C@@H](O)[C@H]3O)c2n1,1,DB08816,__TICAGRELOR,6251910,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,33.1505780406168,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.31,522.568,138.44,9.0,4.0,5.0,51.31,142.13,10.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,1
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@@H]1C(O[C@@H]2O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(=O)O)O[C@@H](OC2[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]2NC(C)=O)[C@H](O)[C@H]1O,1,DB08818,__HYALURONIC_ACID,,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,776.6486,399.71,23.0,14.0,4.0,70.56,155.1,12.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1,DB08860,__PITAVASTATIN,5753675,Completed,NCT02442700,HIV|DYSLIPIDEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,97.8746996858251,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,421.4608,90.65,5.0,3.0,4.0,43.76,115.74,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,1,DB08860,__PITAVASTATIN,5753675,Completed,NCT01301066,DYSLIPIDEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Phoenix, Arizona, United States|Beverly Hills, California, United States|Costa Mesa, California, United States|Long Beach, California, United States|Los Angeles, California, United States|Newport Beach, California, United States|San Francisco, California, United States|Washington, District of Columbia, United States|Coral Gables, Florida, United States|Fort Lauderdale, Florida, United States|Fort Pierce, Florida, United States|Miami Beach, Florida, United States|Miami, Florida, United States|Tampa, Florida, United States|Vero Beach, Florida, United States|Atlanta, Georgia, United States|Decatur, Georgia, United States|Springfield, Massachusetts, United States|Berkley, Michigan, United States|St. Louis, Missouri, United States|Hillsborough, New Jersey, United States|Randolph, New Jersey, United States|New York, New York, United States|Rochester, New York, United States|Huntersville, North Carolina, United States|Addison, Texas, United States|Austin, Texas, United States|Corpus Christi, Texas, United States|Fort Worth, Texas, United States|Harlingen, Texas, United States|Houston, Texas, United States|Longview, Texas, United States|Annandale, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States",C07D405/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,97.8746996858251,623.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,421.4608,90.65,5.0,3.0,4.0,43.76,115.74,8.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,Completed,NCT01715636,HIV NONOCCUPATIONAL POST-EXPOSURE PROPHYLAXIS IN MEN WHO HAVE SEX WITH MEN,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydney Sexual Heatlh Centre, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Melbourne Sexual Health Centre, Melbourne, Victoria, Australia",C07D411/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,"Active, not recruiting",NCT04064632,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Antiviral Therapy Unit, Ospedali Riuniti, Bergamo, Italy",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,Enrolling by invitation,NCT03567304,HIV-1-INFECTION|NEUROCOGNITIVE DYSFUNCTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chiang Mai University Hospital, Chiang Mai, Thailand",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,Unknown status,NCT02404233,HIV POSITIVE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Therapeutic Concepts, P.A., Houston, Texas, United States|Therapeutic Concepts, PA, Houston, Texas, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(/C=C/C#N)cc(C)c1Nc1ccnc(Nc2ccc(C#N)cc2)n1,1,DB08864,__RILPIVIRINE,5814639,Completed,NCT01585038,CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.8,366.4185,97.42,6.0,2.0,3.0,40.63,111.74,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Recruiting,NCT03707847,ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Withdrawn,NCT02487316,SYSTEMIC ANAPLASTIC LARGE-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weiping Liu, Beijing, Beijing, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
C[C@@H](Oc1cc(-c2cnn(C3CCNCC3)c2)cnc1N)c1c(Cl)ccc(F)c1Cl,1,DB08865,__CRIZOTINIB,7230098,Recruiting,NCT03672643,ALK OR ROS1-POSITIVE NSCLC,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fujian Province Oncology Hospital, Fuzhou, Fujian, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|Nanjing Bayi Hospital of PLA, Nanjing, Jiangsu, China|Jilin Provincial Cancer Hospital, Changchun, Jilin, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Shanghai Chest Hospital, Shanghai, Shanghai, China|Sichuan Province Cancer Hospital/Department of Pulmonary Tumor, Chengdu, Sichuan, China|West China Hospital of Sichuan University, Chengdu, Sichuan, China|Department of Respiratory, The First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China|Beijing Cancer Hospital, Internal Department, Beijing, China|Zhongshan Hospital Fudan University, Shanghai, China",C07D413/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,39.49157066880221,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.82,450.337,77.99,5.0,2.0,4.0,45.44,128.43,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Terminated,NCT01436643,DEPRESSION|RELAPSING-REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Achim, Germany|Novartis Investigative Site, Altenholz-Stift, Germany|Novartis Investigative Site, Aschaffenburg, Germany|Novartis Investigative Site, Bad Honnef, Germany|Novartis Investigative Site, Baesweiler, Germany|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bielefeld, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bremerhaven, Germany|Novartis Investigative Site, Butzbach, Germany|Novartis Investigative Site, Grevenbroich, Germany|Novartis Investigative Site, Heidenheim, Germany|Novartis Investigative Site, Klingenmünster, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Merzig, Germany|Novartis Investigative Site, Nienburg, Germany|Novartis Investigative Site, Oberhausen, Germany|Novartis Investigative Site, Oldenburg, Germany|Novartis Investigative Site, Potsdam, Germany|Novartis Investigative Site, Schwalmstadt-Treysa, Germany|Novartis Investigative Site, Stadtroda, Germany|Novartis Investigative Site, Tübingen, Germany|Novartis Investigative Site, Weil am Rhein, Germany|Novartis Investigative Site, Zwickau, Germany",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT01420055,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Agen Cedex 9, France|Novartis Investigative Site, Amiens Cedex 1, France|Novartis Investigative Site, Angers Cedex 1, France|Novartis Investigative Site, Auxerre, France|Novartis Investigative Site, Avignon, France|Novartis Investigative Site, Bayonne, France|Novartis Investigative Site, Beziers, France|Novartis Investigative Site, Bobigny Cedex, France|Novartis Investigative Site, Brest, France|Novartis Investigative Site, Calais, France|Novartis Investigative Site, Castelnau-le-Lez, France|Novartis Investigative Site, Chambray les Tours, France|Novartis Investigative Site, Cherbourg, France|Novartis Investigative Site, Clermont-Ferrand Cedex 1, France|Novartis Investigative Site, Créteil, France|Novartis Investigative Site, Dijon, France|Novartis Investigative Site, Epinal, France|Novartis Investigative Site, Grenoble Cedex 9, France|Novartis Investigative Site, Hagueneau, France|Novartis Investigative Site, La Rochelle cedex 1, France|Novartis Investigative Site, La Seyne sur mer, France|Novartis Investigative Site, Le Kremlin Bicetre, France|Novartis Investigative Site, Le Mans Cedex 09, France|Novartis Investigative Site, Limoges, France|Novartis Investigative Site, Lyon, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Marseille, France|Novartis Investigative Site, Metz, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Montpellier, France|Novartis Investigative Site, Nimes, France|Novartis Investigative Site, Orsay, France|Novartis Investigative Site, Paris, France|Novartis Investigative Site, Poitiers, France|Novartis Investigative Site, Pontoise, France|Novartis Investigative Site, Reims, France|Novartis Investigative Site, Rennes Cedex, France|Novartis Investigative Site, Roanne, France|Novartis Investigative Site, Saint Aubin sur Scie, France|Novartis Investigative Site, Saint Jean, France|Novartis Investigative Site, Sainte Foy les Lyon, France|Novartis Investigative Site, Saumur, France|Novartis Investigative Site, Strasbourg Cedex, France|Novartis Investigative Site, Talant, France|Novartis Investigative Site, Toulouse, France|Novartis Investigative Site, Tourcoing, France|Novartis Investigative Site, Tours Cedex, France",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Terminated,NCT02575365,COGNITION|BRAIN VOLUME LOSS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Kutahya, Turkey",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT01333501,MULTIPLE SCLEROSIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Alzenau, Germany|Novartis Investigative Site, Bamberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Würzburg, Germany|Novartis Investigative Site, Ancona, AN, Italy|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Bergamo, BG, Italy|Novartis Investigative Site, Montichiari, BS, Italy|Novartis Investigative Site, Chieti, CH, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Catania, CT, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Pozzilli, IS, Italy|Novartis Investigative Site, Messina, ME, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Cefalù, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Gallarate, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Napoli, Italy",C07C217/52,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Terminated,NCT03345940,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fondazione IRCCS Istituto Neurologico C. Besta, Neuroimmunology Unit, Milan, Italy",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT03257358,RELAPSING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Cullman, Alabama, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Louisville, Colorado, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Boca Raton, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Ocala, Florida, United States|Novartis Investigative Site, Port Charlotte, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, Savannah, Georgia, United States|Novartis Investigative Site, Suwanee, Georgia, United States|Novartis Investigative Site, Flossmoor, Illinois, United States|Novartis Investigative Site, Kansas City, Kansas, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Louisville, Kentucky, United States|Novartis Investigative Site, Lutherville, Maryland, United States|Novartis Investigative Site, Foxboro, Massachusetts, United States|Novartis Investigative Site, Lexington, Massachusetts, United States|Novartis Investigative Site, Wellesley, Massachusetts, United States|Novartis Investigative Site, Ann Arbor, Michigan, United States|Novartis Investigative Site, Owosso, Michigan, United States|Novartis Investigative Site, Golden Valley, Minnesota, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Saint Louis, Missouri, United States|Novartis Investigative Site, Las Vegas, Nevada, United States|Novartis Investigative Site, Fair Lawn, New Jersey, United States|Novartis Investigative Site, Livingston, New Jersey, United States|Novartis Investigative Site, Patchogue, New York, United States|Novartis Investigative Site, Plainview, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Mooresville, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Dayton, Ohio, United States|Novartis Investigative Site, Toledo, Ohio, United States|Novartis Investigative Site, Westerville, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Philadelphia, Pennsylvania, United States|Novartis Investigative Site, Greer, South Carolina, United States|Novartis Investigative Site, Mount Pleasant, South Carolina, United States|Novartis Investigative Site, Port Royal, South Carolina, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Falls Church, Virginia, United States|Novartis Investigative Site, Vienna, Virginia, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Spokane, Washington, United States|Novartis Investigative Site, Tacoma, Washington, United States|Novartis Investigative Site, Huntington, West Virginia, United States|Novartis Investigative Site, Green Bay, Wisconsin, United States|Novartis Investigative Site, Milwaukee, Wisconsin, United States|Novartis Investigative Site, Neenah, Wisconsin, United States",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT01705236,RELAPSING REMITTING MULTIPLE SCLEROSIS RRMS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Bonn, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Hannover, Germany|Novartis Investigative Site, Heidelberg, Germany|Novartis Investigative Site, Leipzig, Germany|Novartis Investigative Site, Rostock, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Zuerich, Switzerland",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT01578330,MULTIPLE SCLEROSIS|RELAPSING-REMITTING,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Novartis Investigative Site, Altunizade, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Ankara, Turkey|Novartis Investigative Site, Atakum / Samsun, Turkey|Novartis Investigative Site, Bursa, Turkey|Novartis Investigative Site, Fatih / Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Kocaeli, Turkey|Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey|Novartis Investigative Site, Trabzon, Turkey|Novartis Investigative Site, Uskudar / Istanbul, Turkey",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CCCCCCCCc1ccc(CCC(N)(CO)CO)cc1,1,DB08868,__FINGOLIMOD,5604229,Completed,NCT01216072,RELAPSING FORMS OF MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Birmingham, Alabama, United States|Novartis Investigative Site, Cullman, Alabama, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Phoenix, Arizona, United States|Novartis Investigative Site, Tucson, Arizona, United States|Novartis Investigative Site, Anaheim, California, United States|Novartis Investigative Site, Berkeley, California, United States|Novartis Investigative Site, Fresno, California, United States|Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, La Habra, California, United States|Novartis Investigative Site, Loma Linda, California, United States|Novartis Investigative Site, Newport Beach, California, United States|Novartis Investigative Site, Oceanside, California, United States|Novartis Investigative Site, Sacramento, California, United States|Novartis Investigative Site, Walnut Creek, California, United States|Novartis Investigative Site, Boulder, Colorado, United States|Novartis Investigative Site, Colorado Springs, Colorado, United States|Novartis Investigative Site, Fort Collins, Colorado, United States|Novartis Investigative Site, Fairfield, Connecticut, United States|Novartis Investigative Site, New London, Connecticut, United States|Novartis Investigative Site, Stratford, Connecticut, United States|Novartis Investigative Site, Dover, Delaware, United States|Novartis Investigative Site, Newark, Delaware, United States|Novartis Investigative Site, Atlantis, Florida, United States|Novartis Investigative Site, Bradenton, Florida, United States|Novartis Investigative Site, Doral, Florida, United States|Novartis Investigative Site, Fort Lauderdale, Florida, United States|Novartis Investigative Site, Hollywood, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Jacksonville, Florida, United States|Novartis Investigative Site, Lighthouse Point, Florida, United States|Novartis Investigative Site, Maitland, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Miami, Florida, United States|Novartis Investigative Site, Pompano Beach, Florida, United States|Novartis Investigative Site, Ponte Vedra Beach, Florida, United States|Novartis Investigative Site, Port Orange, Florida, United States|Novartis Investigative Site, Sarasota, Florida, United States|Novartis Investigative Site, St. Petersburg, Florida, United States|Novartis Investigative Site, Sunrise, Florida, United States|Novartis Investigative Site, Tallahassee, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Tampa, Florida, United States|Novartis Investigative Site, Vero Beach, Florida, United States|Novartis Investigative Site, West Palm Beach, Florida, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Atlanta, Georgia, United States|Novartis Investigative Site, Columbus, Georgia, United States|Novartis Investigative Site, Decatur, Georgia, United States|Novartis Investigative Site, Idaho Falls, Idaho, United States|Novartis Investigative Site, Elk Grove Village, Illinois, United States|Novartis Investigative Site, Evanston, Illinois, United States|Novartis Investigative Site, Flossmoor, Illinois, United States|Novartis Investigative Site, Northbrook, Illinois, United States|Novartis Investigative Site, Anderson, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Indianapolis, Indiana, United States|Novartis Investigative Site, Merrillville, Indiana, United States|Novartis Investigative Site, Valparaiso, Indiana, United States|Novartis Investigative Site, Des Moines, Iowa, United States|Novartis Investigative Site, Lenexa, Kansas, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Destrehan, Louisiana, United States|Novartis Investigative Site, Hammond, Louisiana, United States|Novartis Investigative Site, Metairie, Louisiana, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Shreveport, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Bethesda, Maryland, United States|Novartis Investigative Site, Boston, Massachusetts, United States|Novartis Investigative Site, Springfield, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Worcester, Massachusetts, United States|Novartis Investigative Site, Detroit, Michigan, United States|Novartis Investigative Site, Grand Rapids, Michigan, United States|Novartis Investigative Site, Kalamazoo, Michigan, United States|Novartis Investigative Site, Southfield, Michigan, United States|Novartis Investigative Site, Bolivar, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Kansas City, Missouri, United States|Novartis Investigative Site, Nixa, Missouri, United States|Novartis Investigative Site, North Kansas City, Missouri, United States|Novartis Investigative Site, St. Louis, Missouri, United States|Novartis Investigative Site, Billings, Montana, United States|Novartis Investigative Site, Freehold, New Jersey, United States|Novartis Investigative Site, Somerset, New Jersey, United States|Novartis Investigative Site, Teaneck, New Jersey, United States|Novartis Investigative Site, Toms River, New Jersey, United States|Novartis Investigative Site, Amherst, New York, United States|Novartis Investigative Site, Latham, New York, United States|Novartis Investigative Site, New York, New York, United States|Novartis Investigative Site, Patchogue, New York, United States|Novartis Investigative Site, Plainview, New York, United States|Novartis Investigative Site, Asheville, North Carolina, United States|Novartis Investigative Site, Burlington, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Greensboro, North Carolina, United States|Novartis Investigative Site, Greenville, North Carolina, United States|Novartis Investigative Site, Raleigh, North Carolina, United States|Novartis Investigative Site, Salisbury, North Carolina, United States|Novartis Investigative Site, Wilmington, North Carolina, United States|Novartis Investigative Site, Winston-Salem, North Carolina, United States|Novartis Investigative Site, Akron, Ohio, United States|Novartis Investigative Site, Bellevue, Ohio, United States|Novartis Investigative Site, Canton, Ohio, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Columbus, Ohio, United States|Novartis Investigative Site, Uniontown, Ohio, United States|Novartis Investigative Site, Oklahoma City, Oklahoma, United States|Novartis Investigative Site, Corvallis, Oregon, United States|Novartis Investigative Site, Eugene, Oregon, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Portland, Oregon, United States|Novartis Investigative Site, Monroeville, Pennsylvania, United States|Novartis Investigative Site, Rumford, Rhode Island, United States|Novartis Investigative Site, Beufort, South Carolina, United States|Novartis Investigative Site, Columbia, Tennessee, United States|Novartis Investigative Site, Cordova, Tennessee, United States|Novartis Investigative Site, Knoxville, Tennessee, United States|Novartis Investigative Site, Nashville, Tennessee, United States|Novartis Investigative Site, Austin, Texas, United States|Novartis Investigative Site, Colleyville, Texas, United States|Novartis Investigative Site, Dallas, Texas, United States|Novartis Investigative Site, Houston, Texas, United States|Novartis Investigative Site, Lubbock, Texas, United States|Novartis Investigative Site, Plano, Texas, United States|Novartis Investigative Site, Round Rock, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, Sherman, Texas, United States|Novartis Investigative Site, Salt Lake City, Utah, United States|Novartis Investigative Site, Newport News, Virginia, United States|Novartis Investigative Site, Richmond, Virginia, United States|Novartis Investigative Site, Roanoke, Virginia, United States|Novartis Investigative Site, Vienna, Virginia, United States|Novartis Investigative Site, Kirkland, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Seattle, Washington, United States|Novartis Investigative Site, Morgantown, West Virginia, United States|Novartis Investigative Site, Calgary, Alberta, Canada|Novartis Investigative Site, Nepean, Ontario, Canada|Novartis Investigative Site, Ottawa, Ontario, Canada|Novartis Investigative Site, Greenfield Park, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Montreal, Quebec, Canada|Novartis Investigative Site, Guaynabo, Puerto Rico",C07C217/52,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,52.0,32.0992217499332,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,307.4708,66.48,3.0,3.0,1.0,38.81,93.28,12.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,1,DB08869,__TESAMORELIN,5861379,Recruiting,NCT03226821,HIV LIPODYSTROPHY SYNDROME|GROWTH HORMONE DEFICIENCY|BODY COMPOSITION,All,"18 Years to 68 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Neuroendocrine Unit and Pituitary Center, Columbia University, New York, New York, United States",C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
CC/C=C/CC(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CC(C)C)C(N)=O)C(C)CC)C(C)C)C(C)O)C(C)CC,1,DB08869,__TESAMORELIN,5861379,Terminated,NCT01591902,DIABETIC RETINOPATHY|HIV,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Southwest Center for HIV/AIDS, Phoenix, Arizona, United States|Spectrum Medical Group, Phoenix, Arizona, United States|5P21 Rand Schrader Clinic, Los Angeles, California, United States|University of California CARE Clinic, Los Angeles, Los Angeles, California, United States|Palmtree Clinical Research, Inc., Palm Springs, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|VAMC, Infectious Disease Section 111W, San Francisco, California, United States|Capital Medical Associates, PC, Washington, District of Columbia, United States|Gary J. Richmond, M.D., PA, Fort Lauderdale, Florida, United States|Orange County Health Department, Orlando, Florida, United States|Triple O Research Institute, West Palm Beach, Florida, United States|Rowan Tree Medical , P.A., Wilton Manors, Florida, United States|Be Well Medical Center, P.C., Berkley, Michigan, United States|Southampton Clinical Research, Inc d.b.a. Central West Clinical Research, Saint Louis, Missouri, United States|Southampton Healthcare, Inc., Saint Louis, Missouri, United States|South Jersey Infectious Disease, Somers Point, New Jersey, United States|Harold Hamm Diabetes Center at the University of Oklahoma, Oklahoma City, Oklahoma, United States|Fanno Creek Clinic, LLC, Portland, Oregon, United States|Central Texas Clinical Research, Austin, Texas, United States|St. Hope Foundation, Inc., Bellaire, Texas, United States|Dallas VA Medical Center, Dallas, Texas, United States|UT Southwestern Medical Center, Atten: HIV Research Unit, Dallas, Texas, United States|Research Access Network, Houston, Texas, United States|Virginia Mason Medical Center, Seattle, Washington, United States",C07K14/60,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,28.8794431097147,5.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-35.0,5005.76,2278.76,83.0,81.0,3.0,505.02,1314.56,176.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,1,DB08873,__BOCEPREVIR,7772178,Completed,NCT01925183,"HEPATITIS C, CHRONIC|HIV",All,18 Years to 64 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,50.333682416476705,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,519.6767,150.7,5.0,4.0,3.0,56.78,138.2,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0
CC(C)(C)NC(=O)N[C@H](C(=O)N1C[C@H]2[C@@H]([C@H]1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,1,DB08873,__BOCEPREVIR,7772178,Terminated,NCT01443923,HEPATITIS|HIV/AIDS,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Unity Health Care, Inc./DC General, Washington, DC, District of Columbia, United States|National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,50.333682416476705,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.93,519.6767,150.7,5.0,4.0,3.0,56.78,138.2,10.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1,1,DB08877,__RUXOLITINIB,7598257,Recruiting,NCT02386800,PRIMARY MYELOFIBROSIS|CHRONIC IDIOPATHIC MYELOFIBROSIS|POST POLYCYTHEMIA VERA MYELOFIBROSIS|POST ESSENTIAL THROMBOCYTHAEMIA MYELOFIBROSIS|STEROID REFRACTORY GRAFT VERSUS HOST DISEASE,All,"1 Month and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Darlinghurst, New South Wales, Australia|Novartis Investigative Site, St Leonards, New South Wales, Australia|Novartis Investigative Site, Herston, Queensland, Australia|Novartis Investigative Site, Wooloongabba, Queensland, Australia|Novartis Investigative Site, Bedford Park, South Australia, Australia|Novartis Investigative Site, Box Hill, Victoria, Australia|Novartis Investigative Site, Clayton, Victoria, Australia|Novartis Investigative Site, Franston, Victoria, Australia|Novartis Investigative Site, Perth, Western Australia, Australia|Novartis Investigative Site, Antwerpen, Belgium|Novartis Investigative Site, Brugge, Belgium|Novartis Investigative Site, Leuven, Belgium|Novartis Investigative Site, Liege, Belgium|Novartis Investigative Site, Pleven, Bulgaria|Novartis Investigative Site, Plovdiv, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Sofia, Bulgaria|Novartis Investigative Site, Vina del Mar, Valparaiso, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Santiago, Chile|Novartis Investigative Site, Beijing, Beijing, China|Novartis Investigative Site, Hangzhou, Zhejiang, China|Novartis Investigative Site, Aachen, Germany|Novartis Investigative Site, Dresden, Germany|Novartis Investigative Site, Magdeburg, Germany|Novartis Investigative Site, Mainz, Germany|Novartis Investigative Site, Ulm, Germany|Novartis Investigative Site, Goudi-Athens, GR, Greece|Novartis Investigative Site, Patras, Greece|Novartis Investigative Site, Budapest, Hungary|Novartis Investigative Site, Debrecen, Hungary|Novartis Investigative Site, Kaposvar, Hungary|Novartis Investigative Site, Kecskemet, Hungary|Novartis Investigative Site, Szeged, Hungary|Novartis Investigative Site, Szombathely, Hungary|Novartis Investigative Site, Afula, Israel|Novartis Investigative Site, Jerusalem, Israel|Novartis Investigative Site, Bari, BA, Italy|Novartis Investigative Site, Firenze, FI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Palermo, PA, Italy|Novartis Investigative Site, Pavia, PV, Italy|Novartis Investigative Site, Reggio Calabria, RC, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Orbassano, TO, Italy|Novartis Investigative Site, Varese, VA, Italy|Novartis Investigative Site, Napoli, Italy|Novartis Investigative Site, Nagoya, Aichi, Japan|Novartis Investigative Site, Seoul, Seocho Gu, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Beirut, Lebanon|Novartis Investigative Site, Monterrey, Nuevo Leon, Mexico|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Lisboa, Portugal|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Petrozavodsk, Russian Federation|Novartis Investigative Site, Soweto, Gauteng, South Africa|Novartis Investigative Site, Cape Town, Western Province, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Pretoria, South Africa|Novartis Investigative Site, Salamanca, Castilla Y Leon, Spain|Novartis Investigative Site, Barcelona, Catalunya, Spain|Novartis Investigative Site, Pamplona, Navarra, Spain|Novartis Investigative Site, Huddinge, Sweden|Novartis Investigative Site, Lulea, Sweden|Novartis Investigative Site, Lund, Sweden|Novartis Investigative Site, Uddevalla, Sweden|Novartis Investigative Site, Bangkok, Bangkoknoi, Thailand|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Ankara, Sihhiye, Turkey|Novartis Investigative Site, Istanbul, Turkey|Novartis Investigative Site, Izmir, Turkey|Novartis Investigative Site, Talas / Kayseri, Turkey",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,33.807675722294,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.94,306.365,83.18,4.0,1.0,4.0,33.04,98.01,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB08880,__TERIFLUNOMIDE,6794410,Recruiting,NCT04410965,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"investigational site CHINA, China, China",2,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,29.7008152118113,294.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.3,270.2073,73.12,3.0,2.0,1.0,23.15,64.39,3.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB08880,__TERIFLUNOMIDE,6794410,Recruiting,NCT04129736,"MULTIPLE SCLEROSIS, PHARMACOKINETICS",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"MS Centre, Gothenburg, Vastra Gotaland, Sweden",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,29.7008152118113,294.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.3,270.2073,73.12,3.0,2.0,1.0,23.15,64.39,3.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1,1,DB08880,__TERIFLUNOMIDE,6794410,Recruiting,NCT03856619,RELAPSING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 024, Ahmedabad, India|Investigational Site Number 017, Bengaluru, India|Investigational Site Number 001, Chandigarh, India|Investigational Site Number 023, Coimbatore, India|Investigational Site Number 007, Gurgaon, India|Investigational Site Number 026, Gurgaon, India|Investigational Site Number 005, Kochi, India|Investigational Site Number 006, Kolkata, India|Investigational Site Number 011, Lucknow, India|Investigational Site Number 020, Ludhiana, India|Investigational Site Number 018, Nashik, India|Investigational Site Number 003, New Delhi, India|Investigational Site Number 025, New Delhi, India|Investigational Site Number 014, Pune, India|Investigational Site Number 022, Thiruvananthapuram, India",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,29.7008152118113,294.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.3,270.2073,73.12,3.0,2.0,1.0,23.15,64.39,3.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C,1,DB08882,__LINAGLIPTIN,6303661,Unknown status,NCT02097342,TYPE 2 DIABETES MELLITUS|INSULIN SENSITIVITY/RESISTANCE,All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Postgraduate Institute of Medical Education & Research, Chandigarh, India",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,59.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.62,472.5422,113.48,7.0,1.0,5.0,51.24,133.43,5.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CCOc1ccc(C[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)O)CC(=O)O)cc1.[Gd+3],1,DB08884,__GADOXETIC_ACID,6039931,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F15/025,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,65.47978397913711,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,681.75,213.94,14.0,2.0,1.0,50.67,159.21,20.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,DB08887,__ICOSAPENT_ETHYL,8188146,Recruiting,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,50.300827532392795,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.8,330.5042,26.3,1.0,0.0,0.0,40.32,110.59,15.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,Recruiting,NCT03934684,RELAPSED REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Hyderabad, Andhra Pradesh, India|Research Site, Bangalore, Karnataka, India|Research Site, Belagavi, Karnataka, India|Research Site, Bengaluru, Karnataka, India|Research Site, Kochi, Kerala, India|Research Site, Kozhikode, Kerala, India|Research Site, Nashik, Maharashtra, India|Research Site, Nashik, Maharashtra, India|Research Site, Pune, Maharashtra, India|Research Site, Meerut, Uttar Pradesh, India",C07K5/0812,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",C07K5/0812,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1,1,DB08889,__CARFILZOMIB,8129346,Active Not Recruiting,,RELAPSED OR REFRACTORY MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0812,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,82.7285981231647,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.21,719.9099,158.47,8.0,4.0,4.0,79.44,198.02,20.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,1,DB08893,__MIRABEGRON,6346532,Completed,NCT02086188,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EvergreenHealth MS Center, Kirkland, Washington, United States",C07D233/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,22.2099016406907,16.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,396.506,100.27,5.0,4.0,3.0,44.2,113.23,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0
Nc1nc(CC(=O)Nc2ccc(CCNC[C@H](O)c3ccccc3)cc2)cs1,1,DB08893,__MIRABEGRON,6346532,Completed,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/26,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,22.2099016406907,16.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.2,396.506,100.27,5.0,4.0,3.0,44.2,113.23,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,"Active, not recruiting",NCT04464642,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bangabandhu Seikh Mujib Medical University, Dhaka, Bangladesh",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Not yet recruiting,NCT04311567,RHEUMATOID ARTHRITIS|INTERSTITIAL LUNG DISEASE DUE TO SYSTEMIC DISEASE (DISORDER)|RA|ILD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Skåne University Hospital, Department of Rheumatology, Lund, Skåne, Sweden|Clinical Rheumatology Research Center, The Sahlgrenska University Hospital, Göteborg, Västra Götaland, Sweden|Karolinska University Hospital, Department of Rheumatology, Stockholm, Sweden",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)c1ncnc2[nH]ccc12,1,DB08895,__TOFACITINIB,7301023,Active Not Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,66.1697365448982,52.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.58,312.3696,88.91,5.0,1.0,3.0,32.65,87.8,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1,1,DB08897,__ACLIDINIUM,5840279,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,29.109427298301807,60.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,484.651,55.76,3.0,1.0,5.0,52.09,141.33,10.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,METASTATIC HORMONE REFRACTORY PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Active Not Recruiting,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
CNC(=O)c1ccc(N2C(=S)N(c3ccc(C#N)c(C(F)(F)F)c3)C(=O)C2(C)C)cc1F,1,DB08899,__ENZALUTAMIDE,7709517,Recruiting,,CASTRATION-RESISTANT PROSTATIC CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D233/70,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,47.6395819216,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.75,464.436,76.44,3.0,1.0,3.0,42.71,113.48,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,1
COc1nc2ccc(Br)cc2cc1[C@@H](c1ccccc1)[C@@](O)(CCN(C)C)c1cccc2ccccc12,1,DB08903,__BEDAQUILINE,7498343,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D249/08,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,50.79365079365071,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.37,555.505,45.59,4.0,1.0,5.0,57.29,154.02,8.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Withdrawn,NCT01076439,ALLERGIC RHINITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT01007253,SEASONAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)","The University of Chicago, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",A61M15/0043,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)SCF,1,DB08906,__FLUTICASONE_FUROATE,5873360,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61M15/0043,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,44.61693258588471,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.73,538.576,93.81,4.0,1.0,5.0,51.55,130.08,6.0,0.0,1.0,0.0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Recruiting,NCT04014192,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",A61K9/2031,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Active Not Recruiting,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1,1,DB08907,__CANAGLIFLOZIN,6723340,Not Yet Recruiting,,GLOMERULONEPHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2031,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,29.8322347481467,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.09,444.51599999999996,90.15,5.0,4.0,4.0,46.5,116.14,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Terminated,NCT03345940,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fondazione IRCCS Istituto Neurologico C. Besta, Neuroimmunology Unit, Milan, Italy",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Unknown status,NCT03092544,MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Multiple Sclerosis Center of Northeastern New York, Latham, New York, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Completed,NCT02471560,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Research site, Drammen, Norway|Research site, Haukeland, Norway|Research Site, Lillehammer, Norway|Research site, Lørenskog, Norway|Research site, Molde, Norway|Research site, Oslo, Norway|Research site, Stavanger, Norway",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Withdrawn,NCT02675413,"MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Washington University (John L. Trotter MS Center), St. Louis, Missouri, United States|Swedish Neuroscience Institute, Seattle, Washington, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Withdrawn,NCT02090348,RELAPSING-REMITTING MULTIPLE SCLEROSIS|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Active Not Recruiting,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COC(=O)/C=C/C(=O)OC,1,DB08908,__DIMETHYL_FUMARATE,6509376,Completed,,RELAPSING FORMS OF MULTIPLE SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,20.4028830160783,482.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.45,144.1253,52.6,2.0,0.0,0.0,13.76,34.15,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CN(C)C/C=C/C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1,1,DB08916,__AFATINIB,6251912,Recruiting,NCT04132102,LUNG SQUAMOUS CELL CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Chest Hospital, Shanghai, Shanghai, China",C07D239/94,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,34.9247417811453,185.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,485.93800000000016,88.61,7.0,2.0,4.0,50.07,131.38,8.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,1,0
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Completed,NCT02211482,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fundacion Huesped, Caba, Buenos Aires, Argentina",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Not yet recruiting,NCT04183738,HIV-INFECTION/AIDS|HUMAN HERPESVIRUS 4 INFECTIONS|CYTOMEGALOVIRUS INFECTIONS|HUMAN HERPESVIRUS 8 INFECTION|HUMAN PAPILLOMA VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Unknown status,NCT02337322,ACQUIRED IMMUNE DEFICIENCY SYNDROME VIRUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic of Barcelona, Barcelona, BCN, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Completed,NCT03218592,HIV/AIDS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Clinical and Translational Research Center, UNC Hospitals, Chapel Hill, North Carolina, United States",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Recruiting,NCT03813979,HIV-1-INFECTION|HEPATIC IMPAIRMENT,All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Radboudumc, Nijmegen, Netherlands|Erasmus medical centre, Rotterdam, Netherlands",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Not yet recruiting,NCT04340388,HIV-1-INFECTION|ANTIVIRAL DRUG ADVERSE REACTION|VASCULAR DISEASES|CARDIOVASCULAR ABNORMALITIES|ABNORMALITY OF ADIPOSE TISSUE|BODY WEIGHT CHANGES|BODY FAT DISORDER|HIV-ASSOCIATED LIPODYSTROPHY SYNDROME,All,"18 Years to 100 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
C[C@@H]1CCO[C@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N21,1,DB08930,__DOLUTEGRAVIR,5905082,Not yet recruiting,NCT04166474,HIV|TUBERCULOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,83.4842604570935,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.98,419.3788,99.18,6.0,2.0,4.0,40.0,102.77,3.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1
COC(=O)N(C)c1c(N)nc(-c2nn(Cc3ccccc3F)c3ncccc23)nc1N,1,DB08931,__RIOCIGUAT,6743798,Unknown status,NCT02625558,SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Cincinnati, Cincinnati, Ohio, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,37.68455204418978,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.27,422.4157,138.07,8.0,2.0,4.0,41.9,135.25,5.0,0.0,1.0,0.0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT03250910,"HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF|HUMAN IMMUNODEFICIENCY VIRUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT02220868,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Saint Michael's Medical Center, Newark, New Jersey, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Terminated,NCT02717949,LIVER DISEASES,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cornell Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UT Southwestern Medical Center, Dallas, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Completed,NCT02339038,HCV HIV,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Unity Health Care, Inc./DC General, Washington, District of Columbia, United States|Family Medical and Conseling Services, Washington, District of Columbia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Withdrawn,NCT02206932,"HEPATITIS C, CHRONIC|HIV CDC CATEGORY A1",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,"Active, not recruiting",NCT02938013,HCV COINFECTION|LIVER DISEASE|HIV,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital : The John G. Bartlett Specialty Practice, Baltimore, Maryland, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](n2ccc(=O)[nH]c2=O)[C@](C)(F)[C@@H]1O)Oc1ccccc1,1,DB08934,__SOFOSBUVIR,7964580,Active Not Recruiting,,DRUG USE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.63,529.4580000000002,152.73,6.0,3.0,3.0,49.89,121.59,11.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1
CCCNC(C)C(=O)Nc1c(C)csc1C(=O)OC,1,DB09009,__ARTICAINE,5858410,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,57.0,18.792993695969106,356.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.93,284.374,67.43,3.0,2.0,1.0,30.54,76.78,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)Oc1ccc(C(c2ccc(OC(C)=O)cc2)c2ccccn2)cc1,1,DB09020,__BISACODYL,7291324,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,60.4858415983901,209.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.71,361.3906,65.49,3.0,0.0,3.0,38.48,100.15,7.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Unknown status,NCT01184599,"GLOMERULONEPHRITIS, IGA|HYPERTENSION",All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kurume University, School of Medicine, Fukuoka, Japan|Department of Internal Medicine, Osaka City General Hospital, Osaka, Japan|Ohno memorial Hospital, Osaka, Japan|Kinki University, Faculty of Medicine, Osaka, Japan",C07C255/13,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,NCT00922311,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine, The University of Hong Kong, Hong Kong, China|Queen Mary Hospital, Hong Kong, China",C07C255/13,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC,1,DB09026,__ALISKIREN,5559111,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",C07C255/13,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,17.708782521201602,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.87,551.7583,146.13,7.0,4.0,1.0,63.28,154.32,19.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0
COC(=O)N[C@H](C(=O)N1CC2(CC2)C[C@H]1c1nc(-c2ccc3c(c2)C(F)(F)c2cc(-c4ccc5[nH]c([C@@H]6[C@H]7CC[C@H](C7)N6C(=O)[C@@H](NC(=O)OC)C(C)C)nc5c4)ccc2-3)c[nH]1)C(C)C,1,DB09027,__LEDIPASVIR,7964580,Completed,NCT02339038,HCV HIV,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Unity Health Care, Inc./DC General, Washington, District of Columbia, United States|Family Medical and Conseling Services, Washington, District of Columbia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,38.9987474075443,17.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.98,888.9999,174.64,6.0,4.0,10.0,97.49,235.47,12.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1
Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1,1,DB09034,__SUVOREXANT,7951797,Recruiting,NCT03110315,MULTIPLE SCLEROSIS|FATIGUE|INSOMNIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","EvergreenHealth Multiple Sclerosis Center, Kirkland, Washington, United States",C07D491/052,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,41.988541859175704,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.86,450.93,80.29,5.0,0.0,5.0,46.68,134.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Unknown status,NCT03639545,"VASCULAR STIFFNESS|HYPOGLYCEMIC AGENTS|DIABETES COMPLICATIONS|DIABETES MELLITUS, TYPE 1",All,"30 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","University Medical Centre Ljubljana, Ljubljana, Slovenia",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(O[C@H]4CCOC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB09038,__EMPAGLIFLOZIN,6303661,Recruiting,NCT04014192,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.3375017967514,32.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.79,450.91,108.61,7.0,4.0,4.0,46.12,113.79,6.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Recruiting,NCT04042376,WALDENSTROM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The First Hospital of Jilin University, Changchun, China|Peking Union Medical College Hospital, Dongcheng, China|Fujian Meidical University Union Hospital, Fuzhou, China|Guangdong Provincial People's Hospital, Guangzhou, China|First affiliated Hospital of Zhejiang University, Hangzhou, China|The People's Hospital of Jiangsu Province, Nanjing, China|Institute of Hematology & Blood Diseases Hospital, Tianjin, China|Wuhan Union Hospital, Wuhan, China|The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China|Henan Cancer Hospital, Zhengzhou, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Enrolling by invitation,NCT03229200,"LYMPHOMA, B-CELL|LYMPHOMA, NON-HODGKIN|LEUKEMIA, B-CELL|GRAFT VS HOST DISEASE|SOLID TUMOR",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Health System - Southern California d/b/a Roy and Patricia Disney Family Cancer Center, The Roy & Patricia Disney Family Cancer Center, Burbank, California, United States|City Of Hope National Medical Center, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University of California Los Angeles (UCLA), Los Angeles, California, United States|Stanford University, Stanford, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Emory University, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Norton Medical Plaza II, 3991 Dutchmans Lane, Louisville, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Henry Ford Health System, Detroit, Michigan, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|TRIO - Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack UMC, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Clinical Research Alliance, Lake Success, New York, United States|Northwell Health, New Hyde Park, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States|University of Rochester, Rochester, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Mid Ohio Oncology/Hematology Inc., DBA The Mark H. Zangmeister Center, Columbus, Ohio, United States|Willamette Valley Cancer Institute and Research Center, Eugene, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States|Texas Oncology, Tyler, Texas, United States|University of Vermont Medical Center, Burlington, Vermont, United States|Northwest Cancer Specialists, Compass Oncology, Vancouver, Washington, United States|Yakima Valley Memorial Hospital, Yakima, Washington, United States|Concord Repatriation General Hospital - Haematology Clinical Trials, Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Flinders Medical Centre, Bedford Park, South Australia, Australia|Ballarat Health Services, Ballarat, Victoria, Australia|Eastern Health, Box Hill, Victoria, Australia|St Vincent Hospital, Fitzroy, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|UZ Leuven, Leuven, Belgium|AZ Turnhout, Turnhout, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|QEII Health Science Centre, Halifax, Nova Scotia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|McGill University Health Center, Montréal, Quebec, Canada|University Hospital Hradec Kralove, Hradec Králové, Kralovehradecky Kraj, Czechia|Hematology and Oncology Masaryk University Hospital Brno, Brno, Czechia|University Hospital Pilsen, Pilsen, Czechia|Charles University Hospital, Prague, Prague, Czechia|IHK FNKV Praha, Praha, Czechia|CHU Hotel Dieu, Nantes, Loire Atlantique, France|Centre Henri Becquerel, Rouen Cedex, France|Centre Hospitalier Saint Brieuc, Saint-Brieuc, France|General Hospital of Athens ""Laiko"", Athens, Attica, Greece|Hadassah Medical Center, Jerusalem, Israel|Rabin Dedical Center, Petach Tikva, Israel|Sourasky Medical Center, Tel Aviv, Israel|Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico, Milano, Italy|Fondazione IRCCS Policlinico San Matteo di Pavia, Pavia, Italy|Azienda Sanitaria Universitaria Integrata Udine, Udine, Italy|Middlemore Hospital, Papatoetoe, Auckland, New Zealand|North Shore Hospital, Auckland, New Zealand|Szpital Specjalistyczny w Brzozowie, Oddział Hematologii Onkologicznej z Klinicznym Oddziałem Przeszczepiania Szpiku, Brzozów, Podkarpackie, Poland|Klinika Hematologii i Transplantologii, Gdańsk, Pomorskie, Poland|SPZOZ ZSM w Chorzowie, Chorzów, Silesia, Poland|Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika, Łódź, Poland|Nizhniy Novgorod Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Nizhegorodskaya, Russian Federation|SBI of Ryazan region ""Regional Clinical Hospital"", Ryazan', Ryazan Region, Russian Federation|Russian Scientific and Research Institute of Hematology and Transfusiology of Federal Medical Biological Agency, Saint Petersburg, Russian Federation|Almazov National Medical Research Centre, Saint Petersburg, Russian Federation|Yaroslavl Regional Clinical Hospital, Yaroslavl, Russian Federation|ICO - Hospital Germans Trias I Pujol, Badalona, Barcelona, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Vall d'Hebron, Barcelona, Spain|Hospital de Sanata Creus i Sant Pau, Barcelona, Spain|ICO l'Hospitalet - Hospital Duran i Reynals, Barcelona, Spain|Hospital Universitario Infanta Leonor, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|University Hospital of Salamanca, Salamanca, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Sunderby hospital, Luleå, Norrbotten, Sweden|Södra Älvsborg Hospital Borås, Borås, Sweden|Karolinska University Hospital, Solna, Sweden|Pamukkale University Medical Faculty, Denizli, Pamukkale, Turkey|Ankara Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey|Gazi University, Ankara, Turkey|VKV American Hospital, Istanbul, Turkey|Dokuz Eylul University, İzmir, Turkey",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
C=CC(=O)N1CCC[C@@H](n2nc(-c3ccc(Oc4ccccc4)cc3)c3c(N)ncnc32)C1,1,DB09053,__IBRUTINIB,7514444,Recruiting,NCT03190330,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL|LYMPHOMA, MANTLE-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Vedanta Institute of Medical Science, Ahmedabad, India|Avron Hospitals Pvt. Ltd, Ahmedabad, India|Post Graduate Institute of Medical Education & Research (PGIMER), Chandigarh, India|Basavatarakam Indo-American Hospital, Hyderabad, India|Bhagwan Mahaveer Cancer Hospital & Research Centre, Jaipur, India|Cytecare Hospitals Pvt. Ltd, Karnataka, India|Apollo Gleneagles Hospital, Kolkata, India|Tata Medical Center, Kolkata, India|Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India|Deenanath Mangeshkar Hospital and Research Centre, Pune, India|Noble Hospital Pvt Ltd, Pune, India|Regional Cancer Centre, Thiruvananthapuram, India|Christian Medical College, Vellore, India",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,27.3024086736894,35.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.76,440.50699999999995,99.16,5.0,1.0,5.0,47.84,138.07,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,0,0
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1,DB09065,__COBICISTAT,5814639,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,35.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,776.03,138.02,7.0,3.0,5.0,83.42,211.49,20.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1,DB09065,__COBICISTAT,5814639,Completed,NCT02351908,HIV INFECTION,All,18 Years to 64 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"SSAT Clinical Research Facility, London, United Kingdom",C07D411/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,35.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,776.03,138.02,7.0,3.0,5.0,83.42,211.49,20.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,1
CC(C)c1nc(CN(C)C(=O)N[C@@H](CCN2CCOCC2)C(=O)N[C@H](CC[C@H](Cc2ccccc2)NC(=O)OCc2cncs2)Cc2ccccc2)cs1,1,DB09065,__COBICISTAT,5814639,Terminated,NCT02503462,AIDS-RELATED DEMENTIA COMPLEX,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Division of Infectious Diseases, University Hospital Basel, Basel, BS, Switzerland",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,35.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,776.03,138.02,7.0,3.0,5.0,83.42,211.49,20.0,1.0,0.0,0.0,1,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,1,DB09074,__OLAPARIB,7151102,Recruiting,NCT04330040,OVARIAN CANCER|BREAST CANCER,Female,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, Ahmedabad, India|Research Site, Bhubaneshwar, India|Research Site, Chandigarh, India|Research Site, Kolkata, India|Research Site, Mumbai, India|Research Site, New Delhi, India",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
O=C(c1cc(Cc2n[nH]c(=O)c3ccccc23)ccc1F)N1CCN(C(=O)C2CC2)CC1,1,DB09074,__OLAPARIB,7151102,"Active, not recruiting",NCT02476968,BRCA OR HRR+ MUTATED OVARIAN CANCER PATIENTS,Female,"18 Years to 130 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Research Site, Plovdiv, Bulgaria|Research Site, Plovdiv, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Varna, Bulgaria|Research Site, Calgary, Alberta, Canada|Research Site, Halifax, Nova Scotia, Canada|Research Site, London, Ontario, Canada|Research Site, Toronto, Ontario, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Montreal, Quebec, Canada|Research Site, Brno, Czechia|Research Site, Brno, Czechia|Research Site, Novy Jicin, Czechia|Research Site, Olomouc, Czechia|Research Site, Ostrava, Czechia|Research Site, Praha 2, Czechia|Research Site, Praha 5, Czechia|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Budapest, Hungary|Research Site, Debrecen, Hungary|Research Site, Kecskemét, Hungary|Research Site, Nyíregyháza, Hungary|Research Site, Bari, Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Perugia, Italy|Research Site, Bialystok, Poland|Research Site, Gdansk, Poland|Research Site, Kielce, Poland|Research Site, Poznan, Poland|Research Site, Poznań, Poland|Research Site, Badalona, Spain|Research Site, Barcelona, Spain|Research Site, Burgos, Spain|Research Site, L'Hospitalet de Llobregat, Spain|Research Site, Madrid, Spain|Research Site, Madrid, Spain|Research Site, San Cristobal de La Laguna, Spain|Research Site, Sevilla, Spain|Research Site, Valencia, Spain|Research Site, Valencia, Spain|Research Site, Zaragoza, Spain|Research Site, Belfast, United Kingdom|Research Site, Birmingham, United Kingdom|Research Site, Cardiff, United Kingdom|Research Site, Glasgow, United Kingdom|Research Site, Leeds, United Kingdom|Research Site, London, United Kingdom|Research Site, Manchester, United Kingdom|Research Site, Newcastle upon Tyne, United Kingdom|Research Site, Oxford, United Kingdom|Research Site, Swansea, United Kingdom|Research Site, Taunton, United Kingdom|Research Site, Wirral, United Kingdom",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,61.63576254132521,26.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.72,434.4628,82.08,4.0,1.0,5.0,43.81,117.53,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1,1,DB09080,__OLODATEROL,5964416,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",F04B53/125,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.2389371444998,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.02,386.44800000000004,100.05,6.0,4.0,3.0,41.34,106.9,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
OCc1cc([C@@H](O)CNCCCCCCOCCOCc2c(Cl)cccc2Cl)ccc1O,1,DB09082,__VILANTEROL,5873360,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",A61M15/0043,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,44.61693258588471,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.39,486.43,91.18,6.0,4.0,2.0,53.67,129.09,16.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0
COc1cc2c(cc1OC)CC(=O)N(CCCN(C)C[C@H]1Cc3cc(OC)c(OC)cc31)CC2,1,DB09083,__IVABRADINE,7361650,Completed,NCT01365286,"ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)",All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Medical University of Lodz, Department of Pneumonology and Allergy, Lodz, Poland",H04L51/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,25.95535842625101,100.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.17,468.594,60.47,6.0,0.0,4.0,54.56,133.51,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,1,DB09089,__TRIMEBUTINE,5693337,Completed,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,28.780878457463107,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.94,387.476,57.23,5.0,0.0,2.0,42.43,108.94,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
CCC(COC(=O)c1cc(OC)c(OC)c(OC)c1)(c1ccccc1)N(C)C,1,DB09089,__TRIMEBUTINE,5693337,Not Yet Recruiting,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,28.780878457463107,189.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.94,387.476,57.23,5.0,0.0,2.0,42.43,108.94,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0
O=C(OOC(=O)c1ccccc1)c1ccccc1,1,DB09096,__BENZOYL_PEROXIDE,7820186,Completed,,P ACNES COLONIZATION,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,94.096388016181,5475.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.75,242.2268,52.6,2.0,0.0,2.0,24.16,64.77,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(OOC(=O)c1ccccc1)c1ccccc1,1,DB09096,__BENZOYL_PEROXIDE,7820186,Completed,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,94.096388016181,5475.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.75,242.2268,52.6,2.0,0.0,2.0,24.16,64.77,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C(OOC(=O)c1ccccc1)c1ccccc1,1,DB09096,__BENZOYL_PEROXIDE,7820186,Completed,,SKIN DISEASES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,94.096388016181,5475.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.75,242.2268,52.6,2.0,0.0,2.0,24.16,64.77,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,LIVER CIRRHOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
C[C@H](N)C(=O)NCC(=O)N[C@H]1CSSC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC1=O,1,DB09099,__SOMATOSTATIN,,Completed,,ACROMEGALY,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,1637.9,613.23,22.0,22.0,6.0,165.8,420.26,26.0,1.0,0.0,0.0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,1,DB09101,__ELVITEGRAVIR,5814639,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,48.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,447.884,87.07,6.0,2.0,3.0,44.8,116.26,7.0,0.0,1.0,0.0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,1,DB09101,__ELVITEGRAVIR,5814639,Unknown status,NCT02470650,PATIENT COMPLIANCE|ANTIRETROVIRAL THERAPY INTOLERANCE,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Josep Mallolas Masferrer, Barcelona, Spain",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,48.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,447.884,87.07,6.0,2.0,3.0,44.8,116.26,7.0,0.0,1.0,0.0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,1,DB09101,__ELVITEGRAVIR,5814639,Completed,,HEPATITIS C INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D411/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,48.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,447.884,87.07,6.0,2.0,3.0,44.8,116.26,7.0,0.0,1.0,0.0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc2c(cc1Cc1cccc(Cl)c1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C,1,DB09101,__ELVITEGRAVIR,5814639,Completed,,HIV-1 INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D411/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,67.3853672560011,48.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,447.884,87.07,6.0,2.0,3.0,44.8,116.26,7.0,0.0,1.0,0.0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc(-c3ccc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)cc3)cc2)[nH]1)C(C)C,1,DB09102,__DACLATASVIR,8329159,Active Not Recruiting,,DRUG USE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,64.1327337316987,5.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.67,738.89,174.64,6.0,4.0,6.0,83.91,201.82,13.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1
O=S(=O)(O)CCS,1,DB09110,__COENZYME_M,,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=S(=O)(O)CCS,1,DB09110,__COENZYME_M,,Unknown Status,,NASAL AND NASAL-TYPE NK/T-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,142.197,54.37,3.0,2.0,0.0,12.54,29.13,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Completed,NCT02352090,CONTRACEPTION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Helsinki University Central Hospital, Kätilöopisto Maternity Hospital, Helsinki, Finland|Oulu University Hospital, Department of Gynecology and Obstetrics, Oulu, Finland",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
C[C@]12CCC3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(O)CC#N,1,DB09123,__DIENOGEST,6133251,Unknown Status,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,483.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,311.425,61.09,3.0,1.0,4.0,35.4,90.19,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,DB09125,__POTASSIUM_CITRATE,,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.7,306.394,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,DB09125,__POTASSIUM_CITRATE,,Recruiting,NCT04422184,DENTIN HYPERSENSITIVITY|PERIODONTAL DISEASES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bauru School of Denstistry, Bauru, SP, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.7,306.394,140.62,7.0,1.0,0.0,14.23,68.14,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Unknown status,NCT02372149,PERIPHERAL NEUROPATHY|DIABETES MELLITUS|CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Toronto General Hospital / Toronto Western Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[Cl-].[Na+],1,DB09153,__SODIUM_CHLORIDE,6248726,Completed,NCT03493503,CHILDHOOD ASTHMA WITH STATUS ASTHMATICUS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Erasmus MC, Rotterdam, Zuid-Holland, Netherlands",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,104.609950923016,13.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.06,58.44300000000001,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
COc1ccc(Oc2cc(N(C)CCOc3ccc(CC4SC(=O)NC4=O)cc3)ncn2)cc1,1,DB09198,__LOBEGLITAZONE,,Active Not Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.84,480.54,102.88,7.0,1.0,4.0,49.64,129.63,10.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0
C[C@H](C(=O)O)c1cccc(C(=O)c2ccccc2)c1,1,DB09214,__DEXKETOPROFEN,4097522,Active Not Recruiting,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07C51/09,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,24.969711903735103,126.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,254.2806,54.37,3.0,1.0,2.0,26.88,72.52,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
COC1=C(OC)C(=O)C(C/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CC/C=C(\C)CCC=C(C)C)=C(C)C1=O,1,DB09270,__UBIDECARENONE,4325942,Completed,,MUSCLE WEAKNESS,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,21.158545350007106,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.94,863.3435,52.6,4.0,0.0,1.0,112.38,286.61,31.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
Cn1c(=O)c2c(ncn2CC2OCCO2)n(C)c1=O,1,DB09273,__DOXOFYLLINE,5788987,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,18.135896014291802,94.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.94,266.257,76.9,5.0,0.0,3.0,25.92,64.69,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Recruiting,NCT03214731,LUPUS NEPHRITIS,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","The 1st Affiliated Hospital, Sun Yet-sen University, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@@H]1CC[C@H]2[C@@H](C)[C@H](OC(=O)CCC(=O)O)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@@]23OO4,1,DB09274,__ARTESUNATE,,Completed,,PLASMODIUM FALCIPARUM MALARIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.35,384.425,100.52,7.0,1.0,4.0,39.46,89.95,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].O=C([O-])CC([O-])(CC(=O)[O-])C(=O)[O-].[Bi+3].[K+].[K+].[K+].[K+].[K+],1,DB09275,__BISMUTH_SUBCITRATE_POTASSIUM,6350468,Unknown Status,,HELICOBACTER PYLORI INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/4808,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,20.3700281319945,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.79,780.654,143.45,7.0,0.0,0.0,13.97,78.69,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CCOC(=O)[N-]c1c[n+](N2CCOCC2)no1,1,DB09282,__MOLSIDOMINE,4731241,Completed,,ATHEROSCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,12.222016879196598,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,242.235,77.91,5.0,0.0,2.0,23.94,76.99,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0
Cn1cc(C(=O)[C@@H]2CCc3[nH]cnc3C2)c2ccccc21,1,DB09290,__RAMOSETRON,6235745,Completed,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,19.220107189059306,160.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.22,279.343,50.68,2.0,1.0,4.0,31.2,82.14,2.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CCOC(=O)[C@H](C)C[C@@H](Cc1ccc(-c2ccccc2)cc1)NC(=O)CCC(=O)O,1,DB09292,__SACUBITRIL,7468390,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,71.2950984619807,9.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.9,411.49800000000016,92.7,4.0,2.0,2.0,44.48,114.06,12.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,1,DB09299,__TENOFOVIR_ALAFENAMIDE,5814639,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.49,476.474,143.48,7.0,2.0,3.0,47.88,122.74,12.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,1,DB09299,__TENOFOVIR_ALAFENAMIDE,5814639,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D411/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,67.3853672560011,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.49,476.474,143.48,7.0,2.0,3.0,47.88,122.74,12.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1,1,DB09299,__TENOFOVIR_ALAFENAMIDE,5814639,Recruiting,NCT02957864,"RENAL INSUFFICIENCY,CHRONIC|HIV|THERAPEUTIC AGENT TOXICITY",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ziekenhuis Rijnstate, Arnhem, Gelderland, Netherlands|MC Slotervaart, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,67.3853672560011,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.49,476.474,143.48,7.0,2.0,3.0,47.88,122.74,12.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1
[F-].[Na+],1,DB09325,__SODIUM_FLUORIDE,8323683,Recruiting,NCT03818945,TOOTH HYPERSENSITIVITY,All,18 Years to 40 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Faculty of Dentistry, Giza, Egypt",A61K9/0058,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,90.58091541920773,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.15,41.9882,0.0,0.0,0.0,0.0,0.44,0.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
[F-].[Na+],1,DB09325,__SODIUM_FLUORIDE,8323683,Completed,NCT02936830,DENTIN HYPERSENSITIVITY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","Riyadh colleges of dentistry and pharmacy olaya campus, Riyadh, ArRiyadh, Saudi Arabia",A61K9/0058,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,90.58091541920773,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.15,41.9882,0.0,0.0,0.0,0.0,0.44,0.87,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61B5/0261,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)O)c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)O)c2ccc3ccccc3c21,1,DB09374,__INDOCYANINE_GREEN_ACID_FORM,6915154,Unknown Status,,"NEOPLASMS, BREAST",,,,,"FISABIO, Elche, Alicante, Spain",A61B5/0261,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,58.7773876260292,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.26,753.99,114.99,7.0,2.0,6.0,87.2,231.13,14.0,1.0,0.0,0.0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1
C#CC1(O)CCC2C3CCC4=CC(=O)CCC4C3CCC21CC,1,DB09389,__NORGESTREL,4145416,Recruiting,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,17.708782521201602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.25,312.453,37.3,2.0,1.0,4.0,36.83,92.03,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1
O=P([O-])(O)O.[Na+],1,DB09449,"__SODIUM_PHOSPHATE,_MONOBASIC",7084130,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,55.6561736380623,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-1.0,119.977,80.59,4.0,2.0,0.0,5.53,13.53,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(O)[C@H](O)[C@@H](O)C(=O)O,1,DB09459,__L-TARTARIC_ACID,,Withdrawn,NCT02568111,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,150.0868,115.06,6.0,4.0,0.0,11.33,26.21,3.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=P([O-])([O-])F.[Na+].[Na+],1,DB09484,__SODIUM_FLUOROPHOSPHATE,,Completed,NCT02923895,DENTIN SENSITIVITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"GSK Investigational Site, Mississauga, Ontario, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.54,143.94899999999996,63.19,3.0,0.0,0.0,4.59,11.35,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CO[Si](C)(C)O[Si](C)(C)C.O=[Si]=O,1,DB09512,__SIMETHICONE,6103260,Terminated,NCT02217982,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rocky Mountain MS Research Group, Salt Lake City, Utah, United States",8,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,36.9617445943448,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.6,238.46099999999998,18.46,2.0,0.0,0.0,18.48,37.63,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,1,DB09570,__IXAZOMIB,7442830,Recruiting,NCT04217967,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"PekingUMCH, Beijing, Beijing, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B(O)O,1,DB09570,__IXAZOMIB,7442830,"Active, not recruiting",NCT03416374,RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kameda Medical Center, Kamogawa, Chiba, Japan|The Jikei University Kashiwa Hospital, Kashiwa, Chiba, Japan|Ogaki Municipal Hospital, Ogaki, Gifu, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Shibukawa Medical Center, Shibukawa, Gunma, Japan|Kobe city Medical Center General Hospital, Kobe, Hyogo, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, Japan|Iwate Medical University, Morioka, Iwate, Japan|Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa, Japan|Suwa Red Cross Hospital, Suwa, Nagano, Japan|Dokkyo Medical University, Koshigaya, Saitama, Japan|Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan|Nippon Medical School Hospital, Bunkyo-ku, Tokyo, Japan|Nihon University Itabashi Hospital, Itabashi-ku, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan|The Jikei University Hospital, Minato-ku, Tokyo, Japan|Kyorin University Hospital, Mitaka, Tokyo, Japan|Japanese Red Cross Medical Center, Shibuya-ku, Tokyo, Japan|Tokyo Disaster Medical Center, Tachikawa, Tokyo, Japan|Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan|Kyoto Kuramaguchi Medical Center, Kyoto, Japan|Niigata Cancer Center Hospital, Niigata, Japan|Osaka Red Cross Hospital, Osaka, Japan",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,14.751842953654,9.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.06,361.03,98.66,4.0,4.0,1.0,36.3,84.56,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
O=[N+]([O-])[O-].[Ag+],1,DB11080,__SILVER_NITRATE,,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.027999999999999997,169.8731,68.88,3.0,0.0,0.0,3.24,9.85,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,"Active, not recruiting",NCT03621553,SARCOIDOSIS|VITAMIN D INSUFFICIENCY,All,"21 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Completed,NCT01400516,RHEUMATOID ARTHRITIS,All,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11093,__CALCIUM_CITRATE,,Active Not Recruiting,,SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.13,498.43199999999996,140.62,7.0,1.0,0.0,14.23,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[Mg+2].[Mg+2].[Mg+2],1,DB11110,__MAGNESIUM_CITRATE,,Recruiting,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.08,451.11300000000006,140.62,7.0,1.0,0.0,14.25,68.14,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.O=C([O-])c1ccccn1.[Cr+3],1,DB11255,__CHROMIUM_PICOLINATE,,Completed,NCT00398853,TYPE 2 DIABETES,All,"25 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Pennington Biomedical Research Center, Baton Rouge, Louisiana, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.9,418.3005,53.02,3.0,0.0,3.0,10.94,41.62,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CN1c2c([nH]c(N)nc2=O)NC[C@@H]1CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1,1,DB11256,__LEVOMEFOLIC_ACID,5798338,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,16.7559908827696,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.58,459.4558,198.48,12.0,7.0,3.0,46.56,126.68,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1
O=P([O-])([O-])[O-].O=P([O-])([O-])[O-].[Ca+2].[Ca+2].[Ca+2],1,DB11348,__CALCIUM_PHOSPHATE,,Not yet recruiting,NCT04540835,POSTOPERATIVE PAIN,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,310.177,86.25,4.0,0.0,0.0,4.93,11.29,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
O=C(CCCN1CCN(c2ccccn2)CC1)c1ccc(F)cc1,1,DB11376,__AZAPERONE,4508715,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,35.64754923099029,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.73,327.403,36.44,4.0,0.0,3.0,36.19,94.27,6.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C,1,DB11574,__ELBASVIR,7973040,Completed,NCT03098121,CHRONIC HEPATITIS C,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taoyuan general hospital, Taoyuan, Taiwan",C07K5/0808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.6,882.035,188.8,7.0,4.0,9.0,100.15,241.52,13.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,1
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4cnc([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]4)ccc32)[nH]1)C(C)C,1,DB11574,__ELBASVIR,7973040,Recruiting,NCT03823911,CARDIOVASCULAR DISEASES|HEPATITIS C|HIV,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Unity Parkside Health Center, Washington, District of Columbia, United States|Institute of Human Virology, CRU, Baltimore, Maryland, United States",C07K5/0808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.6,882.035,188.8,7.0,4.0,9.0,100.15,241.52,13.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,1
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,1,DB11575,__GRAZOPREVIR,7973040,Completed,NCT03098121,CHRONIC HEPATITIS C,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taoyuan general hospital, Taoyuan, Taiwan",C07K5/0808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.26,766.903,195.22,10.0,3.0,7.0,79.37,193.61,7.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1,1,DB11575,__GRAZOPREVIR,7973040,Recruiting,NCT03823911,CARDIOVASCULAR DISEASES|HEPATITIS C|HIV,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Unity Parkside Health Center, Washington, District of Columbia, United States|Institute of Human Virology, CRU, Baltimore, Maryland, United States",C07K5/0808,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,23.589806772212896,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.26,766.903,195.22,10.0,3.0,7.0,79.37,193.61,7.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02513290,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT01940393,URTICARIA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medellin, Medellin, Antioquia, Colombia",C07D335/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02576041,ALLERGIC RHINITIS|URTICARIA,All,21 Years to 55 Years   (Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Azienda Ospedaliero-Universitaria Policlinico, Modena, Italy",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
CCOCCn1c(C2CCN(CCc3ccc(C(C)(C)C(=O)O)cc3)CC2)nc2ccccc21,1,DB11591,__BILASTINE,EP-0818454-A1,Completed,NCT02761252,SEASONAL ALLERGIC RHINOCONJUNCTIVITIS|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Cakovec, Croatia|Rijeka, Croatia|Zagreb, Croatia|Brno, Czechia|Ostrava Hrabuvka, Czechia|Teplice, Czechia|Dreieich, Germany|Heidelberg, Germany|Catania, Italy|Florence, Italy|Modena, Italy|Pavia, Italy|Verona, Italy|Riga, Latvia|Bialystok, Poland|Bielsko-Biala, Poland|Gdansk, Poland|Katowice, Poland|Krakow, Poland|Lodz, Poland|Lublin, Poland|Nowy Duninow, Poland|Poznan, Poland|Rzeszow, Poland|Tarnow, Poland|Wroclaw, Poland|Brasov, Romania|Bucharest, Romania|Cluj Napoca, Romania|Ploieşti, Romania|Bardejov, Slovakia|Levice, Slovakia",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,82.3671943982422,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.02,463.62199999999996,67.59,5.0,1.0,4.0,54.96,135.58,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1,0,1
COC[C@H]1C[C@@H](c2ncc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1,1,DB11613,__VELPATASVIR,7964580,Completed,NCT03250910,"HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF|HUMAN IMMUNODEFICIENCY VIRUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,38.9987474075443,17.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.39,883.0189999999999,193.1,8.0,4.0,9.0,97.05,240.57,13.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,1
Cc1cncc(CN2CCC(=C3c4ccc(Cl)cc4CCc4cccnc43)CC2)c1,1,DB11614,__RUPATADINE,5407941,Unknown status,NCT00258141,ALLERGY,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,"Ulappatorin Lääkäriasema, Espoo, Finland|Koskiklinikka, Tampere Lääkärikeskus, Tampere, Finland",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,23.0312737427873,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.82,415.97,29.02,3.0,0.0,5.0,46.98,133.83,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@@H]2CCCCO2)[C@H](C)O1,1,DB11616,__PIRARUBICIN,4818818,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07H15/252,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,29.14228218238561,628.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.06,627.643,204.3,13.0,5.0,6.0,64.85,157.38,7.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
C[C@]1(COc2ccc(N3CCC(Oc4ccc(OC(F)(F)F)cc4)CC3)cc2)Cn2cc([N+](=O)[O-])nc2O1,1,DB11637,__DELAMANID,EP-1555267-A1,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",A61P11/00,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,48.0,111.246637507957,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.71,534.492,101.12,8.0,0.0,5.0,51.59,124.85,9.0,1.0,0.0,0.0,1,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,0
O=C(NC(Cc1cc(=O)[nH]c2ccccc12)C(=O)O)c1ccc(Cl)cc1,1,DB11656,__REBAMIPIDE,5476858,Completed,NCT03608761,DRY EYE SYNDROMES|SJÖGREN SYNDROME,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Hospital Nacional Profesor A. Posadas, El Palomar, Buenos Aires, Argentina",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,23.425532351793603,66.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.32,370.79,95.5,4.0,3.0,3.0,36.82,98.5,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Recruiting,NCT03917784,PRE-DIABETES,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital General de México Dr. Eduardo Liceaga, Mexico City, Cuauhtémoc, Mexico",C09B61/00,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
COc1cc(/C=C/C(=O)CC(=O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,DB11672,__CURCUMIN,4138212,Not Yet Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C09B61/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.905911825704802,1703.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,368.3799,93.06,6.0,2.0,2.0,38.12,103.81,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
CCOc1cc(N)c(Cl)cc1C(=O)NCC1CN(Cc2ccc(F)cc2)CCO1,1,DB11675,__MOSAPRIDE,4870074,Unknown Status,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D413/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,29.109427298301807,83.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,421.9,76.82,5.0,2.0,3.0,43.79,112.34,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1
OC[C@H]1O[C@@H](c2ccc(F)c(Cc3cc4ccccc4s3)c2)[C@H](O)[C@@H](O)[C@@H]1O,1,DB11698,__IPRAGLIFLOZIN,EP-2009010-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.49,404.45,90.15,5.0,4.0,4.0,40.7,102.41,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Unknown status,NCT02576327,VOMITING,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CN1[C@H]2CC[C@@H]1C[C@H](OC(=O)c1c[nH]c3ccccc13)C2,1,DB11699,__TROPISETRON,5032578,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,9.92217499332635,632.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,284.3529,45.33,2.0,1.0,4.0,31.35,81.5,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,0
CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,1,DB11742,__EBASTINE,4550116,Completed,NCT01940393,URTICARIA,All,"12 Years to 50 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medellin, Medellin, Antioquia, Colombia",A61K9/2054,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,15.178956446744197,335.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.89,469.6576,29.54,3.0,0.0,4.0,55.41,145.38,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1
CC(C)(C)c1ccc(C(=O)CCCN2CCC(OC(c3ccccc3)c3ccccc3)CC2)cc1,1,DB11742,__EBASTINE,4550116,Completed,NCT01144832,IRRITABLE BOWEL SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University hospitals Leuven, Leuven, Vlaams-Brabant, Belgium",A61K9/2054,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,15.178956446744197,335.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.89,469.6576,29.54,3.0,0.0,4.0,55.41,145.38,10.0,0.0,1.0,0.0,0,1,0,0,0,1,1,0,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB11750,__CLOBETASOL,4333927,Unknown status,NCT02360202,BULLOUS PEMPHIGOID,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Rouen University Hospital, Rouen, France",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,14.8504076059056,513.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,410.907,74.6,4.0,2.0,4.0,41.97,105.54,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,1,DB11750,__CLOBETASOL,4333927,Not yet recruiting,NCT03926377,OSTEOPOROSIS|BULLOUS PEMPHIGOID,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,14.8504076059056,513.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.72,410.907,74.6,4.0,2.0,4.0,41.97,105.54,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H]1CO[C@@H]2Cn3cc(C(=O)NCc4ccc(F)cc4F)c(=O)c(O)c3C(=O)N12,1,DB11751,__CABOTEGRAVIR,WO-2006116764-A1,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,56.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.76,405.358,99.18,6.0,2.0,4.0,37.91,97.9,3.0,0.0,1.0,0.0,1,0,1,1,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12,1,DB11793,__NIRAPARIB,8859562,Recruiting,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,122.71299205322399,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.45,320.39599999999996,72.94,3.0,2.0,4.0,36.41,94.92,3.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Not yet recruiting,NCT04054089,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Recruiting,NCT03711253,ACUTE HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"LA County-USC Medical Center Emergency Department, Los Angeles, California, United States|Rand Schrader Health and Research Clinic, Los Angeles, California, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Recruiting,NCT04132674,HUMAN IMMUNODEFICIENCY VIRUS I INFECTION|DRUG USE,All,"19 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Vancouver Infectious Diseases Centre, Vancouver, British Columbia, Canada|Victoria Cool Aid Society, Victoria, British Columbia, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,"Active, not recruiting",NCT04538040,HIV-1 INFECTION,Male,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SFOMG Private Practice, San Francisco, California, United States",7,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Recruiting,NCT03499483,HIV PREVENTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Fenway Community Health, Boston, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
O=C(NCc1c(F)cc(F)cc1F)c1cn2c(c(O)c1=O)C(=O)N1[C@H]3CC[C@H](C3)O[C@@H]1C2,1,DB11799,__BICTEGRAVIR,6703396,Not Yet Recruiting,,DRUG USE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,107.89543933140301,11.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.28,449.38599999999997,99.18,6.0,2.0,5.0,41.14,105.44,3.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1
CNC(=N)NCCC[C@H](N)C(=O)O,1,DB11815,__TILARGININE,EP-0765668-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61K36/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,59.0,31.080720343333503,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,188.2275,111.23,6.0,5.0,0.0,20.01,58.7,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1
CCS(=O)(=O)N1CC(CC#N)(n2cc(-c3ncnc4[nH]ccc34)cn2)C1,1,DB11817,__BARICITINIB,8158616,Recruiting,NCT04086745,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Arthritis & Rheumatology Research, PLLC, Flagstaff, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Gilbert, Arizona, United States|Arizona Arthritis & Rheumatology Research, Glendale, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Mesa, Arizona, United States|Hope Research Institute, Peoria, Arizona, United States|Sun Valley Arthritis Center, LTD, Peoria, Arizona, United States|Hope Research Institute, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Research, Phoenix, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Phoenix, Arizona, United States|Prescott Rheumatology, Prescott, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Sun City, Arizona, United States|Arizona Arthritis & Rheumatology Associates, P. C., Tucson, Arizona, United States|Arthritis and Rheumatism Associates, Jonesboro, Arkansas, United States|Hope Clinical Research, Canoga Park, California, United States|Medvin Clinical Research - Weidmann, Covina, California, United States|TriWest Research Associates LLC, El Cajon, California, United States|St. Joseph Heritage Medical Group, Fullerton, California, United States|MD Medical Corporation, Hemet, California, United States|Newport Huntington Med Grp, Huntington Beach, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Valerius Medical Group and Research Center of Greater Long Beach, Los Alamitos, California, United States|Soha Dolatabadi, MD, Los Angeles, California, United States|Providence St. Joseph's Medical Center, Mission Hills, California, United States|Desert Medical Advances, Palm Desert, California, United States|ACRC Studies, Poway, California, United States|East Bay Rheumatology Medical Group, Inc, San Leandro, California, United States|Dan La, MD Inc, Tujunga, California, United States|Iraj Sabahi Research Inc., Turlock, California, United States|Office: Dr Robin K Dore, Tustin, California, United States|Inland Rheumatology & Osteoporosis Medical Group, Upland, California, United States|Nazanin Firooz, MD Inc., West Hills, California, United States|Nazanin Firooz, MD Inc., West Hills, California, United States|Medvin Clinical Research - Weidmann, Whittier, California, United States|Danbury Clinical Research, LLC, Danbury, Connecticut, United States|Delaware Arthritis, Lewes, Delaware, United States|Bay Area Arthritis and Osteoporosis, Brandon, Florida, United States|SIMED Health, Gainesville, Florida, United States|GNP Research at Mark Jaffe, MD, Hollywood, Florida, United States|Arthritis and Rheumatology Center of South Florida, Margate, Florida, United States|Miami Clinical Reserach, Miami, Florida, United States|Rheumatology Associates of Central Florida, Orlando, Florida, United States|Heuer MD Research, Orlando, Florida, United States|Arthritis Center, Inc, Palm Harbor, Florida, United States|Lovelace Scientific Resources, Riverview, Florida, United States|West Broward Rheumatology Associates, Inc, Tamarac, Florida, United States|Avita Clinical Research, Tampa, Florida, United States|Florida Medical Clinic LLC, Zephyrhills, Florida, United States|Arthritis Center of North Georgia, Gainesville, Georgia, United States|Rockford Orthopedic Associates, Rockford, Illinois, United States|Greater Chicago Specialty Physicians, LLC, Schaumburg, Illinois, United States|Center of Robert Hozman, Skokie, Illinois, United States|Beacon Medical Group Clinical Research, South Bend, Indiana, United States|Graves-Gilbert Clinic, Bowling Green, Kentucky, United States|Western KY Rheumatology PLLC, Hopkinsville, Kentucky, United States|Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States|Arthritis Care Specialists of Maryland, Columbia, Maryland, United States|Klein & Associates, M.D., P.A, Hagerstown, Maryland, United States|NECCR PrimaCare Research, Fall River, Massachusetts, United States|University of Michigan, Brighton, Michigan, United States|Pandit Rheumatology PC, Okemos, Michigan, United States|West County Rheumatology, Saint Louis, Missouri, United States|Clinvest Research LLC, Springfield, Missouri, United States|Allied Clinical Research, Reno, Nevada, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Santa Fe Rheumatology, Santa Fe, New Mexico, United States|NYU Langone, New York, New York, United States|Medication Management, LLC, Greensboro, North Carolina, United States|Cape Fear Arthritis Care, Leland, North Carolina, United States|Carolina Arthritis Associates, Wilmington, North Carolina, United States|Cincinnati Arthritis Associates, Cincinnati, Ohio, United States|Craig S Thompson MD LLC, Marion, Ohio, United States|Paramount Medical Research, Middleburg Heights, Ohio, United States|Arthritis & Rheumatology Center of Oklahoma PLLC, Oklahoma City, Oklahoma, United States|The Oklahoma Center For Arthritis Therapy, Tulsa, Oklahoma, United States|Good Samaritan Hospital Corvallis, Corvallis, Oregon, United States|Pennsylvania Regional Center for Arthritis and Osteoporosis Research, Wyomissing, Pennsylvania, United States|Articularis Healthcare d/b/a/ Low Country Rheumatology, PA, Summerville, South Carolina, United States|Monument Health Clinical Research, a department of Monument Health Rapid City Hospital, Inc., Rapid City, South Dakota, United States|Cumberland Rheumatology, Crossville, Tennessee, United States|Nashville Arthritis and Rheumatology, Nashville, Tennessee, United States|Accent Clinical Research Professionals, LLC, Allen, Texas, United States|Amarillo Center for Clinical Research, Amarillo, Texas, United States|Accurate Clinical Management, Baytown, Texas, United States|Arthritis & Osteoporosis Clinic of Brazos Valley, College Station, Texas, United States|Adriana Pop Moody Clinic PA, Corpus Christi, Texas, United States|Pioneer Research Solutions, Cypress, Texas, United States|Metroplex Clinical Research Center, Dallas, Texas, United States|El Paso Integrated Physicians Group, P.A., an Elligo Health Research, Inc. Healthcare Enabled Research Organization, El Paso, Texas, United States|DM Clinical Research/Rheumatology Clinic of Houston, Houston, Texas, United States|Accurate Clinical Management LLC - Katy, Houston, Texas, United States|Accurate Clinical Research, Houston, Texas, United States|Synergy Group US, Katy, Texas, United States|Accurate Clinical Research, League City, Texas, United States|Southwest Rheumatology, P.A., Mesquite, Texas, United States|Synergy Group US, Missouri City, Texas, United States|Accurate Clinical Research, Inc., San Antonio, Texas, United States|South Texas Arthritis Care Center, San Antonio, Texas, United States|Mt. Olympus Medical Research, Sugar Land, Texas, United States|North Houston Rheumatology Associates, The Woodlands, Texas, United States|Center for Arthritis and Rheumatic Diseases, PC, Chesapeake, Virginia, United States|Spectrum Medical Inc., Danville, Virginia, United States|Arthritis & Osteoporosis Center of Northern Virinia, Manassas, Virginia, United States|TPMG Rheumatology/TPMG Clinical Research, Newport News, Virginia, United States|Arthritis Northwest, PLLC, Spokane, Washington, United States|Rheumatology and Pulmonary Clinic, Beckley, West Virginia, United States|Rheumatic Disease Center, Glendale, Wisconsin, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,37.257438551099604,12.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.08,371.42,120.56,6.0,1.0,4.0,36.72,105.55,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC(O)C(CO)N=C(O)C1CSSCC(N=C(O)C(Cc2ccccc2)N=C([O-])CN(CCN(CCC(C(=O)O)C(=O)O)CC(=O)[O-])CC(=O)[O-])C(O)=NC(Cc2ccccc2)C(O)=NC(Cc2c[nH]c3ccccc23)C(O)=NC(CCCCN)C([O-])=NC(C(C)O)C(O)=N1.[111In+3],1,DB11835,__INDIUM_IN-111_PENTETREOTIDE,6123916,Terminated,NCT00944372,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Miami, Jackson Memorial Hospital, Miami, Florida, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Louisiana State University, Division of Hem/Onc, New Orleans, Louisiana, United States|Hospital of University of Pennsylvania, Division of Nuclear Medicine, Philadelphia, Pennsylvania, United States",A61K38/31,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,75.4676687406312,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.24,1472.41,530.22,30.0,13.0,5.0,136.16,391.61,32.0,1.0,0.0,0.0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,1,0
CCCCC/C=C\C/C=C\C=C\C=C\[C@@H](SC[C@H](N)C(=O)NCC(=O)O)[C@@H](O)CCCC(=O)O,1,DB11858,__LEUKOTRIENE_D4,,Unknown status,NCT02574975,ASTHMA,All,"14 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Zhujiang Hospital, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,496.66,149.95,7.0,5.0,0.0,56.08,140.42,20.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0
CNC(=O)c1ccc(N2C(=S)N(c3cnc(C#N)c(C(F)(F)F)c3)C(=O)C23CCC3)cc1F,1,DB11901,__APALUTAMIDE,8445507,Recruiting,,PROSTATIC NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,73.82492453643809,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.05,477.44,89.33,4.0,1.0,4.0,43.44,113.6,4.0,0.0,1.0,0.0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1
[111In],1,DB11916,__INDIUM_IN-111,,Terminated,NCT00944372,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Miami, Jackson Memorial Hospital, Miami, Florida, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Louisiana State University, Division of Hem/Onc, New Orleans, Louisiana, United States|Hospital of University of Pennsylvania, Division of Nuclear Medicine, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,110.9051,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C(Cn1ccnc1[N+](=O)[O-])NCc1ccccc1,1,DB11989,__BENZNIDAZOLE,5273992,Completed,,CHAGAS DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,13.831906199305902,117.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.92,260.253,90.06,4.0,1.0,2.0,24.96,67.12,5.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1
CS(=O)(=O)n1cc2c(n1)CN([C@H]1CO[C@H](c3cc(F)ccc3F)[C@@H](N)C1)C2,1,DB11992,__OMARIGLIPTIN,WO-2013003249-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,32.7488,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.63,398.43,90.45,6.0,1.0,4.0,39.42,95.14,2.0,0.0,1.0,0.0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0
O=C(Nc1nc(-c2cc(Cl)cs2)c(N2CCN(C3CCCCC3)CC2)s1)c1cnc(N2CCC(C(=O)O)CC2)c(Cl)c1,1,DB11995,__AVATROMBOPAG,7638536,Not Yet Recruiting,,IMMUNE THROMBOCYTOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,83.4514055730097,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.97,649.65,101.9,8.0,2.0,6.0,69.95,169.16,7.0,0.0,1.0,0.0,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1
O=c1c(-c2ccccc2)coc2ccccc12,1,DB12007,__ISOFLAVONE,4234577,Completed,NCT01052116,ASTHMA,All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|University of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore - Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,17.0,20.041479291155802,192.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.51,222.243,26.3,2.0,0.0,3.0,23.64,65.74,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1Oc2cc(cnc2N)-c2c(nn(C)c2C#N)CN(C)C(=O)c2ccc(F)cc21,1,DB12130,__LORLATINIB,8680111,Not yet recruiting,NCT04362072,CARCINOMA|NON-SMALL-CELL LUNG,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Cancer & Blood Center, Llc, Athens, Georgia, United States|Ms Pneumed Janusz Milanowski, Katarzyna Szmygin-Milanowska Spolka Jawna, Lublin, Poland|Elkardia Lubelskie Centrum Kardiologii, Lublin, Poland|Centrum Medyczne Luxmed Sp. z o.o., Lublin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie, Lublin, Poland|Centrum Medyczne EVOMED, Szczecin, Poland|Dom Lekarski Centrum Medyczne Outlet Park, Szczecin, Poland|Dom Lekarski S.A., Szczecin, Poland|Samodzielny Publiczny Szpital Kliniczny Nr 1 im. prof. Tadeusza Sokolowskiego Pomorskiego UM, Szczecin, Poland|Hospital Teresa Herrera (C.H.U.A.C), A Coruña, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain",C07D498/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,12.649130372286901,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.01,406.421,110.06,6.0,1.0,4.0,40.42,121.17,0.0,0.0,1.0,0.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB12148,__MENATETRENONE,5044091,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A23L3/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,16.591716462350302,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,444.659,34.14,2.0,0.0,2.0,54.92,145.51,11.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,,ALCOHOL DEPENDENCE,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Completed,,GLAUCOMA,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
C[N+](C)(C)CCOP(=O)([O-])OP(=O)(O)OC[C@H]1O[C@@H](n2ccc(N)nc2=O)[C@H](O)[C@@H]1O,1,DB12153,__CITICOLINE,4203893,Withdrawn,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",G01N33/531,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,20.6657220887492,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,488.324,213.5,10.0,4.0,2.0,42.54,113.58,10.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0
CC(C)(S)C(=O)N[C@@H](CS)C(=O)O,1,DB12160,__BUCILLAMINE,4241086,Unknown status,NCT00716248,RHEUMATOID ARTHRITIS,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,14.6204234173186,128.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.52,223.31,66.4,3.0,4.0,0.0,22.09,54.7,4.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
COc1cccc(CCc2ccccc2OCC(CN(C)C)OC(=O)CCC(=O)O)c1,1,DB12163,__SARPOGRELATE,5652272,Unknown Status,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,28.4851845007084,36.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.57,429.51300000000003,85.3,6.0,1.0,2.0,46.89,117.35,14.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Recruiting,NCT03855007,RHEUMATOID ARTHRITIS,All,"16 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Qilu Hospital, Jinan, Shandong, China",C07D405/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1,1,DB12233,__IGURATIMOD,4954518,Unknown Status,,IGG4-RELATED DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D405/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,22.899854206451806,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.14,374.37,110.8,5.0,2.0,3.0,36.19,92.79,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC1=NN(c2ccccc2)C(=O)C1,1,DB12243,__EDARAVONE,6933310,Completed,,STROKE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,57.2989178422554,88.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.53,174.203,32.67,2.0,0.0,2.0,18.61,49.49,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccccc1Cl,1,DB12248,__TULOBUTEROL,4018818,Unknown Status,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07C49/86,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,23.4912421199613,364.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.95,227.73,32.26,2.0,2.0,1.0,24.53,63.88,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,1,DB12301,__DORAVIRINE,8486975,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,27.630957514528,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.51,425.749,98.03,5.0,1.0,3.0,36.06,96.41,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,1,DB12301,__DORAVIRINE,8486975,"Active, not recruiting",NCT04538040,HIV-1 INFECTION,Male,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"SFOMG Private Practice, San Francisco, California, United States",4,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,27.630957514528,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.51,425.749,98.03,5.0,1.0,3.0,36.06,96.41,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0
Cn1c(Cn2ccc(C(F)(F)F)c(Oc3cc(Cl)cc(C#N)c3)c2=O)n[nH]c1=O,1,DB12301,__DORAVIRINE,8486975,Not yet recruiting,NCT04334551,HIV INFECTION,All,"18 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinique Du Quartier Latin, Montreal, Quebec, Canada|CHU Martinique, Fort-de-France, Fort De France, Martinique",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,27.630957514528,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.51,425.749,98.03,5.0,1.0,3.0,36.06,96.41,5.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CCc1oc2ccccc2c1C(=O)c1cc(Br)c(O)c(Br)c1,1,DB12319,__BENZBROMARONE,5260066,Recruiting,,HYPERURICEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61L15/44,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,21.7827881476005,98.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.52,424.083,50.44,2.0,1.0,3.0,35.65,92.37,3.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0
CO[C@@]1(NC(=O)C(C(=O)O)c2ccsc2)C(=O)N2[C@@H](C(=O)O)C(C)(C)S[C@@H]21,1,DB12343,__TEMOCILLIN,5543417,Unknown Status,,INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K45/06,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,31.0,21.5199490749296,163.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.13,414.45,133.24,7.0,3.0,3.0,38.91,94.22,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CN(CC(O)CO)C(=O)c1c(I)c(NC(=O)C(CO)CO)c(I)c(C(=O)N(C)CC(O)CO)c1I,1,DB12407,__IOBITRIDOL,6437010,Completed,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",B01J49/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,21.8813527998521,81.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,835.169,191.1,9.0,7.0,1.0,61.59,156.01,12.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,1,0,0
N[C@@H](CC(=O)N1CCc2c(nc(C(F)(F)F)nc2C(F)(F)F)C1)CN1CC(F)(F)CCC1=O,1,DB12412,__GEMIGLIPTIN,WO-2006104356-A1,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,32.7488,6.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.02,489.37,92.42,5.0,1.0,3.0,39.04,97.25,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[O+][O-],1,DB12510,__OZONE,,Unknown Status,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.21,47.997,74.27,3.0,0.0,0.0,2.31,4.24,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
C[C@@H](O)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN(CCN(CCN(CC(=O)O)CC(=O)O)CC(=O)O)CC(=O)O)CSSC[C@@H](C(=O)N[C@H](CO)[C@@H](C)O)NC1=O,1,DB12602,__PENTETREOTIDE,6180082,Terminated,NCT00944372,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"University of Miami, Jackson Memorial Hospital, Miami, Florida, United States|University of Iowa Medical Center, Iowa City, Iowa, United States|Louisiana State University, Division of Hem/Onc, New Orleans, Louisiana, United States|Hospital of University of Pennsylvania, Division of Nuclear Medicine, Philadelphia, Pennsylvania, United States",A61K51/083,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,26.2510523830058,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.0,1394.58,494.22,23.0,17.0,5.0,140.9,353.02,34.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,1,0,0,1,1,0,1,0,0
CCCc1cc(C(N)=S)ccn1,1,DB12667,__PROTIONAMIDE,4005207,Completed,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,29.635105443643603,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.25,180.27,38.91,1.0,1.0,1.0,20.09,54.79,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
O=C(Nc1ccccc1-c1ccc(Cl)cc1)c1cccnc1Cl,1,DB12792,__BOSCALID,6235684,Completed,,DRY EYE,,,,,"FISABIO, Elche, Alicante, Spain",A01N37/50,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,14.751842953654,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.91,343.207,41.99,2.0,1.0,3.0,33.9,95.24,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1,1,DB12808,__TRIFAROTENE,7807708,Enrolling by Invitation,,ACNE VULGARIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C233/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,39.360151132466704,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.12,459.586,70.0,5.0,2.0,4.0,53.11,136.98,8.0,0.0,1.0,0.0,1,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)CC(=O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB12952,__METHYLPREDNISONE,EP-0563249-B1,Completed,NCT00367562,IGA NEPHROPATHY,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Britanico de Buenos Aires, Buenos Aires, Argentina",A61K47/6907,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,64.3298630362019,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.24,372.461,91.67,5.0,2.0,4.0,40.27,102.12,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
O=C1NOCC1/N=C/c1ccc(/C=N/C2CONC2=O)cc1,1,DB12954,__TERIZIDONE,4031231,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",4,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,16.920265303188902,35.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.17,302.29,101.38,6.0,2.0,3.0,29.9,76.99,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,NCT00831376,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Dundee, Angus, United Kingdom",C09K3/30,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1,1,DB13139,__LEVOSALBUTAMOL,5836299,Terminated,,ASTHMA ACUTE,,,,,"FISABIO, Elche, Alicante, Spain",C09K3/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,44.61693258588471,642.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.44,239.3107,72.72,4.0,4.0,1.0,26.87,67.87,5.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
N[C@]1(C(=O)O)C[C@@H]([18F])C1,1,DB13146,__FLUCICLOVINE_(18F),5808146,Recruiting,,METASTATIC HORMONE REFRACTORY PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C229/20,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,34.2019343313004,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.0,132.125,63.32,3.0,2.0,1.0,11.65,27.75,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0
CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.CC(=O)Nc1ccc(C(=O)O)cc1.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.C[C@@H](O)CN(C)C.O=c1[nH]cnc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O,1,DB13156,__INOSINE_PRANOBEX,,Active Not Recruiting,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.9,1115.249,129.2,7.0,4.0,6.0,24.6,61.33,14.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=S(=O)([O-])[O-].[Fe+2],1,DB13257,__FERROUS_SULFATE_ANHYDROUS,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,151.908,80.26,4.0,0.0,0.0,5.81,11.53,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.[Al+3].[Al+3].[O-2].[O-2].[O-2],1,DB13654,__MONTMORILLONITE,,Completed,,DIARRHEA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.66,360.30699999999996,34.14,2.0,0.0,0.0,3.28,2.89,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CN1CCCN=C1/C=C/c1cccc(O)c1,1,DB13670,__OXANTEL,4865598,Completed,,HOOKWORM INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0004,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,19.3186718413109,137.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.26,216.28400000000002,35.83,3.0,1.0,2.0,24.63,66.9,2.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CN(C)CC[C@@H](c1ccc(Cl)cc1)c1ccccn1,1,DB13679,__DEXCHLORPHENIRAMINE,4619934,Completed,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,15.6717797080022,310.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.74,274.79,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
O=C([O-])c1ccccc1-c1c2cc(Br)c(=O)c(Br)c-2oc2c(Br)c([O-])c(Br)cc12.[Na+].[Na+],1,DB13706,__EOSIN,3932356,Not yet recruiting,NCT04527016,ASTHMA IN CHILDREN,All,1 Year to 5 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",C08F2/46,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,37.4217129715189,1701.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.12,691.8589999999997,89.49,5.0,0.0,4.0,46.14,155.26,1.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT02730351,ASTHMA,All,"12 Years to 50 Years   (Child, Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Savannah, Georgia, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Sherwood Park, Alberta, Canada|GSK Investigational Site, Mississauga, Ontario, Canada|GSK Investigational Site, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00689832,"DERMATITIS, ATOPIC",All,2 Years to 15 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Paris, France",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00119158,ATOPIC DERMATITIS,All,"2 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","National Jewish Research Medical Center, Denver, Colorado, United States|Northwestern University School of Medicine, Chicago, Illinois, United States|University of Texas at Houston Medical School, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02402465,ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","The University of Chicago Medicine, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT02238353,ALLERGIC RHINITIS|HOUSE DUST MITE ALLERGY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Uz Leuven Dienst Nko, Leuven, Vlaams Brabant, Belgium",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01439815,ALLERGIC RHINITIS|ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Ora, Inc., Andover, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00848965,"RHINITIS, ALLERGIC, PERENNIAL|ALLERGIC RHINITIS",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Vienna, Austria",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00682643,"RHINITIS, ALLERGIC, PERENNIAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Oxford, Alabama, United States|GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Fresno, California, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Mission Viejo, California, United States|GSK Investigational Site, Rolling Hills Estates, California, United States|GSK Investigational Site, Roseville, California, United States|GSK Investigational Site, Sacramento, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, San Jose, California, United States|GSK Investigational Site, Stockton, California, United States|GSK Investigational Site, Vista, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Colorado Springs, Colorado, United States|GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Wheat Ridge, Colorado, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Conyers, Georgia, United States|GSK Investigational Site, Gainesville, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Stockbridge, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Bethesda, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Bozeman, Montana, United States|GSK Investigational Site, Bellevue, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Ocean, New Jersey, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Asheville, North Carolina, United States|GSK Investigational Site, Raleigh, North Carolina, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Eugene, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Summerville, South Carolina, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, El Paso, Texas, United States|GSK Investigational Site, Kerrville, Texas, United States|GSK Investigational Site, San Antonio, Texas, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, South Burlington, Vermont, United States|GSK Investigational Site, Spokane, Washington, United States|GSK Investigational Site, Greenfield, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00502775,"RHINITIS, ALLERGIC, SEASONAL",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Albany, Georgia, United States|GSK Investigational Site, Columbus, Georgia, United States|GSK Investigational Site, Lawrenceville, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Normal, Illinois, United States|GSK Investigational Site, Evansville, Indiana, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Lafayette, Indiana, United States|GSK Investigational Site, South Bend, Indiana, United States|GSK Investigational Site, Iowa City, Iowa, United States|GSK Investigational Site, Louisville, Kentucky, United States|GSK Investigational Site, Owensboro, Kentucky, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Sunset, Louisiana, United States|GSK Investigational Site, Novi, Michigan, United States|GSK Investigational Site, Ypsilanti, Michigan, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Plymouth, Minnesota, United States|GSK Investigational Site, Jackson, Mississippi, United States|GSK Investigational Site, Columbia, Missouri, United States|GSK Investigational Site, Rolla, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, St. Louis, Missouri, United States|GSK Investigational Site, Warrensburg, Missouri, United States|GSK Investigational Site, Lincoln, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Omaha, Nebraska, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Sylvania, Ohio, United States|GSK Investigational Site, Oklahoma City, Oklahoma, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Spartanburg, South Carolina, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Waco, Texas, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States|GSK Investigational Site, West Allis, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00903227,ASTHMA|ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Asthma and Allergy Research Group, Ninewells Hospital and University of Dundee, Dundee, Angus, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Unknown status,NCT00235053,"ASTHMA|CANDIDIASIS, ORAL|VOICE DISORDERS",All,18 Years to 55 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Allergy & Asthma Medical Group & Research Center, San Diego, California, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Terminated,NCT01554488,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE|OBSTRUCTIVE SLEEP APNEA,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"William S. Middleton Memorial Veterans Hospital, Madison, WI, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01915914,SKIN DISEASES,All,"1 Year to 18 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Shenzhen, Guangdong, China|GSK Investigational Site, Changsha, Hunan, China|GSK Investigational Site, Beijing, China|GSK Investigational Site, Shanghai, China",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00891436,ALLERGIC CONJUNCTIVITIS TO TREE POLLEN OR GRASS POLLEN,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Rush University Medical Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00655109,"CONJUNCTIVITIS, ALLERGIC",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Ophthalmic Research Associates, Inc, North Andover, Massachusetts, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00716963,MILD INTERMITTENT ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","McMaster University, Hamilton, Ontario, Canada",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Withdrawn,NCT04271839,PERSISTENT ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT01255579,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00712335,ASTHMATIC SMOKERS|NON-ASTHMATIC SMOKERS,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Diagnostic,"Asthma and Allergy Center, Inje University Sanggye Paik Hospital, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00292838,ASTHMA|CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD),All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,"Firestone Institute for Respiratory Health, St. Joseph's Healthcare, Hamilton, Ontario, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00118716,BRONCHOSPASM|ACTIVITY/EXERCISE INDUCED BRONCHOSPASM,All,4 Years to 17 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"GSK Investigational Site, Little Rock, Arkansas, United States|GSK Investigational Site, Huntington Beach, California, United States|GSK Investigational Site, Orange, California, United States|GSK Investigational Site, Palmdale, California, United States|GSK Investigational Site, Paramount, California, United States|GSK Investigational Site, San Diego, California, United States|GSK Investigational Site, Torrance, California, United States|GSK Investigational Site, Walnut Creek, California, United States|GSK Investigational Site, Centennial, Colorado, United States|GSK Investigational Site, Englewood, Colorado, United States|GSK Investigational Site, Lakewood, Colorado, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Miami, Florida, United States|GSK Investigational Site, Tallahassee, Florida, United States|GSK Investigational Site, Lilburn, Georgia, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Hoffman Estates, Illinois, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Metairie, Louisiana, United States|GSK Investigational Site, Baltimore, Maryland, United States|GSK Investigational Site, Glen Burnie, Maryland, United States|GSK Investigational Site, North Dartmouth, Massachusetts, United States|GSK Investigational Site, Minneapolis, Minnesota, United States|GSK Investigational Site, Papillion, Nebraska, United States|GSK Investigational Site, Skillman, New Jersey, United States|GSK Investigational Site, Summit, New Jersey, United States|GSK Investigational Site, Commack, New York, United States|GSK Investigational Site, Utica, New York, United States|GSK Investigational Site, Canton, Ohio, United States|GSK Investigational Site, Cincinnati, Ohio, United States|GSK Investigational Site, Dayton, Ohio, United States|GSK Investigational Site, Gresham, Oregon, United States|GSK Investigational Site, Medford, Oregon, United States|GSK Investigational Site, Portland, Oregon, United States|GSK Investigational Site, Erie, Pennsylvania, United States|GSK Investigational Site, Hershey, Pennsylvania, United States|GSK Investigational Site, Philadelphia, Pennsylvania, United States|GSK Investigational Site, Pittsburgh, Pennsylvania, United States|GSK Investigational Site, Charleston, South Carolina, United States|GSK Investigational Site, Mount Pleasant, South Carolina, United States|GSK Investigational Site, Orangeburg, South Carolina, United States|GSK Investigational Site, Dyersburg, Tennessee, United States|GSK Investigational Site, Knoxville, Tennessee, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Houston, Texas, United States|GSK Investigational Site, Murray, Utah, United States|GSK Investigational Site, Richmond, Virginia, United States|GSK Investigational Site, Greenfield, Wisconsin, United States|GSK Investigational Site, Madison, Wisconsin, United States|GSK Investigational Site, Milwaukee, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,NCT00692978,HEALTHY|ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Basic Science","Asthma Lab, Royal Brompton Hospital, London, United Kingdom|Department of Nuclear Medicine, Royal Brompton Hospital, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,ALLERGIC ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF,1,DB13867,__FLUTICASONE,5049389,Completed,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,21.5199490749296,267.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.69,444.51,74.6,4.0,2.0,4.0,43.32,107.87,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,1,0,1
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Recruiting,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)O,1,DB13873,__FENOFIBRIC_ACID,7259186,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",2,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,37.68455204418978,168.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.97,318.75,63.6,4.0,1.0,2.0,32.42,83.19,5.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB13919,__CANDESARTAN,5605919,Unknown status,NCT00564057,HIV INFECTIONS|HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Insubria, Department of Clinical Medicine, Varese, Italy",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CCOc1nc2cccc(C(=O)O)c2n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,DB13919,__CANDESARTAN,5605919,Unknown status,NCT00328302,"DIABETES, TYPE I",All,"17 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Childrens Hospital, Karolinska University Hospital, Huddinge, Stockholm, Sweden",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,36.07466272408049,89.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.44,440.454,118.81,7.0,2.0,5.0,45.29,134.92,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C[C@@H](O)[C@H](NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](Cc2ccccc2)NC(=O)CN2CCN(CC(=O)[O-])CCN(CC(=O)[O-])CCN(CC(=O)[O-])CC2)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@H](Cc2c[nH]c3ccccc23)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(=O)O.[68Ga+3],1,DB13925,__DOTATATE_GALLIUM_GA-68,9375498,Completed,,CARDIAC SARCOIDOSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07B59/008,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,46.5882256309164,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.99,1500.54,505.95,24.0,14.0,6.0,144.31,397.34,26.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,0,1,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Recruiting,NCT04263415,"PCOS|SEMAGLUTIDE|TASTE, ALTERED|TONGUE TISSUE TRANSCRIPTOME|GASTRIC EMPTYING|CENTRAL NEURAL RESPONSE",Female,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"UMC Ljubljana, Ljubljana, Slovenia",A61M5/31593,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C,1,DB13928,__SEMAGLUTIDE,6899699,Completed,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/31593,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,40.9043306844083,25.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-17.0,4113.641,1646.18,67.0,57.0,6.0,427.73,1047.99,149.0,1.0,0.0,0.0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1,1,DB13941,__PIPERAQUINE,EP-1702616-A1,Completed,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,32.7488,23.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.53,535.52,38.74,6.0,0.0,6.0,59.56,153.42,6.0,1.0,0.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13944,__TESTOSTERONE_ENANTHATE,8021335,Completed,,SARCOPENIA,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13944,__TESTOSTERONE_ENANTHATE,8021335,Not Yet Recruiting,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61M5/30,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,49.93942380747029,149.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,400.594,43.37,2.0,0.0,4.0,49.18,116.61,7.0,0.0,1.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Completed,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C,1,DB13946,__TESTOSTERONE_UNDECANOATE,7718640,Recruiting,,HYPOGONADISM,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,74.1863282613606,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.74,456.711,43.37,2.0,0.0,4.0,57.8,135.02,11.0,1.0,0.0,0.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Unknown status,NCT01052623,ATAXIA TELANGIECTASIA|GROWTH FAILURE,All,"3 Years to 18 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Children's Hospital, Goethe-University, Frankfurt am Main, Germany",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,NCT02352090,CONTRACEPTION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Helsinki University Central Hospital, Kätilöopisto Maternity Hospital, Helsinki, Finland|Oulu University Hospital, Department of Gynecology and Obstetrics, Oulu, Finland",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C,1,DB13956,__ESTRADIOL_VALERATE,6133251,Completed,,INFERTILITY,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,47.7381465738516,245.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.28,356.4984,46.53,2.0,1.0,4.0,42.57,102.89,5.0,0.0,1.0,0.0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,1,1,0
CC(=O)O[C@]1(C(C)=O)CC[C@H]2[C@@H]3C=C(C)C4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21C,1,DB13981,__NOMEGESTROL_ACETATE,4544555,Terminated,,CONTRACEPTION,,,,,"FISABIO, Elche, Alicante, Spain",C07J7/0045,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,36.1403724922483,86.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.46,370.48900000000003,60.44,3.0,0.0,4.0,41.78,104.18,3.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1
O=[N+]([O-])[O-],1,DB14049,__NITRATE,,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.84,62.0049,66.2,3.0,0.0,0.0,3.28,8.35,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Enrolling by invitation,NCT04240509,HIV INFECTIONS|SEXUALLY TRANSMITTED DISEASES,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The Miriam Hospital, Providence, Rhode Island, United States",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00924898,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00127959,HEPATITIS B INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, NH, Netherlands",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00192595,HIV INFECTION|HEPATITIS B COINFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Thai Red Cross AIDS Research Centre, Bangkok, Thailand",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00549198,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Aarhus N, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Garches, France|GSK Investigational Site, Levallois-Perret, France|GSK Investigational Site, Saint Denis Cedex 01, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Ferrara, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Legnano (MI, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Lausanne, Switzerland|GSK Investigational Site, St Gallen, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Woolwich, London, London, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Brighton, Sussex East, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Farnworth, Bolton, United Kingdom|GSK Investigational Site, Gloucester, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Middlesborough, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65616,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07F9/65616,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01340950,HIV INFECTIONS|CENTRAL NERVOUS SYSTEM DISEASES|DEMENTIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Beijing Ditan Hospital, Beijing, Beijing, China|Beijing YouAn Hospital, Beijing, Beijing, China",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Unknown status,NCT03120494,HIV/AIDS,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Puerto Rico Community Network for Clinical Research on AIDS (PR-CoNCRA), San Juan, Puerto Rico",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT02844634,HIV|SYPHILIS,Male,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"BC Centre for Disease Control, Vancouver, British Columbia, Canada",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Unknown status,NCT02585947,"NON-HODGKIN'S LYMPHOMA, BURKITT'S",All,"19 Years to 81 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National University, Seoul, Korea, Republic of",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Unknown status,NCT03220152,HIV PREVENTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Instituto Nacional de Infectologia Evandro Chagas (INI) - Fiocruz, Rio de Janeiro, Brazil",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01332227,"HIV, COMBINATION THERAPY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health For Life Clinic Pllc, Little Rock, Arkansas, United States|Eisenhower Medical Center, Palm Springs, California, United States|Metropolis Medical Pc, San Francisco, California, United States|Consultive Medicine, Daytona Beach, Florida, United States|Orange County Health Dept., Orlando, Florida, United States|Triple O Medical Services, P.A., West Palm Beach, Florida, United States|The Research Institute, Springfield, Massachusetts, United States|Aids Care, Rochester, New York, United States|Local Institution, Paris, Cedex 12, France|Local Institution, Lyons Cedex 04, France|Local Institution, Orleans Cedex 2, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Bochum, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Munich, Germany|Local Institution, Genova, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Roma, Italy|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Brighton, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Sheffield, United Kingdom",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01715636,HIV NONOCCUPATIONAL POST-EXPOSURE PROPHYLAXIS IN MEN WHO HAVE SEX WITH MEN,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydney Sexual Heatlh Centre, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Melbourne Sexual Health Centre, Melbourne, Victoria, Australia",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01458977,HIV|DYSLIPIDEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Valle Hebrón, Barcelona, Spain",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT02815566,OSTEOPOROSIS|HIV|MENOPAUSE,Female,40 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vancouver ID Research and Care Centre, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CHU de Québec-Université Laval, Québec, Quebec, Canada|Ospedale San Raffaele, Milan, Italy|Università degli Studi di Modena e Reggio Emilia, Modena, Italy",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT04050371,HIV PREVENTION|TRANSGENDER HEALTH,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"San Francisco AIDS foundation, San Francisco, California, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Recruiting,NCT03058835,PREP ADHERENCE MONITORING,Female,18 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|New Jersey Medical School Clinical Research Center, Newark, New Jersey, United States|West Virginia University, Morgantown, West Virginia, United States",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Terminated,NCT01601899,MITOCHONDRIAL TOXICITY|METABOLIC COMPLICATIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Themba Lethu Clinic, Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng, South Africa",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Completed,NCT01258439,HIV|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holdsworth House Medical Practice, Sydney, New South Wales, Australia|St Vincent Hospital, Clinical Research Program, Sydney, New South Wales, Australia",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Recruiting,NCT02957864,"RENAL INSUFFICIENCY,CHRONIC|HIV|THERAPEUTIC AGENT TOXICITY",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ziekenhuis Rijnstate, Arnhem, Gelderland, Netherlands|MC Slotervaart, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT03771638,"ADHERENCE, MEDICATION|RISK BEHAVIOR|PRE-EXPOSURE PROPHYLAXIS|HIV PREVENTION",All,18 Years to 35 Years   (Adult),Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Emory University, School of Public Health, Atlanta, Georgia, United States",C07F9/65616,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O,1,DB14126,__TENOFOVIR,6057305,"Active, not recruiting",NCT03120936,TRANSGENDER PERSONS|PRE-EXPOSURE PROPHYLAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Tri-City Health Center, Fremont, California, United States|Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Tom Waddell Urban Health Clinic, San Francisco, California, United States|San Francisco Community Health Clinic, San Francisco, California, United States|Castro-Mission Health Center, San Francisco, California, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,92.88075730507809,218.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,287.2123,136.38,8.0,3.0,2.0,25.54,67.54,5.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
CC(C)=CCCC(C)(O)[C@H]1CC[C@]2(C)C1CC[C@@H]1[C@@]3(C)CC[C@H](O)C(C)(C)[C@@H]3CC[C@]12C,1,DB14152,__GINSENOSIDES,,Completed,,FATIGUE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.39,444.744,40.46,2.0,2.0,4.0,55.91,135.64,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0
CCCCCCCCCCCC(=O)OCN1C(=O)CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc21,1,DB14185,__ARIPIPRAZOLE_LAUROXIL,8431576,Completed,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,34.2019343313004,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.91,660.72,62.32,5.0,0.0,4.0,76.95,183.74,20.0,1.0,0.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,1,1
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT01534195,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=P([O-])([O-])O.[Na+].[Na+],1,DB14502,"__SODIUM_PHOSPHATE,_DIBASIC",7687075,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",7,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,64.3955728043697,1.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,141.9588,83.42,4.0,1.0,0.0,5.24,12.41,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00240032,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT01534182,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Arkhangelsk, Russia, Russian Federation|Novartis Investigative Site, Barnaul, Russian Federation|Novartis Investigative Site, Belgorod, Russian Federation|Novartis Investigative Site, Kazan, Russian Federation|Novartis Investigative Site, Kemerovo, Russian Federation|Novartis Investigative Site, Khanty-Mansiysk, Russian Federation|Novartis Investigative Site, Kirov, Russian Federation|Novartis Investigative Site, Krasnodar, Russian Federation|Novartis Investigative Site, Kursk, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, Moscow, Russian Federation|Novartis Investigative Site, N.Novgorod, Russian Federation|Novartis Investigative Site, Nizhniy Novgorod, Russian Federation|Novartis Investigative Site, Nizhny Novgorod, Russian Federation|Novartis Investigative Site, Novosibirsk, Russian Federation|Novartis Investigative Site, Perm, Russian Federation|Novartis Investigative Site, Saransk, Russian Federation|Novartis Investigative Site, Saratov, Russian Federation|Novartis Investigative Site, Smolensk, Russian Federation|Novartis Investigative Site, St. Petersburg, Russian Federation|Novartis Investigative Site, Tomsk, Russian Federation|Novartis Investigative Site, Tumen, Russian Federation|Novartis Investigative Site, Tver, Russian Federation|Novartis Investigative Site, Ufa, Russian Federation|Novartis Investigative Site, Ulyanovsk, Russian Federation|Novartis Investigative Site, Yaroslavl, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT02357368,HIV|CONTRACEPTION,Female,18 Years to 45 Years   (Adult),Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Grady Health System, Atlanta, Georgia, United States|The Ponce de Leon Center of the Grady Health System, Atlanta, Georgia, United States|Emory Clinic, Atlanta, Georgia, United States|Emory University Clinical Research Network, Atlanta, Georgia, United States",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)[O-],1,DB14511,__ACETATE,,Completed,NCT00002345,ANOREXIA|CACHEXIA|HIV INFECTIONS,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Primary Purpose: Treatment,"Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States|Yale Univ Med School, New Haven, Connecticut, United States|Georgetown Univ Med Ctr, Washington, District of Columbia, United States|Miriam Hosp, Providence, Rhode Island, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.29,59.044,40.13,2.0,0.0,0.0,4.96,23.48,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00236106,ATOPIC DERMATITIS,All,5 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single,,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02557269,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Medical University Sofia, University Hospital ""Alexandrovska"", Clinic of Allergy and Asthma, Sofia, Bulgaria",G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00817050,ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00394355,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT02559440,ADENOIDAL HYPERTROPHY,All,5 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT03705793,CHRONIC RHINOSINUSITIS (DIAGNOSIS)|ALLERGIC RHINOSINUSITIS|CHRONIC EOSINOPHILIC RHINOSINUSITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Washington University School of Medicine, Saint Louis, Missouri, United States|Washington University, Saint Louis, Missouri, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00834119,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Terminated,NCT00491374,PERENNIAL ALLERGIC RHINITIS,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Unknown status,NCT02110654,SINUSITIS|NASAL POLYPS|ASTHMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"the first affiliated hospital, Sun Yat-sen University, Guangzhou, Guangdong, China",G06M1/163,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT01118312,ASTHMA|RHINITIS|SINUSITIS,All,"6 Years and older   (Child, Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Arizona, Tucson, Arizona, United States|University of California, San Diego, San Diego, California, United States|National Jewish Health, Denver, Colorado, United States|Nemours Children's Clinic, Jacksonville, Florida, United States|Univeristy of Miami School of Medicine, Miami, Florida, United States|University of South Florida College of Medicine, Tampa, Florida, United States|Northwestern Memorial Hospital, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Louisiana State University Health Sciences Center, New Orleans, Louisiana, United States|University of Missouri, Kansas City School of Medicine, Kansas City, Missouri, United States|Washington University School of Medicine, St. Louis, Missouri, United States|North Shore-Long Island Jewish Health System, New Hyde Park, New York, United States|New York University School of Medicine, New York, New York, United States|New York Medical College, Valhalla, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Davis Heart and Lung Research Institute, Columbus, Ohio, United States|Baylor College of Medicine, Houston, Texas, United States|Vermont Lung Center at the University of Vermont, Burlington, Vermont, United States|Univeristy of Virginia, Charlottesville, Virginia, United States",G06M1/163,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,NCT00359216,PERENNIAL ALLERGIC RHINITIS|OBSTRUCTIVE SLEEP APNEA|SLEEP DISORDER,All,18 Years to 60 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,G06M1/163,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=O)CCl,1,DB14512,__MOMETASONE_FUROATE,5829434,Completed,,"RHINITIS, ALLERGIC, SEASONAL",,,,,"FISABIO, Elche, Alicante, Spain",G06M1/163,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,41.1014599889114,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.27,521.429,93.81,4.0,1.0,5.0,52.31,132.5,5.0,1.0,0.0,0.0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])[O-],1,DB14531,__CARBONATE_ION,,Completed,,TOOTH BLEACHING,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.53,60.0089,63.19,3.0,0.0,0.0,3.52,31.17,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14540,__HYDROCORTISONE_BUTYRATE,4137311,Recruiting,NCT03539601,ATOPIC DERMATITIS,All,"2 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Dermatology Trial Associates, Bryant, Arkansas, United States|California Dermatology & Clinical Research Institute, Encinitas, California, United States|Park Avenue Dermatology, Orange Park, Florida, United States|Lenus Research & Medical Group, LLC, Sweetwater, Florida, United States|ForCare Clinical Research, Tampa, Florida, United States|DS Research, Louisville, Kentucky, United States|Virgo-Carter Pediatrics, Silver Spring, Maryland, United States|M3-Wake Research, Inc., Raleigh, North Carolina, United States|Arlington Research Center Inc, Arlington, Texas, United States|Tanner Clinic, Layton, Utah, United States|Virginia Clinical Research, Inc, Norfolk, Virginia, United States|Hopital Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|University Hospital Antwerp, Edegem, Belgium|Klinikum der Universitat Munchen, Munchen, Bayern, Germany|Universitaetsklinikum Frankfurt, Frankfurt am Main, Hessen, Germany|Fachklinik Bad Bentheim, Fachbereich Dermatologie und Allergologie, Dermatologische Ambulanz, Bad Bentheim, Niedersachsen, Germany|Universitatsklinikum Bonn, Bonn, NRW, Germany|Universitatsklinikum Schleswig-Holstein, Campus Lubeck, Lubeck, Schleswig-holstein, Germany|ISA - Interdisciplinary Study Association GmbH, Berlin, Germany|UOSD Dermatologia Gen. ed Oncologica DU, PO San Salvatore, L'Aquila, AQ, Italy|DiSSal Sezione di Dermatologia Az. Ospedaliera Universitaria, Genova, GE, Italy|Ospedale San Pietro Fatebenefratelli, Roma, RM, Italy|Azienda Ospedaliero - Universitaria Policlinico Tor Vergata, Roma, Rome, Italy|Silmedic sp. z o.o, Katowice, Poland|Krakowskie Centrum Medyczne sp. z o.o., Krakow, Poland|Klinika Ambroziak Sp. z O. O., Warszawa, Poland|ROYALDERM Agnieszka Nawrocka, Warszawa, Poland|Barn och Ungdomskliniken, Orebro, Sweden|Avdelningen for Kliniska Provningar, Orebro, Sweden|Universitatsklinik fuer Dermatologie, Bern, Switzerland|Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland|Universitats-Kinderspital Zurich, Zurich, Switzerland|Rame Medical Ltd, Penntorr Health, Torpoint, Cornwall, United Kingdom|NHS Tayside, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom|NHS Tayside, Dundee, Scotland, United Kingdom|Sheffield Children's NHS Foundation Trust, Sheffield, South Yorkshire, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,16.263167621511702,582.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,47.56,115.78,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
CCCC(=O)O[C@]1(C(=O)CO)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14540,__HYDROCORTISONE_BUTYRATE,4137311,Enrolling by invitation,NCT02116608,GRANULOMA|TRACHEOSTOMY,All,31 Days to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Colorado, Aurora, Colorado, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,16.263167621511702,582.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,47.56,115.78,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COC(=O)CCC1CCCC1,1,DB14541,__HYDROCORTISONE_CYPIONATE,4304765,Completed,,ANXIETY,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0051,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.53,486.649,100.9,5.0,2.0,5.0,54.76,132.33,7.0,0.0,1.0,0.0,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)OCCl,1,DB00873,__LOTEPREDNOL,6106819,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.5591901271073,113.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.2,394.889,83.83,4.0,2.0,4.0,41.29,102.65,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O,1,DB14631,__PREDNISOLONE_PHOSPHATE,6024981,Terminated,,IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0056,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,22.242756524774602,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.92,440.42900000000003,141.36,7.0,4.0,4.0,43.42,109.37,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14643,__METHYLPREDNISOLONE_ACEPONATE,6068860,Completed,NCT00185510,"DERMATITIS, ATOPIC",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,50.727941025483,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,472.57800000000003,106.97,5.0,1.0,4.0,50.86,125.97,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
CCC(=O)O[C@]1(C(=O)COC(C)=O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB14643,__METHYLPREDNISOLONE_ACEPONATE,6068860,Completed,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,50.727941025483,31.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.92,472.57800000000003,106.97,5.0,1.0,4.0,50.86,125.97,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Completed,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)O)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12,1,DB14644,__METHYLPREDNISOLONE_HEMISUCCINATE,WO-2003082251-A2,Not Yet Recruiting,,GLOMERULONEPHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/0007,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.43,474.55,138.2,7.0,3.0,4.0,49.87,123.09,7.0,0.0,1.0,0.0,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Unknown status,NCT03631862,NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,DB14765,__RIVOCERANIB,US-20040259916-A1,Completed,NCT03376958,RELAPSED AND REFRACTORY|DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,28.9451528778825,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.14,397.48199999999997,90.7,5.0,2.0,4.0,43.36,119.16,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,DB14806,__AVEXITIDE,,Recruiting,,INSULIN SECRETION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,3369.8,1390.28,53.0,45.0,7.0,344.43,843.43,108.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,1,1,1
CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O,1,DB14936,__MENAQUINONE_6,6190695,Completed,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,24.37832399022561,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.01,580.8821,34.14,2.0,0.0,2.0,74.54,193.11,17.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Completed,,POSTOPERATIVE PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(=O)OC(C)OC(=O)C(C)c1ccc(-c2ccccc2)c(F)c1,1,DB14938,__FLURBIPROFEN_AXETIL,4766148,Terminated,,DELIRIUM,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/33,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.0,38.5387790303702,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.36,330.355,52.6,2.0,0.0,2.0,34.15,87.16,7.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)n1nccc1-c1ncccc1COc1cccc(O)c1C=O,1,DB14975,__VOXELOTOR,9018210,Not Yet Recruiting,,SICKLE CELL ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,27.95950635536661,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.02,337.379,77.24,5.0,1.0,3.0,35.37,106.25,6.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT00689078,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ophthalmic Research Associates, Andover, Massachusetts, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C,1,DB15566,__PREDNISOLONE_ACETATE,5881926,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,66.49828538573679,109.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.17,402.4807,100.9,5.0,2.0,4.0,42.93,107.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O,1,,_REGADENOSON,,Completed,NCT01019486,CORONARY ARTERY DISEASE|TYPE 1 DIABETES MELLITUS,All,"25 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States|University of Colorado Denver, Aurora, Colorado, United States|University of Colorado Hospital, Aurora, Colorado, United States|University Hospital, the University of Colorado Health Sciences Center, Denver, Colorado, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1.O,1,,_REGADENOSON,,Completed,NCT00862641,"ASTHMA|CORONARY ARTERY DISEASE|PULMONARY DISEASE, CHRONIC OBSTRUCTIVE",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Montgomery, Alabama, United States|Anaheim, California, United States|Encinitas, California, United States|Fullerton, California, United States|Huntington Beach, California, United States|Long Beach, California, United States|Mission Viejo, California, United States|Roseville, California, United States|San Diego, California, United States|San Diego, California, United States|Santa Ana, California, United States|Waterbury, Connecticut, United States|Newark, Delaware, United States|Wilmington, Delaware, United States|Clearwater, Florida, United States|Deland, Florida, United States|Miami, Florida, United States|Trinity, Florida, United States|Winter Park, Florida, United States|Stockbridge, Georgia, United States|Aurora, Illinois, United States|Topeka, Kansas, United States|Shreveport, Louisiana, United States|Auburn, Maine, United States|No. Dartmouth, Massachusetts, United States|Minneapolis, Minnesota, United States|Plymouth, Minnesota, United States|St Louis, Missouri, United States|St. Louis, Missouri, United States|Papillion, Nebraska, United States|Brick, New Jersey, United States|Raleigh, North Carolina, United States|Chardon, Ohio, United States|Cincinnati, Ohio, United States|Cincinnati, Ohio, United States|Oklahoma, Oklahoma, United States|Medford, Oregon, United States|Upland, Pennsylvania, United States|Providence, Rhode Island, United States|Charleston, South Carolina, United States|Easley, South Carolina, United States|Greenville, South Carolina, United States|Spartanburg, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Houston, Texas, United States|New Braunfels, Texas, United States|San Antonio, Texas, United States|Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
O=S(=O)([O-])CCS.[Na+],1,,_MESNA,,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01731886,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University, New York, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00526305,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Central de Asturias, Oviedo, Asturias, Spain|Hospital general de Castellón, Castello, Castellón, Spain|Hospital de Navarra, Pamplona, Navarra, Spain|Hospital Verge de la Cinta, Tortosa, Tarragona, Spain|Complejo Hospitalario Universitario de Albacete, Albacete, Spain|Hospital General de Alicante, Alicante, Spain|Hospital Ntra. Sra. Sonsoles, Avila, Spain|Hospital de Badalona Germans Trias i Pujol, Badalona, Spain|Hospital Clínic, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital vall d'Hebrón, Barcelona, Spain|Basurtuko Ospitalea, Basurto, Spain|Hospital de Cruces, Bilbao, Spain|Hospital de Jerez de la Frontera, Jerez de La Frontera, Spain|Complejo Hospitalario León, Leon, Spain|Hospital Arnau de Vilanova, Lleida, Spain|Complexo Hospitalario Xeral-Calde, Lugo, Spain|Clínica Puerta de Hierro, Madrid, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico San Carlos de Madrid, Madrid, Spain|Hospital de la Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain|Hospital Universitario de la Princesa, Madrid, Spain|Althaia, Xarxa Asistencial de Manresa, Manresa, Spain|Hospital General Morales Meseguer, Murcia, Spain|Hospital General Universitario Morales Meseguer., Murcia, Spain|Hospital Santa María del Rosell, Murcia, Spain|. Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain|H. Carlos Haya, Málaga, Spain|Complejo Asistencial Son Dureta, Palma de Mallorca, Spain|Hospital Son Llatzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Complejo Hospitalario de Pontevedra_Hospital Montecelo, Pontevedra, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Spain|Hospital de Sagunto, Sagunto, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain|Hospital General de Segovia, Segovia, Spain|H.U. Virgen del Rocio, Sevilla, Spain|Hospital Universitario de Canarias, Tenerife, Spain|Hospital Clínico Universitario de Valencia, Valencia, Spain|Hospital Clínic, Valencia, Spain|Hospital dr. Peset, Valencia, Spain|Hospital General Universitario, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico de Valladolid, Valladolid, Spain|Complejo Hospitalario Universitario de Vigo, Vigo, Spain|Hospital de Galdakao, Vizcaya, Spain|Hospital Clínico Lozano Blesa, Zaragoza, Spain",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00307671,VASCULITIS|WEGENER'S GRANULOMATOSIS|MICROSCOPIC POLYANGIITIS|CHURG-STRAUSS SYNDROME|POLYARTERITIS NODOSA,All,65 Years and older   (Older Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Cochin, Paris, France",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT02645565,LUPUS NEPHRITIS,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Clinical Immunology , Jawaharlal Institute of Post graduate Medical Educationa and Research, Pondicherry, India",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01283386,"LYMPHOCYTIC LEUKEMIA, CHRONIC",All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The order of Honour pin Irkutsk regional clinical hospital; Hematology Department, Irkutsk, Russian Federation|Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation|N.N.Blokhin Russian Cancer Research Center; Dept. of Chemotherapy & Hemoblastosis, Moscow, Russian Federation|City Clinical Botkin's Hospital; City Hematological Center, Moscow, Russian Federation|City Clinical Hospital #15; Hematology department, Saint-Petersburg, Russian Federation|Saint-Petersburg SHI City Clinical Hospital #31, St. Petersburg, Russian Federation|GUZ Tula Regioanal Clinical Hospital; Hematology, Tula, Russian Federation|Republican clinical hospital named after G.G. Kuvatov, UFA, Russian Federation",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01088724,POST-TRANSPLANT LYMPHOPROLIFERATIVE DISEASE (PTLD)|NON BURKITT,All,"6 Months to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,"Ospedali Riuniti di Bergamo, Bergamo, BG, Italy",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT00003398,ANEMIA|GRAFT VERSUS HOST DISEASE|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"up to 50 Years   (Child, Adult)",Other,Primary Purpose: Treatment,"Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT00399399,CHURG-STRAUSS SYNDROME,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Unknown status,NCT00400075,POLYARTERITIS NODOSA|MICROSCOPIC POLYANGIITIS,All,"15 Years to 90 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Camillo Ribi, Geneva, Switzerland",6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Terminated,NCT01861561,RENAL INSUFFICIENCY|INFECTION,All,up to 15 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nephrology division, Department of Pediatrics, Siriraj Hospital, Bangkoknoi, Bangkok, Thailand",6,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,Completed,NCT01124526,NON HODGKIN LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Infanta Cristina, Badajoz, Badajoz_Extremadura, Spain|Hospital del Mar, Barcelona, Barcelona_ Cataluña, Spain|Instituto Catalán de Oncología (ICO), Barcelona, Barcelona_Cataluña, Spain|Hospital San Pedro de Alcántara, Cáceres, Cáceres_Extremadura, Spain|Hospital de Puerto Real, Puerto Real, Cádiz_ Andalucía, Spain|Complejo Hospitalario Xeral_Calde, Lugo, Lugo_ Galicia, Spain|Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain|Fundación Hospital Alcorcón, Alcorcón, Madrid, Spain|Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain|Hospital Severo Ochoa, Leganés, Madrid, Spain|Hospital de Móstoles, Móstoles, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Salamanca_Castilla León, Spain|Hospital General de Segovia, Segovia, Segovia_ Castilla León, Spain|Hospital Clínico del Río Hortega, Valladolid, Valladolid_Castilla León, Spain|MD Anderson Internacional España, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Clínico San Carlos, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O.O=P1(N(CCCl)CCCl)NCCCO1,1,,_CYCLOPHOSPHAMIDE,5066647,"Active, not recruiting",NCT03218852,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,14.0618903878929,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT01732757,"CONJUNCTIVITIS, ALLERGIC",All,"10 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Memphis, Tennessee, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@H](O)[C@H]1O,1,,_DEXTRAN,4201772,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,26.0,25.298260744573803,78.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,1,,_VEDOTIN,,Completed,NCT01990534,HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Praha, Prague, Czechia|Brno, Czechia|Heidelberg, Baden Wuerttemberg, Germany|Koeln, Germany|Georgetown, Penang, Malaysia|Ampang, Selangor, Malaysia|Kuala Lumpur, Malaysia|Gdansk, Poland|Krakow, Poland|Warszawa, Poland|Pamplona, Navarra, Spain|Madrid, Spain|Bangkoknoi, Bangkok, Thailand|Patumwan, Bangkok, Thailand|Ratchathewi, Bangkok, Thailand|Izmir, Bornova, Turkey|Ankara, Turkey|Izmir, Turkey",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)[CH]CC2=O)C(C)C)cc1)C(C)C,1,,_VEDOTIN,,"Active, not recruiting",NCT01909934,ANAPLASTIC LARGE-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|UZ Leuven, Leuven, Belgium|Clinical Hospital Centre Rijeka, Rijeka, Croatia|Clinical Hospital Centre Zagreb, Zagreb, Croatia|Clinical Hospital Dubrava, Zagreb, Croatia|Fakultni nemocnice Brno, Brno, Czechia|Fakultni nemocnice Olomouc, Olomouc, Czechia|Fakultni nemocnice Kralovske Vinohrady, Praha 10, Czechia|Vseobecna fakultni nemocnice v Praze, Praha 2, Czechia|Semmelweis Egyetem, Budapest, Hungary|Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary|Pecsi Tudomanyegyetem, Pecs, Hungary|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|SPZOZ MSW zWarminsko-MazurskimCen.Onko.wOlsztynie, Olsztyn, Poland|Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warszawa, Poland|Hospital de Braga, Braga, Portugal|Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria, Lisboa, Portugal|Centro Hospitalar do Porto, E.P.E. - Hospital de Santo Antonio, Porto, Portugal|Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal|Policlinica de Diagnostic Rapid SA, Brasov, Romania|Spitalul Clinic Colentina, Bucuresti, Romania|Spitalul Clinic Coltea, Bucuresti, Romania|Spitalul Clinic Judetean de Urgenta Targu Mures, Targu Mures, Romania|ICO lHospitalet Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Hospital Universitario Ramon y Cajal, Madrid, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Ankara University Medical Faculty, Ankara, Turkey|Pamukkale Uni. Med. Fac., Denizli, Turkey|Istanbul Bilim University Medical Fac., Istanbul, Turkey|Ege University Medical Faculty, Izmir, Turkey|Dokuz Eylul University Faculty of Medicine, Izmir, Turkey|Erciyes University Medical Faculty, Kayseri, Turkey|Royal Cornwall Hospital, Truro, Cornwall, United Kingdom|The Christie, Manchester, Greater Manchester, United Kingdom|Birmingham Heartlands Hospital, Birmingham, West Midlands, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,0,1
CCN(CC)CCOc1ccc(C(=C(Cl)c2ccccc2)c2ccccc2)cc1.O=C(O)CC(O)(CC(=O)O)C(=O)O,1,,_CLOMIPHENE_CITRATE,,Completed,NCT01004068,POLYCYSTIC OVARY SYNDROME|ANOVULATION,Female,18 Years to 35 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Pugliese"" Hospital, Catanzaro, Italy",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0
OC[C@H]1O[C@@H](O)[C@H](F)[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O,1,,_FLUDEOXYGLUCOSE_F_18,,Terminated,NCT02937168,ASTHMA,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Teva Investigational Site 13808, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Enrolling by invitation,NCT04240509,HIV INFECTIONS|SEXUALLY TRANSMITTED DISEASES,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"The Miriam Hospital, Providence, Rhode Island, United States",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00924898,ACUTE HIV INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke University, Durham, North Carolina, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00127959,HEPATITIS B INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Academic Medical Center, Amsterdam, NH, Netherlands",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00544128,HIV INFECTION,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"International Medical Center of Japan, Shinjuku, Tokyo, Japan",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00192595,HIV INFECTION|HEPATITIS B COINFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Vincent's Hospital, Darlinghurst, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Thai Red Cross AIDS Research Centre, Bangkok, Thailand",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00549198,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Innsbruck, Austria|GSK Investigational Site, Salzburg, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Vienna, Austria|GSK Investigational Site, Brugge, Belgium|GSK Investigational Site, Bruxelles, Belgium|GSK Investigational Site, Charleroi, Belgium|GSK Investigational Site, Gent, Belgium|GSK Investigational Site, Leuven, Belgium|GSK Investigational Site, Aalborg, Denmark|GSK Investigational Site, Aarhus N, Denmark|GSK Investigational Site, Hvidovre, Denmark|GSK Investigational Site, Koebenhavn, Denmark|GSK Investigational Site, Odense C, Denmark|GSK Investigational Site, Garches, France|GSK Investigational Site, Levallois-Perret, France|GSK Investigational Site, Saint Denis Cedex 01, France|GSK Investigational Site, Heidelberg, Baden-Wuerttemberg, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Hannover, Niedersachsen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Leipzig, Sachsen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Hamburg, Germany|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Dublin, Ireland|GSK Investigational Site, Ferrara, Emilia-Romagna, Italy|GSK Investigational Site, Modena, Emilia-Romagna, Italy|GSK Investigational Site, Rimini, Emilia-Romagna, Italy|GSK Investigational Site, Roma, Lazio, Italy|GSK Investigational Site, Legnano (MI, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Torino, Piemonte, Italy|GSK Investigational Site, Riga, Latvia|GSK Investigational Site, Alkmaar, Netherlands|GSK Investigational Site, Den Haag, Netherlands|GSK Investigational Site, Groningen, Netherlands|GSK Investigational Site, Rotterdam, Netherlands|GSK Investigational Site, Utrecht, Netherlands|GSK Investigational Site, Amadora, Portugal|GSK Investigational Site, Madrid, Spain|GSK Investigational Site, Valencia, Spain|GSK Investigational Site, Basel, Switzerland|GSK Investigational Site, Bern, Switzerland|GSK Investigational Site, Lausanne, Switzerland|GSK Investigational Site, St Gallen, Switzerland|GSK Investigational Site, Zuerich, Switzerland|GSK Investigational Site, Zurich, Switzerland|GSK Investigational Site, Manchester, Lancashire, United Kingdom|GSK Investigational Site, Woolwich, London, London, United Kingdom|GSK Investigational Site, Edinburgh, Midlothian, United Kingdom|GSK Investigational Site, Brighton, Sussex East, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Birmingham, United Kingdom|GSK Investigational Site, Farnworth, Bolton, United Kingdom|GSK Investigational Site, Gloucester, United Kingdom|GSK Investigational Site, Leicester, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, London, United Kingdom|GSK Investigational Site, Middlesborough, United Kingdom|GSK Investigational Site, Sheffield, United Kingdom",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Not yet recruiting,NCT04518228,HIV INFECTIONS|TUBERCULOSIS,Female,"Child, Adult, Older Adult",NIH|Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65616,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Terminated,NCT01902186,HIV INFECTION|OSTEOPENIA,Female,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Milano, Milano, Italy|University of Torino, Torino, Italy",C07F9/65616,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT03360682,HIV-1-INFECTION|SOLID ORGAN TRANSPLANT,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clínico y provincial de Barcelona, Barcelona, Spain",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01340950,HIV INFECTIONS|CENTRAL NERVOUS SYSTEM DISEASES|DEMENTIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Beijing Ditan Hospital, Beijing, Beijing, China|Beijing YouAn Hospital, Beijing, Beijing, China",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Unknown status,NCT03120494,HIV/AIDS,All,"21 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Puerto Rico Community Network for Clinical Research on AIDS (PR-CoNCRA), San Juan, Puerto Rico",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT02844634,HIV|SYPHILIS,Male,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"BC Centre for Disease Control, Vancouver, British Columbia, Canada",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Unknown status,NCT02585947,"NON-HODGKIN'S LYMPHOMA, BURKITT'S",All,"19 Years to 81 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Seoul National University, Seoul, Korea, Republic of",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Unknown status,NCT03220152,HIV PREVENTION,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Instituto Nacional de Infectologia Evandro Chagas (INI) - Fiocruz, Rio de Janeiro, Brazil",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01332227,"HIV, COMBINATION THERAPY",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health For Life Clinic Pllc, Little Rock, Arkansas, United States|Eisenhower Medical Center, Palm Springs, California, United States|Metropolis Medical Pc, San Francisco, California, United States|Consultive Medicine, Daytona Beach, Florida, United States|Orange County Health Dept., Orlando, Florida, United States|Triple O Medical Services, P.A., West Palm Beach, Florida, United States|The Research Institute, Springfield, Massachusetts, United States|Aids Care, Rochester, New York, United States|Local Institution, Paris, Cedex 12, France|Local Institution, Lyons Cedex 04, France|Local Institution, Orleans Cedex 2, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Bochum, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Munich, Germany|Local Institution, Genova, Italy|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Roma, Italy|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Alicante, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Brighton, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Sheffield, United Kingdom",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01715636,HIV NONOCCUPATIONAL POST-EXPOSURE PROPHYLAXIS IN MEN WHO HAVE SEX WITH MEN,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Sydney Sexual Heatlh Centre, Sydney, New South Wales, Australia|St Vincents Hospital, Sydney, New South Wales, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Melbourne Sexual Health Centre, Melbourne, Victoria, Australia",C07F9/65616,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01458977,HIV|DYSLIPIDEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain|Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain|Hospital Valle Hebrón, Barcelona, Spain",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT02815566,OSTEOPOROSIS|HIV|MENOPAUSE,Female,40 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Vancouver ID Research and Care Centre, Vancouver, British Columbia, Canada|Hamilton Health Sciences, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|McGill University Health Centre, Montréal, Quebec, Canada|CHU de Québec-Université Laval, Québec, Quebec, Canada|Ospedale San Raffaele, Milan, Italy|Università degli Studi di Modena e Reggio Emilia, Modena, Italy",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT04050371,HIV PREVENTION|TRANSGENDER HEALTH,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"San Francisco AIDS foundation, San Francisco, California, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Recruiting,NCT03058835,PREP ADHERENCE MONITORING,Female,18 Years to 64 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|New Jersey Medical School Clinical Research Center, Newark, New Jersey, United States|West Virginia University, Morgantown, West Virginia, United States",C07F9/65616,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Terminated,NCT01601899,MITOCHONDRIAL TOXICITY|METABOLIC COMPLICATIONS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Themba Lethu Clinic, Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng, South Africa",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Completed,NCT01258439,HIV|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Holdsworth House Medical Practice, Sydney, New South Wales, Australia|St Vincent Hospital, Clinical Research Program, Sydney, New South Wales, Australia",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Recruiting,NCT02957864,"RENAL INSUFFICIENCY,CHRONIC|HIV|THERAPEUTIC AGENT TOXICITY",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ziekenhuis Rijnstate, Arnhem, Gelderland, Netherlands|MC Slotervaart, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Maasstad ziekenhuis, Rotterdam, Netherlands",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT03771638,"ADHERENCE, MEDICATION|RISK BEHAVIOR|PRE-EXPOSURE PROPHYLAXIS|HIV PREVENTION",All,18 Years to 35 Years   (Adult),Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Emory University, School of Public Health, Atlanta, Georgia, United States",C07F9/65616,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,Recruiting,NCT02322099,BONE DEMINERALIZATION,All,"30 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Mater Misericordiae University Hospital, Dublin, Ireland|Beaumont Hospital, Dublin, Ireland",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O.O,1,,_TENOFOVIR,WO-2010026603-A2,"Active, not recruiting",NCT03120936,TRANSGENDER PERSONS|PRE-EXPOSURE PROPHYLAXIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Tri-City Health Center, Fremont, California, United States|Bridge HIV, San Francisco Department of Public Health, San Francisco, California, United States|Tom Waddell Urban Health Clinic, San Francisco, California, United States|San Francisco Community Health Clinic, San Francisco, California, United States|Castro-Mission Health Center, San Francisco, California, United States",C07F9/65616,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,Completed,NCT00662545,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General HIV Clinical Trials Group, San Francisco, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,Unknown status,NCT03062813,HEPATITIS B VIRUS ASSOCIATED NEPHROTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,"Active, not recruiting",NCT01907230,RHEUMATOID ARTHRITIS|HEPATITIS B REACTIVATION|EXPOSURE TO HEPATITIS B VIRUS,All,"20 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Division of Gastroenterology & Division of Allergy Immunology and Rheumatology, Taipei Veterans General Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
C=C1[C@@H](n2cnc3c(=O)[nH]c(N)nc32)C[C@H](O)[C@H]1CO,1,,_ENTECAVIR,,Completed,NCT00926757,NON HODGKIN'S LYMPHOMA|HEPATITIS B,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Prevention,"Taipei Veterans General Hospital-Division of Gastroenterology, Division of Oncology, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O,1,,_TENOFOVIR_DISOPROXIL_FUMARATE,WO-2002085358-A2,Completed,NCT02935075,HIV INFECTION,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Second Hospital of Nanjing, Nanjing, Jiangsu, China|Shanghai Public Health Clinical Center, Shanghai, Shanghai, China|Yunnan AIDS care center, Kunming, Yunnan, China",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.7488,159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O,1,,_TENOFOVIR_DISOPROXIL_FUMARATE,WO-2002085358-A2,Completed,NCT01285050,HEPATITIS C INFECTION,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Johns Hopkins University, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,38.0,32.7488,159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0
CC(C)OC(=O)OCOP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)OCOC(=O)OC(C)C.O=C(O)/C=C/C(=O)O,1,,_TENOFOVIR_DISOPROXIL_FUMARATE,WO-2002085358-A2,Completed,NCT04050371,HIV PREVENTION|TRANSGENDER HEALTH,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"San Francisco AIDS foundation, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,38.0,32.7488,159.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0
NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,1,,_FAMOTIDINE,,Completed,NCT00384904,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label),"Garden State Infectious Disease Associates, Pa, Voorhees, New Jersey, United States|Unc Center For Aids Research, Chapel-Hill, North Carolina, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, London, Greater London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
NC(N)=Nc1nc(CSCC/C(N)=N/S(N)(=O)=O)cs1,1,,_FAMOTIDINE,,Completed,NCT01563185,JUVENILE IDIOPATHIC ARTHRITIS,All,10 Years to 16 Years   (Child),Industry|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital, New Orleans, Louisiana, United States|Floating Hospital for Children @ Tufts Medical Center, Boston, Massachusetts, United States|UMASS Memorial Children's Medical Center, Worcester, Massachusetts, United States|Altoona Center for Clinical Research Altoona Arthritis, Duncansville, Pennsylvania, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1,,_ENFUVIRTIDE,WO-2004028455-A2,Completed,NCT00344760,HIV INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland, Institute of Human Virology, Baltimore, Maryland, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,32.7488,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)[C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](Cc1ccccc1)C(N)=O,1,,_ENFUVIRTIDE,WO-2004028455-A2,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,29.0,32.7488,37.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,1,1,0,1,1,0,1
CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.CC(C)OC(=O)[C@H](C)N[P@](=O)(CO[C@H](C)Cn1cnc2c(N)ncnc21)Oc1ccccc1.O=C(O)/C=C/C(=O)O,1,,_TENOFOVIR_ALAFENAMIDE_FUMARATE,,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1
C[C@@H]1NC(=O)[C@@H](N)CNC(=O)[C@H](C2CCNC(=N)N2)NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC1=O.N=C1NCCC([C@@H]2NC(=O)/C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC2=O)N1,1,,_CAPREOMYCIN,,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,1,1,0
CCOP(=S)(OCC)SCSP(=S)(OCC)OCC,1,,_ETHION,4341760,"Active, not recruiting",NCT00042289,HIV INFECTION,Female,"Child, Adult, Older Adult",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UAB Pediatric Infectious Diseases CRS, Birmingham, Alabama, United States|University of California, UC San Diego CRS- Mother-Child-Adolescent HIV Program, La Jolla, California, United States|Miller Children's Hosp. Long Beach CA NICHD CRS, Long Beach, California, United States|Usc La Nichd Crs, Los Angeles, California, United States|David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States|Univ. of California San Francisco NICHD CRS, San Francisco, California, United States|Harbor UCLA Medical Ctr. NICHD CRS, Torrance, California, United States|Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States|Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease, New Haven, Connecticut, United States|Washington Hosp. Ctr. NICHD CRS, Washington, District of Columbia, United States|Univ. of Florida Jacksonville NICHD CRS, Jacksonville, Florida, United States|Pediatric Perinatal HIV Clinical Trials Unit CRS, Miami, Florida, United States|USF - Tampa NICHD CRS, Tampa, Florida, United States|Emory University School of Medicine NICHD CRS, Atlanta, Georgia, United States|Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases, Augusta, Georgia, United States|Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program, Chicago, Illinois, United States|Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States|Univ. of Illinois College of Medicine at Chicago, Dept. of Peds., Chicago, Illinois, United States|Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States|Tulane Univ. New Orleans NICHD CRS, New Orleans, Louisiana, United States|Univ. of Maryland Baltimore NICHD CRS, Baltimore, Maryland, United States|Johns Hopkins Univ. Baltimore NICHD CRS, Baltimore, Maryland, United States|Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States|Boston Medical Center Ped. HIV Program NICHD CRS, Boston, Massachusetts, United States|Baystate Health, Baystate Med. Ctr., Springfield, Massachusetts, United States|WNE Maternal Pediatric Adolescent AIDS CRS, Worcester, Massachusetts, United States|Children's Hospital of Michigan NICHD CRS, Detroit, Michigan, United States|Rutgers - New Jersey Medical School CRS, Newark, New Jersey, United States|Bronx-Lebanon Hospital Center NICHD CRS, Bronx, New York, United States|Jacobi Med. Ctr. Bronx NICHD CRS, Bronx, New York, United States|Nyu Ny Nichd Crs, New York, New York, United States|Metropolitan Hosp. NICHD CRS, New York, New York, United States|Columbia IMPAACT CRS, New York, New York, United States|SUNY Stony Brook NICHD CRS, Stony Brook, New York, United States|DUMC Ped. CRS, Durham, North Carolina, United States|Philadelphia IMPAACT Unit CRS, Philadelphia, Pennsylvania, United States|Regional Med. Ctr. at Memphis, Memphis, Tennessee, United States|St. Jude Children's Research Hospital CRS, Memphis, Tennessee, United States|Texas Children's Hospital CRS, Houston, Texas, United States|Seattle Children's Research Institute CRS, Seattle, Washington, United States|Hosp. General de Agudos Buenos Aires Argentina NICHD CRS, Ciudad de Buenos Aires, Buenos Aires, Argentina|Gaborone CRS, Gaborone, South-East District, Botswana|Molepolole CRS, Gaborone, Botswana|SOM Federal University Minas Gerais Brazil NICHD CRS, Belo Horizonte, Minas Gerais, Brazil|Hosp. Santa Casa Porto Alegre Brazil NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil|Hosp. dos Servidores Rio de Janeiro NICHD CRS, Rio de Janeiro, Brazil|Hospital Federal dos Servidores do Estado NICHD CRS, Rio de Janeiro, Brazil|Instituto de Puericultura e Pediatria Martagao Gesteira - UFRJ NICHD CRS, Rio de Janeiro, Brazil|Hosp. Geral De Nova Igaucu Brazil NICHD CRS, Rio de Janeiro, Brazil|Univ. of Sao Paulo Brazil NICHD CRS, Sao Paulo, Brazil|University of Puerto Rico Pediatric HIV/AIDS Research Program CRS, San Juan, Puerto Rico|San Juan City Hosp. PR NICHD CRS, San Juan, Puerto Rico|Wits RHI Shandukani Research Centre CRS, Johannesburg, Gauteng, South Africa|Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS, Cape Town, Western Cape Province, South Africa|Famcru Crs, Tygerberg, Western Cape Province, South Africa|Kilimanjaro Christian Medical Centre (KCMC), Moshi, Tanzania|Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand|Bhumibol Adulyadej Hosp. CRS, Saimai, Bangkok, Thailand|Phayao Provincial Hosp. CRS, T.Tom, Muang, Phayao, Thailand|Prapokklao Hosp. CRS, Chantaburi, Thailand|Chiangrai Prachanukroh Hospital NICHD CRS, Chiang Mai, Thailand|Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS, Chiang Mai, Thailand|Chonburi Hosp. CRS, Chonburi, Thailand|MU-JHU Research Collaboration (MUJHU CARE LTD) CRS, Kampala, Uganda",A01N57/14,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,17.0,55.0976406086367,486.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,1,,_DIDANOSINE,,Completed,NCT00192660,HIV-ASSOCIATED LIPODYSTROPHY SYNDROME|CARDIOVASCULAR DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"St. Vincent's Hospital, Sydney, New South Wales, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,1,,_DIDANOSINE,,Completed,NCT00256828,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de Área de Elda, Elda, Alicante, Spain|Hospital de Orihuela-Vega Baja, San Bartolomé-Orihuela, Orihuela, Alicante, Spain|Hospital General-Central de Asturias, Oviedo, Asturias, Spain|Hospital Son Dureta, Palma de Mallorca, Baleares, Spain|Hospital Son Llatzer, Palma de Mallorca, Baleares, Spain|Hospital General de Granollers, Granollers, Barcelona, Spain|Hospital de Terrassa, Terrassa, Barcelona, Spain|Hospital Sant Llorenc de Viladecans, Viladecans,, Barcelona, Spain|Hospital General de Jerez de la Frontera11407, Jerez, Cadiz, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain|Hospital Sierrallana de Torrelavega, Torrelavega, Cantabria, Spain|Hospital Provincial Nuestra Señora de la Montaña-Complejo Hospitalario de Cáceres, Caceres, Cáceres, Spain|Hospital Comarcal de la Selva, Blanes, Gerona, Spain|Hospital de Figueres, Figueras, Gerona, Spain|Hospital de Palamós, Palamos, Gerona, Spain|Hospital Donostia, San Sebastian, Guipuzcoa, Spain|Hospital Arquitecto Marcide, Ferrol, La Coruña, Spain|Hospital Príncipe de Asturias, Alcala de Henares, Madrid, Spain|Hospital Severo Ochoa, Leganes, Madrid, Spain|Hospital Costa del Sol, Marbella, Málaga, Spain|Hospital Meixoeiro, Vigo, Pontevedra, Spain|Hospital Xeral-Cíes de Vigo, Vigo, Pontevedra, Spain|Hospital General Universitario Sant Joan de Reus, Reus, Tarragona, Spain|Hospital de Basurto, Bilbao, Vizcaya, Spain|Hospital Universitario de San Juan de Alicante, Alicante, Spain|Hospital del Mar, Barcelona, Spain|Hospital Santa Creu y Sant Pau, Barcelona, Spain|Hospital General Vall D'Hebrón, Barcelona, Spain|Hospital de Mollet, Barcelona, Spain|Consorcio Sanitario de Mataró, Barcelona, Spain|Hospital De Vic, Barcelona, Spain|Hospital General Yagüe, Burgos, Spain|Hospital General de Castellón, Castellon, Spain|Hospital Provincial Reina Sofía de Córdoba, Cordoba, Spain|Hospital Clínico Universitario San Cecilio, Granada, Spain|Hospital Universitario Virgen de las Nieves, Granada, Spain|Hospital General San Jorge, Huesca, Spain|Hospital Ciudad de Jaén, Jaen, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital de la Princesa, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital La Paz, Madrid, Spain|Hospital Carlos Haya, Malaga, Spain|Hospital Virgen de la Victoria, Malaga, Spain|Hospital Comarcal Axarquía de Vélez, Malaga, Spain|Hospital General Universitario de Murcia, Murcia, Spain|Hospital General Universitario Morales Meseguer, Murcia, Spain|Hospital de Covadonga-Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, Spain|Hospital General de Segovia, Segovia, Spain|Hospital La Fe de Valencia, Valencia, Spain|Hospital Doctor Peset, Valencia, Spain|Hospital del Río Hortega, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Miguel Servet, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c1ncn2[C@H]1CC[C@@H](CO)O1,1,,_DIDANOSINE,,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,"Active, not recruiting",NCT02844634,HIV|SYPHILIS,Male,"19 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"BC Centre for Disease Control, Vancouver, British Columbia, Canada",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Recruiting,NCT03980223,GONORRHEA|CHLAMYDIA|SYPHILIS,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"San Francisco City Clinic / San Francisco Department of Public Health, San Francisco, California, United States|University of California, San Francisco / Zuckerberg San Francisco General Hospital/UCSF, San Francisco, California, United States|University of Washington, Seattle, Washington, United States",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Recruiting,NCT04050540,HIV INFECTIONS|HIV/AIDS|NEISSERIA GONORRHEAE INFECTION|CHLAMYDIA TRACHOMATIS INFECTION|SYPHILIS INFECTION,Female,18 Years to 30 Years   (Adult),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Kenya Medical Research Institute, Kisumu, Kenya",6,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Not yet recruiting,NCT02864550,SYPHILIS|SEXUALLY TRANSMITTED INFECTIONS,Male,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00989742,LYMPHANGIOLEIOMYOMATOSIS|TUBEROUS SCLEROSIS,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Nottingham University Hospitals, Nottingham, United Kingdom",6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.O,1,,_DOXYCYCLINE,3957980,Completed,NCT00246324,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"LSU Health Sciences Center Shreveport, Shreveport, Louisiana, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,10.0,23.261257931374306,855.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O[C@H]2CC[C@H](N(C)C)[C@@H](C)O2)/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]1O,1,,_SPIRAMYCIN,,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1
Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,1,,_LEUCOVORIN,4148999,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",C07D487/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,19.5815109139818,2293.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
Nc1nc(O)c2c(n1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-])cc1)N2C=O.[Ca+2],1,,_LEUCOVORIN_CALCIUM,4500711,Recruiting,NCT00004317,TOXOPLASMOSIS,All,"Child, Adult, Older Adult",NIH|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States",C07D475/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,49.93942380747029,299.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1
O=C([O-])CCC(=O)O.[Na+],1,,_SODIUM_SUCCINATE,,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)COC(=O)CCC(=O)[O-])[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12.[Na+],1,,_METHYLPREDNISOLONE_SODIUM_SUCCINATE,4292300,Completed,NCT00627731,ASTHMA,All,"16 Years to 80 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hamamatsu University School of Medicine, Hamamatsu, Japan",A61K9/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,50.333682416476705,144.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1
O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,,_POTASSIUM_CITRATE,,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
O.O=C([O-])CC(O)(CC(=O)[O-])C(=O)[O-].[K+].[K+].[K+],1,,_POTASSIUM_CITRATE,,Recruiting,NCT04422184,DENTIN HYPERSENSITIVITY|PERIODONTAL DISEASES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bauru School of Denstistry, Bauru, SP, Brazil",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT03708848,HELICOBACTER PYLORI INFECTION,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S@@+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_ESOMEPRAZOLE,,Completed,NCT02205489,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Investigational Site Number 056002, Brugge, Belgium|Investigational Site Number 056001, Brussels, Belgium|Investigational Site Number 250009, Dijon, France|Investigational Site Number 250005, Lille Cedex, France|Investigational Site Number 250001, Lyon Bron, France|Investigational Site Number 250006, Nancy, France|Investigational Site Number 250010, Nantes, France|Investigational Site Number 250007, Nimes, France|Investigational Site Number 250008, PARIS Cedex 20, France|Investigational Site Number 250004, RENNES Cedex 9, France|Investigational Site Number 250003, Strasbourg Cedex 2, France|Investigational Site Number 250002, Toulouse, France|Investigational Site Number 528001, Breda, Netherlands|Investigational Site Number 528002, Rotterdam, Netherlands|Investigational Site Number 724001, Barcelona, Spain|Investigational Site Number 724005, Bilbao, Spain|Investigational Site Number 724002, Madrid, Spain|Investigational Site Number 724006, Málaga, Spain|Investigational Site Number 724003, Sevilla, Spain|Investigational Site Number 724004, Valencia, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Unknown status,NCT03062813,HEPATITIS B VIRUS ASSOCIATED NEPHROTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT03918265,AUTOIMMUNE HEMOLYTIC ANEMIA|PURE RED CELL APLASIA|EVANS SYNDROME,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03222687,HENOCH-SCHÖNLEIN PURPURA NEPHRITIS,All,"up to 18 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01828879,"DERMATITIS, ATOPIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hanoi, Vietnam|Hochiminh, Vietnam",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00654355,ATOPIC DERMATITIS,All,2 Years to 15 Years   (Child),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dept of Dermatology, WFUHS, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01745159,MODERATE/SEVERE ATOPIC DERMATITIS,All,2 Years to 15 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Beijing, China|Chongqing, China|Guangzhou, China|Shanghai, China",1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT04114097,ATOPIC DERMATITIS|ATOPIC ECZEMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Department of Dermatology and Allergy, Hellerup, Region Hovedstaden, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03464435,VERNAL KERATOCONJUNCTIVITIS,All,"5 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01850979,SJOGREN SYNDROME|DRY EYE SYNDROME,All,40 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01092806,POST TRANSPLANT DIABETES MELLITUS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Oslo univeristy hospital, Rikshospitalet, Oslo, Norway",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00766909,COMPLICATIONS OF TRANSPLANTED ORGANS AND TISSUE|DIABETES MELLITUS NOS NEW ONSET,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Department of Nephrology, Aarhus University Hospital, Skejby, Aarhus, Jutland, Denmark",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00195429,KIDNEY FAILURE|GRAFT VS HOST DISEASE,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sao Paulo, Brazil",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00843856,"GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hammersmith Hospital, London, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00667056,DERMATITIS,All,"17 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Washington, District of Columbia, United States|Kansas City, Kansas, United States|Shawnee, Kansas, United States|Louisville, Kentucky, United States|New Orleans, Louisiana, United States|Minneapolis, Minnesota, United States|New York, New York, United States|Portland, Oregon, United States|Hershey, Pennsylvania, United States|Lynchburg, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT03737708,RHEUMATOID ARTHRITIS,All,"19 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site KR82003, Daegu, Korea, Republic of|Site KR82007, Daegu, Korea, Republic of|Site KR82006, Daejeon, Korea, Republic of|Site KR82002, Incheon, Korea, Republic of|Site KR82009, Seongnam, Korea, Republic of|Site KR82001, Seoul, Korea, Republic of|Site KR82005, Seoul, Korea, Republic of|Site KR82010, Seoul, Korea, Republic of|Site KR82012, Seoul, Korea, Republic of|Site KR82013, Suwon, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT00125307,"LUPUS NEPHRITIS|LUPUS ERYTHEMATOSUS, SYSTEMIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Recruiting,NCT02630628,LUPUS NEPHRITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Hong Kong, Hong Kong, Hong Kong",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
C=CC[C@@H]1/C=C(\C)C[C@H](C)C[C@H](OC)[C@H]2O[C@@](O)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@H](/C(C)=C/[C@@H]3CC[C@@H](O)[C@H](OC)C3)[C@H](C)[C@@H](O)CC1=O)[C@H](C)C[C@@H]2OC.O,1,,_TACROLIMUS,6121329,Completed,NCT01649427,PHARMACOKINETICS STUDY IN DE NOVO KIDNEY TRANSPLANTATION,All,18 Years to 64 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Bochum, Germany|Novartis Investigative Site, Duesseldorf, Germany|Novartis Investigative Site, Kaiserslautern, Germany|Novartis Investigative Site, Koeln-Merheim, Germany",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,36.7646152898416,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0
CCC(=O)OCC(=O)[C@@]1(OC(=O)CC)[C@@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,1,,_BETAMETHASONE_DIPROPIONATE,4070462,Recruiting,NCT04114097,ATOPIC DERMATITIS|ATOPIC ECZEMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Department of Dermatology and Allergy, Hellerup, Region Hovedstaden, Denmark",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,18.0,14.948972258157198,250.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
C=C[C@]1(C)C[C@@H](OC(=O)CSC2CC3CCC(C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,1,,_RETAPAMULIN,,Completed,NCT01126268,IMPETIGO|FOLLICULITIS|SECONDARILY INFECTED ECZEMA|MINOR SOFT TISSUE INFECTIONS,All,"9 Months to 98 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Houston Medical Center Building, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
C=C[C@]1(C)C[C@@H](OC(=O)CSC2CC3CCC(C2)N3C)[C@]2(C)[C@H](C)CC[C@]3(CCC(=O)[C@H]32)[C@@H](C)[C@@H]1O,1,,_RETAPAMULIN,,Completed,NCT01064947,ATOPIC DERMATITIS|SECONDARY INFECTION,All,"2 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"DermResearch, PLLC, Louisville, Kentucky, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
CC1(C)C(/C=C/C=C/C=C/C=C2\N(CCCCS(=O)(=O)[O-])c3ccc4ccccc4c3C2(C)C)=[N+](CCCCS(=O)(=O)[O-])c2ccc3ccccc3c21.[Na+],1,,_INDOCYANINE_GREEN,3959455,Completed,NCT03969108,THYROID CANCER|THYROID GOITER|GRAVES DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"University Health Network, Toronto, Ontario, Canada",A61K51/0485,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,10.809256863590601,2060.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,1,0,1
C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.C/C(=C\C(=O)OCCCCCCCCC(=O)[O-])C[C@@H]1OC[C@H](C[C@@H]2O[C@H]2[C@@H](C)[C@H](C)O)[C@@H](O)[C@H]1O.O.O.[Ca+2],1,,_MUPIROCIN_CALCIUM,,Completed,NCT00801879,STAPHYLOCOCCUS AUREUS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Project Samaritan Inc., Bronx, New York, United States|Columbia University, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)O,1,,_LOTEPREDNOL,US-20050020551-A1,Completed,NCT01437982,"CONJUNCTIVITIS, SEASONAL ALLERGIC|CONJUNCTIVITIS, GIANT PAPILLARY|INFLAMMATION",All,"Child, Adult, Older Adult",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Bausch & Lomb Korea Ltd, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,50.5308117209799,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1,1,,_BEPOTASTINE,EP-0949260-A1,Completed,NCT01443442,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Eye Car Center, Southern California college of Optometry, Fullerton, California, United States|Eye Care Center, Southern Caalifornia College of Optometry, Fullerton, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,52.8635084909341,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)C(C)C)C(C)C,1,,_TERIPARATIDE,,Completed,NCT01400516,RHEUMATOID ARTHRITIS,All,"45 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1
CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,1,,_DOXYCYCLINE_HYCLATE,,Recruiting,NCT03980223,GONORRHEA|CHLAMYDIA|SYPHILIS,Male,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"San Francisco City Clinic / San Francisco Department of Public Health, San Francisco, California, United States|University of California, San Francisco / Zuckerberg San Francisco General Hospital/UCSF, San Francisco, California, United States|University of Washington, Seattle, Washington, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CCO.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.C[C@H]1c2cccc(O)c2C(=O)C2=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]3[C@@H](O)[C@@H]21.Cl.Cl.O,1,,_DOXYCYCLINE_HYCLATE,,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0
CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccccc3)[C@H]2SC1.O,1,,_CEPHALEXIN,4486411,Not yet recruiting,NCT04297592,INFECTIONS JOINT PROSTHETIC|OVERWEIGHT OR OBESITY|MSSA COLONIZATION|MRSA|CHRONIC KIDNEY DISEASES|DIABETES|AUTOIMMUNE DISEASES|INFLAMMATORY DISEASE|TOBACCO USE,All,"18 Years to 99 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,41.1343148729953,29.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1
CC1=NN(c2ccc(C)c(C)c2)C(=O)/C1=N\Nc1cccc(-c2cccc(C(=O)O)c2)c1O.NCCO.NCCO,1,,_ELTROMBOPAG_OLAMINE,,Completed,NCT01098487,"PURPURA, THROMBOCYTOPAENIC, IDIOPATHIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Hradec Kralove, Czech Republic|GSK Investigational Site, Olomouc, Czech Republic|GSK Investigational Site, Praha 2, Czech Republic|GSK Investigational Site, Caen cedex 9, France|GSK Investigational Site, Créteil, France|GSK Investigational Site, Pessac Cedex, France|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Muenchen, Bayern, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Duesseldorf, Nordrhein-Westfalen, Germany|GSK Investigational Site, Essen, Nordrhein-Westfalen, Germany|GSK Investigational Site, Berlin, Germany|GSK Investigational Site, Shatin, New Territories, Hong Kong|GSK Investigational Site, Debrecen, Hungary|GSK Investigational Site, Győr, Hungary|GSK Investigational Site, Szeged, Hungary|GSK Investigational Site, Ludhiana, India|GSK Investigational Site, Pune, India|GSK Investigational Site, Surat, India|GSK Investigational Site, Vellore, India|GSK Investigational Site, Bologna, Emilia-Romagna, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Milano, Lombardia, Italy|GSK Investigational Site, Padova, Veneto, Italy|GSK Investigational Site, Vicenza, Veneto, Italy|GSK Investigational Site, Seongnam-si Gyeonggi-do, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Seoul, Korea, Republic of|GSK Investigational Site, Karachi, Pakistan|GSK Investigational Site, Lahore, Pakistan|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, Novosibirsk, Russian Federation|GSK Investigational Site, St Petersburg, Russian Federation",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Completed,NCT00002146,CYTOMEGALOVIRUS INFECTIONS|HIV INFECTIONS|HYPOCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"Oklahoma City Veterans Administration Med Ctr, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Recruiting,NCT04497766,ASTHMA IN CHILDREN,All,2 Years to 12 Years   (Child),Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"King edward medical university/mayo hospital lahore, Lahore, Punjab, Pakistan",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O.O.O.O.O.O.O.O=S(=O)([O-])[O-].[Mg+2],1,,_MAGNESIUM_SULFATE,,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+],1,,_FOSCARNET_SODIUM,,Completed,NCT00002146,CYTOMEGALOVIRUS INFECTIONS|HIV INFECTIONS|HYPOCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"Oklahoma City Veterans Administration Med Ctr, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=C([O-])P(=O)([O-])[O-].[Na+].[Na+].[Na+],1,,_FOSCARNET_SODIUM,,Completed,NCT00002125,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Dr Ralph Hansen, Beverly Hills, California, United States|Dr Milan Fiala, Los Angeles, California, United States|Dr G Michael Wool, Los Angeles, California, United States|AIDS Community Research Consortium, Redwood City, California, United States|Ingenix Kern McNeill Decatur, Atlanta, Georgia, United States|Dr John Karedes, Indianapolis, Indiana, United States|Dr Paul Benson, Berkley, Michigan, United States|Dr Ronald Nahass, Somerville, New Jersey, United States|Dr Ronald J Grossman, New York, New York, United States|Community Health Network, Rochester, New York, United States|Austin Infectious Disease Consultants, Austin, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Unknown status,NCT02584738,ASTHMA,All,2 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital General Naval de Alta Especialidad, México, Distrito Federal, Mexico",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT00393367,ASTHMA|ACUTE ASTHMA|REACTIVE AIRWAY EXACERBATION,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Children's Hospital of Philadelphia Emergency Department, Philadelphia, Pennsylvania, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC(C)[N+]1(C)[C@H]2CC[C@@H]1C[C@H](OC(=O)C(CO)c1ccccc1)C2.O.[Br-],1,,_IPRATROPIUM_BROMIDE,US-20040184994-A1,Completed,NCT01691079,"BRONCHOSPASM, EXERCISE-INDUCED",All,"13 Years and older   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of California, San Francisco, San Francisco, California, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,84.30563255919009,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINDESINE,4208414,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,13.1419536335448,1292.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(N)=O)[C@H](O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINDESINE,4208414,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,13.1419536335448,1292.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT00199082,BURKITT'S LYMPHOMA|BURKITT'S LEUKEMIA|MEDIASTINAL NEOPLASMS|LYMPHOBLASTIC LYMPHOMA|LARGE CELL ANAPLASTIC LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Unknown status,NCT02858804,MANTLE CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shuhua Yi, Tianjin, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Completed,NCT03229746,IMMUNE THROMBOCYTOPENIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Assiut university hospital, Assiut, Egypt",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,"Active, not recruiting",NCT03817853,ADVANCED FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scripps Clinical Research Center, La Jolla, California, United States|Rocky Mountain Cancer Center; Medical Oncology, Denver, Colorado, United States|BRCR Medical Center, Inc., Plantation, Florida, United States|Center For Cancer and Blood Disorders, Bethesda, Maryland, United States|Summit Medical Center, Florham Park, New Jersey, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Willamette Valley Cancer Ctr - 520 Country Club, Eugene, Oregon, United States|Texas Onc-Central Austin CA Ct, Austin, Texas, United States|Texas Oncology Cancer Center, Austin, Texas, United States|NOHC - Núcleo de Oncologia e Hematologia do Ceará, Fortaleza, CE, Brazil|Hospital das Clinicas - UFRGS, Porto Alegre, RS, Brazil|Centro de Pesquisas Oncologicas - CEPON, Florianopolis, SC, Brazil|Hospital Amaral Carvalho, Jau, SP, Brazil|Klinikum Chemnitz gGmbH, Klinik für Innere Medizin III, Hämatologie und Onkologie, Chemnitz, Germany|Städtisches Klinikum Dessau, Dessau-Roßlau, Germany|Universitätsklinikum Frankfurt; Medizinische Klinik II; Onkologie, Frankfurt, Germany|OncoResearch Lerchenfeld GmbH, Hamburg, Germany|Klinik der Uni zu Köln; I. Med. Klinik, Köln, Germany|Onkologische Praxis Landshut, Landshut, Germany|Onkologische Schwerpunktpraxis Lübeck, Lübeck, Germany|Chiba Cancer Center, Chiba, Japan|Hokkaido University Hospital, Hokkaido, Japan|Kobe City Medical Center General Hospital, Hyogo, Japan|Kindai University Hospital, Osaka, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan|Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain|Hospital Universitario Puerta del Mar; Servicio de Hematologia, Cádiz, Cadiz, Spain|Hospital del Mar; Servicio de Hematologia, Barcelona, Spain|Hospital Universitario la Paz; Servicio de Hematologia, Madrid, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología, Murcia, Spain|University Hospital of Wales, Cardiff, United Kingdom|Kings College Hospital NHS Foundation Trust, London, United Kingdom|Portsmouth Hospitals NHS Trust - Queen Alexandra Hospital, Portsmouth, United Kingdom|Royal Cornwall Hospital Hematology Department, Truro, United Kingdom",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,1,,_VINCRISTINE,3932417,Recruiting,NCT02752815,DIFFUSE LARGE B-CELL LYMPHOMA,All,"14 Years to 75 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Shanghai Ruijin Hospital, Shanghai, Shanghai, China",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,5781.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Completed,NCT00199056,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Nc1nc2[nH]cnc2c(=S)[nH]1,1,,_THIOGUANINE,,Unknown status,NCT02894645,ACUTE LYMPHOBLASTIC LEUKEMIA,All,1 Year to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Malaya Medical Centre, Kuala Lumpur, Malaysia|Subang Jaya Medical Centre, Subang Jaya, Malaysia|National University Hospital, Singapore, Singapore|KK Women's and Children's Hospital, Singapore, Singapore",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Unknown status,NCT00198991,ADULT ACUTE LYMPHOCYTIC LEUKEMIA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Frankfurt, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT00199017,"LYMPHOMA, LYMPHOBLASTIC",All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital, Medical Dept. II, Frankfurt, Germany",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Sc1ncnc2nc[nH]c12,1,,_MERCAPTOPURINE,,Completed,NCT02036489,ACUTE LYMPHOBKASTIC LEUKEMIA,All,"15 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Germans Trias i Pujol, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Unknown status,NCT01440439,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Wycombe Hospital, High Wycombe, Buckinghamshire, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Completed,NCT00564395,TYPE 1 DIABETES,All,"10 Years to 25 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Children's Hospital Endocrine and Diabetes Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCCCCCCCCCCCCC(=O)NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H]1CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3c[nH]cn3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3c[nH]cn3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N2)[C@@H](C)O)C(=O)O,1,,_INSULIN_DETEMIR,,Terminated,NCT00509925,"DIABETES|DIABETES MELLITUS, TYPE 1",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novo Nordisk Investigational Site, Guildford, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CN[C@@H](C)[C@@H](O)c1ccccc1.CN[C@@H](C)[C@@H](O)c1ccccc1.O=S(=O)(O)O,1,,_PSEUDOEPHEDRINE_SULFATE,4601894,Completed,NCT03443843,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Kingston General Hospital, Kingston, Ontario, Canada",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,15.770344360253803,99.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OCC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,1,,_OMEGA-3-ACID_ETHYL_ESTERS,,Completed,NCT00296153,HUMAN IMMUNODEFICIENCY VIRUS|ISCHEMIC HEART DISEASE,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Aalborg Hospital, Department of Nephrology, Aalborg, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1.Cl,1,,_TRAMADOL_HYDROCHLORIDE,5414129,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,19.975769522988106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT00246168,RHEUMATOID ARTHRITIS,All,"18 Years to 79 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,C07C213/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1cccc(C2(O)CCCCC2CN(C)C)c1,1,,_TRAMADOL,5672755,Completed,NCT02246712,NEUROPATHIC PAIN|TYPE 1 DIABETES MELLITUS|TYPE 2 DIABETES MELLITUS,All,18 Years to 59 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universidade Estadual Paulista Julio de Mesquita Filho, Araraquara, SP, Brazil",C07C213/10,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,10.5135629068358,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0
O=S(=O)([O-])c1cc(O)ccc1O.O=S(=O)([O-])c1cc(O)ccc1O.[Ca+2],1,,_CALCIUM_DOBESILATE,4511557,Unknown status,NCT01382498,DIABETIC RETINOPATHY,All,"40 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Tabriz University of Medical Sciences, Tabriz, Eastern Azerbayjan, Iran, Islamic Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,31.869237561346196,68.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0
Brc1c(NC2=NCCN2)ccc2nccnc12.O=C(O)C(O)C(O)C(=O)O,1,,_BRIMONIDINE_TARTRATE,WO-1995003798-A2,Withdrawn,NCT02568111,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O,1,,_GRAZOPREVIR,,Completed,NCT03098121,CHRONIC HEPATITIS C,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taoyuan general hospital, Taoyuan, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H]2CN1C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]1C[C@H]1CCCCCc1nc3ccc(OC)cc3nc1O2)C(=O)NS(=O)(=O)C1CC1.O,1,,_GRAZOPREVIR,,Recruiting,NCT03823911,CARDIOVASCULAR DISEASES|HEPATITIS C|HIV,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Unity Parkside Health Center, Washington, District of Columbia, United States|Institute of Human Virology, CRU, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C,1,,_ELBASVIR,,Completed,NCT03098121,CHRONIC HEPATITIS C,All,"20 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Taoyuan general hospital, Taoyuan, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,1
COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1nc(-c2ccc3c(c2)O[C@@H](c2ccccc2)n2c-3cc3cc(-c4c[nH]c([C@@H]5CCCN5C(=O)[C@@H](NC(=O)OC)C(C)C)n4)ccc32)c[nH]1)C(C)C,1,,_ELBASVIR,,Recruiting,NCT03823911,CARDIOVASCULAR DISEASES|HEPATITIS C|HIV,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Unity Parkside Health Center, Washington, District of Columbia, United States|Institute of Human Virology, CRU, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,1
COC[C@H]1C[C@@H](c2nc(-c3ccc4c(c3)COc3cc5c(ccc6nc([C@@H]7CC[C@H](C)N7C(=O)[C@@H](NC(=O)OC)C(C)C)[nH]c65)cc3-4)c[nH]2)N(C(=O)[C@H](NC(=O)OC)c2ccccc2)C1,1,,_VELPATASVIR,,Completed,NCT03250910,"HEPATITIS C VIRUS INFECTION, RESPONSE TO THERAPY OF|HUMAN IMMUNODEFICIENCY VIRUS",All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Taiwan University Hospital, Yun-Lin Branch, Douliu, Taiwan|National Taiwan University Hospital, Taipei, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,0
COc1ccc(CC(C)(C)NC[C@H](O)c2cc(O)cc3c2OCC(=O)N3)cc1.Cl,1,,_OLODATEROL_HYDROCHLORIDE,7491719,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,28.4851845007084,3.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@H]12,1,,_TIOTROPIUM,,Completed,NCT00152984,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA",All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"CHU Sart Tilman, Angleur, Belgium|A.Z. VUB, Brussel, Belgium|Boehringer Ingelheim Investigational Site, Genk, Belgium|Boehringer Ingelheim Investigational Site, Hasselt, Belgium|St. Elisabethziekenhuis, Herentals, Belgium|Clinique Reine Astrid, Malmedy, Belgium|Sint-Elisabethziekenhuis, Turnhout, Belgium|VGH Research Pavillion, Vancouver, British Columbia, Canada|BG 034, Room C2027, Winnipeg, Manitoba, Canada|Department of Medicine, Health Sciences Centre, Hamilton, Ontario, Canada|Boehringer Ingelheim Investigational Site, Mississauga, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Respiratory Research Lab, Toronto, Ontario, Canada|Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada|Department of Respiratory Medicine, Toronto, Ontario, Canada|Centre de Recherche Clinique -CUSE, Sherbrooke, Quebec, Canada|Hopital Laval, Ste-Foy, Quebec, Canada|Lungemedicinsk Forskning 2B, Aarhus, Denmark|Lungemedicinsk afdeling Y, Hellerup, Denmark|Medicinsk afdeling B0642, Hiller?d, Denmark|Lungemedicinsk Klinik, Hvidovre, Denmark|H:S Bispebjerg Hospital, K?benhavn NV, Denmark|Lungemedicinsk Forskning, Odense C, Denmark|Hopital d'Annecy, Annecy, France|Hopital Prive Antony, Antony cedex, France|Boehringer Ingelheim Investigational Site, Chamalieres, France|Hopital Gabriel Montpied, Clermont Ferrand cedex 1, France|Hopital Ambroise Pare, Marseille, France|Hopital Notre Dame de Bon Secours, Metz cedex 1, France|Boehringer Ingelheim Investigational Site, Montpellier, France|Hopital Arnaud de Villeneuve, Montpellier, France|Boehringer Ingelheim Investigational Site, Nantes, France|Centre Medical Erdre St Augustin, Nantes, France|Boehringer Ingelheim Investigational Site, Nice, France|Hopital Maison blanche, Reims cedex, France|Boehringer Ingelheim Investigational Site, Berlin, Germany|Boehringer Ingelheim Investigational Site, Berlin, Germany|MEDARS GmbH, Berlin, Germany|Boehringer Ingelheim Investigational Site, Bonn, Germany|Boehringer Ingelheim Investigational Site, Frankfurt/Main, Germany|Boehringer Ingelheim Investigational Site, Furth, Germany|Inamed Research GmbH & Co. KG, Gauting, Germany|Boehringer Ingelheim Investigational Site, Gelnhausen, Germany|ClinPharm Internat. GmbH & Co. KG, Gorlitz, Germany|Pneumologisches Forschungsinstitut GmbH am Krankenhaus, Hamburg, Germany|Med. Einrichtung der Universitat zu Koln, Koln, Germany|Boehringer Ingelheim Investigational Site, Minden, Germany|Boehringer Ingelheim Investigational Site, Munchen, Germany|Boehringer Ingelheim Investigational Site, Rudersdorf, Germany|A. O. Universitaria di Ferrara - Arcispedale S. Anna, Ferrara, Italy|A.O. S. Martino e Cliniche Universitarie di Genova, Genova, Italy|Universita di Genova, Genova, Italy|A.O. Pisana, Pisa, Italy|Ziekenhuisgroep Twent, Almelo, Netherlands|Amphia ziekenhuis, Breda, Netherlands|Atrium medisch centrum, Heerlen, Netherlands|Ziekenhuigroep Twente, Hengelo, Netherlands|Medisch Centrum Leeuwarden, Leeuwarden, Netherlands|Antonius Ziekenhuis, Sneek, Netherlands|Maxima Medisch Centrum, Velthoven, Netherlands|Boehringer Ingelheim Investigational Site, Bellville, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Cape Town, South Africa|Boehringer Ingelheim Investigational Site, Durban, South Africa|Boehringer Ingelheim Investigational Site, George, South Africa|Boehringer Ingelheim Investigational Site, Paarl, South Africa|Boehringer Ingelheim Investigational Site, Pretoria, South Africa|Boehringer Ingelheim Investigational Site, Somerset West, South Africa",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,Completed,NCT02682862,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottish Centre for Respiratory Research, University of Dundee, Ninewells Hospital and Medical School, Dundee, Scotland, United Kingdom",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
C[N+]1(C)[C@H]2C[C@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@@H]1[C@H]1O[C@@H]21.O.[Br-],1,,_TIOTROPIUM_BROMIDE,US-20020111363-A1,"Active, not recruiting",NCT03199976,WHEEZY BRONCHITIS|ASTHMATIC BRONCHITIS|WHEEZING|OBSTRUCTION AIRWAY,All,6 Months to 35 Months   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Helsinki, Finland",A61K9/0078,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,52.0,32.7488,74.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,1,1,0,1
NCCCC[C@@H]1NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](c2ccccc2)NC(=O)[C@@H]2C[C@H](OC(=O)NCCN)CN2C(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccc(OCc3ccccc3)cc2)NC1=O,1,,_PASIREOTIDE,,Completed,NCT03080181,CUSHING DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Recruiting,NCT02407899,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking University People's Hospital, Peking, Beijing, China|Beijing Hospital of the Ministry of Health, Peking, Beijing, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China|Quanzhou First Hospital, Fujian, Quanzhou, Fujian, China|The First Affiliated Hospital of Fujian Medical University, Fujian, Fuzhou, China|Gansu Provincial Hospital, Lanzhou, Gansu, China|Dongguan People's Hospital, Dongguan, Guangdong, China|Guangdong General Hospital, Guangzhou, Guangdong, China|Guangzhou First People's Hospital, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|Hainan General Hospital, Haikou, Hainan, China|Tangshan Gongren Hospital063000, Tangshan, Hebei, China|Tangshan Gongren Hospital, Tangshan, Hebei, China|Harbin Medical University, Harbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First People's Hospital of Changde, Changde, Hunan, China|Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China|The First Affiliated Hospital of South China University, Hengyang, Hunan, China|The Second Hospital University of South China, Hengyang, Hunan, China|The First People's Hospital of Huaihua, Huaihua, Hunan, China|The First People's Hospital of Yueyang, Yueyang, Hunan, China|The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China|Jiangsu Province Hospital, Nanjing, Jiangsu, China|The Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, China|The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Third Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China|The Second Hospital of Jilin University, Changchun, Jilin, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of China Medical University, Shenyang, Liaoning, China|The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China|Shanghai Xuhui District Central Hospital, Shanghai, Shanghai, China|Heping Hospital of Changzhi Medical College, Changzhi, Shanxi, China|Affiliated Heji Hospital of Changzhi Medical College, Changzhi, Shanxi, China|The First Affiliated Hospital of The Fourth Military Medical University, Xi'an, Shanxi, China|First People's Hospital of Yunnan Province, Kunming, Yunnan, China|The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China|The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2.O,1,,_SAXAGLIPTIN,,Unknown status,NCT02307695,TYPE 1 DIABETES,All,"12 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1
COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.COc1ccc(CC(C)NCC(O)c2ccc(O)c(NC=O)c2)cc1.O.O.O=C(O)/C=C/C(=O)O,1,,_FORMOTEROL_FUMARATE,,Completed,NCT02062463,ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 34092, Axbridge, United Kingdom|Teva Investigational Site 34081, Babbacombe, United Kingdom|Teva Investigational Site 34103, Beccles, United Kingdom|Teva Investigational Site 34144, Bishops Stortford, United Kingdom|Teva Investigational Site 34066, Burnhope, United Kingdom|Teva Investigational Site 34064, Bury St Edmunds, United Kingdom|Teva Investigational Site 34107, Bury St Edmunds, United Kingdom|Teva Investigational Site 34072, Cheltenham, United Kingdom|Teva Investigational Site 34063, Chippenham, United Kingdom|Teva Investigational Site 34122, Chipping Norton, United Kingdom|Teva Investigational Site 34134, Clacton-on-Sea, United Kingdom|Teva Investigational Site 34111, Colchester, United Kingdom|Teva Investigational Site 34120, Colchester, United Kingdom|Teva Investigational Site 34126, Colchester, United Kingdom|Teva Investigational Site 34135, Colchester, United Kingdom|Teva Investigational Site 34136, Colchester, United Kingdom|Teva Investigational Site 34143, Colchester, United Kingdom|Teva Investigational Site 34075, Daventry, United Kingdom|Teva Investigational Site 34112, Daventry, United Kingdom|Teva Investigational Site 34083, East Hunsbury, United Kingdom|Teva Investigational Site 34145, East Tillbury, United Kingdom|Teva Investigational Site 34099, Exmouth, United Kingdom|Teva Investigational Site 34110, Exmouth, United Kingdom|Teva Investigational Site 34102, Goldhay, United Kingdom|Teva Investigational Site 34119, Great Yarmouth, United Kingdom|Teva Investigational Site 34068, Harrogate, United Kingdom|Teva Investigational Site 34079, Harrogate, United Kingdom|Teva Investigational Site 34139, Hemel Henpstead, United Kingdom|Teva Investigational Site 34116, Huntingdon, United Kingdom|Teva Investigational Site 34113, Ipswich, United Kingdom|Teva Investigational Site 34098, Lancashire, United Kingdom|Teva Investigational Site 34127, Leicester, United Kingdom|Teva Investigational Site 34128, Leicester, United Kingdom|Teva Investigational Site 34141, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34142, Leigh-on-Sea, United Kingdom|Teva Investigational Site 34082, Liskeard, United Kingdom|Teva Investigational Site 34146, Lister House, United Kingdom|Teva Investigational Site 34147, Liverpool, United Kingdom|Teva Investigational Site 34080, Loughborough, United Kingdom|Teva Investigational Site 34086, Lowestoft, United Kingdom|Teva Investigational Site 34138, Luton, United Kingdom|Teva Investigational Site 34076, Manchester, United Kingdom|Teva Investigational Site 34109, Newton Aycliffe, United Kingdom|Teva Investigational Site 34106, Norwich', United Kingdom|Teva Investigational Site 34091, Norwich, United Kingdom|Teva Investigational Site 34095, Norwich, United Kingdom|Teva Investigational Site 34108, Norwich, United Kingdom|Teva Investigational Site 34123, Norwich, United Kingdom|Teva Investigational Site 34085, Oadby, United Kingdom|Teva Investigational Site 34070, Oldham, United Kingdom|Teva Investigational Site 34114, Orby, United Kingdom|Teva Investigational Site 34118, Oxon, United Kingdom|Teva Investigational Site 34137, Pickering, United Kingdom|Teva Investigational Site 34124, Reading, United Kingdom|Teva Investigational Site 34089, Redditch, United Kingdom|Teva Investigational Site 34100, Sheringham, United Kingdom|Teva Investigational Site 34117, Stalham, United Kingdom|Teva Investigational Site 34105, Stanley, United Kingdom|Teva Investigational Site 34065, Stowmarket, United Kingdom|Teva Investigational Site 34067, Strensall, United Kingdom|Teva Investigational Site 34078, Swindon, United Kingdom|Teva Investigational Site 34140, Thaxted, United Kingdom|Teva Investigational Site 34096, Thornton-Cleveleys, United Kingdom|Teva Investigational Site 34077, Trowbridge, United Kingdom|Teva Investigational Site 34088, Trowbridge, United Kingdom|Teva Investigational Site 34071, Waterlooville, United Kingdom|Teva Investigational Site 34073, Waterlooville, United Kingdom|Teva Investigational Site 34084, Wells-Next-Sea, United Kingdom|Teva Investigational Site 34115, Wisbech, United Kingdom|Teva Investigational Site 34069, Woodbridge, United Kingdom|Teva Investigational Site 34074, Woodbridge, United Kingdom|Teva Investigational Site 34090, Worcester, United Kingdom|Teva Investigational Site 34121, Wymondham, United Kingdom|Teva Investigational Site 34101, York, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0
COc1c(C)c2c(c(O)c1C/C=C(\C)CCC(=O)[O-])C(=O)OC2.[Na+],1,,_MYCOPHENOLATE_SODIUM,,Completed,NCT01112215,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vall d'Hebron Hospital, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT01730872,CHRONIC ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT01534195,ALLERGIC CONJUNCTIVITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Andover Eye Associates, Andover, Massachusetts, United States",A61K9/0051,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)([O-])[O-].[Na+].[Na+],1,,_PREDNISOLONE_SODIUM_PHOSPHATE,4304765,Completed,NCT03698630,ASTHMA|ACUTE ASTHMA,All,2 Years to 16 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Our Lady's Children's Hospital, Crumlin, Dublin, Ireland",A61K9/0051,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,13.799051315222002,388.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,0,0
C=C1CS[C@H]([C@H](NC(=O)CCCC[C@@H](N)C(=O)O)C(=O)O)N=C1C(=O)O,1,,_CEPHALOSPORIN,,Not yet recruiting,NCT04401553,SURGICAL SITE INFECTION|BETA-LACTAM ALLERGY,Female,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Prevention",,,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,1
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1.O=S(=O)(O)O,1,,_ABACAVIR_SULFATE,WO-2002010743-A1,Completed,NCT00005018,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"East Bay AIDS Ctr, Berkeley, California, United States|Pacific Oaks Research, Beverly Hills, California, United States|Altamed Medical Health Services, Los Angeles, California, United States|St Lukes Medical Group, San Diego, California, United States|Pacific Horizons Med Group, San Francisco, California, United States|Gary Richmond MD, Fort Lauderdale, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Saint Josephs Comprehensive Research Institute, Tampa, Florida, United States|Northstar Med Clinic, Chicago, Illinois, United States|Univ of Kentucky Med Ctr, Lexington, Kentucky, United States|Boston Med Ctr / Evans - 556, Boston, Massachusetts, United States|CRI of New England, Brookline, Massachusetts, United States|Univ of Nebraska Medical Ctr, Omaha, Nebraska, United States|Beth Israel Med Ctr, New York, New York, United States|Saint Luke's - Roosevelt Hosp Ctr, New York, New York, United States|Univ of North Carolina / Infectious Disease Division, Chapel Hill, North Carolina, United States|Univ of NC Infectious Diseases, Wilmington, North Carolina, United States|Anderson Clinical Research Inc, Reading, Pennsylvania, United States|Miriam Hosp, Providence, Rhode Island, United States|Burnside Clinic, Columbia, South Carolina, United States|Univ of Texas Med Branch, Galveston, Texas, United States|Univ of Texas / Thomas Street Clinic, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States", A61K38/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0
Nc1nc(NC2CC2)c2ncn([C@H]3C=C[C@@H](CO)C3)c2n1.O=S(=O)(O)O,1,,_ABACAVIR_SULFATE,WO-2002010743-A1,Completed,NCT00005764,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"THE Clinic, Los Angeles, California, United States|Tower Infectious Disease Med Ctr, Los Angeles, California, United States|St Lukes Medical Group, San Diego, California, United States|UCSD Treatment Ctr, San Diego, California, United States|Dupont Circle Physicians Group, Washington, District of Columbia, United States|North Broward Hosp District / HIV Clinical Research, Fort Lauderdale, Florida, United States|Duval County Health Department, Jacksonville, Florida, United States|Infectious Disease Research Institute Inc, Tampa, Florida, United States|Northstar Med Clinic, Chicago, Illinois, United States|Jersey Shore Med Ctr, Neptune, New Jersey, United States|South Jersey Infectious Diseases Inc, Somers Point, New Jersey, United States|Infectious Disease Specialists of NJ, Union, New Jersey, United States|Bronx Veterans Affairs Med Ctr, Bronx, New York, United States|Infectious Diseases Assoc of Brooklyn, Brooklyn, New York, United States|Long Island College Hospital, Brooklyn, New York, United States|Mt Vernon Hospital, Mt. Vernon, New York, United States|Dr Lawrence Fontana, New York, New York, United States|Liberty Medical / Cabrini Hospital / Dept of Infec Diseases, New York, New York, United States|Howard Grossman, New York, New York, United States|Boriken Neighborhood Health Center, New York, New York, United States|Univ of North Carolina / SOCA, Chapel Hill, North Carolina, United States|Summa Health System, Akron, Ohio, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|Philadelphia Veterans Administration Med Ctr, Philadelphia, Pennsylvania, United States|Anderson Clinical Research, Pittsburgh, Pennsylvania, United States|Central Texas Clinical Research, Austin, Texas, United States|Gathe, Joseph, M.D., Houston, Texas, United States|Diversified Med Practices, PA, Houston, Texas, United States|Univ of Texas / Med School at Houston, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States|Swedish Med Ctr, Seattle, Washington, United States", A61K38/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0
CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,,_NELFINAVIR_MESYLATE,5925759,Completed,NCT00006190,HIV INFECTIONS|LIPODYSTROPHY,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Masking: Double|Primary Purpose: Diagnostic,"UT Southwestern Medical Center, Dallas, Texas, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,22.439885829277802,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CS(=O)(=O)O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,1,,_NELFINAVIR_MESYLATE,5925759,Unknown status,NCT00005000,HIV INFECTION,All,"Child, Adult, Older Adult",Industry,Intervention Model: Crossover Assignment|Primary Purpose: Treatment,"Agouron Pharmaceuticals Inc, San Diego, California, United States",C07D413/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,22.439885829277802,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,1,,_INDINAVIR_SULFATE,6248363,Completed,NCT00002386,HIV INFECTIONS|HEMOPHILIA A,Male,"16 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"USCF, San Francisco, California, United States|Georgetown U Med Ctr / Div of Hematology / Oncology, Washington, District of Columbia, United States|Emory Univ, Atlanta, Georgia, United States|Riley Hosp for Children, Indianapolis, Indiana, United States|Tulane Univ School of Medicine / Hematology / Oncology, New Orleans, Louisiana, United States|Univ of North Carolina School of Medicine / Div Hemat / Onco, Chapel Hill, North Carolina, United States|Milton Hershey Med Ctr, Hershey, Pennsylvania, United States|Montreal Gen Hosp, Montreal, Quebec, Canada",4,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cccnc2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)N[C@H]1c2ccccc2C[C@H]1O.O=S(=O)(O)O,1,,_INDINAVIR_SULFATE,6248363,Completed,NCT00002376,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Kaiser Foundation Hospital, San Francisco, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,57.0,18.858703464136802,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,0,1
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
Cn1c(=O)c2nc[nH]c2n(C)c1=O,1,,_THEOPHYLLINE,3935196,Terminated,NCT03269318,ASTHMA,All,5 Years to 11 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"BrightonNHS, Brighton, East Sussex, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.191400234091,1897.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00157937,ASTHMA|ALLERGIC RHINITIS,All,18 Years to 60 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00395408,ASTHMA,All,6 Years to 8 Years   (Child),Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
CC(C)(O)c1ccccc1CC[C@@H](SCC1(CC(=O)[O-])CC1)c1cccc(/C=C/c2ccc3ccc(Cl)cc3n2)c1.[Na+],1,,_MONTELUKAST_SODIUM,6221880,Completed,NCT00380705,ASTHMA|RHINITIS ALLERGIC,All,"6 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,18.5958643914659,27.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,0,1,0,0
Nc1cc[nH]c(=O)n1,1,,_CYTOSINE,,Completed,NCT00853008,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General, Alicante, Spain|Hospital Germans Trias i Pujol, Badalona, Spain|Clínica Teknon, Barcelona, Spain|Hospital Clínic i Provincial, Barcelona, Spain|Hospital de Sant Pau, Barcelona, Spain|Hospital Duran y Reynals, Barcelona, Spain|Hospital Vall d'Hebrón, Barcelona, Spain|Hospital General, Castellón, Spain|Hospital San Pedro de Alcántara, Cáceres, Spain|Hospital Puerta del Mar, Cádiz, Spain|Hospital Josep Trueta, Girona, Spain|Hospital Universitario, Guadalajara, Spain|Hospital Juan Canalejo, La Coruña, Spain|Hospital Xeral, Lugo, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Clínico Universitario, Madrid, Spain|Hospital de Fuenlabrada, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Morales Messeguer, Murcia, Spain|Hospital Carlos Haya, Málaga, Spain|Hospital Virgen de la Victoria, Málaga, Spain|Hospital Central de Asturias, Oviedo, Spain|Hospital Son Llàtzer, Palma de Mallorca, Spain|Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Parc Taulí, Sabadell, Spain|Hospital Clínico Universitario, Salamanca, Spain|Hospital Marqués de Valdecilla, Santander, Spain|Hospital Xeral, Santiago, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Hospital Joan XXIII, Tarragona, Spain|Hospital Mútua de Terrassa, Terrassa, Spain|Hospital Clínico Universitario, Valencia, Spain|Hospital Dr Pesset, Valencia, Spain|Hospital General, Valencia, Spain|Hospital La Fe, Valencia, Spain|Hospital Clínico, Valladolid, Spain|Hospital Virgen de la Concha, Zamora, Spain|Hospital Lozano Blesa, Zaragoza, Spain",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O,1,,_GENTAMICIN,,Terminated,NCT00671528,"DERMATITIS, ATOPIC|ECZEMA, ATOPIC|SKIN DISEASES, ECZEMATOUS",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1
CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.O=S(=O)(O)O,1,,_GENTAMICIN_SULFATE,,Terminated,NCT00671528,"DERMATITIS, ATOPIC|ECZEMA, ATOPIC|SKIN DISEASES, ECZEMATOUS",All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1
C=C1CC[C@H](O)C/C1=C/C=C1\CCC[C@@]2(C)[C@H]1CC[C@@H]2[C@H](C)CCCC(C)(C)O.O,1,,_CALCIFEDIOL,,Completed,NCT02805907,BRONCHIAL ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Servicio Murciano de Salud, Murcia, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,0
CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@H](C(=O)N1CCC[C@H]1C(N)=O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O,1,,_CALCITONIN,,Recruiting,NCT03935984,PRIMARY HYPERPARATHYROIDISM|HYPERCALCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"ProMedica Toledo Hospital, Toledo, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,0
O=C(O)c1ccc2ccccc2c1O.OCc1cc(C(O)CNCCCCCCOCCCCc2ccccc2)ccc1O,1,,_SALMETEROL_XINAFOATE,4572192,Not yet recruiting,NCT04503460,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom",A61N1/3622,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,60.0,29.175137066469496,619.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0
CC(=O)OC(C)C[N+](C)(C)C.[Cl-],1,,_METHACHOLINE_CHLORIDE,4059686,Completed,NCT01907334,ASTHMA,All,4 Years to 11 Years   (Child),Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor),"University of Florida Asthma Research Lab, Gainesville, Florida, United States",A61K9/2027,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,26.021068194418696,247.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0
COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC.Cl,1,,_PRAZOSIN_HYDROCHLORIDE,4092315,Completed,NCT00487032,ALLERGIC RHINITIS|TACHYPHYLAXIS|RHINITIS MEDICAMENTOSA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Perth Royal Infirmary (Tayside NHS Trust), Perth, Perthshire, United Kingdom|Ninewells Hospital and Medical School (Tayside NHS Trust, University of Dundee), Dundee, Tayside, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,26.9410049487669,287.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT03004131,SEASONAL ALLERGIC RHINITIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Inflamax Research, Mississauga, Ontario, Canada",A61K9/14,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1CCCC(n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1.Cl,1,,_AZELASTINE_HYDROCHLORIDE,5811547,Completed,NCT01880840,ALLERGIC RHINITIS,All,6 Months to 5 Years   (Child),Industry|Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clinical Research Center of Alabama,LLC, Birmingham, Alabama, United States|Little Rock Allergy and Asthma Clinical research Center, Little Rock, Alaska, United States|West Coast Clinical Trials, Costa Mesa, California, United States|Southern California Research, Mission Viejo, California, United States|Storms Clinical Research Institute, Colorado Springs, Colorado, United States|Sneeze, Wheeze and Itch Associates, Normal, Illinois, United States|Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma, United States|National Allergy, Asthna & Urticaria Centers of Charleston Pa, Charleston, Pennsylvania, United States|Texas Allergy Research Center, Dallas, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Paul H Ratner,MD, San Antonio, Texas, United States|Live Oak Allergy and Asthma Clinic, San Antonio, Texas, United States|Allergy and Asthma Center, Waco, Texas, United States|Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco, Waco, Texas, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,39.4587157847183,107.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0
CN1C2CCCC1CC(NC(=O)c1nn(C)c3ccccc13)C2,1,,_GRANISETRON,4845092,Completed,NCT00415103,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Hospital Universitario Gregorio Marañón, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitario la Princesa, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,17.478798332614602,34.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0
O=C1OC2(c3ccccc31)c1cc(Br)c(O)c(Br)c1Oc1c2cc(Br)c(O)c1Br,1,,_EOSIN,4400249,Not yet recruiting,NCT04527016,ASTHMA IN CHILDREN,All,1 Year to 5 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Children's Hospital of Fudan University, Shanghai, Shanghai, China",C07D461/00,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,26.415326803425106,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT02646904,ALLERGIC RHINITIS,All,6 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council, Palermo, Sicily, Italy|Institute of Biomedicine and Molecular Immunology, IBIM, Palermo, Italy",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT03369847,ASTHMA|PEDIATRIC ALL,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Kings County Hospital Center, Brooklyn, New York, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Completed,NCT02577497,ASTHMA,All,6 Years to 17 Years   (Child),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Virginia - Fontaine Research Park, Charlottesville, Virginia, United States",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
C[C@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(Cl)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,1,,_BECLOMETHASONE,4041055,Withdrawn,NCT02319564,WHEEZE,All,12 Months to 60 Months   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Alberta Children's Hospital, Calgary, Alberta, Canada",C07J1/0048,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,2076.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1
COCCc1ccc(OCC(O)CNC(C)C)cc1.COCCc1ccc(OCC(O)CNC(C)C)cc1.O=C(O)CCC(=O)O,1,,_METOPROLOL_SUCCINATE,4780318,Completed,NCT03370835,"PULMONARY DISEASE, CHRONIC OBSTRUCTIVE|ASTHMA|ADVERSE EFFECT OF BETA-ADRENORECEPTOR ANTAGONISTS",All,"40 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VA West Los Angeles Medical Center, Los Angeles, California, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,45.471159572065105,71.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0
CC(C)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@H](C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)O)C(C)C,1,,_ANGIOTENSIN,,Completed,NCT00863252,IGA NEPHROPATHY,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Medicine and Geriatrics, United Christian Hospital, Hong Kong, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,1,1,1
Nc1nc(O)c2ncn(COCCO)c2n1,1,,_ACYCLOVIR,,Completed,NCT01026454,HSV INFECTION|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Thika Partners in Prevention, Thika, Kenya",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Nc1nc(O)c2ncn(COCCO)c2n1,1,,_ACYCLOVIR,,Completed,NCT00527618,GENITAL HERPES|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Virology Research Clinic, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Nc1nc(O)c2ncn(COCCO)c2n1,1,,_ACYCLOVIR,,Completed,NCT00362596,HIV|HERPES,Female,18 Years to 49 Years   (Adult),U.S. Fed|Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Prevention,"TUC, Chiang Rai, Thailand",,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CC(C)[C@H](N)C(=O)OCCOCn1cnc2c(=O)nc(N)[nH]c21.Cl,1,,_VALACYCLOVIR_HYDROCHLORIDE,4957924,Terminated,NCT00079911,HERPES GENITALIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Denver, Colorado, United States|GSK Investigational Site, Altamonte Springs, Florida, United States|GSK Investigational Site, Fort Myers, Florida, United States|GSK Investigational Site, Chicago, Illinois, United States|GSK Investigational Site, Boston, Massachusetts, United States|GSK Investigational Site, Voorhees, New Jersey, United States|GSK Investigational Site, Rochester, New York, United States|GSK Investigational Site, Columbia, South Carolina, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Fort Worth, Texas, United States|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Kowloon Bay, Hong Kong",C07D473/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,25.4625351649931,58.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,1,,_ALBUTEROL_SULFATE,4409237,Completed,NCT04207840,PHARMACOKINETICS|EPINEPHRINE|ALBUTEROL|ASTHMA|ANAPHYLAXIS,All,18 Years to 50 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Amphastar Study Site 0035, Cypress, California, United States",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
CC(C)(C)NCC(O)c1ccc(O)c(CO)c1.O=S(=O)(O)O,1,,_ALBUTEROL_SULFATE,4409237,Completed,NCT00667797,ASTHMA|COPD,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research,"Birmingham, Alabama, United States|Chula Vista, California, United States|Oakland, California, United States|Wheat Ridge, Colorado, United States|Waterbury, Connecticut, United States|Washington, District of Columbia, United States|Brandon, Florida, United States|Des Moines, Iowa, United States|Johnson City, New Jersey, United States|Great Neck, New York, United States|Syracuse, New York, United States|Chapel Hill, North Carolina, United States|Winston Salem, North Carolina, United States|Portland, Oregon, United States|Pittsburg, Pennsylvania, United States|Houston, Texas, United States|San Antonio, Texas, United States|Morgantown, West Virginia, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,29.6679603277274,338.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Completed,NCT00467571,CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA|HELICOBACTER PYLORI INFECTION,All,"2 Years to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Terminated,NCT01404832,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS,All,"18 Years and older   (Adult, Older Adult)",U.S. Fed|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Dallas VA Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1,1,,_LANSOPRAZOLE,,Unknown status,NCT00237068,ASTHMA,All,4 Years to 11 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Emory Children's Center, Atlanta, Georgia, United States|Children's Center for Digestive Healthcare, Atlanta, Georgia, United States|Georgia Pediatric Pulmonology Associates/ CHOA, Atlanta, Georgia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,1,,_VINBLASTINE_SULFATE,4303584,"Active, not recruiting",NCT01088750,LYMPHOMA,All,up to 17 Years   (Child),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitaetsklinikum Giessen-Marburg, Giessen, Germany",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,19.975769522988106,398.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Completed,NCT01282138,ALLERGIC CONJUNCTIVITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Contact Alcon Call Center for Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Completed,NCT00789555,PERENNIAL ALLERGIC RHINITIS,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Contact Alcon Call Center For Trial Locations, Fort Worth, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
CN(C)CC/C=C1/c2ccccc2COc2ccc(CC(=O)O)cc21.Cl,1,,_OLOPATADINE_HYDROCHLORIDE,WO-2001054687-A1,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,32.7488,57.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,1,,_DOXORUBICIN_HYDROCHLORIDE,4003996,"Active, not recruiting",NCT02577783,MULTIPLE MYELOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"the First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,28.32091008028911,2302.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,1,1,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,1,,_PROCATEROL,4616022,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,25.659664469496196,329.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2[nH]c(=O)ccc12,1,,_PROCATEROL,4616022,Completed,NCT01091337,ASTHMA,All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Philippine General Hospital, Manila, Philippines",C07D215/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,25.659664469496196,329.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0
CCC(NC(C)C)C(O)c1ccc(O)c2nc(O)ccc12.Cl,1,,_PROCATEROL_HYDROCHLORIDE,4322425,Unknown status,NCT01170429,COUGH VARIANT ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Xin Zhou, Shanghai, Shanghai, China",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,24.509743526561106,47.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
COc1cc([C@@H]2c3cc4c(cc3[C@@H](O[C@@H]3O[C@@H]5CO[C@@H](C)O[C@H]5[C@H](O)[C@H]3O)[C@H]3COC(=O)[C@H]23)OCO4)cc(OC)c1OP(=O)(O)O,1,,_ETOPOSIDE_PHOSPHATE,,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(=O)CO)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O[C@H]2CCCCO2)[C@H](C)O1,1,,_PIRARUBICIN,,Unknown status,NCT01746992,"ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA|PERIPHERIAL T CELL LYMPHOMA,NOT OTHERWISE SPECIFIED|ANGIOIMMUNOBLASTIC T CELL LYMPHOMA|ENTEROPATHY ASSOCIATED T CELL LYMPHOMA|HEPATOSPLENIC T CELL LYMPHOMA|SUBCUTANEOUS PANNICULITIS LIKE T CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ruijin hospital, Shanghai, Shanghai, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT01235819,TYPE 1 DIABETES,All,"12 Years to 30 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Command Hospital, Lucknow, UP, India",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Terminated,NCT01791465,HUMAN IMMUNODEFICIENCY VIRUS INFECTION|DIABETES MELLITUS,All,"18 Years to 99 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt University, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Completed,NCT00948168,TYPE 2 DIABETES,All,"40 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cliniques universitaires St-Luc, Brussels, Brabant, Belgium",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Recruiting,NCT02981069,"DIABETES MELLITUS, TYPE 2",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas Health Science Center, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(N)=O,1,,_EXENATIDE,,Unknown status,NCT02962492,EVALUATE KETOGENIC STRESS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","ECMC Ambulatory Center, 3rd Floor, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1
CCCc1nc(C(C)(C)O)c(C(=O)OCc2oc(=O)oc2C)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_OLMESARTAN_MEDOXOMIL,5616599,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,42.0,26.1524877307542,88.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nn[n-]n2)cc1.[K+],1,,_LOSARTAN_POTASSIUM,5859258,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",C07D403/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,14.4890038809831,18.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT00185094,HYPERTENSION|INSULIN RESISTANCE|METABOLIC SYNDROME,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Birmingham, Alabama, United States|San Diego, California, United States|Miami, Florida, United States|Indianapolis, Indiana, United States|Baltimore, Maryland, United States|Boston, Massachusetts, United States|Rochester, Minnesota, United States|Philadelphia, Pennsylvania, United States|Dallas, Texas, United States|San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT01529749,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Clinic, Barcelona, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Unknown status,NCT02231125,IGA NEPHROPATHY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","The First Hospital of Anhui Medical University, Hefei, Anhui, China|The Second Hospital of Anhui Medical University, Hefei, Anhui, China|Beijing Chao-yang Hospital, Beijing, Beijing, China|China-Japan Friendship Hospital, Beijing, Beijing, China|Chinese PLA General Hospital, Beijing, Beijing, China|Dong Zhi Men Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China|Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China|PLA Navy General Hospital, Beijing, Beijing, China|The Second Artillery General Hospital Of Chinese People's Liberation Army, Beijing, Beijing, China|Da Ping Hospital Of Third Military Medical University, Chongqing, Chongqing, China|Yongchuan Hospital Of Chongqing Medical University, Chongqing, Chongqing, China|Chinese People's Liberation Army No.180 Hospital, Quanzhou, Fujian, China|Chinese People's Liberation Army No.174 Hospital, Xiamen, Fujian, China|The First Hospital of Lanzhou University, Lanzhou, Gansu, China|The Second Hospital of Lanzhou University, Lanzhou, Gansu, China|421 Hospital of PLA, Guangzhou, Guangdong, China|Guangdong Province Hospital of Traditional Chinese Medicine(TCM), Guangzhou, Guangdong, China|Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, China|The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China|The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi, China|Affiliated Hospital of Guiyang Medical College, Guiyang, Guizhou, China|The Affiliated Baiyun Hospital of Guizhou Medical University, Guiyang, Guizhou, China|Affiliated Hospital Of Zun Yi Medical College, Zunyi, Guizhou, China|Hainan Medical College Affiliated Hospital, Haikou, Hainan, China|Hainan Provincial Nong Ken Hospital, Haikou, Hainan, China|Affiliated Hospital of Cheng De Medical College, Chengde, Hebei, China|First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China|Hebei Province Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China|TCM Hospital of Shi Jia Zhuang City, Shijiazhuang, Hebei, China|The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China|Heilongjiang Provincial Academy of Traditional Chinese Medicine, Haerbin, Heilongjiang, China|The Second Affiliated Hospital of Harbin Medical University, Haerbin, Heilongjiang, China|The First Affiliated Hospital of Henan University of Science And Technology, Luoyang, Henan, China|The First Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China|Henan Provincial People's Hospital, Zhengzhou, Henan, China|The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China|Huang Gang Central Hospital, Huanggang, Hubei, China|Hubei Provincial Hospital Of TCM, Wuhan, Hubei, China|Wuhan Integrated TCM & Western Medicine Hospital, Wuhan, Hubei, China|Zhong Nan Hospital of Wuhan University, Wuhan, Hubei, China|The Second Xiang Ya Hospital of Central South University, Changsha, Hunan, China|The Third Xiang Ya Hospital of Central South University, Changsha, Hunan, China|Xiangya Hospital Central South University, Changsha, Hunan, China|Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu, China|Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China|Affiliated Hospital of Nantong University, Nantong, Jiangsu, China|Jiangsu Taizhou People's Hospital, Taizhou, Jiangsu, China|Taizhou Traditional Chinese Medicine Hospital, Taizhou, Jiangsu, China|Xuzhou Central Hospital, Xuzhou, Jiangsu, China|Chinese People's Liberation Army No.94 Hospital, Nanchang, Jiangxi, China|Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China|The First Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China|Jiangxi Pingxiang People's Hospital, Pingxiang, Jiangxi, China|Jilin Province People's Hospital, Changchun, Jilin, China|The First Hospital of Jilin University, Changchun, Jilin, China|The Second Hospital Of Jilin University, Changchun, Jilin, China|Dalian Municipal Central Hospital Affiliated Of Dalian Medical University, Dalian, Liaoning, China|The First Affiliated Hospital Of Dalian Medical University, Dalian, Liaoning, China|First Affiliated Hospital of Liaoning Medical University, Jinzhou, Liaoning, China|People's Liberation Army No.202 Hospital, Shenyang, Liaoning, China|Shengjing Hospital of China Medical University, Shenyang, Liaoning, China|The First Hospital Of China Medical University, Shenyang, Liaoning, China|The General Hospital Of Shenyang Military Region, Shenyang, Liaoning, China|Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China|The General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China|Jinan General Hospital of PLA, Jinan, Shandong, China|Qi Lu Hospital of Shandong University, Jinan, Shandong, China|Affiliated Hospital of Jining Medical University, Jining, Shandong, China|Jining No.1 People's Hospital, Jining, Shandong, China|Chinese People's Liberation Army No.88 Hospital, Taian, Shandong, China|Yantai Yu Huang Ding Hospital, Yantai, Shandong, China|Zaozhuang Municipal Hospital, Zaozhuang, Shandong, China|Chang Hai Hospital of the Second Military Medical University, Shanghai, Shanghai, China|Ren Ji Hospital of Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|Shanghai Sixth People's Hospital Affiliated Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China|The First Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China|Shanxi Provincial People's Hospital, Xian, Shanxi, China|The First Affiliated Hospital of Xi'an Jiao Tong University, Xian, Shanxi, China|Hua Xi Hospital of Sichuan University, Chengdu, Sichuan, China|First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, Tianjin, China|The Second Hospital of Tianjin Medical University, Tianjin, Tianjin, China|Tianjin Hospital of ITCWM, Nankai Hospital, Tianjin, Tianjin, China|The First Hospital of Shi He Zi Medical University, Shihezi, Xinjiang, China|The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China|Yan'an Hospital of Kunming City, Kunming, Yunnan, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
CCCCc1nc(Cl)c(CO)n1Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1,1,,_LOSARTAN,,Completed,NCT01115426,IGA GLOMERULONEPHRITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"""Mater Domini"" Hospital, Catanzaro, Calabria, Italy",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Recruiting,NCT03781596,EOSINOPHILIC ESOPHAGITIS,All,"6 Years to 60 Years   (Child, Adult)",U.S. Fed,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Other","Walter Reed National Military Medical Center, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT00141102,"OSTEOARTHRITIS|ARTHRITIS, RHEUMATOID",All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Pfizer Investigational Site, Genk, Belgium|Pfizer Investigational Site, Gent, Belgium|Pfizer Investigational Site, Hasselt, Belgium|Pfizer Investigational Site, Liège, Belgium|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Goiânia, GO, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Curitiba, PR, Brazil|Pfizer Investigational Site, Rio de Janeiro, RJ, Brazil|Pfizer Investigational Site, Porto Alegre, RS, Brazil|Pfizer Investigational Site, Sao Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, São Paulo, SP, Brazil|Pfizer Investigational Site, Winnipeg, Manitoba, Canada|Pfizer Investigational Site, St. John's, Newfoundland and Labrador, Canada|Pfizer Investigational Site, Hamilton, Ontario, Canada|Pfizer Investigational Site, Newmarket, Ontario, Canada|Pfizer Investigational Site, Windsor, Ontario, Canada|Pfizer Investigational Site, Pointe Claire, Quebec, Canada|Pfizer Investigational Site, Sherbrooke, Quebec, Canada|Pfizer Investigational Site, Ste Foy, Quebec, Canada|Pfizer Investigational Site, Guangzhou, Guangdong, China|Pfizer Investigational Site, Nanjing, Jiangsu, China|Pfizer Investigational Site, Chengdu, Sichuan, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Beijing, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Shanghai, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Tianjin, China|Pfizer Investigational Site, Medellin, Antioquia, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Barranquilla, Atlantico, Colombia|Pfizer Investigational Site, Bogota, Cundinamarca, Colombia|Pfizer Investigational Site, Floridablanca, Santander, Colombia|Pfizer Investigational Site, Cartago, Costa Rica|Pfizer Investigational Site, Heredia, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, San Jose, Costa Rica|Pfizer Investigational Site, Opatija, Croatia|Pfizer Investigational Site, Zagreb, Croatia|Pfizer Investigational Site, Plzen, Bory, Czech Republic|Pfizer Investigational Site, Ostrava, Trebovice, Czech Republic|Pfizer Investigational Site, Ceske Budejovice, Czech Republic|Pfizer Investigational Site, Hradec Kralove, Czech Republic|Pfizer Investigational Site, Prague 1, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 2, Czech Republic|Pfizer Investigational Site, Praha 4, Czech Republic|Pfizer Investigational Site, Praha 6, Czech Republic|Pfizer Investigational Site, Cuenca, Azuay, Ecuador|Pfizer Investigational Site, Guayaquil, Guayas, Ecuador|Pfizer Investigational Site, Quito, Pichincha, Ecuador|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tallinn, Estonia|Pfizer Investigational Site, Tartu, Estonia|Pfizer Investigational Site, Amiens, France|Pfizer Investigational Site, Dijon, France|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Berlin, Germany|Pfizer Investigational Site, Deggingen, Germany|Pfizer Investigational Site, Dresden, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hamburg, Germany|Pfizer Investigational Site, Hoyerswerda, Germany|Pfizer Investigational Site, Kuenzing, Germany|Pfizer Investigational Site, Muenchen, Germany|Pfizer Investigational Site, Nuernberg, Germany|Pfizer Investigational Site, Thessaloniki, Greece|Pfizer Investigational Site, Ciudad de Guatemala, Guatemala|Pfizer Investigational Site, Guatemala 01010, Guatemala|Pfizer Investigational Site, Lai Chi Kok, Hong Kong|Pfizer Investigational Site, Shatin, Hong Kong|Pfizer Investigational Site, Hyderabad, Andhra Pradesh, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Bangalore, Karnataka, India|Pfizer Investigational Site, Ludhiana, Punjab, India|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Seoul, Korea, Republic of|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Riga, Latvia|Pfizer Investigational Site, Alytus, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Kaunas, Lithuania|Pfizer Investigational Site, Klaipeda, Lithuania|Pfizer Investigational Site, Vilnius, Lithuania|Pfizer Investigational Site, Vlaardingen, ZH, Netherlands|Pfizer Investigational Site, Alkmaar, Netherlands|Pfizer Investigational Site, Leidschendam, Netherlands|Pfizer Investigational Site, Ciudad de Panama, Panama|Pfizer Investigational Site, Surco, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lima, Peru|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisboa, Portugal|Pfizer Investigational Site, Lisbon, Portugal|Pfizer Investigational Site, Ponta Delgada, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ponte de Lima, Portugal|Pfizer Investigational Site, Ekaterinburg, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Moscow, Russian Federation|Pfizer Investigational Site, Petrozavodsk, Russian Federation|Pfizer Investigational Site, Smolensk, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, St. Petersburg, Russian Federation|Pfizer Investigational Site, Belgrade, Serbia|Pfizer Investigational Site, Niska Banja, Serbia|Pfizer Investigational Site, Novi Sad, Serbia|Pfizer Investigational Site, Sinapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Singapore, Singapore|Pfizer Investigational Site, Bloemfontein, Free State, South Africa|Pfizer Investigational Site, Johannesburg, Gauteng Province, South Africa|Pfizer Investigational Site, Durban, KZN, South Africa|Pfizer Investigational Site, Parow, Western Cape, South Africa|Pfizer Investigational Site, Bellville, South Africa|Pfizer Investigational Site, Cape Town, South Africa|Pfizer Investigational Site, Kempton Park, South Africa|Pfizer Investigational Site, Observatory Cape Town, South Africa|Pfizer Investigational Site, Partida de Bacarot, Alicante, Spain|Pfizer Investigational Site, Oviedo, Asturias, Spain|Pfizer Investigational Site, Sabadell, Barcelona, Spain|Pfizer Investigational Site, Barakaldo, Vizcaya, Spain|Pfizer Investigational Site, Avila, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Barcelona, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Madrid, Spain|Pfizer Investigational Site, Zaragoza, Spain|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Goteborg, Sweden|Pfizer Investigational Site, Lulea, Sweden|Pfizer Investigational Site, Norrkoping, Sweden|Pfizer Investigational Site, Kaohsiung Hsien, Taiwan|Pfizer Investigational Site, Taichung, Taiwan|Pfizer Investigational Site, Tainan, Taiwan|Pfizer Investigational Site, Taipei, Taiwan|Pfizer Investigational Site, Tao-Yuan, Taiwan|Pfizer Investigational Site, Dnipropetrovsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Donetsk, Ukraine|Pfizer Investigational Site, Ivano-Frankivsk, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kharkiv, Ukraine|Pfizer Investigational Site, Kiev, Ukraine|Pfizer Investigational Site, Kyiv, Ukraine|Pfizer Investigational Site, Lutsk, Ukraine|Pfizer Investigational Site, Lviv, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Odessa, Ukraine|Pfizer Investigational Site, Simferopol, Ukraine|Pfizer Investigational Site, Zaporizhzhia, Ukraine|Pfizer Investigational Site, Helensburgh, Argyle & Clyde, United Kingdom|Pfizer Investigational Site, Maidenhead, Berks, United Kingdom|Pfizer Investigational Site, Aston Clinton, Buckinghamshire, United Kingdom|Pfizer Investigational Site, St Austell, Cornwall, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, East Sussex, United Kingdom|Pfizer Investigational Site, Aldershot, Hampshire, United Kingdom|Pfizer Investigational Site, Basingstoke, Hampshire, United Kingdom|Pfizer Investigational Site, Odiham, Hampshire, United Kingdom|Pfizer Investigational Site, Ashford, Middlesex, United Kingdom|Pfizer Investigational Site, Harrow, Middlesex, United Kingdom|Pfizer Investigational Site, Camberley, Surrey, United Kingdom|Pfizer Investigational Site, East Horsley, Leatherhead, Surrey, United Kingdom|Pfizer Investigational Site, Pound Hill, Crawley, West Sussex, United Kingdom|Pfizer Investigational Site, Bradford-on-Avon, Wiltshire, United Kingdom|Pfizer Investigational Site, Chippenham, Wiltshire, United Kingdom|Pfizer Investigational Site, Upton, Wirral, United Kingdom|Pfizer Investigational Site, Bexhill on Sea, United Kingdom|Pfizer Investigational Site, Canterbury, United Kingdom|Pfizer Investigational Site, Chesterfield, United Kingdom|Pfizer Investigational Site, Glasgow, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, Peterborough, United Kingdom|Pfizer Investigational Site, St Leonards on Sea, United Kingdom|Pfizer Investigational Site, Swindon, United Kingdom|Pfizer Investigational Site, Vale of Glamorgan, United Kingdom|Pfizer Investigational Site, Wansford, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc2[nH]c([S+]([O-])Cc3ncc(C)c(OC)c3C)nc2c1,1,,_OMEPRAZOLE,,Completed,NCT02552537,FOOD ALLERGY,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Diagnostic","Hospital Clinico San Carlos, Madrid, Spain|University Hospital Zurich, Zurich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Completed,NCT00118378,HIV INFECTIONS|FATIGUE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
NC(=O)C[S+]([O-])C(c1ccccc1)c1ccccc1,1,,_MODAFINIL,,Recruiting,NCT03621761,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"The University of Michigan, Ann Arbor, Michigan, United States|The University of Washington, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)CCC(=O)O.O=C(O[C@H]1CN2CCC1CC2)N1CCc2ccccc2[C@@H]1c1ccccc1,1,,_SOLIFENACIN_SUCCINATE,WO-2003099268-A1,Completed,NCT00629642,MULTIPLE SCLEROSIS|NEUROGENIC BLADDER|SPINAL CORD DISEASES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Brisbane, Australia|Melbourne, Australia|Perth, Australia|Randwick, Australia|Antwerpen, Belgium|Esneux, Belgium|Fraiture-en-Condroz, Belgium|Gent, Belgium|Leuven, Belgium|Melsbroek, Belgium|Brno, Czechia|Ceske Budejovice, Czechia|Prague, Czechia|Caen, France|Garches, France|Paris, France|Ploemeur, France|Berlin, Germany|Hagenow, Germany|Heidelberg, Germany|Kiel, Germany|Nyiregyhaza, Hungary|Sopron, Hungary|Szeged, Hungary|Firenze, Italy|Milan, Italy|Rome, Italy|Torino, Italy|Apeldoorn, Netherlands|Eindhoven, Netherlands|Nijmegen, Netherlands|St. Petersburg, Russian Federation|St. Petersburg, Russian Federation|San Juan de Alicante, Alicante, Spain|Badalona, Barcelona, Spain|Getafe, Madrid, Spain|La Coruna, Spain|Cardiff, United Kingdom|Newcastle Upon Tyne, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,27.0,32.7488,31.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,1
CN(C)CCC[C@@]1(c2ccc(F)cc2)OCc2cc(C#N)ccc21.O=C(O)C(=O)O,1,,_ESCITALOPRAM_OXALATE,WO-2003011278-A1,Terminated,NCT00151294,DEPRESSION|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"NewYork Presbyterian Hospital, White Plains, New York, United States",A61P25/24 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,28.0,32.7488,33.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,1,,_ANTIDE,,Terminated,NCT00151294,DEPRESSION|MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"NewYork Presbyterian Hospital, White Plains, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CC(=O)N[C@H](Cc1ccc2ccccc2c1)C(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)N[C@H](Cc1cccnc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@H](CCCCNC(=O)c1cccnc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](C)C(N)=O,1,,_ANTIDE,,Completed,NCT02056106,DEPRESSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"health care facilities receiving technical assistance from Mildmay Uganda, Wakiso, Mpigi, Luwero, Mityana districts, Uganda",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,1,1,1,1,1,1,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Unknown status,NCT03631862,NEWLY DIAGNOSED PERIPHERAL T-CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affilliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
CS(=O)(=O)O.N#CC1(c2ccc(NC(=O)c3cccnc3NCc3ccncc3)cc2)CCCC1,1,,_APATINIB,,Completed,NCT03376958,RELAPSED AND REFRACTORY|DIFFUSE LARGE B CELL LYMPHOMA,All,"14 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Oncology Department of The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1
COc1cc(/C=C/C(=O)/C=C(O)/C=C/c2ccc(O)c(OC)c2)ccc1O,1,,_CURCUMIN,WO-2002069910-A2,Recruiting,NCT03917784,PRE-DIABETES,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Hospital General de México Dr. Eduardo Liceaga, Mexico City, Cuauhtémoc, Mexico",A61K8/315,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O.O=P(O)(O)O,1,,_CHLOROQUINE_DIPHOSPHATE,5021426,Completed,NCT02463331,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O.O=P(O)(O)O,1,,_CHLOROQUINE_DIPHOSPHATE,5021426,Completed,NCT01980745,"HEPATITIS, AUTOIMMUNE",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of São Paulo School of Medicine, Sao Paulo, Brazil",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,171.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
NCCCC[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N1CCC[C@H]1C(=O)O.O.O,1,,_LISINOPRIL,6462022,Completed,NCT01535235,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","San Francisco General Hospital, San Francisco, California, United States",A61K9/2009,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,12.4520010677837,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0
O=C([O-])Cc1ccccc1Nc1c(Cl)cccc1Cl.[Na+],1,,_DICLOFENAC_SODIUM,4234601,Completed,NCT01454791,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","MS Center at Evergreen Healthcare, Kirkland, Washington, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,23.0312737427873,504.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_CETIRIZINE_HYDROCHLORIDE,5993833,Recruiting,NCT03340740,ALLERGIC RHINITIS|ASTHMA,All,"6 Years to 20 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Jacobi Medical Center, Bronx, New York, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_CETIRIZINE_HYDROCHLORIDE,5993833,Completed,NCT00240032,MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,29.3394114868888,77.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C\c1ccc(Cl)cc1,1,,_LUMEFANTRINE,,Unknown status,NCT00620438,HIV INFECTIONS|TUBERCULOSIS,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Infectious Diseases Institute, Makerere University, Kampala, Uganda",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C\c1ccc(Cl)cc1,1,,_LUMEFANTRINE,,Completed,NCT00619944,HIV INFECTION,All,18 Years to 60 Years   (Adult),Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Infectious Diseases Institute, Faculty of Medicine, Makerere University, Kampala, Uganda",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CCCCN(CCCC)CC(O)c1cc(Cl)cc2c1-c1ccc(Cl)cc1/C2=C\c1ccc(Cl)cc1,1,,_LUMEFANTRINE,,Completed,NCT00790881,MALARIA|HIV,All,"18 Years and older   (Adult, Older Adult)",Other,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groote Schuur Hospital, Research ward, Cape Town, South Africa",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0
CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1,1,,_IMATINIB_MESYLATE,WO-2002018368-A1,Completed,NCT01297777,SYSTEMIC MASTOCYTOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle, Toledo, Spain",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,59.0,32.7488,558.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1
CC(C)(S)C(=O)N[C@H](CS)C(=O)O,1,,_BUCILLAMINE,EP-1584615-A1,Unknown status,NCT00716248,RHEUMATOID ARTHRITIS,All,"20 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Department of Rheumatology/Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Saitama, Japan",A61G17/08 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,37.8816813486929,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,1,,_VALGANCICLOVIR,,Completed,NCT00264290,HIV INFECTIONS|CYTOMEGALOVIRUS INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","San Francisco General Hospital - General Clinical Research Center, San Francisco, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,1,,_VALGANCICLOVIR,,Withdrawn,NCT00361933,GIANT LYMPH NODE HYPERPLASIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21,1,,_VALGANCICLOVIR,,Completed,NCT01255644,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical University of Vienna, Vienna, Austria",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,1,0
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00442767,TYPE 1 DIABETES,All,"12 Years to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Montefiore Medical Center, Bronx, New York, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)[C@@H](C)O)C(C)C)[C@@H](C)O,1,,_PRAMLINTIDE,,Completed,NCT00502138,IDDM,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Diabetes & Endocrine Consultants, Chattanooga, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1
CCOc1ccccc1OC(c1ccccc1)C1CNCCO1,1,,_REBOXETINE,5391735,Unknown status,NCT00209807,MAJOR DEPRESSION|PAIN|ABDOMINAL PAIN,All,18 Years to 64 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Hospital Universitari vall d'Hebron, Barcelona, Catalonia, Spain",C07C43/23,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,10.3492884864165,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0
Nc1nc(F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@@H]1O,1,,_FLUDARABINE_PHOSPHATE,4357324,Completed,NCT00220311,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"15 Years to 80 Years   (Child, Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,20.238608595659002,853.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CN(C)CCC(c1ccccc1)c1ccccn1.O=C(O)/C=C\C(=O)O,1,,_PHENIRAMINE_MALEATE,4631284,Unknown status,NCT01390961,ALLERGIC CONJUNCTIVITIS,All,"18 Months and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"Milton M. Hom, OD, FAAO., Azusa, California, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,17.2488141440275,86.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
CC(C)(C)[SiH2]O[Si](C)(C)O[SiH2]C(C)(C)C,1,,_SIMETHICONE,,Terminated,NCT02217982,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rocky Mountain MS Research Group, Salt Lake City, Utah, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0
O=C(O)O,1,,_BICARBONATE,,Completed,NCT02502071,TYPE 1 DIABETES|DIABETIC NEPHROPATHY|DIABETIC KIDNEY DISEASE,All,18 Years to 45 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Davis Center for Diabetes, Aurora, Colorado, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00162955,NON-HODGKIN'S LYMPHOMA,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Graduate School of Medicine, Osaka City University, Osaka, Japan",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Terminated,NCT01129557,"PROTEINURIC KIDNEY DISEASE|DIABETIC NEPHROPATHY|HYPERTENSIVE NEPHROSCLEROSIS|IGA NEPHROPATHY|FOCAL SEGMENTAL GLOMERULOSCLEROSIS|GLOMERULOPATHY (OBESITY-ASSOCIATED)|GLOMERULONEPHRITIS, MEMBRANOUS",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Columbia University Medical Center, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00154271,HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00170937,METABOLIC SYNDROME|HYPERTENSION|PRE-HYPERTENSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Novartis Pharmaceuticals, E. Hanover, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00241072,HYPERTENSION|IMPAIRED GLUCOSE TOLERANCE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00426348,GLOMERULONEPHRITIS|IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Guangdong General Hospital, Guangzhou, Guangdong, China",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Unknown status,NCT02765594,PRIMARY IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peing Union Medical College Hospital, Beijing, China",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Completed,NCT00367562,IGA NEPHROPATHY,All,"21 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital Britanico de Buenos Aires, Buenos Aires, Argentina",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCCCC(=O)N(Cc1ccc(-c2ccccc2-c2nnn[nH]2)cc1)[C@H](C(=O)O)C(C)C,1,,_VALSARTAN,,Withdrawn,NCT00745953,METABOLIC SYNDROME|LIPOTOXICITY,All,18 Years to 50 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Texas Southwestern Medical Center, Dallas, Texas, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=S(=O)(O)O,1,,_HYDROXYCHLOROQUINE_SULFATE,5318960,Unknown status,NCT02765594,PRIMARY IGA NEPHROPATHY,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peing Union Medical College Hospital, Beijing, China",A61K47/44,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,24.1154849175547,142.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,"Active, not recruiting",NCT03774108,PREDIABETES|HIV-1-INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Hospital Civil de Guadalajara, Guadalajara, Jalisco, Mexico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CN(C)C(=N)N=C(N)N.Cl,1,,_METFORMIN_HYDROCHLORIDE,,Withdrawn,NCT02881528,PREDIABETIC STATE,All,5 Years to 16 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","NHS Ayrshire & Arran, Kilmarnock, Ayrshire, United Kingdom|NHS Grampian, Aberdeen, Grampian, United Kingdom|NHS Lanarkshire, Wishaw, Lanarkshire, United Kingdom|NHS Tayside, Dundee, Tayside, United Kingdom|NHS Greater Glasgow & Clyde, Glasgow, United Kingdom",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0
CCc1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1.Cl,1,,_PIOGLITAZONE_HYDROCHLORIDE,5356913,Completed,NCT01589445,TYPE 2 DIABETES,All,40 Years to 50 Years   (Adult),Other,"Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders (BIRDEM), Dhaka, Bangladesh",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,17.8730569416209,190.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,1
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Not yet recruiting,NCT04015596,PANDAS|ANXIETY DISORDER|AUTOIMMUNE DISEASES|OBSESSIVE-COMPULSIVE DISORDER,All,6 Years to 15 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc2cc([C@H](C)C(=O)[O-])ccc2c1.[Na+],1,,_NAPROXEN_SODIUM,4571333,Unknown status,NCT03699293,RHEUMATOID ARTHRITIS|CARDIOVASCULAR DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Inova Heart and Vascular Institute, Falls Church, Virginia, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,27.0,32.1977864021848,421.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
CC1(C)O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@]2(C(=O)CO)O1,1,,_TRIAMCINOLONE_ACETONIDE,3962430,Completed,NCT01154153,"RHINITIS, ALLERGIC, SEASONAL",All,2 Years to 12 Years   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Investigational Site Number 840003, Cypress, California, United States|Investigational Site Number 840006, Stockbridge, Georgia, United States|Investigational Site Number 840007, North Dartmouth, Massachusetts, United States|Investigational Site Number 840010, Plymouth, Minnesota, United States|Investigational Site Number 840001, Omaha, Nebraska, United States|Investigational Site Number 840008, Raleigh, North Carolina, United States|Investigational Site Number 840002, Spartanburg, South Carolina, United States|Investigational Site Number 840005, San Antonio, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,10.842111747674403,919.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl,1,,_BUPIVACAINE_HYDROCHLORIDE,5322689,Completed,NCT04361513,PAIN|JOINT FUNCTION DISORDER|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Minia university, Minya, Egypt",A61K9/0014,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,27.3681184418571,115.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CC#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@@]21C,1,,_ESTROGEN,,Completed,NCT00392093,SYSTEMIC LUPUS ERYTHEMATOSUS,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"I, Mexico, Mexico",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0
Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.Cc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc(-c2ccc(F)cc2)s1.O,1,,_CANAGLIFLOZIN,7943582,Recruiting,NCT04014192,TYPE 2 DIABETES,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peking Union Medical College Hospital, Beijing, Beijing, China",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.4300088297501,8.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1
CCCCCCC(C)(C)c1cc(O)c2c(c1)OC(C)(C)C1CCC(=O)CC21,1,,_NABILONE,3988439,Completed,NCT00480181,NEUROPATHIC PAIN|MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Health Sciences Centre Multiple Sclerosis Clinic, Winnipeg, Manitoba, Canada",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,16.1317480851762,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Unknown status,NCT02232971,"DIABETES MELLITUS, TYPE 1",All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"Hvidovre University Hospital, Hvidovre, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Recruiting,NCT04053712,TYPE 1 DIABETES|HYPOGLYCEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Steno Diabetes Center Copenhagen, Gentofte, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1c[nH]cn1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)O)[C@@H](C)O,1,,_GLUCAGON,,Completed,NCT02516150,TYPE 1 DIABETES,All,"21 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital Diabetes Research Center, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,1,1,1,0,1,1,1,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,1,0,1,0,0
COc1ccc2c(O[C@@H]3C[C@H]4C(=O)N[C@]5(C(=O)NS(=O)(=O)C6CC6)C[C@H]5/C=C\CCCCN(C)C(=O)[C@@H]4C3)cc(-c3nc(C(C)C)cs3)nc2c1C,1,,_SIMEPREVIR,,Withdrawn,NCT02206932,"HEPATITIS C, CHRONIC|HIV CDC CATEGORY A1",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,1,1,0,1
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT01733693,OPIOID-RELATED DISORDERS|HIV|HIV INFECTIONS,All,"18 Years to 68 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fordham University, The Bronx, New York, United States|Albert Einstein College of Medicine of Yeshiva University, The Bronx, New York, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Unknown status,NCT00124358,OPIOID-RELATED DISORDERS|HIV INFECTIONS|AIDS,All,"18 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"El Rio Santa Cruz Neighborhood Health Center, Tucson, Arizona, United States|Organization to Achieve Solutions in Substance Abuse, Oakland, California, United States|University of California San Francisco, San Francisco, California, United States|Yale University School of Medicine AIDS Program, New Haven, Connecticut, United States|University of Miami School of Medicine, Miami, Florida, United States|The CORE Center, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Montefiore Medical Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States|The Miriam Hospital, Providence, Rhode Island, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT01936857,HIV|SUBSTANCE RELATED DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Bac Giang PAC OPC, Bac Giang, Vietnam|Dong Da OPC, Hanoi, Vietnam|Hoang Mai HIV Clinic, Hanoi, Vietnam|Long Bien, Hanoi, Vietnam|Tu Liem, Hanoi, Vietnam|Thanh Hoa PAC OPC, Thanh Hoa, Vietnam",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT00763958,OPIOID DEPENDENCE|HIV,Female,"19 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment",,6,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT00263458,HIV|BUPRENORPHINE|OPIOID DEPENDENCE,All,"19 Years and older   (Adult, Older Adult)",Other|U.S. Fed,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Positive Health Program, San Francisco, California, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
CO[C@@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1Cc4ccc(O)c5c4[C@@]3(CCN1CC1CC1)[C@H]2O5,1,,_BUPRENORPHINE,4464376,Completed,NCT02519387,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|LOWER BACK PAIN|JOINT PAIN|MUSCLE PAIN,All,"40 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital University Sains Malaysia, Kota Bahru, Kelantan, Malaysia|University Malaya Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia|University Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Wilayah Persekutuan, Malaysia",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,25.0,9.88932010924249,327.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,1,1,0,1,0,1,1,0
O=c1ncnc2[nH][nH]cc1-2,1,,_ALLOPURINOL,,Completed,NCT02829177,TYPE 1 DIABETES|DIABETIC NEPHROPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","Steno Diabetes Center, Gentofte, Denmark",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00653224,SEASONAL ALLERGIC RHINITIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Tucson, Arizona, United States|Los Angeles, California, United States|Sacramento, California, United States|San Francisco, California, United States|San Jose, California, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Miami, Florida, United States|Atlanta, Georgia, United States|Gainesville, Georgia, United States|Lawrenceville, Georgia, United States|Stockbridge, Georgia, United States|Normal, Illinois, United States|Louisville, Kentucky, United States|Harvard, Massachusetts, United States|North Dartmouth, Massachusetts, United States|Novi, Michigan, United States|Minneapolis, Minnesota, United States|Berlin, New Jersey, United States|Skillman, New Jersey, United States|Verona, New Jersey, United States|Rochester, New York, United States|Asheville, North Carolina, United States|Charlotte, North Carolina, United States|Wilmington, North Carolina, United States|Cincinnati, Ohio, United States|Edmond, Oklahoma, United States|Oklahoma City, Oklahoma, United States|Portland, Oregon, United States|Pittsburgh, Pennsylvania, United States|Upland, Pennsylvania, United States|Lincoln, Rhode Island, United States|Germantown, Tennessee, United States|San Antonio, Texas, United States|Salt Lake City, Utah, United States|South Burlington, Vermont, United States|Arlington, Virginia, United States|Milwaukee, Wisconsin, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00542607,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00521131,RHINITIS|ALLERGIC|PERENNIAL,All,"12 Years and older   (Child, Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,,A61K9/0095,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
Cl.Cl.O=C(O)COCCN1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2)CC1,1,,_LEVOCETIRIZINE_DIHYDROCHLORIDE,WO-2003059328-A1,Completed,NCT00884325,ATOPIC DERMATITIS|PRURITUS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","DermResearch, PLLC, Louisville, Kentucky, United States",A61K9/0095,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)/C(=N\OCOCCOC)[C@H](C)[C@@H](O)[C@]1(C)O,1,,_ROXITHROMYCIN,4054737,Completed,NCT00439062,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Nazilli State Hospital, Nazilli, Aydin, Turkey",C07D309/10,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,13.9304708515575,576.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT00137657,HIV|MALARIA|DIARRHEA|PNEUMONIA|OPPORTUNISTIC INFECTIONS,All,"15 Years and older   (Child, Adult, Older Adult)",U.S. Fed|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Educational/Counseling/Training,"CDC KEMRI Research Institute, Kisumu, Kenya",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Unknown status,NCT00674921,HIV INFECTION,All,"16 Years to 59 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MRC/UVRI Uganda Research Unit on Aids, Entebbe, Uganda",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT03087890,HIV-1-INFECTION|PNEUMOCYSTIS PNEUMONIA|OPPORTUNISTIC INFECTIONS|PREVENTIVE THERAPY|ANTIBIOTIC SIDE EFFECT,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Amana Regional Referral Hospital, Dar es Salaam, Tanzania|Mbagala District Hospital, Dar es Salaam, Tanzania|Mnazimmoja Health Centre, Dar Es Salaam, Tanzania|Mwananyamala Regional Referral Hospital, Dar es Salaam, Tanzania|Pasada Upendano, Dar es Salaam, Tanzania|Temeke Regional Referral Hospital, Dar es Salaam, Tanzania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
COc1cc(Cc2cnc(N)nc2N)cc(OC)c1OC.Cc1cc(CS(=O)(=O)c2ccc(N)cc2)no1,1,,_COTRIMOXAZOLE,,Completed,NCT01086878,"ACQUIRED IMMUNODEFICIENCY SYNDROME|INFANT, NEWBORN|ANEMIA|NEUTROPENIA|HIV INFECTIONS",All,"Child, Adult, Older Adult",Other|NIH|U.S. Fed,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Scottish Livingstone Hospital, Molepolole, Kweneng, Botswana|Princess Marina Hospital, Gaborone, Botswana",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1
O=C1N=C(O)NC1(c1ccccc1)c1ccccc1,1,,_PHENYTOIN,3962430,Completed,NCT00366067,BRONCHIAL ASTHMA,All,4 Years to 14 Years   (Child),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"""Rea"" Rehabilitation Centre, Tbilisi, Georgia",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,10.842111747674403,884.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
Cc1nc2n(c(=O)c1CCN1CCC(C3NOc4cc(F)ccc43)CC1)CCCC2,1,,_RISPERIDON,,Completed,NCT00190749,SCHIZOPHRENIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., San Diego, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,1,0,1
CC(C)/N=c1\cc2n(-c3ccc(Cl)cc3)c3ccccc3nc-2cc1Nc1ccc(Cl)cc1,1,,_CLOFAZIMINE,4100271,Completed,NCT01290744,BORDERLINE LEPROMATOUS LEPROSY|LEPROMATOUS LEPROSY,All,"15 Years to 70 Years   (Child, Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","Cebu Skin Clinic, Cebu, Vesayas, Philippines",A61K47/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,28.4523296166245,195.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT03186755,"CONJUNCTIVITIS, ALLERGIC|CONJUNCTIVITIS, VERNAL",All,"6 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","CHU Sainte-Justine Hospital, Montréal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](C(=O)O)O[C@@H](O[C@H]3[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]3NC(C)=O)[C@H](O)[C@H]2O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]1O,1,,_HYALURONIC_ACID,,Recruiting,NCT01738243,THYROID EYE DISEASE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Jules Stein Eye Institute, Los Angeles, California, United States|The Jules Stein Eye Institute at UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0
O=C([O-])c1cc(=O)c2c(OCC(O)COc3cccc4oc(C(=O)[O-])cc(=O)c34)cccc2o1.[Na+].[Na+],1,,_CROMOLYN_SODIUM,4161516,Completed,NCT02371941,EOSINOPHILIC ESOPHAGITIS,All,"2 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","LeBonheur Children's Hospital, Memphis, Tennessee, United States",A61K9/1688,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,30.0293640526499,1596.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0
[Na+].[O-]Cl,1,,_SODIUM_HYPOCHLORITE,,Completed,NCT00179959,ATOPIC DERMATITIS,All,6 Months to 17 Years   (Child),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Childrens Memorial Hospital, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,1,,_MEGLUMINE,3937733,Completed,NCT02264535,ALLERGY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry|Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Second Affiliated Hospital of Tianjin University of TCM, Tianjin, China",A61K49/0433,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,46.35824144232939,1671.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1,1,,_BACITRACIN,,Terminated,NCT01350102,"DIABETES, TYPE 1|DIABETES, TYPE 2|FOOT ULCER, DIABETIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,1,1,1,0,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,1,1,1,0,0,1,1,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,1,1,0,1
NC(=O)C[S@@+]([O-])C(c1ccccc1)c1ccccc1,1,,_ARMODAFINIL,,Completed,NCT00737204,HIV INFECTIONS|FATIGUE,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","New York State Psychiatric Institute, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC[C@@H](CO)NCCN[C@@H](CC)CO.Cl,1,,_ETHAMBUTOL_HYDROCHLORIDE,5733572,Completed,NCT00002343,MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of California - Davis Med Ctr / CARES, Sacramento, California, United States",A61K9/1278,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,60.0,40.017248814144004,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nc1nc(O)c2ncn(COC(CO)CO)c2n1,1,,_GANCICLOVIR,,Completed,NCT00000894,CYTOMEGALOVIRUS RETINITIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Univ of Southern California / LA County USC Med Ctr, Los Angeles, California, United States|UCLA CARE Ctr, Los Angeles, California, United States|Univ of Miami / Bascom Palmer Eye Institute, Miami, Florida, United States|Emory Eye Clinic, Atlanta, Georgia, United States|Northwestern Univ / SOCA, Chicago, Illinois, United States|Charity Hosp / Tulane Univ Med School, New Orleans, Louisiana, United States|Johns Hopkins Hosp, Baltimore, Maryland, United States|Cornell Univ Med Ctr, New York, New York, United States|New York Hosp / Cornell Med Ctr, New York, New York, United States|Univ of North Carolina, Chapel Hill, North Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Univ of Texas Galveston, Galveston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CC(=O)C(=O)O,0,DB00119,__PYRUVIC_ACID,,Terminated,NCT00262652,MODERATE ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","David Geffen School of Medicine, UCLA, Los Angeles, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,88.0621,54.37,3.0,1.0,0.0,7.31,17.99,1.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Suspended,NCT01125449,SARCOMA|ADENOCARCINOMA|CARCINOMA|MULTIPLE MYELOMA|DESMOPLASTIC SMALL ROUND CELL TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Situs Cancer Research Center, Rogers, Arkansas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Terminated,NCT00227682,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Terminated,NCT00590603,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Withdrawn,NCT00037063,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Primary Purpose: Prevention,"Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Withdrawn,NCT00112879,STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=C1O[C@H]([C@@H](O)CO)C(O)=C1O,0,DB00126,__ASCORBIC_ACID,7169381,Withdrawn,NCT00085345,STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Palo Verde Hematology Oncology, Glendale, Arizona, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Southbay Oncology / Hematology Medical Group, Campbell, California, United States|Fountain Valley, California, United States|Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States|Hematology Oncology Medical Group of Orange County, Incorporated, Orange, California, United States|Cancer Care Associates Medical Group - Redondo Beach, Redondo Beach, California, United States|Redwood Regional Oncology Center - Sotoyome, Santa Rosa, California, United States|Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital, Soquel, California, United States|San Diego Cancer Center - Vista, Vista, California, United States|Oncotherapeutics, West Hollywood, California, United States|Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center, Miami Beach, Florida, United States|Atlanta Cancer Care - Roswell, Roswell, Georgia, United States|Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Center for Cancer and Blood Disorders at Suburban Hospital, Bethesda, Maryland, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,39.2287315961313,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.6,176.1241,107.22,5.0,4.0,1.0,14.93,37.03,2.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT02589145,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Terminated,NCT01783522,CHEMOTHERAPEUTIC AGENT TOXICITY|MULTIPLE MYELOMA|PERIPHERAL NEUROPATHY,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
NC(=O)CC[C@H](N)C(=O)O,0,DB00130,__L-GLUTAMINE,5288703,Withdrawn,NCT02114502,MYELOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,16.5260066941826,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,-3.3,146.1445,106.41,4.0,3.0,0.0,13.87,33.11,4.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
N[C@@H](Cc1ccc(O)cc1)C(=O)O,0,DB00135,__TYROSINE,,Terminated,NCT00504205,"LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Virginia G. Piper Cancer Center at Scottsdale Healthcare - Shea, Scottsdale, Arizona, United States|South Texas Accelerated Research Therapeutics, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,181.1885,83.55,4.0,3.0,1.0,18.01,47.1,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1,0,DB00152,__THIAMINE,3946115,Withdrawn,NCT00037063,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Primary Purpose: Prevention,"Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States",A23K20/158,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,20.4357379001622,3121.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,265.355,75.91,4.0,2.0,2.0,28.14,73.4,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,0,DB00171,__ATP,3933594,Withdrawn,NCT01045486,ATOPIC DERMATITIS,All,6 Months to 2 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,G01N33/525,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,2074.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,507.181,279.13,14.0,7.0,3.0,38.92,95.81,8.0,1.0,0.0,0.0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
Nc1ncnc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]1O,0,DB00171,__ATP,3933594,Withdrawn,NCT00159315,ASTHMA|COPD|SMOKING,All,"21 Years to 85 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label),"Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital, London, United Kingdom",G01N33/525,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,17.150249491775998,2074.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.84,507.181,279.13,14.0,7.0,3.0,38.92,95.81,8.0,1.0,0.0,0.0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0
C[C@@H](Cc1ccc(O)c(O)c1)[C@H](C)Cc1ccc(O)c(O)c1,0,DB00179,__MASOPROCOL,3995632,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",B01J4/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,26.2510523830058,271.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.44,302.3649,80.92,4.0,4.0,2.0,33.63,86.62,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00227,__LOVASTATIN,6080428,Terminated,NCT00302952,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","University of Alabama, Birmingham, Alabama, United States|University of California, San Francisco, San Francisco, California, United States|University of Colorado, Aurora, Colorado, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Justus J. Fiechtner, MD, PLLC, Lansing, Michigan, United States|Feinstein Institute for Medical Research NS-LIJ Health System, Manhasset, New York, United States|University of Rochester, Rochester, New York, United States|Carolina Bone and Joint, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States|Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Baylor Research Institute, Dallas, Texas, United States|University of Utah, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21,0,DB00227,__LOVASTATIN,6080428,Withdrawn,NCT00689806,SEVERE PERSISTENT ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,13.0,65.4140742109694,5605.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.11,404.5396,72.83,3.0,1.0,3.0,46.11,113.18,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00281879,CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNUSUAL CANCERS OF CHILDHOOD,All,"up to 60 Years   (Child, Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00005987,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00632827,PERIPHERAL T CELL LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University, Saint Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00482053,"LYMPHOMA, B-CELL|LYMPHOMA, NON-HODGKIN|DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)|MALIGNANT LYMPHOMA, NON-HODGKIN",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT02366663,RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01653418,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01500161,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|HODGKINS DISEASE|NON-HODGKINS LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELODYSPLASTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Oncology, Amarillo, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT01220297,HEMATOLOGIC DISEASES|ACUTE-GRAFT-VERSUS-HOST DISEASE|LEUKEMIA|NON-HODGKIN LYMPHOMA (NHL)|HODGKIN LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00003567,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Terminated,NCT00003613,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA,All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT01769911,ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|AIDS-RELATED DIFFUSE LARGE CELL LYMPHOMA|AIDS-RELATED DIFFUSE MIXED CELL LYMPHOMA|AIDS-RELATED DIFFUSE SMALL CLEAVED CELL LYMPHOMA|AIDS-RELATED IMMUNOBLASTIC LARGE CELL LYMPHOMA|AIDS-RELATED LYMPHOBLASTIC LYMPHOMA|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|AIDS-RELATED SMALL NONCLEAVED CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|HEPATOSPLENIC T-CELL LYMPHOMA|HIV-ASSOCIATED HODGKIN LYMPHOMA|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I AIDS-RELATED LYMPHOMA|STAGE II AIDS-RELATED LYMPHOMA|STAGE III AIDS-RELATED LYMPHOMA|STAGE IV AIDS-RELATED LYMPHOMA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years to 66 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT03579927,CD19 POSITIVE|MANTLE CELL LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT FOLLICULAR LYMPHOMA|REFRACTORY B-CELL NON-HODGKIN LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY FOLLICULAR LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=NN(CCCl)C(=O)NCCCl,0,DB00262,__CARMUSTINE,4028410,Withdrawn,NCT02343666,HUMAN IMMUNODEFICIENCY VIRUS 1 POSITIVE|STAGE I ADULT HODGKIN LYMPHOMA|STAGE I ADULT NON-HODGKIN LYMPHOMA|STAGE II ADULT HODGKIN LYMPHOMA|STAGE II ADULT NON-HODGKIN LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT NON-HODGKIN LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT NON-HODGKIN LYMPHOMA,All,"18 Years to 66 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,4.0,30.785026386578693,461.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.24,214.05,61.77,2.0,1.0,0.0,18.8,46.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0
COc1ccc(C(Cl)=C(c2ccc(OC)cc2)c2ccc(OC)cc2)cc1,0,DB00269,__CHLOROTRIANISENE,4310523,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,15.0803917944927,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.95,380.86400000000003,27.69,3.0,0.0,3.0,41.6,119.17,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0
CN1CCC[C@@H]1CCO[C@](C)(c1ccccc1)c1ccc(Cl)cc1,0,DB00283,__CLEMASTINE,4232002,Withdrawn,NCT01125761,DERMATITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment,"LAL Clinica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil|LAL Clínica Pesquisa e Desenvolvimento Ltda, Valinhos, São Paulo, Brazil",A61K9/0078,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,23.1626932791227,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.29,343.89,12.47,2.0,0.0,3.0,39.06,101.65,6.0,0.0,1.0,0.0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00135499,"LYMPHOMA, LARGE-CELL, DIFFUSE",All,"60 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(OC(N)=O)C1O)c1c[nH]cn1,0,DB00290,__BLEOMYCIN,,Terminated,NCT01659099,DIFFUSE LARGE B CELL LYMPHOMA CD20 POSITIVE,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|RHMS Baudour, Baudour, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Hôpital Erasme, Bruxelles, Belgium|Clinique universitaire Saint LUC, Bruxelles, Belgium|CHU de Charleroi, Charleroi, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Ch Jolimont, Haine Saint Paul, Belgium|AZ GROENINGE - Oncology Centre - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liège, Belgium|CHU de Liège - Clinique Saint Joseph, Liège, Belgium|CHU de Liège -Domaine Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Saint Joseph -Hôpital de Warquignies, Mons, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|Centre Hospitalier de Wallonie Picarde - CHwapi, Tournai, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CHU d'Amiens - Hôpital Sud, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|Hôpital de Bayonne - CHU de la Côte Basque, Bayonne, France|CH de Beauvais, Beauvais, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CH de Blois, Blois, France|APHP - Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH Dr Duchenne, Boulogne sur Mer, France|CH Fleyriat, Bourg en Bresse, France|CHU de Brest - Hôpital de Morvan, Brest, France|CH Brive la Gaillarde, Brive la Gaillarde, France|CHU de Caen, Caen, France|Centre François Baclesse, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau Le Lez, France|CH de Chambéry, Chambéry, France|CHU de Châlon sur Saône, Châlon sur Saône, France|APHP - Hôpital Antoine Béclère, Clamart, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU d'Estaing, Clermont Ferrand, France|Pôle Santé Publique, Clermont Ferrand, France|CH de Compiègne, Compiègne, France|CH Sud Francilien, Corbeil Essonnes, France|APHP - Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH de Dunkerque, Dunkerque, France|Institut Daniel Hollard, Grenoble, France|CHU de Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|CH La Rochelle, La Rochelle, France|APHP - Hôpital Bicêtre, Le Kremlin Bicêtre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CH de Lens, Lens, France|CH Saint Vincent de Paul, Lille, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Dupruytren - Limoges, Limoges, France|CH Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|CH Mantes La Jolie, Mantes La Jolie, France|Hôpital de la Conception, Marseille, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CH Marc Jacquet, Melun, France|Hôpital Notre Dame Bon Secours, Metz, France|CHI de Meulan, Meulan en Yvelines, France|CHU de Montpellier - Saint Eloi, Montpellier, France|Centre Val d'Aurélie - Paul Lamarque, Montpellier, France|Centre Auréen de Cancérologie, Mougins, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Centre Catherine de Sienne, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Clinique Valdegour, Nîmes, France|CHR d'Orléans, Orléans, France|APHP - Hôpital Saint Louis, Paris Cedex 10, France|APHP - Hôpital Saint Antoine, Paris Cedex 12, France|Institut Curie, Paris, France|APHP - Hôpital de la Pitié Salpetrière, Paris, France|Hôpital Cochin, Paris, France|APHP - Hôpital Necker, Paris, France|CH Saint Jean, Perpignan, France|CHU de Haut Lévèque, Pessac, France|Hospices Civils de Lyon - CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH d'Annecy, Pringy, France|CHU Robert Debré, Reims, France|Institut du Cancer de Courlancy, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Clinique Mathilde, Rouen, France|CH Yves Le Foll - St Brieuc, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|CHI de Poissy St Germain, Saint germain en laye, France|CHU de Saint Malo, Saint Malo, France|CH de Saint Quentin, Saint Quentin, France|Institut de Cancérologie, St Priest en Jarez, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Hopital Saint Husse, Toulon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU de Tours, Tours, France|CHU de Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CHU de Brabois, Vandœuvre-lès-Nancy, France|CH Bretagne Atlantique, Vannes, France|CH de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif, France",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.41,1415.5520000000001,627.07,28.0,20.0,6.0,139.19,343.83,36.0,1.0,0.0,0.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
NS(=O)(=O)c1cc(C2(O)NC(=O)c3ccccc32)ccc1Cl,0,DB00310,__CHLORTHALIDONE,7157584,Terminated,NCT03325114,TYPE 1 DIABETES MELLITUS|HYPERCALCIURIA,All,"12 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Rochester, Rochester, New York, United States",C07D413/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,23.8197909608,564.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.27,338.76599999999996,109.49,4.0,3.0,3.0,31.29,81.3,2.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314,0,DB00318,__CODEINE,6383471,Terminated,NCT00147355,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina|Hospital Interzonal de Agudos San Juan de Dios, La Plata, Argentina|Hospital Interzonal General de Agudos Oscar Alende, Mar del Plata, Argentina|Hospital Central, Mendoza, Argentina|CAICI, Rosario, Argentina|St. Vincent's Hospital, Sydney, New South Wales, Australia|AIDS Medical Unit, Brisbane, Queensland, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|Gold Coast Sexual Health Clinic, Gold Coast, Queensland, Australia|Nambour Hospital, Nambour, Queensland, Australia|Carlton Clinic, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Kaplan Medical Center, Rehovot, Israel",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,114.0,37.0274543625125,1579.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.2,299.3642,41.93,4.0,1.0,5.0,31.95,84.6,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3[C@@H](C(=O)O)C(C)(C)S[C@H]23)c2ccccc2)C(=O)C1=O,0,DB00319,__PIPERACILLIN,6207661,Withdrawn,NCT03862079,GRAFT-VERSUS-HOST DISEASE PREVENTION,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"M D Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,42.0,25.1011314400706,233.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.67,517.555,156.43,7.0,3.0,4.0,51.77,126.3,6.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1
CN(C)CCC=C1c2ccccc2CCc2ccccc21,0,DB00321,__AMITRIPTYLINE,3965255,Terminated,NCT03591458,TYPE1 DIABETES MELLITUS|HYPOGLYCEMIA UNAWARENESS,All,21 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Utah, Salt Lake City, Utah, United States",A61K9/282,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,25.725374237664,663.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.1,277.4033,3.24,1.0,0.0,3.0,33.74,101.51,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0
COc1cc2nc(N(C)CCCNC(=O)C3CCCO3)nc(N)c2cc1OC,0,DB00346,__ALFUZOSIN,4661491,Terminated,NCT00688948,MULTIPLE SCLEROSIS|BLADDER DYSFUNCTION,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"QE II Health Science Centre, Halifax Infirmary, Halifax, Nova Scotia, Canada",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,11.039241052177598,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,389.4488,111.83,8.0,2.0,3.0,42.71,107.11,8.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0
OC(c1cc(C(F)(F)F)nc2c(C(F)(F)F)cccc12)C1CCCCN1,0,DB00358,__MEFLOQUINE,4826689,Terminated,NCT00746941,PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Research Site, Chicago, Illinois, United States|Research Site, Baltimore, Maryland, United States|Research Site, Boston, Massachusetts, United States|Research Site, St. Louis, Missouri, United States|Research Site, New York, New York, United States|Research Site, Sao Paulo, Brazil|Research Site, Dusseldorf, North Rhine-Westphalia, Germany|Research Site, Berlin, Germany|Research Site, Hamburg, Germany|Research Site, Milano, Italy|Research Site, Barcelona, Spain|Research Site, Madrid, Spain",A61K49/0476,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,33.0,47.5081623852645,557.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.1,378.3122,45.15,3.0,2.0,3.0,31.73,82.58,4.0,0.0,1.0,0.0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,0,DB00361,__VINORELBINE,4307100,Terminated,NCT00545948,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Palm Beach Cancer Institute, West Palm Beach, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Presbyterian HealthCare, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Maria Parham Hospital, Henderson, North Carolina, United States|Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg, North Carolina, United States|Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Johnston Memorial Hospital Authority, Smithfield, North Carolina, United States|Columbus County Hospital, Whiteville, North Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States|Community Memorial Health Center, South Hill, Virginia, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,28.090925891702,2829.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.39,778.947,133.87,8.0,2.0,9.0,84.31,216.99,10.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00928200,RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA|ALLERGY TO PEG E.COLI ASPARAGINASE|ALLERGY TO NATIVE E.COLI ASPARAGINASE,All,"1 Year to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1,0,DB00380,__DEXRAZOXANE,5242901,Terminated,NCT00165087,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 18 Years   (Child, Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ochsner Clinic, New Orleans, Louisiana, United States|Maine Medical Center, Lewiston, Maine, United States|Children's Hospital Boston, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mt. Sinai Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|McMaster University, Hamilton, Ontario, Canada|Laval University, Montreal, Quebec, Canada|Sainte Justine Hosptial, Montreal, Quebec, Canada|San Jorge Children's Hospital, Santurce, Puerto Rico",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,17.380233680363,688.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.0,268.2691,98.82,6.0,2.0,2.0,26.12,64.25,3.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,0,DB00434,__CYPROHEPTADINE,3968115,Terminated,NCT00949117,"LEUKEMIA|LYMPHOMA|MALNUTRITION|MYELODYSPLASTIC SYNDROMES|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC|WEIGHT CHANGES",All,2 Years to 17 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.719645167251905,797.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,287.3981,3.24,1.0,0.0,4.0,34.17,105.17,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1,0,DB00434,__CYPROHEPTADINE,3968115,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.719645167251905,797.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.02,287.3981,3.24,1.0,0.0,4.0,34.17,105.17,0.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
COc1cc(C)c(/C=C/C(C)=C/C=C/C(C)=C/C(=O)O)c(C)c1C,0,DB00459,__ACITRETIN,4105681,Withdrawn,NCT03753867,HIV INFECTION,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07C205/11,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,23.8197909608,206.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.2,326.4293,46.53,3.0,1.0,1.0,38.54,104.17,6.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0
NC(=O)C(c1ccccc1)(c1ccccc1)[C@@H]1CCN(CCc2ccc3c(c2)CCO3)C1,0,DB00496,__DARIFENACIN,5096890,Terminated,NCT00845338,MULTIPLE SCLEROSIS|OVERACTIVE DETRUSOR,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emmendingen, Baden-Württemberg, Germany|Heidelberg, Baden-Württemberg, Germany|Lahr, Baden-Württemberg, Germany|Tübingen, Baden-Württemberg, Germany|Villingen-Schwenningen, Baden-Württemberg, Germany|Planegg, Bayern, Germany|Oberursel, Hessen, Germany|Herne, Nordrhein-Westfalen, Germany|Mönchengladbach, Nordrhein-Westfalen, Germany|Mülheim, Nordrhein-Westfalen, Germany|Mainz, Rheinland-Pfalz, Germany|Halle, Sachsen-Anhalt, Germany|Bad Berka, Thüringen, Germany|Berlin, Germany|Hamburg, Germany",C07D207/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,24.148339801638603,103.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.35,426.55,55.56,3.0,1.0,5.0,48.54,128.37,7.0,0.0,1.0,0.0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,0,1
CC(C)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1,0,DB00499,__FLUTAMIDE,3995060,Terminated,NCT01428193,POLYCYSTIC OVARY SYNDROME|HYPERANDROGENISM,Female,13 Years to 17 Years   (Child),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Center for Research in Reproduction, University of Virginia, Charlottesville, Virginia, United States",1,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,26.6453109920121,2145.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.55,276.2118,74.92,3.0,1.0,1.0,23.2,63.42,4.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(=O)Oc1ccccc1C(=O)Nc1ncc([N+](=O)[O-])s1,0,DB00507,__NITAZOXANIDE,5387598,Terminated,NCT00004986,CRYPTOSPORIDIOSIS|HIV INFECTIONS,All,"13 Years and older   (Child, Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Julie Ryner, Tampa, Florida, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,9.856465225158619,123.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.14,307.282,114.11,5.0,1.0,2.0,27.54,73.89,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,0,DB00518,__ALBENDAZOLE,3956499,Terminated,NCT00817713,HIV INFECTIONS|HELMINTHIASIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chronic Disease Clinic of St. Francis Designated District Hospital, Ifakara, Kilombero, Tanzania",C07D235/32,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1,0,DB00518,__ALBENDAZOLE,3956499,Terminated,NCT01213576,LYMPHATIC FILARIASIS,All,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karonga Prevention Study, Karonga, Malawi",C07D235/32,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,9.13365777531366,309.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.22,265.33099999999996,67.01,3.0,2.0,2.0,29.3,73.01,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,1
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT02134886,HIV INFECTION|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Terminated,NCT01205685,HORMONE-SENSITIVE METASTATIC BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States|Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1,0,DB00530,__ERLOTINIB,5747498,Withdrawn,NCT01013506,BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,23.228403047290502,847.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.13,393.4357,74.73,7.0,1.0,3.0,43.48,107.79,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
COc1cc(C(=O)NS(=O)(=O)c2ccccc2C)ccc1Cc1cn(C)c2ccc(NC(=O)OC3CCCC3)cc12,0,DB00549,__ZAFIRLUKAST,4859692,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/18,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,40.214378118647204,840.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.84,575.675,115.73,6.0,2.0,5.0,62.0,158.58,8.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,1,0,1
C[C@@H](c1ncncc1F)[C@](O)(Cn1cncn1)c1ccc(F)cc1F,0,DB00582,__VORICONAZOLE,5116844,Terminated,NCT03327727,INVASIVE ASPERGILLOSIS|INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States|Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|DMC Harper University Hospital, Detroit, Michigan, United States|University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Infectious Disease, Saint Louis, Missouri, United States|The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium|General Hospital Saint-Jan, Department of Hematology, Brugge, Belgium|Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium|UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir, Belgium|Hamilton Health Sciences, Infectious Disease Research, Hamilton, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Division of Infectios Diseases, Montréal, Quebec, Canada|Grenoble University Hospital Center, Department of Hematology, Grenoble, France|South Lyon Hospital Center, Pierre-Bénite, France|Hautepierre Hospital, Strasbourg, France|University Hospital Jena, Jena, Germany|Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich, Germany|Chonnam National University, Hwasun, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",C07D233/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,9.0,33.4791268814554,78.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.65,349.3105,76.72,5.0,1.0,3.0,30.54,95.28,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1
C[C@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CCl,0,DB00596,__ULOBETASOL,6517847,Terminated,NCT03245385,ATOPIC DERMATITIS,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Clinical Research, North Hollywood, California, United States|Havana Research Institute, Pasadena, California, United States|Vital Pharma Research, Hialeah, Florida, United States|Solutions Through Advanced Research, Jacksonville, Florida, United States|Integrity Research Center, Miami, Florida, United States|Millennium Clinical Research, INC, Miami, Florida, United States|Regenerate Clinical Trials, LLC, Miami, Florida, United States|Life Medical Center and Research, INC, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Elias Research, Troy, Michigan, United States|Montana Medical Research/Elias Research Assoc., Missoula, Montana, United States|L&C Professional Medical Research Institute, Hazleton, Pennsylvania, United States|Sun Research Institute, San Antonio, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,31.0,11.1706605885131,59.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.93,428.9,74.6,4.0,2.0,4.0,42.07,105.37,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,1
C[C@H](N)[C@H](O)c1cccc(O)c1,0,DB00610,__METARAMINOL,4275219,Withdrawn,,PREECLAMPSIA,,,,,"FISABIO, Elche, Alicante, Spain",C07C309/63,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,20.961416045504,260.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.59,167.205,66.48,3.0,3.0,1.0,17.84,46.89,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
NC(N)=NN=Cc1c(Cl)cccc1Cl,0,DB00629,__GUANABENZ,,Terminated,NCT02423083,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING|MULTIPLE SCLEROSIS",All,18 Years to 55 Years   (Adult),NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.25,231.082,76.76,4.0,2.0,1.0,21.58,58.15,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1
NC(N)=NN=Cc1c(Cl)cccc1Cl,0,DB00629,__GUANABENZ,,Terminated,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.25,231.082,76.76,4.0,2.0,1.0,21.58,58.15,2.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01621477,"ACUTE LYMPHOBLASTIC LEUKEMIA|ACUTE MYELOCYTIC LEUKEMIA|CHRONIC MYELOCYTIC LEUKEMIA|JUVENILE MYELOMONOCYTIC LEUKEMIA|MYELODYSPLASTIC SYNDROME|HODGKIN OR NON-HODGKIN LYMPHOMA|SARCOMA, MYELOID",All,"up to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01629511,ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT|CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01500161,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|HODGKINS DISEASE|NON-HODGKINS LYMPHOMA|APLASTIC ANEMIA|MULTIPLE MYELOMA|MYELODYSPLASTIC SYNDROME,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Oncology, Amarillo, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT02518750,"ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN'S|LEUKEMIA, T-CELL|LEUKEMIA, B-CELL",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01158885,"MINIMAL RESIDUAL DISEASE|LEUKEMIA, LYMPHOBLASTIC, ACUTE|LEUKEMIA, MYELOGENOUS, ACUTE",All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Carolina-Levine Children's Hospital, Charlotte, North Carolina, United States|Seattle Children's Hospital, Seattle, Washington, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00852709,MYELODYSPLASTIC SYNDROME|ACUTE MYELOID LEUKEMIA|MYELOPROLIFERATIVE DISORDERS|ACUTE LYMPHOCYTIC LEUKEMIA|ACUTE PROMYELOCYTIC LEUKEMIA|ACUTE LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA|MYELOFIBROSIS|CHRONIC MYELOMONOCYTIC LEUKEMIA|JUVENILE MYELOMONOCYTIC LEUKEMIA,All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|University of Colorado Health Sciences Center and The Children's Hospital, Aurora, Colorado, United States|Pediatrix Hematology/Oncology University of Florida College of Medicine, Gainesville, Florida, United States|Children's Healthcare of Atlanta, Atlanta, Georgia, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|M.D. Anderson Comprehensive Cancer Center, Houston, Texas, United States|Southern Alberta Children's Cancer Program, Calgary, Alberta, Canada",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT02349178,"LEUKEMIA, ACUTE LYMPHOBLASTIC|ACUTE MYELOID LEUKEMIA",All,"up to 39 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Nationwide Children's Hospital, Columbus, Ohio, United States|American Family Children's Hospital, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Froedtert Memorial Lutheran Hospital, Milwaukee, Wisconsin, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT01596699,MYELOID MALIGNANCY|BONE MARROW FAILURE SYNDROME|TRANSFUSION-DEPENDENT RED BLOOD CELL (RBC) DEFECT|CONGENITAL IMMUNODEFICIENCY|METABOLIC DISEASE|SEVERE IMMUNE DYSREGULATION,All,"3 Months to 30 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Francisco, San Francisco, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00882076,LEUKEMIA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00241371,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, St. Louis, Missouri, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00617929,CANCER,All,"Child, Adult, Older Adult",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00691652,LYMPHOMA,All,"18 Years to 89 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00081887,CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA,All,"Child, Adult, Older Adult",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Terminated,NCT00983528,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States|UCSD Medical Center, San Diego, California, United States|Rady Children's Hospital, San Diego, California, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT01677949,ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA,All,"up to 60 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F,0,DB00631,__CLOFARABINE,5661136,Withdrawn,NCT00800566,LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,35.1547259697324,61.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.32,303.677,119.31,7.0,3.0,3.0,26.06,67.0,2.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00369629,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Terminated,NCT00545948,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Palm Beach Cancer Institute, West Palm Beach, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Presbyterian HealthCare, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Maria Parham Hospital, Henderson, North Carolina, United States|Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg, North Carolina, United States|Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Johnston Memorial Hospital Authority, Smithfield, North Carolina, United States|Columbus County Hospital, Whiteville, North Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States|Community Memorial Health Center, South Hill, Virginia, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
Nc1nc(=O)c2c(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)c[nH]c2[nH]1,0,DB00642,__PEMETREXED,5344932,Withdrawn,NCT00712062,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,41.5285734820016,332.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.11,427.4106,186.97,9.0,6.0,3.0,43.24,109.45,9.0,0.0,1.0,0.0,1,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0
C[C@@H]1OC(=O)CC(O)CC(O)CC(O)CCC(O)C(O)C[C@]2(O)CC(O)C(C(=O)O)C(CC(O[C@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,0,DB00646,__NYSTATIN,,Withdrawn,NCT03862079,GRAFT-VERSUS-HOST DISEASE PREVENTION,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.1,926.107,319.61,17.0,12.0,3.0,99.93,243.55,3.0,1.0,0.0,0.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
C=CCN.ClCC1CO1,0,DB00658,__SEVELAMER,5496545,Withdrawn,NCT00837655,"KIDNEY FAILURE, CHRONIC|END-STAGE RENAL DISEASE|INSULIN RESISTANCE|HYPERPHOSPHATEMIA",All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Sahlgrenska University Hospital, Gothenburg, Sweden|Karolinska University Hospital, Stockholm, Sweden",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,22.012772336187602,6.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.68,149.619,12.53,1.0,0.0,1.0,8.38,20.06,2.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1
COc1ccc2c3c1O[C@H]1C[C@@H](O)C=C[C@@]31CCN(C)C2,0,DB00674,__GALANTAMINE,6099863,Withdrawn,NCT03014323,INSULIN SENSITIVITY|OXIDATIVE STRESS,Female,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cyndya Shibao, Nashville, Tennessee, United States",5,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,19.975769522988106,194.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.16,287.3535,41.93,4.0,1.0,4.0,31.5,82.3,1.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0
Clc1ccc2nsnc2c1NC1=NCCN1,0,DB00697,__TIZANIDINE,6455557,Terminated,NCT00464958,SPASTICITY|MULTIPLE SCLEROSIS,All,"20 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tel Aviv Sourasky Medical Center, Tel Aviv, Israel",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,9.856465225158619,619.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.6,253.71099999999998,62.2,5.0,2.0,3.0,23.97,64.77,1.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1,0,DB00705,__DELAVIRDINE,5563142,Terminated,NCT00002420,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Oaks Med Group, Beverly Hills, California, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,31.507833836423696,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,456.561,110.43,6.0,3.0,4.0,50.01,126.64,5.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0
CC(C)(C)C(=O)OCOP(=O)(COCCn1cnc2c(N)ncnc21)OCOC(=O)C(C)(C)C,0,DB00718,__ADEFOVIR_DIPIVOXIL,5663159,Withdrawn,NCT00051077,HIV INFECTIONS|HEPATITIS B|HEPATITIS C,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,,C07F9/6512,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,34.7276124766422,474.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.49,501.4705,166.98,8.0,1.0,2.0,49.0,119.99,15.0,1.0,0.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,0,DB00738,__PENTAMIDINE,4399151,Suspended,NCT03730363,HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,27.170989137353892,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.32,340.4195,118.2,6.0,4.0,2.0,38.85,120.53,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1,0,DB00738,__PENTAMIDINE,4399151,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,27.170989137353892,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.32,340.4195,118.2,6.0,4.0,2.0,38.85,120.53,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN,0,DB00746,__DEFEROXAMINE,3957435,Terminated,NCT00658411,ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA|MYELODYSPLASTIC SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Brigham and Women's Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",G01N33/556,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,17.183104375859802,794.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,560.684,205.84,9.0,6.0,0.0,62.42,144.95,23.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0,0,1,0,0
CCN(CC)C(=S)SSC(=S)N(CC)CC,0,DB00822,__DISULFIRAM,3932346,Terminated,NCT03198559,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia",C08F2/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,17.0,7.523768455204411,392.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.88,296.539,6.48,0.0,0.0,0.0,31.6,88.24,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0
CN(C)/N=N/c1[nH]cnc1C(N)=O,0,DB00851,__DACARBAZINE,4722834,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,28.0,22.965563974619602,1554.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.32,182.187,99.73,5.0,2.0,1.0,17.78,49.71,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00248534,LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Hillman Cancer Center at University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, Wisconsin, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00003567,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT02113007,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale School of Medicine, New Haven, Connecticut, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT01235793,B-CELL LYMPHOMA ORIGINATING IN THE CNS,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cedars Sinai Medical Center, Los Angeles, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT00005812,BRAIN TUMORS|CENTRAL NERVOUS SYSTEM TUMORS|LEPTOMENINGEAL METASTASES,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Norris Cotton Cancer Center, Lebanon, New Hampshire, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Terminated,NCT02477813,SMALL CELL LUNG CANCER RECURRENT,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ircc Irst, Meldola, FC, Italy|Oncologia Medica, Azienda ospedaliera universitaria di Ferrara, Ferrara, FE, Italy|Oncologia Medica AOU Policlinico di Modena, Modena, MO, Italy|U.O. Oncologia Medica, Faenza, RA, Italy|U.O Oncologia medica, Lugo, RA, Italy|UO Oncologia Medica, Ospedale S.Maria delle Croci, Ravenna, RA, Italy|U.O Oncologia medica, Rimini, RN, Italy|Oncologia Medica Ospedale Guglielmo da Saliceto, Piacenza, Italy",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
Cn1nnc2c(C(N)=O)ncn2c1=O,0,DB00853,__TEMOZOLOMIDE,5260291,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,33.0,24.7397277151481,1666.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-1.0,194.1508,105.94,5.0,1.0,2.0,16.88,47.86,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0
COc1ccccc1OCC(O)CO,0,DB00874,__GUAIFENESIN,6372252,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,56.0,23.589806772212896,462.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.76,198.2158,58.92,4.0,2.0,1.0,20.59,51.24,5.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0
Cc1cccn2c(=O)c(-c3nn[nH]n3)cnc12,0,DB00885,__PEMIROLAST,5034230,Terminated,NCT03119714,ALLERGIC ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Lung and Allergy Research Unit C2-88 Karolinska University Hospital Huddinge, Stockholm, Sweden",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,23.8197909608,365.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.13,228.2101,87.13,5.0,1.0,3.0,21.96,63.35,1.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
CN(CCCl)CCCl,0,DB00888,__MECHLORETHAMINE,7872050,Withdrawn,NCT03288818,MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,14.0,58.4159839011068,3535.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.31,156.054,3.24,1.0,0.0,0.0,15.84,38.67,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,0,DB00904,__ONDANSETRON,5344658,Terminated,NCT00147355,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina|Hospital Interzonal de Agudos San Juan de Dios, La Plata, Argentina|Hospital Interzonal General de Agudos Oscar Alende, Mar del Plata, Argentina|Hospital Central, Mendoza, Argentina|CAICI, Rosario, Argentina|St. Vincent's Hospital, Sydney, New South Wales, Australia|AIDS Medical Unit, Brisbane, Queensland, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|Gold Coast Sexual Health Clinic, Gold Coast, Queensland, Australia|Nambour Hospital, Nambour, Queensland, Australia|Carlton Clinic, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Kaplan Medical Center, Rehovot, Israel",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O,0,DB00904,__ONDANSETRON,5344658,Withdrawn,NCT00499668,MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|NAUSEA AND VOMITING|SOLID TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,10.0,19.5486560298979,384.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,293.363,39.82,2.0,0.0,4.0,33.16,86.78,2.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CC(COc1ccccc1)N(CCCl)Cc1ccccc1,0,DB00925,__PHENOXYBENZAMINE,4022893,Terminated,,CARDIOPULMONARY BYPASS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,27.4995379781925,540.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.26,303.82599999999996,12.47,2.0,0.0,2.0,34.09,88.92,8.0,0.0,1.0,0.0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01121757,FOLLICULAR LYMPHOMA|MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01908387,MYELODYSPLASTIC SYNDROMES|CHRONIC MYELOMONOCYTIC LEUKEMIA|ACUTE MYELOID LEUKEMIA|MULTIPLE MYELOMA|NON-HODGKIN LYMPHOMA|HODGKIN LYMPHOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Cancer Center Hospital East, Kashiwa, Chiba, Japan|National Cancer Center Hospital, Tokyo, Japan|The Cancer Institute Hospital of JFCR, Tokyo, Japan",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01747499,"LEUKEMIA, MYELOID, ACUTE|MYELODYSPLASTIC SYNDROMES|PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA",All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Washington University School of Medicine, Saint Louis, Missouri, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT02399917,ACUTE BIPHENOTYPIC LEUKEMIA|ACUTE MYELOID LEUKEMIA ARISING FROM PREVIOUS MYELODYSPLASTIC SYNDROME|RECURRENT ACUTE MYELOID LEUKEMIA|REFRACTORY ACUTE MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT00412919,MULTIPLE MYELOMA,All,"17 Years and older   (Child, Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Alfred Hospital, Melbourne, Victoria, Australia",C07H19/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT00543582,HODGKIN LYMPHOMA|NON-HODGKIN LYMPHOMA (FOLLICULAR OR LARGE DIFFUSE B-CELL LYMPHOMA OR MANTLE CELL LYMPHOMA),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Francis Cancer Research Foundation, Beech Grove, Indiana, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Weill Medical College of Cornell University, New York, New York, United States|University of Texas, MD Anderson, Houston, Texas, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Terminated,NCT01241786,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SMALL LYMPHOCYTIC LYMPHOMA (SLL),All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hackensack University Medical Center, Hackensack, New Jersey, United States",C07H19/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1,0,DB00928,__AZACITIDINE,4058602,Withdrawn,NCT02701673,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/12,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,15.2118113308281,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,244.2047,140.97,8.0,4.0,2.0,21.5,52.19,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@](N)(Cc1ccc(O)c(O)c1)C(=O)O,0,DB00968,__METHYLDOPA,3988341,Withdrawn,NCT03396484,TYPE 1 DIABETES,All,"8 Years and older   (Child, Adult, Older Adult)",NIH,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,C07D209/20,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,28.0580710076182,717.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,211.2145,103.78,5.0,4.0,1.0,20.73,53.79,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3,0,DB00980,__RAMELTEON,6034239,Terminated,NCT00869167,INSOMNIA|ASTHMA,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Northwestern University, Chicago, Illinois, United States",C07D263/62,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,41.0,36.04180783999671,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,259.3434,38.33,2.0,1.0,3.0,29.99,75.52,4.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,0,1,0,1,0,0
CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O,0,DB00995,__AURANOFIN,4330530,Withdrawn,NCT02176135,HIV INFECTION,All,18 Years to 55 Years   (Adult),Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami - AIDS Clinical Research Unit, Miami, Florida, United States",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,16.8217006509373,4.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.99,678.4839999999998,114.43,5.0,0.0,1.0,50.82,114.88,15.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT00855062,HIV-ASSOCIATED COGNITIVE IMPAIRMENT|HIV INFECTIONS,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Infecious Diseas Institute, Kampala, Uganda",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT00361257,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment","UCLA-David Geffen School of Medicine, Los Angeles, California, United States|University of California, San Diego, California, United States|University of Colorado Health Science Center, Denver, Colorado, United States|The Ponce de Leon Ctr. CRS, Atlanta, Georgia, United States|Northwestern University CRS, Chicago, Illinois, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Massachusetts General Hospital, Division of Infectious Diseases, Boston, Massachusetts, United States|Henry Ford Hosp. CRS, Detroit, Michigan, United States|Washington University, St. Louis, Missouri, United States|NYU Med Ctr, Dept of Medicine, New York, New York, United States|1101 University of Rochester Medical Center, Division of Infectious Diseases, Rochester, New York, United States|University of North Carolina, AIDS Clinical Trials Unit, Chapel Hill, North Carolina, United States|The Research and Education Group - Portland CRS, Portland, Oregon, United States|University of Pennsylvania, ACTU, Philadelphia, Pennsylvania, United States|Virginia Commonwealth Univ. Medical Ctr. CRS, Richmond, Virginia, United States|Univ of Washington, Harborview Medical Ctr, Seattle, Washington, United States",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT01073813,MULTIPLE SCLEROSIS|OPTIC NEURITIS,All,18 Years to 60 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Terminated,NCT01134627,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Scleroseklinikken afsnit 2082, Copenhagen, Denmark",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CN(C)c1ccc(O)c2c1C[C@H]1C[C@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]3(O)C(O)=C1C2=O,0,DB01017,__MINOCYCLINE,5908838,Withdrawn,NCT00378781,CANCER,All,"Child, Adult, Older Adult",Other|NIH,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,6,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,18.0,15.3432308671635,351.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.03,457.4764,164.63,9.0,5.0,4.0,45.9,122.54,3.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0
CC(C[N+](C)(C)C)OC(N)=O,0,DB01019,__BETHANECHOL,4474751,Terminated,NCT02058537,EOSINOPHILIC ESOPHAGITIS (EOE),All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States",A61K9/0048,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,54.0,16.591716462350302,288.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.8,161.2221,52.32,1.0,1.0,0.0,17.73,54.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT01904253,SMALL CELL LUNG CANCER (SCLC),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Baden-Württemberg, Germany|Lungenklinik Heckeshorn- HELIOS Kliniken GmbH, Berlin, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Germany|Klinikum Koeln-Merheim, Koplin, Germany|St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz, Mainz, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Turin, Italy|IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A, Aviano, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico, Catania, Italy|Azienda Ospedaliera Instituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera San Gerardo U.O Oncologia Medica, Monza, Italy|Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|A.O.V.V. Ospedale Eugenio Morelli-Sondalo, Sondalo, Italy|National Cancer Center Hospital East, Chiba, Japan|National Kyushi Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Hyogo, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Nippon Medical School Hospital, Tokyo, Japan|Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",C07D491/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Terminated,NCT00005029,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler Air Force Base, Mississippi, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",C07D491/22,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1,0,DB01030,__TOPOTECAN,5004758,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D491/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,28.9451528778825,1800.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,421.4458,103.2,6.0,2.0,5.0,44.86,115.02,3.0,0.0,1.0,0.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
COc1ccc2[nH]cc(CCNC(C)=O)c2c1,0,DB01065,__MELATONIN,4309415,Withdrawn,NCT03688464,ATOPIC DERMATITIS,All,2 Years to 12 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,37.0,32.854884083862,1835.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.42,232.2783,54.12,2.0,2.0,2.0,25.65,66.28,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0
CS(C)=O,0,DB01093,__DIMETHYL_SULFOXIDE,,Terminated,NCT01123915,HIV INFECTION,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St Stephen's Centre, Chelsea and Westminster Foundation Trust, London, United Kingdom",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,78.133,17.07,1.0,0.0,0.0,7.91,20.73,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Nc1[nH]c(=O)ncc1F,0,DB01099,__FLUCYTOSINE,,Terminated,NCT01562132,CRYPTOCOCCAL INFECTION DISSEMINATED,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Family AIDS Care and Education Services, Kisumu, Nyanza, Kenya|Family AIDS Care and Education Services, Sindo, Nyanza, Kenya",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,129.0925,67.48,3.0,2.0,1.0,10.04,28.15,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Terminated,NCT00006812,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"Child, Adult, Older Adult",Other|NIH,Primary Purpose: Treatment,"University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic Cancer Center, Rochester, Minnesota, United States|Ellis Fischel Cancer Center - Columbia, Columbia, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Comprehensive Cancer Center at Wake Forest University, Winston-Salem, North Carolina, United States|Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Center - Calgary, Calgary, Alberta, Canada",C07H19/06,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CCCCCOC(=O)Nc1nc(=O)n([C@@H]2O[C@H](C)[C@@H](O)[C@H]2O)cc1F,0,DB01101,__CAPECITABINE,4966891,Withdrawn,NCT03169790,NON HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07H19/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,23.688371424464503,1258.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,359.3501,120.69,6.0,3.0,2.0,35.81,82.75,7.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1,0,DB01114,__CHLORPHENIRAMINE,6383471,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",A61K47/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,114.0,37.0274543625125,1611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.74,274.788,16.13,2.0,0.0,2.0,30.82,80.85,5.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0
CCCCc1oc2ccccc2c1C(=O)c1cc(I)c(OCCN(CC)CC)c(I)c1,0,DB01118,__AMIODARONE,5134127,Terminated,NCT01511263,PRIMARY AMYLOIDOSIS OF LIGHT CHAIN TYPE,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centro per lo Studio e la Cura delle Amiloidosi Sistemiche - Fondazione IRCCS Policlinico S.Matteo, Pavia, Italy",B82Y5/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,45.0,30.1279287049015,273.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.24,645.3116,42.68,3.0,0.0,3.0,56.78,145.05,11.0,1.0,0.0,0.0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0
CCCCNC(=O)NS(=O)(=O)c1ccc(C)cc1,0,DB01124,__TOLBUTAMIDE,3977404,Terminated,NCT01185548,LYMPHOMA|ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Trent, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",A61F6/144,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,38.0,11.7620485020226,1153.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.04,270.348,75.27,3.0,2.0,1.0,29.1,70.27,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,0,DB01157,__TRIMETREXATE,6017922,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",C07D239/95,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,20.2714634797429,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,369.4176,117.54,8.0,3.0,3.0,40.24,107.7,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC,0,DB01157,__TRIMETREXATE,6017922,Terminated,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D239/95,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,20.2714634797429,6.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.36,369.4176,117.54,8.0,3.0,3.0,40.24,107.7,6.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1
CNNCc1ccc(C(=O)NC(C)C)cc1,0,DB01168,__PROCARBAZINE,3993072,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",A61M31/002,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
CNNCc1ccc(C(=O)NC(C)C)cc1,0,DB01168,__PROCARBAZINE,3993072,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61M31/002,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.240518285796401,326.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,221.2988,53.16,3.0,3.0,1.0,25.88,86.98,5.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00227682,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00005786,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Medical Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00590603,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Duke University Medical Center, Durham, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00006220,LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES,All,"15 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"Washington University Barnard Cancer Center, Saint Louis, Missouri, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00006092,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Terminated,NCT00005595,LYMPHOMA,All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Withdrawn,NCT00112879,STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=[As]O[As]=O,0,DB01169,__ARSENIC_TRIOXIDE,6723351,Withdrawn,NCT00085345,STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|REFRACTORY PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Palo Verde Hematology Oncology, Glendale, Arizona, United States|Comprehensive Blood and Cancer Center, Bakersfield, California, United States|Southbay Oncology / Hematology Medical Group, Campbell, California, United States|Fountain Valley, California, United States|Hematology-Oncology Medical Group of Fresno, Incorporated, Fresno, California, United States|Hematology Oncology Medical Group of Orange County, Incorporated, Orange, California, United States|Cancer Care Associates Medical Group - Redondo Beach, Redondo Beach, California, United States|Redwood Regional Oncology Center - Sotoyome, Santa Rosa, California, United States|Cancer Prevention and Treatment Center at Dominican and Watsonville Community Hospital, Soquel, California, United States|San Diego Cancer Center - Vista, Vista, California, United States|Oncotherapeutics, West Hollywood, California, United States|Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center, Miami Beach, Florida, United States|Atlanta Cancer Care - Roswell, Roswell, Georgia, United States|Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|Center for Cancer and Blood Disorders at Suburban Hospital, Bethesda, Maryland, United States|William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States|Hackensack University Medical Center Cancer Center, Hackensack, New Jersey, United States|Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Utah Cancer Specialists - Administrative Office, Salt Lake City, Utah, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,64.0,11.6963387338549,6.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.07,197.84,43.37,2.0,0.0,0.0,6.91,4.24,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
O=c1[nH]c2ccccc2n1CCCN1CCC(n2c(=O)[nH]c3cc(Cl)ccc32)CC1,0,DB01184,__DOMPERIDONE,4066772,Terminated,NCT00604942,ACHALASIA|GORD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Oesophageal Laboratory, GSTT, London, United Kingdom",C07D235/26,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,19.5815109139818,755.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,425.911,67.92,3.0,2.0,5.0,45.61,119.37,5.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2C(=O)CC[C@@]3(O)[C@H]1C5,0,DB01192,__OXYMORPHONE,5662933,Withdrawn,NCT01206907,CHRONIC PAIN,All,2 Years to 6 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,48.0,21.979917452103706,1154.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.26,301.3371,70.0,5.0,2.0,5.0,30.77,79.56,0.0,0.0,1.0,0.0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,0,DB01200,__BROMOCRIPTINE,5468755,Terminated,NCT01893450,GRAVES OPHTHALMOPATHY,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Care Provider)|Primary Purpose: Treatment,"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico",4,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,39.0,23.8855007289677,1010.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.2,654.595,118.21,6.0,3.0,7.0,66.44,165.51,5.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
O=NN(CCCl)C(=O)NC1CCCCC1,0,DB01206,__LOMUSTINE,4631289,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C07D233/91,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,42.9084786135238,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.62,233.695,61.77,2.0,1.0,1.0,23.61,58.65,4.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0
Cn1c(=O)c2[nH]cnc2n(C)c1=O.Cn1c(=O)c2[nH]cnc2n(C)c1=O.NCCN,0,DB01223,__AMINOPHYLLINE,3965256,Terminated,NCT02270827,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,"Royal Brompton Hospital, London, United Kingdom",A61K9/2013,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,24.5754532947288,845.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-0.77,420.4264,69.3,3.0,1.0,4.0,16.86,44.93,1.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",C07D305/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT00758732,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital of Crete, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""IASO"" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|Department of Medical Oncology, ""Marika Iliadis"" Hospital of Athens, Athens, Greece|Department of Medical Oncology, Air Forces Military Hospital of Athens, Athens, Greece|Medical Oncology Unit, 401 Military Hospital of Athens, Athens, Greece|State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece|First Department of Medical Oncology, ""Metaxa's"" Anticancer Hospital of Pireas, Piraeus, Greece|""Theagenion"" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece|Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki, Greece|Medical Oncology Unit, ""AXEPA"" General Hospital of Thessaloniki, Thessaloniki, Greece",C07D305/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Terminated,NCT03827473,CASTRATION-SENSITIVE PROSTATE CARCINOMA|METASTATIC PROSTATIC ADENOCARCINOMA|STAGE IV PROSTATE CANCER|STAGE IVA PROSTATE CANCER|STAGE IVB PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",C07D305/14,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB01248,__DOCETAXEL,4814470,Withdrawn,NCT03343977,METASTATIC HORMONE-SENSITIVE PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",C07D305/14,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.238608595659002,3874.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,807.8792,224.45,10.0,5.0,6.0,82.15,203.9,13.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CS(=O)(=O)CCNCc1ccc(-c2ccc3ncnc(Nc4ccc(OCc5cccc(F)c5)c(Cl)c4)c3c2)o1,0,DB01259,__LAPATINIB,6391874,Terminated,NCT00317434,OVARIAN CANCER,Female,"19 Years to 90 Years   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Indiana University School of Medicine, Indianapolis, Indiana, United States",C07D401/04,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,32.0,40.6414916117374,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.18,581.058,106.35,7.0,2.0,5.0,61.19,152.42,11.0,1.0,0.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,0,0,1
Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O,0,DB01265,__TELBIVUDINE,6395716,Withdrawn,NCT00051090,HEPATITIS B INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,27.0,33.577691533707,89.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.3,242.2286,99.1,5.0,3.0,2.0,23.25,55.41,2.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00953459,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C,0,DB01268,__SUNITINIB,6573293,Terminated,NCT00387426,"ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA|ACUTE UNDIFFERENTIATED LEUKEMIA|ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOMONOCYTIC LEUKEMIA|CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|MAST CELL LEUKEMIA|MENINGEAL CHRONIC MYELOGENOUS LEUKEMIA|PRIMARY MYELOFIBROSIS|PROGRESSIVE HAIRY CELL LEUKEMIA, INITIAL TREATMENT|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA|UNTREATED HAIRY CELL LEUKEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D403/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,29.0,27.532392862276396,773.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,398.4738,77.23,3.0,3.0,3.0,44.32,116.27,7.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT02518750,"ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN'S|LEUKEMIA, T-CELL|LEUKEMIA, B-CELL",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00981799,RELAPSED T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA|RELAPSED T-CELL LYMPHOBLASTIC LYMPHOMA,All,"1 Year to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital Orange County, Orange, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|New York University Medical Center, New York, New York, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Rainbow Babies, Cleveland, Ohio, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|St. Jude, Memphis, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Hospital, Fort Worth, Texas, United States|Primary Children's, Salt Lake City, Utah, United States|Seattle Children's Hospital, Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Children's Hospital at Westmead, Westmead, New South Wales, Australia|Royal Children's Hospital, Brisbane, Queensland, Australia|Royal Children's Hospital, Melbourne, Melbourne, Victoria, Australia|Sydney Children's Hospital, Sydney, Australia|St. Anna Children's Hospital, Vienna, Austria|Hospital for Sick Kids, Toronto, Ontario, Canada|Sainte Justine University Hospital, Montreal, Quebec, Canada|British Columbia Children's Hospital, Vancouver, Canada|CHU Lille, Lille, France|Bambino Gesù Hospital, Rome, Italy|Erasmus MC - Sophia, Rotterdam, Netherlands",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00005982,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"16 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
COc1nc(N)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O,0,DB01280,__NELARABINE,5424295,Terminated,NCT00005950,ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"16 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07H19/16,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.651368611265106,318.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.81,297.2673,148.77,9.0,4.0,3.0,27.68,69.6,3.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@@]21C,0,DB01380,__CORTISONE_ACETATE,3960757,Suspended,NCT01843530,ACUTE ACE-INDUCED ANGIOEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kath. Klinikum Bochum, Med. Klinik III, Bochum, Germany|Ludwig-Maximilian-Universität, München, Germany|Klinikum rechts der Isar, Hals-Nasen-Ohren Klinik, München, Germany|Universitätsklinikum Ulm, HNO, Ulm, Germany",A61K9/1694,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,35.0890162015647,483.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.35,402.4807,97.74,5.0,1.0,4.0,43.06,105.63,4.0,0.0,1.0,0.0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1C(NC(C)=O)CC2,0,DB01394,__COLCHICINE,7619004,Withdrawn,NCT00000577,ASTHMA|LUNG DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of California at San Diego, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|National Jewish Medical & Research Center, Denver, Colorado, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Wisconsin at Madison, Madison, Wisconsin, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,11.466354545267803,4.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.59,399.43699999999995,83.09,6.0,1.0,3.0,42.41,111.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=Cc5oncc5C[C@]4(C)[C@H]3CC[C@@]21C,0,DB01406,__DANAZOL,4055562,Terminated,NCT00953771,THROMBOTIC THROMBOCYTOPENIC PURPURA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai St. Luke's-Roosevelt, New York, New York, United States",C07J71/0063,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,16.920265303188902,611.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.62,337.4553,46.26,2.0,1.0,5.0,38.56,98.54,0.0,0.0,1.0,0.0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O,0,DB01421,__PAROMOMYCIN,3932615,Terminated,NCT00001128,CRYPTOSPORIDIOSIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Pablo C. Okhuysen, Houston, Texas, United States",A61K9/16,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,22.2099016406907,499.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,-2.9,615.6285,347.32,19.0,13.0,4.0,60.4,134.24,9.0,1.0,0.0,0.0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1
COc1cc(CC(C)N)c(OC)cc1C,0,DB01528,"__4-METHYL-2,5-DIMETHOXYAMPHETAMINE",WO-1998042331-A1,Terminated,NCT00604942,ACHALASIA|GORD,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Diagnostic,"Oesophageal Laboratory, GSTT, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.02,209.2848,44.48,3.0,1.0,1.0,24.09,61.67,4.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0
CC1(C)S[C@@H]2[C@H](NC(=O)[C@H](C(=O)O)c3ccsc3)C(=O)N2[C@H]1C(=O)O,0,DB01607,__TICARCILLIN,4127649,Withdrawn,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,18.201605782459602,934.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.99,384.42699999999996,124.01,6.0,3.0,3.0,36.14,87.93,5.0,0.0,1.0,0.0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1
CC(C)(C)NC(=O)[C@@H]1CN(Cc2cc3ccccc3o2)CCN1C[C@@H](O)C[C@@H](Cc1ccccc1)C(=O)NC1c2ccccc2C[C@H]1O,0,DB02009,__L-756423,,Suspended,NCT00002424,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"UCLA School of Medicine / Ctr for Research and Education, Los Angeles, California, United States|Georgetown Univ Med Ctr, Washington, District of Columbia, United States|ViRx / Dupont Circle Physicians Group, Washington, District of Columbia, United States|Associates in Research, Fort Myers, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|Grady Mem Hosp, Atlanta, Georgia, United States|Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States|The CORE Ctr, Chicago, Illinois, United States|Univ of Kentucky Med Ctr, Lexington, Kentucky, United States|Univ of Kentucky, Lexington, Kentucky, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Henry Ford Hosp, Detroit, Michigan, United States|NYU Med Ctr / C & D Building, New York, New York, United States|Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ, New York, New York, United States|SUNY at Stony Brook / Div of Infectious Disease, Stony Brook, New York, United States|The Miriam Hosp, Providence, Rhode Island, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.3,652.836,118.28,6.0,4.0,6.0,72.8,186.77,12.0,1.0,0.0,0.0,1,1,1,1,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,1,1,0,0,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,1
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT02419755,MIXED LINEAGE ACUTE LEUKEMIA|ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOID LEUKEMIA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01116154,ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTROM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00972842,PERIPHERAL T-CELL NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck, Tirol, Austria|Krankenhaus der Elisabethinen Linz, Linz, Austria|Krankenhaus der Stadt Linz, Linz, Austria|Universitaetsklinik f. Innere Medizin III, Salzburg, Austria|Hanusch Krankenhaus, Vienna, Austria",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT02589145,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00910000,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PERITONEAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States",1,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00882206,LEUKEMIA|LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00744354,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mount Sinai Medical Center, New York, New York, United States|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01483690,ACUTE LYMPHOBLASTIC LEUKEMIA|PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA|PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA,All,"1 Year to 21 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|CHOC, Orange, California, United States|UCSF School of Medicine, San Francisco, California, United States|The Children's Hospital, University of Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Miami Cancer Center, Miami, Florida, United States|Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia, United States|Lurie Children's Hospital, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Dana Farber, Boston, Massachusetts, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Childrens Hospital & Clinics of Minnesota, Minneapolis, Minnesota, United States|University of Minnesota Children's Hospital, Minneapolis, Minnesota, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|New York University Medical Center, New York, New York, United States|Children's Hospital New York-Presbyterian, New York, New York, United States|Levine Children's Hospital at Carolinas Medical Center, Charlotte, North Carolina, United States|Nationwide Childrens Hospital, Columbus, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|St. Jude, Memphis, Tennessee, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States|University of Texas at Southwestern, Dallas, Texas, United States|Cook Children's Medical Center, Forth Worth, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Royal Children's Hospital, Brisbane, Queensland, Australia|Sydney Children's Hospital, Sydney, Australia|Children's Hospital at Westmead, Westmead, NSW, Australia",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01312818,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"2 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Masonic Cancer Center, University if Minnesota, Minneapolis, Minnesota, United States",1,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01578343,MANTLE CELL LYMPHOMA,All,"19 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samsung Medical Center, Seoul, Korea, Republic of",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00785798,RELAPSED LYMPHOMAS|REFRACTORY LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale University School of Medicine, New Haven, Connecticut, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT03198559,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Department of Infectious Diseases, Alfred Hospital, Melbourne, Victoria, Australia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01249443,"HIV INFECTION|RECURRENT ANAL CANCER|RECURRENT BREAST CANCER|RECURRENT ESOPHAGEAL CANCER|RECURRENT GASTRIC CANCER|RECURRENT METASTATIC SQUAMOUS NECK CANCER WITH OCCULT PRIMARY|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT SALIVARY GLAND CANCER|RECURRENT SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|RECURRENT SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|RECURRENT SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|RECURRENT VERRUCOUS CARCINOMA OF THE LARYNX|RECURRENT VERRUCOUS CARCINOMA OF THE ORAL CAVITY|SALIVARY GLAND SQUAMOUS CELL CARCINOMA|STAGE IV ANAL CANCER|STAGE IV BREAST CANCER|STAGE IV ESOPHAGEAL CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV SALIVARY GLAND CANCER|STAGE IV SQUAMOUS CELL CARCINOMA OF THE HYPOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE LIP AND ORAL CAVITY|STAGE IV SQUAMOUS CELL CARCINOMA OF THE NASOPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE OROPHARYNX|STAGE IV SQUAMOUS CELL CARCINOMA OF THE PARANASAL SINUS AND NASAL CAVITY|STAGE IV VERRUCOUS CARCINOMA OF THE LARYNX|STAGE IV VERRUCOUS CARCINOMA OF THE ORAL CAVITY|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|Lombardi Comprehensive Cancer Center at Georgetown University, Washington, District of Columbia, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|John H. Stroger Jr. Hospital of Cook County, Chicago, Illinois, United States|Boston Medical Center, Boston, Massachusetts, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States|Montefiore Medical Center, Bronx, New York, United States|Pennsylvania Oncology Hematology Associates, Philadelphia, Pennsylvania, United States|Benaroya Research Institute at Virginia Mason, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT02707900,HIV-1 INFECTION,All,18 Years to 64 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of North Carolina Hospitals, Chapel Hill, North Carolina, United States",1,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01187446,CUTANEOUS LYMPHOMA|CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University School of Medicine, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|MD Anderson Cancer Center, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00109109,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT01500538,FOLLICULAR LYMPHOMA|MARGINAL ZONE LYMPHOMA|MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Terminated,NCT00958074,CUTANEOUS T-CELL LYMPHOMA STAGE I|CUTANEOUS T-CELL LYMPHOMA STAGE II|CUTANEOUS T-CELL LYMPHOMA STAGE III|CUTANEOUS T-CELL LYMPHOMA STAGE IV,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
O=C(CCCCCCC(=O)Nc1ccccc1)NO,0,DB02546,__VORINOSTAT,6087367,Withdrawn,NCT00837174,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,19.0,13.799051315222002,59.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.88,264.3202,78.43,3.0,3.0,1.0,28.39,73.81,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
N[C@H](CC(=O)O)C(=O)O,0,DB02655,__D-ASPARTIC_ACID,,Terminated,NCT03387046,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING",All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Ospedale Binaghi, Università di Cagliari,ASL 8, Cagliari, Italy|Ospedale Clinicizzato SS. Annunziata, Chieti, Italy|Azienda Socio Sanitaria Territoriale della Valle Olona (presidio di Gallarate), Gallarate, Italy|Azienda Ospedaliero Universitaria San Martino, Genova, Italy|Ospedale P.A.Micone, Genova, Italy|Ospedale San Raffaele, Milano, Italy|A.O.U. Federico II, Napoli, Italy|Azienda Ospedaliera di Rilievo Nazionale A. CardarelliAzienda Ospedaliera di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Seconda Università degli Studi di Napoli, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|I.R.C.C.S. Neuromed-Istituto Neurologico Mediterraneo, Pozzilli, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Azienda Ospedaliera Sant'Andrea-Università di Roma La Sapienza, Roma, Italy|Policlinico Universitario Agostino Gemelli, Roma, Italy|Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Rome, Italy|Ospedale S. Paolo, Savona, Italy|Azienda Ospedaliero Universitaria Ospedali Riuniti, Torrette Di Ancona, Italy",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.5,133.1027,100.62,5.0,3.0,0.0,11.35,26.53,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NC(=O)c1cccnc1,0,DB02701,__NICOTINAMIDE,3931207,Terminated,NCT02758990,"OBESITY|RHINITIS|RHINITIS, ALLERGIC|RESPIRATORY SOUNDS|DYSPNEA|HEADACHE|MIGRAINE DISORDERS|ARTHRITIS|ARTHRALGIA|ANXIETY|SLEEP INITIATION AND MAINTENANCE DISORDERS|SLEEP DEPRIVATION",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Verifomics, LLC, Dallas, Texas, United States",C07D207/44,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,24.7397277151481,6368.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.39,122.1246,55.98,2.0,1.0,1.0,11.71,32.98,1.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
OC[C@H]1O[C@H](O[C@]2(CO)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB02772,__SUCROSE,,Terminated,NCT02499705,INSULIN RESISTANCE|OBESITY,All,13 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","The John B. Pierce Laboratory, New Haven, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.6,342.2965,189.53,11.0,8.0,2.0,31.03,68.77,5.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0
C[C@]12CC[C@H]3[C@@H](CC[C@H]4CC(=O)CC[C@@]43C)[C@@H]1CC[C@@H]2O,0,DB02901,__STANOLONE,4071623,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,20.5014476683299,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.37,290.4403,37.3,2.0,1.0,4.0,34.69,83.6,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0
CC(=O)OCC[N+](C)(C)C,0,DB03128,__ACETYLCHOLINE,6261546,Terminated,NCT00327080,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,26.6124561079282,4066.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.9,146.2074,26.3,1.0,0.0,0.0,16.69,51.35,4.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0
O=C(O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,DB03156,__BETA-D-GLUCURONIC_ACID,4058621,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,10.0,24.1811946857225,7.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-2.3,194.1394,127.45,7.0,5.0,1.0,16.37,35.79,1.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(=O)O,0,DB03166,__ACETIC_ACID,,Terminated,NCT01003769,RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Florida, Jacksonville, Florida, United States|Roswell Park Cancer Institute, Buffalo, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.12,60.052,37.3,2.0,1.0,0.0,5.34,12.64,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
Nc1nc(=O)c2c([nH]1)NC[C@@H](CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)N2C=O,0,DB03256,__(6R)-FOLINIC_ACID,,Terminated,NCT01602016,AUTISM SPECTRUM DISORDER|AUTISTIC DISORDER|AUTISM|ASPERGER'S SYNDROME|PERVASIVE DEVELOPMENT DISORDERS,All,3 Years to 14 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Arkansas Children's Hospital Research Institute, Little Rock, Arkansas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.8,473.4393,215.55,12.0,7.0,3.0,44.63,126.46,9.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1
O=C(CCN1CCN(c2cccc(C(F)(F)F)c2)CC1)c1cc(O)c(O)c([N+](=O)[O-])c1,0,DB03336,__BIA,,Suspended,NCT03740698,"DIABETES MELLITUS, TYPE 1",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Device Feasibility,"Imperial College Clinical Research Facility, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.7,439.3851,109.83,7.0,2.0,3.0,41.6,108.4,7.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT01076556,CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00112723,ADULT LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA|ADULT LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA|ADULT MIXED CELLULARITY HODGKIN LYMPHOMA|ADULT NODULAR SCLEROSIS HODGKIN LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY MULTIPLE MYELOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00101231,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA,All,"1 Year and older   (Child, Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00377104,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA|NONCONTIGUOUS STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1,0,DB03496,__ALVOCIDIB,6087366,Terminated,NCT00098371,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,16.0,52.14070104108911,444.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.81,401.84,90.23,6.0,3.0,4.0,40.85,107.74,2.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
C#Cc1c[nH]c(=O)[nH]c1=O,0,DB03516,__ENILURACIL,5643913,Terminated,NCT00827580,BREAST CANCER|COLON CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Clinical Trials Research Unit, West Virginia University, Morgantown, West Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,31.7049631409269,94.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.91,136.1082,58.2,2.0,2.0,1.0,12.05,33.39,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO,0,DB03754,__TROMETHAMINE,,Terminated,NCT00621530,HIP ARTHROPLASTY,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.1,121.135,86.71,4.0,4.0,0.0,12.02,28.36,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0
CC1=C(N2CC2)C(=O)C(CO)=C(N2CC2)C1=O,0,DB04090,__RH-1,6156744,Terminated,NCT00558727,ADVANCED SOLID TUMORS|NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado Health Science Center, Aurora, Colorado, United States|Hudson-Webber Cancer Research Center, Detroit, Michigan, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Therapy & Research Center, San Antonio, Texas, United States",C07D203/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,18.431589971046602,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.22,234.2512,60.39,5.0,1.0,3.0,23.64,64.97,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CCCCCCCC/C=C/CCCCCCCC(=O)O,0,DB04224,__OLEIC_ACID,3937674,Terminated,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C09D11/108,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,40.7072013799051,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.68,282.4614,37.3,2.0,1.0,0.0,37.64,87.4,15.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O,0,DB04703,__HESPERIDIN,4078137,Withdrawn,NCT01773486,OBESITY|INSULIN RESISTANCE,All,"21 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Maryland, Baltimore, Maryland, United States",C07H17/07,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,22.012772336187602,842.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,610.5606,234.29,15.0,8.0,5.0,58.76,140.77,7.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,1,0,0,0,1,0,1,1,0,0,1
Oc1c(I)cc(Cl)c2cccnc12,0,DB04815,__CLIOQUINOL,4485091,Terminated,NCT00963495,"ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOCYTIC LEUKEMIA|CHRONIC LYMPHOCYTIC LEUKEMIA|MYELODYSPLASIA|LYMPHOMA, NON-HODGKIN|HODGKIN'S LYMPHOMA|MULTIPLE MYELOMA",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Princess Margaret Hospital, Toronto, Ontario, Canada",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,28.5508942688761,484.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.66,305.5,33.12,2.0,1.0,2.0,22.63,60.13,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0,DB04868,__NILOTINIB,7169791,Terminated,NCT00905398,PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA|ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
Cc1cn(-c2cc(NC(=O)c3ccc(C)c(Nc4nccc(-c5cccnc5)n4)c3)cc(C(F)(F)F)c2)cn1,0,DB04868,__NILOTINIB,7169791,Withdrawn,NCT01670084,"B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",C07D405/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,42.9084786135238,336.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.51,529.5158,97.62,6.0,2.0,5.0,52.35,152.85,7.0,1.0,0.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1
C[C@H]1CNCCc2ccc(Cl)cc21,0,DB04871,__LORCASERIN,6953787,Terminated,NCT03192995,COCAINE USE DISORDER,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","San Francisco Department of Public Health, San Francisco, California, United States",5,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,77.0,30.0622189367338,52.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.0,195.69,12.03,1.0,1.0,2.0,21.51,56.65,0.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
CC1(C)CC(C)(C)CC(C)(N)C1,0,DB04926,__NERAMEXANE,6034134,Terminated,NCT00799942,"NYSTAGMUS, CONGENITAL|NYSTAGMUS, ACQUIRED|MULTIPLE SCLEROSIS",All,"18 Years to 81 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,18.333025318795,37.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.74,169.30700000000004,26.02,1.0,1.0,1.0,21.66,53.62,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](COC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC,0,DB04933,__ERITORAN,,Terminated,NCT02267317,INSULIN SENSITIVITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.98,1313.6562,293.63,17.0,7.0,2.0,153.77,346.56,59.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,0,DB04960,__TIPIFARNIB,6545020,Terminated,NCT00243035,REFRACTORY MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States",A61K41/0038,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1
Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C,0,DB04960,__TIPIFARNIB,6545020,Terminated,NCT00360776,STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",A61K41/0038,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,27.105279369186203,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.77,489.39599999999996,64.15,3.0,1.0,5.0,50.16,148.2,4.0,0.0,1.0,0.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,1
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Nc1ccn([C@@H]2CO[C@H](CO)O2)c(=O)n1,0,DB04961,__TROXACITABINE,5817667,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",C07D317/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,48.986632169038295,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.7,213.1906,97.38,6.0,2.0,2.0,19.54,48.73,2.0,0.0,1.0,0.0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Withdrawn,NCT02786485,LEUKEMIA|MYELODYSPLASTIC SYNDROMES|LYMPHOMAS|MULTIPLE MYELOMA|OTHER HIGH-RISK HEMATOLOGICAL MALIGNANCIES,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Withdrawn,NCT03807063,"ACUTE BILINEAL LEUKEMIA|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM, UNCLASSIFIABLE|MYELOPROLIFERATIVE NEOPLASM|RECURRENT ACUTE BIPHENOTYPIC LEUKEMIA|RECURRENT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ACUTE MYELOID LEUKEMIA|RECURRENT BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|RECURRENT CHRONIC MYELOMONOCYTIC LEUKEMIA|RECURRENT MYELODYSPLASTIC SYNDROME",All,"12 Months and older   (Child, Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCc1ccc(OC)c(OC)c1)c1cccc(OCC(=O)NCCNC(=O)COc2cccc([C@@H](CCc3ccc(OC)c(OC)c3)OC(=O)[C@@H]3CCCCN3C(=O)[C@@H](CC)c3cc(OC)c(OC)c(OC)c3)c2)c1)c1cc(OC)c(OC)c(OC)c1,0,DB04974,__RIMIDUCID,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.88,1411.65,262.18,18.0,2.0,8.0,153.98,379.49,39.0,1.0,0.0,0.0,1,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,NCT03117361,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHRU de Lille - Hôpital Claude Huriez, Lille, France|Institut Gustave Roussy, Villejuif, France|Policlinico Vittorio Emanuele Hospital, Catania, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain|Clinica Universidad de Navarra, Pamplona, Navarra, Spain|Institut Català d´Oncologia Girona, Girona, Spain|Institut Català d´Oncologia L´Hospitalet, Hospitalet de Llobregat, Spain|Hospital General Universitario J.M. Morales Meseguer, Murcia, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Complexo Hospitalario Universitario de Santiago, Santiago De Compostela, Spain|Complejo Hospitalario Regional Virgen Del Rocio, Sevilla, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,NCT03070964,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University Medical School, Chicago, Illinois, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Faculty Hospital Ostrava, Ostrava, Czechia|Fakultni Nemocnice Praha, Praha, Czechia|Ospedale Clinico Aviano, Aviano, Pordenone, Italy|Instituto di Ematologia ""Seragnoli"", Bologna, Italy|Spedali Civili di Brescia, Brescia, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|Hospital Clínic i Provincial de Barcelona, Barcelona, Spain|Hospital Universitari Vall d'Hebron, Barcelona, Spain|Centro Oncológico MD Anderson International España, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hospital Universitari Son Espases, Palma de Mallorca, Spain|Hospital Universitario de Salamanca, Salamanca, Spain|Hospital Universitario Marqués de Valdecilla, Santander, Spain|Hospital Virgen del Rocío, Sevilla, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H]2CCCN2C(=O)C(C)=O)[C@@H](C)OC(=O)[C@H](Cc2ccc(OC)cc2)N(C)C(=O)[C@@H]2CCCN2C(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)C(=O)[C@H](C(C)C)OC(=O)C[C@@H]1O,0,DB04977,__PLITIDEPSIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,1110.357,284.74,13.0,4.0,4.0,117.17,288.14,15.0,1.0,0.0,0.0,1,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,1,0,1,0,0,1,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,1,0,1,1,1,1,1,0,1
CC(=O)N1N=C(c2ccc(N)cc2)c2cc3c(cc2C[C@H]1C)OCO3,0,DB04982,__TALAMPANEL,6288057,Terminated,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",C07D491/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,77.50467155383059,20.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.97,337.3725,77.15,5.0,1.0,4.0,36.34,94.65,1.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0
CC(=O)[O-].CC(=O)[O-].N.NC1CCCCC1.[Cl-].[Cl-].[Pt+4],0,DB04996,__SATRAPLATIN,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.17,500.283,26.02,1.0,1.0,1.0,12.44,30.93,0.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
Cc1cn([C@H]2C[C@H](OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cc(C)c(O)nc4=O)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(O)nc(=N)[nH]c54)C[C@@H]3O)[C@@H](COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cc(C)c(O)nc4=O)O[C@@H]3COP(=O)(O)O[C@H]3C[C@H](n4cnc5c(O)nc(=N)[nH]c54)O[C@@H]3COP(=O)(O)OC3CC(n4cnc5c(O)nc(=N)[nH]c54)OC3CO)O2)c(=O)nc1O,0,DB04998,__AGRO100,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-6.3,8272.338,3617.47,190.0,87.0,69.0,735.41,1931.71,152.0,1.0,0.0,0.0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,1,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Terminated,NCT00274651,CUTANEOUS T-CELL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Leland Stanford Junior University, Stanford, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Kansas City Cancer Center, Lenexa, Kansas, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Boston University Medical Center, Boston, Massachusetts, United States|NYU Medical Center, New York, New York, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|MD Anderson Cancer Center, Houston, Texas, United States|Hopitaux du Haut Leveque, Pessac, France|Hospital Purpan, Toulouse, France|Universitatsklinikum Essen, Essen, Germany|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|Rabin Medical Center, Petach Tikva, Israel|Songklanagarind Hospital, Prince of Songkla University, Hat Yai, Thailand|King Chulalongkorn Memorial Hospital, Patumwan, Thailand",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Withdrawn,NCT02701673,LYMPHOMA,All,"15 Years to 65 Years   (Child, Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D213/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
O=C(/C=C/c1cccc(S(=O)(=O)Nc2ccccc2)c1)NO,0,DB05015,__BELINOSTAT,6888027,Withdrawn,NCT02875002,RELAPSED AND REFRACTORY AGGRESSIVE B- AND T-CELL LYMPHOMAS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States|Massey Cancer Center, Richmond, Virginia, United States",C07D213/42,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,63.0,43.17131768619472,10.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.83,318.35,95.5,4.0,3.0,2.0,30.99,83.48,4.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0
[O-][n+]1cccc(C(Cl)=NOC[C@H](O)CN2CCCCC2)c1,0,DB05025,__ARIMOCLOMOL,,Withdrawn,,AMYOTROPHIC LATERAL SCLEROSIS (ALS),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.45,313.78,70.52,5.0,1.0,2.0,32.93,83.13,6.0,0.0,1.0,0.0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C(=O)Nc2ccc(O)cc2)C(C)(C)CCC1,0,DB05076,__FENRETINIDE,4190594,Terminated,NCT00288067,ADULT NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA|B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|CONTIGUOUS STAGE II ADULT LYMPHOBLASTIC LYMPHOMA|CONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA|CONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA|CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|STAGE II MARGINAL ZONE LYMPHOMA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT BURKITT LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT LYMPHOBLASTIC LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 1 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II GRADE 2 FOLLICULAR LYMPHOMA|NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE I ADULT BURKITT LYMPHOMA|STAGE I ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE I ADULT HODGKIN LYMPHOMA|STAGE I ADULT LYMPHOBLASTIC LYMPHOMA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I GRADE 1 FOLLICULAR LYMPHOMA|STAGE I GRADE 2 FOLLICULAR LYMPHOMA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II ADULT HODGKIN LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Washington Medical Center, Seattle, Washington, United States",C07D213/87,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,21.421384422678003,21.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.31,391.5457,49.33,2.0,2.0,2.0,47.58,128.05,6.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0
COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,DB05109,__TRABECTEDIN,8895557,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,26.0,108.913940738002,3.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.04,761.837,168.72,12.0,4.0,9.0,77.72,196.92,4.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00096005,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00103272,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00019708,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NON-HODGKIN LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)C=C(C)[C@H](OC(=N)O)[C@@H](OC)/C=C\C=C(/C)C(O)=NC(=CC1=O)C2=O,0,DB05134,__TANESPIMYCIN,,Terminated,NCT00098488,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,585.698,170.76,11.0,5.0,2.0,61.3,175.25,7.0,1.0,0.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,0,0,1,1,0,1,1,1,0,1,0,1,1,1,1,0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT02700022,DIFFUSE LARGE B-CELL LYMPHOMA|FOLLICULAR LYMPHOMA|BURKITT LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Comprehensive Cancer Center, Duarte, California, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hills, North Carolina, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
COc1cc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2OC)=NC3)ccc1C(=O)O,0,DB05220,__ALISERTIB,WO-2008063525-A1,Terminated,NCT01812005,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University, Atlanta, Georgia, United States|Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.0,518.93,105.93,8.0,2.0,5.0,52.31,137.21,6.0,1.0,0.0,0.0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1
O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1,0,DB05239,__COBIMETINIB,7803839,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D401/12,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,47.7710014579354,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,531.318,64.6,4.0,3.0,4.0,44.75,115.85,4.0,1.0,0.0,0.0,1,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
COCC(=O)[C@@]1(OC(C)=O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3[C@@H](c3ccc(N(C)C)cc3)C[C@@]21C,0,DB05253,__TELAPRISTONE_ACETATE,US-20090149434-A1,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K47/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.63,505.655,72.91,5.0,0.0,5.0,56.9,144.89,7.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CC(C)(CC1Cc2ccccc2C1)NC[C@@H](O)COc1cc(CCC(=O)O)cc(F)c1F,0,DB05255,__RONACALERET,7514473,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C217/54,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.0,64.3955728043697,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.37,447.523,78.79,5.0,3.0,3.0,47.78,118.36,11.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)C3=CC[C@@]21C,0,DB05288,__ANECORTAVE_ACETATE,4041055,Terminated,,MACULAR DEGENERATION,,,,,"FISABIO, Elche, Alicante, Spain",C07J1/0048,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,92.0,20.7314318569169,111.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,386.4813,80.67,4.0,1.0,4.0,42.64,105.81,4.0,0.0,1.0,0.0,0,0,1,1,0,0,1,1,1,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Lu+3],0,DB05296,__MOTEXAFIN_LUTETIUM,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.99,1166.136,178.75,15.0,2.0,5.0,106.08,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
CCOc1ccc(-c2nc(-c3cccc(C(=O)O)n3)cs2)cc1OCC,0,DB05298,__TETOMILAST,5643932,Terminated,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",C07D417/14,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,25.4296802809092,35.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.38,370.42199999999997,81.54,6.0,1.0,3.0,39.86,107.91,7.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT01777464,HOUSE DUST MITE ALLERGY,All,18 Years to 50 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Basic Science,"uz leuven ORL, Leuven, Vlaams Brabant, Belgium",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT00387738,"RHINITIS, ALLERGIC, SEASONAL",All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","Center Of Research Excellence, Oxford, Alabama, United States|Atlanta Allergy & Asthma Clinic, Stockbridge, Georgia, United States|Clinical Research of Atlanta, Stockbridge, Georgia, United States|Sneeze, Wheeze, and Itch Associates, Normal, Illinois, United States|Research Center of Indiana, Indianapolis, Indiana, United States|Asthma and Allergy Research Center, Minneapolis, Minnesota, United States|Clinical Research Institute, Plymouth, Minnesota, United States|Clinical Research of the Ozarks, Columbia, Missouri, United States|Clinical Research of The Ozarks, Rolla, Missouri, United States|Clinical Research Center, Saint Louis, Missouri, United States|Clinical Research of the Ozarks, Warrensburg, Missouri, United States|Midwest Allergy & Asthma Clinic, Omaha, Nebraska, United States|Creighton University, Omaha, Nebraska, United States|Asthma & Allergy Center, Papillion, Nebraska, United States|Princeton Center for Clinical Research, Skillman, New Jersey, United States|Allergy & Asthma Center, High Point, North Carolina, United States|Allergy & Respiratory Center, Canton, Ohio, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|Allergy, Asthma and Clinical Research Center, Oklahoma City, Oklahoma, United States|Asthma & Allergy Research Associates, Upland, Pennsylvania, United States|AARA Research Center, Dallas, Texas, United States|Pharmaceutical Research & Consulting, Dallas, Texas, United States|Kerrville Allergy and Asthma Associates, Kerrville, Texas, United States|Central Texas Health Research, New Braunfels, Texas, United States|Sylvana Research, San Antonio, Texas, United States|Asthma, Allergy & Sinus Center, Greenfield, Wisconsin, United States|University of Wisconsin Madison Medical School, Madison, Wisconsin, United States|Advanced Healthcare, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT01292070,CAT ALLERGY,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH|Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alfred Hospital and Monash University, Melbourne, Victoria, Australia",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Terminated,NCT02047136,DIET MODIFICATION|CHRONIC URTICARIA,All,"8 Years and older   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Hong Kong Sanatorium & Hospital, Hong Kong, China",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
NCCc1c[nH]cn1,0,DB05381,__HISTAMINE,,Withdrawn,NCT00630383,MULTIPLE SCLEROSIS,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Nottingham University Hospital NHS Trust, Nottingham, Nottinghamshire, United Kingdom",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.69,111.1451,54.7,2.0,2.0,1.0,12.08,31.66,2.0,0.0,1.0,0.0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0
Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].Cc1occc(=O)c1[O-].[Ga+3],0,DB05420,__GALLIUM_MALTOLATE,,Terminated,NCT00050687,PROSTATIC NEOPLASMS|MULTIPLE MYELOMA|BLADDER NEOPLASMS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, PA, Springdale, Arkansas, United States|California Cancer Care, Greenbrae, California, United States|Stanford University, Palo Alto, California, United States|Southfield Oncology Institute, Southfield, Michigan, United States|New York Presbyterian Hospital, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,445.032,49.36,3.0,0.0,3.0,11.26,44.27,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00100711,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|The Mayo Clinic, Rochester, Minnesota, United States|The Ohio State University, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00076401,"LEUKEMIA|LEUKEMIA, LYMPHOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Terminated,NCT00089284,NON-HODGKIN'S LYMPHOMA (NHL),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Jesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CC(=O)[O-].CC(=O)[O-].CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[n-]2)C(CCCO)=C4C)C(C)=C3CCCO.[Gd+3],0,DB05428,__MOTEXAFIN_GADOLINIUM,,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.95,1148.4,178.75,15.0,2.0,5.0,103.73,243.08,28.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,1
CCC[C@H](NC(=O)[C@@H]1[C@H]2CCC[C@H]2CN1C(=O)[C@@H](NC(=O)[C@@H](NC(=O)c1cnccn1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,0,DB05521,__TELAPREVIR,7820671,Terminated,NCT01467479,HEPATITIS C INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alabama, Birmingham, Alabama, United States|California, Bakersfield, California, United States|California, Beverly Hills, California, United States|California, Coronado, California, United States|California, Los Angeles, California, United States|California, Oakland, California, United States|California, Palo Alto, California, United States|California, Sacremento, California, United States|California, San Diego, California, United States|California, San Francisco, California, United States|Connecticut, New Haven, Connecticut, United States|DC, Washington DC, District of Columbia, United States|Washington, DC, Washington, District of Columbia, United States|Florida, Bay Pines, Florida, United States|Florida, Jacksonville, Florida, United States|Florida, Miami, Florida, United States|Florida, Orlando, Florida, United States|Florida, West Palm Beach, Florida, United States|Georgia, Atlanta, Georgia, United States|Georgia, Decatur, Georgia, United States|Illinois, Chicago, Illinois, United States|Maine, Portland, Maine, United States|Maryland, Baltimore, Maryland, United States|Maryland, Lutherville, Maryland, United States|Massachusetts, Springfield, Massachusetts, United States|Michigan, Detroit, Michigan, United States|Minnesota, Minneapolis, Minnesota, United States|Missouri, Kansas City, Missouri, United States|Missouri, Saint Louis, Missouri, United States|New Jersey, Newark, New Jersey, United States|New Mexico, Santa Fe, New Mexico, United States|New York, Bronx, New York, United States|New York, New York, New York, United States|New York, Rochester, New York, United States|North Carolina, Durham, North Carolina, United States|Ohio, Cincinnati, Ohio, United States|Ohio, Cleveland, Ohio, United States|Oregon, Portland, Oregon, United States|Pennsylvania, Philadelphia, Pennsylvania, United States|Rhode Island, Providence, Rhode Island, United States|South Carlonia, Columbia, South Carolina, United States|Texas, Dallas, Texas, United States|Texas, Houston, Texas, United States|Utah, Salt Lake City, Utah, United States|Virginia, Richmond, Virginia, United States|Washington, Seattle, Washington, United States|Edmonton, Edmonton, Alberta, Canada|Vancouver, Vancouver, British Columbia, Canada|Hamilton, Hamilton, Ontario, Canada|Toronto, Toronto, Ontario, Canada|Montreal, Montreal, Quebec, Canada|Bonn, Bonn, Germany|Essen, Essen, Germany|Hamburg, Hamburg, Germany|Munchen, Munchen, Germany|Puerto Rico, San Juan, Puerto Rico|Spain, Badalona, Spain|Barcelona, Barcelona, Spain|Madrid, Madrid, Spain",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,109.83387749235001,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.56,679.8493,179.56,8.0,4.0,5.0,74.37,180.04,14.0,1.0,0.0,0.0,1,1,1,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,1
CS(=O)(=O)O.O=c1[nH]c2c(c3ccccc13)Cc1cc(S(=O)(=O)NCCCN3CCOCC3)ccc1-2,0,DB05549,__INO-1001,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.22,535.63,87.74,5.0,2.0,5.0,47.65,121.05,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1
CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21,0,DB05575,__MOTESANIB,US-20030125339-A1,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,48.9209224008706,24.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.59,373.4509,78.94,5.0,3.0,4.0,40.66,114.77,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
O.O.O.O.O.O.O.O.O.O=C([O-])[C@@H]1O[Sb]2([O-])(O[Sb]34(O)O[C@H]([C@H](C(=O)[O-])O3)[C@@H]([C@H](O)CO)O4)O[C@H]1[C@@H]([C@H](O)CO)O2.[Na+].[Na+].[Na+],0,DB05630,__SODIUM_STIBOGLUCONATE,,Terminated,NCT00311558,CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.4,907.88,269.08,17.0,5.0,4.0,39.78,96.29,8.0,1.0,0.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1
CCCCCCCOC(=O)NC1=NC(=O)N([C@H]2C[C@H](O)[C@@H](CO)O2)CN1,0,DB05644,__KP-1461,,Terminated,NCT00504452,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Health for Life Clinic, Little Rock, Arkansas, United States|Living Hope Clinical Foundation, Long Beach, California, United States|Light Source Medical/U. of Southern California, Los Angeles, California, United States|ACTU at CARES/UC Davis, Sacramento, California, United States|UCSD Antiviral Research Center, San Diego, California, United States|Quest Clinical Research, San Francisco, California, United States|Dupont Circle Physician's Group, Washington, District of Columbia, United States|Whitman-Walker Clinic, Washington, District of Columbia, United States|Comprehensive Care Center -- HIV Clinical Research, Fort Lauderdale, Florida, United States|Wohlfeiler, Piperato and Associates, LLC, North Miami Beach, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States|AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States|Northstar Medical Center, Chicago, Illinois, United States|University of Kansas School of Medicine - PriVia, The Research Centers of Via Christi, Wichita, Kansas, United States|Institute of Human Virology, University of Maryland, Baltimore, Maryland, United States|Community Research Initiative of New England, Boston, Massachusetts, United States|Dybedal Center for Clinical Research, Kansas City University of Medicine and Biosciences, Kansas City, Missouri, United States|St. Michael's Medical Center, Newark, New Jersey, United States|Southwest CARE Center, Santa Fe, New Mexico, United States|Albany Medical College, Albany, New York, United States|AIDS Community Research Initiative of America, New York, New York, United States|Mount Sinai Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University of Cincinnati Medical Center, Cincinnati, Ohio, United States|Thomas Jefferson University, Division of Infectious Disease, Philadelphia, Pennsylvania, United States|Charlton Methodist Hospital, Dallas, Texas, United States|University of Texas Health Science Center, Houston, Texas, United States|CARE-ID, Annandale, Virginia, United States|University of Washington AIDS Clinical Trials Unit, Seattle, Washington, United States|Clinical Research Puerto Rico, Inc., San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.47,372.42199999999997,132.72,7.0,4.0,2.0,39.64,89.83,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0
CO[C@H]1[C@H]([C@@]2(C)O[C@@H]2CC=C(C)C)[C@]2(CC[C@H]1OC(=O)N[C@@H](C(N)=O)C(C)C)CO2,0,DB05864,__PPI-2458,,Terminated,NCT00100347,"NON-HODGKIN'S LYMPHOMA,|SOLID TUMORS",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universtiy of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University of New Mexico, Albuquerque, New Mexico, United States|Columbia University Medical Center, New York, New York, United States|University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.07,424.531,115.71,5.0,2.0,3.0,46.28,110.43,9.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,0
CC(C)=CCOc1cc(NC(=S)c2ccoc2C)ccc1Cl,0,DB05871,__UC-781,US-20030007983-A1,Withdrawn,NCT00385554,HIV INFECTION,All,21 Years to 45 Years   (Adult),U.S. Fed|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Prevention,"Centers for Disease Control and Prevention, Atlanta, Georgia, United States|CONRAD, Arlington, Virginia, United States|BOTUSA HIV Prevention Research Unit, Gaborone and Francistown, Botswana",C07D335/02,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,108.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.07,335.848,34.4,1.0,1.0,2.0,35.48,97.63,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Withdrawn,NCT01680796,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CN1CCN(c2ccc3nc(-c4c(N)c5c(F)cccc5[nH]c4=O)[nH]c3c2)CC1,0,DB05928,__DOVITINIB,US-20030158224-A1,Withdrawn,NCT02065323,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States",1,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,21.3556746545103,29.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.34,392.43800000000016,90.28,5.0,3.0,5.0,42.46,112.36,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0
CCOC(=O)C1=CCCC[C@H]1S(=O)(=O)Nc1ccc(F)cc1Cl,0,DB05943,__RESATORVID,US-20110184034-A1,Terminated,,SEPSIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,361.81,72.47,3.0,1.0,2.0,33.37,85.5,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,1,0,1,0,1
COC(=O)N[C@H](C(=O)NCCCC[C@@H](CO)N(CC(C)C)S(=O)(=O)c1ccc(N)cc1)C(c1ccccc1)c1ccccc1,0,DB05961,__PPL-100,EP-1575914-B1,Terminated,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,122.778701821392,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.51,624.7909999999998,151.06,6.0,4.0,3.0,67.78,172.03,16.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0
CC1(C)CC(=O)c2c(C(F)(F)F)nn(-c3ccc(C(N)=O)c(N[C@H]4CC[C@H](OC(=O)CN)CC4)c3)c2C1,0,DB06070,__SNX-5422,7358370,Terminated,NCT02973399,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States|Wexner Medical Center, Ohio State University, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,25.561099817244703,4.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.15,521.5409999999998,142.33,6.0,3.0,4.0,51.66,131.81,8.0,0.0,1.0,0.0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,0,DB06174,__NOSCAPINE,4029797,Terminated,NCT00912899,REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA, Los Angeles, California, United States|St. Vincent's Comprehensive Cancer Center, New York City, New York, United States|Weill Medical College of Cornell University, New York City, New York, United States|Columbia Presbyterian Hospital, New York City, New York, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,47.8038563420193,253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,413.4205,75.69,7.0,0.0,5.0,42.19,107.08,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
COc1ccc2c(c1OC)C(=O)O[C@@H]2[C@H]1c2c(cc3c(c2OC)OCO3)CCN1C,0,DB06174,__NOSCAPINE,4029797,Terminated,NCT00183950,NON-HODGKIN'S LYMPHOMA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,47.8038563420193,253.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,413.4205,75.69,7.0,0.0,5.0,42.19,107.08,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01445340,MYCOSIS FUNGOIDES|CUTANEOUS T-CELL LYMPHOMA|NEOPLASMS,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01738594,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IVA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IVB MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01742793,HODGKIN'S LYMPHOMA|MATURE T-CELL LYMPHOMA|MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT01979276,MULTIPLE MYELOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00079443,RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT02061449,CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute, New York, New York, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00383565,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT00091195,PRIMARY PERITONEAL CAVITY CANCER|RECURRENT OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"High Point Regional Hospital, High Point, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",C12P21/02,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Terminated,NCT02203578,GRAFT VS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT02281279,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT03355768,"LYMPHOMA, T-CELL, PERIPHERAL",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
C/C=C1\NC(=O)[C@H]2CSSCC/C=C/[C@H](CC(=O)N[C@H](C(C)C)C(=O)N2)OC(=O)[C@H](C(C)C)NC1=O,0,DB06176,__ROMIDEPSIN,7608280,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C12P21/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,7.0,19.3515267253947,2.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.95,540.69,142.7,5.0,4.0,2.0,54.55,142.09,2.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,NCT00435578,"CARCINOMA, SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"California Cancer Center, Greenbrae, California, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States",C07C291/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07C291/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
O=P(NCCCl)(NCCCl)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,DB06177,__GLUFOSFAMIDE,EP-1336602-A1,Terminated,,SMALL CELL LUNG CANCER (SCLC),,,,,"FISABIO, Elche, Alicante, Spain",C07C291/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,11.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,383.16,140.51,7.0,6.0,1.0,34.33,78.35,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Withdrawn,NCT00458744,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"1 Year to 21 Years   (Child, Adult)",Other|NIH,Primary Purpose: Treatment,,A61K39/395,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
Nc1nc(N)c2nc(CNc3ccc(C(=O)N[C@@H](CCCNC(=O)c4ccccc4C(=O)O)C(=O)O)cc3)cnc2n1,0,DB06178,__TALOTREXIN,EP-1180369-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",A61K39/395,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,58.7116778578615,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.35,573.56,248.43,13.0,7.0,4.0,58.38,154.27,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,1
C[As](C)SC[C@H](NC(=O)CC[C@H](N)C(=O)O)C(=O)NCC(=O)O,0,DB06179,__DARINAPARSIN,,Withdrawn,NCT01139359,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.7,411.3,158.82,7.0,5.0,0.0,36.38,79.89,11.0,0.0,1.0,0.0,1,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00646165,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Clinic I Provincial, Barcelona, Spain",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00742495,RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA|B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKAEMIA|T-CELL NON-HODGKIN'S LYMPHOMA,All,"2 Years to 18 Years   (Child, Adult)",Industry|Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vienna, Austria|Prague, Czech Republic|Prof Gerard Michel, Marseilles, France|Charite Universitymedicine, Berlin, Germany|Dr Giovanna Gioriani, Pavia, Italy|Sally Kinsey, Leeds, United Kingdom",C07D487/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,DB06185,__FORODESINE,5985848,Terminated,NCT00419081,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Medical Center, Chicago, Illinois, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|New York Medical College Division of Oncology, Valhalla, New York, United States|Liberty Hematology and Oncology, Columbia, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,25.0682765559867,9.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,266.2533,129.97,6.0,6.0,3.0,25.81,66.37,2.0,0.0,1.0,0.0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Cc1ccc(C(=O)N(CCCN)[C@@H](c2nc3cc(Cl)ccc3c(=O)n2Cc2ccccc2)C(C)C)cc1,0,DB06188,__ISPINESIB,US-20100063073-A1,Terminated,NCT00101244,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",A61P29/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,45.996837717406905,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.71,517.07,79.0,4.0,1.0,4.0,56.32,151.42,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Terminated,NCT00577161,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States|Ventura County Hematology Oncology Specialist, Oxnard, California, United States|Capitol Comprehensive Cancer Care, Jefferson City, Missouri, United States|Heartland Hematology Oncology Associates, Kansas City, Missouri, United States|Cancer Care Center, Albany, New York, United States|Interlakes Foundation, Inc., Rochester, New York, United States|Hematology Oncology Consultants, Columbus, Ohio, United States|Utah Hematology Oncology, P.C., Ogden, Utah, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Terminated,NCT00060671,"LYMPHOMA, FOLLICULAR|LYMPHOMA, MIXED-CELL, FOLLICULAR|LYMPHOMA, SMALL CLEAVED-CELL, FOLLICULAR|LYMPHOMA, LOW-GRADE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Clinical Research Center, Tucson, Arizona, United States|Sutter Health Western Division Cancer Research Group, Greenbrae, California, United States|Kenmar Research Institute, Los Angeles, California, United States|Rocky Moutain Cancer Center, Denver, Colorado, United States|Pasco, Hernando Oncology Associates, P.A., New Port Richey, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Orange Park Cancer Center, Orange Park, Florida, United States|University of Chicago Medical Center Hematology / Oncology, Chicago, Illinois, United States|Illinois Masonic Cancer Center, Chicago, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Hope Center, Terre Haute, Indiana, United States|Commonwealth Hematology/Oncology, Danville, Kentucky, United States|New England Hematology / Oncology Associates, Wellesley, Massachusetts, United States|St. Joseph Oncology, St Joseph, Missouri, United States|Christian Hospital, St Louis, Missouri, United States|St. Johns Mercy Medical Center, St. Louis, Missouri, United States|Hematology - Oncology Centers of N. Rockies, Billings, Montana, United States|Great Falls Clinic, Great Falls, Montana, United States|East Orange VA Medical Center, East Orange, New Jersey, United States|Hematology Oncology Associates of NJ, Paramus, New Jersey, United States|Summit Medical Group/Overlook Onc Center, Summit, New Jersey, United States|New Mexico Oncology / Hematology, Albuquerque, New Mexico, United States|HemOnCare, P.C., Brooklyn, New York, United States|Glens Falls Cancer Center, Glens Falls, New York, United States|North Shore - Long Island Jewish Health System, New Hyde Park, New York, United States|New York University, New York, New York, United States|Upstate NY Cancer Research, Rochester, New York, United States|South Shore Hematology-Oncology Associates, Rockville Centre, New York, United States|Clinworks, Inc, Charlotte, North Carolina, United States|Private Practice, Canton, Ohio, United States|Blair Medical Associates, Altoona, Pennsylvania, United States|Lancaster Cancer Center, LTD, Lancaster, Pennsylvania, United States|Santee Hematology Oncology, Sumter, South Carolina, United States|The West Clinic, Memphis, Tennessee, United States|Central Utah Medical Clinic Hematology-Oncology, Provo, Utah, United States|Oncology of Wisconsin, Glendale, Wisconsin, United States|Marshfield Clinic, Marshfield, Wisconsin, United States|Rhinelander Regional Medical Group Onc., Rhinelander, Wisconsin, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O,0,DB06193,__PIXANTRONE,5506232,Withdrawn,NCT02800889,LYMPHOMA|SOLID TUMOR (EXCLUDING CNS),All,"6 Months to 21 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital Los Angeles, Los Angeles, California, United States",C07D221/08,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,24.411178874309503,15.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.57,325.372,123.13,7.0,4.0,3.0,35.09,95.28,6.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1
CC[C@H](CO)Nc1nc(NCc2ccccc2)c2ncn(C(C)C)c2n1,0,DB06195,__SELICICLIB,US-20020049218-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61P17/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,28.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.11,354.4493,87.89,6.0,3.0,3.0,40.43,106.14,8.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,0,0,1,1,1,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1
CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1,0,DB06199,__ATRASENTAN,5767144,Terminated,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",C07D403/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,36.5674859853385,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.09,510.6218,88.54,7.0,1.0,4.0,55.33,140.14,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,1
NC(=O)c1cn(Cc2c(F)cccc2F)nn1,0,DB06201,__RUFINAMIDE,6740669,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D249/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,68.5352881989363,45.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.95,238.1935,73.8,3.0,1.0,2.0,20.42,67.07,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0
COC[C@@H](NC(C)=O)C(=O)NCc1ccccc1,0,DB06218,__LACOSAMIDE,5654301,Withdrawn,NCT02342977,OSTEOARTHRITIS|RHEUMATOID ARTHRITIS|AVASCULAR NECROSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|U.S. Fed,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Richard L. Roudebush Veterans Affairs Medical Center, Indianapolis, Indiana, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,54.7362368837142,182.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.18,250.2936,67.43,3.0,2.0,1.0,26.68,67.57,6.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1
CC(=O)[C@]1(N)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](O)[C@H](O)CO2)C1)C(=O)c1ccccc1C3=O,0,DB06263,__AMRUBICIN,4673668,Terminated,NCT01904253,SMALL CELL LUNG CANCER (SCLC),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Klinikum Mannheim GmbH Universitaetsklinikum, Mannheim, Baden-Württemberg, Germany|Lungenklinik Heckeshorn- HELIOS Kliniken GmbH, Berlin, Germany|LungenClinic Grosshansdorf, Grosshansdorf, Germany|Klinikum Koeln-Merheim, Koplin, Germany|St. Hildegardis-Krankenhaus- Katholisches Klinikum Mainz, Mainz, Germany|LMU-Campus Innenstadt, Muenchen, Germany|Azienda Ospedaliero-Universitaria S. Luigi Gonzaga, Orbassano, Turin, Italy|IRCCS Centro di Riferimento Oncologico di Aviano, Divisione Oncologia Medica A, Aviano, Italy|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico, Catania, Italy|Azienda Ospedaliera Instituti Ospitalieri di Cremona, Cremona, Italy|Azienda Ospedaliera Universitaria Careggi, Firenze, Italy|IEO Istituto Europeo di Oncologia, Milano, Italy|Azienda Ospedaliera San Gerardo U.O Oncologia Medica, Monza, Italy|Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia, Reggio Emilia, Italy|A.O.V.V. Ospedale Eugenio Morelli-Sondalo, Sondalo, Italy|National Cancer Center Hospital East, Chiba, Japan|National Kyushi Cancer Center, Fukuoka, Japan|Hyogo Cancer Center, Hyogo, Japan|Saitama Cancer Center, Saitama, Japan|Shizuoka Cancer Center, Shizuoka, Japan|Nippon Medical School Hospital, Tokyo, Japan|Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan",C07D413/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,19.0,26.185342614838,50.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.4,483.473,176.61,10.0,5.0,5.0,48.75,122.01,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,0,0
Cc1ccc(C(=O)C(C)CN2CCCCC2)cc1,0,DB06264,__TOLPERISONE,4912116,Terminated,NCT00532532,MUSCLE SPASTICITY,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Annes University Hospital, Brno, Czech Republic|University Hospital Hradec Kralove, Hradec Kralove, Czech Republic|University Hospital Plzen, Plzen, Czech Republic|University Hospital Motol, Praha, Czech Republic|Facharzt fur Neurologie, Bad Saarow, Germany|Facharztin fur Neurologie und Psychiatrie, Berlin, Germany|Facharzt fur Neurologie und Psychiatrie, Berlin, Germany|Private practice, Berlin, Germany|Neurological practice, Bochum, Germany|Neuro-Consil GmbH, Dusseldorf, Germany|X-pert-med GmbH, Graefelfing, Germany|Asklepios Klinik Nord-Heidberg, Hamburg, Germany|Neurological practice, Koln, Germany|City Hospital #33, Nizhniy Novgorod, Russian Federation|Regional Clinical Hospital named Semashko, Nizhniy Novgorod, Russian Federation|Institute of Human Brain, St. Petersburg, Russian Federation|Leningrad Regional Clinical Hospital, St. Petersburg, Russian Federation|Nikolaevskaya Hospital, Complex Rehabilitation Department, St. Petersburg, Russian Federation|Clinical Center of Serbia Institute of Neurology, Belgrade, Serbia|Clinical Center Nis Clinic of Neurology, Nis, Serbia|Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine|Central Clinical Hospital Ukrzalinznytsi (Dept. Neur. No. 1), Kharkiv, Ukraine|Central Clinical Hospital Ukrzalinznytsi (Dept. Neur. No. 3), Kharkiv, Ukraine|Institute of Neurology, Psychiatry and Narcology of AMS of Ukraine, Kharkiv, Ukraine|Institute of Clinical Radiology of the Scientific Centre of Radiation Medicine of the AMS of Ukraine, Kyiv, Ukraine|Odesa Regional Psychoneurological Dispensary, Odesa, Ukraine|M.O.Semashko Republican Clinical Hospital, Simferopol, Ukraine|Uzhgorod Regional Centre of Neurosurgery and Neurology, Uzhorod, Ukraine",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.0,27.13813425327001,71.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.75,245.36599999999999,20.31,2.0,0.0,2.0,29.6,76.35,4.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)Nc1onc(C)c1Cl)OCO2,0,DB06268,__SITAXENTAN,,Terminated,NCT01050491,EFFECT OF SITAXSENTAN ON AIRWAY REMODELING IN SEVERE ASTHMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Clinical Investigation center 07, Hopital Bichat, Paris, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.35,454.905,107.73,6.0,1.0,4.0,43.12,105.8,5.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0
COc1cc(F)c(F)c(Nc2ccc(I)cc2F)c1NS(=O)(=O)C1(C[C@H](O)CO)CC1,0,DB06309,__REFAMETINIB,US-20090082457-A1,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,19.7786402184849,30.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.11,572.337,107.89,6.0,4.0,3.0,46.34,116.29,8.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0
COc1cc(C(=O)c2c(C)oc3c(OP(=O)(O)O)c(OC)ccc23)cc(OC)c1OC,0,DB06313,__BNC105,,Withdrawn,NCT01624493,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States|Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia|Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia|Christchurch Hospital, Christchurch, Canterbury, New Zealand",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.13,452.352,133.89,8.0,2.0,3.0,43.41,109.33,8.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0
CC(C)[C@@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@H](NCCCNCCCCNCCCN)C[C@@H]1C[C@H]3O)OS(=O)(=O)O,0,DB06333,__TRODUSQUEMINE,,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.59,685.07,145.94,8.0,6.0,4.0,84.8,192.01,20.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0
CCOc1ccc(-c2ccc(Cn3c(CC(C)(C)C(=O)O)c(SC(C)(C)C)c4cc(OCc5ccc(C)cn5)ccc43)cc2)cn1,0,DB06346,__FIBOFLAPON,US-20070105866-A1,Terminated,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,56.4775457401589,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,7.63,637.84,86.47,6.0,1.0,5.0,73.86,186.32,13.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1
Cc1cc(Nc2ncc(F)c(N[C@H]3[C@@H](C(N)=O)[C@@H]4C=C[C@H]3C4)n2)ccc1N1CCN(C)CC1,0,DB06347,__CENISERTIB,8030483,Terminated,,HAEMATOLOGICAL MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,32.5591901271073,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.17,451.55,99.41,7.0,3.0,5.0,48.42,130.05,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1
CNc1cc2[nH]c(=O)n(-c3ccc(NC(=O)NS(=O)(=O)c4ccc(Cl)s4)cc3)c(=O)c2cc1F,0,DB06350,__ELINOGREL,WO-2012072824-A1,Terminated,,MYOCARDIAL INFARCTION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,38.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.24,523.94,136.71,6.0,4.0,4.0,49.7,125.95,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,1
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,NCT00084487,EXTENSIVE STAGE SMALL CELL LUNG CANCER|LIMITED STAGE SMALL CELL LUNG CANCER|RECURRENT SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Western Reserve University, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCN(CC)CCN1C(=O)c2c(c3c4cccc(Cl)c4n([C@@H]4O[C@H](CO)[C@@H](OC)[C@H](O)[C@H]4O)c3c3[nH]c4c(Cl)cccc4c23)C1=O,0,DB06362,__BECATECARIN,US-20030225150-A1,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,46.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.14,669.56,140.49,8.0,4.0,7.0,69.43,173.48,8.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,0,DB06365,__SAPACITABINE,US-20050014716-A1,Terminated,NCT01253460,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0
CCCCCCCCCCCCCCCC(=O)Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2C#N)c(=O)n1,0,DB06365,__SAPACITABINE,US-20050014716-A1,Terminated,NCT00476554,CUTANEOUS T-CELL LYMPHOMA (CTCL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Hospitals and Clinics, Stanford, California, United States|Timothy Kuzel, M.D., Chicago, Illinois, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,2.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.83,490.645,135.25,7.0,3.0,2.0,56.94,132.29,17.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0
NS(=O)(=O)c1ccc(S(=O)(=O)Nc2cccc3c(Cl)c[nH]c23)cc1,0,DB06370,__INDISULAM,6060498,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,20.4357379001622,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.21,385.846,122.12,4.0,3.0,3.0,35.23,90.94,3.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0
C[C@@H]1O[C@@H](O[C@H]2C[C@](O)(C(=O)CO)Cc3c(O)c4c(c(O)c32)C(=O)c2ccccc2C4=O)[C@H](I)[C@H](O)[C@H]1O,0,DB06420,__ANNAMYCIN,5902604,Terminated,NCT00430443,ACUTE LYMPHOCYTIC LEUKEMIA|ACUTE MYELOGENOUS LEUKEMIA,All,"12 Months to 21 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Phoenix Children's Hospital, Phoenix, Arizona, United States|Denver Children's Hospital, Denver, Colorado, United States|Vanderbilt Children's Hospital, Nashville, Tennessee, United States",A61K9/1277,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,47.1467586603421,55.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.16,640.379,191.05,11.0,6.0,5.0,55.55,139.24,4.0,1.0,0.0,0.0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0
CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,0,DB06497,__APLAVIROC,EP-1378510-A1,Terminated,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,50.66223125731529,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,577.722,119.41,6.0,3.0,5.0,63.45,159.43,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1
CCCCN1C(=O)[C@@H]([C@H](O)C2CCCCC2)NC(=O)C12CCN(Cc1ccc(Oc3ccc(C(=O)O)cc3)cc1)CC2,0,DB06497,__APLAVIROC,EP-1378510-A1,Terminated,,HIV-1 INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,9.0,50.66223125731529,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.77,577.722,119.41,6.0,3.0,5.0,63.45,159.43,10.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,1
COc1ccc(OC(=O)N(CC(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cc1,0,DB06510,__MURAGLITAZAR,EP-1607103-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.04,516.55,111.33,6.0,1.0,4.0,54.85,149.03,12.0,1.0,0.0,0.0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1,0,DB06532,__PAFURAMIDINE,WO-2005086754-A2,Terminated,NCT00302341,"PNEUMONIA, INTERSTITIAL PLASMA CELL|PNEUMOCYSTIS CARINII PNEUMONIA|PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California, San Francisco, California, United States|The University of Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|NYU School of Medicine, New York, New York, United States|UNC AIDS Clinical Trials, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Medical University of SC, Charleston, South Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,32.7488,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.65,364.405,103.36,6.0,4.0,3.0,40.58,145.42,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1,0,DB06532,__PAFURAMIDINE,WO-2005086754-A2,Terminated,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,34.0,32.7488,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.65,364.405,103.36,6.0,4.0,3.0,40.58,145.42,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CCO[C@@H](Cc1ccc(OCCc2ccc(OS(C)(=O)=O)cc2)cc1)C(=O)O,0,DB06536,__TESAGLITAZAR,6258850,Terminated,NCT00263965,TYPE 2 DIABETES,All,"30 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Site, Helsinki, Finland|Research Site, Pisa, Italy|Research Site, Oxford, United Kingdom",C07C309/65,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,23.688371424464503,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.18,408.465,99.13,6.0,1.0,2.0,42.56,103.52,11.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
O=c1[nH]oc2c1CCNC2,0,DB06554,__GABOXADOL,4278676,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/62,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,36.8303250580094,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.3,140.1399,50.36,3.0,2.0,2.0,13.31,35.5,0.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1
CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](S)CCN1C(=O)N(C)C(C)(C)C1=O)C(C)(C)C,0,DB06573,__REBIMASTAT,WO-2003048119-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61K38/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.75,499.67,127.92,5.0,4.0,1.0,54.52,131.54,11.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,1
C=C(C)[C@@H]1CC[C@]2(C(=O)O)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC[C@H](OC(=O)CC(C)(C)C(=O)O)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,0,DB06581,__BEVIRIMAT,WO-2013090405-A1,Terminated,,HIV INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.88,584.8262,100.9,5.0,2.0,5.0,68.0,161.75,7.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,0,1,0,0,1,1,1,1,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,1,1,1,0
CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,0,DB06595,__MIDOSTAURIN,7973031,Terminated,NCT00866281,ACUTE MYELOID LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA,All,"3 Months to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Seattle Children's Hospital CPKC412A2114, Seattle, Washington, United States|Novartis Investigative Site, Paris Cedex 19, France|Novartis Investigative Site, Genova, GE, Italy|Novartis Investigative Site, Monza, MB, Italy|Novartis Investigative Site, Roma, RM, Italy|Novartis Investigative Site, Torino, TO, Italy|Novartis Investigative Site, Rotterdam, Netherlands|Novartis Investigative Site, Stockholm, Sweden",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,104.182837429926,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.52,570.649,77.73,4.0,1.0,9.0,60.58,162.61,3.0,1.0,0.0,0.0,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1
CO[C@@H]1[C@H](N(C)C(=O)c2ccccc2)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4,0,DB06595,__MIDOSTAURIN,7973031,Withdrawn,NCT03760445,"LEUKEMIA, MYELOID, ACUTE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.0,104.182837429926,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.52,570.649,77.73,4.0,1.0,9.0,60.58,162.61,3.0,1.0,0.0,0.0,0,0,0,0,1,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,1
Nc1nc(N)c2ncn([C@H]3CO[C@@H](CO)O3)c2n1,0,DB06619,__AMDOXOVIR,5767122,Terminated,NCT01737359,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Rosario, Santa Fe, Argentina|Research Site, Rosario, Santa Fe, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina|Research Site, Buenos Aires, Argentina",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,36.3375017967514,221.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.91,252.234,134.33,8.0,3.0,3.0,23.97,62.03,2.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0
CCOC(=O)Nc1ccc(NCc2ccc(F)cc2)nc1N,0,DB06623,__FLUPIRTINE,4481205,Terminated,NCT00623415,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,18 Years to 60 Years   (Adult),Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NeuroCure Clinical Research Center, Charité Berlin, Berlin, Germany|Carl-Thiem-Clinic Cottbus, Cottbus, Germany|University of Göttingen, Department of Neurology, Göttingen, Germany|University of Ulm, Department of Neurology, Ulm, Germany",C07D213/75,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,22.0,38.1445204213638,262.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.61,304.3195,89.27,5.0,3.0,2.0,31.37,85.49,6.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1
COc1nc(C)cnc1NS(=O)(=O)c1cccnc1-c1ccc(-c2nnco2)cc1,0,DB06629,__ZIBOTENTAN,6060475,Terminated,NCT00929162,PATIENTS WITH ADVANCED OVARIAN CANCER SENSITIVE TO PLATINUM-BASED CHEMOTHERAPY,Female,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Berlin, Germany|Research Site, Dresden, Germany|Research Site, Dusseldorf, Germany|Research Site, Essen, Germany|Research Site, Karlsruhe, Germany|Research Site, Kassel, Germany|Research Site, Kiel, Germany|Research Site, Lich, Germany|Research Site, Magdeburg, Germany|Research Site, Marburg, Germany|Research Site, Munchen, Germany|Research Site, Rostock, Germany|Research Site, Wiesbaden, Germany|Research Site, Milano, MI, Italy|Research Site, Perugia, PG, Italy|Research Site, Aviano, PN, Italy|Research Site, Campobasso, Italy|Research Site, Modena, Italy|Research Site, Napoli, Italy|Research Site, Roma, Italy",C07D401/14,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,16.8217006509373,43.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,424.44,132.99,8.0,1.0,4.0,42.05,118.89,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1
CN1CCC[C@H]1CCNC(=O)c1cn2c3cc4ccccc4cc3oc3c(N4CCC(c5cnccn5)C4)c(F)cc(c1=O)c32,0,DB06638,__QUARFLOXIN,,Terminated,NCT00955292,ADVANCED SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Scottsdale, Arizona, United States|San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.48,604.686,90.9,7.0,1.0,8.0,66.2,169.69,6.0,0.0,1.0,0.0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,1,1,1
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,0,DB06641,__PERIFOSINE,EP-1135193-B1,Terminated,NCT01002248,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","La Verne, California, United States|San Francisco, California, United States|San Pablo, California, United States|Aurora, Colorado, United States|Boulder, Colorado, United States|Colorado Springs, Colorado, United States|Denver, Colorado, United States|Lakewood, Colorado, United States|Littleton, Colorado, United States|Longmont, Colorado, United States|Parker, Colorado, United States|Pueblo, Colorado, United States|Thornton, Colorado, United States|Niles, Illinois, United States|Winfield, Illinois, United States|Baltimore, Maryland, United States|Columbia, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Morristown, New Jersey, United States|Great Neck, New York, United States|Fargo, North Dakota, United States|Portland, Oregon, United States|Tualatin, Oregon, United States|Kingsport, Tennessee, United States|Bedford, Texas, United States|Dallas, Texas, United States|Fort Worth, Texas, United States|Kerrville, Texas, United States|San Antonio, Texas, United States|San Antonio, Texas, United States|Tyler, Texas, United States|Ogden, Utah, United States|Christiansburg, Virginia, United States|Roanoke, Virginia, United States|Salem, Virginia, United States|Seattle, Washington, United States|Spokane, Washington, United States|Vancouver, Washington, United States|Milwaukee, Wisconsin, United States|Winnipeg, Manitoba, Canada|Montreal, Quebec, Canada|Montreal, Quebec, Canada|Quebec City, Quebec, Canada|Brno, Czech Republic, Czechia|Prague, Czech Republic, Czechia|Dublin 24, Ireland|Keryx / AOI Pharmaceuticals Investigative Site, Dublin 7, Ireland|Dublin 8, Ireland|Dublin 9, Ireland|Galway, Ireland|Limerick, Ireland|Sligo, Ireland|Tullamore, Ireland|Waterford, Ireland|Afula, Israel|Ashkelon, Israel|Beer Sheva, Israel|Haifa, Israel|Jerusalem, Israel|Jerusalem, Israel|Nahariya, Israel|Petah Tikva, Israel|Rehovot, Israel|Tel Aviv, Israel|Tel-Hashomer, Israel|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Seoul, Korea, Republic of|Moscow, Russian Federation|Moscow, Russian Federation|Saint Petersburg, Russian Federation|Saint Petersburg, Russian Federation|Samara, Russian Federation|Kosice, Slovak Republic, Slovakia|Badalona, Spain|Barcelona, Spain|Barcelona, Spain|Barcelona, Spain|La Laguna, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Madrid, Spain|Pamplona, Spain|Valencia, Spain|Zaragoza, Spain",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,34.7933222448099,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.82,461.668,58.59,2.0,0.0,1.0,58.14,142.15,20.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0
CCCCCCCCCCCCCCCCCCOP(=O)([O-])OC1CC[N+](C)(C)CC1,0,DB06641,__PERIFOSINE,EP-1135193-B1,Terminated,NCT00058214,ADENOCARCINOMA OF THE PROSTATE|RECURRENT PROSTATE CANCER|STAGE IIB PROSTATE CANCER|STAGE III PROSTATE CANCER|STAGE IV PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC Davis Cancer Center, Sacramento, California, United States",6,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,34.7933222448099,15.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.82,461.668,58.59,2.0,0.0,1.0,58.14,142.15,20.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0
COC[C@@H](c1ccc(C(F)(F)F)cc1)N1CCN(C2(C)CCN(C(=O)c3c(C)ncnc3C)CC2)C[C@@H]1C,0,DB06652,__VICRIVIROC,WO-2006096444-A2,Withdrawn,NCT00243568,HIV INFECTIONS|ACQUIRED IMMUNODEFICIENCY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,, A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,64.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.29,533.6288,61.8,6.0,0.0,4.0,56.3,142.64,7.0,0.0,1.0,0.0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,0,DB06685,__LAQUINIMOD,6077851,Terminated,NCT00745615,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,18 Years to 50 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Teva Investigational Site 382, Hradec Kralove 3, Czechia|Teva Investigational Site 380, Praha 2, Czechia|Teva Investigational Site 384, Praha 5- Motol, Czechia|Teva Investigational Site 681, Berlin, Germany|Teva Investigational Site 684, Erfurt, Germany|Teva Investigational Site 687, Hamburg, Germany|Teva Investigational Site 683, Mainz, Germany|Teva Investigational Site 686, Ulm, Germany|Teva Investigational Site 685, Wuerzburg, Germany|Teva Investigational Site 580, Debrecen, Hungary|Teva Investigational Site 581, Gyula, Hungary|Teva Investigational Site 583, Miskolc, Hungary|Teva Investigational Site 584, Veszprem, Hungary|Teva Investigational Site 981, Ramat -Gan, IL, Israel|Teva Investigational Site 982, Haifa, Israel|Teva Investigational Site 980, Jerusalem, Israel|Teva Investigational Site 483, Cagliari, Italy|Teva Investigational Site 484, Milano, Italy|Teva Investigational Site 486, Milano, Italy|Teva Investigational Site 488, Siena, Italy|Teva Investigational Site 281, Bydgoszcz, Poland|Teva Investigational Site 280, Katowice, Poland|Teva Investigational Site 285, Katowice, Poland|Teva Investigational Site 283, Lodz, Poland|Teva Investigational Site 284, Lublin, Poland|Teva Investigational Site 282, Wroclaw, Poland|Teva Investigational Site 186, Moscow, Russian Federation|Teva Investigational Site 187, Moscow, Russian Federation|Teva Investigational Site 188, Moscow, Russian Federation|Teva Investigational Site 189, Moscow, Russian Federation|Teva Investigational Site 180, Saint Petersburg, Russian Federation|Teva Investigational Site 181, St. Petersburg, Russian Federation|Teva Investigational Site 182, St. Petersburg, Russian Federation|Teva Investigational Site 184, St. Petersburg, Russian Federation|Teva Investigational Site 185, St. Petersburg, Russian Federation|Teva Investigational Site 782, Barakaldo, Spain|Teva Investigational Site 785, Barcelona, Spain|Teva Investigational Site 781, Bilbao, Spain|Teva Investigational Site 784, L'Hospitalet de Llobregat, Spain|Teva Investigational Site 780, Madrid, Spain|Teva Investigational Site 783, Sevilla, Spain|Teva Investigational Site 884, Liverpool, United Kingdom|Teva Investigational Site 882, London, United Kingdom|Teva Investigational Site 881, Sheffield, United Kingdom|Teva Investigational Site 883, Stoke on Trent, United Kingdom",C07D215/22,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,13.9633257356413,266.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,356.81,60.85,3.0,1.0,3.0,35.31,97.31,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,0,DB06685,__LAQUINIMOD,6077851,Terminated,NCT01047319,RELAPSING MULTIPLE SCLEROSIS,All,"Child, Adult, Older Adult",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Teva Investigational Site 1267, Homewood, Alabama, United States|Teva Investigational Site 1237, Phoenix, Arizona, United States|Teva Investigational Site 1279, Phoenix, Arizona, United States|Teva Investigational Site 1276, Tucson, Arizona, United States|Teva Investigational Site 1272, Pasadena, California, United States|Teva Investigational Site 1238, Sacramento, California, United States|Teva Investigational Site 1280, Aurora, Colorado, United States|Teva Investigational Site 1282, Sarasota, Florida, United States|Teva Investigational Site 1275, Atlanta, Georgia, United States|Teva Investigational Site 1250, Peoria, Illinois, United States|Teva Investigational Site 1260, Indianapolis, Indiana, United States|Teva Investigational Site 1263, Shreveport, Louisiana, United States|Teva Investigational Site 1269, Baltimore, Maryland, United States|Teva Investigational Site 1273, Albany, New York, United States|Teva Investigational Site 1264, Amherst, New York, United States|Teva Investigational Site 1261, Akron, Ohio, United States|Teva Investigational Site 1245, Cleveland, Ohio, United States|Teva Investigational Site 1247, Columbus, Ohio, United States|Teva Investigational Site 1244, Portland, Oregon, United States|Teva Investigational Site 1281, Nashville, Tennessee, United States|Teva Investigational Site 1270, Roanoke, Virginia, United States|Teva Investigational Site 1253, Tacoma, Washington, United States|Teva Investigational Site 5914, Pleven, Bulgaria|Teva Investigational Site 5915, Pleven, Bulgaria|Teva Investigational Site 5917, Plovdiv, Bulgaria|Teva Investigational Site 4212, Ruse, Bulgaria|Teva Investigational Site 5916, Shumen, Bulgaria|Teva Investigational Site 5920, Sofia, Bulgaria|Teva Investigational Site 5907, Sofia, Bulgaria|Teva Investigational Site 5910, Sofia, Bulgaria|Teva Investigational Site 5909, Sofia, Bulgaria|Teva Investigational Site 5919, Sofia, Bulgaria|Teva Investigational Site 5906, Sofia, Bulgaria|Teva Investigational Site 5908, Sofia, Bulgaria|Teva Investigational Site 5911, Sofia, Bulgaria|Teva Investigational Site 5912, Sofia, Bulgaria|Teva Investigational Site 5918, Stara Zagora, Bulgaria|Teva Investigational Site 5913, Varna, Bulgaria|Teva Investigational Site 4211, Veliko Tarnovo, Bulgaria|Teva Investigational Site 6003, Osijek, Croatia|Teva Investigational Site 6005, Varazdin, Croatia|Teva Investigational Site 6001, Zagreb, Croatia|Teva Investigational Site 6002, Zagreb, Croatia|Teva Investigational Site 6006, Zagreb, Croatia|Teva Investigational Site 5419, Olomouc, Czechia|Teva Investigational Site 5418, Praha 2, Czechia|Teva Investigational Site 5420, Praha 5- Motol, Czechia|Teva Investigational Site 5421, Teplice, Czechia|Teva Investigational Site 5508, Kohtla-Jarve, Estonia|Teva Investigational Site 5507, Tallinn, Estonia|Teva Investigational Site 5509, Tartu, Estonia|Teva Investigational Site 8102, Tbilisi, Georgia|Teva Investigational Site 8104, Tbilisi, Georgia|Teva Investigational Site 8103, Tbilisi, Georgia|Teva Investigational Site 6703, Berlin, Germany|Teva Investigational Site 6402, Berlin, Germany|Teva Investigational Site 6400, Ulm, Germany|Teva Investigational Site 8041, Jerusalem, Israel|Teva Investigational Site 8040, Ramat Gan, Israel|Teva Investigational Site 3056, Bologna, Italy|Teva Investigational Site 3053, Cefalu, Italy|Teva Investigational Site 3054, Chieti, Italy|Teva Investigational Site 3061, Empoli, Italy|Teva Investigational Site 3049, Firenze, Italy|Teva Investigational Site 3055, Napoli, Italy|Teva Investigational Site 3048, Rome, Italy|Teva Investigational Site 3052, Rome, Italy|Teva Investigational Site 3050, Rome, Italy|Teva Investigational Site 5708, Kaunas, Lithuania|Teva Investigational Site 5707, Siauliai, Lithuania|Teva Investigational Site 6500, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 6501, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 6502, Skopje, Macedonia, The Former Yugoslav Republic of|Teva Investigational Site 5337, Bialystok, Poland|Teva Investigational Site 5329, Gdansk, Poland|Teva Investigational Site 5338, Gdansk, Poland|Teva Investigational Site 6602, Gorzow Wielkopolski, Poland|Teva Investigational Site 5333, Grodzisk Mazowiecki, Poland|Teva Investigational Site 5334, Katowice, Poland|Teva Investigational Site 5339, Katowice, Poland|Teva Investigational Site 6603, Kielce, Poland|Teva Investigational Site 4213, Konskie, Poland|Teva Investigational Site 5332, Koscierzyna, Poland|Teva Investigational Site 5345, Krakow, Poland|Teva Investigational Site 5328, Lodz, Poland|Teva Investigational Site 5330, Olsztyn, Poland|Teva Investigational Site 5331, Szczecin, Poland|Teva Investigational Site 5336, Warsaw, Poland|Teva Investigational Site 5340, Warszawa, Poland|Teva Investigational Site 5341, Warszawa, Poland|Teva Investigational Site 5335, Wroclaw, Poland|Teva Investigational Site 5235, Balotesti, Romania|Teva Investigational Site 5218, Bucharest, Romania|Teva Investigational Site 5214, Bucuresti, Romania|Teva Investigational Site 5213, Bucuresti, Romania|Teva Investigational Site 5215, Cluj-Napoca, Romania|Teva Investigational Site 5217, Constanta, Romania|Teva Investigational Site 8209, Craiova, Romania|Teva Investigational Site 5216, Iasi, Romania|Teva Investigational Site 5219, Sibiu, Romania|Teva Investigational Site 5043, Barnaul, Russian Federation|Teva Investigational Site 5033, Moscow, Russian Federation|Teva Investigational Site 5041, Moscow, Russian Federation|Teva Investigational Site 5032, Moscow, Russian Federation|Teva Investigational Site 5038, Novosibirsk, Russian Federation|Teva Investigational Site 5042, Novosibirsk, Russian Federation|Teva Investigational Site 5035, Saint Petersburg, Russian Federation|Teva Investigational Site 5037, Samara, Russian Federation|Teva Investigational Site 5036, St. Petersburg, Russian Federation|Teva Investigational Site 5034, St. Petersburg, Russian Federation|Teva Investigational Site 5044, Ufa, Russian Federation|Teva Investigational Site 6200, Bratislava, Slovakia|Teva Investigational Site 6201, Bratislava, Slovakia|Teva Investigational Site 6202, Nitra, Slovakia|Teva Investigational Site 6203, Zilina, Slovakia|Teva Investigational Site 9007, Bloemfontein, South Africa|Teva Investigational Site 9001, Cape Town, South Africa|Teva Investigational Site 9004, Johannesburg, South Africa|Teva Investigational Site 9003, Parktown- Johannesburg, South Africa|Teva Investigational Site 9008, Pietermaritzburg, South Africa|Teva Investigational Site 9005, Pretoria, South Africa|Teva Investigational Site 9006, Rosebank, South Africa|Teva Investigational Site 3147, Barcelona, Spain|Teva Investigational Site 3154, Figueres-Girona, Spain|Teva Investigational Site 3149, L'Hospitalet de Llobregat, Spain|Teva Investigational Site 3152, Madrid, Spain|Teva Investigational Site 3151, Malaga, Spain|Teva Investigational Site 3148, Sevilla, Spain|Teva Investigational Site 3153, Tortosa-Tarragona, Spain|Teva Investigational Site 6503, Chernihiv, Ukraine|Teva Investigational Site 5823, Chernivtsi, Ukraine|Teva Investigational Site 5811, Dnipropetrovsk, Ukraine|Teva Investigational Site 5812, Donetsk, Ukraine|Teva Investigational Site 5814, Ivano-Frankivsk, Ukraine|Teva Investigational Site 5817, Kharkiv, Ukraine|Teva Investigational Site 5818, Kharkiv, Ukraine|Teva Investigational Site 5815, Kharkiv, Ukraine|Teva Investigational Site 5822, Kyiv, Ukraine|Teva Investigational Site 5809, Lviv, Ukraine|Teva Investigational Site 5820, Odessa, Ukraine|Teva Investigational Site 5821, Poltava, Ukraine|Teva Investigational Site 5810, Vinnytsya, Ukraine|Teva Investigational Site 5819, Zaporizhzhya, Ukraine|Teva Investigational Site 5816, Zaporizhzhya, Ukraine",C07D215/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,40.0,13.9633257356413,266.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,356.81,60.85,3.0,1.0,3.0,35.31,97.31,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1,0,DB06685,__LAQUINIMOD,6077851,Terminated,,RELAPSING MULTIPLE SCLEROSIS (RMS),,,,,"FISABIO, Elche, Alicante, Spain",C07D215/22,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,40.0,13.9633257356413,266.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.77,356.81,60.85,3.0,1.0,3.0,35.31,97.31,3.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0
[Al+3].[OH-].[OH-].[OH-],0,DB06723,__ALUMINUM_HYDROXIDE,,Withdrawn,NCT00000809,HIV INFECTIONS|HIV SERONEGATIVITY,All,up to 3 Days   (Child),NIH,Primary Purpose: Prevention,,,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.45,78.0036,0.0,0.0,0.0,0.0,1.78,0.0,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Oc1ccc([C@@H]2Oc3ccc(O)cc3[C@@H]3CCC[C@@H]32)cc1,0,DB07933,__ERTEBEREL,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.85,282.3337,49.69,3.0,2.0,4.0,30.27,80.5,1.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1
CNC(=O)c1ccc(C)c(-n2c(C)cc(OCc3ccc(F)cc3F)c(Br)c2=O)c1,0,DB07941,__PH-797804,US-20040058964-A1,Withdrawn,,PAIN,,,,,"FISABIO, Elche, Alicante, Spain",C07D213/64,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,70.0,40.3786525390665,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.21,477.29900000000004,58.64,3.0,1.0,3.0,43.79,116.85,4.0,0.0,1.0,0.0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0
COc1ccc2c(OCc3nnc4ccc(-c5ccccc5)nn34)ccnc2c1,0,DB08079,__AMG-208,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.66,383.4027,74.43,6.0,0.0,5.0,40.72,119.54,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0
CCOCn1c(Cc2ccccc2)c(C(C)C)c(=O)[nH]c1=O,0,DB08188,__EMIVIRINE,5604209,Terminated,NCT00002418,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Primary Purpose: Treatment,"Pacific Oaks Med Group, Beverly Hills, California, United States|Univ of Colorado / Health Science Ctr, Denver, Colorado, United States|AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States|Brown Univ School of Medicine, Providence, Rhode Island, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States",7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,32.5920450111912,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.57,302.3682,58.64,3.0,1.0,2.0,32.87,85.41,6.0,0.0,1.0,0.0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0
Cn1cc(-c2ccncc2)c(-c2ccc(OCc3ccc4ccccc4n3)cc2)n1,0,DB08387,__MARDEPODECT,WO-2005120514-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.01,392.4525,52.83,4.0,0.0,5.0,43.9,127.18,5.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1
CC(C)c1nc(COC(N)=O)n(Cc2ccncc2)c1Sc1cc(Cl)cc(Cl)c1,0,DB08502,__CAPRAVIRINE,5910506,Suspended,NCT00004999,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: Double|Primary Purpose: Treatment,"Arizona Clinical Research Ctr Inc, Tucson, Arizona, United States|Univ of Southern California, Los Angeles, California, United States|Highland Gen Hosp / San Francisco Gen Hosp, Oakland, California, United States|ViRx Inc, Palm Springs, California, United States|Research & Treatment at the California Pacific Med Ctr, San Francisco, California, United States|Harbor - UCLA Med Ctr, Torrance, California, United States|IDC Research Initiative, Altamonte Springs, Florida, United States|Bach and Godofsky, Bradenton, Florida, United States|Community Health Care, Fort Lauderdale, Florida, United States|Univ of Florida, Jacksonville, Florida, United States|Univ of Miami School of Medicine, Miami, Florida, United States|South Shore Hosp, Miami, Florida, United States|Specialty Med Care Ctrs of South Florida Inc, Miami, Florida, United States|Orange County Health Dept, Orlando, Florida, United States|Larry Bush, Palm Springs, Florida, United States|Infectious Diseases Associates, Sarasota, Florida, United States|Infectious Disease Research Institute, Tampa, Florida, United States|Treasure Coast Infectious Disease Consultants, Vero Beach, Florida, United States|Polk County Health Dept, Winter Haven, Florida, United States|Sky Blue, Boise, Idaho, United States|Northwestern Univ Med Ctr, Chicago, Illinois, United States|The CORE Ctr, Chicago, Illinois, United States|Indiana Univ Infectious Disease Research Clinic, Indianapolis, Indiana, United States|Univ of Iowa, Iowa City, Iowa, United States|Univ of Kansas School of Medicine, Wichita, Kansas, United States|University of Louisville / ID Division, Louisville, Kentucky, United States|HIV Outpatient Clinics / LA State Univ Med Ctr, New Orleans, Louisiana, United States|Fenway Community Health Ctr, Boston, Massachusetts, United States|Hawthorne Med Associates / PAACA, New Bedford, Massachusetts, United States|Kansas City AIDS Research Consortium, Kansas City, Missouri, United States|Univ of Nebraska Medical Ctr, Omaha, Nebraska, United States|Paul Alessi, Cherry Hill, New Jersey, United States|VAMC New Jersey Healthcare System, East Orange, New Jersey, United States|St Mary's Hosp Family Treatment Ctr, Hoboken, New Jersey, United States|Univ of Med & Dentistry of New Jersey, Newark, New Jersey, United States|Bentley-Salick Medical Practice PC, New York, New York, United States|Univ of Rochester Med Ctr, Rochester, New York, United States|Univ of Cincinnati / Holmes Hosp, Cincinnati, Ohio, United States|Med Univ of South Carolina, Charleston, South Carolina, United States|Julio Arroyo, West Columbia, South Carolina, United States|Southwest Infectious Diseases Associates, Dallas, Texas, United States|Univ TX Galveston Med Branch, Galveston, Texas, United States|Joseph C Gathe, Houston, Texas, United States|Thomas Street Clinic, Houston, Texas, United States|Hampton Roads Med Specialists, Hampton, Virginia, United States|Wisconsin AIDS Research Consortium, Milwaukee, Wisconsin, United States|Canadian HIV Trials Network, Vancouver, British Columbia, Canada|QEII Health Science Centre, Halifax, Nova Scotia, Canada|Sunnybrook Health Science Centre, Toronto, Ontario, Canada|Montreal Chest Institute, Montreal, Quebec, Canada|Immunity Care and Research Inc, Santo Domingo, Dominican Republic|Univ of Puerto Rico School of Med, Rio Piedras, Puerto Rico|Clinical Research Puerto Rico Inc, San Juan, Puerto Rico",C07D401/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.0,24.279759337974,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.76,451.369,83.03,3.0,1.0,3.0,45.41,115.68,8.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1
Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1,0,DB08639,__DAPIVIRINE,EP-0945443-A1,Withdrawn,NCT01242579,HIV INFECTION,Female,18 Years to 40 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,A61P31/12,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,52.6663791864309,27.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,329.3984,73.63,5.0,2.0,3.0,37.16,100.8,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1,0,DB08639,__DAPIVIRINE,EP-0945443-A1,Withdrawn,NCT03044379,HIV 1 INFECTION,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",A61P31/12,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,52.6663791864309,27.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,329.3984,73.63,5.0,2.0,3.0,37.16,100.8,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0
Cc1cc(C)c(Nc2ccnc(Nc3ccc(C#N)cc3)n2)c(C)c1,0,DB08639,__DAPIVIRINE,EP-0945443-A1,Withdrawn,NCT03074786,HIV-1 INFECTION,Female,"16 Years to 21 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CAPRISA, eThekwini Clinical Research Site, Durban, KwaZulu-Natal, South Africa",A61P31/12,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,52.6663791864309,27.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.12,329.3984,73.63,5.0,2.0,3.0,37.16,100.8,4.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0
NCCc1c[nH]c2ccccc12,0,DB08653,__TRYPTAMINE,3930948,Terminated,,QUALITY OF LIFE,,,,,"FISABIO, Elche, Alicante, Spain",C12N9/88,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.0,17.281669028111402,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.21,160.2157,41.81,1.0,2.0,2.0,18.34,50.37,2.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Terminated,NCT01944943,DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN LYMPHOMA|PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA|CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hôpital Henri MONDOR, Creteil, France|CHU Dijon _ Hôpital d'Enfants, Dijon, France|CHRU de Lille _ Hôpital Huriez, Lille, France|CHU de Nantes _ Hôtel Dieu, Nantes, France|Hôpital Saint-Louis, Paris, France|CHU Haut Lévèque, Pessac, France|CH Lyon Sud, Pierre-Bénite, France|CHU Pontchaillou, Rennes, France|Centre Henri Becquerel, Rouen, France|Hôpital René Huguenin _ Institut Curie, Saint-Cloud, France",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1,0,DB08828,__VISMODEGIB,7888364,Terminated,NCT02337517,CHRONIC GRAFT VERSUS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",C07D417/12,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,55.0,65.4469290950532,8.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.22,421.29699999999997,76.13,4.0,1.0,3.0,39.49,107.81,4.0,0.0,1.0,0.0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C,0,DB08834,__TAUROURSODEOXYCHOLIC_ACID,5260074,Terminated,NCT03878654,ASTHMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vermont Lung Center, Colchester, Vermont, United States",A61K9/5073,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,16.591716462350302,243.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.38,499.71,123.93,6.0,4.0,4.0,56.75,130.68,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,1,0,0
C=C1C[C@@H]2CC[C@@]34C[C@@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,DB08871,__ERIBULIN,6214865,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",C07D493/22,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,21.8156430316844,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,729.908,146.39,12.0,2.0,9.0,82.15,186.0,4.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
NC[C@H](CC(=O)O)c1ccc(Cl)cc1,0,DB08891,__ARBACLOFEN,WO-2010017504-A1,Withdrawn,NCT02869425,MULTIPLE SCLEROSIS|SPERM,Male,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Advance Medical Pain Management & Research Clinic, Miami, Florida, United States|Meridien Research, Tampa, Florida, United States",C07C269/04,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.11,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
NC[C@H](CC(=O)O)c1ccc(Cl)cc1,0,DB08891,__ARBACLOFEN,WO-2010017504-A1,Withdrawn,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C269/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.82,213.66099999999997,63.32,3.0,2.0,1.0,21.11,54.83,4.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0
Cc1ccc(C(=O)Nc2ccc(CN3CCN(C)CC3)c(C(F)(F)F)c2)cc1C#Cc1cnc2cccnn12,0,DB08901,__PONATINIB,8114874,Terminated,NCT01650805,CHRONIC MYELOID LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"US Oncology - Providence Health System, Site #167, Burbank, California, United States|UCLA Department of Medicine, Site #027, Los Angeles, California, United States|Bay Area Cancer Research Group, Site #156, Pleasant Hill, California, United States|Bay Area Cancer Research Group, Site #157, Pleasant Hill, California, United States|Rocky Mountain Cancer Centers, Site #191, Boulder, Colorado, United States|Cancer Center of Central Connecticut, Site #147, Southington, Connecticut, United States|Christiana Care Health Services, Site #155, Newark, Delaware, United States|University Cancer Institute, Site #149, Boynton Beach, Florida, United States|Florida Cancer Specialists, Site #180, Fort Meyers, Florida, United States|Florida Cancer Specialists, Site #179, St. Petersburg, Florida, United States|Emory University, Site #058, Atlanta, Georgia, United States|John H. Stroger, Jr. Hospital of Cook County, Site #192, Chicago, Illinois, United States|University of Chicago, Site #001, Chicago, Illinois, United States|Loyola University Chicago, Site #054, Maywood, Illinois, United States|Franciscan St. Francis Health, Site #138, Indianapolis, Indiana, United States|University of Iowa Hospitals and Clinics, Site #050, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Associates, Site #198, Sioux City, Iowa, United States|US Oncology - Cancer Center of Kansas, Site #168, Wichita, Kansas, United States|Willis-Knighton Cancer Center, Site #196, Shreveport, Louisiana, United States|University of Maryland, Greenebaum Cancer Center, Site #040, Baltimore, Maryland, United States|Greater Baltimore Medical Center, Site #140, Baltimore, Maryland, United States|St. Agnes Healthcare, Site #185, Baltimore, Maryland, United States|Massachusetts General Hospital, Site #047, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Site #008, Boston, Massachusetts, United States|University of Massachusetts Worcester, Site #152, Worcester, Massachusetts, United States|University of Michigan Medical Center, Site #011, Ann Arbor, Michigan, United States|Providence Cancer Institute, Site #197, Southfield, Michigan, United States|Mayo Clinic, Site #044, Rochester, Minnesota, United States|Oncology Research Park Nicollet Institute, Site #195, St. Louis Park, Minnesota, United States|Saint Luke's Hospital, Site #162, Kansas City, Missouri, United States|Mercy Clinic - Cancer & Hematology, Site #151, Springfield, Missouri, United States|Nebraska Hematology-Oncology, P.C., Site # 133, Lincoln, Nebraska, United States|US Oncology - Comprehensive Cancer Center of Nevada, Site #169, Las Vegas, Nevada, United States|John Theurer Cancer Center, Site #128, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Site #166, Albuquerque, New Mexico, United States|Maimonides Cancer Center, Site #177, Brooklyn, New York, United States|Winthrop University Hospital, Site #153, Mineola, New York, United States|Beth Israel Medical Center, Site #145, New York, New York, United States|Mount Sinai School of Medicine, Site #189, New York, New York, United States|Memorial Sloan-Kettering Cancer Center, Site #078, New York, New York, United States|Weill Cornell Medical College, Site #006, New York, New York, United States|New York Medical College, Site #146, Valhalla, New York, United States|Southeastern Medical Oncology Center, Site #188, Goldsboro, North Carolina, United States|Signal Point Clinical Research Center, Site #139, Middletown, Ohio, United States|University of Oklahoma, Site #028, Oklahoma City, Oklahoma, United States|Providence Cancer Center Oncology and Hematology Care Eastside, Site #194, Portland, Oregon, United States|Kaiser Permanente Northwest, Site #200, Portland, Oregon, United States|Oregon Health & Science University, Site #048, Portland, Oregon, United States|Gettysburg Cancer Center, Site #160, Gettysburg, Pennsylvania, United States|Western Pennsylvania Hospital, Site #159, Pittsburgh, Pennsylvania, United States|Medical University of South Carolina, Site #148, Charleston, South Carolina, United States|Carolina Hematology Oncology, Site #143, Sumter, South Carolina, United States|Associates in Oncology & Hematology, Site #186, Chattanooga, Tennessee, United States|Sarah Cannon Research Institute, Site #076, Nashville, Tennessee, United States|US Oncology - Texas Oncology Austin, Site #172, Austin, Texas, United States|US Oncology - Texas Oncology Dallas, Site #171, Dallas, Texas, United States|University of Texas Southwestern Medical Center, Site #178, Dallas, Texas, United States|Baylor College of Medicine, Site #063, Houston, Texas, United States|US Oncology - Texas Oncology Midland, Site #173, Midland, Texas, United States|US Oncology - Cancer Care Center of South Texas, Site #170, San Antonio, Texas, United States|Huntsman Cancer Institute, Site #043, Salt Lake City, Utah, United States|VCU Massey Cancer Center, Dalton Oncology Clinic, Site #069, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Site #100, Seattle, Washington, United States|US Oncology - Northwest Cancer Specialists, Site #174, Vancouver, Washington, United States|West Virginia University, Site #154, Morgantown, West Virginia, United States|Green Bay Oncology, Ltd. / St. Mary's Hospital Medical Center, Site #193, Green Bay, Wisconsin, United States|University of Wisconsin, Site #030, Madison, Wisconsin, United States|Canberra Hospital, Site #971, Garran, Australian Capital Territory, Australia|Royal North Shore Hospital, Site #941, Sydney, New South Wales, Australia|Royal Adelaide Hospital, Site #951, Adelaide, South Australia, Australia|The Peter MacCallum Cancer Center, Site #950, East Melbourne, Victoria, Australia|Box Hill Hospital, Site #940, Melbourne, Victoria, Australia|Royal Perth Hospital, Site #972, Perth, Western Australia, Australia|Medizinische Universitat Wien / AKH, Universitatsklinik fur Inniere Medizin I, Site #561, Wien, Austria|UZ Brussel - Department Hematology, Site #544, Brussel, Belgium|Clinique Universitaire de Saint-Luc, Department of Haematology, Site #508, Bruxelles, Belgium|UZ Gent - Department Hematology, Site #756, Gent, Belgium|UZ Gasthuisberg - Department of Hematology, Site #700, Leuven, Belgium|University Health Network, Princess Margaret Hospital, Site #083, Toronto, Ontario, Canada|Jewish General Hospital, Site #129, Montreal, Quebec, Canada|Fakultni nemocnice Brno, Interni hematologicka a onkologicka klinika, Site #514, Brno, Czech Republic|FN Hradec Kralove, Site #517, Hradec Kralove, Czech Republic|Fakultni nemocnice Olomouc, Hematoonkologicka klinika, Site #515, Olomouc, Czech Republic|Ustav hematologie a krevni transfuse, Site #516, Praha, Czech Republic|Helsinki University Central Hospital, Site #542, Helsinki, Finland|Institut Bergonie, Site #772, Bordeaux, France|CHRU de Brest, Hopital Morvan, Site #523, Brest, France|CHU Henri Mondor, Site #520, Creteil Cedex, France|Centre Hospitalier de Versailles, Site #958, Le Chesnay Cedex, France|Hospital Claude Huriez, Site #952, Lille Cedex, France|Institut Paoli Calmette, Site #519, Marseille, France|CHU de Brabois, Site #953, Nancy Cedex, France|CHU de Nantes, Site #521, Nantes Cedex, France|Service Hematologie - Hospital Archet I, Site #509, Nice Cedex, France|Hopital Saint-Louis, Site #957, Paris, France|Hospital Saint Antoine, Site #518, Paris, France|Centre Hospitalier Lyon Sud, Site #956, Pierre Benite, France|CHU de Poitiers, Site #954, Poitiers, France|CHU Purpan, Site #955, Toulouse Cedex, France|Universitätsklinikum Aachen, AÖR, Site #513, Aachen, Germany|Charite - Universitatsmedizin Berlin, Site #701, Berlin, Germany|Universitatsklinikum Carl Gustav Carus an der TU Dresden, Site #526, Dresden, Germany|Universitatsklinikum Freiburg, Site #527, Freiburg, Germany|Universitatsklinikum Hamburg-Eppendorf, Site #524, Hamburg, Germany|Universitatsklinikum Jena, Site #946, Jena, Germany|Universitatsklinikum Koln-AOR, Site #525, Koln, Germany|Universitat Heidelberg, CML - Studienzentrale III. Medizinische Klinik, Site #947, Mannheim, Germany|Klinikum rechts der Isar, Site #949, Munchen, Germany|Prince of Wales Hospital, Site #974, Hong Kong, Hong Kong|Queen Mary Hospital, Site #973, Hong Kong, Hong Kong|Unita Operativa di Ematologia con Trapianto, Site #529, Bari, Italy|Istituto di Ematologia ""L. & A. Seragnoli"", Site #959, Bologna, Italy|A.O. Universitaria Policlinico Vittorio Emanuele di Catania, Site #530, Catania, Italy|Clinica Ematologica, Site #528, Genova, Italy|Ospedale Niguarda Ca' Granda di Milano, Site #531, Milan, Italy|S.C. Ematologia, Site #960, Modena, Italy|San Gerardo Hospital, Site #961, Monza, Italy|U.O.C Ematologia con trapianto di midollo osseo, Site #560, Napoli, Italy|Universita Federico II, Site #510, Napoli, Italy|SCDU Medicina Interna II - Indirizzo Ematologico, Site #785, Orbassano, Italy|Dipartimento di Biotecnologie Cellulari ed Ematologia Universita La Sapienza - Policlinico Umberto I, Site #511, Rome, Italy|U.O. di Ematologia - Ospedale S. Eugenio, Site #962, Rome, Italy|The Catholic University of Korea, Site #938, Seocho-gu, Seoul, Korea, Republic of|VU Medical Centre - Department Haematology, Site #948, Amsterdam, Netherlands|Auckland City Hospital, Site #921, Grafton, Auckland, New Zealand|Christchurch Hospital, Site #922, Christchurch, New Zealand|Waikato Hospital, Site #977, Hamilton, New Zealand|North Shore Hospital, Site #976, Takapuna, New Zealand|Klinika Hematologii i Transplantologii, Uniwersyteckie Centrum Medyczne, Site #548, Gdansk, Poland|Malopolskie Centrum Medyczne, Site #546, Krakow, Poland|Klinika Hematologii Wojewodzkiego Szpitala Specjalistycznego, Site #550, Lodz, Poland|Oddzial Hematologii, Site #551, Rzeszow, Poland|Katedra i Klinika Hematologii, Site #547, Wroclaw, Poland|Instituto Portugues de Oncologia, Site #545, Lisboa, Portugal|Fundacion de Investigacion de Diego, Site #199, San Juan, Puerto Rico|Singapore General Hospital, Site #939, Singapore, Singapore|Narodny onkologicky ustav, Site #532, Bratislava, Slovakia|Univerzitna nemocnica Martin, Site #533, Martin, Slovakia|Complejo Hospitalario Universitario A Coruna, Hospital ""Teresa Herrera,"" Site #554, A Coruna, Spain|Hospital Universitari Germans Trias i Pujol, Site #512, Badalona, Spain|Hospital Clinic, Site #963, Barcelona, Spain|Institut Catala d' Oncologia de Girona, S. de Hematologia Clinica, Site #734, Girona, Spain|Hospital Universitari Son Espases, Site #553, Islas Baleares, Spain|Hospital Universitario La Princesa, Site #555, Madrid, Spain|Hospital Gregorio Maranon, Site #536, Madrid, Spain|H.U. Ramon y Cajal, Site #538, Madrid, Spain|Hospital Universitario 12 de Octubre, Site #537, Madrid, Spain|Hospital La Paz, Site #966, Madrid, Spain|Hospital Universitario Central de Asturias, Site #535, Oviedo, Spain|Hospital Universitario de Salamanca, Site #965, Salamanca, Spain|Hospital Clinico Universitario de Valencia, Site #964, Valencia, Spain|Skane University Hospital, Site #944, Lund, Sweden|Karolinska University Hospital Huddinge, Site #534, Stockholm, Sweden|Karolinska University Hospital Solna, Site #763, Stockholm, Sweden|Uppsala University Hospital, Site #945, Uppsala, Sweden|Kantonsspital Aarau, Site #541, Aarau, Switzerland|Kantonsspital St. Gallen, Site #707, St Gallen, Switzerland|Kaohsiung Chang Gung Memorial Hospital, Site #980, Kaohsiung, Taiwan|China Medical University Hospital, Site #978, Taiching, Taiwan|National Taiwan University Hospital, Site #979, Taipei, Taiwan|Western General Hospital, Site #556, Edinburgh, United Kingdom|Kent and Medway Cancer Research Network, Site #558, Gillingham, United Kingdom|University of Glasgow, Site #797, Glasgow, United Kingdom|St. James University Hospital, Site #540, Leeds, United Kingdom|Royal Liverpool University Hospital, Site #969, Liverpool, United Kingdom|Hammersmith Hospital, Site #967, London, United Kingdom|Newcastle University, Site #970, Newcastle, United Kingdom|Norfolk & Norwich University Hospital Foundation Trust, Site #557, Norwich, United Kingdom|Nottingham University Hospitals NHS Trust, Site #968, Nottingham, United Kingdom|Oxford University Hospitals NHS Trust, Site #543, Oxford, United Kingdom",C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,61.76718207766071,6.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.94,532.5595,65.77,5.0,1.0,5.0,55.69,152.63,7.0,0.0,1.0,0.0,1,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,1,1,1,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1
CC(=O)Nc1cccc(-n2c(=O)n(C3CC3)c(=O)c3c(Nc4ccc(I)cc4F)n(C)c(=O)c(C)c32)c1,0,DB08911,__TRAMETINIB,7378423,Withdrawn,NCT02140840,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States",C07C275/50,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,26.0,35.548984578738704,23.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.45,615.3948,102.06,5.0,2.0,5.0,55.43,156.38,5.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,0
CN1CCN(C(c2ccccc2)c2ccc(Cl)cc2)CC1,0,DB08936,__CHLORCYCLIZINE,4000302,Withdrawn,,SEASONAL ALLERGIC RHINITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,18.0,20.4357379001622,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.16,300.82599999999996,6.48,2.0,0.0,3.0,33.89,89.74,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0
CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,0,DB09031,__MILTEFOSINE,,Terminated,NCT01170949,CHRONIC URTICARIA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Charité University, Berlin, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,407.57599999999996,58.59,2.0,0.0,0.0,50.59,125.51,20.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01980875,CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sansum Clinic, Santa Barbara, California, United States|UCLA Jonsson Comprehensive Cancer Center, Santa Monica, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Saint Francis Cancer Center, Greenville, South Carolina, United States|St Vincent Hospital, Sydney, Darlinghurst, New South Wales, Australia|UZ Ghent- hematology, Ghent, Belgium|Royal Victoria Regional Health Centre - Simcoe Musk, Barrie, Ontario, Canada|Centre Hospitalier du Mans, Le Mans, France|Centre Hospitalier de Perpignan, Perpignan Cedex 9, France|Szpital Specjalistyczny w Brzozowie, Oddzial Hematologii Onkologicznej, Brzozow, Podkarpackie, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|Wojewódzki Szpital Specjalistyczny w Legnicy, Legnica, Poland|Wojewodzki Szpital Specjalistyczny, im. M. Kopernika Klinika Hematologii Uniwersytetu Medycznego, Lodz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii, Olsztyn, Poland|Hospital Universitario de Salamanca, Salamanca, Spain|East Kent Hospitals University NHS Foundation Trust, Canterbury, Kent, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01732926,INDOLENT NON-HODGKIN'S LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Clearview Cancer Institute, Huntsville, Alabama, United States|Ironwood Cancer and Research Center, Chandler, Arizona, United States|Comprehensive Blood and Cancer Center (Bakersfield), Bakersfield, California, United States|Saint Jude Heritage Healthcare (TORI), Fullerton, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Cancer Care Associates, Redondo Beach, California, United States|San Luis Obispo Oncology and Hematology, San Luis Obispo, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Central Coast Medical Oncology Group, Santa Maria, California, United States|St Joseph Heritage Healthcare System, Santa Rosa, California, United States|Kaiser Permanente Vallejo Medical Center, Vallejo, California, United States|Sylvester Comprehensive Cancer Center/UMHC, Deerfield Beach, Florida, United States|Cancer Specialists of North Florida, Jacksonville, Florida, United States|Northwest Georgia Oncology Centers, PC, Marietta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Joliet Oncology Hematology Associates Ltd., Joliet, Illinois, United States|Cancer Center of Kansas, Wichita, Kansas, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|North Shore Hematology/Oncology Associates, East Setauket, New York, United States|Weill Cornell Medical College, New York, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Bon Secours Saint Francis Hospital, Greenville, South Carolina, United States|Texas Oncology, P.A., Bedford, Texas, United States|Charles A. Sammons Cancer Center, Dallas, Texas, United States|Texas Oncology, P.A., Denton, Texas, United States|Brooke Army Medical Center, Fort Sam Houston, Texas, United States|Texas Oncology, P.A., Harlingen, Texas, United States|Texas Oncology, P.A., Weslaco, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|Northwest Medical Specialists, Tacoma, Washington, United States|Aurora BayCare Medical Center, Green Bay, Wisconsin, United States|Froedtert Hospital and Medical College of Wisconsin, Milwaukee, Wisconsin, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Haematology and Oncology Clinics of Australia Gold Coast, South Brisbane, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Adelaide Cancer Centre, Kurralta Park, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Saint Vincent's Hospital, Fitzroy, Victoria, Australia|Western Hospital, Footscray, Victoria, Australia|Royal Perth Hospital, Perth, Western Australia, Australia|Tom Baker Cancer Center, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Fraser Clinical Trials, Inc., New Westminster, British Columbia, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Queen Elizabeth II Health Sciences Centre, Centre for Clinical Research, Halifax, Nova Scotia, Canada|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Hôpital Charles Lemoyne, Greenfield Park, Quebec, Canada|McGill University Health Centre, Montréal, Quebec, Canada|Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, Quebec, Canada|Centre Hospitalier Affilie Universitaire de Quebec, Quebec, Canada|CancerCare Manitoba, Winnipeg, Canada|Fakultní Nemocnice Ostrava, Ostrava - Poruba, Severomoravsky KRAJ, Czechia|Fakultní nemocnice Brno, Brno, Czechia|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|CHR Metz, Metz Cedex 03, Alsace, France|Centre Hospitalier Universitaire de Strasbourg - Hôpital Hautepierre, Strasbourg Cedex, Alsace, France|Institut Bergonié, Bordeaux Cedex, Aquitaine, France|Centre Henri-Becquerel, Rouen Cedex 1, Haute-normandie, France|Hôpital Necker-Enfants Malades, Paris, Ile-de-france, France|Centre Jean Bernard, Le Mans, PAYS DE LA Loire, France|Centre Hospitalier Lyon Sud, Pierre Bénite Cedex, Rhone-alpes, France|Centre Hospitalier Universitaire Brest, Brest Cedex, France|Centre Hospitalier de Dunkerque, Dunkerque, France|Centre Hospitalier Départmental La Roche sur Yon, La Roche sur Yon, France|Centre Léon Bérard, Lyon Cedex 08, France|Institut Paoli Calmettes, Marseille, France|Hôpital Hôtel-Dieu, Nantes cedex 1, France|Centre Hospitalier Universitaire de Poitiers, Poitiers Cedex, France|Centre Hospitalier Régional et Universitaire - Hôpital Bretonneau, Tours, France|Institut Gustave Roussy, Villejuif, France|Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH, Villingen-Schwenningen, Baden-wuerttemberg, Germany|Gemeinschaftspraxis Dres. Söling Und Siehl, Kassel, Hessen, Germany|Vivantes Klinikum am Urban, Berlin, Germany|Charite - Campus Virchow, Berlin, Germany|Klinikum der Ludwig-Maximilians-Universität München, München, Germany|Barzilai Medical Center, Ashkelon, Israel|Soroka University Medical Center, Beer Sheva, Israel|Rambam Health Corp., Haifa, Israel|Hadassah Medical Organization, Ein Kerem, Jerusalem, Israel|Centro di Riferimento Oncologico di Aviano, Aviano, Italy|Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi, Bologna, Italy|Spedali Civili Di Brescia Azienda Ospedaliera, Brescia, Italy|IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Ospedale San Raffaele-IRCCS, Milano, Italy|Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milano, Italy|Azienda Ospedaliero Universitaria (AOU) ""Maggiore della Carita"" di Novara, Novara, Italy|Azienda Ospedaliera Ospedali Riuniti Marche Nord, Pesaro, Italy|Azienda Unità Sanitaria Locale di Piacenza-Ospedale Guglielmo da Saliceto, Piacenza, Italy|Azienda Ospedaliera Universitaria Senese - Policlinico S. Maria alle Scotte, Siena, Italy|Azienda Ospedaliera Città della Salute e della Scienza di Torino, Torino, Italy|Dong-A University Medical Center, Busan, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Uniwersyteckie Centrum Kliniczne, Gdansk, Poland|Malopolskie Centrum Medyczne S.C., Kraków, Poland|Szpital Kliniczny nr 1, Katedra i Klinika Hematoonkologii i Transplantacji Szpiku, Lublin, Poland|Wojewódzki Szpital Specjalistyczny im. Mikolaja Kopernika w Lodzi, Lódz, Poland|Samodzielny Publiczny Zaklad Opieki Zdrowotnej Ministerstwa Spraw Wewnetrznych z Warminsko-Mazurskim, Olsztyn, Poland|Wojewódzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku, Slupsk, Poland|Centralny Szpital Kliniczny MSW w Warszawie, Warszawa, Poland|Instytut Hematologii i Transfuzjologii, Warszawa, Poland|Centrum Onkologii i Hipertermii, Warszawa, Poland|Sverdlovsk Regional Clinical Hospital #1, Ekaterinburg, Russian Federation|Central City Hospital # 7, Ekaterinburg, Russian Federation|N. N. Blokhin Russian Cancer Research Center, Moscow, Russian Federation|Nizhny Novgorod Regional Clinical Hospital n.a. N.A. Semashko, Nizhniy Novgorod, Russian Federation|Ryazan Regional Clinical Hospital, Ryazan, Russian Federation|FGU Russian Scientific Research Institute of Hematology and Transfusiology, Saint Petersburg, Russian Federation|FSI ""V.A. Almazov Federal Centre of Heart, Blood and Endocrinology of Rosmedtechnologies"", Saint Petersburg, Russian Federation|Saint Petersburg I.P. Pavlov State Medical University, Saint-Petersburg, Russian Federation|Saratov State Medical University, Saratov, Russian Federation|State Budgetary Healthcare Institution ""Volgograd Regional Clinical Oncology Dispensary #1"", Volgograd, Russian Federation|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain|Hospital Universitari Germans Trias i Pujol, Badalona, Spain|Hospital Universitario La Princesa, Madrid, Spain|Hospital General Universitario Gregorio Marañon, Madrid, Spain|Hospital Clínico Universitario de Salamanca, Salamanca, Spain|Hospital Universitario de Canarias, San Cristobal de La Laguna, Spain|Hospital Universitario Virgen del Rocio, Sevilla, Spain|Hospital Universitari i Politecnic La Fé de Valencia, Valencia, Spain|Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden|Länssjukhuset Ryhov, Jönköping, Sweden|Changhua Christian Hospital, Changhua city, Taiwan|China Medical University Hospital, Taichung, Taiwan|National Cheng-Kung University Hospital, Tainan, Taiwan|National Taiwan University Hospital, Taipei, Taiwan|Kent and Canterbury Hospital, Canterbury, England, United Kingdom|University Hospital Coventry, Coventry, England, United Kingdom|Royal Bournemouth General Hospital, Dorset, England, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom|Barts and The London NHS Trust, London, England, United Kingdom|University College London Hospitals National Health Society Foundation Trust, London, England, United Kingdom|Guys and Saint Thomas NHS Foundation Trust, London, England, United Kingdom|Imperial College Healthcare NHS Trust, London, England, United Kingdom|Maidstone Hospital, Maidstone, England, United Kingdom|Christie Hospital NHS Foundation Trust, Manchester, England, United Kingdom|Oxford University Hospitals NHS Trust, Oxford, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Mount Vernon Hospital, Middlesex, United Kingdom|New Cross Hospital, Wolverhampton, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01796470,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Collaborative Research Group LLC, Boynton Beach, Florida, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01090414,"CHRONIC LYMPHOCYTIC LEUKEMIA|LYMPHOMA, NON-HODGKIN",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Clearview Cancer Institute, Huntsville, Alabama, United States|UCLA, Los Angeles, California, United States|Stanford Cancer Center, Palo Alto, California, United States|Center for Cancer & Blood Disorders, PC, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Long Island Jewish medical Center, New Hyde Park, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Weill Medical College of Cornell, New York, New York, United States|Mount Sinai School of Medicine, New York, New York, United States|The Ohio State University Medical Center, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Willamette Valley Cancer Institute and Research Center, Springfield, Oregon, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|MD Anderson Cancer and Research Center, Houston, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Yakima Regional Cancer Care, Yakima, Washington, United States|University of Wisconsin, Madison, Wisconsin, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02928510,ABSENCE OF SIGNS OR SYMPTOMS|B-CELL NON-HODGKIN LYMPHOMA|DIGESTIVE SYSTEM SIGNS AND SYMPTOMS|INDOLENT ADULT NON-HODGKIN LYMPHOMA|RECURRENT B-CELL NON-HODGKIN LYMPHOMA|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT INDOLENT ADULT NON-HODGKIN LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02538614,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University, Columbus, Ohio, United States|University of Utah, Salt Lake City, Utah, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02258529,FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Shores Medical Group, Long Beach, California, United States|Florida Cancer Specialists, Fort Myers, Florida, United States|St. Agnes Hospital, Baltimore, Maryland, United States|Prarie Lakes Health Care Systems, Inc., Watertown, South Dakota, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02044822,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology Associates, PC - HOPE, Tucson, Arizona, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|The University of Chicago Medicine, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Duke University, Durham, North Carolina, United States|GHS Cancer Institute, Greenville, North Carolina, United States|Compass Oncology, Portland, Oregon, United States|Willamette Valley Cancer Center and Research Institute, Springfield, Oregon, United States|Hospital of the University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States|St Vincent's Hospital, Sydney, Darlinghurst, New South Wales, Australia|St George Hospital, Kogarah, New South Wales, Australia|Icon Cancer Foundation, South Brisbane, Queensland, Australia|St Vincent's Hospital, Melbourne, Fitzroy, Victoria, Australia|Liverpool Hospital, Liverpool, Australia|Innsbruck University Hospital, Inner Medicine,, Innsbruck, Austria|Univ. Klinik für Innere Medizin III LKH, Salzburg, Austria|Medizinische Universität Wien, Univ. Klinik f. Innere Med. I, Abteilung für Hämatologie und Hämostaseologie, Vienna, Austria|AZ Sint-Jan AV Brugge-Oostende, Brugge, Belgium|University Hospital Leuven, Leuven, Belgium|University Hospital, Brno, Czechia|Faculty Hospital Hradec Kralove, Hradec Kralove, Czechia|Hemato-Onkologicka Klinika Fn, Olomuc, Czechia|Faculty hospital Ostrava, Ostrava-Poruba, Czechia|Faculty Hospital Kralovske Vinohrady, Prague 10, Czechia|Vseobecna Fakultim Nemocnice, Praha, Czechia|Aalborg University Hospital, Aalborg, Denmark|Centre Hospitalier Universitaire Hôpital Avicenne, Bobigny, France|CHRU de Lille, Hopital Claude Huriez, Lille, France|Centre Hospitalier Universitaire Nancy, Nancy, France|Hopital Pitie-Salpetriere, Paris cedex 13, France|University of Debrecen HSC Institute of internal Medicine, Department of Hematology, Debrecen, Hungary|Institute of Hematology ""L. e A. Seràgnoli"", Bologna, Italy|A.O.Spedali Civili Brescia, Brescia, Italy|A.O.Niguarda Ca' Granda, Milan, Italy|Azienda Ospedaliero Universitaria Policlinico di Modena, Modena, Italy|SCDU Medicina II ed Ematologia, A.O.U. San Luigi Gonzaga, Orbassano, Italy|Uniwersyteckie Centrum Kliniczne, Gdańsk, Pomorskie, Poland|Szpital Specjalistyczny w Brzozowie, Brzozow, Poland|Malopolskie Centrum Medyczne s.c., Krakow, Poland|Wojewodzki Szpital Specjalistyczny, Lodz, Poland|Centrum Onkologii-Instytut Marii Sklodowskiej -Curie klinika Nowotworow Ukladu Chlonnego, Warszawa, Poland|Samodzielny Publiczny Szpital Kliniczny, Wroclaw, Poland|Centro Hospitalar De Lisboa Norte, E.P.E. - Hospital Santa Maria, Lisbon, Portugal|IPO Porto Francisco Gentil, E.P.E, Porto, Portugal|Emergency County Clinical Hospital Brasov, Brasov, Romania|Spitalul Clinic Colentina, Bucharest, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain|Hospital Clinic, Barcelona, Cataluña, Spain|Hospital Universitario Puerta De Hierro, Madrid, Spain|Hospital Clinico Universitario De Valencia (Chuv), Valencia, Spain|Saint James's University Hospital, Leeds, United Kingdom|Royal Liverpool & Broadgreen Univ. Hospitals, Liverpool, United Kingdom|University Hospital Southampton NHS Trust, Southampton, United Kingdom",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT01203930,CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|SMALL LYMPHOCYTIC LYMPHOMA (SLL),All,65 Years and older   (Older Adult),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California, San Diego, Moores Cancer Center, La Jolla, California, United States|Stanford University School of Medicine, Stanford, California, United States|Columbia University - Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|The Universtity of Texas MD Anderson Cancer Center, Houston, Texas, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Terminated,NCT02590588,AMYLOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Boston Medical Center, Boston, Massachusetts, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Withdrawn,NCT02662296,PROLYMPHOCYTIC LEUKEMIA|RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D473/38,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1,0,DB09054,__IDELALISIB,6800620,Withdrawn,NCT03349346,DIFFUSE LARGE B-CELL LYMPHOMA|MEDIASTINAL B-CELL LYMPHOMA,All,"1 Year to 18 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Centre Hospitalier Régional Universitaire de Lille, Lille, France|Istituto Giannina Gaslini, Genova, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|Infantile Regina Margherita Hospital, Torino, Italy|Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego we Wroclawiu, Wrocław, Poland|Hospital Vall d´Hebrón, Barcelona, Spain|Hospital Universitario HM Monteprincipe, Madrid, Spain",C07D473/38,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,43.0,20.961416045504,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.03,415.43199999999996,99.16,6.0,2.0,5.0,41.41,116.83,5.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O,0,DB09061,__CANNABIDIOL,10195159,Terminated,NCT04129489,AUTOIMMUNE HEPATITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Belinson Medical Center, Petach Tikva, Israel",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,46.2268219059939,452.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,6.1,314.469,40.46,2.0,2.0,2.0,38.35,98.53,6.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Terminated,NCT02465528,TUMORS WITH ABERRATIONS IN ALK|ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMOR|GLIOBLASTOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",C07D239/48,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(=Nc3ccccc3S(=O)(=O)C(C)C)[nH]2)c(OC(C)C)cc1C1CCNCC1,0,DB09063,__CERITINIB,7153964,Withdrawn,NCT02729961,"ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE|CD30-POSITIVE NEOPLASTIC CELLS PRESENT|SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA",All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D239/48,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,69.9480482145424,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.23,558.135,105.24,8.0,3.0,4.0,61.33,153.86,9.0,1.0,0.0,0.0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,1
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,DB09073,__PALBOCICLIB,6936612,Terminated,NCT02030483,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1
CC(=O)c1c(C)c2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n(C2CCCC2)c1=O,0,DB09073,__PALBOCICLIB,6936612,Terminated,NCT03515200,"ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE|ACUTE LYMPHOBLASTIC LEUKEMIA WITH FAILED REMISSION",All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Jude Children's Research Hospital, Memphis, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,31.442124068256,23.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.12,447.5328,103.35,8.0,2.0,5.0,49.69,127.47,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,1,1,1
COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O,0,DB09078,__LENVATINIB,7253286,Terminated,NCT01133756,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Texas Oncology - Austin Central, Austin, Texas, United States",4,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,51.6478777798312,65.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.03,426.86,115.57,4.0,3.0,4.0,42.29,112.21,6.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0
COc1c(-c2ccc3cc(NS(C)(=O)=O)ccc3c2)cc(-n2ccc(=O)[nH]c2=O)cc1C(C)(C)C,0,DB09183,__DASABUVIR,6037157,Terminated,NCT02194998,HEPATITIS C INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Rush University CRS, Chicago, Illinois, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Houston AIDS Research Team CRS, Houston, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,15.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.7,493.58,104.81,5.0,2.0,4.0,53.19,134.04,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0
Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1,0,DB09297,__PARITAPREVIR,6037157,Terminated,NCT02194998,HEPATITIS C INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Alabama CRS, Birmingham, Alabama, United States|UCLA CARE Center CRS, Los Angeles, California, United States|University of Colorado Hospital CRS, Aurora, Colorado, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Rush University CRS, Chicago, Illinois, United States|Johns Hopkins University CRS, Baltimore, Maryland, United States|New Jersey Medical School Clinical Research Center CRS, Newark, New Jersey, United States|Weill Cornell Chelsea CRS, New York, New York, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|Penn Therapeutics, CRS, Philadelphia, Pennsylvania, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|The Miriam Hospital Clinical Research Site (TMH CRS) CRS, Providence, Rhode Island, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|Houston AIDS Research Team CRS, Houston, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States|Puerto Rico AIDS Clinical Trials Unit CRS, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,18.0,44.584077701800794,10.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.5,765.89,189.65,10.0,3.0,8.0,78.72,200.98,6.0,0.0,1.0,0.0,1,0,1,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,0,1,0,1,0,0,1,1,0,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,1,1
[K+].[O-][Cl+3]([O-])([O-])[O-],0,DB09418,__POTASSIUM_PERCHLORATE,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.97,138.549,74.27,4.0,0.0,0.0,5.23,11.91,0.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CCCCC(CC)COC(=O)CC(C(=O)OCC(CC)CCCC)S(=O)(=O)O,0,DB11089,__DOCUSATE,4156715,Terminated,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K8/466,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,17.9716215938725,95.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,422.577,106.97,5.0,1.0,0.0,46.82,107.35,18.0,1.0,0.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0
OC[C@H](O)[C@@H](O)[C@H](O)CO,0,DB11195,__XYLITOL,,Withdrawn,NCT01561508,DIABETES,All,"8 Years to 18 Years   (Child, Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","University of Alabama at Birmingham, Birmingham, Alabama, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.5,152.1458,101.15,5.0,5.0,0.0,14.42,32.44,4.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0
O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C([O-])[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Cu+2],0,DB11246,__COPPER_GLUCONATE,4112066,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",A61Q11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,26.481036571592803,532.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.0,453.841,141.28,7.0,5.0,0.0,16.62,49.11,10.0,0.0,1.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0
O=C(O)c1cc(O)c2c(c1)C(C1c3cc(C(=O)O)cc(O)c3C(=O)c3c(OC4OC(CO)C(O)C(O)C4O)cccc31)c1cccc(OC3OC(CO)C(O)C(O)C3O)c1C2=O,0,DB11365,__SENNOSIDES,,Terminated,,DIABETIC GASTROPARESIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.94,862.7460000000003,347.96,20.0,12.0,8.0,81.49,205.44,9.0,1.0,0.0,0.0,0,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,0,DB11526,__MASITINIB,EP-1525200-B1,Terminated,NCT01470131,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Medical and Surgical Specialists, Galesburg, Illinois, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Froedtert & Medical College of Wisconsin-CLCC, Milwaukee, Wisconsin, United States|CHU Estaing, Clermont Ferrand, France|Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France|CH Le Mans, Le Mans, France|Hôpital Universitaire Dupuytren, Limoges, France|Hôpital Ambroise Paré, Marseille, France|Hôpital de l'Hôtel Dieu, Nantes, France|Hôpital Saint Louis, Paris, France|Centre Hospitalier Saint Jean, Perpignan, France", A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,50.333682416476705,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,498.65,73.39,6.0,2.0,5.0,55.33,147.0,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nc(-c2cccnc2)cs1,0,DB11526,__MASITINIB,EP-1525200-B1,Terminated,NCT01410695,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARTMEDI UPD s.r.o, Hostivice, Czechia", A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,28.0,50.333682416476705,14.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.18,498.65,73.39,6.0,2.0,5.0,55.33,147.0,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03399539,RECURRENT PLASMA CELL MYELOMA|T(11;14),All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT02992522,"B-CELL LYMPHOMA, UNCLASSIFIABLE, WITH FEATURES INTERMEDIATE BETWEEN DIFFUSE LARGE B-CELL LYMPHOMA AND BURKITT LYMPHOMA|GRADE 1 FOLLICULAR LYMPHOMA|GRADE 2 FOLLICULAR LYMPHOMA|GRADE 3A FOLLICULAR LYMPHOMA|RECURRENT BURKITT LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|REFRACTORY BURKITT LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY FOLLICULAR LYMPHOMA|TRANSFORMED RECURRENT NON-HODGKIN LYMPHOMA",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University, Atlanta, Georgia, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT02755597,RELAPSED/REFRACTORY MULTIPLE MYELOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Univ of Colorado Cancer Center /ID# 149130, Aurora, Colorado, United States|VA Eastern Colorado Healthcare System /ID# 156524, Aurora, Colorado, United States|Duke University Medical Center /ID# 149099, Durham, North Carolina, United States|Gabrail Cancer Center Research /ID# 149098, Canton, Ohio, United States|Royal Prince Alfred Hospital /ID# 149108, Camperdown, New South Wales, Australia|Concord Repatriation & Gen Hos /ID# 149106, Concord, New South Wales, Australia|Liverpool Hospital /ID# 149110, Liverpool, New South Wales, Australia|Royal Brisbane and Women's Hospital /ID# 149105, Herston, Queensland, Australia|The Queen Elizabeth Hospital /ID# 149104, Woodville, South Australia, Australia|Royal Hobart Hospital /ID# 149111, Hobart, Tasmania, Australia|Peter MacCallum Cancer Ctr /ID# 149107, Melbourne, Victoria, Australia|Alfred Health /ID# 150085, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 149112, Melbourne, Victoria, Australia|Fiona Stanley Hospital /ID# 148967, Murdoch, Western Australia, Australia|Perth Blood Institute Ltd /ID# 148966, Nedlands, Western Australia, Australia|Universidade Federal de Goias /ID# 149290, Goiania, Goias, Brazil|Liga Norte Rigrandese Contra o /ID# 149023, Natal, Rio Grande Do Norte, Brazil|Hospital Sao Lucas da PUCRS /ID# 149027, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HC /ID# 149025, São Paulo, Sao Paulo, Brazil|Instituto Nacional de Câncer José de Alencar Gomes da Silva (INCA) /ID# 149020, Rio de Janeiro, Brazil|Clinica Sao Germano /ID# 149851, Sao Paulo, Brazil|Victoria Hospital /ID# 149846, London, Ontario, Canada|CISSS de la Monteregie /ID# 149844, Greenfield Park, Quebec, Canada|CHU Dupuytren /ID# 149292, Limoges CEDEX 1, Franche-Comte, France|Centre Hospitalier Lyon Sud /ID# 149300, Pierre Benite CEDEX, Rhone, France|CHRU de Brest - Hopital Morvan /ID# 149299, Brest, France|CHU de Grenoble - Albet Michal /ID# 149301, Grenoble, France|CHU de Nantes, Hotel Dieu -HME /ID# 149294, Nantes, France|Charité Universitätsmedizin Campus Mitte /ID# 148949, Berlin, Germany|Universitaetsklinikum Dresden /ID# 148948, Dresden, Germany|Asklepios Klinik Altona /ID# 150116, Hamburg, Germany|Dél-pesti Centrumkórház- Országos Hematológiai és Infektológiai Intézet /ID# 152518, Budapest IX, Budapest, Hungary|Semmelweis Egyetem /ID# 152519, Budapest, Hungary|Semmelweis Egyetem /ID# 152520, Budapest, Hungary|Debreceni Egyetem Klinikai Központ /ID# 152517, Debrecen, Hungary|Somogy Megyei Kaposi Mor Oktat /ID# 152516, Kaposvár, Hungary|Galway University Hospital /ID# 149061, Galway, Ireland|A.O.U. Policlinico S.Orsola-Malpighi /ID# 148936, Bologna, Emilia-Romagna, Italy|AP Romano Umberto I /ID# 148939, Rome, Lazio, Italy|A.O. Univ. Ospedali Riuniti /ID# 148942, Ancona, Marche, Italy|Ospedale S.Eugenio /ID# 148938, Rome, Italy|Ospedale Molinette /ID# 148943, Turin, Italy|Nagoya City University Hospital /ID# 150943, Nagoya-shi, Aichi, Japan|Kyushu University Hospital /ID# 150896, Fukuoka-shi, Fukuoka, Japan|Ogaki Municipal Hospital /ID# 150783, Ogaki-shi, Gifu, Japan|Gunma University Hospital /ID# 150275, Maebashi-shi, Gunma, Japan|National Hospital Organization Shibukawa Medical Center /ID# 150281, Shibukawa-shi, Gunma, Japan|Hiroshima Red Cross Hospital /ID# 150242, Hiroshima-shi, Hiroshima, Japan|Kobe City Med Ctr General Hosp /ID# 150944, Kobe-shi, Hyogo, Japan|National Hospital Organization Mito Medical Center /ID# 151051, Higashi Ibaraki-gun, Ibaraki, Japan|Kyoto Prefect Univ Med /ID# 150719, Kyoto-shi, Kyoto, Japan|JCHO Kyoto Kuramaguchi Medical /ID# 150781, Kyoto-shi, Kyoto, Japan|Tohoku University Hospital /ID# 150945, Sendai-shi, Miyagi, Japan|Okayama Medical Center /ID# 150717, Okayama-shi, Okayama, Japan|Japanese Red Cross Osaka Hospi /ID# 150716, Osaka-shi, Osaka, Japan|Saitama Medical Center Saitama Medical University /ID# 151044, Kawagoe shi, Saitama, Japan|Tochigi Cancer Center /ID# 150192, Utsunomiya-shi, Tochigi, Japan|National Cancer Center Hospital /ID# 151039, Chuo-ku, Tokyo, Japan|The Cancer Institute Hosp JFCR /ID# 150780, Koto-ku, Tokyo, Japan|Japanese Red Cross Medical Center /ID# 149902, Shibuya-ku, Tokyo, Japan|National Hospital Organization Disaster Medical Center /ID# 150784, Tachikawa-shi, Tokyo, Japan|National Cancer Center /ID# 150889, Goyang, Gyeonggido, Korea, Republic of|Seoul National Univ Bundang ho /ID# 150888, Seongnam, Gyeonggido, Korea, Republic of|Gachon University Gil Medical Center /ID# 150893, Incheon, Incheon Gwang Yeogsi, Korea, Republic of|Chonnam National University Hospital /ID# 150894, Gwangju, Jeonranamdo, Korea, Republic of|Severance Hospital /ID# 150891, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Samsung Medical Center /ID# 150892, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Cath Univ Seoul St Mary's Hosp /ID# 150895, Seoul, Seoul Teugbyeolsi, Korea, Republic of|Seoul National University Hospital /ID# 150890, Seoul, Korea, Republic of|Kemerovo Regional Clinical Hospital n.a. S.V. Belyaev /ID# 148955, Kemerovo, Kemerovskaya Oblast, Russian Federation|State Institution of Health of the Ryazan Regional Clinical Hospital /ID# 148956, Ryazan, Ryazanskaya Oblast, Russian Federation|LLC Novaya Klinika /ID# 148974, Pyatigorsk, Stavropol Skiy Kray, Russian Federation|Central Clinical Hosp 2 /ID# 148954, Moscow, Russian Federation|Clinical Onco Dispensary /ID# 148953, Omsk, Russian Federation|Samara State Medical Universit /ID# 148952, Samara, Russian Federation|Medical Clinica of Bashkir /ID# 151206, UFA, Russian Federation|Hospital Duran i Reynals /ID# 148989, L'Hospitalet de Llobregat, Barcelona, Spain|Hospital Univ de la Princesa /ID# 148980, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 148981, Madrid, Spain|Hospital Universitario Dr. Peset /ID# 148986, Valencia, Spain|China Medical University Hosp /ID# 154446, Taichung City, Taichung, Taiwan|National Taiwan Univ Hosp /ID# 154444, Taipei City, Taipei, Taiwan|Changhua Christian Hospital /ID# 154447, Changhua County, Taiwan|Taipei Veterans General Hosp /ID# 154445, Taipei City, Taiwan|Cherkassy Regional Onc Ctr /ID# 152414, Cherkasy, Ukraine|Communal Non-profit Enterprise City Clinical Hospital No.4 /ID# 152411, Dnipro, Ukraine|National Cancer Institute /ID# 152413, Kiev, Ukraine|Leicester Royal Infirmary /ID# 149057, Leicester, England, United Kingdom|Blackpool Teaching Hosp NHS /ID# 149058, Blackpool, United Kingdom|East Kent Hosp Univ NHS Trust /ID# 149059, Canterbury, United Kingdom|St Bartholomew's Hospital, Bar /ID# 149050, London, United Kingdom|University College Hospitals /ID# 149044, London, United Kingdom|King's College Hospital NHS /ID# 149045, London, United Kingdom|Manchester Royal Infirmary, Ma /ID# 149046, Manchester, United Kingdom|Nottingham Univ Hospitals NHS /ID# 149047, Nottingham, United Kingdom|Queens Hospital /ID# 149055, Romford, United Kingdom|The Royal Wolverhampton NHS Tr /ID# 149043, Wolverhampton, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03797261,ACUTE MYELOID LEUKEMIA|NON-HODGKIN'S LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope /ID# 207393, Duarte, California, United States|USC Norris Cancer Center /ID# 207396, Los Angeles, California, United States|Miami Cancer Institute - Baptist Health South Florida /ID# 209825, Miami, Florida, United States|University of Iowa Hospitals and Clinics /ID# 207459, Iowa City, Iowa, United States|Univ Kansas Med Ctr /ID# 207480, Kansas City, Kansas, United States|Dana-Farber Cancer Institute /ID# 207367, Boston, Massachusetts, United States|Washington University-School of Medicine /ID# 206995, Saint Louis, Missouri, United States|NYU Langone Medical Center /ID# 207390, New York, New York, United States|Unc /Id# 207388, Chapel Hill, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208482, Pittsburgh, Pennsylvania, United States|Calvary Mater Newcastle /ID# 211455, Waratah, New South Wales, Australia|Royal Adelaide Hospital /ID# 210602, Adelaide, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210601, Fitzroy, Victoria, Australia|Alfred Hospital /ID# 210350, Melbourne, Victoria, Australia|Box Hill Hospital /ID# 210599, Melbourne, Victoria, Australia|Universitaetsklinikum Leipzig /ID# 209824, Leipzig, Sachsen, Germany|Charite Universitatsmedizin B- /ID# 207987, Berlin, Germany|Universitaetklinikum Dresden /ID# 207803, Dresden, Germany|Universitaetsklinikum Frankfurt /ID# 207984, Frankfurt, Germany|Univ Klinik Eppendorf Hamburg /ID# 207788, Hamburg, Germany",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Suspended,NCT03713580,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Terminated,NCT03000660,AL AMYLOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tufts Medical Center, Boston, Massachusetts, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Terminated,NCT03135262,"FOLLICULAR LYMPHOMA|LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Norton Cancer Institute - Dutchmans, Louisville, Kentucky, United States|Mount Sinai Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Swedish Cancer Inst., Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Klinikum Augsburg, Augsburg, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Kassel; Klinik für Onkologie und Hämatologie, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03856112,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA|T(11;14) NEGATIVE,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03785184,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope /ID# 212211, Duarte, California, United States|Marin Cancer Care /ID# 208476, Greenbrae, California, United States|University of California, Los Angeles /ID# 208516, Los Angeles, California, United States|Karmanos Cancer Institute /ID# 208805, Detroit, Michigan, United States|Henry Ford Hospital /ID# 208481, Detroit, Michigan, United States|Duke University Hospital /ID# 208306, Durham, North Carolina, United States|UPMC Hillman Cancer Ctr /ID# 208121, Pittsburgh, Pennsylvania, United States|Westmead Hospital /ID# 210267, Westmead, New South Wales, Australia|Flinders Centre for Innovation /ID# 210697, Bedford Park, South Australia, Australia|St. Vincents Hosp Melbourne /ID# 210266, Fitzroy, Victoria, Australia|Austin Hospital /ID# 210268, Heidelberg, Victoria, Australia|Monash Medical Centre /ID# 210269, Melbourne, Victoria, Australia|Tom Baker Cancer Centre /ID# 208549, Calgary, Alberta, Canada|Princess Margaret Cancer Centr /ID# 208923, Toronto, Ontario, Canada|Hopital Maisonneuver-Rosemont /ID# 208550, Montreal, Quebec, Canada|McGill Univ HC /ID# 208486, Montreal, Quebec, Canada|Clinica Universitar de Navarra - Pamplona /ID# 209883, Pamplona, Navarra, Comunidad, Spain|Hospital Clinic de Barcelona /ID# 209888, Barcelona, Spain|Hspital Universitario Gregorio Maranon /ID# 209926, Madrid, Spain|Clinica Universitar de Navarra - Madrid /ID# 210131, Madrid, Spain|Hosp Univ 12 de Octubre /ID# 209887, Madrid, Spain|Hospital Univ Dr. Peset /ID# 209884, Valencia, Spain",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03701321,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|Mayo Clinic, Rochester, Minnesota, United States|Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT04285268,"HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED|RECURRENT BURKITT LYMPHOMA|RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA|RECURRENT HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS|REFRACTORY BURKITT LYMPHOMA|REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA|REFRACTORY HIGH GRADE B-CELL LYMPHOMA WITH MYC AND BCL2 OR BCL6 REARRANGEMENTS",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,0,DB11581,__VENETOCLAX,8546399,Withdrawn,NCT03343678,"LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,40.214378118647204,25.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.92,868.45,172.03,10.0,3.0,8.0,93.95,238.59,12.0,1.0,0.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,1,0,1,1,1,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,0,1
C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2ncc(OC)c3ccc(Cl)cc23)CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1,0,DB11586,__ASUNAPREVIR,,Withdrawn,NCT02762448,HEPATITIS C INFECTION,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Prospective,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.12,748.2860000000003,182.33,9.0,3.0,5.0,76.14,186.82,13.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,1,0,1
C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@](O)(Cn1cncn1)c1cc(F)ccc1F,0,DB11633,__ISAVUCONAZOLE,EP-1757609-A1,Terminated,NCT03327727,INVASIVE ASPERGILLOSIS|INVASIVE PULMONARY ASPERGILLOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment,"University of Alabama at Birmingham Hospital, Division of Infectious Diseases, Birmingham, Alabama, United States|UC San Diego Moores Cancer Center, La Jolla, California, United States|UC Davis Health, Dept. of Internal Medicine, Div. of Infectious Diseases, Sacramento, California, United States|Christiana Care Health Services, Department of Medicine, Newark, Delaware, United States|Medical College of Georgia at Augusta University, Augusta, Georgia, United States|DMC Harper University Hospital, Detroit, Michigan, United States|University of Minnesota, Department of Medicine, Minneapolis, Minnesota, United States|Washington University School of Medicine, Division of Infectious Disease, Saint Louis, Missouri, United States|The University of Texas Health Science Center, Department of Internal Medicine, Houston, Texas, United States|Fred Hutchinson Cancer Research Center (FHCRC), Seattle, Washington, United States|Medical College of Wisconsin, Milwaukee, Wisconsin, United States|University Hospital Antwerp (UZA), Department of Hematology, Edegem, Antwerp, Belgium|General Hospital Saint-Jan, Department of Hematology, Brugge, Belgium|Jules Bordet Institute, Department of Infectious Disease, Brussels, Belgium|University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology, Leuven, Belgium|UCL Mont-Godinne University Hospitals, Department of Hematology, Yvoir, Belgium|Hamilton Health Sciences, Infectious Disease Research, Hamilton, Ontario, Canada|Toronto General Hospital, Toronto, Ontario, Canada|McGill University Health Centre (MUHC), Division of Infectios Diseases, Montréal, Quebec, Canada|Grenoble University Hospital Center, Department of Hematology, Grenoble, France|South Lyon Hospital Center, Pierre-Bénite, France|Hautepierre Hospital, Strasbourg, France|University Hospital Jena, Jena, Germany|Hospital Neuperlach - Municipal Hospital Munich GmbH, Clinic of Hematology and Oncology, Munich, Germany|Chonnam National University, Hwasun, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,36.0,102.277254153062,2.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.46,437.47,87.62,5.0,1.0,4.0,42.74,123.94,6.0,0.0,1.0,0.0,1,1,1,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0
Clc1ccc(CCCOCCCN2CCCCC2)cc1,0,DB11642,__PITOLISANT,7169928,Terminated,NCT04026750,TYPE 1 DIABETES|HYPOGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Basic Science","High Point Clinical Trials Center, High Point, North Carolina, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,17.0,31.967802213597803,39.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.47,295.85,12.47,2.0,0.0,2.0,35.5,86.81,8.0,0.0,1.0,0.0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1
NC(=O)C1=C(O)C[C@@H]2C[C@@H]3Cc4cccc(O)c4C(=O)C3=C(O)[C@]2(O)C1=O,0,DB11647,__INCYCLINIDE,,Terminated,NCT00020683,AIDS-RELATED KAPOSI SARCOMA|HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"AIDS - Associated Malignancies Clinical Trials Consortium, Rockville, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.38,371.345,158.15,7.0,5.0,4.0,35.79,95.12,1.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,0,DB11648,__AFURESERTIB,US-20090209607-A1,Terminated,NCT02235740,CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Cary, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
Cn1ncc(Cl)c1-c1cc(C(=O)N[C@H](CN)Cc2cccc(F)c2)sc1Cl,0,DB11648,__AFURESERTIB,US-20090209607-A1,Terminated,NCT02177682,"NEOPLASMS, HAEMATOLOGIC",All,"20 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Aichi, Japan|Novartis Investigative Site, Fukuoka, Japan|Novartis Investigative Site, Miyagi, Japan|Novartis Investigative Site, Niigata, Japan|Novartis Investigative Site, Tokyo, Japan",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,66.0,55.5904638698946,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.45,427.32,72.94,3.0,2.0,3.0,40.89,116.81,5.0,0.0,1.0,0.0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,1,0,1
CCc1nn(CCO)c(CC)c1Oc1cc(C#N)cc(C#N)c1,0,DB11649,__LERSIVIRINE,WO-2002085860-A1,Terminated,NCT01254656,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Pfizer Investigational Site, Darlinghurst, New South Wales, Australia|Pfizer Investigational Site, Melbourne, Victoria, Australia|Pfizer Investigational Site, Nova Iguacu, RJ, Brazil|Pfizer Investigational Site, Toronto, Ontario, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Montreal, Quebec, Canada|Pfizer Investigational Site, Milano, Italy|Pfizer Investigational Site, Torino, Italy|Pfizer Investigational Site, Mexico, Distrito Federal, Mexico|Pfizer Investigational Site, Bydgoszcz, Poland|Pfizer Investigational Site, Warszawa, Poland|Pfizer Investigational Site, Johannesburg, Gauteng, South Africa|Pfizer Investigational Site, Pretoria, Gauteng, South Africa|Pfizer Investigational Site, Soweto, Gauteng, South Africa|Pfizer Investigational Site, Durban, Kwazulu-Natal, South Africa|Pfizer Investigational Site, Cape Town, Western Cape, South Africa|Pfizer Investigational Site, Pretoria, South Africa|Pfizer Investigational Site, Lugano, Switzerland|Pfizer Investigational Site, St. Gallen, Switzerland|Pfizer Investigational Site, Zuerich, Switzerland|Pfizer Investigational Site, Brighton, East Sussex, United Kingdom|Pfizer Investigational Site, London, United Kingdom|Pfizer Investigational Site, London, United Kingdom",A61P31/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,41.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.55,310.3504,94.86,4.0,1.0,2.0,33.29,97.83,6.0,0.0,1.0,0.0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1,0,DB11658,__QAV-680,EP-1761529-B1,Terminated,NCT01103037,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","West Coast Clinical Trials, Cypress, California, United States|American Health Research, Charlotte, North Carolina, United States|North Carolina Clinical Research, Raleigh, North Carolina, United States|Novartis Investigative Site, Berlin, Germany|Novartis Investigative Site, Hamburg, Germany|Novartis Investigative Site, Wiesbaden, Germany|Novartis Investigative Site, Moscow, Russian Federation",A61K45/06 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,10.0,71.9521961436579,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.73,358.41,89.26,5.0,1.0,3.0,36.7,94.91,5.0,0.0,1.0,0.0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,NCT02614508,RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Emory University/Winship Cancer Institute, Atlanta, Georgia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
Nc1cc(C(F)(F)F)c(-c2cc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB11666,__BUPARLISIB,WO-2009076170-A2,Terminated,,METASTATIC BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,32.7488,38.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.44,410.3935,89.63,8.0,1.0,4.0,39.25,103.58,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O,0,DB11682,__DAPRODUSTAT,,Terminated,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.48,393.44,124.09,6.0,2.0,3.0,40.18,96.89,5.0,0.0,1.0,0.0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0
CCNc1cc(O)c2c(c1)/C=C/C[C@H](O)[C@H](O)C(=O)/C=C\[C@@H](C)[C@H](C)OC2=O,0,DB11687,__E-6201,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.09,389.44800000000004,116.09,6.0,4.0,2.0,41.34,109.72,2.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Suspended,NCT03213691,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III CHILDHOOD NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT CHILDHOOD CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT NEUROBLASTOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM,All,"12 Months to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",C07D401/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Terminated,NCT01752569,AIDS-RELATED KAPOSI'S SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Brighton and Sussex University Hospitals, Brighton, United Kingdom|Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom|Royal Free Hospital, London, United Kingdom|Chelsea & Westminster Hospital, London, United Kingdom|The Christie Hospital, Manchester, United Kingdom|Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21,0,DB11689,__SELUMETINIB,7425637,Terminated,NCT01278615,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|Illinois CancerCare-Peoria, Peoria, Illinois, United States|Southern Illinois University, Springfield, Illinois, United States|Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne, Indiana, United States|Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Massachusetts Memorial Health Care, Worcester, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Saint John's Mercy Medical Center, Saint Louis, Missouri, United States|Weill Medical College of Cornell University, New York, New York, United States|M D Anderson Cancer Center, Houston, Texas, United States",C07D401/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,42.9084786135238,5.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,457.68,88.41,5.0,3.0,3.0,40.61,102.61,6.0,0.0,1.0,0.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,1,0
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Withdrawn,NCT02677948,"CHRONIC LYMPHOCYTIC LEUKEMIA|LYMPHOMA, SMALL LYMPHOCYTIC",All,"18 Years to 79 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States",A61P35/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1,0,DB11697,__PACRITINIB,WO-2010068181-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61P35/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.78,472.589,68.74,7.0,1.0,5.0,52.32,139.43,4.0,0.0,1.0,0.0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,NCT00003505,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Burzynski Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,NCT00003502,CONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|NONCONTIGUOUS STAGE II MANTLE CELL LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Primary Purpose: Treatment,"Burzynski Clinic, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C1CC[C@H](NC(=O)Cc2ccccc2)C(=O)N1,0,DB11702,__ANTINEOPLASTON_A10,,Withdrawn,,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.37,246.266,75.27,3.0,2.0,2.0,24.89,64.2,3.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,0,DB11703,__ACALABRUTINIB,7459554,Withdrawn,NCT02735876,MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D487/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
CC#CC(=O)N1CCC[C@H]1c1nc(-c2ccc(C(=O)Nc3ccccn3)cc2)c2c(N)nccn12,0,DB11703,__ACALABRUTINIB,7459554,Withdrawn,,MANTLE CELL LYMPHOMA (MCL),,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,68.0,49.6108749666317,7.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.69,465.517,118.51,6.0,2.0,5.0,51.0,135.72,5.0,0.0,1.0,0.0,1,1,0,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0
Cc1cc(O[C@@H](CCC(F)(F)F)c2ccc(C(=O)NCCC(=O)O)cc2)cc(C)c1-c1ccc(C(C)(C)C)cc1,0,DB11704,__ADOMEGLIVANT,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.28,555.638,75.63,4.0,2.0,3.0,59.13,150.1,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
CCC[C@@H](Nc1c(Cc2cccc(C(=O)N(C)C)c2O)c(=O)c1=O)c1ccc(C)o1,0,DB11711,__NAVARIXIN,,Withdrawn,,ASTHMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.43,410.47,99.85,5.0,2.0,3.0,43.63,114.86,8.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,1,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Terminated,NCT00757250,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"LAC+USC Medical Center, Rand Schrader Clini, Los Angeles, California, United States|UCSD Division of Infectious Diseases, San Diego, California, United States|Harbor - UCLA Medical Center, Torrance, California, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)O,0,DB11720,__ANGIOTENSIN_1-7,,Withdrawn,NCT01882387,HEMATOLOGIC MALIGNANCIES,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Siteman Cancer Center, St Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.4,899.02,377.24,16.0,13.0,3.0,92.45,238.19,25.0,1.0,0.0,0.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,0,1,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
O=C(CN[C@@H]1CCNC1)N1CCC[C@H]1B(O)O,0,DB11723,__DUTOGLIPTIN,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,241.1,84.83,5.0,4.0,2.0,25.94,58.91,4.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0
CSCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCC(=O)N1)C(C)C)C(N)=O,0,DB11724,__BOMBESIN,,Suspended,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.3,1619.87,686.13,22.0,23.0,4.0,166.6,418.43,51.0,1.0,0.0,0.0,1,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,1,1,1,1,1,0,1,1,1,0,1,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,1,0,1,1,0
CN(C)C(=O)c1cc2cnc(Nc3ccc(N4CCNCC4)cn3)nc2n1C1CCCC1,0,DB11730,__RIBOCICLIB,8324225,Terminated,NCT02414724,LYMPHOMA|SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,66.3997207334852,15.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.5,434.548,91.21,7.0,2.0,5.0,49.13,125.59,5.0,0.0,1.0,0.0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,1,1
C=CCSS(=O)CC=C,0,DB11780,__ALLICIN,5705152,Withdrawn,NCT00029250,HIV INFECTIONS|HYPERCHOLESTEROLEMIA|HYPERTRIGLYCERIDEMIA|HYPERGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Bastyr University Center for Natural Health, Seattle, Washington, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States",A61K36/8962,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,40.017248814144004,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.16,162.273,17.07,1.0,0.0,0.0,17.01,44.93,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0
CC[C@H](NC(=O)[C@H](C)NC)C(=O)N1C[C@@H](O)C[C@H]1Cc1c(-c2[nH]c3cc(F)ccc3c2C[C@@H]2C[C@H](O)CN2C(=O)[C@H](CC)NC(=O)[C@H](C)NC)[nH]c2cc(F)ccc12,0,DB11782,__BIRINAPANT,,Terminated,NCT01486784,ACUTE MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.21,806.957,194.92,8.0,8.0,6.0,86.23,214.65,15.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,1,0,1,0,0
CCCOc1ccc(S(=O)(=O)N2CCN(CCO)CC2)cc1-c1nc2c(CCC)cn(CC)c2c(=O)[nH]1,0,DB11792,__MIRODENAFIL,US-20030171361-A1,Terminated,,ERECTILE DYSFUNCTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,56.7403848128298,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.85,531.67,116.47,7.0,2.0,4.0,57.75,146.61,10.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1
O[C@H]1CC[C@H](Nc2ncc3nc(Nc4c(F)cc(F)cc4F)n([C@H]4CCOC4)c3n2)CC1,0,DB11798,__TANZISERTIB,US-20120100213-A1,Terminated,,FIBROSIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/2866,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,20.0,25.692519353580106,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.77,448.4415,97.12,7.0,3.0,5.0,44.11,111.52,5.0,0.0,1.0,0.0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1,1,0,0,1,1,0,1,0,1
COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC,0,DB11800,__TIVOZANIB,US-20040229876-A1,Terminated,NCT01972516,OVARIAN CANCER|FALLOPIAN TUBE CANCER|PRIMARY PERITONEAL CARCINOMA,Female,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D335/02,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,84.0,34.760467360726,23.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.25,454.86300000000006,107.74,5.0,2.0,4.0,44.26,120.85,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0
CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c(Cl)ccc5c4OCO5)ncnc3c2)CC1,0,DB11805,__SARACATINIB,WO-2003045395-A1,Terminated,NCT02737202,PULMONARY LYMPHANGIOLEIOMYOMATOSIS,Female,"18 Years to 65 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States|Loyola Medical Center, Chicago, Illinois, United States|Laboratory of Translational Research NHLBI, Bethesda, Maryland, United States|University of Cincinnati, Cincinnati, Ohio, United States|Baylor College of Medicine - Ben Taub General Hospital, Houston, Texas, United States",5,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,13.0,32.7488,21.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.53,542.026,90.44,10.0,1.0,6.0,57.31,143.64,8.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,1,1,1,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,1,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1
N[C@@H](CNC(=O)CC[C@@H](NC(=O)c1ccc(NCc2c[nH]c3ncnc(=O)c-3n2)cc1)C(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CS)C(=O)O,0,DB11810,__ETARFOLATIDE,,Withdrawn,,"NEOPLASMS, BREAST",,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,730.71,332.53,17.0,11.0,3.0,69.5,176.33,19.0,1.0,0.0,0.0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,1
CC(=O)NCCOC(=O)[C@H](Oc1cccc(C(F)(F)F)c1)c1ccc(Cl)cc1,0,DB11811,__ARHALOFENATE,US-20120232302-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,69.0,32.7488,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.98,415.79,64.63,3.0,1.0,2.0,38.21,95.9,9.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0
C=Cc1c(C)c2cc3nc(c(CC(=O)N[C@@H](CC(=O)O)C(=O)O)c4[nH]c(cc5nc(cc1[nH]2)C(C)=C5CC)c(C)c4C(=O)O)[C@@H](CCC(=O)O)[C@@H]3C,0,DB11812,__TALAPORFIN,,Terminated,,MACULAR DEGENERATION,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.23,711.7719999999997,235.66,11.0,7.0,5.0,76.96,189.23,12.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,1,0,1,1,1,0,0,0,0,1,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,0
C/C=C(/C)C(=O)O[C@H]1C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@@H](OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)O)C(=O)O)C(=O)O)C(=O)O)C(=O)O)C[C@](C)(OC(C)=O)[C@H]2[C@@H]1OC(=O)CCCCCCC,0,DB11813,__MIPSAGARGIN,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.5,1409.5410000000006,529.98,23.0,13.0,3.0,148.12,339.89,50.0,1.0,0.0,0.0,1,1,1,0,1,1,0,1,0,0,1,1,0,1,1,1,1,1,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,1,1,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,0,1
COC(=O)N1CCN(Cc2cccc(NC(=O)Nc3ccc(C)nc3)c2F)CC1,0,DB11816,__OMECAMTIV_MECARBIL,US-20060014761-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,61.0,45.2411753834781,10.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.05,401.44199999999995,86.8,4.0,2.0,3.0,40.95,109.19,5.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT01383447,PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University, Baltimore, Maryland, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
Nc1ccccc1NC(=O)c1ccc(CNC(=O)OCc2cccnc2)cc1,0,DB11841,__ENTINOSTAT,WO-2004058234-A2,Terminated,NCT00866333,HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Tower Cancer Research Foundation, Beverly Hills, California, United States|University of Colorado, Denver, Colorado, United States|Johns Hopkins, Baltimore, Maryland, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|MD Anderson Cancer Center, Houston, Texas, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,51.0,32.7488,59.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.07,376.416,106.34,4.0,3.0,3.0,39.39,108.29,7.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,0,DB11842,__ANGIOTENSIN_II,9572856,Withdrawn,NCT01702688,HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Brigham and Women's Hospital, Boston, Massachusetts, United States",A61K38/085,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,8.0,86.2112158360541,2637.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.87,1046.1786,408.84,17.0,13.0,4.0,107.02,269.81,29.0,1.0,0.0,0.0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,1,1,0,1,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,1,1,0,1
CC(C)(Cc1cccc(CC(=O)NCc2cccc(-c3ccc(O)cc3)c2)c1)NC[C@H](O)c1ccc(O)c(NS(C)(=O)=O)c1,0,DB11871,__PF-00610355,US-20050182091-A1,Withdrawn,NCT00830427,"ASTHMA, BRONCHIAL|LUNG DISEASES, OBSTRUCTIVE|RESPIRATORY TRACT DISEASES|BRONCHIAL DISEASES",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,23.0,29.8650896322306,5.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.38,617.76,147.99,7.0,6.0,4.0,67.4,172.11,12.0,1.0,0.0,0.0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,1,1,0,0,0,0,1,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,0,1
CCNC(=O)c1noc(-c2cc(C(C)(C)C)c(O)cc2O)c1-c1ccc(CN2CCOCC2)cc1,0,DB11881,__AUY922,WO-2004072051-A1,Terminated,NCT01485536,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,66.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.31,479.577,108.06,6.0,3.0,4.0,52.65,136.25,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1
O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,0,DB11883,__SB-705498,WO-2005079192-A2,Terminated,NCT00461682,IRRITABLE COLON,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Primary Purpose: Treatment,"GSK Investigational Site, London, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.66,429.241,57.26,3.0,2.0,3.0,35.69,97.33,4.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
O=C(Nc1ccccc1Br)N[C@@H]1CCN(c2ccc(C(F)(F)F)cn2)C1,0,DB11883,__SB-705498,WO-2005079192-A2,Terminated,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.66,429.241,57.26,3.0,2.0,3.0,35.69,97.33,4.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1
CC(C)[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,0,DB11890,__CILENGITIDE,WO-2003032961-A2,Terminated,NCT00006222,SARCOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,-0.96,588.6659999999998,235.91,10.0,8.0,2.0,59.8,159.97,9.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,0,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,1,1,1
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,0,DB11899,__MK-8776,,Terminated,NCT00907517,"MYELOGENOUS LEUKEMIA, ACUTE|LEUKEMIA, LYMPHOCYTIC, ACUTE|LEUKEMIA, LYMPHOBLASTIC, ACUTE, PHILADELPHIA-POSITIVE|MYELOGENOUS LEUKEMIA, CHRONIC, AGGRESSIVE PHASE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,376.26199999999994,86.06,5.0,2.0,4.0,35.95,114.26,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1
Cn1cc(-c2cnn3c(N)c(Br)c([C@@H]4CCCNC4)nc23)cn1,0,DB11899,__MK-8776,,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,376.26199999999994,86.06,5.0,2.0,4.0,35.95,114.26,2.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1
Cc1nc(NNC(=O)[C@H](CC2CCCC2)CN(O)C=O)c(F)c(N2CCN3CCOC[C@@H]3C2)n1,0,DB11912,__LANOPEPDEN,WO-2009061879-A1,Terminated,,BACTERIAL INFECTIONS,,,,,"FISABIO, Elche, Alicante, Spain",A61P11/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,199.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.6,479.55699999999996,123.16,9.0,3.0,4.0,50.61,126.0,8.0,0.0,1.0,0.0,1,1,1,1,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,1,1,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,0,DB11941,__TASISULAM,WO-2003035629-A1,Terminated,NCT01185548,LYMPHOMA|ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cardiff, South Glamorgan, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sheffield, Trent, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leeds, West Yorkshire, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Leicester, United Kingdom|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom",A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,415.1,63.24,3.0,1.0,2.0,33.94,81.11,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0
O=C(NS(=O)(=O)c1ccc(Br)s1)c1ccc(Cl)cc1Cl,0,DB11941,__TASISULAM,WO-2003035629-A1,Terminated,NCT01209832,ADVANCED CANCER,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Bordeaux, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lille, France|For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Rennes, France",A61P25/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,32.7488,17.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.47,415.1,63.24,3.0,1.0,2.0,33.94,81.11,2.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,0,1,0,0
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Suspended,NCT02303392,PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Terminated,NCT02314247,PERIPHERAL T-CELL LYMPHOMA (PTCL)|CUTANEOUS T-CELL LYMPHOMA (CTCL),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Concord Repatriation General Hospital (CRGH), Concord, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Cabrini Hospital, Malvern, Victoria, Australia|National Cancer Centre, Singapore, Singapore",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
O=C(/C=C\n1cnc(-c2cc(C(F)(F)F)cc(C(F)(F)F)c2)n1)NNc1cnccn1,0,DB11942,__SELINEXOR,9079865,Withdrawn,NCT02389543,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,35.483274810571,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.85,443.31300000000016,97.62,6.0,2.0,3.0,35.61,120.0,7.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,1
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Suspended,NCT03370185,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tempe, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|QUEST Research Institute, Royal Oak, Michigan, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Morristown, New Jersey, United States|Medical Oncology Associates PS, WA, Spokane, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Terminated,NCT02391545,CD20+ FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Palo Alto, California, United States|Hackensack, New Jersey, United States|Rochester, New York, United States|Dallas, Texas, United States|Kortrijk, Belgium|Leuven, Belgium|Wilrijk, Belgium|Clermont-Ferrand, France|Marseille Cedex 05, France|Pessac, France|Rouen Cedex 1, France|Tours Cedex 01, France|Bologna, Italy|Varese, Italy|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Leeds, United Kingdom|London, United Kingdom",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Terminated,NCT02204982,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Frankston, Victoria, Australia|Bordeaux, France|Bologna, Italy|Terni, Italy|Gdynia, Poland",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02576275,INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA|MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Plainville, Connecticut, United States|Plantation, Florida, United States|Thomasville, Georgia, United States|East Setauket, New York, United States|Cookeville, Tennessee, United States|Knoxville, Tennessee, United States|Spokane, Washington, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C[C@H](Nc1ncnc2[nH]cnc12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,DB11952,__DUVELISIB,8193182,Withdrawn,NCT02605694,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Miami, Florida, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,39.0,34.694757592558304,4.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.91,416.87,86.8,5.0,2.0,5.0,42.2,118.53,4.0,0.0,1.0,0.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0
C=C1C[C@H]2C=Nc3cc(OCCCOc4cc5c(cc4OC)C(=O)N4CC(=C)C[C@H]4C=N5)c(OC)cc3C(=O)N2C1,0,DB11965,__SJG-136,,Terminated,NCT00301769,ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|DE NOVO MYELODYSPLASTIC SYNDROMES|PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|SECONDARY MYELODYSPLASTIC SYNDROMES,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.68,556.619,102.26,8.0,0.0,6.0,61.87,157.22,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0
Cc1c([C@@H](O)CN2CCN(C[C@H](O)c3ccc4c(c3C)COC4=O)CC2)ccc2c1COC2=O,0,DB11968,__MK-7145,US-20100286123-A1,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,46.686790283168,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.33,466.534,99.54,6.0,2.0,5.0,49.95,128.43,6.0,0.0,1.0,0.0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1
Nc1cc(N2CCN(CCP(=O)(O)O)CC2)nc(NC[C@H]2CC[C@H](CNCCCNC3CCCCC3)CC2)n1,0,DB11970,__BURIXAFOR,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.41,566.732,151.9,11.0,6.0,4.0,65.83,161.18,14.0,1.0,0.0,0.0,1,0,1,1,1,0,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,1,0,0,1
COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@@H]1C[C@@H]2CN(C)C[C@@H]2C1,0,DB11973,__TESEVATINIB,US-20080166359-A1,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,65.0,44.058399556459,12.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.51,491.39,59.51,6.0,1.0,5.0,51.0,127.76,6.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,0,0,0,0
COc1ccc(-c2cc3c(C)nc(N)nc3n([C@H]3CC[C@H](OCCO)CC3)c2=O)cn1,0,DB11974,__PF-04691502,WO-2008032162-A1,Withdrawn,,"NEOPLASMS, BREAST",,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.8,425.4809,123.69,8.0,2.0,4.0,46.64,117.41,6.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,0,1,1,0,1,1,1
CNC(=N)NCCC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)NNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H]1C[C@@H](O)CN1C(=O)[C@@H](Cc1ccc(O)cc1)NC(C)=O)[C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(N)=O,0,DB11975,__TAK-448,,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.26,1225.376,475.71,17.0,18.0,5.0,126.85,326.01,31.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,0,0
CN1CCN(C2CCN(C(=O)Nc3cc(Oc4ccc(NC(=O)C5(C(=O)Nc6ccc(F)cc6)CC5)c(F)c4)ccn3)CC2)CC1,0,DB11977,__GOLVATINIB,EP-1889836-A1,Terminated,,ADVANCED OR METASTATIC SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",A61P35/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,26.0,81.710096716565,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.19,633.701,119.14,6.0,3.0,6.0,64.23,172.48,8.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0
COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)O)c3ccccc3)c2=O)c1F,0,DB11979,__ELAGOLIX,6872728,Terminated,,ENDOMETRIOSIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,86.0,25.692519353580106,8.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.68,631.6,99.18,6.0,2.0,4.0,59.44,156.06,12.0,1.0,0.0,0.0,1,1,1,1,0,1,1,1,1,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0
COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1,0,DB11991,__OPROZOMIB,,Terminated,NCT01832727,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|University of Kansas Cancer Center and Medical Pavilion, Westwood, Kansas, United States|Center for Cancer and Blood Disorders, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Division of Hematology/ Oncology, UNC at Chapel Hill, Chapel Hill, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States|CHRU, Hopital Huriez - Department of Hematology, Lille CEDEX, France|CHU Hotel Dieu - Service d'Hematologie Clinique, NANTES Cedex, France|CHU de NANCY - Hopital de BRABOlS, Vandoeuvre Les Nancy, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.04,532.61,148.25,8.0,3.0,3.0,53.03,134.34,14.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,1
CN1C[C@H]2[C@@H](C1)[C@@H]2CN(Cc1ccc(F)c(Cl)c1)C(=O)c1cn(C)cn1,0,DB11993,__PF-03463275,,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.08,376.86,41.37,3.0,0.0,4.0,38.83,100.25,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,1,1,0
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,0,DB12010,__FOSTAMATINIB,7449458,Terminated,NCT00805467,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Maria, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Mayfiled Village, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Oklahoma City, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Medellín, Colombia|Research Site, Bordeaux, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Würzburg, Germany|Research Site, Siena, Italy|Research Site, Udine, Italy|Research Site, Chihuahua, Mexico|Research Site, Cuernava, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Leon, Mexico|Research Site, Mexcio, Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, Białystok, Poland|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Toruń, Poland|Research Site, Wroclaw, Poland|Research Site, Zyrardów, Poland|Research Site, Brailari, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Sf. Gheorghe, Romania|Research Site, Sibiu, Romania",6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,0,DB12010,__FOSTAMATINIB,7449458,Withdrawn,NCT00752999,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC,0,DB12010,__FOSTAMATINIB,7449458,Withdrawn,NCT02433236,IGA NEPHROPATHY,All,"18 Years to 72 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,6,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,33.7419659541263,14.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.78,580.4595,186.72,13.0,4.0,4.0,54.48,137.1,10.0,1.0,0.0,0.0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
Cc1c(CC(=O)O)c2cccnc2n1Cc1ccc(S(C)(=O)=O)cc1C(F)(F)F,0,DB12011,__FEVIPIPRANT,7666878,Terminated,NCT03650400,ASTHMA,All,6 Years to 11 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Orange, California, United States|Novartis Investigative Site, Minneapolis, Minnesota, United States|Novartis Investigative Site, Columbia, Missouri, United States|Novartis Investigative Site, Charlotte, North Carolina, United States|Novartis Investigative Site, Cincinnati, Ohio, United States|Novartis Investigative Site, Cleveland, Ohio, United States|Novartis Investigative Site, Tulsa, Oklahoma, United States|Novartis Investigative Site, Medford, Oregon, United States|Novartis Investigative Site, Boerne, Texas, United States|Novartis Investigative Site, El Paso, Texas, United States|Novartis Investigative Site, San Antonio, Texas, United States|Novartis Investigative Site, London, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,13.0,56.280416435655695,5.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.87,426.41,89.26,5.0,1.0,3.0,38.66,100.88,6.0,0.0,1.0,0.0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,0,DB12016,__PONESIMOD,WO-2014027330-A1,Terminated,NCT02461134,CHRONIC GRAFT VERSUS HOST DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Virginia Piper Cancer Institute, Scottsdale, Arizona, United States|Moore Cancer Center - UCSD, La Jolla, California, United States|David Geffen School of Med at UCLA, Los Angeles, California, United States|Northwestern University, Chicago, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|National Cancer Institute, Bethesda, Maryland, United States|University of Minnesota - Masonic Cancer CTR CLIN TRIALS CTR, Minneapolis, Minnesota, United States|Washington Univ School of Med, Oncology (St.Louis), Saint Louis, Missouri, United States|Stony Brook Univ. Medical Center, Stony Brook, New York, United States|Fred Hutchinson Cancer Res CTR, Seattle, Washington, United States",C07C45/81 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,460.97,82.36,5.0,2.0,3.0,49.67,125.69,8.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0
CCC/N=C1\S/C(=C\c2ccc(OC[C@H](O)CO)c(Cl)c2)C(=O)N1c1ccccc1C,0,DB12016,__PONESIMOD,WO-2014027330-A1,Terminated,NCT02907177,MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UAB Dpt of Neurology, Birmingham, Alabama, United States|Neuro-Pain Medical Center, Fresno, California, United States|SC3 Research - Pasadena, Pasadena, California, United States|Care Access Research - Santa Clarita, Santa Clarita, California, United States|Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, United States|University of Colorado Hospital, Aurora, Colorado, United States|Mountain View Clinical Research, Inc, Denver, Colorado, United States|Associated Neurologists, Danbury, Connecticut, United States|Bradenton Research Center, Bradenton, Florida, United States|Neurology Associates - MS Center of Greater Orlando, Maitland, Florida, United States|Neurology Assoc of Ormond Beach - CNS Trials, Ormond Beach, Florida, United States|Suncoast Neuroscience Associates, Inc, Saint Petersburg, Florida, United States|The MS Center of Vero Beach, Vero Beach, Florida, United States|Fort Wayne Neurological Center - North Office, Fort Wayne, Indiana, United States|University of Kansas Med Center, Kansas City, Kansas, United States|MidAmerica Neuroscience Research Foundation/Rowe Neurology, Lenexa, Kansas, United States|Henry Ford Health System - Neurology, Detroit, Michigan, United States|Univ of New Mexico - Health Sciences Center, Albuquerque, New Mexico, United States|NYU Langone Medical Center - MS Comprehensive Care Center, New York, New York, United States|Riverhills Healthcare, Inc., Cincinnati, Ohio, United States|OhioHealth Research Institute, Columbus, Ohio, United States|Neurology and Neuromuscular Center, Oklahoma City, Oklahoma, United States|Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States|Thomas Jefferson University Hospital - Dpt Neurology MS Center, Philadelphia, Pennsylvania, United States|Advanced Neuroscience Institute, Franklin, Tennessee, United States|Neurology Center of San Antonio, San Antonio, Texas, United States|Austin Health - Neuro-Immunology Clinical Research, Education and Support Service, Heidelberg, Victoria, Australia|MS Ambulanz Maida, Wien, Austria|Medizinische Universität Wien, Universitätsklinik für Neurologie, Wien, Austria|Hospital universitair Brussels_neurology department, Brussels, Belgium|Hospital - Universitair Gent __Neurology Department, Gent, Belgium|Hospital - Revalidatie & MS Centrum Overpelt_Neurology Department, Overpelt, Belgium|""Multiprofile Hospital for Active Treatment of Neurology and Psychiatry - Sveti Naum"" EAD - Neurology Clinic for Movement Disorders, Sofia, Bulgaria|""University Multiprofile Hospital for Active Treatment - Alexandrovska"" EAD, Neurology Clinic, Sofia, Bulgaria|University Multiprofile Hospital for Active Treatment ""Sv. Ivan Rilski"" EAD, Neurology Clinic, Sofia, Bulgaria|University of Alberta, Edmonton, Canada|Fakultní nemocnice u sv. Anny Brno, RS Centrum, Brno, Czechia|Fakultní nemocnice Hradec Králové, Neurologická klinika, Hradec Králové, Czechia|Nemocnice Jihlava, Neurologické oddělení, Jihlava, Czechia|Pardubicka krajska nemocnice, MS Centrum, Pardubice, Czechia|Krajská zdravotní a.s. - Nemonice Teplice o.z., RS Centrum, Teplice, Czechia|Aalborg Universitetshospital, Skleroseklinikken Neurologisk afdelning, Aalborg, Denmark|Glostrup Hospital, Neurologisk afdelning, Glostrup, Denmark|Hôpital Avicenne, Service de Neurologie, Bobigny, France|Hosp Gabriel Montpied, Dept Neurology, Clermont Ferrand, France|Centre Hospitalier Sud Francilien - Service de Neurologie, Corbeil-Essonnes, France|CHU de Dijon - Hôpital François Miterrand, Service de Neurologie, Dijon, France|CHRU de Lille - Hôpital Roger Salengro, Service de Neurologie, Lille, France|Hopital Gui de Chauliac - CHU Montpellier, Montpellier, France|Hôpital Central - CHU Nancy, Département Neurologie, Nancy, France|Hôpital Universitaire Carémeau, Service de Neurologie, Nimes, France|CHI POISSY-Saint Germay en Laye_Service de Neurologie et Réeducation, Poissy, France|Hosp Pontchaillou, Dept Cardiology, Rennes, France|Hosp Charles Nicolle Dept Neurology, Rouen, France|Zentrum für klinische Forschung Dr. med. Irma Schöll, Bad Homburg, Germany|Neurologische Klinik und Poliklinik - Universitätsklinikum Carl Gustav Carus, Zentrum für klinische Neurowissenschaften, Dresden, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Giessen Klinik und Poliklinik für Neurologie, Giessen, Germany|Universitätsmedizin Greifswald - Körperschaft des öffentlichen Rechts - Klinik und Poliklinik für Neurologie, Greifswald, Germany|Medizinische Hochschule Hannover, Neurologie, Hannover, Germany|AFL Arzneimittelforschung Leipzig GmbH, Leipzig, Germany|Universitätsklinikum Münster, Klinik für Allgemeine Neurologie, Münster, Germany|Medizinzentrum Siegerland Weidenau, Siegen, Germany|NeuroPoint GmbH, Gesellschaft für vorbeugende Gesundheitspflege, Ulm, Germany|Gemeinschaftspraxis Dr. med. Joachim Springub / Wolfgang Schwarz, Studienzentrum Nord-West (Study Center), Westerstede, Germany|Naval Hospital of Athens - Neurology Dpt, Athens, Greece|401 Military Hospital of Athens - Neurology Dept, Athens, Greece|Aeginition Hospital - Neurology Department, Athens, Greece|Medical Center of Athens - Neurology Dpt, Marousi, Greece|General Hospital of Thessaloniki, Thessaloniki, Greece|Uzsoki utcai Kórház, Neurológiai Osztály, Budapest, Hungary|Valeomed EGÉSZSÉGÜGYI KÖZPONT, Esztergom, Hungary|Pest Megyei Flór Ferenc Kórház, Neurológia és Stroke ambulancia, Kistarcsa, Hungary|Fondazione Istituto San Raffaele , Unità Operativa di Neurologia, Cefalù, Italy|Università degli Studi di Firenze - Azienda Ospedaliero Universitaria Careggi - CTO - SOD Neurologia 2, Firenze, Italy|AOU San Martino di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DINOGMI), Genova, Italy|Istituto Neurologico Carlo Besta, UOC Neurologia 4, Neuroimmunologia e Malattie Neuromuscolari, Centro Sclerosi Multipla, Milano, Italy|Azienda Ospedaliera Universitaria (AOU) ""Federico II"" - Centro Regionale Per la Sclerosi Multipla c/o Clinica Neurologica II - Dipartimento di Scienze, Napoli, Italy|AOU Università degli Studi della Campania L. Vanvitelli - I° Policlinico - DAI di Medicina Interna e Specialistica CS, Centro Sclerosi Multipla, Napoli, Italy|Azienda Ospedaliero Universitaria San Luigi Gonzaga - Centro Sclerosi Multipla CRESM, Orbassano, Italy|IRCCS NEUROMED - Istituto Neurologico Mediterraneo - Unità Operativa di Neurologia I, Pozzilli, Italy|Azienda Ospedaliera S. Andrea di Roma - Unità Operativa Complessa di Neurologia, Roma, Italy|Azienda Ospedaliera Universitaria Senese - Dipartimento di Scienze Neurologiche e neurosensoriali - UOSA Neurologia Sperimentale, Siena, Italy|Unidad de Investigacion en Salud de Chihuahua SC, Médica Sur, Unidad de Neurociencias, Tlalpan, DF, Mexico|Desarrollo Ético en Investigación Clínica S.C ., Guadalajara, Jalisco, Mexico|Axis Heilsa S. de R.L. de C.V. (Althian), Nuevo Leon, Monterrey, Mexico|Unidad de Investigación de Salud en Chihuahua, Chihuahua, Mexico|Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Neurologii i Oddziat Udarowy, Bialystok, Poland|B&B Robert Bonek, Pawel Bochniak S.C, Bydgoszcz, Poland|COPERNICUS - Podmiot Leczniczy Sp. z o.o., Gdansk, Poland|Centrum Terapii SM, Katowice, Poland|Neuro-Medic Janusz Zbrojkiewicz Poradnia Weilospecjalistyczna, Katowice, Poland|Centrum Kompleksowej Rehabilitacji, Konstancin-Jeziorna, Poland|Centrum Opieki Zdrowotnej Orkan - Med., Ksawerów, Poland|Instytut Psychiatrii i Neurologii, II Klinika Neurologiczna, Warszawa, Poland|WroMedica, J. Bielicka A. Strzałkowska SC, Wroclaw, Poland|Centro Hospitalar de Lisboa Central, Lisboa, Portugal|Hospital de Santa Maria - Neurology Department, Lisboa, Portugal|Centro Hospitalar de São João, E.P.E. - Hospital de São João - Neurology Department, Porto, Portugal|State Budgetary Healthcare Institution Regional Clinical Hospital No 3, Chelyabinsk, Russian Federation|Center of Professional Therapy, LLC, Krasnodar, Russian Federation|Moscow State Budgetary Healthcare Institution Filatov City Clinical Hospital No.15 of Moscow Health Department, Moscow, Russian Federation|Neuro-Clinic, LLC, Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution Pirogov City Clinical Hospital No. 1 of Moscow Health Department, Moscow, Russian Federation|Moscow State Budgetary Healthcare Institution City Clinical Hospital No. 24 of Moscow Health Department, Moscow, Russian Federation|Hospital Santa Creu I Sant Pau - Neurology Dpt, Barcelona, Spain|Hosp Virgen de la Arrixaca, Neurology, El Palmar, Spain|Hosp Gregorio Marañón, Neurology, Madrid, Spain|Hospital Clinico San Carlos, Neurology, Madrid, Spain|Hospital Santa Caterina - Neurology Department, Salt, Spain|Complejo Hospitalario Universitario de Santiago de Compostela (CHUS) - Neurology Department 2, Santiago de Compostela, Spain|Hospital Universitario Virgen Macarena - Neurofisiology Department, Sevilla, Spain|Centro de Neurologia Avanzada, Neurology, Sevilla, Spain|Univeritätsspital Basel Neurologie, Neurologische Klinik und Poliklinik, Basel, Switzerland|Ospedale Regionale di Lugano - Civico e Italiano, Neurologia, Lugano, Lugano, Switzerland|Queen Square MS Centre / NMR research Unit UCL Institute of Neurology, London, United Kingdom|Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom|Royal Hallamshire Hospital, Sheffield, United Kingdom|University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, United Kingdom",C07C45/81 ,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,20.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.01,460.97,82.36,5.0,2.0,3.0,49.67,125.69,8.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,DYSLIPIDEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
COc1ccc(CC2OC(=O)NC2=O)cc1C(=O)NCc1ccc(C(F)(F)F)cc1,0,DB12055,__MK-0767,,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.53,422.36,93.73,4.0,2.0,3.0,38.43,99.23,7.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,1
O=C(CBr)N1CC([N+](=O)[O-])([N+](=O)[O-])C1,0,DB12060,__RRX-001,,Terminated,NCT02096341,MALIGNANT SOLID TUMOR|LYMPHOMAS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sarah Cannon Research Institute, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.92,268.02299999999997,106.59,5.0,0.0,1.0,18.33,44.1,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02861040,RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Withdrawn,NCT02875002,RELAPSED AND REFRACTORY AGGRESSIVE B- AND T-CELL LYMPHOMAS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States|Sidney Kimmel Comprehensive Cancer, Baltimore, Maryland, United States|Massey Cancer Center, Richmond, Virginia, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C,0,DB12062,__VOLASERTIB,WO-2007054551-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",3,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,35.0,32.7488,17.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.65,618.8126,106.17,9.0,2.0,6.0,72.64,178.34,10.0,0.0,1.0,0.0,1,1,1,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,1,0,1
CCOc1ccn(-c2ccc(F)cc2)c(=O)c1C(=O)Nc1ccc(Oc2ccnc(N)c2Cl)c(F)c1,0,DB12064,__BMS-777607,,Withdrawn,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.46,512.893,106.78,5.0,2.0,4.0,49.23,132.8,7.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,1,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,0
CNC(=O)c1ccc2cc([C@@]3(O)CCn4cncc43)ccc2c1,0,DB12066,__ORTERONEL,WO-2012068435-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,17.0,32.7488,7.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.36,307.353,67.15,3.0,2.0,4.0,33.21,88.3,2.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
Cc1[nH]c(/C=C2\C(=O)Nc3ccccc32)c(C)c1CCC(=O)O,0,DB12072,__ORANTINIB,6395734,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/34,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,23.0,36.0089529559128,31.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.22,310.3471,82.19,3.0,3.0,3.0,34.37,90.47,4.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0
C#C[C@@]1(CO)C=C[C@H](n2cc(C)c(=O)[nH]c2=O)O1,0,DB12074,__CENSAVUDINE,EP-2228373-A1,Terminated,,HIV-1 INFECTION,,,,,"FISABIO, Elche, Alicante, Spain",C07D307/32,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,97.4475861927349,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.42,248.238,78.87,4.0,2.0,2.0,24.03,62.79,2.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1
O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1,0,DB12101,__CC-220,WO-2014025958-A2,Withdrawn,NCT02192489,SARCOIDOSIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,29.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.07,449.50699999999995,88.18,6.0,1.0,5.0,47.73,122.29,6.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1
C=Cc1cc(C(=O)Nc2ccc(C(=N)N)cc2)c(-c2ccc(C(=O)NCC3CC3)nc2C(=O)O)cc1OC,0,DB12120,__AVORALSTAT,,Terminated,NCT02670720,HEREDITARY ANGIOEDEMA|HAE,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"Leuven, Belgium|Grenoble, France|Lille, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.58,513.554,167.49,8.0,5.0,4.0,54.86,154.82,10.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,0,1,0,1,0,0,1,1,0,1,1,1,0,1,1,0,0,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT02404220,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope, Duarte, California, United States|UCLA, Los Angeles, California, United States|UC Irvine Medical Center, Orange, California, United States|University of California San Diego (UCSD), San Diego, California, United States|University of Chicago, Chicago, Illinois, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan-Kettering, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Bon Secour St. Francis Hospital, Greenville, South Carolina, United States|University of WA, Seattle, Washington, United States|Princess Margaret, Toronto, Ontario, Canada|Medizinische Klinik mit Schwerpunkt Hepatologie & Gastroenterology, Berlin, Germany|Medizinische Klinik und Poliklinik I, Wurzburg, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT02568683,NON-HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Forrest General Hospital, Hattiesburg, Mississippi, United States|Medical University of South Carolina, Charleston, South Carolina, United States|Groupe Hospitalier du Haut Leveque, Pessac, Aquitaine, France|Centre Hospitalier Régional Universitaire de Lille (CHRU de Lille), Lille cedex, NORD Pas-de-calais, France|Institut Paoli Calmettes, Marseille, Provence Alpes COTE D'azur, France|Centre Hospitalier Universitaire de Dijon Hôpital du Bocage, Dijon Cedex, France|Centre Hospital Lyon Sud, Pierre Benite, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT03225924,DLBCL,All,"60 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Institut Jules Bordet, Bruxelles, Belgium|Clinique Universite Catholique de Louvain Saint-Luc, Bruxelles, Belgium|University Hospital Gent, Gent, Belgium|Hopital Joliment, Haine-Saint-Paul, Belgium|Az Groeninge, Kortrijk, Belgium|UCL Namur, Yvoir, Belgium|Ch de Bourg En Bresse, Bourg-en-Bresse, France|CHU Côte de Nacre, Caen, France|CHU Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|Ch de Versailles - Hopital Andre Mignot, Le Chesnay, France|Clinique Victor Hugo, Le Mans, France|Chu de Limoges - Hopital Dupuytren, Limoges, France|Clinique de La Sauvegarde, Lyon, France|CHU Lyon Sud, Lyon, France|CHU Montpellier, Montpellier, France|Ch Region Mulhouse Et Sud Alsace, Mulhouse, France|Hopital Necker Paris, Paris, France|Chu de Bordeaux, Pessac, France|Ch Annecy Genevois, Pringy, France|Chu de Reims - Hopital Robert Debre, Reims, France|Chu de Rennes - Pontchaillou, Rennes, France|Ch de Roubaix-Hopital Victor Provo, Roubaix, France|Iuct Oncopole de Toulouse, Toulouse, France|Hôpital Bretonneau- Centre H. Kaplan, Tours, France|Ch de Valenciennes, Valenciennes, France|Chru de Nancy, Vandœuvre-lès-Nancy, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT01796470,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|INDOLENT NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Ventura County Hematology Oncology Specialists, Oxnard, California, United States|Cancer Center of Santa Barbara, Santa Barbara, California, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Collaborative Research Group LLC, Boynton Beach, Florida, United States|Weill Cornell Medical College, New York, New York, United States|University of Rochester, James P. Wilmot Cancer Center, Rochester, New York, United States|Signal Point Clinical Research Center, LLC, Middletown, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Charleston Hematology Oncology, Charleston, South Carolina, United States|MD Anderson Cancer Center, Houston, Texas, United States|Northwest Medical Specialties, Tacoma, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
c1cn2cc(-c3ccc4cn[nH]c4c3)nc(Nc3ccc(N4CCOCC4)cc3)c2n1,0,DB12121,__ENTOSPLETINIB,,Terminated,NCT01799889,CHRONIC LYMPHOCYTIC LEUKEMIA|MANTLE CELL LYMPHOMA|DIFFUSE LARGE B-CELL LYMPHOMA|NON-FL INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Arizona Oncology Associates, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Rocky Mountain Cancer Centers, LLP, Boulder, Colorado, United States|Kaiser Permanente of Colorado, Denver, Colorado, United States|Cancer Center of Central Connecticut, Southington, Connecticut, United States|Florida Cancer - Colonial, Fort Myers, Florida, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Ocala Oncology Center, Ocala, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Gwinnett Hospital System Dba The Center for Cancer Care, Lawrenceville, Georgia, United States|Northwest Georgia Oncology Center, Marietta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Indiana University Simon Cancer Center, Indianapolis, Indiana, United States|Hematology Oncology Clinic, PLLC, Baton Rouge, Louisiana, United States|Tufts Medical Center, Boston, Massachusetts, United States|University of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Minnesota Oncology Hematology, PA, Minneapolis, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States|One Medical Center Drive, Lebanon, New Hampshire, United States|Summit Medical Group, P.A., Florham Park, New Jersey, United States|Clinical Research Alliance, New York, New York, United States|University of North Carolina, Chapel Hill, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Oncology Hematology Care, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States|Williamette Valley Cancer Center and Research Institute, Springfield, Oregon, United States|Prairie Lakes Health Care System, Inc., Watertown, South Dakota, United States|Jones Clinic PC, Germantown, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology-Austin Midtown, Austin, Texas, United States|Texas Oncology-Medical City Dallas, Dallas, Texas, United States|Center for Cancer and Blood Disorders, Fort Worth, Texas, United States|Cancer Care Network of South Texas, San Antonio, Texas, United States|Cancer Care Center of South Texas, San Antonio, Texas, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Columbia Basin Hematology and Oncology, Kennewick, Washington, United States|University of Washington, Seattle, Washington, United States|Northwest Cancer Specialists, PC, Vancouver, Washington, United States|Yakima Valley Memorial Hospital North Star Lodge, Yakima, Washington, United States|Royal Victoria Regional Health Centre, Barrie, Ontario, Canada|Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,411.4591,83.37,6.0,2.0,6.0,44.44,120.86,4.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,NCT02219048,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Clinical Research Center of Alabama, Birmingham, Alabama, United States|Pulmonary Associates, Pa, Phoenix, Arizona, United States|Little Rock Allergy & Asthma Clinical Research Center, Little Rock, Arkansas, United States|California Research Medical Group, Inc, Fullerton, California, United States|California Allergy and Asthma Medical Group, Inc., Los Angeles, California, United States|Jonathan Corren MD, Inc., Los Angeles, California, United States|Integrated Research Group, Incorporated, Riverside, California, United States|Peninsula Research Associates, Rolling Hills Estates, California, United States|Allergy Associates Medical Group, San Diego, California, United States|Asthma and Allergy Associates, PC, Colorado Springs, Colorado, United States|Colorado Allergy and Asthma Centers, PC, Denver, Colorado, United States|University of South Florida - Asthma, Allergy and Immunology Clinical Research Unit, Tampa, Florida, United States|Florida Pulmonary Research Institute, LLC, Winter Park, Florida, United States|Chesapeake Clinical Research, Inc., Baltimore, Maryland, United States|Northeast Medical Research Associates, Inc., North Dartmouth, Massachusetts, United States|Clinical Research Institute, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Associated Specialists in Medicine, PC, Saint Louis, Missouri, United States|The Clinical Research Center, L.L.C., Saint Louis, Missouri, United States|The Asthma and Allergy Center, Bellevue, Nebraska, United States|North Shore Long Island Jewish Health System, New Hyde Park, New York, United States|American Health Research, Charlotte, North Carolina, United States|Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States|Bernstein Clinical Research Center, Cincinnati, Ohio, United States|University of Pittsburgh Asthma Institute, Pittsburgh, Pennsylvania, United States|Upstate Pharmaceutical Research, Greenville, South Carolina, United States|The Allergy & Asthma Clinic of Central Texas, Killeen, Texas, United States|University of Wisconsin School of Medicine & Public Health, Madison, Wisconsin, United States",C07D471/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
CC(C)(C)c1cc(NC(=O)NCc2ccccc2Sc2ccc3nnc(-c4ccccc4SCCO)n3c2)n(-c2ccc(O)c(Cl)c2)n1,0,DB12138,__PF-03715455,7511057,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",C07D471/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,43.66414094745271,8.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.95,700.273,129.6,6.0,4.0,6.0,72.53,208.94,11.0,1.0,0.0,0.0,1,1,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,0,1,1,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,1,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,1,0,1
Cc1cccc([C@H](C)c2c[nH]c(=S)[nH]2)c1C,0,DB12143,__REZATOMIDINE,US-20100029659-A1,Terminated,,FIBROMYALGIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,38.900182755292704,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.74,232.35,24.06,0.0,2.0,2.0,26.53,73.33,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
Cc1cccc([C@H](C)c2c[nH]c(=S)[nH]2)c1C,0,DB12143,__REZATOMIDINE,US-20100029659-A1,Terminated,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,38.900182755292704,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.74,232.35,24.06,0.0,2.0,2.0,26.53,73.33,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0
c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2,0,DB12145,__AZD-0328,US-20030166935-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,11.7620485020226,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.51,216.28400000000002,25.36,3.0,0.0,4.0,23.72,61.85,0.0,0.0,1.0,0.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Terminated,NCT02456675,REFRACTORY HODGKIN LYMPHOMA|RECURRENT ADULT HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
N#CCC1(n2cc(-c3ncnc4[nH]ccc34)cn2)CN(C2CCN(C(=O)c3ccnc(C(F)(F)F)c3F)CC2)C1,0,DB12154,__ITACITINIB,US-20110224190-A1,Terminated,NCT03721965,ACUTE GRAFT-VERSUS-HOST DISEASE,All,up to 17 Years   (Child),Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope National Medical Center, Duarte, California, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's Hospital Colorado - Center for Cancer and Blood Disorders, Aurora, Colorado, United States|Nemours/A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Nicklaus Children's Hospital, Miami, Florida, United States|University of Minnesota Medical Center, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States|Doernbecher Children's Hospital - Division of Pediatric Hematology, Portland, Oregon, United States|Children's Hospital of Philadelphia - Center for Childhood Cancer Research, Philadelphia, Pennsylvania, United States|Sarah Cannon Research Institute, LLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Fred Hutchinson Cancer Research Center, Seattle, Washington, United States|Centre Hospitalier Universitaire de Rennes, Rennes, Cedex 2, France|Hopitaux Universitaires De Strasbourg, Strasbourg, Cedex, France|CHU de Grenoble, Grenoble, France|CHU de Grenoble, Grenoble, France|Robert Debre Hospital, Paris, France|Hopitaux Universitaires De Strasbourg, Strasbourg Cedex, France|CHRU Nancy, Vandœuvre-lès-Nancy, France|CHU Nancy, Vandœuvre-lès-Nancy, France|Universitaetsklinikum Aachen, AoeR, Aachen, Germany|Universitatsklinikum Jena, Klinik fur Kinder und Jugendmedizin, Jena, Germany|Policlinico S. Orsola-Malpighi, Bologna, Italy|Azienda Ospedaliero Unversitatia Policlinico - Vittorio Emanuele - Presido Ospedaliero G. Rodolico, Catania, Italy|Fondazione MBBM, Monza, Italy|Ospedale Pediatrico Bambino Gesu, Roma, Italy|AOU Citta della Salute e della Scienza di Torino - Ospedale Regina Margherita, Torino, Italy|Hospital Vall D Hebron, Barcelona, Spain|Hospital Clinico de Santiago de Compostela, Santiago De Compostela, Spain|Hospital Universitari i Politecnic La Fe, Valencia, Spain|Birmingham Childrens Hospital, Birmingham, United Kingdom|Bristol Royal Hospital for Children, Bristol, United Kingdom|Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom|Great Ormond Street Hospital for Children, London, United Kingdom|Central Manchester University Hospital - Royal Manchester Children's Hospital, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Surrey Quays, United Kingdom",4,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,55.0,39.754409741473104,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.35,553.526,119.62,7.0,1.0,6.0,51.98,146.86,6.0,0.0,1.0,0.0,1,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,1,1,1,1,1,1,0,1,0,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,1,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",C07D335/02,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00612612,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00538187,ADULT NON-HODGKIN LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00719901,REFRACTORY MULTIPLE MYELOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Terminated,NCT00918931,LEUKEMIA|SYSTEMIC MASTOCYTOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,0,DB12191,__OBATOCLAX,EP-1644363-B1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",C07D335/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,19.0,92.8479024209942,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.14,317.392,53.17,2.0,2.0,4.0,37.32,100.22,3.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,0,DB12226,__TERAMEPROCOL,US-20060135461-A1,Terminated,NCT00664677,LEUKEMIAS|ACUTE MYELOID LEUKEMIA (AML)|ACUTE LYMPHOCYTIC LEUKEMIA (ALL)|ADULT T CELL LEUKEMIA (ATL)|CHRONIC MYELOID LEUKEMIA (CML-BP)|CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)|MYELODYSPLASTIC SYNDROME (MDS)|CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML),All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UNC, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.77,358.478,36.92,4.0,0.0,2.0,41.9,104.55,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
COc1ccc(C[C@H](C)[C@H](C)Cc2ccc(OC)c(OC)c2)cc1OC,0,DB12226,__TERAMEPROCOL,US-20060135461-A1,Terminated,NCT00664586,REFRACTORY SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Sarah Cannon Cancer Center, Nashville, Tennessee, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,3.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.77,358.478,36.92,4.0,0.0,2.0,41.9,104.55,9.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0
O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1,0,DB12228,__TELCAGEPANT,EP-2007764-B1,Terminated,,MIGRAINE DISORDERS,,,,,"FISABIO, Elche, Alicante, Spain",C07D335/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,28.68231380521161,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.44,566.523,97.88,4.0,2.0,5.0,52.43,134.6,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0
OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O,0,DB12236,__BEXAGLIFLOZIN,WO-2009026537-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",A61P3/00 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,30.0,32.7488,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.33,464.94,108.61,7.0,4.0,4.0,49.38,118.44,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1
CC/C(=C(/c1ccc(/C=C/C(=O)O)cc1)c1ccc2[nH]ncc2c1)c1ccc(F)cc1Cl,0,DB12253,__GDC-0810,WO-2012037411-A2,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,52.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.36,446.91,65.98,3.0,2.0,4.0,46.2,135.99,6.0,0.0,1.0,0.0,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,1,1,0,1
COc1ccc(S(=O)(=O)Nc2cccnc2Nc2ccc(O)cc2)cc1,0,DB12254,__ABT-751,5250549,Terminated,NCT00439296,RECURRENT PEDIATRIC ALL|RELAPSED PEDIATRIC ALL|ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY PEDIATRIC ALL,All,"up to 21 Years   (Child, Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Childrens Hospital Los Angeles, Los Angeles, California, United States|Stanford University Medical Center, Palo Alto, California, United States|UCSF School of Medicine, San Francisco, California, United States|C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States|Seattle Children's Hospital, Seattle, Washington, United States",C07H15/26,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,25.9225035421671,29.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.4,371.41,100.55,6.0,3.0,3.0,38.29,97.98,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,1,0
O=C(O)CNC(=O)c1ncc(-c2cccc(Cl)c2)cc1O,0,DB12255,__VADADUSTAT,US-20070299086-A1,Withdrawn,,ANEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,39.5572804369699,9.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.53,306.7,99.52,5.0,3.0,2.0,29.63,75.51,4.0,0.0,1.0,0.0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1
CSc1ccc(OCc2ncc([N+](=O)[O-])n2C)cc1,0,DB12265,__FEXINIDAZOLE,US-20070116729-A1,Terminated,,VISCERAL LEISHMANIASIS,,,,,"FISABIO, Elche, Alicante, Spain",A61K9/32,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,44.0,76.946138524405,4.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.28,279.31,70.19,4.0,0.0,2.0,28.53,72.64,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,1
COc1cc(N2CCC(N3CCN(C)CC3)CC2)ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1,0,DB12267,__BRIGATINIB,9012462,Withdrawn,NCT04260009,ANAPLASTIC LYMPHOMA KINASE POSITIVE (ALK +) ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMORS|SOLID TUMORS,All,"1 Year to 25 Years   (Child, Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07F9/65717,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,72.0,70.99940450522591,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.11,584.1,85.86,9.0,2.0,5.0,64.1,164.77,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1
CC(C)OP(=O)(OC(C)C)C(Cc1cc(C(C)(C)C)c(O)c(C(C)(C)C)c1)P(=O)(OC(C)C)OC(C)C,0,DB12276,__APOMINE,6048995,Terminated,,OSTEOPOROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07F9/404,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,11.0,19.7129304503172,11.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.53,562.665,91.29,3.0,1.0,1.0,61.56,151.23,14.0,1.0,0.0,0.0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,NCT03135262,"FOLLICULAR LYMPHOMA|LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Colorado, Aurora, Colorado, United States|The University of Chicago Medical Center, Chicago, Illinois, United States|Norton Cancer Institute - Dutchmans, Louisville, Kentucky, United States|Mount Sinai Medical Center, New York, New York, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Swedish Cancer Inst., Seattle, Washington, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Klinikum Augsburg, Augsburg, Germany|Universitätsklinikum ""Carl Gustav Carus"" der Technischen Universität Dresden, Dresden, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Klinikum Kassel; Klinik für Onkologie und Hämatologie, Kassel, Germany|Universitätsklinikum Köln, Köln, Germany|Klinikum rechts der Isar der TU München, München, Germany|Universitätsklinikum Würzburg; Studienzentrale Hämatologie/Onkologie, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Goyang-si, Korea, Republic of|Severance Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,NCT02624986,NON-HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic Arizona, Phoenix, Arizona, United States|University of Colorado, Aurora, Colorado, United States|Norton Medical Plaza II, Louisville, Kentucky, United States|Swedish Cancer Institute, Cary, North Carolina, United States|Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States|Guthrie Clinic, Sayre, Pennsylvania, United States|Rhode Island Hospital, Providence, Rhode Island, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Prince of Wales Hospital, Randwick, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Linear Clinical Research Limited, Nedlands, Western Australia, Australia|Zentralklinikum Augsburg, Augsburg, Germany|Charité Research Organisation GmbH Campus-Virchow-Klinikum, Berlin, Germany|SLK-Kliniken Heilbronn GmbH, Heilbronn, Germany|Universitätsklinikum Köln, Köln, Germany|Universitätsklinikum Wurzburg, Würzburg, Germany|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|National Cancer Center, Gyeonggi-do, Korea, Republic of|Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|North Shore Hospital, Auckland, New Zealand|Christchurch Hospital, Christchurch, New Zealand|Auckland Clinical Studies Limited, Grafton, New Zealand",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COc1cc(C(=O)O)ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,0,DB12325,__IDASANUTLIN,US-20100152190-A1,Terminated,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,47.0,35.18758085381621,9.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.75,616.49,111.45,6.0,3.0,4.0,60.11,156.9,8.0,0.0,1.0,0.0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,0,1,0,0
COC1=C(OC)[C@H](O)[C@H](C/C=C(\C)CC/C=C(\C)CCC=C(C)C)[C@@H](C)C1=O,0,DB12326,__ANTROQUINONOL,,Terminated,NCT04110873,ATOPIC DERMATITIS,All,"20 Years to 65 Years   (Adult, Older Adult)",Other|Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Chung Shan Medical University Hospital, Taichung, Taiwan",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,5.21,390.564,55.76,4.0,1.0,1.0,46.93,120.07,10.0,0.0,1.0,0.0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,0
C[C@]12C(=O)OC(=O)[C@@]1(C)[C@@H]1CC[C@H]2O1,0,DB12328,__CANTHARIDIN,4298752,Terminated,NCT03426995,RHEUMATOID ARTHRITIS,Male,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","GSK Investigational Site, Cambridge, United Kingdom",C07D493/04,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,16.0,13.4705024743834,63.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.1,196.202,52.6,3.0,0.0,3.0,18.54,45.4,0.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CNCc1ccc(-c2[nH]c3cc(F)cc4c3c2CCNC4=O)cc1,0,DB12332,__RUCAPARIB,6495541,Terminated,NCT02711137,SOLID TUMORS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of California, La Jolla, California, United States|Sarah Cannon Research Institute at Health One, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States|University of Michigan, Ann Arbor, Michigan, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|University of Rochester, Wilmot Cancer Center, Rochester, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Consultants, P.A., Houston, Texas, United States|The Methodist Hospital, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|MultiCare Institute for Research and Innovation, Tacoma, Washington, United States|Institut Jules Bordet, Clinical Trial Conduct Unit, Brussels, Belgium|HÔPITAL SAINT-LOUIS, Service Hématologie Adultes, Paris, France",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.0,35.2204357379001,20.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.39,323.371,56.92,2.0,3.0,4.0,35.19,92.91,3.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Withdrawn,NCT01423539,DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fountain Valley, California, United States|Hudson, Florida, United States|Lawrenceville, Georgia, United States|Centralia, Illinois, United States|Harvey, Illinois, United States|Terre Haute, Indiana, United States|Hazard, Kentucky, United States|Paducah, Kentucky, United States|Rockville, Maryland, United States|Jefferson City, Missouri, United States|Great Falls, Montana, United States|Newark, Ohio, United States|Nashville, Tennessee, United States",C07D487/08,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,0,DB12340,__NAVITOCLAX,7390799,Withdrawn,,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/08,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,12.0,25.4296802809092,41.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.77,974.613,128.36,10.0,2.0,7.0,99.45,256.36,16.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,1,1,0,1,1,1,0,1,0,0,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,1,0,1,0,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,1,1,0,1,0,1
CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,0,DB12369,__SOTRASTAURIN,WO-2005039549-A1,Withdrawn,NCT02285244,PROLYMPHOCYTIC LEUKEMIA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,16.0,32.7488,20.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.12,438.4812,94.22,6.0,2.0,6.0,46.82,126.14,3.0,0.0,1.0,0.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0
Cn1nc(N)c2cn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c3ncnc1c23,0,DB12405,__TRICIRIBINE,5633235,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,34.7276124766422,177.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,320.309,144.47,8.0,4.0,4.0,31.22,90.56,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O,0,DB12406,__LISOFYLLINE,5281731,Terminated,NCT01603121,TYPE 1 DIABETES,All,18 Years to 45 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,"Eastern Virginia Medical School Strelitz Diabetes Center, Norfolk, Virginia, United States",C07F7/1804,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,5.0,14.1604550401445,245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.78,280.328,78.67,4.0,1.0,2.0,30.03,74.65,5.0,0.0,1.0,0.0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,0,0
C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CC=C2n1cnc2ccccc21,0,DB12415,__GALETERONE,WO-2008154382-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,32.7488,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.95,388.5451,38.05,2.0,1.0,6.0,46.69,118.58,1.0,0.0,1.0,0.0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,0,0,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,0,0,0,0
Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB12427,__ORVEPITANT,WO-2004091615-A1,Withdrawn,NCT03464526,PRURITUS|ATOPIC DERMATITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,14.0,32.7488,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.65,628.636,47.1,3.0,0.0,5.0,58.9,151.59,6.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0
Cc1cc(F)ccc1[C@H]1C[C@@H](N2CCN3C(=O)CC[C@H]3C2)CCN1C(=O)N(C)[C@H](C)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB12427,__ORVEPITANT,WO-2004091615-A1,Withdrawn,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,14.0,32.7488,2.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.65,628.636,47.1,3.0,0.0,5.0,58.9,151.59,6.0,1.0,0.0,0.0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O,0,DB12442,__ALVESPIMYCIN,,Terminated,NCT01126502,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.84,616.7455,169.52,9.0,4.0,2.0,66.39,172.38,8.0,0.0,1.0,0.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0
COc1c(C)cc2c(c1O)[C@@H]1[C@@H]3Cc4c(OC(C)=O)c(C)c5c(c4[C@H](CNC(=O)/C=C/c4cccc(C(F)(F)F)c4)N3[C@@H](O)[C@H](C2)N1C)OCO5,0,DB12454,__ZALYPSIS,,Terminated,NCT00359294,SOLID TUMORS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.33,709.7189999999997,130.03,9.0,3.0,7.0,70.93,180.8,8.0,1.0,0.0,0.0,1,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,0,1,1,1,1,0
Nc1nc(=O)n([C@H]2C=C[C@@H](CO)O2)cc1F,0,DB12470,__DEXELVUCITABINE,6194391,Terminated,NCT00300573,HIV INFECTIONS|HUMAN IMMUNODEFICIENCY VIRUS,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Long Beach, California, United States|Brandon, Florida, United States|Fort Lauderdale, Florida, United States|Miami, Florida, United States|Plantation, Florida, United States|Atlanta, Georgia, United States|Chicago, Illinois, United States|New York, New York, United States|Portland, Oregon, United States|Dallas, Texas, United States|San Juan, Puerto Rico",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,32.0,20.1728988274913,7.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-0.89,227.195,88.15,5.0,2.0,2.0,20.03,53.14,2.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,0,DB12483,__COPANLISIB,7511041,Terminated,NCT02455297,"LYMPHOMA, MANTLE-CELL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Baltimore, Maryland, United States|Hackensack, New Jersey, United States|New York, New York, United States|New York, New York, United States|Burlington, Vermont, United States",C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1
COc1c(OCCCN2CCOCC2)ccc2c1N=C(NC(=O)c1cnc(N)nc1)N1CCN=C21,0,DB12483,__COPANLISIB,7511041,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,C07D471/14,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,12.0,66.3997207334852,19.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.02,480.529,139.79,11.0,2.0,5.0,51.71,132.78,7.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,1,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,0,1
CN1CCC(CNc2ccc3ncc(-c4cccc(OC(F)(F)F)c4)n3n2)CC1,0,DB12494,__SGI-1776,WO-2008058126-A2,Terminated,NCT00848601,PROSTATE CANCER|NON-HODGKINS LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"UCLA, Los Angeles, California, United States|Cancer Therapy Research Center, San Antonio, Texas, United States|Royal Marsden Hospital, Sutton, England, United Kingdom",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,34.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.53,405.425,54.69,5.0,1.0,4.0,39.98,112.63,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,1
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,NCT00557518,"DIABETES MELLITUS, TYPE 1|DIABETIC NEPHROPATHY",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia|International Diabetes Institute, Caulfield, Victoria, Australia|Dept. of Clinical and Biomedical Science Myers House, Geelong, Victoria, Australia|Austin Health, Heidelburg, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Steno Diabetes Center, Gentofte, Denmark",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1sc[n+](CC(=O)c2ccccc2)c1C,0,DB12497,__ALAGEBRIUM,6007865,Terminated,,DIABETIC NEPHROPATHY,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,45.0,25.2654058604899,17.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,-0.77,232.32,20.95,1.0,0.0,2.0,24.97,65.98,3.0,0.0,1.0,0.0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1oc(-c2ccccc2)nc1COc1ccc(CO/N=C(\CCC(=O)O)c2ccccc2)cc1,0,DB12511,__IMIGLITAZAR,6251926,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,27.0,19.3515267253947,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.16,470.525,94.15,6.0,1.0,4.0,52.47,141.78,11.0,1.0,0.0,0.0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,1,1,0
CC[C@H](Nc1cc(C)nc2c(-c3ccc(OC)cc3C)c(C)nn12)c1nc(C)no1,0,DB12512,__VERUCERFONT,WO-2006044958-A1,Withdrawn,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,25.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.05,406.49,90.37,6.0,1.0,4.0,45.29,127.24,5.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1
O=C(O)CC[C@H](NC(=O)N[C@@H](CCCCNCc1ccc([123I])cc1)C(=O)O)C(=O)O,0,DB12514,__IOFOLASTAT_I-123,,Withdrawn,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.82,531.337,165.06,8.0,6.0,1.0,46.59,114.95,14.0,1.0,0.0,0.0,1,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1
CCN1CCC[C@H]1CNC(=O)c1c(O)c(Cl)cc(Cl)c1OC,0,DB12518,__RACLOPRIDE,6150353,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,14.4890038809831,77.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.19,347.24,61.8,4.0,2.0,2.0,35.02,88.07,5.0,0.0,1.0,0.0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0
Cc1cc(C)c2nc(-c3cnc(NCCCC4CCN(C)CC4)nc3C)[nH]c2c1,0,DB12522,__TOREFORANT,WO-2007117399-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,32.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.72,392.551,69.73,5.0,2.0,4.0,48.0,131.1,6.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,1,1,1,1,0,0,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0,1,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
CC(=O)N(C)c1cccc(-c2ccnc3c(C(=O)c4cccs4)cnn23)c1,0,DB12590,__INDIPLON,US-20030004346-A1,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",C07D487/04 ,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,48.9537772849545,44.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.01,376.43,67.57,4.0,0.0,4.0,39.66,114.23,4.0,0.0,1.0,0.0,0,0,0,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,1,1,1
O=C(NCC12CC3CC(CC(C3)C1)C2)c1cc(CCCNCCCO)ccc1Cl,0,DB12594,__AZD-9056,WO-2001044170-A1,Withdrawn,NCT00920608,RHEUMATOID ARTHRITIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science,,A61P1/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,13.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.33,419.01,61.36,3.0,3.0,4.0,47.83,118.78,10.0,0.0,1.0,0.0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,1,1,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0
CC(C)NCCCn1c(Sc2cc3c(cc2I)OCO3)nc2c(N)ncnc21,0,DB12638,__PU-H71,WO-2014018862-A1,Terminated,NCT01581541,SOLID TUMORS|LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,1.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.61,512.368,100.11,7.0,2.0,4.0,46.94,119.54,7.0,0.0,1.0,0.0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0
C[C@@H](Oc1nnc(-c2ccncc2)n1C)c1cc(-c2cccc(Cl)c2)on1,0,DB12644,__AZD-2066,US-20100041706-A1,Terminated,NCT00939094,NEUROPATHIC PAIN|MECHANICAL HYPERSENSITIVITY,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Research Site, Tucson, Arizona, United States|Research Site, Los Angeles, California, United States|Research Site, Sacramento, California, United States|Research Site, San Francisco, California, United States|Research Site, Walnut Creek, California, United States|Research Site, Boulder, Colorado, United States|Research Site, Atlantis, Florida, United States|Research Site, Aventura, Florida, United States|Research Site, Clearwater, Florida, United States|Research Site, Fort Myers, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, Palm Beach Gardens, Florida, United States|Research Site, Sarasota, Florida, United States|Research Site, St Petersburg, Florida, United States|Research Site, Sunrise, Florida, United States|Research Site, Canton, Georgia, United States|Research Site, Marietta, Georgia, United States|Research Site, Evansville, Indiana, United States|Research Site, New Orleans, Louisiana, United States|Research Site, Brockton, Massachusetts, United States|Research Site, Bingham Farms, Michigan, United States|Research Site, Las Vegas, Nevada, United States|Research Site, Reno, Nevada, United States|Research Site, Lumberton, New Jersey, United States|Research Site, Willingboro, New Jersey, United States|Research Site, Albuquerque, New Mexico, United States|Research Site, Jacksonville, North Carolina, United States|Research Site, Winston-salem, North Carolina, United States|Research Site, Kettering, Ohio, United States|Research Site, Portland, Oregon, United States|Research Site, Bridgeville, Pennsylvania, United States|Research Site, Philadelphia, Pennsylvania, United States|Research Site, Austin, Texas, United States|Research Site, Dallas, Texas, United States|Research Site, Irving, Texas, United States|Research Site, Lexington, Texas, United States|Research Site, Longview, Texas, United States|Research Site, San Antonio, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,12.0,32.7488,1.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.61,381.82,78.86,5.0,0.0,4.0,38.7,112.85,5.0,0.0,1.0,0.0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,0,1
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,0,DB12645,__GIVINOSTAT,EP-2344253-B1,Terminated,NCT01557452,JUVENILE IDIOPATHIC ARTHRITIS,All,"2 Years to 18 Years   (Child, Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"1st Faculty of Medicine and General Faculty Hospital, Praha, Czech Republic",2,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,55.0319308404689,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.18,421.49699999999996,90.9,5.0,3.0,3.0,47.59,122.49,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
CCN(CC)Cc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1,0,DB12645,__GIVINOSTAT,EP-2344253-B1,Terminated,NCT01261624,POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS,All,2 Years to 17 Years   (Child),Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Universitair Ziekenhuis Gent, Gent, Belgium|1st Faculty of Medicine and General Faculty Hospital, Praha 2, Praha, Czech Republic|Ospedale Meyer, Firenze, FI, Italy|Policlinico G. Martino, Messina, ME, Italy|Istituto Gaetano Pini, Milano, MI, Italy|Azienda Ospedaliera-Università di Padova, Padova, PD, Italy|Institutul pentru Ocrotirea Mamei si Copilului ""Alfred Rusescu"", Bucarest, Romania|Spitalul Clinic de Urgenta pentru Copii ""M.S. Curie"", Bucarest, Romania|Mother and Child Health Institute ""Dr Vukan Cupic"", Novi Beograd, Belgrade, Serbia|Institute of Rheumatology Belgrade, Belgrade, Serbia|University Clinical Center Nis, Nis, Serbia|Children's Hospital - University Medical Centre Ljubljana, Ljubljana, Slovenia|Hospital Ramón y Cajal, Madrid, Spain",2,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,55.0319308404689,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.18,421.49699999999996,90.9,5.0,3.0,3.0,47.59,122.49,9.0,0.0,1.0,0.0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0
NC(=O)C1(NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](Cc2csc3ccccc23)NC(=O)C2CCNCC2)CCNCC1,0,DB12678,__RELAMORELIN,,Terminated,,DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.82,790.98,199.34,7.0,8.0,7.0,84.58,218.07,15.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,0,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,0
CCNC(=O)[C@H]1O[C@@H](n2cnc3c(NCC(c4ccccc4)c4ccccc4)nc(C(=O)NCCNC(=O)NC4CCN(c5ccccn5)CC4)nc32)[C@H](O)[C@@H]1O,0,DB12691,__UK-432097,US-20030013675-A1,Terminated,,CHRONIC OBSTRUCTIVE PULMONARY DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,42.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.08,777.8713,220.78,12.0,7.0,7.0,83.68,212.67,14.0,1.0,0.0,0.0,1,1,0,1,1,1,1,1,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,1,1,1,1,1,1,1,0,0,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1
S=C=NCCc1ccccc1,0,DB12695,__PHENETHYL_ISOTHIOCYANATE,6348220,Withdrawn,NCT00968461,LEUKEMIA|LYMPHOPROLIFERATIVE DISORDERS,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,24.0,34.3990636358036,128.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.41,163.239,12.36,1.0,0.0,1.0,18.1,50.7,3.0,0.0,1.0,0.0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CC(C)[C@H](C(=O)Nc1ccc(C(=O)NO)cc1)c1ccccc1,0,DB12707,__AR-42,,Suspended,NCT02569320,RECURRENT PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.48,312.369,78.43,3.0,3.0,2.0,32.81,90.21,5.0,0.0,1.0,0.0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0
CCOC(=O)[C@H](C)NP(=O)(COCCn1cnc2c(NC3CC3)nc(N)nc21)N[C@@H](C)C(=O)OCC,0,DB12762,__RABACFOSADINE,,Terminated,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.62,526.535,184.61,9.0,4.0,3.0,52.56,133.52,17.0,1.0,0.0,0.0,1,1,0,1,0,1,0,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,0,1,0,1
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Terminated,,MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Withdrawn,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
O=C(NCc1ccncc1)C12CC3CC(C1)CC(c1ccc(Cl)cc1)(C3)C2,0,DB12764,__ABC-294640,7338961,Withdrawn,,DIFFUSE LARGE B-CELL LYMPHOMA,,,,,"FISABIO, Elche, Alicante, Spain",C07D211/58,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.0,20.632867204665306,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.56,380.92,41.99,2.0,1.0,5.0,42.19,106.94,4.0,0.0,1.0,0.0,1,0,0,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,1,1,1
Nc1ccn([C@H]2CO[C@@H](CO)S2)c(=O)n1,0,DB12855,__APRICITABINE,7968703,Terminated,NCT00612898,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UAB, 845 19th St South, South Beville Biomedical Research Building, Birmingham, Alabama, United States|University of Alabama at Birmingham, Birmingham, Alabama, United States|Southwest Center for HIV/AIDS, Phoenix, Arizona, United States|Living Hope Clinical Foundation, Inc, Long Beach, California, United States|Kaiser Permanente Medical Center, San Francisco, California, United States|AIDS Research Alliance, West Hollywood, California, United States|Denver Health & Hospital Authority, Denver, Colorado, United States|Georgetown University, Washington, District of Columbia, United States|George Washington University, Washington, District of Columbia, United States|Gary Richmond, MD, Fort Lauderdale, Florida, United States|Orlando Immunology Center, Orlando, Florida, United States|Infectious Disease Research Institute, Inc, Tampa, Florida, United States|Treasure Coast Infectious Diseases Consultants, Vero Beach, Florida, United States|Aids Research Consortium Of Atlanta Inc., Atlanta, Georgia, United States|Atlanta Infectious Disease Group, PC, Atlanta, Georgia, United States|University of Hawaii, Honolulu, Hawaii, United States|Northwestern University, Chicago, Illinois, United States|University of Kansas School of Medicine, Wichita, Kansas, United States|Fenway Community Health Center, Boston, Massachusetts, United States|Community Research Intiative of New England, Boston, Massachusetts, United States|I.D. Care, Inc., Hillsborough, New Jersey, United States|Saint Michael's Medical Center, Newark, New Jersey, United States|Summa Health System, Akron, Ohio, United States|The Research & Education Institute, Portland, Oregon, United States|Central Texas Clinical Research, Austin, Texas, United States|Nicholaos C Bellos, MD, PA, Dallas, Texas, United States|North Texas Infectious Diseases Consultants, P.A., Dallas, Texas, United States|Tarrant County Infection Disease Associates, Fort Worth, Texas, United States|University of Texas Medical Brach, Galveston, Texas, United States|Therapeutic Concepts, Houston, Texas, United States|Resarch Access Network, Houston, Texas, United States|DCOL Center for Clinical Research, Longview, Texas, United States|Swedish Medical Center, Seattle, Washington, United States|407 Doctors, Darlinghurst, New South Wales, Australia|Parramatta Sexual Health Clinic, Parramatta, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Carlton Clinic, Carlton, Victoria, Australia|Melbourne Sexual Health Centre, Carlton, Victoria, Australia|The Alfred, Melbourne, Victoria, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Prahran Market Clinic, South Yarra, Victoria, Australia|Prins Leopold Institute voor Tropische Geneeskunde, Antwerpen, Belgium|Hopitaux IRIS Sud, Bruxelles, Belgium|Cliniques Universitaires Saint-Luc, Bruxelles, Belgium|Ubc Downtown I.D. Clinic, Vancouver, British Columbia, Canada|Hamilton Health Sciences Corporation, Hamilton, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada|Centre Hospitalier Universitaire de Quebec, Quebec, Canada|EPIMED GmbH, Berlin, Germany|Charite-Universitatsmedizin Berlin, Berlin, Germany|Ruhr-Universitat Bochum, Bochum, Germany|Universitatsklinikum Bonn, Bonn, Germany|Klinikum Dortmund gGmbH, Dortmund, Germany|Universitatsklinikum Essen, Essen, Germany|Klinikum der Johann-Wolfgang Goethe-Universitat, Frankfurt, Germany|Praxis fuer Innere Medizin, Freiburg, Germany|Praxis Dr.Schneider, Furth, Germany|Dr. med. Birger Kuhlmann, Hannover, Germany|Klinikum der Universitat Munchen - Innenstadt, Munchen, Germany|Gemeinschaftspraxis E. Schnaitmann, Dr. med. A. Schaffert, Dr. med. A. Trein, Dr. med. E. Ibler, Stuttgart, Germany|Praxis Dres. Ulmer, Frietsch, Muller, Stuttgart, Germany|Soroka University Medical Center, Beer-Sheva, Israel|Rambam Medical Center, Haifa, Israel|Hadassah University Hospital Ein Kerem, Jerusalem, Israel|The Chaim Sheba Medical Center, Ramat-Gan, Israel|Kaplan Medical Center, Rehovot, Israel|Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel|Ospedale S.Maria Annunziata, Antella, Italy|Azienda Ospedaliera Universitaria di Ferrara Arcispedale S.Anna, Ferrara, Italy|Azienda Ospedaliera Universitaria San Martino, Genova, Italy|Fondazione Centro San Raffaele del Monte Tabor, Milano, Italy|Ospedale Luigi Sacco, Milano, Italy|Azienda Ospedaliero-Universitaria di Modena Policlinico, Modena, Italy|Azienda Ospedaliera Cotugno, Napoli, Italy|Azienda Ospedaliera di Padova, Padova, Italy|Istituto Nazionale Malattie Infettive ""Lazzaro Spallanzani"" IRCCS, Roma, Italy|Comprensorio Amedeo di Savoia - Birago Di Vische, Torino, Italy|Hospital Nacional CASE-EsSalud, Arequipa, Peru|Investigaciones Medicas en Salud, Lima, Peru|Hospital Dos de Mayo, Lima, Peru|Via Libre, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Edgardo Rebagliati Hospital, Lima, Peru|Instituto De Investigacion Cientifica, Ponce, Puerto Rico|University of Puerto Rico, San Juan, Puerto Rico|Hope Clinical Research, San Juan, Puerto Rico|Mahidol University Hospital for Tropical Diseases, Bangkok, Thailand|Pharmongkutklao Hospital, Bangkok, Thailand|The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand|Ramathibodi Hospital, Mahidol University, Bangkok, Thailand|Sirraj Hospital, Mahidol Universoty, Bangkok, Thailand|Maharaj Nakorn Chiang Mai, Chiang Mai University, Chiang Mai, Thailand|Khon Kaen University, Khon Kaen, Thailand|Bamrasnaradura Institution, Nonthaburi, Thailand|Birmingham Heartlands Hospital, Birmingham, United Kingdom|St Bartholomew's Hospital, London, United Kingdom|Royal Free Hospital, London, United Kingdom|Guy's King's & St. Thomas' School of Medicine, London, United Kingdom|St Mary's Hospital, London, United Kingdom",C07D411/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,75.69765292921821,2.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.1,229.25,88.15,5.0,2.0,2.0,21.69,55.09,2.0,0.0,1.0,0.0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0
O[C@H]([C@@H]1CO1)[C@@H](O)[C@H]1CO1,0,DB12873,__DIANHYDROGALACTITOL,US-20020037328-A1,Withdrawn,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,13.0,11.663483849771,2.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,-1.4,146.142,62.22,4.0,2.0,2.0,13.67,31.38,3.0,0.0,1.0,0.0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT02889523,"LYMPHOMA, LARGE B-CELL, DIFFUSE",All,"60 Years to 80 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"CHRU Lille - Hôpital Claude Huriez, Lille Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|CHU Lyon Sud, Pierre-Bénite Cedex, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Suspended,NCT03213665,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III HODGKIN LYMPHOMA|ANN ARBOR STAGE III NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV HODGKIN LYMPHOMA|ANN ARBOR STAGE IV NON-HODGKIN LYMPHOMA|EWING SARCOMA/PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|LOW GRADE GLIOMA|RECURRENT EPENDYMOMA|RECURRENT EWING SARCOMA|RECURRENT GLIOMA|RECURRENT HEPATOBLASTOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT LANGERHANS CELL HISTIOCYTOSIS|RECURRENT MALIGNANT GERM CELL TUMOR|RECURRENT MALIGNANT GLIOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT MEDULLOBLASTOMA|RECURRENT NEUROBLASTOMA|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT OSTEOSARCOMA|RECURRENT PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT RHABDOID TUMOR|RECURRENT RHABDOMYOSARCOMA|RECURRENT SOFT TISSUE SARCOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY LANGERHANS CELL HISTIOCYTOSIS|REFRACTORY MALIGNANT GERM CELL TUMOR|REFRACTORY MALIGNANT GLIOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY MEDULLOBLASTOMA|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY OSTEOSARCOMA|REFRACTORY PERIPHERAL PRIMITIVE NEUROECTODERMAL TUMOR|REFRACTORY RHABDOID TUMOR|REFRACTORY SOFT TISSUE SARCOMA|RHABDOID TUMOR|STAGE III SOFT TISSUE SARCOMA AJCC V7|STAGE IV SOFT TISSUE SARCOMA AJCC V7|WILMS TUMOR,All,"12 Months to 21 Years   (Child, Adult)",NIH|Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Providence Alaska Medical Center, Anchorage, Alaska, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Banner University Medical Center - Tucson, Tucson, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|Rady Children's Hospital - San Diego, San Diego, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|AdventHealth Orlando, Orlando, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Southern Illinois University School of Medicine, Springfield, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Saint Vincent Hospital and Health Care Center, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Maine Children's Cancer Program, Scarborough, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids, Michigan, United States|Bronson Methodist Hospital, Kalamazoo, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Albany Medical Center, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|New York Medical College, Valhalla, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Scott and White Memorial Hospital, Temple, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
CCN(c1cc(-c2ccc(CN3CCOCC3)cc2)cc(C(=O)NCc2c(C)cc(C)[nH]c2=O)c1C)C1CCOCC1,0,DB12887,__TAZEMETOSTAT,8410088,Withdrawn,NCT03217253,ANN ARBOR STAGE III B-CELL NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV B-CELL NON-HODGKIN LYMPHOMA|METASTATIC MALIGNANT SOLID NEOPLASM|STAGE III HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIA HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIB HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IIIC HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IV HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IVA HEPATOCELLULAR CARCINOMA AJCC V7|STAGE IVB HEPATOCELLULAR CARCINOMA AJCC V7|UNRESECTABLE SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,25.0,11.630628965687098,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.44,572.75,83.14,6.0,2.0,5.0,66.04,171.5,9.0,0.0,1.0,0.0,1,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,1,1,1,1,0,1
O=C[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO,0,DB12907,__MANNOSE,3932678,Withdrawn,NCT00886496,"FEVER, SWEATS, AND HOT FLASHES|INFECTION|LEUKEMIA|LYMPHOMA|MYELODYSPLASTIC SYNDROMES|NEUTROPENIA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,2 Years to 17 Years   (Child),Industry|NIH,Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Children's Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States",A23L27/30,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,18.628719275549802,11245.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-2.4,180.1559,118.22,6.0,5.0,0.0,16.24,37.35,5.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0
CC(/C=N/N=C(N)N)=N\N=C(N)N,0,DB12967,__MITOGUAZONE,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.93,184.2024,153.52,8.0,4.0,0.0,18.58,48.85,3.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB12973,__SERLOPITANT,US-20100209496-A1,Terminated,NCT03540160,PRURITUS|PRURIGO NODULARIS|ATOPIC DERMATITIS|PSORIASIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Study Site 504, Birmingham, Alabama, United States|Study Site 204, Fremont, California, United States|Study Site 383, North Hollywood, California, United States|Study Site 356, San Diego, California, United States|Study Site 514, Santa Ana, California, United States|Study Site 501, Aventura, Florida, United States|Study Site 210, Coral Gables, Florida, United States|Study Site 534, Fort Lauderdale, Florida, United States|Study Site 531, Miami, Florida, United States|Study Site 222, North Miami Beach, Florida, United States|Study Site 510, Newnan, Georgia, United States|Study Site 388, Skokie, Illinois, United States|Study Site 228, Louisville, Kentucky, United States|Study Site 527, New Orleans, Louisiana, United States|Study Site 525, Glenn Dale, Maryland, United States|Study Site 506, Ann Arbor, Michigan, United States|Study Site 515, Detroit, Michigan, United States|Study Site 371, Saint Joseph, Missouri, United States|Study Site 528, Saint Louis, Missouri, United States|Study Site 227, Omaha, Nebraska, United States|Study Site 526, Henderson, Nevada, United States|Study Site 201, East Windsor, New Jersey, United States|Study Site 529, Verona, New Jersey, United States|Study Site 507, Brooklyn, New York, United States|Study Site 508, Buffalo, New York, United States|Study Site 500, New York, New York, United States|Study Site 517, New York, New York, United States|Study Site 341, High Point, North Carolina, United States|Study Site 516, Bexley, Ohio, United States|Study Site 509, Cleveland, Ohio, United States|Study Site 524, Dublin, Ohio, United States|Study Site 112, Tulsa, Oklahoma, United States|Study Site 523, Philadelphia, Pennsylvania, United States|Study Site 522, Pittsburgh, Pennsylvania, United States|Study Site 345, Johnston, Rhode Island, United States|Study Site 343, Spartanburg, South Carolina, United States|Study Site 511, Knoxville, Tennessee, United States|Study Site 365, Austin, Texas, United States|Study Site 520, Bellaire, Texas, United States|Study Site 502, Dallas, Texas, United States|Study Site 224, Houston, Texas, United States|Study Site 359, Pflugerville, Texas, United States|Study Site 226, Webster, Texas, United States|Study Site 336, Richmond, Virginia, United States|Study Site 806, Spokane, Washington, United States|Study Site 532, Morgantown, West Virginia, United States|Study Site 649, Graz, Austria|Study Site 648, Linz, Austria|Study Site 650, Vienna, Austria|Study Site 623, Bad Bentheim, Germany|Study Site 607, Berlin, Germany|Study Site 641, Berlin, Germany|Study Site 600, Bielefeld, Germany|Study Site 617, Bochum, Germany|Study Site 608, Bonn, Germany|Study Site 642, Buxtehude, Germany|Study Site 606, Dresden, Germany|Study Site 621, Erlangen, Germany|Study Site 602, Frankfurt am main, Germany|Study Site 639, Hamburg, Germany|Study Site 605, Heidelberg, Germany|Study Site 611, Leipzig, Germany|Study Site 620, Mahlow, Germany|Study Site 614, Mainz, Germany|Study Site 601, Münster, Germany|Study Site 618, Osnabrück, Germany|Study Site 615, Selters, Germany|Study Site 643, Stuttgart, Germany|Study Site 636, Bydgoszcz, Poland|Study Site 628, Iwonicz-Zdrój, Poland|Study Site 633, Kraków, Poland|Study Site 624, Kraków, Poland|Study Site 635, Kraków, Poland|Study Site 631, Olsztyn, Poland|Study Site 625, Osielsko, Poland|Study Site 645, Poznań, Poland|Study Site 644, Poznań, Poland|Study Site 634, Rzeszów, Poland|Study Site 638, Szczecin, Poland|Study Site 632, Toruń, Poland|Study Site 627, Warszawa, Poland|Study Site 637, Wrocław, Poland|Study Site 630, Wrocław, Poland|Study Site 647, Wrocław, Poland|Study Site 629, Łódź, Poland",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,37.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.29,555.5369999999998,29.54,3.0,0.0,5.0,51.54,134.58,7.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1,0,DB12973,__SERLOPITANT,US-20100209496-A1,Terminated,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,37.0,32.7488,3.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,5.29,555.5369999999998,29.54,3.0,0.0,5.0,51.54,134.58,7.0,1.0,0.0,0.0,0,1,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1
C[C@@H](O)[C@@H](C)Oc1nc(Nc2ccc([S@](=N)(=O)C3CC3)cc2)ncc1C(F)(F)F,0,DB12974,__RONICICLIB,8735412,Terminated,,SMALL CELL LUNG CANCER (SCLC),,,,,"FISABIO, Elche, Alicante, Spain",C07D239/47,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,55.5576089858107,3.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.24,430.45,108.19,7.0,3.0,3.0,39.89,101.21,8.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,1,0,1,1,0,1,0,1,0,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,1
FC(F)(F)c1ccc(CNc2ccc(Cc3c[nH]c4ncc(Cl)cc34)cn2)cn1,0,DB12978,__PEXIDARTINIB,7893075,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,39.064457175712,7.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,4.64,417.82,66.49,4.0,2.0,4.0,39.33,105.89,6.0,0.0,1.0,0.0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc([nH]c4nc(n1)-c1ccccc1-4)-c1ccccc1-3)c1ccccc21,0,DB12983,__PHTHALOCYANINE,3931097,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C08F255/04,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.79,514.552,108.92,6.0,2.0,9.0,57.9,155.73,0.0,1.0,0.0,0.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
Cc1nc2c(-c3cnc(N)nc3)nc(N3CCOCC3)nc2n1C(C)C,0,DB12986,__VS-5584,,Terminated,NCT01991938,NON HEMATOLOGIC CANCERS|METASTATIC CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The Royal Marsden, Sutton, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.96,354.418,107.87,8.0,1.0,4.0,38.53,99.61,3.0,0.0,1.0,0.0,0,1,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,1,1,0,1,0,1
O=C(O)CCn1c2c(c3ccccc31)C[C@H](NS(=O)(=O)c1ccc(F)cc1)CC2,0,DB13036,__RAMATROBAN,6362214,Withdrawn,NCT00311051,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Research Center Borstel, Borstel, Germany",C07D209/88,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,21.0928355818394,30.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.3,416.47,88.4,4.0,2.0,4.0,42.28,107.08,5.0,0.0,1.0,0.0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,0,0
C=CCc1cccc(/C=N/NC(=O)CN2CCN(Cc3ccccc3)CC2)c1O,0,DB13048,__PAC-1,,Withdrawn,,METASTATIC RENAL CELL CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.72,392.50300000000004,68.17,5.0,2.0,3.0,44.13,117.92,8.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
O=C(O)c1ccc(C(F)(F)F)cc1-c1ccc2c(c1)OC[C@H](Cc1ccccc1)[C@H]2O,0,DB13053,__CP-195543,WO-2001034134-A2,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,4.41,428.407,66.76,4.0,2.0,4.0,41.92,109.38,5.0,0.0,1.0,0.0,1,1,0,1,0,1,1,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0
O=C(O)c1ccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2C(c2c(F)cccc2F)=NC3)cc1,0,DB13061,__MLN8054,US-20050256102-A1,Terminated,,ADVANCED MALIGNANCIES,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,62.0,50.9907800981539,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,476.86199999999997,87.47,6.0,2.0,5.0,46.81,124.5,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,1,0,1,0,1,1,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,0,1,0,0,1,0,1
CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC,0,DB13125,__LUSUTROMBOPAG,7601746,Terminated,,IMMUNE THROMBOCYTOPENIA (ITP),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,24.0,62.0957309184993,4.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.94,591.54,97.75,6.0,2.0,3.0,63.73,157.53,13.0,1.0,0.0,0.0,1,1,0,1,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,1,0,1,0,1,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,0
Nc1ncnc2c1ncn2CCOCP(=O)(O)O,0,DB13868,__ADEFOVIR,5627165,Withdrawn,NCT00051077,HIV INFECTIONS|HEPATITIS B|HEPATITIS C,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double|Primary Purpose: Treatment,,C07F9/4087,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,38.0,31.4092691841721,389.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.8,273.1857,136.38,8.0,3.0,2.0,23.56,63.12,5.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CCCNC(=O)c1nnc2c(-c3c(F)cccc3OC)cccc2c1N,0,DB13994,__AZD-7325,US-20070142328-A1,Suspended,,PHARMACOKINETICS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,104.0,20.961416045504,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.53,354.385,90.13,5.0,2.0,3.0,36.88,99.23,4.0,0.0,1.0,0.0,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,0,DB14104,__LINOLEIC_ACID,3932476,Terminated,,DISSEMINATED SCLEROSIS,,,,,"FISABIO, Elche, Alicante, Spain",C07C231/02,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
CCCCC/C=C\C/C=C\CCCCCCCC(=O)O,0,DB14104,__LINOLEIC_ACID,3932476,Terminated,NCT00638196,MULTIPLE SCLEROSIS,All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"University of Rochester, Rochester, New York, United States",C07C231/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,10757.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,7.06,280.4455,37.3,2.0,1.0,0.0,35.86,88.52,14.0,1.0,0.0,0.0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
F[B-](F)(F)F.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[C-]#[N+]CC(C)(C)OC.[Cu+],0,DB14106,__TETRAKIS(2-METHOXYISOBUTYLISOCYANIDE)COPPER(I)_TETRAFLUOROBORATE,,Terminated,,ISCHEMIC HEART DISEASE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.94,602.99,13.59,1.0,0.0,0.0,12.7,41.61,8.0,0.0,1.0,0.0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0
O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ca+2].[Na+].[Na+],0,DB14598,__EDETATE_CALCIUM_DISODIUM_ANHYDROUS,,Withdrawn,NCT01101412,"CHRONIC MYELOPROLIFERATIVE DISORDERS|INFECTION|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.03,374.26800000000003,167.0,10.0,0.0,0.0,24.74,105.69,11.0,0.0,1.0,0.0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB14649,__DEXAMETHASONE_ACETATE,WO-2003030823-A2,Terminated,NCT02419469,LEUKEMIA|PRECURSOR-B ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOBLASTIC LYMPHOMA|LYMPHOMA,All,"12 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,32.7488,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.6,434.4977,100.9,5.0,2.0,4.0,45.02,111.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1
CC(=O)OCC(=O)[C@@]1(O)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,DB14649,__DEXAMETHASONE_ACETATE,WO-2003030823-A2,Terminated,NCT01878708,T-CELL LYMPHOMA|RELAPSED T-CELL LYMPHOMA|REFRACTORY T-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",A61K45/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,36.0,32.7488,49.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.6,434.4977,100.9,5.0,2.0,4.0,45.02,111.64,4.0,0.0,1.0,0.0,0,0,1,0,0,0,0,1,1,0,1,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,1,0,1
C[C@]12CC[C@@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@H]3[C@@H]1CC[C@@H]2OP(=O)(O)O,0,DB14674,__ESTRAMUSTINE_PHOSPHATE,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.23,520.38,96.3,4.0,2.0,4.0,53.82,127.09,8.0,0.0,1.0,0.0,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,1,1,1,1,1,1,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,0,DB14681,__CORTISONE,3934580,Suspended,NCT01843530,ACUTE ACE-INDUCED ANGIOEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kath. Klinikum Bochum, Med. Klinik III, Bochum, Germany|Ludwig-Maximilian-Universität, München, Germany|Klinikum rechts der Isar, Hals-Nasen-Ohren Klinik, München, Germany|Universitätsklinikum Ulm, HNO, Ulm, Germany",A61F6/142,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,14.0,14.521858765067,2498.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.98,360.444,91.67,5.0,2.0,4.0,38.95,96.47,2.0,0.0,1.0,0.0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,1,1,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,0,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O,0,DB14777,__MUREPAVADIN,,Terminated,,PNEUMONIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.8,1553.8370000000002,617.98,22.0,22.0,7.0,161.06,403.1,21.0,1.0,0.0,0.0,0,1,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,1,0,1,1,0,1,0,1,1,1,1,0,1,0,1,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,1,1,0,1,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0
C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,0,DB14785,__FENEBRUTINIB,8716274,Terminated,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,18.070186246124106,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,664.811,119.3,9.0,2.0,8.0,75.41,192.2,7.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1
C[C@H]1CN(C2COC2)CCN1c1ccc(Nc2cc(-c3ccnc(N4CCn5c(cc6c5CC(C)(C)C6)C4=O)c3CO)cn(C)c2=O)nc1,0,DB14785,__FENEBRUTINIB,8716274,Terminated,,URTICARIA,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,21.0,18.070186246124106,128.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.82,664.811,119.3,9.0,2.0,8.0,75.41,192.2,7.0,0.0,1.0,0.0,1,1,1,1,0,0,1,0,1,0,1,1,0,0,1,0,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,0,1,0,1,0,1,1,0,1,1,0,0,0,1,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,1,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1
CC(C)C[C@@H](NC(=O)[C@H](NC(=O)[C@@H](CO)NC(=O)[C@H]1CCCN1C(=O)[C@@H](CC(C)C)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@@H](Cc1ccccc1)NC(=O)[C@H](NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](N)Cc1c[nH]c2ccccc12)[C@@H](C)O)[C@@H](C)O)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCCN)C(=O)O,0,DB14786,__NEROFE,,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.76,1897.215,666.11,25.0,25.0,9.0,199.41,511.75,54.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,1,0,1,0,1,0,0,1,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,0,0,1,0,0,0,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,0,0,1,0,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,1,1,1,0,1,0,1,0,0,1,1,0,1,1,0
COc1cc(Cl)ccc1[C@H]1c2[nH]c3cccc(F)c3c2C2(CC2)CN1C(C)=O,0,DB14802,__ONO-2952,7964726,Terminated,,IRRITABLE BOWEL SYNDROME,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.0,65.972607240395,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.24,398.86,45.33,2.0,1.0,5.0,41.28,105.98,2.0,0.0,1.0,0.0,1,0,0,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C(=O)OC[C@@]1(CCl)O[C@@H](n2ccc(N)nc2=O)[C@H](F)[C@@H]1OC(=O)C(C)C,0,DB14808,__LUMICITABINE,,Terminated,,RESPIRATORY SYNCYTIAL VIRUS (RSV),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.11,433.86,120.52,6.0,1.0,2.0,41.59,98.79,9.0,0.0,1.0,0.0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,1,0,1,1,1,0,0,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0
Cc1nc(C(=O)N2CCCC[C@H]2CNC(=O)c2cccc3occc23)c(-c2ccc(F)cc2)s1,0,DB14822,__SB-649868,,Withdrawn,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.64,477.55,75.44,3.0,1.0,5.0,49.12,128.06,5.0,0.0,1.0,0.0,1,0,1,0,1,0,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,1,1,1,0,1,1,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,1,1,1,0,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,0,1,0,1,0,1,0,1,1,1,0,0,0,0,1,1,1,0,0,0,0,0,0,1,1,0,1,0,0
O=[N+]([O-])c1nccn1CC(O)C[18F],0,DB14830,__FLUOROMISONIDAZOLE_F-18,,Withdrawn,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.46,188.149,81.19,4.0,1.0,1.0,15.65,40.27,4.0,0.0,1.0,0.0,0,1,1,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0
Nc1cc(C(F)(F)F)c(-c2nc(N3CCOCC3)nc(N3CCOCC3)n2)cn1,0,DB14846,__BIMIRALISIB,WO-2010052569-A2,Withdrawn,,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL),,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.16,411.389,102.52,9.0,1.0,4.0,38.5,113.66,4.0,0.0,1.0,0.0,0,0,0,0,1,0,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,1,1,1,0,1,0,1
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,0,DB14867,__PARSACLISIB,,Withdrawn,NCT03780166,PEMPHIGUS VULGARIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,432.88,107.95,6.0,2.0,4.0,42.87,123.54,5.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0
CCOc1c([C@H](C)n2nc(C)c3c(N)ncnc32)cc(Cl)c(F)c1[C@@H]1CNC(=O)C1,0,DB14867,__PARSACLISIB,,Withdrawn,,PEMPHIGUS VULGARIS (PV),,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.67,432.88,107.95,6.0,2.0,4.0,42.87,123.54,5.0,0.0,1.0,0.0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,0,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0
CCCCCCCCCCCCCCCC(=O)NCC(O)COP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cc(C)c(=O)[nH]c2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(=O)[nH]c(N)nc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2ccc(N)nc2=O)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1NP(=O)(S)OCC1OC(n2cnc3c(N)ncnc32)CC1N,0,DB14909,__IMETELSTAT,,Withdrawn,NCT01568632,SOLID TUMORS|LYMPHOMA,All,"1 Year to 21 Years   (Child, Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-3.2,4610.18,1587.05,74.0,45.0,35.0,442.86,1045.35,95.0,1.0,0.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,1,1,0,0,1,0,1,1,0,1,0,0,1,1,1,1,1,0,1,0,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,1,1,1,1,1,0,1,1,0,1,1,1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,1,1,1,1,1,1,1,1,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,0
COc1cc2c(cc1OCCC[18F])CCN1C[C@@H](CC(C)C)[C@H](O)C[C@H]21,0,DB14945,__FLORBENAZINE_F-18,,Terminated,,TYPE 1 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.2,364.49199999999996,41.93,4.0,1.0,3.0,42.07,101.86,7.0,0.0,1.0,0.0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0
CCC[C@H](c1ccc(C(=O)NCCC(=O)O)cc1)[C@H](c1ccc(Cl)cc1)c1c[nH]c2c(F)cc(C)cc12,0,DB14957,__MK-3577,EP-2079688-B1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,57.923160639848795,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,6.27,521.03,82.19,3.0,3.0,4.0,55.92,144.7,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,0,0,1,1,1,0,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
O=C(c1ccc(O)c(F)c1)N(c1ccc(O)cc1)c1ccc(F)cc1,0,DB14969,__GTX-758,US-20070265296-A1,Terminated,,PROSTATE CANCER,,,,,"FISABIO, Elche, Alicante, Spain",1,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,181.0,60.0587281052999,3.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.09,341.314,60.77,3.0,2.0,3.0,32.11,88.88,3.0,0.0,1.0,0.0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0
CN(Cc1ccc(/C=C/C(=O)NO)cc1)CC12CC3CC(CC(C3)C1)C2,0,DB14979,__MARTINOSTAT,,Withdrawn,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,354.494,52.57,3.0,2.0,4.0,40.91,105.37,6.0,0.0,1.0,0.0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
CC(C)Oc1ccc(-c2nn([C@@H](C)c3oc4ccc(F)cc4c(=O)c3-c3cccc(F)c3)c3ncnc(N)c23)cc1F,0,DB14989,__UMBRALISIB,US-20140011819-A1,Suspended,NCT03776864,HODGKIN'S LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,22.0,27.13813425327001,4.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.2,571.56,105.15,7.0,1.0,6.0,56.6,163.22,6.0,1.0,0.0,0.0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,0,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0
CC(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@@H]1CSSC[C@H](C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCCN)C(O)=N[C@H](CC(=N)O)C(=O)O)N=C(O)[C@@H](CCC(=N)O)N=C1O,0,DB15008,__GO-203-2C,,Withdrawn,NCT02658396,MULTIPLE MYELOMA|MULTIPLE MYELOMA IN RELAPSE|REFRACTORY MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,2352.8,1353.82,72.0,55.0,1.0,242.72,738.97,81.0,1.0,0.0,0.0,1,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0
CC(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@@H]1CSSC[C@H](C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCNC(=N)N)C(O)=N[C@H](CCCCN)C(O)=N[C@H](CC(=N)O)C(=O)O)N=C(O)[C@@H](CCC(=N)O)N=C1O,0,DB15008,__GO-203-2C,,Withdrawn,,MULTIPLE MYELOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.57,2352.8,1353.82,72.0,55.0,1.0,242.72,738.97,81.0,1.0,0.0,0.0,1,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,0,0,1,0,1,1,1,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,0,0,0,1,0,1,0,1,1,0,0,1,0,1,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,1,0
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Terminated,,DEPRESSION,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
O=C(c1ccc2nonc2c1)N1CCCCC1,0,DB15012,__FARAMPATOR,6110935,Withdrawn,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,8.0,42.4813651204336,128.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.87,231.255,59.23,3.0,0.0,3.0,23.67,63.15,1.0,0.0,1.0,0.0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,1,0,1
CCCCCCCC/C(=C\CCCCCCCC(=O)O)[N+](=O)[O-],0,DB15026,__CXA-10,WO-2009129495-A1,Withdrawn,NCT03680976,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,21.0,32.7488,14.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,5.26,327.465,80.44,4.0,1.0,0.0,39.06,92.77,16.0,1.0,0.0,0.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,0
C[C@H]1[C@H]2N(C(=O)CN(C)N2C(=O)NCc2ccccc2)[C@@H](Cc2ccc(OP(=O)(O)O)cc2)C(=O)N1Cc1cccc2cccnc12,0,DB15034,__PRI-724,WO-2014061828-A1,Terminated,,ADVANCED SOLID TUMORS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,32.7488,5.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.09,658.6519999999998,155.85,8.0,3.0,6.0,65.6,171.76,8.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,1,1,0,1,1,1
CN1C(=O)c2c(nn(Cc3ccc(-c4cccc(F)n4)cc3)c2Nc2ccccc2)N2C1=N[C@@H]1CCC[C@@H]12,0,DB15039,__ITI-214,US-20120238589-A1,Terminated,,SCHIZOPHRENIA,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,19.0,27.2695537896055,3.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,5.04,507.57300000000004,78.65,6.0,1.0,7.0,54.23,154.78,5.0,1.0,0.0,0.0,1,0,1,0,1,1,0,0,1,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0
CCc1ccc([C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc1Cc1ccc2c(c1)OCCO2,0,DB15048,__LICOGLIFLOZIN,WO-2011048112-A1,Withdrawn,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",7,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.96,416.47,108.61,7.0,4.0,4.0,44.51,109.51,5.0,0.0,1.0,0.0,0,1,0,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1
C[C@H](NP(=O)(OC[C@H]1O[C@@H](n2ccc(N)nc2=O)C(F)(F)[C@@H]1O)Oc1ccccc1)C(=O)OCc1ccccc1,0,DB15057,__NUC-1031,,Terminated,,OVARIAN CANCER,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.43,580.482,162.01,7.0,3.0,4.0,53.24,134.78,12.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,0,1,0,1,1,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,0,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,1,0,1
Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21,0,DB15147,__TINOSTAMUSTINE,,Terminated,NCT03687125,MULTIPLE MYELOMA IN RELAPSE|MULTIPLE MYELOMA PROGRESSION|MULTIPLE MYELOMA WITH FAILED REMISSION,All,"18 Years to 75 Years   (Adult, Older Adult)",Industry,Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama, Birmingham, Alabama, United States|University of Kansas Medical Center Kansas City, Kansas City, Kansas, United States|Memorial Sloan Kettering Cancer Centre, New York, New York, United States|Carolinas Healthcare System, Charlotte, North Carolina, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Froedtert & Medical College of Wisconsin, Cancer Center - Froedtert Hospital, Milwaukee, Wisconsin, United States|Oslo Myeloma Center, Oslo University Hospital, Oslo, Norway|Universitatsspital Basel, Basel, Switzerland|Universitatsspital Bern, Bern, Switzerland|Department of Clinical Research Oncology/Hematology, Kantonsspital St. Gallen, Saint Gallen, Switzerland|University Hospital Zurich, Zürich, Switzerland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,415.36,70.39,4.0,2.0,2.0,46.02,110.31,12.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0
Cn1c(CCCCCCC(=O)NO)nc2cc(N(CCCl)CCCl)ccc21,0,DB15147,__TINOSTAMUSTINE,,Withdrawn,NCT04279938,RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.61,415.36,70.39,4.0,2.0,2.0,46.02,110.31,12.0,0.0,1.0,0.0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,1,0
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,0,DB15170,__EVOBRUTINIB,WO-2012170976-A2,Terminated,NCT04032171,RELAPSING REMITTING MULTIPLE SCLEROSIS,All,18 Years to 55 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Please Contact U.S. Medical Information, Rockland, Massachusetts, United States|Please Contact the Communication Center, Darmstadt, Germany",6,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.94,429.524,93.37,5.0,2.0,4.0,45.68,128.81,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
C=CC(=O)N1CCC(CNc2ncnc(N)c2-c2ccc(Oc3ccccc3)cc2)CC1,0,DB15170,__EVOBRUTINIB,WO-2012170976-A2,Terminated,,SYSTEMIC LUPUS ERYTHEMATOSUS,,,,,"FISABIO, Elche, Alicante, Spain",6,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,22.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,3.94,429.524,93.37,5.0,2.0,4.0,45.68,128.81,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0
CN1CCN(Cc2ccc(Nc3ncc(Cl)c(Nc4ccccc4S(=O)(=O)N(C)C)n3)cc2)CC1,0,DB15187,__DUBERMATINIB,,Terminated,,CHRONIC LYMPHOCYTIC LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.57,516.06,93.7,8.0,2.0,4.0,55.45,141.3,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,1,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,1,0,1,1,0,0,1,0,0,0,0,1,1,1,0,0,0,1
Cc1sc2c(c1C)C(c1ccc(Cl)cc1)=N[C@@H](CC(=O)Nc1ccc(O)cc1)c1nnc(C)n1-2,0,DB15189,__BIRABRESIB,EP-0989131-A1,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",A61P1/00,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,63.08137744101521,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,4.04,491.99,92.4,5.0,2.0,5.0,50.88,146.03,4.0,0.0,1.0,0.0,1,0,0,0,0,1,0,0,1,0,1,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,0,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1
C=C(C)[C@@H]1CC[C@]2(NCCN3CCS(=O)(=O)CC3)CC[C@]3(C)[C@H](CC[C@@H]4[C@@]5(C)CC=C(c6ccc(C(=O)O)cc6)C(C)(C)[C@@H]5CC[C@]43C)[C@@H]12,0,DB15193,__BMS-955176,,Terminated,NCT02386098,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"GSK Investigational Site, Beverly Hills, California, United States|GSK Investigational Site, Los Angeles, California, United States|GSK Investigational Site, Palm Springs, California, United States|GSK Investigational Site, New Haven, Connecticut, United States|GSK Investigational Site, DeLand, Florida, United States|GSK Investigational Site, Fort Lauderdale, Florida, United States|GSK Investigational Site, Orlando, Florida, United States|GSK Investigational Site, Tampa, Florida, United States|GSK Investigational Site, West Palm Beach, Florida, United States|GSK Investigational Site, Atlanta, Georgia, United States|GSK Investigational Site, Indianapolis, Indiana, United States|GSK Investigational Site, Bronx, New York, United States|GSK Investigational Site, New York, New York, United States|GSK Investigational Site, Tulsa, Oklahoma, United States|GSK Investigational Site, Austin, Texas, United States|GSK Investigational Site, Dallas, Texas, United States|GSK Investigational Site, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina|GSK Investigational Site, Rosario, Santa Fe, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Buenos Aires, Argentina|GSK Investigational Site, Córdoba, Argentina|GSK Investigational Site, Mar del Plata, Argentina|GSK Investigational Site, Darlinghurst, Sydney, New South Wales, Australia|GSK Investigational Site, Darlinghurst, New South Wales, Australia|GSK Investigational Site, Sydney, New South Wales, Australia|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Vancouver, British Columbia, Canada|GSK Investigational Site, Winnipeg, Manitoba, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Toronto, Ontario, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Montreal, Quebec, Canada|GSK Investigational Site, Santiago, Región Metro De Santiago, Chile|GSK Investigational Site, Providencia, Santiago De Chile, Chile|GSK Investigational Site, Santiago, Chile|GSK Investigational Site, Barranquilla, Colombia|GSK Investigational Site, Bogota, Colombia|GSK Investigational Site, Bogotá, Colombia|GSK Investigational Site, Cali, Colombia|GSK Investigational Site, Juarez, Chihuahua, Mexico|GSK Investigational Site, Guadalajara, Jalisco, Mexico|GSK Investigational Site, DF, Mexico|GSK Investigational Site, Distrito Federal, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Mexico City, Mexico|GSK Investigational Site, Oaxaca, Mexico|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, Lima, Peru|GSK Investigational Site, San Juan, Puerto Rico|GSK Investigational Site, Ekaterinburg, Russian Federation|GSK Investigational Site, Irkutsk, Russian Federation|GSK Investigational Site, Krasnodar, Russian Federation|GSK Investigational Site, Moscow, Russian Federation|GSK Investigational Site, St. Petersburg, Russian Federation|GSK Investigational Site, Port Elizabeth, Eastern Cape, South Africa|GSK Investigational Site, Bloemfontein, Free State, South Africa|GSK Investigational Site, Tembisa, South Africa|GSK Investigational Site, Westdene, South Africa|GSK Investigational Site, Kaohsiung, Taiwan|GSK Investigational Site, Taipei, Taiwan|GSK Investigational Site, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,6.82,691.03,86.71,6.0,2.0,7.0,81.48,199.33,7.0,0.0,1.0,0.0,1,0,0,0,0,1,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,0,0,1,1,1,1,0,1,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,1,1,0,1,1,0,1,0,1,1,1,0,1,1,1
CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(=O)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N2,0,DB15195,__MIBENRATIDE,,Withdrawn,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-1.5,2097.27,940.67,37.0,32.0,5.0,203.7,528.21,32.0,1.0,0.0,0.0,1,1,0,1,1,1,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,1,1,0,0,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,1,0,0,1,1,0,0,1,1,0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,0,1,0,0,1,1,0,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,1,0,1,1,1
CN1N=C2CCN(C(=O)[C@@H](COCc3ccccc3)NC(=O)C(C)(C)N)C[C@@]2(Cc2ccccc2)C1=O,0,DB15205,__CAPROMORELIN,6107306,Terminated,,AGING,,,,,"FISABIO, Elche, Alicante, Spain",C07K5/0202,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,87.0,17.7416374052855,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.59,505.619,117.33,6.0,2.0,4.0,54.59,140.17,9.0,0.0,1.0,0.0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,1,0,0,1,0,1
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,0,DB15219,__TOMIVOSERTIB,,Terminated,NCT02937675,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Samuel Oschin comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, United States|Florida Cancer Specialist, Sarasota, Florida, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|University of Rochester, Rochester, New York, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Baylor Scott & White Research Institute, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|West Virginia University, Morgantown, West Virginia, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0
Cc1cc(Nc2cc(N)ncn2)c(=O)n2c1C(=O)NC21CCCCC1,0,DB15219,__TOMIVOSERTIB,,Terminated,,HEPATOCELLULAR CARCINOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.53,340.38699999999994,113.24,6.0,3.0,4.0,35.86,97.64,2.0,0.0,1.0,0.0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0
CC[C@@H](Oc1cccc(-n2c(C)c(C(=O)c3ccc(OC)cc3)c3ccc(OC(F)(F)F)cc32)c1)C(=O)O,0,DB15242,__MK-0533,US-20050277685-A1,Terminated,,TYPE 2 DIABETES,,,,,"FISABIO, Elche, Alicante, Spain",C07D209/10,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,39.0,42.2842358159305,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.4,527.496,86.99,6.0,1.0,4.0,51.64,138.96,10.0,1.0,0.0,0.0,1,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,1,1,1,1,0,0,1,0,0,1,0,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0
Cc1cc(-c2ccccc2)c(C(=O)C(=O)Nc2ccc(N3CCN(c4ncc(F)cn4)CC3)cc2)n1C,0,DB15245,__OLOROFIM,,Withdrawn,,ACUTE MYELOID LEUKEMIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.17,498.56199999999995,83.36,6.0,1.0,5.0,52.99,144.16,6.0,0.0,1.0,0.0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,0,0,0,1,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1
CC(C)(C)c1ccc(S(=O)(=O)Nc2ccc(Cl)cc2C(=O)c2cc[n+]([O-])cc2)cc1,0,DB15250,__VERCIRNON,US-20130059893-A1,Withdrawn,,ULCERATIVE COLITIS,,,,,"FISABIO, Elche, Alicante, Spain",4,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,16.0,37.848826464609104,128.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,4.15,444.93,90.18,4.0,1.0,3.0,45.01,118.09,5.0,0.0,1.0,0.0,1,1,0,0,1,0,1,0,1,1,1,0,0,0,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,1,1,0
C[C@@H](NC(=O)c1ncnc(N)c1Cl)c1ncc(C(=O)Nc2cc(C(F)(F)F)c(Cl)cn2)s1,0,DB15266,__TAK-580,,Terminated,,MELANOMA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.15,506.29,135.78,7.0,3.0,3.0,43.95,114.04,6.0,0.0,1.0,0.0,1,1,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,1,1,1,0,0,1,0,1,0,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,0,1,1,0,1,0,0,0,0,1,0,0,1,0,1
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)[C@@H](C)CC)C(=O)NCC(=O)O,0,DB15272,__EDRATIDE,,Terminated,NCT00203151,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.6,2309.574,883.21,33.0,31.0,10.0,242.59,603.24,67.0,1.0,0.0,0.0,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,1
CNC(=O)c1ccccc1Nc1cc(Nc2ccc(N3CCOCC3)cc2OC)ncc1C(F)(F)F,0,DB15273,__VS-4718,,Withdrawn,NCT02215629,RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA|RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.55,501.51,87.75,7.0,3.0,4.0,50.39,131.1,8.0,1.0,0.0,0.0,1,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,1,1,0,1,0,0,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,1,1,1,0,1,1,1
Cc1c(-c2c(F)cc(C(N)=O)c3[nH]c4c(c23)CC[C@H](C(C)(C)O)C4)cccc1-n1c(=O)c2cccc(F)c2n(C)c1=O,0,DB15291,__BMS-986142,US-20140378475-A1,Terminated,NCT02843659,SJÖGREN'S SYNDROME,All,"18 Years to 70 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","St Joseph Heritage Healthcare, Fullerton, California, United States|Local Institution, Palo Alto, California, United States|Local Institution, Sarasota, Florida, United States|North Georgia Rheumatology Group, Lawrenceville, Georgia, United States|Clinical Pharmacology Study Group, Worcester, Massachusetts, United States|Local Institution, Tupelo, Mississippi, United States|Arthritis And Osteoporosis Associates, Pa, Freehold, New Jersey, United States|New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, United States|Local Institution, Mineola, New York, United States|Pmg Research Of Wilmington Llc, Wilmington, North Carolina, United States|Paramount Medical Research & Consulting, Llc, Middleburg Heights, Ohio, United States|Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Wexford, Pennsylvania, United States|Acme Research, Llc, Orangeburg, South Carolina, United States|West Tennessee Research Institute, Jackson, Tennessee, United States|Tekton Research Inc, Austin, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Bogota, Cundinamarca, Colombia|Local Institution, Bogota, Colombia|Local Institution, Cali, Colombia|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Local Institution, Mexico City, Distrito Fededral, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Veracruz, Mexico|Local Institution, Cercado De Lima, Lima, Peru|Local Institution, Lima, Peru|Instituto De Ginecologia Y Reproduccion Inv. Clinical Sac, Lima, Peru|Klinika Reumatologii i Chorob Wewnetrznych, Wroclaw, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Moscow, Russian Federation|Local Institution, Stellenbosch, Western CAPE, South Africa",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,22.505595597445502,2.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.71,572.613,119.73,4.0,3.0,6.0,59.43,155.31,2.0,0.0,1.0,0.0,0,0,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,1,0,1,0,1,1,1,1,1,0,1,1,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,1,0,1,0,0,0,1,1,1,1,1,1,0,0
CC[C@H](Nc1ncnc2[nH]cnc12)c1oc2ccccc2c(=O)c1-c1cccc(F)c1,0,DB15295,__TENALISIB,US-20140364447-A1,Terminated,NCT03471351,CLASSICAL HODGKIN LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago, Chicago, Illinois, United States|Rhizen Pharmaceuticals investigational trial site; Karmanos Cancer Institute,, Detroit, Michigan, United States|University of Washington, Seattle, Washington, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,40.4443623072342,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.31,415.42800000000005,92.79,6.0,2.0,5.0,41.59,116.09,5.0,0.0,1.0,0.0,1,1,1,0,0,0,1,0,1,0,1,0,0,1,0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0
CCCCCCC(=O)N[C@@H]1CSSC[C@@H](C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N2C[C@H](C(N)=O)NC(=O)[C@@H]2CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](CCCC)NC(=O)[C@H](CCCNC(=N)N)NC(=O)CNC(=O)[C@@H](C)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC1=O,0,DB15355,__PL-3994,,Withdrawn,NCT01304628,ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Cranbury, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,-0.27,1875.21,762.94,30.0,28.0,5.0,190.05,507.91,36.0,1.0,0.0,0.0,1,1,1,1,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,1,1,1,0,1,0,0,1,0,1,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,1,1,0,1,0,1,0,1,0,1,1,1,1,1,0,0,1,1,0,1,1,1,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,1,1
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](OC(=O)C3CCCC3)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)C)c4cccs4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C,0,DB15384,__SIMOTAXEL,,Terminated,,NEOPLASMS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.25,896.01,230.52,10.0,4.0,7.0,91.58,221.91,16.0,1.0,0.0,0.0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,0,0,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,1,1,1,1,0,1,1,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1
C[C@@]1(C(=O)Nc2ccc(F)nc2)CCCN1c1nc(Nc2cc(C3CC3)[nH]n2)c2cccn2n1,0,DB15399,__BMS-754807,8492328,Terminated,,BREAST CANCER,,,,,"FISABIO, Elche, Alicante, Spain",C12Q1/6886,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,7.0,62.2600053389186,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,3.81,461.4948,116.13,7.0,3.0,6.0,48.1,139.75,6.0,0.0,1.0,0.0,1,0,1,1,1,1,1,0,1,0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,1,1,1,0,0,1,1,0,0,1,0,1,1,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1,0,1
CNC(=O)C[C@H]1COc2cc(F)ccc2N1C(=O)c1ccc2c(c1)NC(=O)CO2,0,DB15418,__AZD-9977,,Terminated,,HEART FAILURE,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.26,399.37800000000004,96.97,5.0,2.0,4.0,38.12,101.36,3.0,0.0,1.0,0.0,1,0,1,1,0,0,1,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0
O=C(CCc1ccc(CN[C@H](C(=O)OC2CCCC2)C2CCCCC2)cn1)NO,0,DB15440,__GSK-3117391,,Terminated,,RHEUMATOID ARTHRITIS,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,3.07,403.523,100.55,5.0,3.0,3.0,45.52,108.98,10.0,0.0,1.0,0.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,1,1,1,1,0,1
C[C@]12CC[C@@H]3[C@H]4CC[C@@](C)(O)C[C@H]4CC[C@H]3[C@@H]1CC[C@@H]2C(=O)Cn1cc(C#N)cn1,0,DB15490,__ZURANOLONE,,Suspended,,INSOMNIA,,,,,"FISABIO, Elche, Alicante, Spain",,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,4.03,409.574,78.91,4.0,1.0,5.0,47.55,127.19,3.0,0.0,1.0,0.0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,1,1,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,1,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,1,1,0,1,1,1
CCS(=O)(=O)N1CCN(c2ccc(Nc3ncc(C(N)=O)c(NC4CC4)n3)cc2)CC1,0,DB15499,__CERDULATINIB,WO-2012045020-A1,Withdrawn,NCT04021082,"PERIPHERAL T-CELL LYMPHOMA (PTCL NOS)|NODAL LYMPHOMAS OF T FOLLICULAR HELPER (TFH)|FOLLICULAR T-CELL LYMPHOMA (FTCL)|AITL|ALCL|HSTCL|EATL I,II|MEITL, EATL TYPE II|NASAL LYMPHOMA",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,24.0,32.7488,3.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.08,445.54,133.55,8.0,3.0,4.0,47.74,121.17,7.0,0.0,1.0,0.0,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,1
N#CCC1CCN(c2nc(Nc3ccc(N4CCC(O)CC4)cc3)c3c(=O)[nH]ncc3n2)CC1,0,DB15670,__GUSACITINIB,US-20130053346-A1,Terminated,,ATOPIC DERMATITIS,,,,,"FISABIO, Elche, Alicante, Spain",5,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,29.0,20.8628513932524,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,3.46,460.542,129.77,9.0,3.0,5.0,49.8,131.72,5.0,0.0,1.0,0.0,1,0,0,0,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,1,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,1,0,1
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01445340,MYCOSIS FUNGOIDES|CUTANEOUS T-CELL LYMPHOMA|NEOPLASMS,All,"18 Years to 100 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01738594,RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE I CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE II CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IIIA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IIIB MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IVA MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IVB MYCOSIS FUNGOIDES/SEZARY SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01742793,HODGKIN'S LYMPHOMA|MATURE T-CELL LYMPHOMA|MULTIPLE MYELOMA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Yale Cancer Center, New Haven, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT01979276,MULTIPLE MYELOMA,All,"18 Years to 100 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00079443,RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT02061449,CUTANEOUS T-CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"NYU Cancer Institute, New York, New York, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00383565,RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT00091195,PRIMARY PERITONEAL CAVITY CANCER|RECURRENT OVARIAN EPITHELIAL CANCER,Female,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"High Point Regional Hospital, High Point, North Carolina, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Terminated,NCT02203578,GRAFT VS HOST DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT04233697,"LYMPHOMA, T-CELL",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT02281279,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT03355768,"LYMPHOMA, T-CELL, PERIPHERAL",All,"18 Years to 90 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Other,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
C/C=C1\NC(=O)[C@@H](CS)NC(=O)[C@@H](C(C)C)CC(=O)C[C@@H](/C=C/CCS)OC(=O)[C@H](C(C)C)NC1=O,0,,_ROMIDEPSIN,,Withdrawn,NCT02757248,PTCL|CTCL,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Suspended,NCT03432741,BREAST ADENOCARCINOMA|RECURRENT BREAST CARCINOMA|RECURRENT HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES|RECURRENT NON-HODGKIN LYMPHOMA|RECURRENT PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|REFRACTORY HODGKIN LYMPHOMA|REFRACTORY MYCOSIS FUNGOIDES|REFRACTORY NODAL MARGINAL ZONE LYMPHOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV BREAST CANCER AJCC V6 AND V7,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT00060112,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Stanford, California, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Terminated,NCT02414724,LYMPHOMA|SOLID NEOPLASM,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Roswell Park Cancer Institute, Buffalo, New York, United States",C07D307/33,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cl.Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1,0,,_GEMCITABINE_HYDROCHLORIDE,5223608,Withdrawn,NCT00369954,FALLOPIAN TUBE CANCER|OVARIAN CANCER|PERITONEAL CAVITY CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,C07D307/33,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,35.5818394628226,119.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0
Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(C(=O)NOCCO)cc21.O=S(=O)(O)O,0,,_SELUMETINIB_SULFATE,,Suspended,NCT03213691,ADVANCED MALIGNANT SOLID NEOPLASM|ANN ARBOR STAGE III CHILDHOOD NON-HODGKIN LYMPHOMA|ANN ARBOR STAGE IV CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT CHILDHOOD CENTRAL NERVOUS SYSTEM NEOPLASM|RECURRENT CHILDHOOD NON-HODGKIN LYMPHOMA|RECURRENT MALIGNANT SOLID NEOPLASM|RECURRENT NEUROBLASTOMA|REFRACTORY MALIGNANT SOLID NEOPLASM|REFRACTORY NEUROBLASTOMA|REFRACTORY NON-HODGKIN LYMPHOMA|REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM NEOPLASM,All,"12 Months to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Children's Hospital of Alabama, Birmingham, Alabama, United States|Banner Children's at Desert, Mesa, Arizona, United States|Phoenix Childrens Hospital, Phoenix, Arizona, United States|Arkansas Children's Hospital, Little Rock, Arkansas, United States|Kaiser Permanente Downey Medical Center, Downey, California, United States|Loma Linda University Medical Center, Loma Linda, California, United States|Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Mattel Children's Hospital UCLA, Los Angeles, California, United States|Valley Children's Hospital, Madera, California, United States|Children's Hospital and Research Center at Oakland, Oakland, California, United States|Kaiser Permanente-Oakland, Oakland, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, United States|Yale University, New Haven, Connecticut, United States|Alfred I duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, United States|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States|Nicklaus Children's Hospital, Miami, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Hospital, Orlando, Florida, United States|Nemours Children's Clinic - Pensacola, Pensacola, Florida, United States|Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, United States|Saint Mary's Hospital, West Palm Beach, Florida, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Memorial Health University Medical Center, Savannah, Georgia, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Saint Luke's Mountain States Tumor Institute, Boise, Idaho, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States|Saint Jude Midwest Affiliate, Peoria, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|Blank Children's Hospital, Des Moines, Iowa, United States|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States|Norton Children's Hospital, Louisville, Kentucky, United States|Children's Hospital New Orleans, New Orleans, Louisiana, United States|Ochsner Medical Center Jefferson, New Orleans, Louisiana, United States|Eastern Maine Medical Center, Bangor, Maine, United States|Sinai Hospital of Baltimore, Baltimore, Maryland, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, United States|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Mercy Hospital Saint Louis, Saint Louis, Missouri, United States|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|University Medical Center of Southern Nevada, Las Vegas, Nevada, United States|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, United States|Summerlin Hospital Medical Center, Las Vegas, Nevada, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Morristown Medical Center, Morristown, New Jersey, United States|Saint Peter's University Hospital, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, United States|Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|NYP/Weill Cornell Medical Center, New York, New York, United States|University of Rochester, Rochester, New York, United States|State University of New York Upstate Medical University, Syracuse, New York, United States|Mission Hospital, Asheville, North Carolina, United States|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, United States|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Children's Hospital Medical Center of Akron, Akron, Ohio, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|Nationwide Children's Hospital, Columbus, Ohio, United States|Dayton Children's Hospital, Dayton, Ohio, United States|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, United States|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States|Legacy Emanuel Children's Hospital, Portland, Oregon, United States|Oregon Health and Science University, Portland, Oregon, United States|Geisinger Medical Center, Danville, Pennsylvania, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, United States|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, United States|East Tennessee Childrens Hospital, Knoxville, Tennessee, United States|Saint Jude Children's Research Hospital, Memphis, Tennessee, United States|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States|Dell Children's Medical Center of Central Texas, Austin, Texas, United States|Medical City Dallas Hospital, Dallas, Texas, United States|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States|Cook Children's Medical Center, Fort Worth, Texas, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|M D Anderson Cancer Center, Houston, Texas, United States|Children's Hospital of San Antonio, San Antonio, Texas, United States|Methodist Children's Hospital of South Texas, San Antonio, Texas, United States|University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States|Primary Children's Hospital, Salt Lake City, Utah, United States|University of Vermont and State Agricultural College, Burlington, Vermont, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States|Seattle Children's Hospital, Seattle, Washington, United States|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, United States|Madigan Army Medical Center, Tacoma, Washington, United States|West Virginia University Healthcare, Morgantown, West Virginia, United States|University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|San Jorge Children's Hospital, San Juan, Puerto Rico|University Pediatric Hospital, San Juan, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,1,0,1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,0,1,1,0,0,0,1,0,0,1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,1,1,1,0,0,1,1,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Suspended,NCT03399539,RECURRENT PLASMA CELL MYELOMA|T(11;14),All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Siteman Cancer Center at Washington University, Saint Louis, Missouri, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Suspended,NCT01864018,AMYLOIDOSIS|PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CC(C)C[C@H](NC(=O)CNC(=O)c1cc(Cl)ccc1Cl)B1OC(=O)C(CC(=O)O)(CC(=O)O)O1,0,,_IXAZOMIB_CITRATE,,Withdrawn,NCT03856112,RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA|T(11;14) NEGATIVE,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,1,1,1,1,1,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,0,1,0,1,0,1,0,0
CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-],0,,_PYRIDOSTIGMINE_BROMIDE,5298504,Suspended,NCT03312244,HIV-1-INFECTION|CD4+ T LYMPHOCYTOPENIA|IMMUNE DEFICIENCY|IMMUNO-SENESCENCE,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Tlalpan, Mexico",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,3.0,22.505595597445502,96.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0
C[C@]12CC(=O)[C@H]3[C@@H](CCC4=C[C@H](O)CC[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,0,,_CORTISONE,,Suspended,NCT01843530,ACUTE ACE-INDUCED ANGIOEDEMA,All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","Kath. Klinikum Bochum, Med. Klinik III, Bochum, Germany|Ludwig-Maximilian-Universität, München, Germany|Klinikum rechts der Isar, Hals-Nasen-Ohren Klinik, München, Germany|Universitätsklinikum Ulm, HNO, Ulm, Germany",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN,,Suspended,NCT00433173,METABOLIC SYNDROME,Male,"50 Years to 75 Years   (Adult, Older Adult)",NIH|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN,,Terminated,NCT01205685,HORMONE-SENSITIVE METASTATIC BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vanderbilt-Ingram Oncology Cool Springs, Franklin, Tennessee, United States|Vanderbilt One Hundre Oaks, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN,,Terminated,NCT01377389,PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN,,Withdrawn,NCT01013506,BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,0,1,1,1,1,1,1
CC(=O)O.CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O,0,,_GOSERELIN_ACETATE,5811547,Suspended,NCT00433173,METABOLIC SYNDROME,Male,"50 Years to 75 Years   (Adult, Older Adult)",NIH|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States",A61K9/14,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,39.4587157847183,173.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,1,0,1,0,1,0,1,1,1,0,1,0,1,0,0,1,1,0,1,0,0,0,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,1,1,1,1,1,1,1,1,1,1
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Suspended,NCT03370185,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arizona Oncology, Tempe, Arizona, United States|Genesis Cancer Center, Hot Springs, Arkansas, United States|Moores UC San Diego Cancer Center, La Jolla, California, United States|Ingalls Memorial Hospital, Harvey, Illinois, United States|QUEST Research Institute, Royal Oak, Michigan, United States|St. Vincent Frontier Cancer Center, Billings, Montana, United States|Summit Medical Group, Morristown, New Jersey, United States|Medical Oncology Associates PS, WA, Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Terminated,NCT02391545,CD20+ FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Los Angeles, California, United States|Palo Alto, California, United States|Hackensack, New Jersey, United States|Rochester, New York, United States|Dallas, Texas, United States|Kortrijk, Belgium|Leuven, Belgium|Wilrijk, Belgium|Clermont-Ferrand, France|Marseille Cedex 05, France|Pessac, France|Rouen Cedex 1, France|Tours Cedex 01, France|Bologna, Italy|Varese, Italy|Badalona, Barcelona, Spain|Barcelona, Spain|Madrid, Spain|Salamanca, Spain|Leeds, United Kingdom|London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Terminated,NCT02204982,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Frankston, Victoria, Australia|Bordeaux, France|Bologna, Italy|Terni, Italy|Gdynia, Poland",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02576275,INDOLENT NON-HODGKIN'S LYMPHOMA|FOLLICULAR LYMPHOMA|SMALL LYMPHOCYTIC LYMPHOMA|MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Plainville, Connecticut, United States|Plantation, Florida, United States|Thomasville, Georgia, United States|East Setauket, New York, United States|Cookeville, Tennessee, United States|Knoxville, Tennessee, United States|Spokane, Washington, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02640833,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA|NON-HODGKIN LYMPHOMA,All,"18 Years to 99 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Site Reference ID/Investigator# 145677, Tucson, Arizona, United States|Site Reference ID/Investigator# 147922, Chicago, Illinois, United States|Site Reference ID/Investigator# 148562, Harvey, Illinois, United States|Site Reference ID/Investigator# 148561, Goshen, Indiana, United States|Site Reference ID/Investigator# 145674, Baltimore, Maryland, United States|Site Reference ID/Investigator# 145145, Boston, Massachusetts, United States|Site Reference ID/Investigator# 148010, Detroit, Michigan, United States|Site Reference ID/Investigator# 147747, St. Louis, Missouri, United States|Site Reference ID/Investigator# 145146, Lebanon, New Hampshire, United States|Site Reference ID/Investigator# 148559, Greenville, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
C[C@H](Nc1ncnc2nc[nH]c12)c1cc2cccc(Cl)c2c(=O)n1-c1ccccc1,0,,_DUVELISIB,,Withdrawn,NCT02605694,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Miami, Florida, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,1,1,0,0,1,0,0,1,0,0,0,0,1,1,1,1,0,1,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0
CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.CC(C)(C)NC[C@H](O)c1ccc(O)c(CO)c1.O=C(O)C(O)C(O)C(=O)O,0,,_LEVALBUTEROL_TARTRATE,,Terminated,NCT02150499,ASTHMA,All,up to 48 Months   (Child),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Score Physician Alliance, LLC, Saint Petersburg, Florida, United States|Northern Illinios Research Associates, Dekalb, Illinois, United States|Northern Illinois Associates, Dekalb, Illinois, United States|Michael W. Simon, MD, PSC, Nicholasville, Kentucky, United States|Willis-Knighton Physician Network / Portico Pediatrics, Shreveport, Louisiana, United States|Mid Michigan Sleep Center, Grand Blanc, Michigan, United States|Craig Spiegel, MD, Bridgeton, Missouri, United States|St. Peter's University Hospital, New Brunswick, New Jersey, United States|Capital Pediatrics & Adolescent Center PLLC, Raleigh, North Carolina, United States|Capitol Pediatric & Adolescent Center PLLC, Raleigh, North Carolina, United States|Dayton Clinical Research, Dayton, Ohio, United States|Charleston Allergy & Asthma Research, Summerville, South Carolina, United States|Holston Medical Group, Kingsport, Tennessee, United States|TTS Research, Boerne, Texas, United States|Allergy Asthma Research Institute, Waco, Texas, United States|PI-Coor Clinical Research, Burke, Virginia, United States|Advanced Pediatrics, Vienna, Virginia, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0
CC[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@H](C(=O)NCC(=O)O)[C@@H](C)CC)[C@@H](C)CC,0,,_EDRATIDE,,Terminated,NCT00203151,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,1,1,0,1,1,0,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,0,1,1,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C,0,,_MAFODOTIN,,Terminated,NCT02855359,"DIFFUSE, LARGE B-CELL, LYMPHOMA|FOLLICULAR LYMPHOMA, GRADE 3B|TRANSFORMED LYMPHOMA / DLBCL",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Saint Bernards Cancer Center, Jonesboro, Arkansas, United States|City of Hope, Duarte, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|University of Colorado Health Memorial Hospital, Colorado Springs, Colorado, United States|Poudre Valley Hospital Harmony Campus, Fort Collins, Colorado, United States|Central Georgia Cancer Care, Macon, Georgia, United States|Loyola University Medical Center, Maywood, Illinois, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Tulane University Hospital and Clinic, New Orleans, Louisiana, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Hattiesburg Clinic (Forrest General Hospital), Hattiesburg, Mississippi, United States|Research Medical Center, Kansas City, Missouri, United States|San Juan Oncology Associates, Farmington, New Mexico, United States|Montefiore Medical Center - Bronx, Bronx, New York, United States|Mount Sinai Hospital, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Regional Medical Oncology Center, Wilson, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology / Sarah Cannon Research Institute, Nashville, Tennessee, United States|Baylor Health - Baylor University Medical Center, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Scott and White Memorial Hospital - Temple, Temple, Texas, United States|Kadlec Clinic Hematology and Oncology, Kennewick, Washington, United States|Vista Oncology INC PS, Olympia, Washington, United States|Northwest Medical Specialties, PLLC, Tacoma, Washington, United States|Ponce Medical School Foundation, Ponce, Puerto Rico",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1
CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)CCCCCN1C(=O)C=CC1=O)C(C)C,0,,_MAFODOTIN,,Terminated,NCT02592876,"LYMPHOMA, B-CELL|LYMPHOMA, LARGE B-CELL, DIFFUSE|LYMPHOMA, FOLLICULAR, GRADE 3B|FOLLICULAR LYMPHOMA, GRADE 3B",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States|City of Hope National Medical Center, Duarte, California, United States|Scripps Mercy Cancer Center, San Diego, California, United States|Colorado Blood Cancer Institute, Denver, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Shands Cancer Center / University of Florida, Gainesville, Florida, United States|University of Miami, Miami, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute / Emory University School of Medicine, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Cardinal Bernardin Cancer Center / Loyola University Medical Center, Maywood, Illinois, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of Minnesota, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|University of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|UNC Lineberger Comprehensive Cancer Center / University of North Carolina, Chapel Hill, North Carolina, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|MD Anderson Cancer Center / University of Texas, Houston, Texas, United States|San Antonio Military Medical Center, San Antonio, Texas, United States|University of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance / University of Washington, Seattle, Washington, United States|Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin, United States|Medical College of Wisconsin (Milwaukee), Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,1,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,1,0,0,1,0,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,1,1,1,1,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,0,0,1,1,1,0,0,1,1,1,1,1,0,0,0,1,1,1,0,1,0,1,0,1,1,1,1,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O,0,,_DAUNORUBICIN_CITRATE,US-20010018919-A1,Terminated,NCT00427414,SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States|Instituto De Infectologia Emilio Ribas Hospital, Cerqueira Cesar - Sao Paulo/SP, Brazil|Centro de Referencia e Tratamento DST/AIDS, Sao Paulo, Brazil",A61B17/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,26.9410049487669,10.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,1,1,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,1,1,1,1,1,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00953459,LUNG CANCER,All,"18 Years to 120 Years   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Vrije Universiteit Medisch Centrum, Amsterdam, Netherlands",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
CCN(CC)CCNC(=O)c1c(C)[nH]c(/C=C2\C(=O)Nc3ccc(F)cc32)c1C.O=C(O)C[C@H](O)C(=O)O,0,,_SUNITINIB_MALATE,EP-2638896-A1,Terminated,NCT00387426,"ACCELERATED PHASE CHRONIC MYELOGENOUS LEUKEMIA|ACUTE UNDIFFERENTIATED LEUKEMIA|ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA IN REMISSION|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(15;17)(Q22;Q12)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ATYPICAL CHRONIC MYELOID LEUKEMIA, BCR-ABL1 NEGATIVE|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOMONOCYTIC LEUKEMIA|CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|MAST CELL LEUKEMIA|MENINGEAL CHRONIC MYELOGENOUS LEUKEMIA|PRIMARY MYELOFIBROSIS|PROGRESSIVE HAIRY CELL LEUKEMIA, INITIAL TREATMENT|PROLYMPHOCYTIC LEUKEMIA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SECONDARY ACUTE MYELOID LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|T-CELL LARGE GRANULAR LYMPHOCYTE LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE MYELOID LEUKEMIA|UNTREATED HAIRY CELL LEUKEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",2,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,47.0,32.7488,128.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,1,1,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,1,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,1,0,0
OC[C@@H]1O[C@H](O[C@]2(CCl)O[C@H](CCl)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H](O)[C@H]1Cl,0,,_SUCRALOSE,,Terminated,NCT02499705,INSULIN RESISTANCE|OBESITY,All,13 Years to 17 Years   (Child),Other,"Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Basic Science","The John B. Pierce Laboratory, New Haven, Connecticut, United States",,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1
CC1(C)CC(C)(C)CC(C)(N)C1.CS(=O)(=O)O,0,,_NERAMEXANE_MESYLATE,WO-2010118889-A1,Terminated,NCT00799942,"NYSTAGMUS, CONGENITAL|NYSTAGMUS, ACQUIRED|MULTIPLE SCLEROSIS",All,"18 Years to 81 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Leicester, Leicester Royal Infirmary, Ophthalmology Group, Leicester, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,21.0,32.7488,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0
CCCCCC/C=C\CCCCCCCCCC(=O)N[C@H]1[C@H](OC[C@H]2O[C@H](OP(=O)(O)O)[C@H](NC(=O)CC(=O)CCCCCCCCCCC)[C@@H](OCCCCCCCCCC)[C@@H]2O)O[C@H](OC)[C@@H](OP(=O)(O)O)[C@@H]1OCC[C@@H](CCCCCCC)OC,0,,_ERITORAN,,Terminated,NCT02267317,INSULIN SENSITIVITY,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Audie L. Murphy VA Hospital, STVHCS, San Antonio, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,1,1,0,0,1,0,1,1,1,0,1,0,0,0,1,1,0,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,1,0,1,1,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,1,1,1,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,1,1,0,0,0,1,1,1,0,0
COc1cc(NCc2ccc3nc(N)nc(N)c3c2C)cc(OC)c1OC.O=C(O)[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O,0,,_TRIMETREXATE_GLUCURONATE,,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,1,0,0,1,1,0,0,1,1,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,1
N=C(N)c1ccc(OCCCCCOc2ccc(C(=N)N)cc2)cc1.O=S(=O)(O)CCO,0,,_PENTAMIDINE_ISETHIONATE,,Terminated,NCT00000730,"PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Julio Arroyo, West Columbia, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0
CC[C@H](C)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(C)C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)C(C)C,0,,_DIRUCOTIDE,,Terminated,NCT00870155,SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS,All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"St. Michaels Hospital, Toronto, Ontario, Canada|Copenhagen University Hospital, Kobenhavn, Denmark|West Tallinn Central Hospital, Tallinn, Estonia|Terveystalo Turku Kuvantaminen, Turku, Finland|Heinrich Heine Universitaets, Duesseldorf, North Rhine Westphalia, Germany|Vecmilgravis Hospital, Riga, Latvia|Maaslandziekenhuis, Sittard, Netherlands|Hospital Duran I Reynals, Barcelona, Spain|Karolinska Universitetssjukhus, Stockholm, Sweden|Walton Hospital, Liverpool, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,1,1,0,1,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,1,1,1,1,0,1,0,0,1,0,1,1,0,0,1,1,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,0,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,0,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+],0,,_FOSTAMATINIB_DISODIUM,,Terminated,NCT00805467,RHEUMATOID ARTHRITIS,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Research Site, La Jolla, California, United States|Research Site, Palm Desert, California, United States|Research Site, Palo Alto, California, United States|Research Site, San Diego, California, United States|Research Site, Santa Maria, California, United States|Research Site, Hamden, Connecticut, United States|Research Site, Washington, District of Columbia, United States|Research Site, Aventura, Florida, United States|Research Site, Boca Raton, Florida, United States|Research Site, Gainesville, Florida, United States|Research Site, Ocala, Florida, United States|Research Site, Orange Park, Florida, United States|Research Site, Orlando, Florida, United States|Research Site, South Miami, Florida, United States|Research Site, Venice, Florida, United States|Research Site, Boise, Idaho, United States|Research Site, Coeur D'Alene, Idaho, United States|Research Site, South Bend, Indiana, United States|Research Site, Elizabethtown, Kentucky, United States|Research Site, Cumberland, Maryland, United States|Research Site, Hagerstown, Maryland, United States|Research Site, Lansing, Michigan, United States|Research Site, Omaha, Nebraska, United States|Research Site, Roslyn, New York, United States|Research Site, Smithtown, New York, United States|Research Site, Raleigh, North Carolina, United States|Research Site, Mayfiled Village, Ohio, United States|Research Site, Erie, Pennsylvania, United States|Research Site, Willow Grove, Pennsylvania, United States|Research Site, Wyomissing, Pennsylvania, United States|Research Site, Jackson, Tennessee, United States|Research Site, Austin, Texas, United States|Research Site, San Antonio, Texas, United States|Research Site, Oklahoma City, Washington, United States|Research Site, Spokane, Washington, United States|Research Site, Antwerp, Belgium|Research Site, Gent, Belgium|Research Site, Liege, Belgium|Research Site, Plovdiv, Bulgaria|Research Site, Ruse, Bulgaria|Research Site, Sofia, Bulgaria|Research Site, Barranquilla, Colombia|Research Site, Bogota, Colombia|Research Site, Bucaramanga, Colombia|Research Site, Medellín, Colombia|Research Site, Bordeaux, France|Research Site, Hamburg, Germany|Research Site, Leipzig, Germany|Research Site, Würzburg, Germany|Research Site, Siena, Italy|Research Site, Udine, Italy|Research Site, Chihuahua, Mexico|Research Site, Cuernava, Mexico|Research Site, Del. Cuauhtemoc, Mexico|Research Site, Guadalajara, Mexico|Research Site, Leon, Mexico|Research Site, Mexcio, Mexico|Research Site, Mexico, Mexico|Research Site, Morelia, Mexico|Research Site, San Luis Potosí, Mexico|Research Site, Jesus Maria, Peru|Research Site, Lima, Peru|Research Site, Białystok, Poland|Research Site, Bytom, Poland|Research Site, Elblag, Poland|Research Site, Grodzisk Mazowiecki, Poland|Research Site, Krakow, Poland|Research Site, Lublin, Poland|Research Site, Toruń, Poland|Research Site, Wroclaw, Poland|Research Site, Zyrardów, Poland|Research Site, Brailari, Romania|Research Site, Bucuresti, Romania|Research Site, Cluj-Napoca, Romania|Research Site, Sf. Gheorghe, Romania|Research Site, Sibiu, Romania",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+],0,,_FOSTAMATINIB_DISODIUM,,Withdrawn,NCT00752999,SYSTEMIC LUPUS ERYTHEMATOSUS,All,"18 Years and older   (Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)([O-])[O-])C(=O)C(C)(C)O4)n2)cc(OC)c1OC.O.O.O.O.O.O.[Na+].[Na+],0,,_FOSTAMATINIB_DISODIUM,,Withdrawn,NCT02433236,IGA NEPHROPATHY,All,"18 Years to 72 Years   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,0,0,0,1,1,0,0,1,0,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,0,1
COc1ccc2c3c1O[C@H]1[C@@H](O)C=C[C@H]4[C@@H](C2)N(C)CC[C@]314.O.O=P(O)(O)O,0,,_CODEINE_PHOSPHATE,,Terminated,NCT00147355,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Hospital General de Agudos JM Ramos Mejia, Buenos Aires, Argentina|FUNCEI, Buenos Aires, Argentina|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina|Hospital Prof. Alejandro Posadas, Buenos Aires, Argentina|Hospital Interzonal de Agudos San Juan de Dios, La Plata, Argentina|Hospital Interzonal General de Agudos Oscar Alende, Mar del Plata, Argentina|Hospital Central, Mendoza, Argentina|CAICI, Rosario, Argentina|St. Vincent's Hospital, Sydney, New South Wales, Australia|AIDS Medical Unit, Brisbane, Queensland, Australia|Cairns Base Hospital, Cairns, Queensland, Australia|Gold Coast Sexual Health Clinic, Gold Coast, Queensland, Australia|Nambour Hospital, Nambour, Queensland, Australia|Carlton Clinic, Melbourne, Victoria, Australia|The Alfred Hospital, Melbourne, Victoria, Australia|Kaplan Medical Center, Rehovot, Israel",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,1,0,1,1,0,0,0,1,1,0,1,1,0,0,1,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1.O=S(=O)(O)O,0,,_BLEOMYCIN_SULFATE,,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,1,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT03488225,"ACUTE LYMPHOBLASTIC LEUKEMIA IN REMISSION|B ACUTE LYMPHOBLASTIC LEUKEMIA|B ACUTE LYMPHOBLASTIC LEUKEMIA, PHILADELPHIA CHROMOSOME NEGATIVE",All,"16 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT01005914,LEUKEMIA,All,18 Years to 60 Years   (Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"OHSU Knight Cancer Institute, Portland, Oregon, United States",C07D519/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00882206,LEUKEMIA|LYMPHOMA,All,"2 Years to 60 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Minnesota Amplatz Children's Hospital, Minneapolis, Minnesota, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00365274,ANAPLASTIC LARGE CELL LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00736450,CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE I ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA,All,"19 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Saint Francis Medical Center, Grand Island, Nebraska, United States|UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT00080847,CONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|NONCONTIGUOUS STAGE II ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA,All,19 Years to 59 Years   (Adult),NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Southwest Oncology Group, San Antonio, Texas, United States",C07D519/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Terminated,NCT01439347,ACUTE LYMPHOBLASTIC LEUKEMIA,All,"60 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UC San Diego Moores Cancer Center, La Jolla, California, United States|UCLA, Los Angeles, California, United States|Emory University, Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University Fienberg School of Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Nebraska Medical Center, Omaha, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Cornell, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|The University of Texas, M.D. Anderson Cancer Center, Houston, Texas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT01670084,"B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL1 POSITIVE|PHILADELPHIA CHROMOSOME POSITIVE ADULT PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED ADULT ACUTE LYMPHOBLASTIC LEUKEMIA",All,"18 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic in Arizona, Scottsdale, Arizona, United States|Mayo Clinic, Rochester, Minnesota, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT00900445,ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA,All,"10 Years to 19 Years   (Child, Adult)",Other|NIH,,"Childrens Oncology Group, Philadelphia, Pennsylvania, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT02538926,B ACUTE LYMPHOBLASTIC LEUKEMIA|B LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT B LYMPHOBLASTIC LYMPHOMA|RECURRENT T LYMPHOBLASTIC LEUKEMIA/LYMPHOMA|REFRACTORY B LYMPHOBLASTIC LYMPHOMA|REFRACTORY T LYMPHOBLASTIC LYMPHOMA|T ACUTE LYMPHOBLASTIC LEUKEMIA|T LYMPHOBLASTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O,0,,_VINCRISTINE_SULFATE,3932417,Withdrawn,NCT02861040,RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|REFRACTORY ADULT ACUTE LYMPHOBLASTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University, Palo Alto, California, United States|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States",C07D519/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,26.6453109920121,4259.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,0,1,0,0,0,1,1,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,1,1,1,1,1,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00135499,"LYMPHOMA, LARGE-CELL, DIFFUSE",All,"60 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium|Hôpital Henri Mondor, Créteil, France|Hôpital Saint Louis, Paris, France|Service d'Hématologie - Centre Hospitalier Lyon-Sud, Pierre-Bénite cedex, France|Centre Hospitalier Robert Debré, Reims, France|Centre Henri Becquerel, Rouen, France|Institut Gustave Roussy, Villejuif, France|Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT00225173,HODGKIN DISEASE,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford University Medical Center, Stanford, California, United States",A61K9/1075,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
Cc1c(N)nc([C@H](CC(N)=O)NC[C@H](N)C(N)=O)nc1C(=O)N[C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@H](C(=O)NCCc1nc(-c2nc(C(=O)NCCC[S+](C)C)cs2)cs1)[C@@H](C)O)[C@@H](O[C@@H]1O[C@@H](CO)[C@@H](O)[C@H](O)[C@@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](OC(N)=O)[C@@H]1O)c1c[nH]cn1,0,,_BLEOMYCIN,WO-1994008564-A1,Terminated,NCT01659099,DIFFUSE LARGE B CELL LYMPHOMA CD20 POSITIVE,All,18 Years to 60 Years   (Adult),Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"ZNA Stuivenberg, Antwerpen, Belgium|Hôpital Saint Joseph, Arlon, Belgium|RHMS Baudour, Baudour, Belgium|AZ St Jan Brugge Oostende AV, Brugge, Belgium|Institut Jules Bordet, Bruxelles, Belgium|CHU Brugmann, Bruxelles, Belgium|Hôpital Erasme, Bruxelles, Belgium|Clinique universitaire Saint LUC, Bruxelles, Belgium|CHU de Charleroi, Charleroi, Belgium|Grand Hôpital de Charleroi, Charleroi, Belgium|Universitair Ziekenhuis Gent, Gent, Belgium|Ch Jolimont, Haine Saint Paul, Belgium|AZ GROENINGE - Oncology Centre - Campus Maria's Voorzienigheid, Kortrijk, Belgium|CHR de la Citadelle, Liège, Belgium|CHU de Liège - Clinique Saint Joseph, Liège, Belgium|CHU de Liège -Domaine Sart Tilman, Liège, Belgium|CHU Ambroise Paré, Mons, Belgium|Clinique Saint Joseph -Hôpital de Warquignies, Mons, Belgium|Clinique Sainte Elisabeth, Namur, Belgium|Clinique Saint Pierre, Ottignies, Belgium|Heilig Hart Ziekenhuis, Roeselare, Belgium|Centre Hospitalier de Wallonie Picarde - CHwapi, Tournai, Belgium|CH de la Tourelle-Peltzer, Verviers, Belgium|Université Catholique de Louvain Mont Godinne, Yvoir, Belgium|CH d'Abbeville, Abbeville, France|CHU d'Amiens - Hôpital Sud, Amiens, France|CHU d'Angers, Angers, France|CH Victor Dupouy, Argenteuil, France|CH d'Arras, Arras, France|CH d'Avignon, Avignon, France|Hôpital de Bayonne - CHU de la Côte Basque, Bayonne, France|CH de Beauvais, Beauvais, France|CHU de Besançon - Hôpital Jean Minjoz, Besançon, France|CH de Blois, Blois, France|APHP - Hôpital Avicenne, Bobigny, France|Institut Bergonié, Bordeaux, France|Polyclinique Bordeaux Nord Aquitaine, Bordeaux, France|CH Dr Duchenne, Boulogne sur Mer, France|CH Fleyriat, Bourg en Bresse, France|CHU de Brest - Hôpital de Morvan, Brest, France|CH Brive la Gaillarde, Brive la Gaillarde, France|CHU de Caen, Caen, France|Centre François Baclesse, Caen, France|CH de Cannes, Cannes, France|Clinique Du Parc, Castelnau Le Lez, France|CH de Chambéry, Chambéry, France|CHU de Châlon sur Saône, Châlon sur Saône, France|APHP - Hôpital Antoine Béclère, Clamart, France|Hôpital d'Instruction des Armées Percy, Clamart, France|CHU d'Estaing, Clermont Ferrand, France|Pôle Santé Publique, Clermont Ferrand, France|CH de Compiègne, Compiègne, France|CH Sud Francilien, Corbeil Essonnes, France|APHP - Hôpital Henri Mondor, Créteil, France|CHU de Dijon, Dijon, France|CH de Dunkerque, Dunkerque, France|Institut Daniel Hollard, Grenoble, France|CHU de Grenoble, Grenoble, France|CHD Vendée, La Roche Sur Yon, France|CH La Rochelle, La Rochelle, France|APHP - Hôpital Bicêtre, Le Kremlin Bicêtre, France|CH du Mans, Le Mans, France|Clinique Victor Hugo, Le Mans, France|CH de Lens, Lens, France|CH Saint Vincent de Paul, Lille, France|CHRU Lille - Hôpital Claude Huriez, Lille, France|CHU Dupruytren - Limoges, Limoges, France|CH Bretagne Sud, Lorient, France|Centre Léon Bérard, Lyon, France|CH Mantes La Jolie, Mantes La Jolie, France|Hôpital de la Conception, Marseille, France|Institut Paoli Calmettes, Marseille, France|CH de Meaux, Meaux, France|CH Marc Jacquet, Melun, France|Hôpital Notre Dame Bon Secours, Metz, France|CHI de Meulan, Meulan en Yvelines, France|CHU de Montpellier - Saint Eloi, Montpellier, France|Centre Val d'Aurélie - Paul Lamarque, Montpellier, France|Centre Auréen de Cancérologie, Mougins, France|CH de Mulhouse - Hôpital Emile Muller, Mulhouse Cedex, France|CHU de Nantes - Hôtel Dieu, Nantes, France|Centre Catherine de Sienne, Nantes, France|Centre Antoine Lacassagne, Nice Cedex 2, France|CHU de Nice, Nice, France|CHU de Nîmes, Nîmes, France|Clinique Valdegour, Nîmes, France|CHR d'Orléans, Orléans, France|APHP - Hôpital Saint Louis, Paris Cedex 10, France|APHP - Hôpital Saint Antoine, Paris Cedex 12, France|Institut Curie, Paris, France|APHP - Hôpital de la Pitié Salpetrière, Paris, France|Hôpital Cochin, Paris, France|APHP - Hôpital Necker, Paris, France|CH Saint Jean, Perpignan, France|CHU de Haut Lévèque, Pessac, France|Hospices Civils de Lyon - CHU Lyon Sud, Pierre Bénite, France|CHU de Poitiers, Poitiers, France|CH René Dubos, Pontoise, France|CH d'Annecy, Pringy, France|CHU Robert Debré, Reims, France|Institut du Cancer de Courlancy, Reims, France|CHU de Rennes, Rennes, France|CH de Roubaix, Roubaix, France|Centre Henri Becquerel, Rouen, France|Clinique Mathilde, Rouen, France|CH Yves Le Foll - St Brieuc, Saint Brieuc, France|Centre René Huguenin, Saint Cloud, France|CHI de Poissy St Germain, Saint germain en laye, France|CHU de Saint Malo, Saint Malo, France|CH de Saint Quentin, Saint Quentin, France|Institut de Cancérologie, St Priest en Jarez, France|Strasbourg Oncologie Libérale, Strasbourg, France|CHU de Strasbourg, Strasbourg, France|Hopital Saint Husse, Toulon, France|Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O), Toulouse, France|CHU de Tours, Tours, France|CHU de Valence, Valence, France|CH de Valenciennes, Valenciennes, France|CHU de Brabois, Vandœuvre-lès-Nancy, France|CH Bretagne Atlantique, Vannes, France|CH de Versailles, Versailles, France|Institut Gustave Roussy, Villejuif, France",A61K9/1075,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,9.0,32.7488,22.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,1,0,1,0,1,1,1,0,1,1,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,1,1,1,1,0,0,0,1,1,0,1,1,1,1,0,0,0,1,0,1,1,1,0,1,0,1,1,1,1,1,0,1,1,1,1,0,0,1,1,1,0,1,0,0,0,1,0,1,1,1,1,0,1,0,0,1,0,1,1,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,1,1,1,1,1,1,1,1,1,1,1,1,1,1,0
CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2.O=C(O)C(O)C(O)C(=O)O.O=C(O)C(O)C(O)C(=O)O,0,,_VINORELBINE_TARTRATE,5994409,Terminated,NCT00920153,LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"FILO French Innovative Leukemia Organization, Tours Cedex, France",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,40.0,23.688371424464503,559.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,1,1,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,1,1,0,1,1,1,1,1,1,1,1,0,0,1,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,1,0,1,0,1,0,1,1,0,1,0,1,1,1,1,1,1,0,1,1,0,0,1,1,1,0,1,0,1,1,1,0,1,0,0,1,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,1,1,1,1,0
O.O.O.O.O.O=S([O-])([O-])=S.[Na+].[Na+],0,,_SODIUM_THIOSULFATE,,Terminated,NCT00074165,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|DRUG/AGENT TOXICITY BY TISSUE/ORGAN|LYMPHOMA|THROMBOCYTOPENIA,All,"18 Months to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States|Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
CO[C@H]1/C=C\C=C(/C)C(=O)NC2=CC(=O)C(NCCN(C)C)=C(C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@@H]1OC(N)=O)C2=O.Cl,0,,_ALVESPIMYCIN_HYDROCHLORIDE,,Terminated,NCT01126502,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,1,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,1,0,1,1,1,0,0
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00100711,CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|The Mayo Clinic, Rochester, Minnesota, United States|The Ohio State University, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00076401,"LEUKEMIA|LEUKEMIA, LYMPHOCYTIC, CHRONIC",All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00089284,NON-HODGKIN'S LYMPHOMA (NHL),All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Northwestern University, Chicago, Illinois, United States|Jesse B. Brown Veterans Affairs Medical Center, Chicago, Illinois, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Terminated,NCT00087191,ADVANCED ADULT PRIMARY LIVER CANCER|CARCINOMA OF THE APPENDIX|FALLOPIAN TUBE CANCER|GASTROINTESTINAL STROMAL TUMOR|LOCALIZED EXTRAHEPATIC BILE DUCT CANCER|LOCALIZED GALLBLADDER CANCER|LOCALIZED GASTROINTESTINAL CARCINOID TUMOR|LOCALIZED RESECTABLE ADULT PRIMARY LIVER CANCER|LOCALIZED UNRESECTABLE ADULT PRIMARY LIVER CANCER|METASTATIC GASTROINTESTINAL CARCINOID TUMOR|OVARIAN SARCOMA|OVARIAN STROMAL CANCER|PRIMARY PERITONEAL CAVITY CANCER|RECURRENT ADULT PRIMARY LIVER CANCER|RECURRENT ADULT SOFT TISSUE SARCOMA|RECURRENT COLON CANCER|RECURRENT EXTRAHEPATIC BILE DUCT CANCER|RECURRENT GALLBLADDER CANCER|RECURRENT GASTRIC CANCER|RECURRENT GASTROINTESTINAL CARCINOID TUMOR|RECURRENT NON-SMALL CELL LUNG CANCER|RECURRENT OVARIAN EPITHELIAL CANCER|RECURRENT OVARIAN GERM CELL TUMOR|RECURRENT PANCREATIC CANCER|RECURRENT RECTAL CANCER|RECURRENT SMALL INTESTINE CANCER|RECURRENT UTERINE SARCOMA|REGIONAL GASTROINTESTINAL CARCINOID TUMOR|SMALL INTESTINE ADENOCARCINOMA|SMALL INTESTINE LEIOMYOSARCOMA|SMALL INTESTINE LYMPHOMA|STAGE 0 NON-SMALL CELL LUNG CANCER|STAGE I ADULT SOFT TISSUE SARCOMA|STAGE I COLON CANCER|STAGE I GASTRIC CANCER|STAGE I NON-SMALL CELL LUNG CANCER|STAGE I OVARIAN EPITHELIAL CANCER|STAGE I OVARIAN GERM CELL TUMOR|STAGE I PANCREATIC CANCER|STAGE I RECTAL CANCER|STAGE I UTERINE SARCOMA|STAGE II ADULT SOFT TISSUE SARCOMA|STAGE II COLON CANCER|STAGE II GASTRIC CANCER|STAGE II NON-SMALL CELL LUNG CANCER|STAGE II OVARIAN EPITHELIAL CANCER|STAGE II OVARIAN GERM CELL TUMOR|STAGE II PANCREATIC CANCER|STAGE II RECTAL CANCER|STAGE II UTERINE SARCOMA|STAGE III ADULT SOFT TISSUE SARCOMA|STAGE III COLON CANCER|STAGE III GASTRIC CANCER|STAGE III OVARIAN EPITHELIAL CANCER|STAGE III OVARIAN GERM CELL TUMOR|STAGE III PANCREATIC CANCER|STAGE III RECTAL CANCER|STAGE III UTERINE SARCOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV ADULT SOFT TISSUE SARCOMA|STAGE IV COLON CANCER|STAGE IV GASTRIC CANCER|STAGE IV NON-SMALL CELL LUNG CANCER|STAGE IV OVARIAN EPITHELIAL CANCER|STAGE IV OVARIAN GERM CELL TUMOR|STAGE IV PANCREATIC CANCER|STAGE IV RECTAL CANCER|STAGE IV UTERINE SARCOMA|UNRESECTABLE EXTRAHEPATIC BILE DUCT CANCER|UNRESECTABLE GALLBLADDER CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,"Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCc1c(CC)c2cc3nc(cnc4cc(OCCOCCOCCOC)c(OCCOCCOCCOC)cc4ncc4nc(cc1[nH]2)C(CCCO)=C4C)C(C)=C3CCCO,0,,_MOTEXAFIN,,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,0,0,0,1,1,1,0,0,1,0,0,0,0,1,1,1,0,0,1,1,0,0,0,0,1,0,1,0,0,1,1,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,1
CCCCCCCCCCC(=O)O,0,,_UNDECANOATE,3932476,Terminated,NCT01516554,MULTIPLE SCLEROSIS|FATIGUE,Male,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Health Sciences Centre, Winnipeg, Manitoba, Canada",C07C231/02,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,10.0,30.3907677775724,567.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT02168907,B-CELL ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|TESTICULAR LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT00947388,RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Terminated,NCT02420210,DIFFUSE LARGE B-CELL LYMPHOMA,All,70 Years and older   (Older Adult),Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Withdrawn,NCT00939328,LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21,0,,_BENDAMUSTINE_HYDROCHLORIDE,US-20060159713-A1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,78.0,87.78825027207952,8.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,1,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,1,1,0,0,1,1,0
CONC(=N)c1ccc(-c2ccc(-c3ccc(C(=N)NOC)cc3)o2)cc1.O=C(O)/C=C\C(=O)O,0,,_PAFURAMIDINE_MALEATE,,Terminated,NCT00302341,"PNEUMONIA, INTERSTITIAL PLASMA CELL|PNEUMOCYSTIS CARINII PNEUMONIA|PNEUMONIA, PNEUMOCYSTIS CARINII|HIV INFECTIONS",All,"13 Years to 65 Years   (Child, Adult, Older Adult)",Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of California, San Francisco, California, United States|The University of Chicago, Chicago, Illinois, United States|Henry Ford Health System, Detroit, Michigan, United States|NYU School of Medicine, New York, New York, United States|UNC AIDS Clinical Trials, Chapel Hill, North Carolina, United States|University of Cincinnati, Cincinnati, Ohio, United States|Medical University of SC, Charleston, South Carolina, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Terminated,NCT02134886,HIV INFECTION|RECURRENT NON-SMALL CELL LUNG CARCINOMA|STAGE IIIA NON-SMALL CELL LUNG CANCER|STAGE IIIB NON-SMALL CELL LUNG CANCER|STAGE IV NON-SMALL CELL LUNG CANCER,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States|University of California San Diego, San Diego, California, United States|Albert Einstein College of Medicine, Bronx, New York, United States|Montefiore Medical Center-Einstein Campus, Bronx, New York, United States|Montefiore Medical Center - Moses Campus, Bronx, New York, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1.Cl,0,,_ERLOTINIB_HYDROCHLORIDE,EP-0817775-B1,Withdrawn,NCT01013506,BREAST CANCER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,28.0,75.2376845520441,61.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,1,1,0,0,1,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT02775006,"CARCINOMA, NON-SMALL CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"VUmc Medical Center, Amsterdam, Noord-Holland, Netherlands|Gelre Ziekenhuis, Apeldoorn, Netherlands|Amphia Hospital, Breda, Netherlands|Jeroen Bosch Hospital, Den Bosch, Netherlands|Haga, Den Haag, Netherlands|Albert Schweitzer ziekenhuis, Dordrecht, Netherlands|Ziekenhuis Gelderse Vallei, Ede, Netherlands|Maxima Medisch Centrum, Eindhoven, Netherlands|Martini Ziekenhuis, Groningen, Netherlands|Spaarne Gasthuis, Hoofddorp, Netherlands|MCL, Leeuwarden, Netherlands|Maastricht University Medical Center, Maastricht, Netherlands|Laurentius Hospital, Roermond, Netherlands|St. Fransicus Gasthuis, Rotterdam, Netherlands|Ikazia, Rotterdam, Netherlands|Erasmus MC, Rotterdam, Netherlands|Medical Center Haaglanden, the Hague, Netherlands|St. Antonius ziekenhuis, Utrecht, Netherlands|VieCuri Medisch Centrum voor Noord-Limburg, Venlo, Netherlands",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT00758732,OVARIAN CANCER,Female,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University Hospital of Crete, Heraklion, Crete, Greece|University General Hospital of Alexandroupolis, Dep of Medical Oncology, Alexandroupolis, Greece|""IASO"" General Hospital of Athnes, Dep of Medical Oncology, Athens, Greece|""Laikon"" General Hospital, Medical Oncology Unit, Propedeutic Dep of Internal Medicine, Athens, Greece|Department of Medical Oncology, ""Marika Iliadis"" Hospital of Athens, Athens, Greece|Department of Medical Oncology, Air Forces Military Hospital of Athens, Athens, Greece|Medical Oncology Unit, 401 Military Hospital of Athens, Athens, Greece|State General Hospital of Larissa, Dep of Medical Oncology, Larissa, Greece|First Department of Medical Oncology, ""Metaxa's"" Anticancer Hospital of Pireas, Piraeus, Greece|""Theagenion"" Anticancer Hospital of Thessaloniki, 2nd Dep of Medical Oncology, Thessaloniki, Greece|Interbalkan Hospital, division of Oncology, Pylaia, Thessaloniki, Thessaloniki, Greece|Medical Oncology Unit, ""AXEPA"" General Hospital of Thessaloniki, Thessaloniki, Greece",,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Terminated,NCT03827473,CASTRATION-SENSITIVE PROSTATE CARCINOMA|METASTATIC PROSTATIC ADENOCARCINOMA|STAGE IV PROSTATE CANCER|STAGE IVA PROSTATE CANCER|STAGE IVB PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@@]1(C)C(=O)[C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c4ccccc4)C[C@@](O)([C@@H](OC(=O)c4ccccc4)[C@@H]12)C3(C)C.O.O.O,0,,_DOCETAXEL,,Withdrawn,NCT03343977,METASTATIC HORMONE-SENSITIVE PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States",,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,0,0,1,1,1,1,1,0,0,0,1,1,0,1,1,0,1,0,0,0,1,0,1,1,1,0,1,1,1,0,1,0,1,1,1,1,1,0,0,1,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,0,1,1,1,1,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,0,1,0,1,0,1,1,0,1,1,1,1,1,0,1,0,0
CC(C)Nc1cccnc1N1CCN(C(=O)c2cc3cc(NS(C)(=O)=O)ccc3[nH]2)CC1.CS(=O)(=O)O,0,,_DELAVIRDINE_MESYLATE,5874430,Terminated,NCT00002420,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",Industry,Masking: None (Open Label)|Primary Purpose: Treatment,"Pacific Oaks Med Group, Beverly Hills, California, United States",C07D265/18,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,22.0,16.7559908827696,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,0,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,0,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Terminated,NCT00005987,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"up to 70 Years   (Child, Adult, Older Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"University of Minnesota Cancer Center, Minneapolis, Minnesota, United States",7,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
Cl.Cl.O=C1c2c(O)ccc(O)c2C(=O)c2c(NCCNCCO)ccc(NCCNCCO)c21,0,,_MITOXANTRONE_HYDROCHLORIDE,5792753,Withdrawn,NCT00005998,LYMPHOMA,All,"18 Years to 70 Years   (Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,,7,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,65.74262305180801,73.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0
CC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,,_DEXAMETHASONE_ACETATE,3962430,Terminated,NCT02419469,LEUKEMIA|PRECURSOR-B ACUTE LYMPHOBLASTIC LEUKEMIA|LYMPHOBLASTIC LYMPHOMA|LYMPHOMA,All,"12 Years to 30 Years   (Child, Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Texas MD Anderson Cancer Center, Houston, Texas, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,10.842111747674403,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
CC(=O)O[C@]1(C(=O)CO)[C@H](C)C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,,_DEXAMETHASONE_ACETATE,3962430,Terminated,NCT01878708,T-CELL LYMPHOMA|RELAPSED T-CELL LYMPHOMA|REFRACTORY T-CELL LYMPHOMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States",A61L2/0023,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,10.842111747674403,311.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,1,1,0,1,0,0,0,0,0,1,1,1,0,0,1,0,1,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,0,1,0,1
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Terminated,NCT00275106,LYMPHOMA,All,"up to 21 Years   (Child, Adult)",Other,Allocation: Randomized|Primary Purpose: Treatment,"Kinderklinik, Giessen, Germany|Our Lady's Hospital for Sick Children Crumlin, Dublin, Ireland|Birmingham Children's Hospital, Birmingham, England, United Kingdom|Institute of Child Health at University of Bristol, Bristol, England, United Kingdom|Addenbrooke's Hospital, Cambridge, England, United Kingdom|Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom|Leicester Royal Infirmary, Leicester, England, United Kingdom|Royal Liverpool Children's Hospital, Alder Hey, Liverpool, England, United Kingdom|Royal London Hospital, London, England, United Kingdom|Great Ormond Street Hospital for Children, London, England, United Kingdom|Royal Manchester Children's Hospital, Manchester, England, United Kingdom|Sir James Spence Institute of Child Health, Newcastle-Upon-Tyne, England, United Kingdom|Queen's Medical Centre, Nottingham, England, United Kingdom|Oxford Radcliffe Hospital, Oxford, England, United Kingdom|Children's Hospital - Sheffield, Sheffield, England, United Kingdom|Southampton General Hospital, Southampton, England, United Kingdom|Royal Marsden - Surrey, Sutton, England, United Kingdom|Royal Belfast Hospital for Sick Children, Belfast, Northern Ireland, United Kingdom|Royal Aberdeen Children's Hospital, Aberdeen, Scotland, United Kingdom|Royal Hospital for Sick Children, Edinburgh, Scotland, United Kingdom|Royal Hospital for Sick Children, Glasgow, Scotland, United Kingdom|Childrens Hospital for Wales, Cardiff, Wales, United Kingdom",A61K47/6889,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Withdrawn,NCT00019409,LEUKEMIA,All,"1 Year to 20 Years   (Child, Adult)",NIH,Allocation: Randomized|Primary Purpose: Treatment,"Pediatric Oncology Branch, Bethesda, Maryland, United States|Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, United States|Kidwai Memorial Institute of Oncology, Bangalore, India|Cancer Institute (W.I.A.), Madras, India|Tata Memorial Centre, Mumbai, India|All-India Institute of Medical Sciences, New Delhi, India",A61K47/6889,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.Cl,0,,_DAUNORUBICIN_HYDROCHLORIDE,4671958,Withdrawn,NCT00900445,ACUTE LYMPHOBLASTIC LEUKEMIA|UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA,All,"10 Years to 19 Years   (Child, Adult)",Other|NIH,,"Childrens Oncology Group, Philadelphia, Pennsylvania, United States",A61K47/6889,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,49.0,63.01566767284739,236.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,1,0,1,0,1,1,1,0,1,0,1,0,1,1,1,0,1,0,1,0,1,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,1,0,0,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,0,0,0,1,0,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00687674,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(C(F)(F)F)c3)cc2)ccn1.Cc1ccc(S(=O)(=O)O)cc1,0,,_SORAFENIB_TOSYLATE,WO-2003068228-A1,Terminated,NCT00303966,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,32.0,32.7488,11.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,1,1,0,0,0,1,1,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,1,1,0,1,0,1,1,0,0,1,0,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00369629,LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Terminated,NCT00545948,"CARCINOMA, NON-SMALL-CELL LUNG",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Palm Beach Cancer Institute, West Palm Beach, Florida, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Presbyterian HealthCare, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Maria Parham Hospital, Henderson, North Carolina, United States|Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg, North Carolina, United States|Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States|Johnston Memorial Hospital Authority, Smithfield, North Carolina, United States|Columbus County Hospital, Whiteville, North Carolina, United States|Beaufort Memorial Hospital, Beaufort, South Carolina, United States|Coastal Cancer Center, Myrtle Beach, South Carolina, United States|Community Memorial Health Center, South Hill, Virginia, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@H](CCC(=O)O)C(=O)O)cc3)c2c(=O)[nH]1,0,,_PEMETREXED,WO-2001056575-A1,Withdrawn,NCT00712062,PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,20.0,32.7488,392.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,1,0,1,1,0,0,0,1,1,0,0,1,1,0,1,0,1,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,1,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,0,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Terminated,NCT00062231,"CHRONIC MYELOPROLIFERATIVE DISORDERS|FEVER, SWEATS, AND HOT FLASHES|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUTROPENIA|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Masking: Double|Primary Purpose: Supportive Care,"Hopital Universitaire Erasme, Brussels, Belgium|Cliniques Universitaires Saint-Luc, Brussels, Belgium|U.Z. Gasthuisberg, Leuven, Belgium|Institut Bergonie, Bordeaux, France|Institut Curie Hopital, Paris, France|Charite - Campus Charite Mitte, Berlin, Germany|Charite - Universitaetsmedizin Berlin - Campus Benjamin Franklin, Berlin, Germany|Medizinische Universitaetsklinik I at the University of Cologne, Cologne, Germany|Klinikum der Albert - Ludwigs - Universitaet Freiburg, Freiburg, Germany|Ruprecht - Karls - Universitaet Heidelberg, Heidelberg, Germany|Klinikum der Stadt Mannheim, Mannheim, Germany|Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt, Rostock, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Wolfson Medical Center, Holon, Israel|Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy|Universita Degli Studi di Udine, Udine, Italy|National Cancer Institute - Bratislava, Bratislava, Slovakia|St. Elizabeth Cancer Institute Hospital, Bratislava, Slovakia|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|Hopital D'Yverdon, Yverdon, Switzerland|Hacettepe University - Faculty of Medicine, Ankara, Turkey|Ibn-i Sina Hospital, Ankara, Turkey|Marmara University Hospital, Istanbul, Turkey",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
COc1c(N2C[C@@H]3CCCN[C@@H]3C2)c(F)cc2c(=O)c(C(=O)O)cn(C3CC3)c12.Cl,0,,_MOXIFLOXACIN_HYDROCHLORIDE,6548079,Terminated,NCT00324324,BREAST CANCER|CHRONIC MYELOPROLIFERATIVE DISORDERS|GESTATIONAL TROPHOBLASTIC TUMOR|INFECTION|LEUKEMIA|LYMPHOMA|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|NEUROBLASTOMA|OVARIAN CANCER|TESTICULAR GERM CELL TUMOR,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,14.2590196923961,67.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,1,1,0,1,1,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,0,1,1,1,1,0,0,1,0,0,1,1,0,0,0,0,0,1,0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,1,0,1,0,0
CNNCc1ccc(C(=O)NC(C)C)cc1.Cl,0,,_PROCARBAZINE_HYDROCHLORIDE,4978332,Terminated,NCT00003113,LYMPHOMA,All,"60 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,20.0,38.6701985667056,42.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
CNNCc1ccc(C(=O)NC(C)C)cc1.Cl,0,,_PROCARBAZINE_HYDROCHLORIDE,4978332,Withdrawn,NCT00734773,BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA|NEUROTOXICITY,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,20.0,38.6701985667056,42.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,1,1
COc1ccc2c3c1O[C@H]1C(=O)CC[C@@]4(O)[C@@H](C2)N(C)CC[C@]314.Cl,0,,_OXYCODONE_HYDROCHLORIDE,4126684,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.425532351793603,207.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,1,0,0,1,1,1,1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,0,0,0,0,1,1,1,0,1,1,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0
CCC(=O)C(CC(C)N(C)C)(c1ccccc1)c1ccccc1.Cl,0,,_METHADONE_HYDROCHLORIDE,4126684,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,7.0,23.425532351793603,2832.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,1,0,0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0
CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.CN1CC[C@]23c4c5ccc(O)c4O[C@H]2[C@@H](O)C=C[C@H]3[C@H]1C5.O=S(=O)(O)O,0,,_MORPHINE_SULFATE,4083982,Terminated,NCT00726830,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"Palmetto Hematology Oncology, PC at Gibbs Regional Cancer Center, Spartanburg, South Carolina, United States|M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,3.0,12.3205815314482,167.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,1,1,1,1,0,0,1,1,0,0,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0
CN(C)CCC=C1c2ccccc2COc2ccccc21.Cl,0,,_DOXEPIN_HYDROCHLORIDE,4370324,Terminated,NCT02062632,ESOPHAGEAL CARCINOMA|HYPOPHARYNGEAL CARCINOMA|LARYNGEAL CARCINOMA|LYMPHOMA|MESOTHELIOMA|METASTATIC MALIGNANT NEOPLASM IN THE LUNG|METASTATIC MALIGNANT NEOPLASM IN THE PLEURA|METASTATIC MALIGNANT NEOPLASM IN THE SPINAL CORD|NON-SMALL CELL LUNG CARCINOMA|SARCOMA|SMALL CELL LUNG CARCINOMA|THYMIC CARCINOMA|THYMOMA|THYROID GLAND CARCINOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care","Mayo Clinic, Rochester, Minnesota, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay, Wisconsin, United States",0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,28.2552003121213,135.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0
C[C@@H](CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1.Cl,0,,_DEXRAZOXANE_HYDROCHLORIDE,6308714,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",A61N7/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,28.0,35.64754923099029,86.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,1,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00933985,"ACUTE LEUKEMIAS OF AMBIGUOUS LINEAGE|ACUTE UNDIFFERENTIATED LEUKEMIA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|BLASTIC PHASE CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD BURKITT LYMPHOMA|CHILDHOOD CHRONIC MYELOGENOUS LEUKEMIA|CHILDHOOD DIFFUSE LARGE CELL LYMPHOMA|CHILDHOOD IMMUNOBLASTIC LARGE CELL LYMPHOMA|CHILDHOOD NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|CUTANEOUS B-CELL NON-HODGKIN LYMPHOMA|HEPATOSPLENIC T-CELL LYMPHOMA|INTRAOCULAR LYMPHOMA|NONCUTANEOUS EXTRANODAL LYMPHOMA|PERIPHERAL T-CELL LYMPHOMA|RECURRENT CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT CHILDHOOD ACUTE MYELOID LEUKEMIA|RECURRENT CHILDHOOD ANAPLASTIC LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT CHILDHOOD LARGE CELL LYMPHOMA|RECURRENT CHILDHOOD LYMPHOBLASTIC LYMPHOMA|RECURRENT CHILDHOOD SMALL NONCLEAVED CELL LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT/REFRACTORY CHILDHOOD HODGKIN LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY HAIRY CELL LEUKEMIA|RELAPSING CHRONIC MYELOGENOUS LEUKEMIA|SMALL INTESTINE LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"up to 21 Years   (Child, Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Alabama at Birmingham, Birmingham, Alabama, United States|Childrens Hospital of Orange County, Orange, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Indiana University Medical Center, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota Medical Center-Fairview, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University Medical Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States|Baylor College of Medicine, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Hospital for Sick Children, Toronto, Ontario, Canada|Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada",A61K38/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00612612,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Dana-Farber Cancer Institute, Boston, Massachusetts, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00538187,ADULT NON-HODGKIN LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"City of Hope Medical Center, Duarte, California, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00719901,REFRACTORY MULTIPLE MYELOMA|STAGE I MULTIPLE MYELOMA|STAGE II MULTIPLE MYELOMA|STAGE III MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Terminated,NCT00918931,LEUKEMIA|SYSTEMIC MASTOCYTOSIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UT MD Anderson Cancer Center, Houston, Texas, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C.CS(=O)(=O)O,0,,_OBATOCLAX_MESYLATE,WO-2013121428-A1,Withdrawn,NCT01238146,EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States",A61K38/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,37.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,1,0,1,1,0,0,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00112619,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CARCINOMA OF UNKNOWN PRIMARY|LEUKEMIA|LYMPHOMA|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC",All,"3 Years to 21 Years   (Child, Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Memorial Hospital - Chicago, Chicago, Illinois, United States|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Dan L. Duncan Cancer Center at Baylor College of Medicine, Houston, Texas, United States|Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States",A61K49/0021,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Terminated,NCT00005029,OVARIAN CANCER|PRIMARY PERITONEAL CAVITY CANCER,Female,"up to 120 Years   (Child, Adult, Older Adult)",Other|NIH,Primary Purpose: Treatment,"University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States|CCOP - Greater Phoenix, Phoenix, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States|Chao Family Comprehensive Cancer Center, Orange, California, United States|Women's Cancer Center, Palo Alto, California, United States|University of Colorado Cancer Center, Denver, Colorado, United States|Vincent T. Lombardi Cancer Research Center, Georgetown University, Washington, District of Columbia, United States|Walter Reed Army Medical Center, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Emory University Hospital - Atlanta, Atlanta, Georgia, United States|MBCCOP - Hawaii, Honolulu, Hawaii, United States|MBCCOP - University of Illinois at Chicago, Chicago, Illinois, United States|Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States|University of Chicago Cancer Research Center, Chicago, Illinois, United States|CCOP - Central Illinois, Decatur, Illinois, United States|CCOP - Evanston, Evanston, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|CCOP - Iowa Oncology Research Association, Des Moines, Iowa, United States|University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States|Albert B. Chandler Medical Center, University of Kentucky, Lexington, Kentucky, United States|Johns Hopkins Oncology Center, Baltimore, Maryland, United States|Medicine Branch, Bethesda, Maryland, United States|Radiation Oncology Branch, Bethesda, Maryland, United States|Tufts University School of Medicine, Boston, Massachusetts, United States|University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, United States|CCOP - Ann Arbor Regional, Ann Arbor, Michigan, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|University of Minnesota Cancer Center, Minneapolis, Minnesota, United States|University of Mississippi Medical Center, Jackson, Mississippi, United States|Keesler Medical Center - Keesler AFB, Keesler Air Force Base, Mississippi, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|CCOP - Kansas City, Kansas City, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|CCOP - Cancer Research for the Ozarks, Springfield, Missouri, United States|CCOP - Montana Cancer Consortium, Billings, Montana, United States|CCOP - Missouri Valley Cancer Consortium, Omaha, Nebraska, United States|CCOP - Southern Nevada Cancer Research Foundation, Las Vegas, Nevada, United States|Cooper Hospital/University Medical Center, Camden, New Jersey, United States|Cancer Center of Albany Medical Center, Albany, New York, United States|State University of New York Health Science Center at Brooklyn, Brooklyn, New York, United States|North Shore University Hospital, Manhasset, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|University of Rochester Cancer Center, Rochester, New York, United States|State University of New York Health Sciences Center - Stony Brook, Stony Brook, New York, United States|Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina, United States|Duke Comprehensive Cancer Center, Durham, North Carolina, United States|Brookview Research, Inc., Winston-Salem, North Carolina, United States|Comprehensive Cancer Center of Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|Barrett Cancer Center, The University Hospital, Cincinnati, Ohio, United States|Ireland Cancer Center, Cleveland, Ohio, United States|Cleveland Clinic Cancer Center, Cleveland, Ohio, United States|Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States|University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, United States|CCOP - St. Francis Hospital/Natalie Warren Bryant Cancer Center, Tulsa, Oklahoma, United States|CCOP - Columbia River Program, Portland, Oregon, United States|Abington Memorial Hospital, Abington, Pennsylvania, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States|Kimmel Cancer Center of Thomas Jefferson University - Philadelphia, Philadelphia, Pennsylvania, United States|Pennsylvania Hospital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|CCOP - MainLine Health, Wynnewood, Pennsylvania, United States|Medical University of South Carolina, Charleston, South Carolina, United States|CCOP - Greenville, Greenville, South Carolina, United States|CCOP - Upstate Carolina, Spartanburg, South Carolina, United States|CCOP - Baptist Cancer Institute, Memphis, Tennessee, United States|Simmons Cancer Center - Dallas, Dallas, Texas, United States|University of Texas - MD Anderson Cancer Center, Houston, Texas, United States|CCOP - Scott and White Hospital, Temple, Texas, United States|Cancer Center, University of Virginia HSC, Charlottesville, Virginia, United States|University of Washington Medical Center, Seattle, Washington, United States|Tacoma General Hospital, Tacoma, Washington, United States|NCIC-Clinical Trials Group, Kingston, Ontario, Canada",A61K49/0021,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(CN(C)C)c(O)ccc3nc2-1.Cl,0,,_TOPOTECAN_HYDROCHLORIDE,5962216,Withdrawn,NCT00109798,CENTRAL NERVOUS SYSTEM TUMORS|LYMPHOMA,All,"18 Years to 75 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,A61K49/0021,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,43.0,30.1279287049015,7.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,0,1,0,1,1,1,0,0,1,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,1,0,0,1,0,1,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,1,0,0,0,1,1,0,1,1,0,0,0,0
O=c1ccc2cc3ccoc3cc2o1,0,,_PSORALEN,4169840,Terminated,NCT00724061,LYMPHOMA,All,"18 Years to 120 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States",C07D493/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.0,22.5713053656132,1003.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0
NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O,0,,_KETOROLAC_TROMETHAMINE,5091182,Terminated,NCT00621530,HIP ARTHROPLASTY,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,12.0,19.1215425368077,386.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,1,1,1,0
CN(C)CCC(c1ccc(Cl)cc1)c1ccccn1.O=C(O)/C=C\C(=O)O,0,,_CHLORPHENIRAMINE_MALEATE,4256763,Terminated,NCT02722083,"RHINITIS, ALLERGIC",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment,"Germantown, Tennessee, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,11.0,29.897944516314503,544.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,1,0,1,0,0,0,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,0,1,1,1,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,1,1,0,0
NC[C@@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@@H](O[C@@H]3[C@@H](O)[C@H](N)C[C@H](N)[C@H]3O[C@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3N)[C@@H]2O)[C@H](N)[C@@H](O)[C@@H]1O.O=S(=O)(O)O,0,,_PAROMOMYCIN_SULFATE,5780049,Terminated,NCT00001128,CRYPTOSPORIDIOSIS|HIV INFECTIONS,All,"18 Years and older   (Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Pablo C. Okhuysen, Houston, Texas, United States",A61K8/8158,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,13.0,37.29029343518339,40.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,1,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,1,0,0,0,0,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1
CC(C)[C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](NC(=O)[C@H](N)Cc2ccc3ccccc3c2)CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)NC1=O,0,,_LANREOTIDE,,Terminated,NCT00288522,THYROID-ASSOCIATED OPHTHALMOPATHY,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Hospital General d'Alacant, Alicante, Spain",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,1,0,1,0,1,0,0,0,0,1,1,1,0,1,0,0,0,1,1,1,0,1,1,0,1,1,0,1,1,1,1,1,0,0,0,0,1,1,0,1,1,1,0,1,0,0,1,0,0,1,1,0,1,1,0,1,1,1,1,0,0,1,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,1,1,0,1,0,1,1,1,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,1,1,0,1,0,1,0,1,0,1,0,0
Cc1ncc(CO)c(CO)c1O.Cl,0,,_PYRIDOXINE_HYDROCHLORIDE,4053593,Terminated,NCT00486213,"DERMATOLOGIC COMPLICATIONS|PALMAR-PLANTAR ERYTHRODYSESTHESIA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","National Cancer Centre - Singapore, Singapore, Singapore",A23K20/174,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,12.0,22.505595597445502,658.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,1
Cl.O=c1[nH]cnc2c([C@@H]3N[C@H](CO)[C@@H](O)[C@H]3O)c[nH]c12,0,,_FORODESINE_HYDROCHLORIDE,,Terminated,NCT00419081,LEUKEMIA|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Chicago Medical Center, Chicago, Illinois, United States|Louisana State University Health Sciences Center, Shreveport, Louisiana, United States|New York Medical College Division of Oncology, Valhalla, New York, United States|Liberty Hematology and Oncology, Columbia, South Carolina, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Terminated,NCT02465528,TUMORS WITH ABERRATIONS IN ALK|ANAPLASTIC LARGE CELL LYMPHOMA|INFLAMMATORY MYOFIBROBLASTIC TUMOR|GLIOBLASTOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Novartis Investigative Site, Brno, Czech Republic, Czechia|Novartis Investigative Site, Copenhagen, Denmark|Novartis Investigative Site, Lyon Cedex, France|Novartis Investigative Site, Saint-Herblain Cédex, France|Novartis Investigative Site, Strasbourg, France|Novartis Investigative Site, Tel Aviv, Israel|Novartis Investigative Site, Milano, MI, Italy|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Seoul, Korea, Republic of|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Madrid, Spain|Novartis Investigative Site, Bangkok, Thailand|Novartis Investigative Site, Bangkok, Thailand",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1,0,,_CERITINIB,,Withdrawn,NCT02729961,"ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE|CD30-POSITIVE NEOPLASTIC CELLS PRESENT|SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA",All,"12 Years and older   (Child, Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,1,1,1,0,1,1,0,0,0,0,1,0,1,1,0,0,0,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,0,1,0,1,0,0,0,1,1,0,0,0,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,1,1,1,0,0,0,1
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,0,,_CYPROHEPTADINE_HYDROCHLORIDE,4913865,Terminated,NCT00949117,"LEUKEMIA|LYMPHOMA|MALNUTRITION|MYELODYSPLASTIC SYNDROMES|UNSPECIFIED CHILDHOOD SOLID TUMOR, PROTOCOL SPECIFIC|WEIGHT CHANGES",All,2 Years to 17 Years   (Child),Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.39109632641321,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
CN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1.Cl,0,,_CYPROHEPTADINE_HYDROCHLORIDE,4913865,Terminated,NCT01132547,CANCER,All,"2 Years to 21 Years   (Child, Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care","Miller Children's Hospital, Long Beach, California, United States|Connecticut Children's Medical Center, Hartford, Connecticut, United States|A.I. duPont Hospital for Children, Wilmington, Delaware, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Hospital of Southwest Florida at Lee Memorial, Fort Myers, Florida, United States|Nemours Children's Clinic - Jacksonville, Jacksonville, Florida, United States|Arnold Palmer Hospital for Children, Orlando, Florida, United States|Nemours Children's Clinic - Orlando, Orlando, Florida, United States|Nemours Children's Hospital Pensacola, Pensacola, Florida, United States|Kapiolani Medical Center for Women and Children, Honolulu, Hawaii, United States|Ochsner Clinic Foundation, New Orleans, Louisiana, United States|Columbia University Medical Center, New York, New York, United States|CHRISTUS Santa Rosa Children's Hospital, San Antonio, Texas, United States|Children's Hospital of The King's Daughters, Norfolk, Virginia, United States",A61K9/14,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,5.0,46.39109632641321,101.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0
Oc1cc(O)c2c(c1)OC(c1ccc(O)c(O)c1)C(O)C2,0,,_CATECHIN,4094969,Terminated,NCT00942422,MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|PRECANCEROUS CONDITION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States",A01N25/22,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,24.0,35.9103883036612,1741.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,1
CN1CC[C@H](c2c(O)cc(O)c3c(=O)cc(-c4ccccc4Cl)oc23)[C@H](O)C1.Cl,0,,_ALVOCIDIB_HYDROCHLORIDE,WO-2014083132-A1,Terminated,NCT01076556,CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE I SMALL LYMPHOCYTIC LYMPHOMA|STAGE II CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE II SMALL LYMPHOCYTIC LYMPHOMA|STAGE III CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV CHRONIC LYMPHOCYTIC LEUKEMIA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",C12N5/067 ,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,88.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,1,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,0,0,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,1,1,0,1,1,0,1,0,0,1,0,1,0,1,1,0,1,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0
CCc1cccc2c3c([nH]c12)[C@@](CC)(CC(=O)O)OCC3,0,,_SDX-101,4420476,Terminated,NCT00293111,MULTIPLE MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory University School of Medicine, Atlanta, Georgia, United States|Johns Hopkins School of Medicine, Baltimore, Maryland, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Cleveland Clinic Foundation, Cleveland, Ohio, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States",C07D491/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,30.0,18.661574159633602,128.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,0,1,0,1,1,0,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,1,0,1,1,1,1,0,1,1,0,0,1,0,0,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,1,0,0
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,0,,_IVERMECTIN,4389397,Terminated,NCT00817713,HIV INFECTIONS|HELMINTHIASIS,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Chronic Disease Clinic of St. Francis Designated District Hospital, Ifakara, Kilombero, Tanzania",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,0,,_IVERMECTIN,4389397,Terminated,NCT01213576,LYMPHATIC FILARIASIS,All,18 Years to 55 Years   (Adult),Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Karonga Prevention Study, Karonga, Malawi",3,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
CC[C@H](C)[C@H]1O[C@]2(CC[C@@H]1C)C[C@@H]1C[C@@H](C/C=C(\C)[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)/C=C/C=C3\CO[C@@H]4[C@H](O)C(C)=C[C@@H](C(=O)O1)[C@]34O)O2.CO[C@H]1C[C@H](O[C@H]2[C@H](C)O[C@@H](O[C@@H]3/C(C)=C/C[C@@H]4C[C@@H](C[C@]5(CC[C@H](C)[C@@H](C(C)C)O5)O4)OC(=O)[C@@H]4C=C(C)[C@@H](O)[C@H]5OC/C(=C\C=C\[C@@H]3C)[C@@]45O)C[C@@H]2OC)O[C@@H](C)[C@@H]1O,0,,_IVERMECTIN,4389397,Withdrawn,NCT03553615,ATOPIC DERMATITIS,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Stanford Hospital and Clinics, Stanford, California, United States",3,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,6.0,20.961416045504,1324.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,0,0,1,1,0,1,0,1,1,1,1,1,0,0,0,0,1,1,0,0,0,1,1,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,1,0,0,0,1,1,1,1,1,0,0,1,1,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,1,1,0,0,0,1,1,0,1,1,1,1,0,1,0,0,1,0,0,1,1,1,0,1
Cc1cccn2c(=O)c(-c3nnn[nH]3)cnc12,0,,_PEMIROLAST,,Terminated,NCT03119714,ALLERGIC ASTHMA,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Lung and Allergy Research Unit C2-88 Karolinska University Hospital Huddinge, Stockholm, Sweden",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,1,1,0,1,1,0,0,0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,1,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,1
CC(=O)O[C@H]1CC[C@@]2(C)C(=CC[C@H]3[C@@H]4CC=C(c5cccnc5)[C@@]4(C)CC[C@@H]32)C1,0,,_ABIRATERONE_ACETATE,5604213,Terminated,NCT03827473,CASTRATION-SENSITIVE PROSTATE CARCINOMA|METASTATIC PROSTATIC ADENOCARCINOMA|STAGE IV PROSTATE CANCER|STAGE IVA PROSTATE CANCER|STAGE IVB PROSTATE CANCER,Male,"18 Years and older   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States",C07J41/0005,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,22.0,28.6494589211277,4.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,1,0,0,1,1,1,1,1,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,1,0,1,0,1
C#Cc1cnc(O)nc1O,0,,_ENILURACIL,5643913,Terminated,NCT00827580,BREAST CANCER|COLON CANCER,All,"18 Years and older   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double|Primary Purpose: Treatment,"Clinical Trials Research Unit, West Virginia University, Morgantown, West Virginia, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,4.0,31.7049631409269,94.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12.O=P(O)(O)O,0,,_CHLOROQUINE_PHOSPHATE,5021426,Terminated,NCT00308620,HIV INFECTION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Minnesota ACTU, Minneapolis, Minnesota, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,11.0,15.2118113308281,90.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,1,1,1,1,0,0,0,0,1,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,0
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC,0,,_ERIBULIN,,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
C=C1C[C@@H]2CC[C@@]34C[C@H]5O[C@H]6[C@@H](O3)[C@H]3O[C@H](CC[C@@H]3O[C@H]6[C@H]5O4)CC(=O)C[C@H]3[C@H](C[C@H]4O[C@@H](CC[C@@H]1O2)C[C@@H](C)C4=C)O[C@H](C[C@H](O)CN)[C@@H]3OC.CS(=O)(=O)O,0,,_ERIBULIN_MESYLATE,,Terminated,NCT02082626,PEDIATRIC CANCER|SOLID TUMORS|LYMPHOMA,All,"up to 20 Years   (Child, Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Jimmy Everest Center for Cancer and Blood Disorders in Children, Oklahoma City, Oklahoma, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,1,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,1,1,1,0,1,0,1,0,1,0,0,0,1,0,1,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,0,1,1,0,0,0,0,0,1,0,1,1,1,1,0,1,1,0,0,1,1,1,0,0,0,0
C[S+](C)[O-],0,,_DIMETHYL_SULFOXIDE,,Terminated,NCT01123915,HIV INFECTION,All,18 Years to 60 Years   (Adult),Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","St Stephen's Centre, Chelsea and Westminster Foundation Trust, London, United Kingdom",,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1occc(=O)c1O,0,,_MALTOL,3940499,Terminated,NCT00050687,PROSTATIC NEOPLASMS|MULTIPLE MYELOMA|BLADDER NEOPLASMS|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Highlands Oncology Group, PA, Springdale, Arkansas, United States|California Cancer Care, Greenbrae, California, United States|Stanford University, Palo Alto, California, United States|Southfield Oncology Institute, Southfield, Michigan, United States|New York Presbyterian Hospital, New York, New York, United States",A23G4/06,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,3.0,17.183104375859802,881.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00354185,"ADULT NASAL TYPE EXTRANODAL NK/T-CELL LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|INTRAOCULAR LYMPHOMA|NODAL MARGINAL ZONE B-CELL LYMPHOMA|POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00096005,"ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|AIDS-RELATED PERIPHERAL/SYSTEMIC LYMPHOMA|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT GRADE III LYMPHOMATOID GRANULOMATOSIS|RECURRENT ADULT HODGKIN LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|STAGE III ADULT BURKITT LYMPHOMA|STAGE III ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE III ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE III ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE III ADULT HODGKIN LYMPHOMA|STAGE III ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE III ADULT LYMPHOBLASTIC LYMPHOMA|STAGE III ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE III CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE III GRADE 1 FOLLICULAR LYMPHOMA|STAGE III GRADE 2 FOLLICULAR LYMPHOMA|STAGE III GRADE 3 FOLLICULAR LYMPHOMA|STAGE III MANTLE CELL LYMPHOMA|STAGE III MARGINAL ZONE LYMPHOMA|STAGE III MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE III SMALL LYMPHOCYTIC LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT HODGKIN LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV ADULT T-CELL LEUKEMIA/LYMPHOMA|STAGE IV CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV MYCOSIS FUNGOIDES/SEZARY SYNDROME|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC|WALDENSTRÖM MACROGLOBULINEMIA",All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Mayo Clinic, Rochester, Minnesota, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00103272,ADULT ACUTE BASOPHILIC LEUKEMIA|ADULT ACUTE EOSINOPHILIC LEUKEMIA|ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA (M7)|ADULT ACUTE MINIMALLY DIFFERENTIATED MYELOID LEUKEMIA (M0)|ADULT ACUTE MONOBLASTIC LEUKEMIA (M5A)|ADULT ACUTE MONOCYTIC LEUKEMIA (M5B)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITH MATURATION (M2)|ADULT ACUTE MYELOBLASTIC LEUKEMIA WITHOUT MATURATION (M1)|ADULT ACUTE MYELOID LEUKEMIA WITH 11Q23 (MLL) ABNORMALITIES|ADULT ACUTE MYELOID LEUKEMIA WITH INV(16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(16;16)(P13;Q22)|ADULT ACUTE MYELOID LEUKEMIA WITH T(8;21)(Q22;Q22)|ADULT ACUTE MYELOMONOCYTIC LEUKEMIA (M4)|ADULT ERYTHROLEUKEMIA (M6A)|ADULT PURE ERYTHROID LEUKEMIA (M6B)|ANAPLASTIC LARGE CELL LYMPHOMA|ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA|EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|RECURRENT ADULT ACUTE LYMPHOBLASTIC LEUKEMIA|RECURRENT ADULT ACUTE MYELOID LEUKEMIA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT T-CELL LEUKEMIA/LYMPHOMA|RECURRENT CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT MYCOSIS FUNGOIDES/SEZARY SYNDROME|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|SMALL INTESTINE LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|WALDENSTRÖM MACROGLOBULINEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00019708,"EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF MUCOSA-ASSOCIATED LYMPHOID TISSUE|NODAL MARGINAL ZONE B-CELL LYMPHOMA|NON-HODGKIN LYMPHOMA|RECURRENT ADULT BURKITT LYMPHOMA|RECURRENT ADULT DIFFUSE LARGE CELL LYMPHOMA|RECURRENT ADULT DIFFUSE MIXED CELL LYMPHOMA|RECURRENT ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|RECURRENT ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|RECURRENT ADULT LYMPHOBLASTIC LYMPHOMA|RECURRENT GRADE 1 FOLLICULAR LYMPHOMA|RECURRENT GRADE 2 FOLLICULAR LYMPHOMA|RECURRENT GRADE 3 FOLLICULAR LYMPHOMA|RECURRENT MARGINAL ZONE LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|SPLENIC MARGINAL ZONE LYMPHOMA|STAGE IV ADULT BURKITT LYMPHOMA|STAGE IV ADULT DIFFUSE LARGE CELL LYMPHOMA|STAGE IV ADULT DIFFUSE MIXED CELL LYMPHOMA|STAGE IV ADULT DIFFUSE SMALL CLEAVED CELL LYMPHOMA|STAGE IV ADULT IMMUNOBLASTIC LARGE CELL LYMPHOMA|STAGE IV ADULT LYMPHOBLASTIC LYMPHOMA|STAGE IV GRADE 1 FOLLICULAR LYMPHOMA|STAGE IV GRADE 2 FOLLICULAR LYMPHOMA|STAGE IV GRADE 3 FOLLICULAR LYMPHOMA|STAGE IV MANTLE CELL LYMPHOMA|STAGE IV MARGINAL ZONE LYMPHOMA|STAGE IV SMALL LYMPHOCYTIC LYMPHOMA|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"19 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of Nebraska Medical Center, Omaha, Nebraska, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
C=CCNC1=C2C[C@@H](C)C[C@H](OC)[C@H](O)[C@@H](C)/C=C(\C)[C@H](OC(N)=O)[C@@H](OC)/C=C\C=C(/C)C(=O)NC(=CC1=O)C2=O,0,,_TANESPIMYCIN,,Terminated,NCT00098488,B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA|PROLYMPHOCYTIC LEUKEMIA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Medical Center, Columbus, Ohio, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,1,1,0,1,1,1,0,0,1,0,1,0,1,0,0,1,1,0,0,1,0,1,1,1,1,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,0,1,0,0,0,0,1,1,1,0,0,1,1,1,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,1,1,0,0,0,1,0,0,1,1,1,1,0,1,1,1,1,1,1,0,1,1,0,1,0,0,0,1,0,0,0,0,1,0,1,1,1,0,0
CCc1c(C)c2cc3nc(cc4nc(cc5cc(C)c(cc1[nH]2)[nH]5)C(C)=C4CCC(=O)O)C(CCC(=O)O)=C3C,0,,_PHOTOFRIN,,Terminated,NCT01966809,"BRAIN TUMOR, RECURRENT",All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Medical College of Wisconsin/ Froedtert Hospital, Milwaukee, Wisconsin, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,1,1,0,0,1,1,0,1,1,0,0,1,1,0,1,1,0,1,0,0,0,1,1,1,0,1,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,0
O=C(O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1,0,,_TETRAXETAN,4508625,Terminated,NCT01147393,FOLLICULAR LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Weill Cornell Medical College, New York, New York, United States",B03C1/01,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,34.0,17.8730569416209,1632.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1
CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1.O=C(O)CC(O)(CC(=O)O)C(=O)O,0,,_FENTANYL_CITRATE,4486423,Terminated,NCT00899951,"BRAIN AND CENTRAL NERVOUS SYSTEM TUMORS|CHRONIC MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|PAIN|PRECANCEROUS CONDITION|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Observational Model: Cohort|Time Perspective: Prospective,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States",4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,8.0,19.4829462617302,148.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,0,1,1,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,0,1,1,0,0,1,1,1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,1,0,0,1,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,,_LEUPROLIDE_ACETATE,4851211,Terminated,NCT00275262,"HODGKIN DISEASE|LYMPHOMA, NON-HODGKIN|MULTIPLE MYELOMA|MANTLE CELL LYMPHOMA",All,"18 Years to 65 Years   (Adult, Older Adult)",Industry|Other,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Saint Louis, Missouri, United States|New York, New York, United States|Durham, North Carolina, United States|Houston, Texas, United States",A61K9/008,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CC(=O)O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H]1CCC(=O)N1,0,,_LEUPROLIDE_ACETATE,4851211,Terminated,NCT01257802,"LUPUS ERYTHEMATOSUS, SYSTEMIC|SYSTEMIC VASCULITIS|ISOLATED ANGIITIS OF CENTRAL NERVOUS SYSTEM|LUNG DISEASE WITH SYSTEMIC SCLEROSIS|LUNG DISEASE INTERSTITIAL DIFFUSE",Female,18 Years to 40 Years   (Adult),Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","University of Michigan, Ann Arbor, Michigan, United States|The Ohio State University, Columbus, Ohio, United States",A61K9/008,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,11.0,31.967802213597803,302.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,0,1,0,0,0,0,1,0,1,0,1,0,1,1,1,0,1,0,0,1,1,0,1,0,1,0,1,1,1,1,0,0,1,1,1,0,1,0,1,1,0,0,0,1,1,0,0,1,0,0,1,1,1,1,1,1,0,1,1,0,1,1,1,1,0,0,1,0,1,1,1,0,0,1,0,1,1,1,1,1,0,0,0,1,0,1,1,1,1,1,0,0,1,1,1,1,0,1,0,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,0
CCC(=O)O[C@]1(C(=O)CCl)[C@@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,0,,_HALOBETASOL_PROPIONATE,4619921,Terminated,NCT03245385,ATOPIC DERMATITIS,All,"12 Years to 70 Years   (Child, Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Providence Clinical Research, North Hollywood, California, United States|Havana Research Institute, Pasadena, California, United States|Vital Pharma Research, Hialeah, Florida, United States|Solutions Through Advanced Research, Jacksonville, Florida, United States|Integrity Research Center, Miami, Florida, United States|Millennium Clinical Research, INC, Miami, Florida, United States|Regenerate Clinical Trials, LLC, Miami, Florida, United States|Life Medical Center and Research, INC, Miami, Florida, United States|Vista Health Research, Miami, Florida, United States|Elias Research, Troy, Michigan, United States|Montana Medical Research/Elias Research Assoc., Missoula, Montana, United States|L&C Professional Medical Research Institute, Hazleton, Pennsylvania, United States|Sun Research Institute, San Antonio, Texas, United States",C07J21/00,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.0,30.259348241236896,346.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,0,0,1,1,0,1,0,1,1,0,1,0,0,0,1,1,0,1,0,0,0,0,1,1,1,1,0,1,1,0,1,1,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,1,1,1,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,0,,_RETINAL,3953524,Terminated,NCT00880139,DIABETIC RETINOPATHY|INFLAMMATION,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Cohort|Time Perspective: Cross-Sectional,"Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
CC1=C(/C=C/C(C)=C/C=C/C(C)=C/C=O)C(C)(C)CCC1,0,,_RETINAL,3953524,Terminated,NCT02473029,HORTON DISEASE,All,"18 Years and older   (Adult, Older Adult)",Other,Observational Model: Case-Only|Time Perspective: Cross-Sectional,"Fondation Ophtalmologique A. de Rotchschild, Paris, France",C07C33/02,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,25.561099817244703,248.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,1,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0
O=c1[nH]c2cnc(-n3cnc4ccc(F)cc43)nc2n1[C@@H]1CCOc2c(F)cccc21,0,,_VS-5584,,Terminated,NCT01991938,NON HEMATOLOGIC CANCERS|METASTATIC CANCER|LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"HonorHealth Research Institute, Scottsdale, Arizona, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Tennessee Oncology, Nashville, Tennessee, United States|The Royal Marsden, Sutton, London, United Kingdom",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,1,0,1,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,0,1,1,1,0,0,0,1,1,1,0,1,0,1,0,0,0,1,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,1,0,0,1,0,0,1,0,0,1,0,0,0,1,1,1,1,0,0,0,1,0,0,0,1,1,0,1,1,0,0,1,1,0,0,0,1
O=C(c1ccc(/C=C/c2n[nH]c3ccccc23)cc1)N1CCNCC1,0,,_KW-2449,7470717,Terminated,NCT00346632,ACUTE MYELOGENOUS LEUKEMIA|ACUTE LYMPHOBLASTIC LEUKEMIA|MYELODYSPLASTIC SYNDROMES|CHRONIC MYELOGENOUS LEUKEMIA,All,"18 Years and older   (Adult, Older Adult)",Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Johns Hopkins Hospital, Baltimore, Maryland, United States|Contact Kyowa, Princeton, New Jersey, United States|Weill Cornell/New York Presbyterian Hospital, New York, New York, United States|M.D. Anderson Cancer Center, Houston, Texas, United States",C07D231/56,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,15.0,53.0277829113534,128.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,1,1,0,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,1,1,1,0,1,1,1,0,0,0,0,0,1,0,0,0,1,0,0,1,0,1,0,0,1,0,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,0
CC(C)[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](Cc2ccccc2)C(=O)N1C,0,,_CILENGITIDE,WO-2003032961-A2,Terminated,NCT00006222,SARCOMA,All,"18 Years and older   (Adult, Older Adult)",NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"University of California San Diego Cancer Center, La Jolla, California, United States|UCSF Cancer Center and Cancer Research Institute, San Francisco, California, United States|Vanderbilt Cancer Center, Nashville, Tennessee, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,23.0,32.7488,128.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,1,1,0,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,1,1,1,1,1,1,1,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,0,1,1,1,0,0,0,1,1,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,1
c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21,0,,_PHTHALOCYANINE,3931097,Terminated,NCT00023790,BREAST CANCER|HEAD AND NECK CANCER|LYMPHOMA|METASTATIC CANCER|NON-MELANOMATOUS SKIN CANCER|SARCOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States",C08F255/04,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,13.0762438653771,6019.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0
CN[C@@H]1C[C@H]2O[C@@](C)([C@@H]1OC)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)N[C@H]4O,0,,_UCN-01,,Terminated,NCT00082017,"LYMPHOMA, LARGE-CELL, KI-1|LYMPHOMA, T-CELL",All,"12 Years and older   (Child, Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,1,1,0,0,0,1,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,1,1,0,0,1,1,1,1,1,1,0,0,0,1,1,1,0,1,0,0,0,0,1,1,0,1,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,1,1,0,0,1,0,0,0,1,1,0,0,0,1,1,1,0,0,0,0
N=C(N)N/N=C/c1c(Cl)cccc1Cl,0,,_GUANABENZ,4027039,Terminated,NCT02423083,"MULTIPLE SCLEROSIS, RELAPSING-REMITTING|MULTIPLE SCLEROSIS",All,18 Years to 55 Years   (Adult),NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States",5,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,5.0,23.1626932791227,823.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.Cl.[Cl-],0,,_THIAMINE_HYDROCHLORIDE,3959509,Withdrawn,NCT00037063,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Primary Purpose: Prevention,"Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States",A23L13/42,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,12.1563071110289,896.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
Cc1ncc(C[n+]2csc(CCO)c2C)c(N)n1.[Cl-],0,,_THIAMINE,3946115,Withdrawn,NCT00037063,HIV INFECTION,All,"13 Years and older   (Child, Adult, Older Adult)",NIH,Primary Purpose: Prevention,"Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States|Case Western Reserve Univ, Cleveland, Ohio, United States|MetroHealth Med Ctr, Cleveland, Ohio, United States|Univ of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States",A23K20/158,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,8.0,20.4357379001622,2969.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,1,0,1,0,1,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,0,0,1,1,1,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,0,1,0,0,1,0,0,0,0,1,1,0,1,0,0,0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1
O.O=C([O-])CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Ca+2].[Na+].[Na+],0,,_EDETATE_CALCIUM_DISODIUM,,Withdrawn,NCT01101412,"CHRONIC MYELOPROLIFERATIVE DISORDERS|INFECTION|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASMS|UNSPECIFIED ADULT SOLID TUMOR, PROTOCOL SPECIFIC",All,"18 Years and older   (Adult, Older Adult)",Other|NIH,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Supportive Care",,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0
N#CC[C@H](C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1.O=P(O)(O)O,0,,_RUXOLITINIB_PHOSPHATE,US-20080312259-A1,Withdrawn,NCT02528877,"ACUTE MYELOID LEUKEMIA IN REMISSION|PRIMARY MYELOFIBROSIS|PRIMARY MYELOFIBROSIS, PREFIBROTIC STAGE|SECONDARY ACUTE MYELOID LEUKEMIA|SECONDARY MYELOFIBROSIS",All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,"City of Hope Medical Center, Duarte, California, United States",5,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,60.0,32.7488,16.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,1,1,1,0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,1,1,0,0,1,0,0,0,1,0,1,0,1,1,1,0,1,1,0,1,1,0,0,1,0,0,0,0,1,0,0,1,0,1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1
CC(=O)O.CN1CCN(c2nc(C3=C(c4c[nH]c5ccccc45)C(=O)NC3=O)c3ccccc3n2)CC1,0,,_SOTRASTAURIN_ACETATE,,Withdrawn,NCT02285244,PROLYMPHOCYTIC LEUKEMIA|RECURRENT MANTLE CELL LYMPHOMA|RECURRENT SMALL LYMPHOCYTIC LYMPHOMA|REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|RICHTER SYNDROME,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,1,0,0,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,1,0,1,0,0,1,1,0,1,1,0,0,1,0,1,1,0,0,0,1,0,1,1,1,0,0,1,0,1,1,0,0,1,0,0,0,0,0,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,1,1,1,0,0
N=C(N)NCCC[C@@H]1NC(=O)[C@@H]2CSSC[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC1=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@H](C(=O)NCCOCCOCCOCCNC(=O)COCC(N)=O)CSCC(=O)N[C@@H](CCCCNC(=O)COCC(=O)NCCOCCOCCOCCOCCOCCNC(=O)CO/N=C/c1ccc(F)cc1)C(=O)N2,0,,_FLUCICLATIDE,,Withdrawn,NCT01571726,MULTIPLE MYELOMA|SMOLDERING MULTIPLE MYELOMA|MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE,All,"18 Years to 99 Years   (Adult, Older Adult)",NIH,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,0,1,1,1,1,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,1,1,1,0,0,0,0,1,1,0,0,1,0,1,1,1,1,1,1,1,1,1,0,1,0,1,1,1,1,0,1,1,1,1,0,0,1,0,1,0,0,1,0,0,1,1,1,0,0,0,1,1,1,1,1,1,1,1,1,1,0,0,1,1,0,1,1,0,1,0,1,1,1,0,1,0,0,0,1,0,1,0,1,1,0,1,0,1,0,0,1,1,0,0,0,1,0,1,1,1
C[C@@]12C[C@@]3(O)O[C@@H](O1)[C@]1(COC(=O)c4ccccc4)[C@@H]3C[C@@]21O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O,0,,_PAEONIFLORIN,,Withdrawn,NCT02878863,"HEPATITIS, AUTOIMMUNE",All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital, Chengdu, Sichuan, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,1,1,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,0,0,0,1,0,0,1,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,1,0,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,1,0,1,1,0
CCCCCCCCCCCCCCSCC(=O)OC[C@H](COP(=O)([O-])OCC[N+](C)(C)C)OC(=O)CSCCCCCCCCCCCCCC,0,,_PHOSPHATIDYLCHOLINE,,Withdrawn,NCT02878863,"HEPATITIS, AUTOIMMUNE",All,"20 Years to 70 Years   (Adult, Older Adult)",Other,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"West China Hospital, Chengdu, Sichuan, China",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,0,1,0,0,1,0,0,0,1,0,0,0,1,0,0,1,0,0,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,1,1,1,0,0,0,1,0,1,1,0,1,1,0,1,1,0,0,0,0,1,0,0,0,1,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,1,0,0
CO/N=C(\C(=O)N[C@@H]1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CS[C@H]12)c1ccco1,0,,_CEFUROXIME_AXETIL,,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,1,1,1,1,0,0,0,1,1,1,1,1,1,1,1,0,1,0,0,0,0,1,0,0,1,0,0,1,0,0,1,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,1,1,0,0,0,0,1,0,0,0,1,1,1,1,1,1,0,0,0,1,0,0,1,1,1,0,0,0,0,0,0,1,1,1,0,1,0,1
CN[C@@H](C)[C@@H](O)c1ccccc1.Cl,0,,_PSEUDOEPHEDRINE_HYDROCHLORIDE,4181719,Withdrawn,NCT00000752,HIV INFECTIONS|SINUSITIS,All,"12 Years and older   (Child, Adult, Older Adult)",NIH|Industry,Masking: Double|Primary Purpose: Treatment,"Univ of California / San Diego Treatment Ctr, San Diego, California, United States|Stanford at Kaiser / Kaiser Permanente Med Ctr, San Francisco, California, United States|Montefiore Drug Treatment Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Family Health Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Samaritan Village Inc / Bronx Municipal Hosp, Bronx, New York, United States|Jack Weiler Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr / Bronx Municipal Hosp, Bronx, New York, United States|Montefiore Med Ctr Adolescent AIDS Program, Bronx, New York, United States|North Central Bronx Hosp / Bronx Municipal Hosp, Bronx, New York, United States|Thomas Jefferson Univ Hosp, Philadelphia, Pennsylvania, United States",5,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,14.0,19.220107189059306,39.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0
CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(=O)O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,0,,_ANGIOTENSIN_II,,Withdrawn,NCT01702688,HYPERTENSION,All,"18 Years to 65 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other,"Brigham and Women's Hospital, Boston, Massachusetts, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,0,1,1,0,0,1,0,1,1,1,0,0,1,0,0,1,1,0,0,1,0,0,1,0,1,0,0,1,1,0,1,0,0,0,0,1,1,0,0,1,1,0,1,0,1,0,1,0,0,1,0,1,1,0,1,0,0,1,1,1,0,1,1,1,1,1,1,1,0,1,1,0,0,0,1,0,1,1,1,1,1,1,0,1,1,1,1,1,0,0,0,1,0,1,0,1,1,1,0,0,0,1,1,0,0,1,1,0,1,1,1,1,0,0,1,0,1,0,1,1,1,1,1,1,1
COc1cc2c(cc1O)CCN[C@]21CS[C@H]2c3c(OC(C)=O)c(C)c4c(c3[C@@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4,0,,_TRABECTEDIN,,Withdrawn,NCT03884972,REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA|REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,1,0,1,0,0,0,1,0,0,1,1,0,0,1,0,1,1,0,0,0,1,1,0,0,1,1,0,0,1,1,0,1,1,0,1,1,0,0,1,1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,1,1,1,1,0,0,1,0,1,1,1,1,1,1,1,0,1,1,0,1,1,0,0,0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,1,0,1,0,0,1,1,1,1,1,1,0,1,1,0,0,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0
C=CCS[S+]([O-])CC=C,0,,_ALLICIN,5705152,Withdrawn,NCT00029250,HIV INFECTIONS|HYPERCHOLESTEROLEMIA|HYPERTRIGLYCERIDEMIA|HYPERGLYCEMIA,All,"18 Years to 65 Years   (Adult, Older Adult)",NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"Bastyr University Center for Natural Health, Seattle, Washington, United States|University of Washington Harborview Medical Center, Seattle, Washington, United States",A61K36/8962,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,12.0,40.017248814144004,70.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,0
N=C(N)c1ccc(-c2cc3ccc(C(=N)N)cc3[nH]2)cc1,0,,_DAPI,5939282,Withdrawn,NCT01242579,HIV INFECTION,Female,18 Years to 40 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention",,C12Q1/04,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,24.805437483315806,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
N=C(N)c1ccc(-c2cc3ccc(C(=N)N)cc3[nH]2)cc1,0,,_DAPI,5939282,Withdrawn,NCT03044379,HIV 1 INFECTION,All,18 Years to 45 Years   (Adult),Industry,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Other","University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States",C12Q1/04,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,24.805437483315806,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
N=C(N)c1ccc(-c2cc3ccc(C(=N)N)cc3[nH]2)cc1,0,,_DAPI,5939282,Withdrawn,NCT03074786,HIV-1 INFECTION,Female,"16 Years to 21 Years   (Child, Adult)",Industry,Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"CAPRISA, eThekwini Clinical Research Site, Durban, KwaZulu-Natal, South Africa",C12Q1/04,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,8.0,24.805437483315806,77.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,1,1,1,0,0,0,1,0,0,0,1,0,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0
CC[C@H](C)C(=O)O[C@H]1C[C@H](O)C=C2C=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(=O)[O-])[C@H]21.[Na+],0,,_PRAVASTATIN_SODIUM,5151360,Withdrawn,NCT01515813,HIV-1 INFECTION,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"UCLA CARE Center CRS (601), Los Angeles, California, United States|Harbor-UCLA Med. Ctr. CRS (603), Torrance, California, United States|Washington University CRS (2101), St. Louis, Missouri, United States|Unc Aids Crs (3201), Chapel Hill, North Carolina, United States|Duke University Medical Center Adult CRS (1601), Durham, North Carolina, United States|Regional Center for Infectious Disease, Wendover Medical Center CRS (3203), Greensboro, North Carolina, United States|The Ohio State University AIDS CRS (2301), Colombus, Ohio, United States|Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States|Houston AIDS Research Team CRS (31473), Houston, Texas, United States",C07C215/40,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,6.0,14.948972258157198,597.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,0,1,0,1,1,1,1,0,0,0,1,0,1,0,0,1,0,0,0,1,1,1,1,1,0,0,1,1,1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,1,1,1,1,0,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,1,1,1,1,0
COc1cc2c(c(OC)c1OC)-c1ccc(OC)c(=O)cc1[C@@H](NC(C)=O)CC2,0,,_COLCHICINE,4008719,Withdrawn,NCT00000577,ASTHMA|LUNG DISEASES,All,"18 Years to 75 Years   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: Treatment,"University of California at San Diego, La Jolla, California, United States|University of California, San Francisco, San Francisco, California, United States|National Jewish Medical & Research Center, Denver, Colorado, United States|Brigham and Women's Hospital, Boston, Massachusetts, United States|Washington University, St. Louis, Missouri, United States|Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States|University of Wisconsin at Madison, Madison, Wisconsin, United States",A61F9/0017,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,63.0,12.6819852563707,1803.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,1,0,0,1,0,1,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,0,0,1,0,0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,1,0,1,0,0
O=C([O-])CCCc1ccccc1.[Na+],0,,_SODIUM_PHENYLBUTYRATE,5605930,Withdrawn,NCT00387530,GASTRIC CANCER|HEAD AND NECK CANCER|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Rebecca and John Moores UCSD Cancer Center, La Jolla, California, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,25.0,35.680404115074204,128.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,1,1,1,0,0,0,1,0,0,0,1,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0
Cl.N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O,0,,_MELPHALAN_HYDROCHLORIDE,4997651,Withdrawn,NCT03328936,HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENT|RECURRENT PLASMA CELL MYELOMA|REFRACTORY PLASMA CELL MYELOMA,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States",1,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,16.0,27.4995379781925,71.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,1,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,0,0,1,1,1,0,0,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0
Cc1nccn1CC1CCc2c(c3ccccc3n2C)C1=O.Cl,0,,_ONDANSETRON_HYDROCHLORIDE,5470868,Withdrawn,NCT00499668,MYELOPROLIFERATIVE DISORDERS|LEUKEMIA|LYMPHOMA|LYMPHOPROLIFERATIVE DISORDER|MULTIPLE MYELOMA AND PLASMA CELL NEOPLASM|MYELODYSPLASTIC SYNDROMES|NAUSEA AND VOMITING|SOLID TUMOR,All,"18 Years and older   (Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care,,4,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,9.0,23.688371424464503,175.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,1,0,1,0,0,0,0,1,0,1,0,1,0,1,0,0,0,1,1,0,0,1,0,0,0,0,0,1,0,1,1,0,0,0,1,1,1,0,0,0,0,1,1,0,1,1,0,0,0,1,0,0,0,1,0,1,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0
CN(CCCl)CCCl.Cl,0,,_MECHLORETHAMINE_HYDROCHLORIDE,4198419,Withdrawn,NCT03288818,MYCOSIS FUNGOIDES,All,"18 Years and older   (Adult, Older Adult)",Other|Industry,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,"Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States",C07C323/00,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,73.0,15.146101562660403,341.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0
C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@]2(O)C[C@H](O)[C@@H](C(=O)O)[C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@H]1C)O2,0,,_NYSTATIN,,Withdrawn,NCT03862079,GRAFT-VERSUS-HOST DISEASE PREVENTION,All,"16 Years to 75 Years   (Child, Adult, Older Adult)",Other|NIH,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention,"M D Anderson Cancer Center, Houston, Texas, United States",,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,1,0,1,0,1,1,0,1,1,0,1,1,0,0,1,1,1,1,1,1,1,1,1,0,1,1,1,1,0,1,1,0,0,0,0,1,1,0,0,1,1,1,0,0,1,1,0,0,1,0,0,0,0,0,1,1,0,0,1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,1,0,0,0,1,1,0,1,1,1,0,0,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0
Cc1c(OCC(F)(F)F)ccnc1C[S@@+]([O-])c1nc2ccccc2[nH]1,0,,_DEXLANSOPRAZOLE,,Withdrawn,NCT01479231,GASTROESOPHAGEAL REFLUX DISEASE|EOSINOPHILIC ESOPHAGITIS|DYSPHAGIA,All,"18 Years to 80 Years   (Adult, Older Adult)",Other,Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment,,,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,15.0,32.7488,128.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,0,0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,1,1,0,0,1,0,0,0,1,0,1,1,1,0,1,0,0,1,0,0,0,0,1,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,1,1,0,0,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,0,1,1,0,1,0,1,1,0,0,0,0,0,0,0,1,0,1,0,0,1,0,0,1,0,1,0,0,0
CN(C)CCOC(c1ccccc1)c1ccccc1.Cl,0,,_DIPHENHYDRAMINE_HYDROCHLORIDE,3934576,Terminated,NCT00000875,HIV INFECTION,All,"18 Years and older   (Adult, Older Adult)",NIH,Intervention Model: Parallel Assignment|Primary Purpose: Treatment,"The Ctr For Blood Research Inc, Boston, Massachusetts, United States",A61M39/223,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,6.0,26.415326803425106,4425.0,0.0,1.0,0.0,0.0,0.0,0.0,0.0,0.0,1.0,2.1233,442.0703,112.1969,5.0,2.0,3.0,44.7137,115.5493,5.0,0.0,0.0,1.0,0,1,1,0,0,1,0,0,0,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,1,0,1,0,1,0,0,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0
